nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,source_class,delayed_posting,expanded_access_nctid,expanded_access_status_for_nctid,fdaaa801_violation,baseline_type_units_analyzed,patient_registry,sponsors,countries,organ_systems
NCT00000392,,2000-01-17,2015-07-17,,2017-02-27,2000-01-17,2000-01-18,ESTIMATED,2015-07-29,2015-08-04,ESTIMATED,,,,2017-02-27,2017-02-28,ACTUAL,1990-01,,1990-01-31,2013-10,2013-10-31,1996-08,ACTUAL,1996-08-31,1996-08,ACTUAL,1996-08-31,,INTERVENTIONAL,,,Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.,Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.,COMPLETED,,PHASE2,215,ACTUAL,National Institute of Mental Health (NIMH),,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 08:37:22,2024-10-13 08:37:22,NIH,,,,,,,National Institute of Mental Health (NIMH),United States,"Blood and lymphatic system disorders|Immune system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00001941,,2000-01-18,2012-04-23,,2012-08-13,2000-01-18,2000-01-19,ESTIMATED,2012-07-02,2012-08-09,ESTIMATED,,,,2012-08-13,2012-08-20,ESTIMATED,1999-12,,1999-12-31,2012-08,2012-08-31,2011-02,ACTUAL,2011-02-28,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,,,Anti-Tac for Treatment of Leukemia,A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia,COMPLETED,,PHASE1/PHASE2,34,ACTUAL,National Institutes of Health Clinical Center (CC),Study was closed to accrual since the cessation of the production of daclizumab.,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 15:49:25,2024-10-13 15:49:25,NIH,,,,,,,National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00002850,,1999-11-01,2014-07-10,,2015-10-13,2003-01-26,2003-01-27,ESTIMATED,2015-02-11,2015-02-13,ESTIMATED,,,,2015-10-13,2015-11-11,ESTIMATED,1997-03,,1997-03-31,2015-10,2015-10-31,2012-01,ACTUAL,2012-01-31,2011-04,ACTUAL,2011-04-30,,INTERVENTIONAL,,"Patients with symptomatic and untreated MM receiving chemotherapy without an active infection during the 7 days prior to initiation of chemotherapy and off antibiotics for the prior 7 days were eligable for this study. They were required to receive myelosuppressive and/or immunosuppressive chemotherapy, and were randomized on a 1:1 basis.",Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy,Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma,COMPLETED,,PHASE3,212,ACTUAL,University of Rochester,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 22:31:13,2024-10-13 22:31:13,OTHER,,,,,,,Eastern Cooperative Oncology Group|Gary Morrow|National Cancer Institute (NCI),Peru|South Africa|United States,Gastrointestinal disorders|General disorders|Infections and infestations|Renal and urinary disorders
NCT00004978,,2000-03-10,2011-01-20,2009-10-16,2021-11-02,2001-08-30,2001-08-31,ESTIMATED,2011-03-21,2011-04-25,ESTIMATED,2009-10-16,2009-10-20,ESTIMATED,2021-11-02,2021-11-05,ACTUAL,2000-03,,2000-03-31,2012-10,2012-10-31,2008-11,ACTUAL,2008-11-30,2008-11,ACTUAL,2008-11-30,,INTERVENTIONAL,ESPRIT,,An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy,"A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mm^3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial",COMPLETED,,PHASE3,4150,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 05:06:15,2024-10-13 05:06:15,NIH,,,,,,,Chiron Corporation|National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|France|Germany|Ireland|Israel|Italy|Japan|Morocco|Netherlands|Norway|Poland|Portugal|Singapore|Spain|Sweden|Switzerland|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00006604,,2000-12-06,2016-01-29,,2021-11-03,2001-08-30,2001-08-31,ESTIMATED,2016-03-07,2016-04-05,ESTIMATED,,,,2021-11-03,2021-11-05,ACTUAL,2000-11,,2000-11-30,2016-03,2016-03-31,2014-09,ACTUAL,2014-09-30,2011-10,ACTUAL,2011-10-31,,INTERVENTIONAL,,"Participants accrued and treated at the dose ultimately selected for their groups.

NOTE: (1) Final Dose not established for Grps 1, 2; (2) Grp 5a started with n=12, but (1) participant inadvertently enrolled,never received ATV, final n=11; (3) Grp 8 started with n=15, but (1) participant inadvertently enrolled, never received ATV, final n=14.","Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents","Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents",COMPLETED,,PHASE1/PHASE2,195,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,9,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:25:50,2024-10-14 00:25:50,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|South Africa|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00013611,,2001-03-24,2010-11-08,,2011-08-02,2001-03-24,2001-03-26,ESTIMATED,2010-11-08,2010-12-13,ESTIMATED,,,,2011-08-02,2011-08-08,ESTIMATED,2001-03,,2001-03-31,2011-08,2011-08-31,2007-01,ACTUAL,2007-01-31,2007-01,ACTUAL,2007-01-31,,INTERVENTIONAL,SILCAAT,,Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study),"A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients With Low CD4+ Counts Under Active Antiretroviral Therapy (SILCAAT Amendment 4)",COMPLETED,,PHASE3,1695,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 16:32:06,2024-10-13 16:32:06,OTHER,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|University of Minnesota,Netherlands|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00016718,,2001-05-31,2017-08-01,2010-01-20,2021-11-03,2001-08-30,2001-08-31,ESTIMATED,2017-10-16,2017-10-17,ACTUAL,2010-01-20,2010-01-22,ESTIMATED,2021-11-03,2021-11-05,ACTUAL,2001-08,,2001-08-31,2017-09,2017-09-30,2009-01,ACTUAL,2009-01-31,2009-01,ACTUAL,2009-01-31,,INTERVENTIONAL,,,"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","An Open-Label Study to Evaluate the Safety, Tolerance, Antiviral Activity, and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once-Daily Regimen in HIV Infected, Antiretroviral Therapy Naive or Very Limited Antiretroviral Exposed Pediatric Subjects",COMPLETED,,PHASE1/PHASE2,43,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 11:39:25,2024-10-14 11:39:25,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00018031,,2001-06-27,2013-01-18,,2014-09-25,2001-06-27,2001-06-28,ESTIMATED,2014-09-25,2014-10-01,ESTIMATED,,,,2014-09-25,2014-10-01,ESTIMATED,2001-06,,2001-06-30,2014-09,2014-09-30,2009-04,ACTUAL,2009-04-30,2009-04,ACTUAL,2009-04-30,,INTERVENTIONAL,HEPCPR,,Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients,"A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin",COMPLETED,,PHASE2,36,ACTUAL,National Institutes of Health Clinical Center (CC),,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 03:11:24,2024-10-13 03:11:24,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Eye disorders|General disorders|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders"
NCT00022763,,2001-08-11,2015-12-04,,2016-01-19,2001-08-30,2001-08-31,ESTIMATED,2016-01-19,2016-02-15,ESTIMATED,,,,2016-01-19,2016-02-15,ESTIMATED,2001-08,,2001-08-31,2016-01,2016-01-31,,,,2004-12,ACTUAL,2004-12-31,,INTERVENTIONAL,,,T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents,A Phase I/II Pharmacokinetic and Safety Study of T-20 in Combination With an Optimized Background in HIV Infected Children and Adolescents,COMPLETED,,PHASE2,52,ACTUAL,Hoffmann-La Roche,,,,,,,,,,,,,,,,,,,,,,2024-10-14 23:41:58,2024-10-14 23:41:58,INDUSTRY,,,,,,,Hoffmann-La Roche|Trimeris,United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00035932,,2002-05-06,2010-10-14,,2010-11-29,2002-05-07,2002-05-08,ESTIMATED,2010-11-29,2010-12-24,ESTIMATED,,,,2010-11-29,2010-12-24,ESTIMATED,2001-11,,2001-11-30,2010-11,2010-11-30,2009-03,ACTUAL,2009-03-31,2003-07,ACTUAL,2003-07-31,,INTERVENTIONAL,,,"Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV","Phase III Open Label Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV",COMPLETED,,PHASE3,571,ACTUAL,Bristol-Myers Squibb,,3,,,TRUE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:03:31,2024-10-13 00:03:31,INDUSTRY,,,,,,,Bristol-Myers Squibb,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00039741,,2002-06-07,2011-12-19,2010-08-19,2021-11-03,2002-06-10,2002-06-11,ESTIMATED,2012-03-26,2012-04-24,ESTIMATED,2011-05-16,2011-05-17,ESTIMATED,2021-11-03,2021-11-05,ACTUAL,2002-08,,2002-08-31,2019-01,2019-01-31,2010-03,ACTUAL,2010-03-31,2009-08,ACTUAL,2009-08-31,,INTERVENTIONAL,,,Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children,"A Phase II/III Randomized, Open-Label Study of Combination Antiretroviral Regimens and Treatment-Switching Strategies in HIV-1-Infected Antiretroviral Naive Children Between 30 Days and 18 Years of Age",COMPLETED,,PHASE2/PHASE3,266,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 00:53:47,2024-10-14 00:53:47,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|PENTA Foundation,Bahamas|Brazil|Puerto Rico|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00040664,,2002-07-05,2009-08-06,,2017-01-19,2002-07-09,2002-07-10,ESTIMATED,2010-02-05,2010-02-23,ESTIMATED,,,,2017-01-19,2017-03-03,ACTUAL,2002-07,,2002-07-31,2017-01,2017-01-31,2008-10,ACTUAL,2008-10-31,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years,"A 48 Week, Phase II, Open-Label Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir QD and GW433908/Ritonavir BID When Administered to HIV-1 Infected, Antiretroviral Naive and Experienced, Pediatric Subjects 2-18 Years Old",COMPLETED,,PHASE2,69,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 05:17:37,2024-10-13 05:17:37,INDUSTRY,,,,,,,ViiV Healthcare,Canada|Italy|Netherlands|Portugal|Romania|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00042289,,2002-07-26,2021-10-05,,2022-06-28,2002-07-31,2002-08-01,ESTIMATED,2022-06-28,2022-07-22,ACTUAL,,,,2022-06-28,2022-07-22,ACTUAL,2003-06-09,ACTUAL,2003-06-09,2022-06,2022-06-30,2020-09-30,ACTUAL,2020-09-30,2020-09-30,ACTUAL,2020-09-30,,OBSERVATIONAL,,"The baseline analysis population is all mothers enrolled. Each study arm was designed as a separate single-arm evaluation. Participants were able to enroll in multiple arms, simultaneously; thus, the reporting groups are not mutually exclusive and totals do not represent the number of unique participants. There were 1037 unique mothers, including 8 who enrolled in 3 arms and 60 who enrolled in 2 arms.",Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy,Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum,COMPLETED,,,1578,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"Over the course of the study, some study arms were discontinued or closed for reasons such as there being sufficient pharmacokinetic data from other studies or lack of enrollment (as specified in Protocol Section 8.42), leading to a low number of participants in those arms. In addition, due to the COVID-19 pandemic there was a delay in running assays for certain arms and/or analyzing PK results; the results for those arms will be reported when available.",,49,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 03:52:04,2024-10-13 03:52:04,NIH,,,,,,FALSE,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Botswana|Brazil|Puerto Rico|South Africa|Tanzania|Thailand|Uganda|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00050089,,2002-11-20,2013-09-11,,2015-04-03,2002-11-21,2002-11-22,ESTIMATED,2014-01-17,2014-02-13,ESTIMATED,,,,2015-04-03,2015-04-23,ESTIMATED,2001-01,,2001-01-31,2015-04,2015-04-30,2007-12,ACTUAL,2007-12-31,2007-12,ACTUAL,2007-12-31,,INTERVENTIONAL,OPTIMA,HIV-positive patients with a CD4 count \<=300 cells/ul who had prior anti-retroviral treatment failure requiring retreatment,CSP #512 - Options in Management With Anti-Retrovirals,"CSP #512 - Options in Management With Anti-Retrovirals (OPTIMA), Management of Patients With HIV Infection for Whom First and Second-line Highly Active Anti-Retroviral Therapy Has Failed",COMPLETED,,NA,368,ACTUAL,VA Office of Research and Development,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 10:52:51,2024-10-13 10:52:51,FED,,,,,,,Canadian Institutes of Health Research (CIHR)|Medical Research Council|US Department of Veterans Affairs,Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00054717,,2003-02-07,2009-09-09,,2014-06-23,2003-02-07,2003-02-10,ESTIMATED,2009-11-02,2009-11-19,ESTIMATED,,,,2014-06-23,2014-07-02,ESTIMATED,2003-01,,2003-01-31,2014-04,2014-04-30,,,,2008-09,ACTUAL,2008-09-30,,INTERVENTIONAL,,"Safety Set, all patients treated with at least one dose of study drug",Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST),"Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.",COMPLETED,,PHASE3,630,ACTUAL,Boehringer Ingelheim,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 02:41:08,2024-10-13 02:41:08,INDUSTRY,,,,,,,Boehringer Ingelheim,Australia|Canada|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00055237,,2003-02-21,2012-06-19,,2017-08-07,2003-02-20,2003-02-21,ESTIMATED,2012-06-19,2012-07-26,ESTIMATED,,,,2017-08-07,2017-09-06,ACTUAL,2003-02-26,ACTUAL,2003-02-26,2017-08,2017-08-31,2010-03-15,ACTUAL,2010-03-15,2010-03-15,ACTUAL,2010-03-15,,INTERVENTIONAL,,,Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients,Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma,COMPLETED,,PHASE2,19,ACTUAL,National Institutes of Health Clinical Center (CC),,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 19:47:33,2024-10-14 19:47:33,NIH,,,,,,,National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00057330,,2003-03-31,2011-09-29,,2018-07-26,2003-03-31,2003-04-01,ESTIMATED,2011-09-29,2011-11-03,ESTIMATED,,,,2018-07-26,2018-08-27,ACTUAL,2003-01-14,,2003-01-14,2013-05,2013-05-31,2009-08-22,ACTUAL,2009-08-22,2009-08-22,ACTUAL,2009-08-22,,INTERVENTIONAL,,,HerpeVac Trial for Young Women,"A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative",COMPLETED,,PHASE3,8323,ACTUAL,GlaxoSmithKline,"Out of the 8323 subjects enrolled and vaccinated, 7850 subjects were followed throughout the study, e. a. for safety and adverse event assessment (4488 in the Herpes Simplex Virus Group and 3662 in the Havrix Group).",2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 05:39:26,2024-10-14 05:39:26,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00061633,,2003-05-30,2009-12-02,,2019-01-14,2003-05-30,2003-06-02,ESTIMATED,2009-12-02,2010-01-11,ESTIMATED,,,,2019-01-14,2019-01-16,ACTUAL,2003-06,,2003-06-30,2019-01,2019-01-31,2004-01,ACTUAL,2004-01-31,2004-01,ACTUAL,2004-01-31,,INTERVENTIONAL,FAST,,Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI),"A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)",COMPLETED,,PHASE2,169,ACTUAL,Cumberland Pharmaceuticals,,2,,,,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:37:17,2024-10-15 01:37:17,INDUSTRY,,,,,,,Cumberland Pharmaceuticals,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00061633,,2003-05-30,2009-12-02,,2019-01-14,2003-05-30,2003-06-02,ESTIMATED,2009-12-02,2010-01-11,ESTIMATED,,,,2019-01-14,2019-01-16,ACTUAL,2003-06,,2003-06-30,2019-01,2019-01-31,2004-01,ACTUAL,2004-01-31,2004-01,ACTUAL,2004-01-31,,INTERVENTIONAL,FAST,,Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI),"A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)",COMPLETED,,PHASE2,169,ACTUAL,Cumberland Pharmaceuticals,,2,,,,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:37:17,2024-10-15 01:37:17,INDUSTRY,,,,,,,Cumberland Pharmaceuticals,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00062647,,2003-06-09,2009-12-02,,2019-01-14,2003-06-11,2003-06-12,ESTIMATED,2011-02-22,2011-03-22,ESTIMATED,,,,2019-01-14,2019-01-16,ACTUAL,2003-08,,2003-08-31,2019-01,2019-01-31,2006-08,ACTUAL,2006-08-31,2006-08,ACTUAL,2006-08-31,,INTERVENTIONAL,ASSURE,,Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia,"A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia",COMPLETED,,PHASE2,60,ACTUAL,Cumberland Pharmaceuticals,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 01:24:19,2024-10-14 01:24:19,INDUSTRY,,,,,,,Cumberland Pharmaceuticals,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00071760,,2003-10-30,2012-03-02,,2023-10-09,2003-10-30,2003-10-31,ESTIMATED,2012-07-19,2012-08-23,ESTIMATED,,,,2023-10-09,2023-10-10,ACTUAL,2003-10-23,ACTUAL,2003-10-23,2023-10,2023-10-31,2022-03-29,ACTUAL,2022-03-29,2011-07-05,ACTUAL,2011-07-05,,INTERVENTIONAL,,Participants who received both single and multiple doses of FPV/RTV were included in Intent to Treat-Exposed (ITT-E) population.,Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects,"A 48 Week, Phase II, Open-label, 2-cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-experienced Pediatric Subjects Aged 4 Weeks to <2 Years.",COMPLETED,,PHASE2,59,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:08:12,2024-10-13 06:08:12,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Mexico|Panama|Portugal|Puerto Rico|Russian Federation|South Africa|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00071760,,2003-10-30,2012-03-02,,2023-10-09,2003-10-30,2003-10-31,ESTIMATED,2012-07-19,2012-08-23,ESTIMATED,,,,2023-10-09,2023-10-10,ACTUAL,2003-10-23,ACTUAL,2003-10-23,2023-10,2023-10-31,2022-03-29,ACTUAL,2022-03-29,2011-07-05,ACTUAL,2011-07-05,,INTERVENTIONAL,,Participants who received both single and multiple doses of FPV/RTV were included in Intent to Treat-Exposed (ITT-E) population.,Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects,"A 48 Week, Phase II, Open-label, 2-cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-experienced Pediatric Subjects Aged 4 Weeks to <2 Years.",COMPLETED,,PHASE2,59,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:08:12,2024-10-13 06:08:12,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Mexico|Panama|Portugal|Puerto Rico|Russian Federation|South Africa|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00074412,,2003-12-11,2013-05-30,,2023-01-24,2003-12-12,2003-12-15,ESTIMATED,2013-07-05,2013-09-16,ESTIMATED,,,,2023-01-24,2023-02-16,ACTUAL,2007-01,,2007-01-31,2023-01,2023-01-31,2011-11,ACTUAL,2011-11-30,2011-09,ACTUAL,2011-09-30,,INTERVENTIONAL,,,Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding,A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding,COMPLETED,,PHASE3,2026,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),The rate of maternal highly active antiretroviral therapy use was higher than expected in our study. Thus there were fewer infant infections which decreased the power to detect differences in HIV transmission risks between study groups.,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 00:13:26,2024-10-14 00:13:26,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA),South Africa|Tanzania|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00074581,,2003-12-16,2016-09-09,,2021-11-03,2003-12-16,2003-12-17,ESTIMATED,2016-09-09,2016-10-31,ESTIMATED,,,,2021-11-03,2021-11-05,ACTUAL,2005-02,,2005-02-28,2016-11,2016-11-30,2015-05,ACTUAL,2015-05-31,2015-05,ACTUAL,2015-05-31,,INTERVENTIONAL,,,Preventing Sexual Transmission of HIV With Anti-HIV Drugs,A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples,COMPLETED,,PHASE3,3526,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 19:34:17,2024-10-13 19:34:17,NIH,,,,,,,HIV Prevention Trials Network|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Brazil|India|Kenya|Malawi|South Africa|Thailand|United States|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00075803,,2004-01-09,2013-02-22,,2022-12-06,2004-01-12,2004-01-13,ESTIMATED,2015-08-05,2015-09-04,ESTIMATED,,,,2022-12-06,2023-01-04,ACTUAL,2003-11,,2003-11-30,2022-12,2022-12-31,2007-09,ACTUAL,2007-09-30,2006-09,ACTUAL,2006-09-30,,INTERVENTIONAL,,,Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101),A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101),COMPLETED,,PHASE3,600,ACTUAL,Medical College of Wisconsin,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,,2024-10-13 10:52:51,2024-10-13 10:52:51,OTHER,,,,,,,"Blood and Marrow Transplant Clinical Trials Network|Medical College of Wisconsin|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)|National Marrow Donor Program",United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00076999,,2004-02-09,2011-06-27,,2014-04-25,2004-02-09,2004-02-10,ESTIMATED,2011-06-27,2011-07-25,ESTIMATED,,,,2014-04-25,2014-05-12,ESTIMATED,2003-11,,2003-11-30,2014-04,2014-04-30,,,,2010-06,ACTUAL,2010-06-30,,INTERVENTIONAL,,,Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children,"Multiple-dose, Open-label, Randomized, Safety and Pharmacokinetic Study of Tipranavir in Combination With Low-dose Ritonavir in HIV-infected Pediatric Patients",COMPLETED,,PHASE1,115,ACTUAL,Boehringer Ingelheim,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 17:28:56,2024-10-14 17:28:56,INDUSTRY,,,,,,,Boehringer Ingelheim,Argentina|Brazil|Canada|France|Germany|Italy|Mexico|Puerto Rico|Spain|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00077675,,2004-02-10,2009-12-02,,2019-01-14,2004-02-12,2004-02-13,ESTIMATED,2009-12-02,2010-01-11,ESTIMATED,,,,2019-01-14,2019-01-16,ACTUAL,2004-02,,2004-02-29,2019-01,2019-01-31,2004-09,ACTUAL,2004-09-30,2004-09,ACTUAL,2004-09-30,,INTERVENTIONAL,FAST2,,Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI),"A Phase 2, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Standard Therapy for Treatment of Complicated Gram-Positive Skin and Skin Structure Infections (Gram Positive cSSSI)",COMPLETED,,PHASE2,201,ACTUAL,Cumberland Pharmaceuticals,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 13:28:38,2024-10-13 13:28:38,INDUSTRY,,,,,,,Cumberland Pharmaceuticals,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00078403,,2004-02-24,2010-11-05,,2021-11-04,2004-02-24,2004-02-25,ESTIMATED,2011-03-30,2011-04-27,ESTIMATED,,,,2021-11-04,2021-11-08,ACTUAL,2004-07,,2004-07-31,2016-11,2016-11-30,2009-02,ACTUAL,2009-02-28,2007-05,ACTUAL,2007-05-31,,INTERVENTIONAL,,"All Arm A, B and C participants.",Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV),Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Coinfected Subjects (SLAM-C),COMPLETED,,PHASE2,333,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 18:11:05,2024-10-14 18:11:05,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00082628,,2004-05-13,2017-10-02,,2017-10-02,2004-05-14,2004-05-17,ESTIMATED,2017-10-02,2018-07-20,ACTUAL,,,,2017-10-02,2018-07-20,ACTUAL,2004-05-28,ACTUAL,2004-05-28,2017-09,2017-09-30,2005-09-28,ACTUAL,2005-09-28,2005-09-28,ACTUAL,2005-09-28,,INTERVENTIONAL,,The modified ITT Population (ITT) for Period I was defined as all subjects who had a baseline and at least one post-baseline efficacy measurement.,Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients,"A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS",COMPLETED,,PHASE3,326,ACTUAL,EMD Serono,,5,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 03:20:11,2024-10-14 03:20:11,INDUSTRY,,,,,,,EMD Serono,Canada|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00084136,,2004-06-07,2011-07-13,,2018-09-11,2004-06-07,2004-06-08,ESTIMATED,2011-07-13,2011-08-09,ESTIMATED,,,,2018-09-11,2018-10-10,ACTUAL,2005-05,,2005-05-31,2018-09,2018-09-30,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,INTERVENTIONAL,PEARLS,,"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","Randomized, Open-Label Evaluation of Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combinations for Initial Treatment of HIV-1 Infected Persons From Resource-Limited Settings (PEARLS) Trial",COMPLETED,,PHASE4,1571,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 00:43:25,2024-10-13 00:43:25,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Haiti|India|Malawi|Peru|Puerto Rico|South Africa|Thailand|United States|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00084149,,2004-06-07,2016-01-05,,2021-11-02,2004-06-07,2004-06-08,ESTIMATED,2018-08-14,2018-09-13,ACTUAL,,,,2021-11-02,2021-11-04,ACTUAL,2004-02,,2004-02-29,2018-08,2018-08-31,2008-01,ACTUAL,2008-01-31,2008-01,ACTUAL,2008-01-31,,INTERVENTIONAL,,,"Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV","A Randomized Phase II Study of the Safety, Immunologic, and Virologic Effects of Cyclosporine A in Conjunction With Trizivir(R) and Kaletra(R) Versus Trizivir(R) and Kaletra(R) Alone During Primary HIV-1 Infection",COMPLETED,,PHASE2,54,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:09:29,2024-10-15 01:09:29,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Gastrointestinal disorders
NCT00085917,,2004-06-16,2010-04-12,,2011-06-21,2004-06-16,2004-06-17,ESTIMATED,2011-05-13,2011-06-15,ESTIMATED,,,,2011-06-21,2011-06-27,ESTIMATED,2004-06,,2004-06-30,2011-06,2011-06-30,2008-11,ACTUAL,2008-11-30,2008-11,ACTUAL,2008-11-30,,INTERVENTIONAL,PIFNPK,,Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients,A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Twice-Weekly Peginterferon Alpha 2a and Ribavirin Induction Therapy for Chronic Hepatitis C in Patients Who Are Coinfected With HIV-1,COMPLETED,,PHASE2,29,ACTUAL,National Institutes of Health Clinical Center (CC),Small number of enrolled participants,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 01:11:36,2024-10-14 01:11:36,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Blood and lymphatic system disorders|General disorders|Hepatobiliary disorders|Psychiatric disorders
NCT00087490,,2004-07-09,2012-06-29,,2012-06-29,2004-07-12,2004-07-13,ESTIMATED,2012-06-29,2012-08-08,ESTIMATED,,,,2012-06-29,2012-08-08,ESTIMATED,2004-10,,2004-10-31,2012-06,2012-06-30,2007-07,ACTUAL,2007-07-31,2007-07,ACTUAL,2007-07-31,,INTERVENTIONAL,,,Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA),Linezolid in the Treatment of Subjects With Complicated Skin and Soft Tissue Infections Proven to be Due to Methicillin-Resistant Staphylococcus Aureus,COMPLETED,,PHASE4,1077,ACTUAL,Pfizer,"Comparing duration of intravenous (IV) therapy for linezolid (LZD) and vancomycin (VAN) in study, participants in LZD group had option to switch to oral therapy while those in VAN group had to remain on IV therapy until completion of study treatment.",,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 11:30:46,2024-10-13 11:30:46,INDUSTRY,,,,,,,Pfizer,Argentina|Belgium|Brazil|Chile|Colombia|Germany|Ireland|Italy|Malaysia|Mexico|Portugal|Russian Federation|Singapore|South Africa|Spain|United Kingdom|United States|Venezuela,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00089505,,2004-08-05,2010-08-30,,2018-09-11,2004-08-05,2004-08-06,ESTIMATED,2011-01-07,2011-02-04,ESTIMATED,,,,2018-09-11,2018-10-12,ACTUAL,2006-11,,2006-11-30,2018-09,2018-09-30,2011-02,ACTUAL,2011-02-28,2010-08,ACTUAL,2010-08-31,,INTERVENTIONAL,OCTANE,,NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission,Optimal Combination Therapy After Nevirapine Exposure,COMPLETED,,PHASE3,745,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:52:02,2024-10-14 02:52:02,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Kenya|Malawi|South Africa|Uganda|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00089583,,2004-08-06,2012-02-24,,2017-01-20,2004-08-09,2004-08-10,ESTIMATED,2012-05-17,2012-06-21,ESTIMATED,,,,2017-01-20,2017-03-07,ACTUAL,2004-07,,2004-07-31,2017-01,2017-01-31,2013-07,ACTUAL,2013-07-31,2011-03,ACTUAL,2011-03-31,,INTERVENTIONAL,,,"48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection","A 48 Week, Phase II, Non-Comparative, Open-label, Multi-Cohort, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GW433908/Ritonavir BID When Administered to HIV-1 Infected, PI-Naïve and Experienced, Pediatric Subjects, 2 to 18 Years Old and of GW433908 BID Administered to PI-Naïve, Pediatric Subjects 2 to < 6 Years Old",COMPLETED,,PHASE2,110,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 21:10:58,2024-10-14 21:10:58,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Belgium|Canada|Chile|Romania|Russian Federation|South Africa|Spain|United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00090220,,2004-08-25,2009-10-30,2009-10-29,2017-03-23,2004-08-26,2004-08-27,ESTIMATED,2010-01-05,2010-02-01,ESTIMATED,2009-10-29,2009-11-01,ESTIMATED,2017-03-23,2017-04-21,ACTUAL,2004-06-16,ACTUAL,2004-06-16,2017-03,2017-03-31,2015-11-12,ACTUAL,2015-11-12,2009-05-21,ACTUAL,2009-05-21,,INTERVENTIONAL,,All randomized participants,"A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)","Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study",COMPLETED,,PHASE3,3819,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 15:34:55,2024-10-14 15:34:55,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00090233,,2004-08-25,2009-06-29,,2015-09-18,2004-08-26,2004-08-27,ESTIMATED,2011-04-06,2011-05-05,ESTIMATED,,,,2015-09-18,2015-10-05,ESTIMATED,2001-01,,2001-01-31,2015-09,2015-09-30,2004-10,ACTUAL,2004-10-31,2004-10,ACTUAL,2004-10-31,,INTERVENTIONAL,,,Rotavirus Efficacy and Safety Trial (REST)(V260-006),"Safety and Efficacy of Pentavalent (G1, G2, G3, G4 , and P1) Human-Bovine Reassortant Rotavirus Vaccine in Healthy Infants",COMPLETED,,PHASE3,69274,ACTUAL,Merck Sharp & Dohme LLC,"70,301 participants randomized, 69,274 evaluated, when DSMB first recommended ending enrollment.",2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 23:41:58,2024-10-14 23:41:58,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00090766,,2004-09-03,2016-06-24,,2016-09-14,2004-09-03,2004-09-06,ESTIMATED,2016-09-14,2016-10-31,ESTIMATED,,,,2016-09-14,2016-10-31,ESTIMATED,2004-05,,2004-05-31,2016-03,2016-03-31,2005-05,ACTUAL,2005-05-31,2005-05,ACTUAL,2005-05-31,,INTERVENTIONAL,,Safety population included all participants who received at least one dose of valganciclovir,A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients,Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients,COMPLETED,,PHASE2/PHASE3,63,ACTUAL,Hoffmann-La Roche,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 02:27:29,2024-10-14 02:27:29,INDUSTRY,,,,,,,Hoffmann-La Roche,Australia|Canada|France|Germany|Mexico|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00091819,,2004-09-17,2009-11-03,,2019-01-14,2004-09-20,2004-09-21,ESTIMATED,2009-11-03,2009-12-08,ESTIMATED,,,,2019-01-14,2019-01-16,ACTUAL,2005-01,,2005-01-31,2019-01,2019-01-31,2006-06,ACTUAL,2006-06-30,2006-06,ACTUAL,2006-06-30,,INTERVENTIONAL,ATLAS1,,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,"A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus",COMPLETED,,PHASE3,862,ACTUAL,Cumberland Pharmaceuticals,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 19:29:55,2024-10-14 19:29:55,INDUSTRY,,,,,,,Cumberland Pharmaceuticals,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00092443,,2004-09-22,2009-05-19,,2015-09-11,2004-09-24,2004-09-27,ESTIMATED,2009-05-19,2009-07-10,ESTIMATED,,,,2015-09-11,2015-09-14,ESTIMATED,2002-09,,2002-09-30,2015-09,2015-09-30,2004-06,ACTUAL,2004-06-30,2004-06,ACTUAL,2004-06-30,,INTERVENTIONAL,,,Dose Confirmation Efficacy Study (V260-007),"Study of the Efficacy, Safety, and Immunogenicity of V260 at Expiry",COMPLETED,,PHASE3,1312,ACTUAL,Merck Sharp & Dohme LLC,Safety has been reported in the literature.,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 00:37:39,2024-10-13 00:37:39,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00092547,,2004-09-23,2009-11-03,,2018-01-22,2004-09-27,2004-09-28,ESTIMATED,2010-04-09,2010-05-04,ESTIMATED,,,,2018-01-22,2018-02-20,ACTUAL,2003-10-08,ACTUAL,2003-10-08,2018-01,2018-01-31,2015-06-01,ACTUAL,2015-06-01,2005-11-03,ACTUAL,2005-11-03,,INTERVENTIONAL,,,A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018),"A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study).",COMPLETED,,PHASE3,1781,ACTUAL,Merck Sharp & Dohme LLC,"The difference between the prior and final data is a minor change in the definition of the per-protocol immunogenicity population, which was applied down to the base study. Also, protocol violators were identified and excluded from the analysis.",3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 23:33:16,2024-10-13 23:33:16,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00095212,,2004-11-01,2010-01-21,,2010-04-09,2004-11-01,2004-11-02,ESTIMATED,2010-03-01,2010-03-15,ESTIMATED,,,,2010-04-09,2010-04-14,ESTIMATED,2004-09,,2004-09-30,2010-04,2010-04-30,2009-02,ACTUAL,2009-02-28,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,,,Androgen Effects in HIV-infected Women,Androgen Effects in HIV-infected Women,COMPLETED,,NA,25,ACTUAL,Massachusetts General Hospital,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 08:23:13,2024-10-14 08:23:13,OTHER,,,,,,,Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),United States,"Ear and labyrinth disorders|Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT00098306,,2004-12-06,2012-04-02,,2012-04-02,2004-12-06,2004-12-07,ESTIMATED,2012-04-02,2012-04-27,ESTIMATED,,,,2012-04-02,2012-04-27,ESTIMATED,2004-11,,2004-11-30,2012-04,2012-04-30,2011-04,ACTUAL,2011-04-30,2007-04,ACTUAL,2007-04-30,,INTERVENTIONAL,MOTIVATE 1,,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects.",COMPLETED,,PHASE2/PHASE3,601,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:15:10,2024-10-15 01:15:10,INDUSTRY,,,,,,,Pfizer|ViiV Healthcare,Canada|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00098722,,2004-12-07,2012-04-16,,2012-04-16,2004-12-07,2004-12-08,ESTIMATED,2012-04-16,2012-05-16,ESTIMATED,,,,2012-04-16,2012-05-16,ESTIMATED,2004-12,,2004-12-31,2012-04,2012-04-30,2011-04,ACTUAL,2011-04-30,2007-04,ACTUAL,2007-04-30,,INTERVENTIONAL,MOTIVATE 2,,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects",COMPLETED,,PHASE2/PHASE3,474,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 00:18:36,2024-10-15 00:18:36,INDUSTRY,,,,,,,Pfizer|ViiV Healthcare,Australia|Belgium|Canada|France|Germany|Italy|Netherlands|Poland|Spain|Sweden|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00098748,,2004-12-07,2010-03-25,,2010-11-19,2004-12-07,2004-12-08,ESTIMATED,2010-10-14,2010-10-21,ESTIMATED,,,,2010-11-19,2010-12-07,ESTIMATED,2004-11,,2004-11-30,2010-11,2010-11-30,2009-04,ACTUAL,2009-04-30,2005-12,ACTUAL,2005-12-31,,INTERVENTIONAL,,,"Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects","A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced, Non CCR5-Tropic HIV-1 Infected Subjects",COMPLETED,,PHASE2/PHASE3,190,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 23:29:48,2024-10-14 23:29:48,INDUSTRY,,,,,,,Pfizer|ViiV Healthcare,Australia|Belgium|Canada|Germany|Netherlands|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00099359,,2004-12-10,2012-04-25,,2012-10-26,2004-12-10,2004-12-13,ESTIMATED,2012-10-26,2012-12-04,ESTIMATED,,,,2012-10-26,2012-12-04,ESTIMATED,2004-02,,2004-02-29,2011-02,2011-02-28,2011-02,ACTUAL,2011-02-28,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,,,Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission,Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission,COMPLETED,,PHASE3,1735,ACTUAL,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 00:07:27,2024-10-14 00:07:27,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Brazil|Puerto Rico|South Africa|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00099632,,2004-12-17,2011-12-06,,2021-11-02,2004-12-17,2004-12-20,ESTIMATED,2012-01-18,2012-01-19,ESTIMATED,,,,2021-11-02,2021-11-04,ACTUAL,2006-03,,2006-03-31,2019-01,2019-01-31,2011-11,ACTUAL,2011-11-30,2010-04,ACTUAL,2010-04-30,,INTERVENTIONAL,,,Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy,Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine,COMPLETED,,PHASE2,484,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,6,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:03:12,2024-10-14 17:03:12,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Haiti|India|Malawi|South Africa|Tanzania|Uganda,"Blood and lymphatic system disorders|Injury, poisoning and procedural complications|Pregnancy, puerperium and perinatal conditions"
NCT00100048,,2004-12-22,2010-01-21,,2015-09-04,2004-12-22,2004-12-23,ESTIMATED,2010-03-25,2010-03-29,ESTIMATED,,,,2015-09-04,2015-09-09,ESTIMATED,2005-01,,2005-01-31,2015-09,2015-09-30,2010-07,ACTUAL,2010-07-31,2006-10,ACTUAL,2006-10-31,,INTERVENTIONAL,,,A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED),"Multicenter, Double-Blind, Randomized, Dose Ranging Study to Compare the Safety and Activity of MK0518 Plus Tenofovir and Lamivudine (3TC) Versus Efavirenz Plus Tenofovir and Lamivudine (3TC) in ART-Naive, HIV-Infected Patients",COMPLETED,,PHASE2,206,ACTUAL,Merck Sharp & Dohme LLC,,10,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 21:56:26,2024-10-13 21:56:26,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Canada|Chile|Colombia|Peru|Puerto Rico|Thailand|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00100698,,2005-01-04,2010-04-09,,2010-07-22,2005-01-04,2005-01-05,ESTIMATED,2010-07-19,2010-07-22,ESTIMATED,,,,2010-07-22,2010-07-27,ESTIMATED,2004-01,,2004-01-31,2010-07,2010-07-31,2009-04,ACTUAL,2009-04-30,2007-10,ACTUAL,2007-10-31,,INTERVENTIONAL,,,Physiologic Growth Hormone Effects in HIV Lipodystrophy,Physiologic Growth Hormone Effects in HIV Lipodystrophy,COMPLETED,,NA,56,ACTUAL,Massachusetts General Hospital,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 13:39:19,2024-10-13 13:39:19,OTHER,,,,,,,Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),United States,"Endocrine disorders|Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT00102960,,2005-02-04,2017-01-17,,2021-10-29,2005-02-04,2005-02-07,ESTIMATED,2018-11-28,2018-11-30,ACTUAL,,,,2021-10-29,2021-11-02,ACTUAL,2005-07,,2005-07-31,2021-10,2021-10-31,2013-01,ACTUAL,2013-01-31,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,,Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth,"A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting",COMPLETED,,PHASE3,377,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"The CHER study did not include an early continuous therapy Arm, had not been powered to test for differences between early therapy 40 weeks vs. 96 weeks and never assessed in-utero vs. intrapartum infections.",3,,,FALSE,,,,TRUE,,,,,,,,,,,NO,Data may be made available through a formal request to the protocol team,2024-10-13 19:40:01,2024-10-13 19:40:01,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00105079,,2005-03-04,2011-03-29,,2011-09-23,2005-03-04,2005-03-07,ESTIMATED,2011-09-23,2011-11-02,ESTIMATED,,,,2011-09-23,2011-11-02,ESTIMATED,2005-04,,2005-04-30,2011-09,2011-09-30,2008-07,ACTUAL,2008-07-31,2007-08,ACTUAL,2007-08-31,,INTERVENTIONAL,,,GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection,"A 48-week, Randomized, Open-label, 2-arm Study to Compare the Efficacy of Saquinavir/Ritonavir Twice Daily (BID) Plus Emtricitabine/Tenofovir Once Daily (QD) Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients (GEMINI Study)",COMPLETED,,PHASE3,337,ACTUAL,Hoffmann-La Roche,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 14:21:02,2024-10-14 14:21:02,INDUSTRY,,,,,,,Hoffmann-La Roche,Canada|France|Puerto Rico|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Social circumstances|Vascular disorders"
NCT00105157,,2005-03-08,2009-09-14,,2015-12-03,2005-03-08,2005-03-09,ESTIMATED,2010-03-29,2010-04-12,ESTIMATED,,,,2015-12-03,2015-12-04,ESTIMATED,2005-03,,2005-03-31,2015-12,2015-12-31,2009-07,ACTUAL,2009-07-31,2006-10,ACTUAL,2006-10-31,,INTERVENTIONAL,,,Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED),"Multicenter Study to Evaluate the Safety and Efficacy of MK0518 in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance",COMPLETED,,PHASE2,179,ACTUAL,Merck Sharp & Dohme LLC,"Due to a 3:1 randomization of MK-0518 to placebo and more discontinuations for placebo in the doubleblind phase, exposure for MK-0518 and placebo differs significantly with follow-up times of 336.3 and 39.7 patient-years, respectively.",4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 10:03:49,2024-10-14 10:03:49,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Belgium|Brazil|Denmark|France|Germany|Italy|Malaysia|Mexico|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00106964,,2005-04-01,2012-10-26,,2017-02-27,2005-04-01,2005-04-04,ESTIMATED,2013-04-30,2013-06-28,ESTIMATED,,,,2017-02-27,2017-03-29,ACTUAL,2004-01,,2004-01-31,2016-02,2016-02-29,2009-06,ACTUAL,2009-06-30,2008-01,ACTUAL,2008-01-31,,INTERVENTIONAL,,,Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth,"A Randomized, Open-Label Trial of Three Hepatitis B Vaccination Schemas in HIV-Positive Youth",COMPLETED,,PHASE4,371,ACTUAL,"University of North Carolina, Chapel Hill",,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 12:34:19,2024-10-14 12:34:19,OTHER,,,,,,,"National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute on Drug Abuse (NIDA)|University of North Carolina, Chapel Hill",Brazil|South Africa|United States,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Nervous system disorders
NCT00107978,,2005-04-11,2009-11-03,,2019-01-14,2005-04-11,2005-04-12,ESTIMATED,2010-01-08,2010-02-01,ESTIMATED,,,,2019-01-14,2019-01-16,ACTUAL,2005-02,,2005-02-28,2019-01,2019-01-31,2006-05,ACTUAL,2006-05-31,2006-05,ACTUAL,2006-05-31,,INTERVENTIONAL,ATLAS2,,Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus,"A Phase 3, Randomized, Double-Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus",COMPLETED,,PHASE3,1035,ACTUAL,Cumberland Pharmaceuticals,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:55:21,2024-10-13 15:55:21,INDUSTRY,,,,,,,Cumberland Pharmaceuticals,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00108160,,2005-04-14,2013-12-16,,2014-03-20,2005-04-14,2005-04-15,ESTIMATED,2013-12-16,2014-02-04,ESTIMATED,,,,2014-03-20,2014-04-16,ESTIMATED,2005-04,,2005-04-30,2014-03,2014-03-31,2012-08,ACTUAL,2012-08-31,2012-08,ACTUAL,2012-08-31,,INTERVENTIONAL,,,Preventing Staphylococcal (Staph) Infection,Intermittent Mupirocin to Prevent Staphylococcal Infection,COMPLETED,,PHASE4,146,ACTUAL,VA Office of Research and Development,"The study is underpowered to detect differences between the two treatment arms. We achieved only 75% of target enrollment, and 41.1% dropped out before reaching a primary endpoint. Our re-infection rate was also lower than anticipated (14.4%).",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 06:01:52,2024-10-13 06:01:52,FED,,,,,,,Saint Joseph Mercy Health System|University of Michigan|US Department of Veterans Affairs,United States,"Cardiac disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
NCT00108862,,2005-04-19,2011-09-27,,2018-09-11,2005-04-19,2005-04-20,ESTIMATED,2011-09-27,2011-11-02,ESTIMATED,,,,2018-09-11,2018-10-11,ACTUAL,2006-08,,2006-08-31,2018-09,2018-09-30,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,STRIDE,,Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis,A Strategy Study of Immediate Versus Deferred Initiation of Antiretroviral Therapy for AIDS Disease-Free Survival in HIV-Infected Persons Treated for Tuberculosis With CD4 Less Than 250 Cells/mm^3,COMPLETED,,PHASE4,809,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:36:26,2024-10-15 02:36:26,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Brazil|Congo|Haiti|India|Kenya|Malawi|Peru|South Africa|Thailand|Uganda|United States|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00109590,,2005-04-29,2012-06-26,2010-01-20,2021-11-03,2005-04-29,2005-05-02,ESTIMATED,2012-11-05,2012-11-06,ESTIMATED,2010-01-20,2010-01-22,ESTIMATED,2021-11-03,2021-11-05,ACTUAL,2006-06,,2006-06-30,2019-01,2019-01-31,2009-11,ACTUAL,2009-11-30,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth,Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Didanosine/Lopinavir/Ritonavir,COMPLETED,,PHASE2,175,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 01:00:44,2024-10-13 01:00:44,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Thailand,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00110591,,2005-05-10,2023-02-15,,2023-02-15,2005-05-10,2005-05-11,ESTIMATED,2023-02-15,2023-03-14,ACTUAL,,,,2023-02-15,2023-03-14,ACTUAL,2004-04-16,,2004-04-16,2023-02,2023-02-28,2008-03-31,ACTUAL,2008-03-31,2005-11-07,ACTUAL,2005-11-07,,INTERVENTIONAL,,,Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers,"A Phase I, Randomized, Double Blind, Placebo Controlled, Single-Dose, Rising Dose Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO 140 in Healthy Volunteers",COMPLETED,,PHASE1,20,ACTUAL,"CytoDyn, Inc.",,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 02:07:38,2024-10-14 02:07:38,INDUSTRY,,,,,,,"CytoDyn, Inc.",United States,"Cardiac disorders|Gastrointestinal disorders|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00110812,,2005-05-13,2012-12-12,2010-01-30,2021-11-02,2005-05-13,2005-05-16,ESTIMATED,2014-04-07,2014-05-12,ESTIMATED,2010-01-30,2010-02-02,ESTIMATED,2021-11-02,2021-11-04,ACTUAL,2005-09,,2005-09-30,2014-04,2014-04-30,2011-02,ACTUAL,2011-02-28,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,STALWART,,Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People,"STALWART: A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 With and Without Concomitant Antiretroviral Therapy in Patients With HIV-1 Infection and CD4+ Cell Counts of 300 Cells/mm3 or More",COMPLETED,,PHASE2,267,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"All randomized patients were followed through 28 Feb 2009. A subset of 222 consenting patients were followed 2 additional years, through 28 Feb 2011.",3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:52:22,2024-10-13 06:52:22,NIH,,,,,,,Chiron Corporation|National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Australia|Chile|Gambia|Germany|Ireland|Italy|Morocco|Poland|Portugal|Seychelles|Spain|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00112047,,2005-05-27,2010-06-22,,2010-10-11,2005-05-27,2005-05-30,ESTIMATED,2010-10-11,2010-10-13,ESTIMATED,,,,2010-10-11,2010-10-13,ESTIMATED,2003-07,,2003-07-31,2010-10,2010-10-31,2009-06,ACTUAL,2009-06-30,2005-02,ACTUAL,2005-02-28,,INTERVENTIONAL,,,Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects,"A Phase 3, Randomized, Multicenter Study of the Treatment of Antiretroviral-Naive HIV-1 Infected Subjects Comparing Tenofovir Disoproxil Fumarate and Emtricitabine in Combination With Efavirenz vs Combivir (Lamivudine/Zidovudine) and Efavirenz",COMPLETED,,PHASE3,517,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:07:20,2024-10-13 18:07:20,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00116844,,2005-06-30,2017-03-16,,2017-08-02,2005-06-30,2005-07-01,ESTIMATED,2017-08-02,2018-02-12,ACTUAL,,,,2017-08-02,2018-02-12,ACTUAL,2005-03-29,ACTUAL,2005-03-29,2017-08,2017-08-31,2006-01-10,ACTUAL,2006-01-10,2006-01-10,ACTUAL,2006-01-10,,INTERVENTIONAL,,The ITTE population was defined as consisting of all participants who received at least one dose of investigational product and at least one safety and/or efficacy evaluation.,VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.,Valacyclovir for the Suppression of HSV-2 Viral Shedding in HSV-2 Seropositive Individuals With No History of Symptomatic GH,COMPLETED,,PHASE4,73,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 09:33:05,2024-10-13 09:33:05,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00118898,,2005-07-07,2010-01-08,,2018-09-11,2005-07-07,2005-07-12,ESTIMATED,2010-12-07,2011-01-10,ESTIMATED,,,,2018-09-11,2018-10-12,ACTUAL,2005-09,,2005-09-30,2018-09,2018-09-30,2009-11,ACTUAL,2009-11-30,2009-11,ACTUAL,2009-11-30,,INTERVENTIONAL,,,Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults,"A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects",COMPLETED,,PHASE3,1864,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,"HIV-1 drug resistance testing and HLA-B\*5701 testing were not standard of care during enrollment. EFV and RTV-boosted ATV were open-label, and blinded FTC/TDF vs. ABC/3TC were unblinded in the \>=100,000 cp/mL screening viral load stratum Feb 2008.",4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:27:07,2024-10-13 09:27:07,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00119106,,2005-07-08,2015-07-28,,2021-01-27,2005-07-11,2005-07-13,ESTIMATED,2021-01-25,2021-01-27,ACTUAL,,,,2021-01-27,2021-02-10,ACTUAL,2005-06,,2005-06-30,2015-02,2015-02-28,2014-10,ACTUAL,2014-10-31,2013-07,ACTUAL,2013-07-31,,INTERVENTIONAL,,,"Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand","Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection Among Injection Drug Users in Bangkok, Thailand",COMPLETED,,PHASE2/PHASE3,2413,ACTUAL,Centers for Disease Control and Prevention,Participants could have under-reported stigmatised behaviours such as injecting drugs.30,2,,,FALSE,,,,TRUE,,,,,,,,Data available after 2014,"Concept sheets are reviewed and approved, modified, or declined by research team.",,YES,"Concept sheets are reviewed and approved, modified, or declined by research team.",2024-10-13 03:46:56,2024-10-13 03:46:56,FED,,,,,,,"Bangkok Metropolitan Administration Medical College and Vajira Hospital|Centers for Disease Control and Prevention|Ministry of Health, Thailand",Thailand,Investigations|Renal and urinary disorders
NCT00119379,,2005-07-11,2016-12-08,,2017-05-15,2005-07-11,2005-07-13,ESTIMATED,2017-04-04,2017-05-12,ACTUAL,,,,2017-05-15,2017-06-07,ACTUAL,2005-04,,2005-04-30,2017-05,2017-05-31,2008-10,ACTUAL,2008-10-31,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults,Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy,COMPLETED,,PHASE2,50,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),Small sample size; Lack of control arm where tNRTI therapy was continued without any intervention; Adherence measured by sachet/pill count method.,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 08:23:13,2024-10-14 08:23:13,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00119405,,2005-07-11,2016-06-13,,2017-02-10,2005-07-11,2005-07-13,ESTIMATED,2017-02-10,2017-03-30,ACTUAL,,,,2017-02-10,2017-03-30,ACTUAL,2005-04,,2005-04-30,2007-12,2007-12-31,2010-11,ACTUAL,2010-11-30,2010-11,ACTUAL,2010-11-30,,OBSERVATIONAL,,,Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs),Role of Mitochondria in the Development of HIV Atrophy,COMPLETED,,,18,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,,,,FALSE,,,,FALSE,,,,,,SAMPLES_WITH_DNA,Fat and Blood for mitochindrial DNA and different nuclear genes that regulate fat and lipid metabolism,,,,,,2024-10-13 09:21:12,2024-10-13 09:21:12,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Hepatobiliary disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00122681,,2005-07-20,2009-11-30,,2018-07-02,2005-07-20,2005-07-22,ESTIMATED,2009-12-16,2010-01-20,ESTIMATED,,,,2018-07-02,2018-08-20,ACTUAL,2004-05-06,ACTUAL,2004-05-06,2017-08,2017-08-31,2009-11-26,ACTUAL,2009-11-26,2006-11-03,ACTUAL,2006-11-03,,INTERVENTIONAL,,,Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18,"A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age.",COMPLETED,,PHASE3,18729,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 19:28:19,2024-10-13 19:28:19,INDUSTRY,,,,,,,GlaxoSmithKline,Australia|Belgium|Brazil|Canada|Finland|Germany|Italy|Mexico|Philippines|Puerto Rico|Spain|Taiwan|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00128180,,2005-08-05,2011-12-05,,2014-12-05,2005-08-05,2005-08-09,ESTIMATED,2012-07-09,2012-07-10,ESTIMATED,,,,2014-12-05,2014-12-24,ESTIMATED,2003-01,,2003-01-31,2014-12,2014-12-31,2011-10,ACTUAL,2011-10-31,2010-12,ACTUAL,2010-12-31,,INTERVENTIONAL,,,Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome,"A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Methylprednisolone as a Treatment for Presumed Hantavirus Cardiopulmonary Syndrome",COMPLETED,,PHASE2,66,ACTUAL,University of New Mexico,"While the study reached the target accrual of 60 confirmed cases, it was not powered to detect a difference in mortality. Higher disease severity in the placebo group at entry complicated both the efficacy and safety analyses.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:03:01,2024-10-13 07:03:01,OTHER,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|University of New Mexico,Chile|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00128219,,2005-08-05,2009-08-03,,2015-01-15,2005-08-05,2005-08-09,ESTIMATED,2010-07-01,2010-07-05,ESTIMATED,,,,2015-01-15,2015-01-27,ESTIMATED,2003-07,,2003-07-31,2009-08,2009-08-31,2008-12,ACTUAL,2008-12-31,2008-12,ACTUAL,2008-12-31,,INTERVENTIONAL,,,Prevention of GBS Colonization Via Immunity,"A Phase II Randomized, Double-Blinded, Comparative Clinical Trial for a Group B Streptococcus Serotype III-Tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Acquisition of GBS Type III",COMPLETED,,PHASE2,667,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 10:27:59,2024-10-14 10:27:59,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00129766,,2005-08-10,2013-06-21,,2013-06-21,2005-08-10,2005-08-12,ESTIMATED,2013-06-21,2013-08-28,ESTIMATED,,,,2013-06-21,2013-08-28,ESTIMATED,2004-11,,2004-11-30,2013-06,2013-06-30,2006-05,ACTUAL,2006-05-31,2006-05,ACTUAL,2006-05-31,,INTERVENTIONAL,,,Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children,"A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children",COMPLETED,,PHASE3,6635,ACTUAL,MedImmune LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:24:49,2024-10-13 20:24:49,INDUSTRY,,,,,,,MedImmune LLC,Argentina|Australia|Austria|Brazil|Bulgaria|Canada|Chile|Czech Republic|Denmark|France|Germany|Greece|Hungary|Iceland|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Turkey|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00130286,,2005-08-12,2013-12-16,,2014-02-10,2005-08-12,2005-08-15,ESTIMATED,2014-02-10,2014-02-13,ESTIMATED,,,,2014-02-10,2014-02-13,ESTIMATED,2005-03,,2005-03-31,2014-02,2014-02-28,2010-08,ACTUAL,2010-08-31,2010-08,ACTUAL,2010-08-31,,INTERVENTIONAL,,,Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance,"Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance",COMPLETED,,PHASE1/PHASE2,77,ACTUAL,Weill Medical College of Cornell University,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 21:34:22,2024-10-13 21:34:22,OTHER,,,,,,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Weill Medical College of Cornell University,United States,"Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders"
NCT00130832,,2005-08-12,2009-08-07,,2015-03-12,2005-08-12,2005-08-16,ESTIMATED,2010-08-17,2010-09-09,ESTIMATED,,,,2015-03-12,2015-04-01,ESTIMATED,2005-10,,2005-10-31,2015-03,2015-03-31,2006-07,ACTUAL,2006-07-31,2006-07,ACTUAL,2006-07-31,,INTERVENTIONAL,,,Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED),Safety and Immunogenicity of Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants,COMPLETED,,PHASE3,735,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 21:22:54,2024-10-13 21:22:54,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Brazil|Costa Rica|Guatemala|Mexico,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00131677,,2005-08-17,2013-08-08,,2014-01-22,2005-08-17,2005-08-19,ESTIMATED,2014-01-22,2014-03-10,ESTIMATED,,,,2014-01-22,2014-03-10,ESTIMATED,2005-02,,2005-02-28,2013-08,2013-08-31,2009-08,ACTUAL,2009-08-31,2009-08,ACTUAL,2009-08-31,,INTERVENTIONAL,,"400 participants enrolled (200 in San Francisco, 121 in Atlanta, and 79 in Boston). 201 were randomized to TDF and 199 to placebo. Participants were distributed similarly in terms of age, ethnicity, education, no. male partners in previous 3 mo., and no. of unprotected anal sexual contacts within the previous 3 mo.",Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men,Phase II Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men,COMPLETED,,PHASE2,400,ACTUAL,Centers for Disease Control and Prevention,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 01:11:36,2024-10-14 01:11:36,FED,,,,,,,AIDS Research Consortium of Atlanta|Centers for Disease Control and Prevention|San Francisco Department of Public Health,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00143312,,2005-08-31,2009-04-02,,2009-09-23,2005-09-01,2005-09-02,ESTIMATED,2009-04-02,2009-06-01,ESTIMATED,,,,2009-09-23,2009-10-06,ESTIMATED,2005-02,,2005-02-28,2009-09,2009-09-30,2008-04,ACTUAL,2008-04-30,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,VOSIFI,,Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants,"Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).",COMPLETED,,PHASE4,45,ACTUAL,Pfizer,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:19:01,2024-10-13 20:19:01,INDUSTRY,,,,,,,European Society for Blood and Marrow Transplantation|Pfizer,Belgium|France|Germany|Portugal|Spain|Sweden|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00144170,,2005-09-02,2009-09-11,,2014-06-23,2005-09-02,2005-09-05,ESTIMATED,2009-11-17,2009-12-23,ESTIMATED,,,,2014-06-23,2014-07-02,ESTIMATED,2003-02,,2003-02-28,2014-04,2014-04-30,,,,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2),"Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) Versus Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients (RESIST 2: Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir)",COMPLETED,,PHASE3,882,ACTUAL,Boehringer Ingelheim,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 22:31:13,2024-10-13 22:31:13,INDUSTRY,,,,,,,Boehringer Ingelheim,Argentina|Austria|Belgium|Brazil|Denmark|France|Germany|Greece|Ireland|Italy|Mexico|Netherlands|Portugal|Spain|Sweden|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00145795,,2005-09-01,2012-10-24,,2022-05-23,2005-09-02,2005-09-05,ESTIMATED,2013-08-23,2013-08-27,ESTIMATED,,,,2022-05-23,2022-06-15,ACTUAL,2004-04,,2004-04-30,2022-05,2022-05-31,2009-12,ACTUAL,2009-12-31,2009-06,ACTUAL,2009-06-30,,INTERVENTIONAL,,,A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment,Randomized Trial of a Switch to a Kaletra + Current Dual Nucleoside Reverse Transcriptase Inhibitor (NRTI) Backbone Versus Continuation of the Current Regimen in Patients With Poor Immune Responses to Highly Active Antiretroviral Therapy (HAART) in Patients With Complete Viral Suppression: A Pilot Study,COMPLETED,,PHASE4,20,ACTUAL,University of Chicago,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 05:14:37,2024-10-14 05:14:37,OTHER,,,,,,,Abbott|University of Chicago,United States,Gastrointestinal disorders
NCT00146328,,2005-09-05,2009-05-26,,2014-01-31,2005-09-05,2005-09-07,ESTIMATED,2009-05-26,2009-07-16,ESTIMATED,,,,2014-01-31,2014-03-06,ESTIMATED,2001-04,,2001-04-30,2014-01,2014-01-31,,,,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,,,Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects,A Long Term Open Label Rollover Trial Assessing the Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV-1 Infected Subjects,COMPLETED,,PHASE2/PHASE3,997,ACTUAL,Boehringer Ingelheim,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 19:22:39,2024-10-13 19:22:39,INDUSTRY,,,,,,,Boehringer Ingelheim,Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|France|Germany|Greece|Italy|Mexico|Netherlands|Portugal|Puerto Rico|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00149890,,2005-09-06,2011-01-20,,2011-08-17,2005-09-06,2005-09-08,ESTIMATED,2011-08-17,2011-09-22,ESTIMATED,,,,2011-08-17,2011-09-22,ESTIMATED,2004-03,,2004-03-31,2011-08,2011-08-31,2009-03,ACTUAL,2009-03-31,2009-03,ACTUAL,2009-03-31,,INTERVENTIONAL,,,"Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids","A Multicenter, Open-label, Randomized, Two Arm Study to Investigate the Efficacy and Safety of a Therapy Avoiding Intraoperative Steroids in Combination With Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients",COMPLETED,,PHASE3,77,ACTUAL,Novartis,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 02:07:38,2024-10-14 02:07:38,INDUSTRY,,,,,,,Novartis,Germany|Switzerland,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00150345,,2005-09-06,2010-04-05,,2012-01-17,2005-09-06,2005-09-08,ESTIMATED,2010-07-22,2010-08-18,ESTIMATED,,,,2012-01-17,2012-01-19,ESTIMATED,2005-01,,2005-01-31,2012-01,2012-01-31,2009-04,ACTUAL,2009-04-30,2009-04,ACTUAL,2009-04-30,,INTERVENTIONAL,IDEA,,Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients,Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In High-Risk Neutropenic Patients With Fever And A Positive Panfungal Polymerase Chain Reaction Assay (IDEA Study),COMPLETED,,PHASE3,147,ACTUAL,Pfizer,One participant in the Immediate Voriconazole treatment group was incorrectly included in the original Primary efficacy analysis and has now been excluded; IFI was identified on the day study treatment started (not prior to study treatment).,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 01:54:24,2024-10-14 01:54:24,INDUSTRY,,,,,,,Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)|Pfizer,Germany,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00153543,,2005-09-08,2024-08-19,,2024-09-26,2005-09-08,2005-09-12,ESTIMATED,2024-09-26,2024-10-01,ACTUAL,,,,2024-09-26,2024-10-01,ACTUAL,2002-05,ACTUAL,2002-05-31,2024-09,2024-09-30,2003-06,ACTUAL,2003-06-30,2003-06,ACTUAL,2003-06-30,,INTERVENTIONAL,,,Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders,Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders,COMPLETED,,PHASE1,86,ACTUAL,Centers for Disease Control and Prevention,There were a small number of subjects in each study group.,3,,,,,,,,,,,,,,,,,,NO,Aggregate data can be shared.,2024-10-14 15:59:32,2024-10-14 15:59:32,FED,,,,,,,Alaska Native Tribal Health Consortium|Centers for Disease Control and Prevention|Southcentral Foundation,United States,General disorders
NCT00157950,,2005-09-07,2010-08-17,,2016-01-07,2005-09-07,2005-09-12,ESTIMATED,2010-08-17,2010-09-14,ESTIMATED,,,,2016-01-07,2016-02-04,ESTIMATED,2005-10,,2005-10-31,2016-01,2016-01-31,2006-06,ACTUAL,2006-06-30,2006-06,ACTUAL,2006-06-30,,INTERVENTIONAL,,,Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED),"An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea",COMPLETED,,PHASE3,176,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 05:40:18,2024-10-13 05:40:18,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Korea, Republic of","General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders"
NCT00162097,,2005-09-09,2010-07-28,,2010-09-07,2005-09-09,2005-09-13,ESTIMATED,2010-07-28,2010-08-25,ESTIMATED,,,,2010-09-07,2010-09-14,ESTIMATED,2004-11,,2004-11-30,2010-09,2010-09-30,2008-03,ACTUAL,2008-03-31,2008-03,ACTUAL,2008-03-31,,INTERVENTIONAL,,,Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment,Pharmacokinetics of Efavirenz During Treatment of HIV-1 Infected Subjects With Hepatic Impairment.,COMPLETED,,PHASE1,21,ACTUAL,Bristol-Myers Squibb,"The study was terminated early leading to a small number of participants treated and analyzed. Due to the small sample size, no conclusion could be made for participants with Child-Pugh scores B and C (moderate and severe hepatic impairment).",4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 17:34:55,2024-10-14 17:34:55,INDUSTRY,,,,,,,Bristol-Myers Squibb,Italy|Spain|United States,"Infections and infestations|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders"
NCT00189462,,2005-09-13,2014-09-23,,2020-10-30,2005-09-13,2005-09-19,ESTIMATED,2014-10-06,2014-10-08,ESTIMATED,,,,2020-10-30,2020-11-18,ACTUAL,2004-03,,2004-03-31,2020-10,2020-10-31,2005-12,ACTUAL,2005-12-31,2005-12,ACTUAL,2005-12-31,,INTERVENTIONAL,,,A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children,A Pilot Study to Evaluate the Efficacy of Montelukast in the Treatment of Acute Otitis Media (AOM) in Children,COMPLETED,,PHASE4,99,ACTUAL,West Penn Allegheny Health System,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 21:56:26,2024-10-13 21:56:26,OTHER,,,,,,,Deborah Gentile|Merck Sharp & Dohme LLC,United States,General disorders
NCT00194532,,2005-09-13,2011-03-30,,2014-06-03,2005-09-13,2005-09-19,ESTIMATED,2011-03-30,2011-04-28,ESTIMATED,,,,2014-06-03,2014-06-10,ESTIMATED,2005-06,,2005-06-30,2014-06,2014-06-30,2009-02,ACTUAL,2009-02-28,2009-02,ACTUAL,2009-02-28,,INTERVENTIONAL,,,Cefpodoxime vs Ciprofloxacin for Acute Cystitis,Cefpodoxime vs Ciprofloxacin for Acute Cystitis,COMPLETED,,NA,300,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 00:37:39,2024-10-13 00:37:39,OTHER,,,,,,,University of Washington,United States,Gastrointestinal disorders|Nervous system disorders|Reproductive system and breast disorders
NCT00195351,,2005-09-12,2009-02-27,,2013-02-20,2005-09-16,2005-09-19,ESTIMATED,2009-04-16,2009-06-10,ESTIMATED,,,,2013-02-20,2013-02-25,ESTIMATED,2005-09,,2005-09-30,2013-02,2013-02-28,2008-02,ACTUAL,2008-02-29,2008-02,ACTUAL,2008-02-29,,INTERVENTIONAL,,,Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection,"A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection",COMPLETED,,PHASE4,467,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 22:31:13,2024-10-13 22:31:13,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,Argentina|Brazil|Canada|Chile|Mexico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00196937,,2005-09-13,2009-11-12,,2019-12-06,2005-09-13,2005-09-20,ESTIMATED,2010-07-08,2010-08-06,ESTIMATED,,,,2019-12-06,2019-12-11,ACTUAL,2004-10-07,ACTUAL,2004-10-07,2019-12,2019-12-31,2005-12-15,ACTUAL,2005-12-15,2005-12-15,ACTUAL,2005-12-15,,INTERVENTIONAL,,,Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18,"Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up",COMPLETED,,PHASE3,667,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=1513,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 23:11:12,2024-10-13 23:11:12,INDUSTRY,,,,,,,GlaxoSmithKline,Germany|Poland,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Vascular disorders"
NCT00196976,,2005-09-13,2017-01-11,,2018-05-07,2005-09-13,2005-09-20,ESTIMATED,2017-01-11,2017-03-01,ACTUAL,,,,2018-05-07,2018-06-08,ACTUAL,2005-03-24,,2005-03-24,2017-04,2017-04-30,2006-03-03,ACTUAL,2006-03-03,2006-03-01,ACTUAL,2006-03-01,,INTERVENTIONAL,,,Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old,"Evaluate the Immunogenicity, Reactogenicity, Safety of 4 Different Formulations of GSK Biologicals' Conjugate Vaccine (MenACWY) vs 1 Dose of MenC-CRM197 or Mencevax™ ACWY in Children Aged 12-14 Months & 3-5 Years",COMPLETED,,PHASE2,461,ACTUAL,GlaxoSmithKline,None reported.,14,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 18:07:20,2024-10-13 18:07:20,INDUSTRY,,,,,,,GlaxoSmithKline,Austria|Greece,"Gastrointestinal disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00205803,,2005-09-19,2010-03-26,,2012-07-06,2005-09-19,2005-09-20,ESTIMATED,2012-07-06,2012-08-15,ESTIMATED,,,,2012-07-06,2012-08-15,ESTIMATED,2004-09,,2004-09-30,2012-07,2012-07-31,2007-05,ACTUAL,2007-05-31,,,,,INTERVENTIONAL,,,Study Evaluating Pneumococcal Vaccine in Healthy Infants,"A Phase I/II, 2-stage, Randomized, Double-Blind Trial of the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in Healthy Infants",COMPLETED,,PHASE1/PHASE2,249,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,,,,,,,,,,,,,,,,,,2024-10-14 12:34:19,2024-10-14 12:34:19,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT00207142,,2005-09-16,2009-06-02,,2010-01-07,2005-09-20,2005-09-21,ESTIMATED,2009-12-03,2010-01-07,ESTIMATED,,,,2010-01-07,2010-01-12,ESTIMATED,2005-11,,2005-11-30,2010-01,2010-01-31,2008-01,ACTUAL,2008-01-31,2007-08,ACTUAL,2007-08-31,,INTERVENTIONAL,INDUMA,,Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study),"A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing the Efficacy of a Treatment Maintenance Phase With Unboosted vs. Boosted Reyataz After an Induction Phase With Reyataz and Ritonavir in Treatment Naive HIV Patients (the INDUMA Study)",COMPLETED,,PHASE4,252,ACTUAL,Bristol-Myers Squibb,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 06:40:51,2024-10-13 06:40:51,INDUSTRY,,,,,,,Bristol-Myers Squibb,Estonia|France|Germany|Greece|Ireland|Italy|Latvia|Portugal|Russian Federation|Spain|United Kingdom,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00212888,,2005-09-13,2017-03-28,,2019-03-19,2005-09-13,2005-09-21,ESTIMATED,2019-03-19,2019-06-17,ACTUAL,,,,2019-03-19,2019-06-17,ACTUAL,2004-04,,2004-04-30,2019-03,2019-03-31,2010-11,ACTUAL,2010-11-30,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,Combination Vaccination Before HIV Treatment Interruption,A Pilot Study to Determine the Impact of Therapeutic HIV Vaccination Followed by a Scheduled Interruption of Antiretroviral Therapy on HIV-Specific Immune Function and Virologic Rebound in Patients With Prolonged Viral Suppression,COMPLETED,,PHASE1/PHASE2,52,ACTUAL,Ottawa Hospital Research Institute,,,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:19:47,2024-10-13 15:19:47,OTHER,,,,,,,Canadian Institutes of Health Research (CIHR)|CIHR Canadian HIV Trials Network|Ontario HIV Treatment Network|Ottawa Hospital Research Institute,Canada,General disorders|Skin and subcutaneous tissue disorders
NCT00214461,,2005-09-16,2012-03-13,,2012-04-09,2005-09-16,2005-09-22,ESTIMATED,2012-03-13,2012-04-09,ESTIMATED,,,,2012-04-09,2012-04-11,ESTIMATED,2005-11,,2005-11-30,2012-04,2012-04-30,2006-02,ACTUAL,2006-02-28,2006-02,ACTUAL,2006-02-28,,INTERVENTIONAL,,,"Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers","A Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study of the Safety, Tolerability and Immunogenicity of a Clostridium Difficile Toxoid Vaccine, Alum Adsorbed, in Healthy Elderly Volunteers (> or =65 Years)",COMPLETED,,PHASE1,48,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 22:02:15,2024-10-13 22:02:15,INDUSTRY,,,,,,,Sanofi,United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00223080,,2005-09-13,2016-10-24,,2019-04-10,2005-09-13,2005-09-22,ESTIMATED,2017-12-29,2018-10-19,ACTUAL,,,,2019-04-10,2019-04-24,ACTUAL,2003-10,,2003-10-31,2019-04,2019-04-30,2009-06,ACTUAL,2009-06-30,2006-07,ACTUAL,2006-07-31,,INTERVENTIONAL,,Modified Intent to Treat (MITT) Population - those participants who were infection free at entry into the study,HIV Vaccine Trial in Thai Adults,A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults,COMPLETED,,PHASE3,16402,ACTUAL,U.S. Army Medical Research and Development Command,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 00:15:55,2024-10-13 00:15:55,FED,,,,,,,"Armed Forces Research Institute of Medical Sciences, Thailand|Henry M. Jackson Foundation for the Advancement of Military Medicine|Mahidol University|MCM Vaccines B.V.|Ministry of Health, Thailand|Royal Thai Army Medical Department|The Emmes Company, LLC|Tripler Army Medical Center|United States Army Medical Materiel Development Activity|U.S. Army Medical Research and Development Command|VaxGen|Walter Reed Army Institute of Research (WRAIR)",Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00227370,,2005-09-26,2013-01-24,,2024-09-25,2005-09-26,2005-09-28,ESTIMATED,2013-04-25,2013-04-29,ESTIMATED,,,,2024-09-25,2024-10-04,ACTUAL,2003-07,,2003-07-31,2024-09,2024-09-30,2008-12,ACTUAL,2008-12-31,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,Valgan,,Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation,"A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation",COMPLETED,,PHASE3,136,ACTUAL,Duke University,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 09:33:59,2024-10-14 09:33:59,OTHER,,,,,,,Duke University|Roche Pharma AG,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00230971,,2005-09-30,2009-09-30,,2013-02-20,2005-09-30,2005-10-03,ESTIMATED,2010-04-05,2010-04-26,ESTIMATED,,,,2013-02-20,2013-02-25,ESTIMATED,2005-10,,2005-10-31,2013-02,2013-02-28,2008-09,ACTUAL,2008-09-30,2008-09,ACTUAL,2008-09-30,,INTERVENTIONAL,,,Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI),"A Multicenter, Open-Label, Randomized Comparative Study of Tigecycline vs Ceftriaxone Sodium Plus Metronidazole for the Treatment of Hospitalized Subjects With Complicated Intra-abdominal Infection",COMPLETED,,PHASE4,473,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 15:19:47,2024-10-13 15:19:47,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,Australia|China|Czech Republic|Denmark|Finland|France|Germany|Greece|Hong Kong|India|Italy|Philippines|Portugal|Saudi Arabia|South Africa|Spain|Switzerland|Taiwan|Turkey|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00231413,,2005-10-03,2019-11-25,,2019-11-25,2005-10-03,2005-10-04,ESTIMATED,2019-11-25,2019-12-12,ACTUAL,,,,2019-11-25,2019-12-12,ACTUAL,2005-03-04,ACTUAL,2005-03-04,2019-11,2019-11-30,2006-03-27,ACTUAL,2006-03-27,2006-03-27,ACTUAL,2006-03-27,,INTERVENTIONAL,,,Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.,"A Dose-range Study to Assess the Safety and Immunogenicity of a Novel HPV Vaccine When Administered Intramuscularly According to a 3-dose Schedule (0,1,6-month) in Healthy Adult Females (18-25 Years of Age)",COMPLETED,,PHASE2,383,ACTUAL,GlaxoSmithKline,,7,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=1504,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2024-10-15 01:37:17,2024-10-15 01:37:17,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00241644,,2005-10-18,2009-06-18,,2016-10-27,2005-10-18,2005-10-19,ESTIMATED,2009-06-18,2009-08-04,ESTIMATED,,,,2016-10-27,2016-12-09,ESTIMATED,2005-10,,2005-10-31,2016-10,2016-10-31,2008-06,ACTUAL,2008-06-30,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,,,Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants,"Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants",COMPLETED,,PHASE3,2089,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 11:46:42,2024-10-13 11:46:42,INDUSTRY,,,,,,,GlaxoSmithKline,Malawi|South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00242216,,2005-10-18,2013-05-02,,2013-12-12,2005-10-18,2005-10-19,ESTIMATED,2013-08-12,2013-10-17,ESTIMATED,,,,2013-12-12,2014-01-15,ESTIMATED,2004-05,,2004-05-31,2013-12,2013-12-31,2010-03,ACTUAL,2010-03-31,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,,"""The Once A Day Protease Inhibitor Regimens""","""PIQD: The Once a Day Protease Inhibitor Regimens."" Ritonavir Boosted Atazanavir vs. Ritonavir Boosted Fosamprenavir Used in Combination With Tenofovir and Emtricitabine in HIV-1 Infected Antiretroviral Treatment-Naïve Patients.",COMPLETED,,PHASE4,76,ACTUAL,"The University of Texas Health Science Center, Houston",High porportion of subject did not complete the study.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 03:30:58,2024-10-13 03:30:58,OTHER,,,,,,,"The University of Texas Health Science Center, Houston",United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00243230,,2005-10-20,2021-03-31,,2021-05-12,2005-10-20,2005-10-21,ESTIMATED,2021-05-12,2021-06-08,ACTUAL,,,,2021-05-12,2021-06-08,ACTUAL,2005-09-19,ACTUAL,2005-09-19,2021-05,2021-05-31,2011-03-17,ACTUAL,2011-03-17,2007-10-19,ACTUAL,2007-10-19,,INTERVENTIONAL,VICTOR-E1,The analysis population included all randomized participants.,Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672),Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E1),COMPLETED,,PHASE2,116,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 23:33:16,2024-10-13 23:33:16,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Brazil|Canada|Chile|Colombia|Dominican Republic|France|Germany|Guatemala|Italy|Peru|Puerto Rico|South Africa|Switzerland|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00244712,,2005-10-25,2009-04-23,,2010-06-03,2005-10-26,2005-10-27,ESTIMATED,2009-08-07,2009-09-15,ESTIMATED,,,,2010-06-03,2010-06-08,ESTIMATED,2005-07,,2005-07-31,2010-06,2010-06-30,2008-04,ACTUAL,2008-04-30,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,HEAT,,Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV,"A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects",COMPLETED,,PHASE4,688,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 06:35:41,2024-10-13 06:35:41,INDUSTRY,,,,,,,GlaxoSmithKline,Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00246376,,2005-10-27,2015-10-20,,2016-02-25,2005-10-27,2005-10-30,ESTIMATED,2016-02-25,2016-03-21,ESTIMATED,,,,2016-02-25,2016-03-21,ESTIMATED,2004-01,,2004-01-31,2016-02,2016-02-29,2012-02,ACTUAL,2012-02-29,2009-09,ACTUAL,2009-09-30,,INTERVENTIONAL,HeartPositive,,"Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia","Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy",COMPLETED,,NA,221,ACTUAL,Baylor College of Medicine,"High dropout rate, especially by loss to follow-up (with no explanation). Flushing was common among patients taking niacin, and this (with transportation and socio-economc problems) could have contributed to the high drop-out rate.",5,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:14:10,2024-10-14 02:14:10,OTHER,,,,,,,"Baylor College of Medicine|Legacy Community Health Center|National Heart, Lung, and Blood Institute (NHLBI)",United States,Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT00250276,,2005-11-07,2017-01-31,,2019-12-27,2005-11-07,2005-11-08,ESTIMATED,2017-01-31,2017-03-17,ACTUAL,,,,2019-12-27,2020-01-02,ACTUAL,2005-10-28,ACTUAL,2005-10-28,2019-12,2019-12-31,2007-03-01,ACTUAL,2007-03-01,2007-03-01,ACTUAL,2007-03-01,,INTERVENTIONAL,,,Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.,"Assess Lot-to-lot Consistency of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Following Manufacturing Adjustments Administered Intramuscularly According to a 0,1,6-mth Schedule in Healthy Female Subjects (18-25 y)",COMPLETED,,PHASE3,798,ACTUAL,GlaxoSmithKline,None reported.,4,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=1515,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-15 01:37:17,2024-10-15 01:37:17,INDUSTRY,,,,,,,GlaxoSmithKline,Denmark|Lithuania|Poland,"Cardiac disorders|Endocrine disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions"
NCT00255177,,2005-11-15,2009-04-22,,2009-10-30,2005-11-15,2005-11-17,ESTIMATED,2009-08-17,2009-09-23,ESTIMATED,,,,2009-10-30,2009-11-03,ESTIMATED,2005-11,,2005-11-30,2009-10,2009-10-31,2008-01,ACTUAL,2008-01-31,2007-09,ACTUAL,2007-09-30,,INTERVENTIONAL,,,Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients,"A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients",COMPLETED,,PHASE2,44,ACTUAL,"VGX Pharmaceuticals, LLC",,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 19:29:55,2024-10-14 19:29:55,INDUSTRY,,,,,,,"VGX Pharmaceuticals, LLC",United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00258856,,2005-11-24,2009-10-19,,2014-01-21,2005-11-24,2005-11-28,ESTIMATED,2009-10-19,2009-11-25,ESTIMATED,,,,2014-01-21,2014-02-14,ESTIMATED,2006-01,,2006-01-31,2014-01,2014-01-31,2007-11,ACTUAL,2007-11-30,2007-03,ACTUAL,2007-03-31,,INTERVENTIONAL,,,Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®,Persistence of Bactericidal Antibodies in Children Aged 7 to 15 Years Who Received a Single Dose of Menactra® or Menomune®-A/C/Y/W-135 Five Years Earlier,COMPLETED,,PHASE2,234,ACTUAL,Sanofi,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 10:09:42,2024-10-14 10:09:42,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00261807,,2005-12-01,2018-03-29,,2022-01-25,2005-12-01,2005-12-05,ESTIMATED,2021-03-24,2021-03-26,ACTUAL,,,,2022-01-25,2022-01-27,ACTUAL,2005-06,,2005-06-30,2022-01,2022-01-31,2008-05,ACTUAL,2008-05-31,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,,"Patients with severe necrotrotizing skin infections requiring surgical debridement, as well as antimicrobial therapy.",Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections,"Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections.",COMPLETED,,NA,25,ACTUAL,"University of Maryland, Baltimore",,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 03:30:58,2024-10-13 03:30:58,OTHER,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)|University of Maryland, Baltimore",United States,Blood and lymphatic system disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Skin and subcutaneous tissue disorders
NCT00262522,,2005-12-05,2009-07-09,,2012-02-03,2005-12-05,2005-12-07,ESTIMATED,2009-08-19,2009-08-20,ESTIMATED,,,,2012-02-03,2012-02-06,ESTIMATED,2005-11,,2005-11-30,2012-02,2012-02-29,2008-07,ACTUAL,2008-07-31,2008-07,ACTUAL,2008-07-31,,INTERVENTIONAL,,,"Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects","A Phase 3, Randomized, Open-label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects",COMPLETED,,PHASE3,664,ACTUAL,Abbott,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:24:49,2024-10-13 20:24:49,INDUSTRY,,,,,,,Abbott,Australia|Belgium|Canada|Czech Republic|France|Germany|Greece|Ireland|Italy|Netherlands|Poland|Puerto Rico|Russian Federation|Singapore|Spain|Switzerland|Taiwan|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00263666,,2005-12-08,2009-02-13,,2020-11-04,2005-12-08,2005-12-09,ESTIMATED,2009-03-12,2009-03-13,ESTIMATED,,,,2020-11-04,2020-11-23,ACTUAL,2005-03-16,ACTUAL,2005-03-16,2020-10,2020-10-31,2008-02-13,ACTUAL,2008-02-13,2008-02-07,ACTUAL,2008-02-07,,INTERVENTIONAL,,,"A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa","A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Reactogenicity and Immunogenicity of Three Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine",COMPLETED,,PHASE2,100,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 08:32:07,2024-10-13 08:32:07,INDUSTRY,,,,,,,GlaxoSmithKline,South Africa,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00264290,,2005-12-09,2013-08-13,,2020-07-20,2005-12-09,2005-12-12,ESTIMATED,2013-08-27,2013-11-08,ESTIMATED,,,,2020-07-20,2020-07-31,ACTUAL,2006-08,,2006-08-31,2020-07,2020-07-31,2008-11,ACTUAL,2008-11-30,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,Valganciclovir to Reduce T Cell Activation in HIV Infection,Valganciclovir to Reduce T Cell Activation in HIV Infection,COMPLETED,,PHASE4,30,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 17:34:55,2024-10-14 17:34:55,OTHER,,,,,,,"Roche Pharma AG|University of California, San Francisco",United States,Cardiac disorders
NCT00264290,,2005-12-09,2013-08-13,,2020-07-20,2005-12-09,2005-12-12,ESTIMATED,2013-08-27,2013-11-08,ESTIMATED,,,,2020-07-20,2020-07-31,ACTUAL,2006-08,,2006-08-31,2020-07,2020-07-31,2008-11,ACTUAL,2008-11-30,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,Valganciclovir to Reduce T Cell Activation in HIV Infection,Valganciclovir to Reduce T Cell Activation in HIV Infection,COMPLETED,,PHASE4,30,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 17:34:55,2024-10-14 17:34:55,OTHER,,,,,,,"Roche Pharma AG|University of California, San Francisco",United States,Cardiac disorders
NCT00264875,,2005-12-12,2009-02-20,,2021-01-20,2005-12-12,2005-12-13,ESTIMATED,2009-02-20,2009-03-23,ESTIMATED,,,,2021-01-20,2021-01-22,ACTUAL,2006-02,,2006-02-28,2018-10,2018-10-31,2008-02,ACTUAL,2008-02-29,2008-02,ACTUAL,2008-02-29,,INTERVENTIONAL,,,Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy,"An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy",COMPLETED,,PHASE3,220,ACTUAL,Pfizer,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:47:42,2024-10-13 20:47:42,INDUSTRY,,,,,,,Pfizer's Upjohn has merged with Mylan to form Viatris Inc.,Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00269399,,2005-12-22,2019-09-06,,2019-09-30,2005-12-22,2005-12-23,ESTIMATED,2019-09-06,2019-10-01,ACTUAL,,,,2019-09-30,2019-10-14,ACTUAL,2005-12,,2005-12-31,2019-09,2019-09-30,2008-12,ACTUAL,2008-12-31,2008-12,ACTUAL,2008-12-31,,INTERVENTIONAL,,Modified Intent-to-Treat (MITT) population included all randomized subjects who had acute diarrhea and with a positive C. difficile stool toxin assay within ± 48 hours of screening and received at least one dose of study drug.,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),"A Double-Blind, Randomized, Controlled Trial of Rifaximin Compared to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)",COMPLETED,,PHASE3,237,ACTUAL,"Bausch Health Americas, Inc.",,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 12:14:37,2024-10-13 12:14:37,INDUSTRY,,,,,,,"Bausch Health Americas, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00269477,,2005-12-22,2009-11-10,,2016-04-12,2005-12-22,2005-12-23,ESTIMATED,2009-11-10,2009-12-14,ESTIMATED,,,,2016-04-12,2016-04-14,ESTIMATED,2005-12,,2005-12-31,2016-04,2016-04-30,2007-12,ACTUAL,2007-12-31,2007-02,ACTUAL,2007-02-28,,INTERVENTIONAL,,,Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®,Persistence of Bactericidal Antibodies in Adolescents and Adults Aged 15 to 23 Years Who Received a Single Dose of Menactra® or Menomune®-A/C/Y/W-135 Five Years Earlier,COMPLETED,,PHASE2,145,ACTUAL,Sanofi,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:21:42,2024-10-14 17:21:42,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00270205,,2005-12-21,2011-09-07,2010-01-30,2021-11-02,2005-12-21,2005-12-26,ESTIMATED,2011-09-07,2011-10-13,ESTIMATED,2010-01-30,2010-02-02,ESTIMATED,2021-11-02,2021-11-04,ACTUAL,2006-01,,2006-01-31,2017-12,2017-12-31,2010-09,ACTUAL,2010-09-30,2010-09,ACTUAL,2010-09-30,,INTERVENTIONAL,,,"Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART","A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of LC002, a DermaVir Vaccine, in HIV-1-Infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)",COMPLETED,,PHASE1/PHASE2,28,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),This is a Phase I/II small sample study that was not powered for the secondary efficacy endpoints.,6,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 05:34:06,2024-10-14 05:34:06,NIH,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00270296,,2005-12-22,2017-03-14,2010-03-26,2021-10-29,2005-12-22,2005-12-26,ESTIMATED,2017-04-27,2017-06-05,ACTUAL,2010-03-26,2010-03-30,ESTIMATED,2021-10-29,2021-11-02,ACTUAL,2006-06,,2006-06-30,2021-10,2021-10-31,2010-09,ACTUAL,2010-09-30,2009-03,ACTUAL,2009-03-31,,INTERVENTIONAL,,,Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV,Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana,COMPLETED,,PHASE2,730,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,,TRUE,,,,,,,,,,,,2024-10-14 18:04:38,2024-10-14 18:04:38,NIH,,,,,,,Harvard School of Public Health (HSPH)|National Institute of Allergy and Infectious Diseases (NIAID),Botswana,Blood and lymphatic system disorders
NCT00272779,,2006-01-05,2010-12-03,,2011-04-07,2006-01-05,2006-01-09,ESTIMATED,2011-04-07,2011-05-09,ESTIMATED,,,,2011-04-07,2011-05-09,ESTIMATED,2005-11,,2005-11-30,2011-04,2011-04-30,2008-10,ACTUAL,2008-10-31,2007-06,ACTUAL,2007-06-30,,INTERVENTIONAL,,,BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada,"A 96 Week Study Comparing the Antiviral Efficacy and Safety of Atazanavir/Ritonavir With Lopinavir/Ritonavir, Each in Combination With Fixed Dose Tenofovir-Emtricitabine in HIV-1 Infected Treatment in Naive Subjects",COMPLETED,,PHASE3,1057,ACTUAL,Bristol-Myers Squibb,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 09:09:57,2024-10-14 09:09:57,INDUSTRY,,,,,,,Bristol-Myers Squibb,Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Colombia|Costa Rica|Denmark|Dominican Republic|France|Germany|Guatemala|Hong Kong|Indonesia|Italy|Mexico|Netherlands|Panama|Peru|Portugal|Puerto Rico|Singapore|South Africa|Spain|Taiwan|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00285584,,2006-01-31,2012-03-13,,2017-11-14,2006-01-31,2006-02-02,ESTIMATED,2012-05-17,2012-06-20,ESTIMATED,,,,2017-11-14,2017-12-12,ACTUAL,2002-09,,2002-09-30,2017-11,2017-11-30,2004-09,ACTUAL,2004-09-30,2004-03,ACTUAL,2004-03-31,,INTERVENTIONAL,,,Bupropion For Reducing High-Risk Behaviors in Depressed Men Who Have Sex With Men (MSM),"Drug Abuse, Depression and Responses to HIV Counseling",COMPLETED,,PHASE1,41,ACTUAL,NYU Langone Health,We achieved substantially lower recruitment than needed to adequately test the study hypothesis. We also experienced substantial losses-to-follow-up.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 11:22:25,2024-10-14 11:22:25,OTHER,,,,,,,GlaxoSmithKline|National Institute on Drug Abuse (NIDA)|NYU Langone Health,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00289991,,2006-02-09,2010-02-09,,2015-10-16,2006-02-09,2006-02-10,ESTIMATED,2010-02-09,2010-03-10,ESTIMATED,,,,2015-10-16,2015-11-20,ESTIMATED,2006-03,,2006-03-31,2015-10,2015-10-31,2009-02,ACTUAL,2009-02-28,2009-02,ACTUAL,2009-02-28,,INTERVENTIONAL,IMPROVIT,,Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT),"Prospective, Open-Label, Comparative, Multi-Center Study Of Voriconazole Compared To Itraconazole For The Primary Prophylaxis Of Invasive Fungal Infection (IFI) With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)",COMPLETED,,PHASE3,489,ACTUAL,Pfizer,Data was excluded from 1 site due to Good Clinical Practices deviations.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 04:03:57,2024-10-13 04:03:57,INDUSTRY,,,,,,,Pfizer,Canada|Czech Republic|Egypt|France|Greece|Israel|Jordan|Portugal|Russian Federation|Spain|Switzerland|Turkey|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00290290,,2006-02-09,2012-11-15,,2014-09-10,2006-02-09,2006-02-13,ESTIMATED,2014-07-18,2014-08-11,ESTIMATED,,,,2014-09-10,2014-09-18,ESTIMATED,2003-09,,2003-09-30,2014-09,2014-09-30,2008-05,ACTUAL,2008-05-31,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,,,Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections,"Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical-Site Antisepsis:A Prospective, Randomized, Multicenter Clinical Trial",COMPLETED,,PHASE3,849,ACTUAL,Baylor College of Medicine,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 19:45:33,2024-10-13 19:45:33,OTHER,,,,,,,Baylor College of Medicine|Medical College of Wisconsin|Michael E. DeBakey VA Medical Center|US Department of Veterans Affairs,United States,Skin and subcutaneous tissue disorders|Surgical and medical procedures
NCT00290329,,2006-02-10,2017-01-23,,2018-05-08,2006-02-10,2006-02-13,ESTIMATED,2017-01-23,2017-03-14,ACTUAL,,,,2018-05-08,2018-06-08,ACTUAL,2006-01-14,,2006-01-14,2017-01,2017-01-31,2006-10-17,ACTUAL,2006-10-17,2006-10-01,ACTUAL,2006-10-01,,INTERVENTIONAL,,,"Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years","Multicentric, Surveillance Study to Monitor Safety of GSK Biologicals' Purified Meningococcal Polysaccharide Vaccine of Serogroups ACWY in 3,000 Filipino Subjects Aged Above 2 Years When Administered According to the Prescribing Information.",COMPLETED,,PHASE4,249,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 03:33:16,2024-10-14 03:33:16,INDUSTRY,,,,,,,GlaxoSmithKline,Philippines,General disorders
NCT00291343,,2006-02-13,2017-01-12,,2018-04-26,2006-02-13,2006-02-14,ESTIMATED,2017-04-21,2017-08-03,ACTUAL,,,,2018-04-26,2018-06-06,ACTUAL,2006-02-01,,2006-02-01,2017-04,2017-04-30,2007-03-15,ACTUAL,2007-03-15,2007-03-15,ACTUAL,2007-03-15,,INTERVENTIONAL,,,Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study,Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study,COMPLETED,,PHASE3,296,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 22:37:01,2024-10-13 22:37:01,INDUSTRY,,,,,,,GlaxoSmithKline,Philippines,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders"
NCT00293254,,2006-02-15,2009-08-20,,2017-02-14,2006-02-15,2006-02-17,ESTIMATED,2009-09-29,2009-09-30,ESTIMATED,,,,2017-02-14,2017-03-21,ACTUAL,2006-02,,2006-02-28,2017-02,2017-02-28,2011-05,ACTUAL,2011-05-31,2007-10,ACTUAL,2007-10-31,,INTERVENTIONAL,,,A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiretroviral Therapies",COMPLETED,,PHASE3,351,ACTUAL,Merck Sharp & Dohme LLC,"Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 83 of 119 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.",2,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 05:34:49,2024-10-13 05:34:49,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Brazil|Canada|Colombia|Mexico|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00293267,,2006-02-14,2009-08-18,,2015-09-04,2006-02-15,2006-02-17,ESTIMATED,2009-09-25,2009-09-28,ESTIMATED,,,,2015-09-04,2015-09-07,ESTIMATED,2006-02,,2006-02-28,2015-09,2015-09-30,2011-05,ACTUAL,2011-05-31,2007-08,ACTUAL,2007-08-31,,INTERVENTIONAL,,,A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2),"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Optimized Background Therapy Alone, in HIV-Infected Patients With Documented Resistance to at Least 1 Drug in Each of the 3 Classes of Licensed Oral Antiviral Therapies",COMPLETED,,PHASE3,352,ACTUAL,Merck Sharp & Dohme LLC,"Adverse events are reported by original treatment group for the entire 240-week study, including double-blind, open-label, and OLPVF phases; 94 of 118 participants in the placebo group also received raltegravir in the open-label or OLPVF phase.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Belgium|Denmark|France|Germany|Italy|Peru|Portugal|Spain|Switzerland|Taiwan|Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00294047,,2006-02-17,2011-12-08,,2019-12-27,2006-02-17,2006-02-20,ESTIMATED,2012-02-23,2012-03-27,ESTIMATED,,,,2019-12-27,2020-01-02,ACTUAL,2006-02-16,ACTUAL,2006-02-16,2019-12,2019-12-31,2014-01-29,ACTUAL,2014-01-29,2014-01-29,ACTUAL,2014-01-29,,INTERVENTIONAL,,,Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older,"A Study to Evaluate Safety, Immunogenicity and Efficacy of GSK Biologicals HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above",COMPLETED,,PHASE3,5752,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=1517,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 09:22:22,2024-10-14 09:22:22,INDUSTRY,,,,,,,GlaxoSmithKline,Australia|Belgium|Canada|Mexico|Netherlands|Peru|Philippines|Portugal|Russian Federation|Singapore|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00294515,,2006-02-21,2010-06-02,,2018-02-28,2006-02-21,2006-02-22,ESTIMATED,2010-06-02,2010-07-05,ESTIMATED,,,,2018-02-28,2018-03-29,ACTUAL,2006-03-31,ACTUAL,2006-03-31,2018-02,2018-02-28,2009-08-31,ACTUAL,2009-08-31,2008-08-31,ACTUAL,2008-08-31,,INTERVENTIONAL,IMPACT,,IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients,"A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients",COMPLETED,,PHASE3,326,ACTUAL,Hoffmann-La Roche,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-13 18:31:10,2024-10-13 18:31:10,INDUSTRY,,,,,,,Hoffmann-La Roche,Australia|Belgium|Brazil|Canada|France|Germany|Italy|New Zealand|Poland|Romania|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00296504,,2006-02-24,2011-09-30,,2013-04-11,2006-02-24,2006-02-27,ESTIMATED,2011-09-30,2011-11-08,ESTIMATED,,,,2013-04-11,2013-04-19,ESTIMATED,2001-11,,2001-11-30,2012-06,2012-06-30,2010-10,ACTUAL,2010-10-31,2010-10,ACTUAL,2010-10-31,,INTERVENTIONAL,,,A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects,An Open-Label Phase III Study to Assess the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Subjects,COMPLETED,,PHASE3,753,ACTUAL,ViiV Healthcare,,,,,,,,,FALSE,,,,,,,,,,,,,2024-10-13 15:07:24,2024-10-13 15:07:24,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Costa Rica|France|Germany|Hungary|Israel|Italy|Latvia|Panama|Poland|Portugal|Puerto Rico|South Africa|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00300677,,2006-03-07,2009-08-26,,2009-10-05,2006-03-07,2006-03-09,ESTIMATED,2009-10-05,2009-10-14,ESTIMATED,,,,2009-10-05,2009-10-14,ESTIMATED,2007-03,,2007-03-31,2009-10,2009-10-31,2008-08,ACTUAL,2008-08-31,2008-08,ACTUAL,2008-08-31,,INTERVENTIONAL,,,To Determine The Amount Of Voriconazole In The Brain After 2 Loading Doses And 3 Maintenance Doses Over 3 Days,Assessment Of Voriconazole Penetration Into The Brain By Fluorine-Magnetic Resonance Spectroscopy,COMPLETED,,PHASE4,12,ACTUAL,Pfizer,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 00:35:58,2024-10-15 00:35:58,INDUSTRY,,,,,,,"McLean Hospital. Belmont, MA.|Pfizer",United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00303069,,2006-03-13,2010-09-23,,2015-06-29,2006-03-13,2006-03-15,ESTIMATED,2010-09-23,2010-10-20,ESTIMATED,,,,2015-06-29,2015-07-22,ESTIMATED,2005-11,,2005-11-30,2015-06,2015-06-30,2006-07,ACTUAL,2006-07-31,2006-07,ACTUAL,2006-07-31,,INTERVENTIONAL,,,V710 First-In-Man (FIM) Study (V710-001),"A Sequential-Panel, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine in Healthy Adults 18 to 55 Years of Age",COMPLETED,,PHASE1,124,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-12 23:41:00,2024-10-12 23:41:00,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00303823,,2006-03-15,2012-07-13,,2015-04-14,2006-03-15,2006-03-17,ESTIMATED,2012-07-13,2012-08-17,ESTIMATED,,,,2015-04-14,2015-05-05,ESTIMATED,2005-09,,2005-09-30,2013-04,2013-04-30,2011-02,ACTUAL,2011-02-28,2010-11,ACTUAL,2010-11-30,,INTERVENTIONAL,,,Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia,A Phase II Trial of Polyphenon E for Cervical Cancer Prevention,COMPLETED,,PHASE2,98,ACTUAL,National Cancer Institute (NCI),,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 03:12:16,2024-10-15 03:12:16,NIH,,,,,,,National Cancer Institute (NCI),United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00305227,,2006-03-20,2014-06-03,,2023-03-18,2006-03-20,2006-03-21,ESTIMATED,2014-06-03,2014-07-04,ESTIMATED,,,,2023-03-18,2023-04-14,ACTUAL,2006-03,,2006-03-31,2023-03,2023-03-31,2012-04,ACTUAL,2012-04-30,2012-04,ACTUAL,2012-04-30,,INTERVENTIONAL,,,Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection,Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infections,COMPLETED,,PHASE2,100,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:35:34,2024-10-14 18:35:34,OTHER,,,,,,,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Osel, Inc.|University of Washington",United States,General disorders|Renal and urinary disorders|Reproductive system and breast disorders
NCT00307034,,2006-03-24,2016-12-13,,2018-05-08,2006-03-24,2006-03-27,ESTIMATED,2017-02-16,2017-04-04,ACTUAL,,,,2018-05-08,2018-06-08,ACTUAL,2006-01-01,,2006-01-01,2017-02,2017-02-28,2007-01-25,ACTUAL,2007-01-25,2007-01-01,ACTUAL,2007-01-01,,INTERVENTIONAL,,,Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule,"An Open, Randomized, Phase IIIa Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered Intramuscularly According to a 2-4-11 Months Vaccination Schedule",COMPLETED,,PHASE3,351,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 11:33:55,2024-10-14 11:33:55,INDUSTRY,,,,,,,GlaxoSmithKline,Denmark|Norway|Slovakia|Sweden,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00307151,,2006-03-24,2011-07-05,,2017-03-15,2006-03-24,2006-03-27,ESTIMATED,2011-07-05,2011-08-03,ESTIMATED,,,,2017-03-15,2017-04-13,ACTUAL,2005-12,,2005-12-31,2017-03,2017-03-31,2016-12,ACTUAL,2016-12-31,2010-12,ACTUAL,2010-12-31,,INTERVENTIONAL,P1060,,Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV,"Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-to-Child HIV Transmission",COMPLETED,,PHASE2,452,ACTUAL,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,Accrual to Cohort I was terminated early by the Data Safety Monitoring Committee after enrollment of 164 of the planned 288 subjects.,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:30:57,2024-10-13 20:30:57,NETWORK,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID),India|Malawi|South Africa|Tanzania|Uganda|United States|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00307164,,2006-03-23,2011-08-23,2009-09-10,2021-11-02,2006-03-23,2006-03-27,ESTIMATED,2011-08-23,2011-10-04,ESTIMATED,2009-09-10,2009-09-14,ESTIMATED,2021-11-02,2021-11-04,ACTUAL,2006-09,,2006-09-30,2019-01,2019-01-31,2008-12,ACTUAL,2008-12-31,2008-12,ACTUAL,2008-12-31,,INTERVENTIONAL,,,Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy,"A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy",COMPLETED,,PHASE2/PHASE3,167,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 16:26:35,2024-10-13 16:26:35,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT00309166,,2006-03-28,2016-12-19,,2018-02-05,2006-03-28,2006-03-31,ESTIMATED,2018-02-05,2018-09-17,ACTUAL,,,,2018-02-05,2018-09-17,ACTUAL,2006-04-05,ACTUAL,2006-04-05,2018-02,2018-02-28,2007-06-19,ACTUAL,2007-06-19,2007-06-01,ACTUAL,2007-06-01,,INTERVENTIONAL,,,Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.,"An Observer-blind, Randomized, Controlled Study to Assess the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Male Subjects Aged 10-18 Years",COMPLETED,,PHASE2,270,ACTUAL,GlaxoSmithKline,None reported.,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 13:50:53,2024-10-13 13:50:53,INDUSTRY,,,,,,,GlaxoSmithKline,Finland,Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00314951,,2006-04-13,2011-07-01,2010-08-27,2017-03-23,2006-04-13,2006-04-17,ESTIMATED,2011-09-16,2011-10-26,ESTIMATED,2010-08-27,2010-08-31,ESTIMATED,2017-03-23,2017-04-21,ACTUAL,2006-05-02,ACTUAL,2006-05-02,2017-03,2017-03-31,2008-08-21,ACTUAL,2008-08-21,2008-07-23,ACTUAL,2008-07-23,,INTERVENTIONAL,,,Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018),"A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated Diarrhea",COMPLETED,,PHASE3,629,ACTUAL,"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 13:38:09,2024-10-14 13:38:09,INDUSTRY,,,,,,,"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00316264,,2006-04-18,2012-10-03,,2012-11-13,2006-04-18,2006-04-20,ESTIMATED,2012-11-13,2012-12-11,ESTIMATED,,,,2012-11-13,2012-12-11,ESTIMATED,2006-04,,2006-04-30,2012-11,2012-11-30,2007-02,ACTUAL,2007-02-28,2007-02,ACTUAL,2007-02-28,,INTERVENTIONAL,,,Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season,"A Phase 2, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), and Palivizumab When Administered in the Same Season",COMPLETED,,PHASE2,260,ACTUAL,MedImmune LLC,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 22:08:13,2024-10-13 22:08:13,INDUSTRY,,,,,,,MedImmune LLC,Australia|Brazil|Chile|New Zealand,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00316589,,2006-04-19,2018-12-07,,2018-12-07,2006-04-19,2006-04-21,ESTIMATED,2018-12-07,2019-01-03,ACTUAL,,,,2018-12-07,2019-01-03,ACTUAL,2006-06,,2006-06-30,2018-12,2018-12-31,2009-10,ACTUAL,2009-10-31,2009-03,ACTUAL,2009-03-31,,INTERVENTIONAL,,Full Analysis Set,Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients,"A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl.",COMPLETED,,PHASE2,581,ACTUAL,Bavarian Nordic,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 14:55:33,2024-10-13 14:55:33,INDUSTRY,,,,,,,Bavarian Nordic|National Institutes of Health (NIH),Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00316693,,2006-04-19,2009-11-12,,2018-08-30,2006-04-19,2006-04-21,ESTIMATED,2009-11-12,2009-12-16,ESTIMATED,,,,2018-08-30,2018-09-04,ACTUAL,2006-04-26,,2006-04-26,2018-08,2018-08-31,2009-02-10,ACTUAL,2009-02-10,2009-02-10,ACTUAL,2009-02-10,,INTERVENTIONAL,,,"Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine","A Phase II Study to Assess the Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) Vaccine Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Japanese Female Subjects Aged 20 - 25 Years.",COMPLETED,,PHASE2,1046,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-15 00:41:27,2024-10-15 00:41:27,INDUSTRY,,,,,,,GlaxoSmithKline,Japan,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00316706,,2006-04-19,2009-11-12,,2012-09-13,2006-04-19,2006-04-21,ESTIMATED,2010-02-12,2010-03-01,ESTIMATED,,,,2012-09-13,2012-09-18,ESTIMATED,2005-10,,2005-10-31,2012-09,2012-09-30,2009-01,ACTUAL,2009-01-31,2009-01,ACTUAL,2009-01-31,,INTERVENTIONAL,,,Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine,"A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013",COMPLETED,,PHASE3,1245,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 23:29:48,2024-10-14 23:29:48,INDUSTRY,,,,,,,GlaxoSmithKline,Colombia|Germany|Honduras|Panama|Taiwan,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00317109,,2006-02-03,2017-01-10,,2018-04-26,2006-04-20,2006-04-24,ESTIMATED,2017-01-10,2017-03-01,ACTUAL,,,,2018-04-26,2018-06-06,ACTUAL,2006-04-19,,2006-04-19,2017-01,2017-01-31,2007-05-17,ACTUAL,2007-05-17,2007-05-01,ACTUAL,2007-05-01,,INTERVENTIONAL,,,Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects,"Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007",COMPLETED,,PHASE3,168,ACTUAL,GlaxoSmithKline,None reported.,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 20:30:57,2024-10-13 20:30:57,INDUSTRY,,,,,,,GlaxoSmithKline,South Africa,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders"
NCT00318409,,2006-04-24,2013-04-24,,2014-10-09,2006-04-24,2006-04-26,ESTIMATED,2014-10-09,2014-10-17,ESTIMATED,,,,2014-10-09,2014-10-17,ESTIMATED,2006-09,,2006-09-30,2014-10,2014-10-31,2007-11,ACTUAL,2007-11-30,2007-11,ACTUAL,2007-11-30,,INTERVENTIONAL,,,Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM,Pilot Study of Acceptability of Bupropion Treatment for Methamphetamine Dependence Among Men Who Have Sex With Men.,COMPLETED,,PHASE2,30,ACTUAL,San Francisco Department of Public Health,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 05:57:38,2024-10-14 05:57:38,OTHER_GOV,,,,,,,"National Institute on Drug Abuse (NIDA)|Public Health Foundation Enterprises, Inc.|San Francisco Department of Public Health",United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00318591,,2006-04-26,2011-02-23,,2021-01-26,2006-04-26,2006-04-27,ESTIMATED,2011-04-26,2011-05-25,ESTIMATED,,,,2021-01-26,2021-02-10,ACTUAL,2006-04,,2006-04-30,2015-08,2015-08-31,2009-10,ACTUAL,2009-10-31,2009-10,ACTUAL,2009-10-31,,INTERVENTIONAL,,,Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections,"A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters.",COMPLETED,,NA,219,ACTUAL,Coloplast A/S,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 14:55:33,2024-10-13 14:55:33,INDUSTRY,,,,,,,Coloplast A/S,Canada|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00321672,,2006-05-02,2010-06-16,,2011-05-13,2006-05-02,2006-05-04,ESTIMATED,2011-05-13,2011-06-14,ESTIMATED,,,,2011-05-13,2011-06-14,ESTIMATED,2006-06,,2006-06-30,2011-05,2011-05-31,2007-12,ACTUAL,2007-12-31,2007-12,ACTUAL,2007-12-31,,INTERVENTIONAL,,,Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy,"A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy",COMPLETED,,PHASE3,494,ACTUAL,NeurogesX,Differences between the 60- and 30-minute Control groups prevented pooling according to prespecified criteria resulting in treatment comparisons between 60- and 30-minute NGX-4010 groups and their respective Control groups with relatively low power.,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 14:08:24,2024-10-13 14:08:24,INDUSTRY,,,,,,,NeurogesX,Australia|Canada|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00323492,,2006-05-05,2009-03-20,,2010-01-13,2006-05-05,2006-05-09,ESTIMATED,2009-11-20,2009-12-23,ESTIMATED,,,,2010-01-13,2010-01-20,ESTIMATED,2005-09,,2005-09-30,2010-01,2010-01-31,2008-03,ACTUAL,2008-03-31,2007-07,ACTUAL,2007-07-31,,INTERVENTIONAL,TOTEM,,TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada,Open-label Randomized Multicenter Trial to Evaluate the Impact on the Lipid Profile of the Substitution of the NRTIs of a HAART Regimen by a Once Daily Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Maintained Treatment in HIV Infected Controlled Patients.,COMPLETED,,PHASE4,92,ACTUAL,Gilead Sciences,"Comparison of adverse events between Truvada and maintain baseline regimen groups is inappropriate since numbers at risk (and exposure to study drug) are not balanced, as described in the adverse event treatment group descriptions.",4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 06:14:24,2024-10-13 06:14:24,INDUSTRY,,,,,,,Gilead Sciences,France,"Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00324168,,2006-05-05,2012-11-29,,2018-07-06,2006-05-05,2006-05-10,ESTIMATED,2013-04-10,2013-06-14,ESTIMATED,,,,2018-07-06,2018-08-01,ACTUAL,2006-09,,2006-09-30,2018-07,2018-07-31,2012-12,ACTUAL,2012-12-31,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,SCUT,,Steroids for Corneal Ulcers Trial,Steroids for Corneal Ulcers Trial,COMPLETED,,PHASE4,500,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 08:23:13,2024-10-14 08:23:13,OTHER,,,,,,,"Aravind Eye Hospitals, India|Dartmouth-Hitchcock Medical Center|National Eye Institute (NEI)|Thomas M. Lietman",India|United States,Eye disorders|General disorders|Infections and infestations
NCT00326716,,2006-05-15,2011-01-05,,2011-11-04,2006-05-16,2006-05-17,ESTIMATED,2011-03-07,2011-04-07,ESTIMATED,,,,2011-11-04,2011-11-16,ESTIMATED,2006-06,,2006-06-30,2011-11,2011-11-30,2009-08,ACTUAL,2009-08-31,2009-01,ACTUAL,2009-01-31,,INTERVENTIONAL,,,Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women,A Study of the Pharmacokinetics of Atazanavir (ATV)/Ritonavir(RTV) Administered as Part of Highly Active Antiretroviral Therapy (HAART) in HIV-1 Infected Pregnant Women,COMPLETED,,PHASE1,69,ACTUAL,Bristol-Myers Squibb,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 14:52:00,2024-10-14 14:52:00,INDUSTRY,,,,,,,Bristol-Myers Squibb,Puerto Rico|South Africa|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00326963,,2006-05-16,2016-03-23,,2016-07-07,2006-05-16,2006-05-17,ESTIMATED,2016-07-07,2016-08-16,ESTIMATED,,,,2016-07-07,2016-08-16,ESTIMATED,2006-03,,2006-03-31,2016-07,2016-07-31,2007-05,ACTUAL,2007-05-31,2007-04,ACTUAL,2007-04-30,,INTERVENTIONAL,,Baseline analysis was performed on all randomized participants including two participants who does not received study drug.,BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.,"A Multicenter, Open-label Study Evaluating the Safety and Efficacy of a New Protease Inhibitor (Darunavir) With Fuzeon® (Enfuvirtide) Plus Background Antiretroviral Regimen in HIV-1 Infected, Triple-class Treatment-experienced Patients",COMPLETED,,PHASE4,142,ACTUAL,Hoffmann-La Roche,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 12:34:19,2024-10-14 12:34:19,INDUSTRY,,,,,,,Hoffmann-La Roche|Trimeris,Australia|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00328263,,2006-05-17,2012-08-28,,2014-07-15,2006-05-17,2006-05-19,ESTIMATED,2014-07-15,2014-08-07,ESTIMATED,,,,2014-07-15,2014-08-07,ESTIMATED,2006-03,,2006-03-31,2014-07,2014-07-31,2007-10,ACTUAL,2007-10-31,2007-03,ACTUAL,2007-03-31,,INTERVENTIONAL,,,Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients,"A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy and Safety of BIO-K*+ CL-1285* in the Prevention of Antibiotic-associated Diarrhea in Adult Patients Exposed to Nosocomial Infection.",COMPLETED,,PHASE3,472,ACTUAL,Bio-K Plus International Inc.,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 23:27:20,2024-10-13 23:27:20,INDUSTRY,,,,,,,Bio-K Plus International Inc.|JSS Medical Research Inc.,Canada,Gastrointestinal disorders|General disorders|Nervous system disorders
NCT00329745,,2006-05-24,2009-07-02,,2016-10-27,2006-05-24,2006-05-25,ESTIMATED,2009-09-11,2009-10-14,ESTIMATED,,,,2016-10-27,2016-12-09,ESTIMATED,2007-01,,2007-01-31,2016-10,2016-10-31,2008-07,ACTUAL,2008-07-31,2008-07,ACTUAL,2008-07-31,,INTERVENTIONAL,,,"Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)","A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-country and Multi-center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants.",COMPLETED,,PHASE3,8687,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 17:40:56,2024-10-14 17:40:56,INDUSTRY,,,,,,,GlaxoSmithKline,Singapore,"Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT00337467,,2006-06-14,2010-05-21,,2010-06-18,2006-06-15,2006-06-16,ESTIMATED,2010-06-18,2010-07-19,ESTIMATED,,,,2010-06-18,2010-07-19,ESTIMATED,2006-06,,2006-06-30,2010-06,2010-06-30,2009-05,ACTUAL,2009-05-31,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,OREY,,Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression,"Phase IIIb Multicenter, Single Arm, Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Maintenance With Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in HIV-Infected Patients Evidencing Virologic Suppression OREY (Only REYataz) Study",COMPLETED,,PHASE3,61,ACTUAL,Bristol-Myers Squibb,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 23:44:43,2024-10-13 23:44:43,INDUSTRY,,,,,,,Bristol-Myers Squibb,Spain,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Vascular disorders"
NCT00337818,,2006-06-15,2009-11-12,,2017-05-25,2006-06-15,2006-06-16,ESTIMATED,2010-02-12,2010-03-02,ESTIMATED,,,,2017-05-25,2017-05-30,ACTUAL,2006-06,,2006-06-30,2017-05,2017-05-31,2009-01,ACTUAL,2009-01-31,2006-06,ACTUAL,2006-06-30,,INTERVENTIONAL,,,Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women,"A Long-term, Open, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1/AS04 Vaccine in Healthy Female Subjects Vaccinated Either Pre- or Post-menarche in the Primary Study",COMPLETED,,PHASE3,770,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 12:20:10,2024-10-13 12:20:10,INDUSTRY,,,,,,,GlaxoSmithKline,Denmark|Estonia|Finland,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders"
NCT00339040,,2006-06-19,2011-09-07,2010-08-03,2021-11-03,2006-06-19,2006-06-20,ESTIMATED,2011-12-12,2012-01-16,ESTIMATED,2010-08-03,2010-08-05,ESTIMATED,2021-11-03,2021-11-05,ACTUAL,2006-10,,2006-10-31,2019-01,2019-01-31,2009-08,ACTUAL,2009-08-31,2009-08,ACTUAL,2009-08-31,,INTERVENTIONAL,,,Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children,"Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in HIV Infected Children 7 to 12 Years of Age",COMPLETED,,PHASE2,130,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 22:38:08,2024-10-14 22:38:08,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00343889,,2006-06-21,2013-09-09,,2013-11-11,2006-06-21,2006-06-23,ESTIMATED,2013-11-11,2013-12-10,ESTIMATED,,,,2013-11-11,2013-12-10,ESTIMATED,2006-08,,2006-08-31,2013-11,2013-11-30,2008-04,ACTUAL,2008-04-30,2007-11,ACTUAL,2007-11-30,,INTERVENTIONAL,,,"Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine","Immunogenicity Study of a DTaP-Hep B-PRP-T Combined Vaccine Compared to Tritanrix-HepB/Hib™, Both Given Concomitantly With the Oral Polio Vaccine at 6, 10, and 14 Weeks of Age in Healthy Infants in the Philippines",COMPLETED,,PHASE3,379,ACTUAL,Sanofi,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:24:49,2024-10-13 20:24:49,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Philippines,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders
NCT00344032,,2006-06-23,2009-11-12,,2018-05-24,2006-06-23,2006-06-26,ESTIMATED,2009-11-12,2009-12-15,ESTIMATED,,,,2018-05-24,2018-07-20,ACTUAL,2006-07-28,,2006-07-28,2016-11,2016-11-30,2007-12-04,ACTUAL,2007-12-04,2007-12-01,ACTUAL,2007-12-01,,INTERVENTIONAL,,,Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women,"Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV-16/18 VLP/AS04 Vaccine Administered Intramuscularly at 0, 1, 6 Months in Healthy Indian Female Subjects Aged 18-35 Yrs",COMPLETED,,PHASE3,354,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 16:07:16,2024-10-13 16:07:16,INDUSTRY,,,,,,,GlaxoSmithKline,India,"Congenital, familial and genetic disorders|Eye disorders|General disorders|Infections and infestations|Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders"
NCT00344318,,2006-06-23,2017-08-31,,2018-05-16,2006-06-23,2006-06-26,ESTIMATED,2018-05-16,2018-12-07,ACTUAL,,,,2018-05-16,2018-12-07,ACTUAL,2006-08-07,ACTUAL,2006-08-07,2018-05,2018-05-31,2007-10-17,ACTUAL,2007-10-17,2007-04-27,ACTUAL,2007-04-27,,INTERVENTIONAL,,,Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine,"To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age",COMPLETED,,PHASE3,806,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 23:24:26,2024-10-14 23:24:26,INDUSTRY,,,,,,,GlaxoSmithKline,Philippines|Poland,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00345358,,2006-06-27,2016-11-28,2012-03-09,2018-07-20,2006-06-27,2006-06-28,ESTIMATED,2018-07-20,2019-01-15,ACTUAL,2012-03-09,2012-03-14,ESTIMATED,2018-07-20,2019-01-15,ACTUAL,2006-09-18,ACTUAL,2006-09-18,2018-07,2018-07-31,2007-11-15,ACTUAL,2007-11-15,2007-11-15,ACTUAL,2007-11-15,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine,"Evaluate Immunogenicity, Safety & Reactogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine Given as Catch-up Immunization in Children Older Than 7 mo of Age or as 3-dose Primary Immunization in Children Before 6 mo of Age",COMPLETED,,PHASE3,600,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 00:09:32,2024-10-13 00:09:32,INDUSTRY,,,,,,,GlaxoSmithKline,Czech Republic|Finland,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00345878,,2006-06-28,2009-11-12,,2018-05-24,2006-06-28,2006-06-29,ESTIMATED,2009-11-12,2009-12-15,ESTIMATED,,,,2018-05-24,2018-07-20,ACTUAL,2006-09-25,,2006-09-25,2016-11,2016-11-30,2007-12-21,ACTUAL,2007-12-21,2007-12-21,ACTUAL,2007-12-21,,INTERVENTIONAL,,,Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years,"Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up",COMPLETED,,PHASE3,271,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 17:21:42,2024-10-14 17:21:42,INDUSTRY,,,,,,,GlaxoSmithKline,Malaysia,"General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders"
NCT00346697,,2006-06-29,2014-07-15,,2014-11-04,2006-06-29,2006-06-30,ESTIMATED,2014-11-04,2014-11-05,ESTIMATED,,,,2014-11-04,2014-11-05,ESTIMATED,2006-10,,2006-10-31,2014-11,2014-11-30,2010-04,ACTUAL,2010-04-30,2010-04,ACTUAL,2010-04-30,,INTERVENTIONAL,,,Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients,"A Randomized, Double-Blind, Placebo-Controlled Study of N-3 Fatty Acid on Plasma Triglyceride Levels in Hypertriglyceridemic HIV Patients Receiving Highly Active Antiretroviral Therapy",COMPLETED,,PHASE4,48,ACTUAL,"Brown, Todd, M.D., Ph.D.",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:15:55,2024-10-13 00:15:55,INDIV,,,,,,,"Brown, Todd, M.D., Ph.D.|GlaxoSmithKline|National Center for Complementary and Integrative Health (NCCIH)",United States,Gastrointestinal disorders|Skin and subcutaneous tissue disorders
NCT00350272,,2006-07-06,2016-02-22,2014-01-20,2023-08-07,2006-07-07,2006-07-10,ESTIMATED,2016-02-22,2016-03-22,ESTIMATED,2014-01-20,2014-02-13,ESTIMATED,2023-08-07,2023-08-30,ACTUAL,2006-05,,2006-05-31,2023-08,2023-08-31,2009-04,ACTUAL,2009-04-30,2007-08,ACTUAL,2007-08-31,,INTERVENTIONAL,,"The baseline analysis population was the safety population, defined as all randomized participants who received at least one dose of the study drug.","Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants","A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected Treatment-naive Participants. There is a 36 Week, Open-label, Extension Phase for Eligible Participants.",COMPLETED,,PHASE2,76,ACTUAL,"Alexion Pharmaceuticals, Inc.",,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,Individual participant data are available to only this study's Principal Investigator upon request.,2024-10-15 00:12:34,2024-10-15 00:12:34,INDUSTRY,,,,,,,"Achillion, a wholly owned subsidiary of Alexion|Alexion Pharmaceuticals, Inc.",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00350298,,2006-07-07,2020-12-10,2010-10-25,2021-01-21,2006-07-07,2006-07-10,ESTIMATED,2021-01-21,2021-02-09,ACTUAL,2010-10-26,2010-11-01,ESTIMATED,2021-01-21,2021-02-09,ACTUAL,2006-07-20,ACTUAL,2006-07-20,2021-01,2021-01-31,2008-06-25,ACTUAL,2008-06-25,2008-06-25,ACTUAL,2008-06-25,,INTERVENTIONAL,,200 subjects who met the eligibility criteria and signed the informed consent randomized to receive study treatment: 101 in the GS-CDA1 and MDX-1388 (Monoclonal antibody (Mab)) treatment group and 99 in the placebo treatment group.,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody to Clostridium Difficile Toxin A (GS-CDA1) and a Human Monoclonal Antibody to Clostridium Difficile Toxin B (MDX-1388) in Patients Being Treated for Clostridium Difficile Associated Disease",COMPLETED,,PHASE2,200,ACTUAL,MassBiologics,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:55:21,2024-10-13 15:55:21,OTHER,,,,,,,MassBiologics|Medarex,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00352053,,2006-07-13,2010-03-05,,2015-06-15,2006-07-13,2006-07-14,ESTIMATED,2010-07-23,2010-08-19,ESTIMATED,,,,2015-06-15,2015-07-14,ESTIMATED,2006-06,,2006-06-30,2015-06,2015-06-30,2013-12,ACTUAL,2013-12-31,2008-09,ACTUAL,2008-09-30,,INTERVENTIONAL,,Safety Analysis Set: participants were randomized and received at least 1 dose of study medication.,Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Tenofovir DF as Part of an Optimized Antiretroviral Regimen in HIV-1-Infected Adolescents",COMPLETED,,PHASE3,87,ACTUAL,Gilead Sciences,"Participants left the study for a number of reasons (eg, turned 18 years old, switched to a different HIV treatment regimen), which led to small numbers of participants analyzed at later time points, and the study was concluded earlier than planned.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:43:52,2024-10-13 15:43:52,INDUSTRY,,,,,,,Gilead Sciences,Brazil|Panama|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00352911,,2006-07-13,2009-04-15,,2010-03-04,2006-07-13,2006-07-17,ESTIMATED,2009-12-22,2010-01-27,ESTIMATED,,,,2010-03-04,2010-03-09,ESTIMATED,2006-07,,2006-07-31,2010-03,2010-03-31,2007-11,ACTUAL,2007-11-30,2007-06,ACTUAL,2007-06-30,,INTERVENTIONAL,,,Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects,"A Randomized, Placebo-controlled, Dose Escalating, Phase II Trial of the Anti -HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects",COMPLETED,,PHASE2,19,ACTUAL,"VGX Pharmaceuticals, LLC",,2,,,,,,,,,,,,,,,,,,,,2024-10-13 18:07:20,2024-10-13 18:07:20,INDUSTRY,,,,,,,"VGX Pharmaceuticals, LLC",United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00353366,,2006-07-17,2011-07-07,,2021-02-23,2006-07-17,2006-07-18,ESTIMATED,2011-07-07,2011-08-03,ESTIMATED,,,,2021-02-23,2021-03-16,ACTUAL,2006-11-16,ACTUAL,2006-11-16,2021-02,2021-02-28,2010-07-17,ACTUAL,2010-07-17,2010-03-31,ACTUAL,2010-03-31,,OBSERVATIONAL,,,To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination,"Open, Multicentric, Post-marketing Surveillance Study to Evaluate Safety and Reactogenicity of GSK Bio's Live Attenuated Oral Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to Prescribing Information, in Filipino Subjects Aged at Least 6 Weeks of Age at the Time of First Vaccination",COMPLETED,,,1439,ACTUAL,GlaxoSmithKline,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 06:52:22,2024-10-13 06:52:22,INDUSTRY,,,,,,FALSE,GlaxoSmithKline,Philippines,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00353977,,2006-07-18,2013-04-30,,2014-06-05,2006-07-18,2006-07-19,ESTIMATED,2014-06-05,2014-07-08,ESTIMATED,,,,2014-06-05,2014-07-08,ESTIMATED,2004-05,,2004-05-31,2014-06,2014-06-30,2008-03,ACTUAL,2008-03-31,2008-03,ACTUAL,2008-03-31,,INTERVENTIONAL,,,Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors,A Pilot Trial of an Accelerated Immunization Schedule With ALVAC-pp65 (vCP260) for Inducing CMV-Specific Immunity in Stem Cell Allotransplant Donors and Healthy Volunteers,COMPLETED,,PHASE2,38,ACTUAL,National Institutes of Health Clinical Center (CC),,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 22:31:13,2024-10-13 22:31:13,NIH,,,,,,,"National Heart, Lung, and Blood Institute (NHLBI)",United States,Blood and lymphatic system disorders|Cardiac disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT00356369,,2006-07-25,2017-04-05,2012-07-26,2018-06-05,2006-07-25,2006-07-26,ESTIMATED,2018-05-08,2018-06-04,ACTUAL,2012-07-26,2012-08-03,ESTIMATED,2018-06-05,2018-07-03,ACTUAL,2006-12-23,ACTUAL,2006-12-23,2018-05,2018-05-31,2008-02-28,ACTUAL,2008-02-28,2007-09-07,ACTUAL,2007-09-07,,INTERVENTIONAL,,,Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine,Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age),COMPLETED,,PHASE2,500,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 05:50:54,2024-10-13 05:50:54,INDUSTRY,,,,,,,GlaxoSmithKline,Lebanon|Philippines|Saudi Arabia,General disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders
NCT00357552,,2006-07-25,2012-05-23,,2018-02-21,2006-07-25,2006-07-27,ESTIMATED,2012-08-23,2012-09-25,ESTIMATED,,,,2018-02-21,2018-03-20,ACTUAL,2008-01,,2008-01-31,2018-02,2018-02-28,2012-05,ACTUAL,2012-05-31,2010-10,ACTUAL,2010-10-31,,INTERVENTIONAL,,,Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy,A Pilot Study of Lopinavir/Ritonavir in Participants Experiencing Virologic Relapse on NNRTI-Containing Regimens,COMPLETED,,NA,123,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 00:09:32,2024-10-13 00:09:32,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),India|Malawi|South Africa|Tanzania|Thailand,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00358917,,2006-07-28,2009-11-12,,2011-04-07,2006-07-28,2006-08-01,ESTIMATED,2010-01-07,2010-02-01,ESTIMATED,,,,2011-04-07,2011-04-11,ESTIMATED,2006-08,,2006-08-31,2011-04,2011-04-30,2008-11,ACTUAL,2008-11-30,2008-11,ACTUAL,2008-11-30,,INTERVENTIONAL,,,Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects,"A Phase 3, Randomized, Open-Label Study of Lopinavir/Ritonavir (LPV/r) Tablets 800/200 Milligram (mg) Once-Daily (QD) Versus 400/100 mg Twice-Daily (BID) When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-Experienced, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects",COMPLETED,,PHASE3,599,ACTUAL,Abbott,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 00:13:26,2024-10-14 00:13:26,INDUSTRY,,,,,,,Abbott,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00359619,,2006-07-18,2012-12-19,2011-02-04,2019-12-27,2006-08-01,2006-08-02,ESTIMATED,2015-01-08,2015-02-10,ESTIMATED,2011-02-04,2011-02-09,ESTIMATED,2019-12-27,2020-01-02,ACTUAL,2006-09-12,ACTUAL,2006-09-12,2019-12,2019-12-31,2007-01-30,ACTUAL,2007-01-30,2007-01-30,ACTUAL,2007-01-30,,INTERVENTIONAL,,,Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine,"A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study",COMPLETED,,PHASE2,383,ACTUAL,GlaxoSmithKline,,7,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=1524,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 11:41:43,2024-10-13 11:41:43,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT00363142,,2006-08-11,2009-06-11,,2010-10-21,2006-08-11,2006-08-15,ESTIMATED,2009-08-21,2009-09-24,ESTIMATED,,,,2010-10-21,2010-11-05,ESTIMATED,2006-05,,2006-05-31,2010-10,2010-10-31,2008-06,ACTUAL,2008-06-30,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,,,A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects,See Detailed Description.,COMPLETED,,PHASE3,211,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 22:26:35,2024-10-14 22:26:35,INDUSTRY,,,,,,,GlaxoSmithKline,Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT00363142,,2006-08-11,2009-06-11,,2010-10-21,2006-08-11,2006-08-15,ESTIMATED,2009-08-21,2009-09-24,ESTIMATED,,,,2010-10-21,2010-11-05,ESTIMATED,2006-05,,2006-05-31,2010-10,2010-10-31,2008-06,ACTUAL,2008-06-30,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,,,A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects,See Detailed Description.,COMPLETED,,PHASE3,211,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 22:26:35,2024-10-14 22:26:35,INDUSTRY,,,,,,,GlaxoSmithKline,Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT00363545,,2006-08-11,2017-01-05,,2018-05-09,2006-08-11,2006-08-15,ESTIMATED,2017-01-05,2017-02-23,ACTUAL,,,,2018-05-09,2018-06-08,ACTUAL,2006-09-01,ACTUAL,2006-09-01,2018-05,2018-05-31,2007-04-12,ACTUAL,2007-04-12,2007-04-12,ACTUAL,2007-04-12,,INTERVENTIONAL,,,"To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)","A Study to Assess the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated HRV Vaccine, Given as a Two-dose Primary Vaccination, in Healthy Infants Previously Uninfected With HRV",COMPLETED,,PHASE3,1274,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 00:55:42,2024-10-13 00:55:42,INDUSTRY,,,,,,,GlaxoSmithKline,Panama,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00364793,,2006-08-15,2014-03-06,,2014-04-11,2006-08-15,2006-08-16,ESTIMATED,2014-03-06,2014-04-11,ESTIMATED,,,,2014-04-11,2014-04-29,ESTIMATED,2007-02,,2007-02-28,2014-04,2014-04-30,2013-07,ACTUAL,2013-07-31,2011-12,ACTUAL,2011-12-31,,INTERVENTIONAL,,Treated participants who received at least one dose of study drug (EFV) were analyzed.,"Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children",An Open-label Study of Liquid and Sprinkled Formulations of Efavirenz Administered in Combination With Didanosine and Emtricitabine in HIV-infected Infants and Children 3 Months to 6 Years of Age.,COMPLETED,,PHASE1/PHASE2,56,ACTUAL,Bristol-Myers Squibb,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 22:37:01,2024-10-13 22:37:01,INDUSTRY,,,,,,,Bristol-Myers Squibb,Argentina|Brazil|Colombia|Mexico|Panama|Russian Federation|South Africa|Thailand,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00366249,,2006-08-17,2009-07-14,,2010-04-22,2006-08-17,2006-08-21,ESTIMATED,2009-07-14,2009-08-21,ESTIMATED,,,,2010-04-22,2010-04-28,ESTIMATED,2007-01,,2007-01-31,2010-04,2010-04-30,2009-03,ACTUAL,2009-03-31,2009-03,ACTUAL,2009-03-31,,INTERVENTIONAL,,,Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.,"A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline Versus Ertapenem for the Treatment of Foot Infections in Subjects With Diabetes",COMPLETED,,PHASE3,1061,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 13:45:03,2024-10-13 13:45:03,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,"Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|Colombia|Croatia|Denmark|Estonia|Finland|France|Germany|Greece|Hungary|India|Italy|Korea, Republic of|Latvia|Lithuania|Mexico|Panama|Peru|Poland|Portugal|Romania|Russian Federation|Slovakia|South Africa|Spain|Sweden|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00367744,,2006-08-21,2016-10-05,,2016-12-08,2006-08-21,2006-08-23,ESTIMATED,2016-12-08,2017-02-06,ESTIMATED,,,,2016-12-08,2017-02-06,ESTIMATED,2006-07,,2006-07-31,2006-08,2006-08-31,2008-12,ACTUAL,2008-12-31,2008-12,ACTUAL,2008-12-31,,INTERVENTIONAL,,,Rosiglitazone Effect on Mitochondria and Lipoatrophy,Placebo Controlled Study of Rosiglitazone in HIV Lipoatrophy,COMPLETED,,PHASE2,71,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),Limitations of the study include a relative small sample size as well as loss of follow up of 9 participants at the end of the study.,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-15 00:06:20,2024-10-15 00:06:20,NIH,,,,,,,GlaxoSmithKline|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Hepatobiliary disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00369824,,2006-08-28,2009-09-03,,2018-05-24,2006-08-28,2006-08-29,ESTIMATED,2009-09-03,2009-10-08,ESTIMATED,,,,2018-05-24,2018-07-20,ACTUAL,2006-09-26,,2006-09-26,2016-11,2016-11-30,2008-02-13,ACTUAL,2008-02-13,2007-11-22,ACTUAL,2007-11-22,,INTERVENTIONAL,,,Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects,"A Randomized, Open Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine Co-administered Intramuscularly With Boostrix® and/or Menactra™ in Healthy Female Subjects Aged 11-18 Years",COMPLETED,,PHASE3,1330,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 03:11:24,2024-10-13 03:11:24,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00369941,,2006-08-29,2009-09-18,,2017-02-14,2006-08-29,2006-08-30,ESTIMATED,2010-04-20,2010-05-11,ESTIMATED,,,,2017-02-14,2017-03-21,ACTUAL,2006-08,,2006-08-31,2017-02,2017-02-28,2012-02,ACTUAL,2012-02-29,2009-05,ACTUAL,2009-05-31,,INTERVENTIONAL,,,"A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)","A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA™",COMPLETED,,PHASE3,566,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 14:01:33,2024-10-14 14:01:33,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Brazil|Canada|Chile|Colombia|France|Germany|India|Italy|Mexico|Peru|Puerto Rico|Spain|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00370396,,2006-08-30,2017-08-31,,2019-06-06,2006-08-30,2006-08-31,ESTIMATED,2018-05-15,2018-11-26,ACTUAL,,,,2019-06-06,2019-06-10,ACTUAL,2006-09-25,ACTUAL,2006-09-25,2019-06,2019-06-30,2007-11-06,ACTUAL,2007-11-06,2007-06-04,ACTUAL,2007-06-04,,INTERVENTIONAL,,,Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.,"To Assess the Safety, Reactogenicity & Immunogenicity of a 4th Dose of GSK Biologicals' Pneumococcal Vaccine or Prevenar™ in Children (12-18 Months) Previously Vaccinated in the Primary Study NCT00307554 With Either Pneumococcal Vaccine or Prevenar™",COMPLETED,,PHASE3,1200,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 06:17:57,2024-10-14 06:17:57,INDUSTRY,,,,,,,GlaxoSmithKline,Finland|France|Poland,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00371150,,2006-08-29,2012-03-22,,2012-03-22,2006-08-31,2006-09-01,ESTIMATED,2012-03-22,2012-04-16,ESTIMATED,,,,2012-03-22,2012-04-16,ESTIMATED,2006-11,,2006-11-30,2012-03,2012-03-31,2011-03,ACTUAL,2011-03-31,2011-03,ACTUAL,2011-03-31,,INTERVENTIONAL,,,Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection,A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Who Are Nucleoside-Naive,COMPLETED,,PHASE4,131,ACTUAL,Bristol-Myers Squibb,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-12 23:35:36,2024-10-12 23:35:36,INDUSTRY,,,,,,,Bristol-Myers Squibb,Brazil|Mexico|Puerto Rico|South Africa|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT00371540,,2006-08-31,2016-08-29,,2016-11-01,2006-08-31,2006-09-04,ESTIMATED,2016-08-29,2016-10-26,ESTIMATED,,,,2016-11-01,2016-12-20,ESTIMATED,2006-02,,2006-02-28,2016-11,2016-11-30,2008-04,ACTUAL,2008-04-30,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,,HIV infected patients who were clinically stable on ART for at least 3 months,Extending HIV Care Beyond the Rural Health Center,Extending HIV Care Beyond the Rural Health Center,COMPLETED,,NA,208,ACTUAL,Indiana University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 01:37:23,2024-10-14 01:37:23,OTHER,,,,,,,Indiana University School of Medicine|Moi Univeristy,Kenya,"Injury, poisoning and procedural complications"
NCT00371631,,2006-08-31,2014-11-13,,2014-11-20,2006-08-31,2006-09-04,ESTIMATED,2014-11-20,2014-11-24,ESTIMATED,,,,2014-11-20,2014-11-24,ESTIMATED,2006-10,,2006-10-31,2014-11,2014-11-30,2008-04,ACTUAL,2008-04-30,2008-02,ACTUAL,2008-02-29,,INTERVENTIONAL,,,Colonizing Neurogenic Bladders With Benign Flora,Colonizing Neurogenic Bladders With Benign Flora,COMPLETED,,PHASE1,13,ACTUAL,VA Office of Research and Development,Lack of placebo control.,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 20:35:44,2024-10-14 20:35:44,FED,,,,,,,US Department of Veterans Affairs,United States,Musculoskeletal and connective tissue disorders|Renal and urinary disorders
NCT00372229,,2006-09-05,2016-12-22,,2020-02-26,2006-09-05,2006-09-06,ESTIMATED,2020-02-26,2020-03-11,ACTUAL,,,,2020-02-26,2020-03-11,ACTUAL,2006-05,,2006-05-31,2020-02,2020-02-29,2015-10,ACTUAL,2015-10-31,2015-10,ACTUAL,2015-10-31,,INTERVENTIONAL,,The safety population included all randomized participants.,A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation,A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration,COMPLETED,,PHASE3,299,ACTUAL,Hoffmann-La Roche,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 18:42:10,2024-10-13 18:42:10,INDUSTRY,,,,,,,Hoffmann-La Roche,Austria|Germany,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00376935,,2006-09-14,2011-10-04,2009-10-20,2021-11-02,2006-09-14,2006-09-15,ESTIMATED,2011-12-22,2012-01-30,ESTIMATED,2009-10-20,2009-10-22,ESTIMATED,2021-11-02,2021-11-04,ACTUAL,2006-12,,2006-12-31,2019-01,2019-01-31,2008-09,ACTUAL,2008-09-30,2008-07,ACTUAL,2008-07-31,,INTERVENTIONAL,,,Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults,A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less,COMPLETED,,PHASE2,99,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 14:37:52,2024-10-13 14:37:52,NIH,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00377403,,2006-09-14,2011-03-31,,2012-12-24,2006-09-14,2006-09-18,ESTIMATED,2011-06-03,2011-06-29,ESTIMATED,,,,2012-12-24,2012-12-28,ESTIMATED,2006-10,,2006-10-31,2012-12,2012-12-31,2010-08,ACTUAL,2010-08-31,2009-05,ACTUAL,2009-05-31,,INTERVENTIONAL,,,Treatment of Acute Sinusitis,Randomized Clinical Trial to Evaluate Guidelines for Acute Rhinosinusitis (Phase IV Study),COMPLETED,,PHASE4,172,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:09:30,2024-10-13 09:09:30,OTHER,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|Washington University School of Medicine,United States,General disorders
NCT00377741,,2006-09-15,2015-11-26,,2015-11-26,2006-09-15,2006-09-18,ESTIMATED,2015-11-26,2015-12-31,ESTIMATED,,,,2015-11-26,2015-12-31,ESTIMATED,2004-12,,2004-12-31,2015-11,2015-11-30,2006-06,ACTUAL,2006-06-30,2006-06,ACTUAL,2006-06-30,,INTERVENTIONAL,,,A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.,"Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant Recipients With or Without Cystic Fibrosis",COMPLETED,,PHASE1,31,ACTUAL,Hoffmann-La Roche,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 11:14:41,2024-10-13 11:14:41,INDUSTRY,,,,,,,Hoffmann-La Roche,United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00378560,,2006-09-18,2010-04-21,,2017-03-20,2006-09-19,2006-09-20,ESTIMATED,2010-05-27,2010-06-29,ESTIMATED,,,,2017-03-20,2017-04-17,ACTUAL,2006-06-12,ACTUAL,2006-06-12,2017-03,2017-03-31,2009-09-16,ACTUAL,2009-09-16,2009-09-16,ACTUAL,2009-09-16,,INTERVENTIONAL,,,V501 Efficacy Study in Women Aged 18 to 26 (V501-027),V501 Phase II Efficacy Study in Women Aged 18 to 26,COMPLETED,,PHASE2,1021,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 20:53:21,2024-10-14 20:53:21,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00379821,,2006-09-21,2011-06-30,2010-07-01,2014-08-07,2006-09-21,2006-09-25,ESTIMATED,2011-06-30,2011-07-27,ESTIMATED,2010-07-01,2010-07-07,ESTIMATED,2014-08-07,2014-08-11,ESTIMATED,2007-02,,2007-02-28,2014-07,2014-07-31,2012-09,ACTUAL,2012-09-30,2009-08,ACTUAL,2009-08-31,,INTERVENTIONAL,,,Chloroquine Alone or in Combination for Malaria in Children in Malawi,"A Longitudinal Study of Chloroquine as Monotherapy or in Combination With Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria in Children in Blantyre, Malawi",COMPLETED,,PHASE3,640,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 04:04:40,2024-10-14 04:04:40,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Malawi,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00380367,,2006-09-22,2009-01-22,,2023-05-02,2006-09-22,2006-09-26,ESTIMATED,2009-03-12,2009-04-14,ESTIMATED,,,,2023-05-02,2023-05-31,ACTUAL,2007-05-03,ACTUAL,2007-05-03,2023-05,2023-05-31,2008-02-04,ACTUAL,2008-02-04,2008-02-04,ACTUAL,2008-02-04,,INTERVENTIONAL,,,"Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)","Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India",COMPLETED,,PHASE3,110,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 00:09:32,2024-10-13 00:09:32,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,India,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00388583,,2006-10-16,2011-07-14,2010-03-30,2012-04-13,2006-10-16,2006-10-17,ESTIMATED,2011-08-10,2011-09-13,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2012-04-13,2012-04-18,ESTIMATED,2006-09,,2006-09-30,2012-04,2012-04-30,2008-09,ACTUAL,2008-09-30,2007-06,ACTUAL,2007-06-30,,INTERVENTIONAL,,,"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects","Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects",COMPLETED,,PHASE2,817,ACTUAL,Sanofi,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 01:17:48,2024-10-13 01:17:48,INDUSTRY,,,,,,,Sanofi,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00388583,,2006-10-16,2011-07-14,2010-03-30,2012-04-13,2006-10-16,2006-10-17,ESTIMATED,2011-08-10,2011-09-13,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2012-04-13,2012-04-18,ESTIMATED,2006-09,,2006-09-30,2012-04,2012-04-30,2008-09,ACTUAL,2008-09-30,2007-06,ACTUAL,2007-06-30,,INTERVENTIONAL,,,"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects","Immunogenicity and Safety of The Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Ambulatory Elderly Subjects",COMPLETED,,PHASE2,817,ACTUAL,Sanofi,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 01:17:48,2024-10-13 01:17:48,INDUSTRY,,,,,,,Sanofi,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00389207,,2006-10-17,2012-01-13,,2013-12-09,2006-10-17,2006-10-18,ESTIMATED,2012-02-20,2012-03-26,ESTIMATED,,,,2013-12-09,2014-01-27,ESTIMATED,2006-10,,2006-10-31,2013-12,2013-12-31,,,,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,,,Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults,"Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.",COMPLETED,,PHASE3,576,ACTUAL,Boehringer Ingelheim,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 22:02:15,2024-10-13 22:02:15,INDUSTRY,,,,,,,Boehringer Ingelheim,Argentina|Germany|Italy|Mexico|Poland|Portugal|Romania|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00390780,,2006-10-19,2012-09-07,,2013-09-05,2006-10-19,2006-10-20,ESTIMATED,2013-07-26,2013-08-29,ESTIMATED,,,,2013-09-05,2013-09-16,ESTIMATED,2006-07,,2006-07-31,2013-02,2013-02-28,2008-01,ACTUAL,2008-01-31,2007-12,ACTUAL,2007-12-31,,INTERVENTIONAL,,,Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients,"A Comparative Randomized, Double-blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of Miconazole Lauriad 50mg Administered Once a Day and Mycelex Troches (Clotrimazole 10mg) Administered Five Times a Day in the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients",COMPLETED,,PHASE3,578,ACTUAL,Valerio Therapeutics,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 23:21:52,2024-10-13 23:21:52,INDUSTRY,,,,,,,Valerio Therapeutics,Canada|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00390910,,2006-10-20,2017-05-05,2009-05-20,2018-06-05,2006-10-20,2006-10-23,ESTIMATED,2018-06-05,2018-12-17,ACTUAL,2009-05-21,2009-09-28,ESTIMATED,2018-06-05,2018-12-17,ACTUAL,2006-10-01,ACTUAL,2006-10-01,2017-05,2017-05-31,2008-05-02,ACTUAL,2008-05-02,2007-07-02,ACTUAL,2007-07-02,,INTERVENTIONAL,,,Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants,Study to Assess the Safety and Immunogenicity of GSK Biologicals 10-valent Pneumococcal Conjugate Vaccine When Co-administered With DTPa-HBV-IPV/Hib (Infanrix-Hexa) Vaccine in Preterm Infants as a 3-dose Primary Immunization Course During the First 6 Months of Life.,COMPLETED,,PHASE3,286,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 18:31:10,2024-10-13 18:31:10,INDUSTRY,,,,,,,GlaxoSmithKline,Greece|Spain,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00391053,,2006-10-20,2010-01-14,,2016-04-12,2006-10-20,2006-10-23,ESTIMATED,2010-03-26,2010-04-30,ESTIMATED,,,,2016-04-12,2016-04-14,ESTIMATED,2006-10,,2006-10-31,2016-04,2016-04-30,2008-02,ACTUAL,2008-02-29,2007-07,ACTUAL,2007-07-31,,INTERVENTIONAL,,,"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly","Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.",COMPLETED,,PHASE3,3851,ACTUAL,Sanofi,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 23:01:29,2024-10-14 23:01:29,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00391053,,2006-10-20,2010-01-14,,2016-04-12,2006-10-20,2006-10-23,ESTIMATED,2010-03-26,2010-04-30,ESTIMATED,,,,2016-04-12,2016-04-14,ESTIMATED,2006-10,,2006-10-31,2016-04,2016-04-30,2008-02,ACTUAL,2008-02-29,2007-07,ACTUAL,2007-07-31,,INTERVENTIONAL,,,"Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly","Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone® in Adults ≥ 65 Years of Age.",COMPLETED,,PHASE3,3851,ACTUAL,Sanofi,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 23:01:29,2024-10-14 23:01:29,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00391391,,2006-10-23,2011-10-12,2010-03-30,2011-11-21,2006-10-23,2006-10-24,ESTIMATED,2011-10-12,2011-11-22,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2011-11-21,2011-12-01,ESTIMATED,2006-10,,2006-10-31,2011-11,2011-11-30,2007-10,ACTUAL,2007-10-31,2007-03,ACTUAL,2007-03-31,,INTERVENTIONAL,,,"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children","Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Healthy Infants and Young Children.",COMPLETED,,PHASE2,520,ACTUAL,Sanofi,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:03:51,2024-10-15 01:03:51,INDUSTRY,,,,,,,Sanofi,United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00391391,,2006-10-23,2011-10-12,2010-03-30,2011-11-21,2006-10-23,2006-10-24,ESTIMATED,2011-10-12,2011-11-22,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2011-11-21,2011-12-01,ESTIMATED,2006-10,,2006-10-31,2011-11,2011-11-30,2007-10,ACTUAL,2007-10-31,2007-03,ACTUAL,2007-03-31,,INTERVENTIONAL,,,"Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children","Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Healthy Infants and Young Children.",COMPLETED,,PHASE2,520,ACTUAL,Sanofi,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:03:51,2024-10-15 01:03:51,INDUSTRY,,,,,,,Sanofi,United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00392808,,2006-10-25,2013-08-06,,2013-08-06,2006-10-25,2006-10-26,ESTIMATED,2013-08-06,2013-10-11,ESTIMATED,,,,2013-08-06,2013-10-11,ESTIMATED,2007-01,,2007-01-31,2013-08,2013-08-31,2009-05,ACTUAL,2009-05-31,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,CSISP-MENC1,,Immunogenicity of the Booster Dose of Two MenC Vaccines,"Randomized, Open Label, Active Control, Parallel Assignment Clinical Trial to Evaluate the Immunogenicity of Polysaccharide Meningococcal C Vaccines Conjugated With Tetanus Toxoid or CRM197 Given as a Booster Dose at 14-18 Months of Life.",COMPLETED,,PHASE4,389,ACTUAL,Centro Superior de Investigación en Salud Publica,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 00:47:13,2024-10-15 00:47:13,OTHER_GOV,,,,,,,Centro Superior de Investigación en Salud Publica,Spain,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00394914,,2006-10-31,2013-08-27,,2015-06-23,2006-10-31,2006-11-02,ESTIMATED,2013-08-27,2013-10-31,ESTIMATED,,,,2015-06-23,2015-07-16,ESTIMATED,2006-08,,2006-08-31,2015-06,2015-06-30,2007-04,ACTUAL,2007-04-30,2007-04,ACTUAL,2007-04-30,,INTERVENTIONAL,,,Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295),A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure,COMPLETED,,PHASE2,311,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 23:21:52,2024-10-13 23:21:52,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Nervous system disorders
NCT00396630,,2006-11-06,2009-02-13,,2018-01-09,2006-11-06,2006-11-07,ESTIMATED,2009-02-13,2009-03-13,ESTIMATED,,,,2018-01-09,2018-02-06,ACTUAL,2007-01-23,ACTUAL,2007-01-23,2017-11,2017-11-30,2008-02-13,ACTUAL,2008-02-13,2008-01-23,ACTUAL,2008-01-23,,INTERVENTIONAL,,,A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.,"A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.",COMPLETED,,PHASE3,200,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 10:03:49,2024-10-14 10:03:49,INDUSTRY,,,,,,,GlaxoSmithKline,Dominican Republic,General disorders|Infections and infestations
NCT00399360,,2006-11-13,2012-05-18,,2012-09-13,2006-11-13,2006-11-14,ESTIMATED,2012-09-13,2012-09-14,ESTIMATED,,,,2012-09-13,2012-09-14,ESTIMATED,2006-12,,2006-12-31,2012-09,2012-09-30,2012-06,ACTUAL,2012-06-30,2011-06,ACTUAL,2011-06-30,,INTERVENTIONAL,,,Lifestyle Modification and Metformin Use in the Treatment of HIV,Strategies for the Treatment of HIV Associated Metabolic Syndrome,COMPLETED,,NA,50,ACTUAL,Massachusetts General Hospital,The study was relatively small and may have been underpowered to assess effect on secondary endpoints and to assess the effects of lifestyle modification. The sample size may have limited our ability to determine differences in dropout rates.,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:01:52,2024-10-13 06:01:52,OTHER,,,,,,,Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),United States,Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders
NCT00402727,,2006-11-21,2009-10-13,,2014-11-03,2006-11-21,2006-11-22,ESTIMATED,2009-12-08,2010-01-11,ESTIMATED,,,,2014-11-03,2014-11-07,ESTIMATED,2006-09,,2006-09-30,2014-11,2014-11-30,2008-06,ACTUAL,2008-06-30,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,,,Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection,"A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections",COMPLETED,,PHASE3,813,ACTUAL,Bayer,Ten patients (six from the moxifloxacin group and 4 from the comparator group) did not receive study medication. They were excluded from the safety analyses. No adverse events were reported in these patients.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:23:16,2024-10-14 18:23:16,INDUSTRY,,,,,,,Bayer,Austria|Belgium|Bulgaria|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Latvia|Lithuania|Netherlands|Poland|Romania|Russian Federation|South Africa|Spain|Ukraine|United Kingdom,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00405704,,2006-11-29,2014-12-04,,2020-04-13,2006-11-29,2006-11-30,ESTIMATED,2015-04-15,2015-04-16,ESTIMATED,,,,2020-04-13,2020-04-21,ACTUAL,2007-05,ACTUAL,2007-05-31,2020-04,2020-04-30,2014-05,ACTUAL,2014-05-31,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,RIVUR,,Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR),Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR),COMPLETED,,PHASE3,607,ACTUAL,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Results may not apply to children with different demographic or clinical characteristics or in locales where choice of TMP-SMZ may be limited by susceptibility patterns or clinical acceptability. Some subgroup analyses had limited statistical power.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://repository.niddk.nih.gov/studies/rivur/?query=rivur,YES,Data are available at the NIDDK Central Repository: https://repository.niddk.nih.gov/studies/rivur/?query=rivur,2024-10-13 10:37:14,2024-10-13 10:37:14,NIH,,,,,,,"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of North Carolina, Chapel Hill",Canada|United States,General disorders
NCT00405821,,2006-11-29,2012-07-18,,2012-08-28,2006-11-29,2006-11-30,ESTIMATED,2012-08-28,2012-09-28,ESTIMATED,,,,2012-08-28,2012-09-28,ESTIMATED,2006-11,,2006-11-30,2012-08,2012-08-31,2010-11,ACTUAL,2010-11-30,2010-10,ACTUAL,2010-10-31,,INTERVENTIONAL,,,Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda,"A Randomized, Double-Blind, Placebo-Controlled Trial of Acyclovir Prophylaxis Versus Placebo Among HIV-1/HSV-2 Co-Infected Individuals in Uganda",COMPLETED,,PHASE2,440,ACTUAL,National Institutes of Health Clinical Center (CC),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 00:36:58,2024-10-14 00:36:58,NIH,,,,,,,Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)|Translational Genomics Research Institute|University of Washington,Uganda|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00411645,,2006-12-12,2015-05-15,2014-07-21,2021-06-02,2006-12-12,2006-12-14,ESTIMATED,2015-05-15,2015-06-03,ESTIMATED,2014-07-21,2014-07-24,ESTIMATED,2021-06-02,2021-06-11,ACTUAL,2006-12-13,ACTUAL,2006-12-13,2021-06,2021-06-30,2009-05-23,ACTUAL,2009-05-23,2008-11-10,ACTUAL,2008-11-10,,INTERVENTIONAL,,,Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients,"A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.",COMPLETED,,PHASE3,681,ACTUAL,Takeda,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 05:56:17,2024-10-13 05:56:17,INDUSTRY,,,,,,,Shire,Belgium|Canada|France|Germany|Italy|Spain|Sweden|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00411749,,2006-12-14,2010-07-19,,2017-03-23,2006-12-14,2006-12-15,ESTIMATED,2010-07-19,2010-08-18,ESTIMATED,,,,2017-03-23,2017-04-21,ACTUAL,2006-12-11,ACTUAL,2006-12-11,2017-03,2017-03-31,2009-09-18,ACTUAL,2009-09-18,2009-09-18,ACTUAL,2009-09-18,,INTERVENTIONAL,,,V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028),V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years,COMPLETED,,PHASE2,107,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-15 02:48:17,2024-10-15 02:48:17,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00412893,,2006-12-18,2015-03-19,2014-03-12,2019-03-25,2006-12-18,2006-12-19,ESTIMATED,2015-03-19,2015-03-31,ESTIMATED,2014-03-12,2014-04-09,ESTIMATED,2019-03-25,2019-04-05,ACTUAL,2007-03-07,ACTUAL,2007-03-07,2019-03,2019-03-31,2013-03-28,ACTUAL,2013-03-28,2013-03-28,ACTUAL,2013-03-28,,INTERVENTIONAL,,Intent-to-treat (ITT) population consisted of all randomized participants who received at least one administration of study drug.,Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis,"A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.",COMPLETED,,PHASE3,527,ACTUAL,Astellas Pharma Inc,"Company makes no warranties or representations of any kind as to the posting, expressed or implied, including warranties of merchantability and fitness for a particular purpose, and shall not be liable for any damages.",2,,,FALSE,,,,TRUE,,,,,,,,Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.,"Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.",https://www.clinicalstudydatarequest.com/,YES,"Access to anonymized individual participant level data collected during the trial, in addition to study-related supporting documentation, is planned for trials conducted with approved product indications and formulations, as well as compounds terminated during development. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.",2024-10-15 02:53:42,2024-10-15 02:53:42,INDUSTRY,,,,,,,Astellas Pharma Inc|Basilea Pharmaceutica International Ltd,"Argentina|Australia|Belgium|Brazil|Canada|Chile|China|Colombia|Egypt|France|Germany|Hungary|India|Israel|Italy|Korea, Republic of|Lebanon|Malaysia|Mexico|Netherlands|New Zealand|Peru|Philippines|Poland|Russian Federation|Saudi Arabia|Singapore|South Africa|Spain|Switzerland|Thailand|Turkey|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00413153,,2006-12-15,2009-11-04,,2010-03-05,2006-12-18,2006-12-19,ESTIMATED,2010-01-26,2010-03-03,ESTIMATED,,,,2010-03-05,2010-03-09,ESTIMATED,2006-05,,2006-05-31,2010-03,2010-03-31,2008-12,ACTUAL,2008-12-31,2008-12,ACTUAL,2008-12-31,,INTERVENTIONAL,,,Metabolic Effects of Switching Kaletra to Boosted Reyataz,Metabolic Effects of Switching Kaletra to Boosted Reyataz,COMPLETED,,NA,15,ACTUAL,Massachusetts General Hospital,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:15:37,2024-10-13 08:15:37,OTHER,,,,,,,Bristol-Myers Squibb|Massachusetts General Hospital,United States,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Skin and subcutaneous tissue disorders
NCT00414518,,2006-12-19,2012-09-06,,2013-01-16,2006-12-19,2006-12-21,ESTIMATED,2013-01-16,2013-02-20,ESTIMATED,,,,2013-01-16,2013-02-20,ESTIMATED,2007-01,,2007-01-31,2013-01,2013-01-31,2010-02,ACTUAL,2010-02-28,2010-02,ACTUAL,2010-02-28,,INTERVENTIONAL,,,Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection,An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States,COMPLETED,,NA,16,ACTUAL,"University of Colorado, Denver",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:06:14,2024-10-15 02:06:14,OTHER,,,,,,,"National Institute of Allergy and Infectious Diseases (NIAID)|University of Colorado, Denver",United States|Zimbabwe,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00414635,,2006-12-20,2010-07-22,,2017-08-24,2006-12-20,2006-12-21,ESTIMATED,2010-12-06,2011-01-04,ESTIMATED,,,,2017-08-24,2017-09-25,ACTUAL,2006-08,,2006-08-31,2017-07,2017-07-31,2009-12,ACTUAL,2009-12-31,2009-12,ACTUAL,2009-12-31,,INTERVENTIONAL,,,"FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment","A Randomized Controlled Trial of a Weekly Schedule of Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment (5/2 Intermittent Treatment Schedule) Versus Continuous Treatment in Individuals With Virologic Suppression on This Combination",COMPLETED,,PHASE4,60,ACTUAL,Community Research Initiative of New England,"Conclusions are limited by the small ""n"" studied. The results are only applicable to the specific drug regimen studied and thus can not be generalized to all ART. We only studied individuals already virologically undetectable.",2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-15 03:24:24,2024-10-15 03:24:24,OTHER,,,,,,,Community Research Initiative of New England|The Campbell Foundation,United States,General disorders|Skin and subcutaneous tissue disorders
NCT00420316,,2007-01-10,2017-01-05,,2018-07-23,2007-01-10,2007-01-11,ESTIMATED,2017-01-05,2017-02-23,ACTUAL,,,,2018-07-23,2018-08-28,ACTUAL,2007-02-12,ACTUAL,2007-02-12,2018-07,2018-07-31,2007-08-08,ACTUAL,2007-08-08,2007-08-08,ACTUAL,2007-08-08,,INTERVENTIONAL,,,Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.,To Assess Long-term Efficacy & Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine (Rotarix) in the Primary Vaccination Study (102247).,COMPLETED,,PHASE3,1613,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 12:31:22,2024-10-13 12:31:22,INDUSTRY,,,,,,,GlaxoSmithKline,Finland,"Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00420745,,2007-01-09,2009-03-13,,2018-05-08,2007-01-09,2007-01-11,ESTIMATED,2009-03-13,2009-05-04,ESTIMATED,,,,2018-05-08,2018-06-08,ACTUAL,2007-01-25,,2007-01-25,2016-11,2016-11-30,2008-03-25,ACTUAL,2008-03-25,2008-03-01,ACTUAL,2008-03-01,,INTERVENTIONAL,,,"To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants","Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants",COMPLETED,,PHASE3,1009,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 19:23:54,2024-10-14 19:23:54,INDUSTRY,,,,,,,GlaxoSmithKline,France|Poland|Portugal|Spain,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00423046,,2007-01-16,2009-11-12,,2019-12-27,2007-01-16,2007-01-17,ESTIMATED,2010-07-29,2010-08-25,ESTIMATED,,,,2019-12-27,2020-01-02,ACTUAL,2007-01-24,ACTUAL,2007-01-24,2019-12,2019-12-31,2012-05-14,ACTUAL,2012-05-14,2008-03-07,ACTUAL,2008-03-07,,INTERVENTIONAL,,,Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age,"Phase IIIb, Observer-blind Study to Compare Immunogenicity of GSK Biologicals' HPV-16/18 L1/AS04 Vaccine Versus Gardasil® [Quadrivalent Human Papillomavirus (HPV-6,11,16,18 L1 VLP) Recombinant Vaccine Merck & Co., Inc.]",COMPLETED,,PHASE3,1106,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=206,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 19:29:55,2024-10-14 19:29:55,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00423657,,2007-01-16,2010-10-12,,2017-02-02,2007-01-16,2007-01-18,ESTIMATED,2010-10-12,2010-11-18,ESTIMATED,,,,2017-02-02,2017-03-14,ACTUAL,2007-03,,2007-03-31,2017-02,2017-02-28,2007-12,ACTUAL,2007-12-31,2007-12,ACTUAL,2007-12-31,,INTERVENTIONAL,,,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,"A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection (cSSSI)",COMPLETED,,PHASE3,680,ACTUAL,Forest Laboratories,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 03:05:50,2024-10-15 03:05:50,INDUSTRY,,,,,,,Forest Laboratories,Argentina|Austria|Brazil|Chile|Germany|Latvia|Mexico|Poland|Russian Federation|Ukraine|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00424190,,2007-01-16,2010-10-12,,2017-02-02,2007-01-16,2007-01-18,ESTIMATED,2010-10-12,2010-11-07,ESTIMATED,,,,2017-02-02,2017-03-14,ACTUAL,2007-02,,2007-02-28,2017-02,2017-02-28,2007-11,ACTUAL,2007-11-30,2007-11,ACTUAL,2007-11-30,,INTERVENTIONAL,cSSSI,,Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections,"A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection",COMPLETED,,PHASE3,698,ACTUAL,Forest Laboratories,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 00:47:13,2024-10-15 00:47:13,INDUSTRY,,,,,,,Forest Laboratories,Argentina|Brazil|Chile|Germany|Mexico|Peru|Poland|Romania|Russian Federation|Ukraine|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00426361,,2007-01-23,2009-11-12,2009-08-20,2018-05-24,2007-01-23,2007-01-24,ESTIMATED,2010-07-30,2010-08-23,ESTIMATED,2009-08-20,2009-08-21,ESTIMATED,2018-05-24,2018-07-20,ACTUAL,2007-02-13,,2007-02-13,2017-04,2017-04-30,2008-07-25,ACTUAL,2008-07-25,2008-03-17,ACTUAL,2008-03-17,,INTERVENTIONAL,,,Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects,A Multicentre Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) Co-administered With Boostrix Polio (dTpa-IPV) in Healthy Female Subjects Aged 10-18 Years,COMPLETED,,PHASE3,751,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 13:01:13,2024-10-14 13:01:13,INDUSTRY,,,,,,,GlaxoSmithKline,France|Germany|Norway|Spain,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders"
NCT00426660,,2007-01-22,2011-06-02,,2016-05-23,2007-01-23,2007-01-25,ESTIMATED,2011-09-12,2011-10-17,ESTIMATED,,,,2016-05-23,2016-06-29,ESTIMATED,2007-02,,2007-02-28,2016-05,2016-05-31,2010-06,ACTUAL,2010-06-30,2010-06,ACTUAL,2010-06-30,,INTERVENTIONAL,,,Expanded Access Program for Maraviroc At Multiple Centers,"A Multicenter, Open Label, Expanded Access Trial Of Maraviroc",COMPLETED,,PHASE3,1047,ACTUAL,ViiV Healthcare,"Viral loads were not available for subjects uniformly as this expanded access study followed local country guidelines and practices that could vary significantly between countries, and testing frequency may have been affected by insurance status.",1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 16:57:09,2024-10-14 16:57:09,INDUSTRY,,,,,,,ViiV Healthcare,Argentina|Australia|Austria|Belgium|Canada|Chile|Colombia|Costa Rica|Dominican Republic|France|Germany|Greece|Hong Kong|India|Ireland|Italy|Malaysia|Mexico|Netherlands|Peru|Portugal|Puerto Rico|Romania|Spain|Switzerland|Taiwan|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00427895,,2007-01-25,2012-08-01,,2021-11-11,2007-01-26,2007-01-29,ESTIMATED,2012-08-01,2012-09-05,ESTIMATED,,,,2021-11-11,2021-11-15,ACTUAL,2007-02-27,ACTUAL,2007-02-27,2021-11,2021-11-30,2011-08-01,ACTUAL,2011-08-01,2011-08-01,ACTUAL,2011-08-01,,INTERVENTIONAL,,,Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults,"A Phase 3, Randomized, Active-controlled, Modified Double-blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-valent Pneumococcal Conjugate Vaccine (13vpnc) Compared To A 23-valent Pneumococcal Polysaccharide Vaccine (23vps) In Adults 60 To 64 Years Old Who Are Naive To 23vps And The Safety, Tolerability, And Immunogenicity Of 13vpnc In Adults 18-59 Years Old Who Are Naïve To 23vps",COMPLETED,,PHASE3,2141,ACTUAL,Pfizer,,7,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 18:31:10,2024-10-13 18:31:10,INDUSTRY,,,,,,,Pfizer,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00427908,,2007-01-26,2017-05-04,2012-08-02,2018-05-08,2007-01-26,2007-01-29,ESTIMATED,2018-05-08,2018-06-04,ACTUAL,2012-08-02,2012-08-07,ESTIMATED,2018-05-08,2018-06-04,ACTUAL,2007-02-07,ACTUAL,2007-02-07,2018-05,2018-05-31,2007-12-03,ACTUAL,2007-12-03,2007-12-03,ACTUAL,2007-12-03,,INTERVENTIONAL,,,Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612,Evaluate Non-Inferiority and Persistence of the Immune Response of GSK Biologicals' Meningococcal Vaccine 134612 Versus Meningitec™ or Mencevax™ ACWY in Healthy Subjects (1-10 Years of Age),COMPLETED,,PHASE2,613,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 18:59:42,2024-10-14 18:59:42,INDUSTRY,,,,,,,GlaxoSmithKline,Finland,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00432042,,2007-02-05,2017-09-01,,2018-02-19,2007-02-05,2007-02-06,ESTIMATED,2018-02-19,2018-03-19,ACTUAL,,,,2018-02-19,2018-03-19,ACTUAL,2007-01-12,ACTUAL,2007-01-12,2018-02,2018-02-28,2008-03-27,ACTUAL,2008-03-27,2008-03-27,ACTUAL,2008-03-27,,INTERVENTIONAL,,,Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035),"An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age",COMPLETED,,PHASE3,955,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 20:01:59,2024-10-13 20:01:59,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany|Italy,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00432380,,2007-02-06,2017-03-23,,2019-12-27,2007-02-06,2007-02-07,ESTIMATED,2017-09-05,2017-09-11,ACTUAL,,,,2019-12-27,2020-01-02,ACTUAL,2007-03-09,ACTUAL,2007-03-09,2019-12,2019-12-31,2007-09-04,ACTUAL,2007-09-04,2007-09-04,ACTUAL,2007-09-04,,INTERVENTIONAL,,,A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.,Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Liquid Vaccine (GSK 357941A) in Healthy Infants.,COMPLETED,,PHASE2,375,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=273,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 07:59:37,2024-10-13 07:59:37,INDUSTRY,,,,,,,GlaxoSmithKline,Philippines,General disorders|Immune system disorders|Infections and infestations
NCT00433992,,2007-02-09,2017-03-28,,2017-09-01,2007-02-09,2007-02-12,ESTIMATED,2017-06-16,2017-07-31,ACTUAL,,,,2017-09-01,2017-09-05,ACTUAL,2006-04,,2006-04-30,2017-09,2017-09-30,2009-12,ACTUAL,2009-12-31,2009-10,ACTUAL,2009-10-31,,OBSERVATIONAL,,,Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications,Effects of Thymidine Sparing Regimens on Mitochondrial Metabolism and Adipocyte Apoptosis,COMPLETED,,,56,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),Limitations included small sample size and premature study discontinuation before week 96,,2,,FALSE,,,,TRUE,,,,,,SAMPLES_WITH_DNA,Blood collection,,,,NO,,2024-10-13 06:57:59,2024-10-13 06:57:59,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT00434512,,2007-02-12,2019-02-08,2009-06-08,2019-09-04,2007-02-12,2007-02-13,ESTIMATED,2019-09-04,2019-10-01,ACTUAL,2009-09-28,2009-09-30,ESTIMATED,2019-09-04,2019-10-01,ACTUAL,2007-02-20,ACTUAL,2007-02-20,2019-09,2019-09-30,2008-06-13,ACTUAL,2008-06-13,2008-06-13,ACTUAL,2008-06-13,,INTERVENTIONAL,,,Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers,"A Dose-ranging Study to Compare the Safety and Immunogenicity of a Candidate Human Deficiency Virus (HIV) Vaccine 732461, Adjuvanted or Not, Administered According to a 0, 1 Month Schedule to Healthy Adult HIV Seronegative Volunteers.",COMPLETED,,PHASE2,180,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2024-10-14 00:25:50,2024-10-14 00:25:50,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00435929,,2007-02-15,2015-12-02,,2018-02-28,2007-02-15,2007-02-16,ESTIMATED,2015-12-02,2016-01-08,ESTIMATED,,,,2018-02-28,2018-03-29,ACTUAL,2006-09,,2006-09-30,2018-02,2018-02-28,2009-11,ACTUAL,2009-11-30,2009-11,ACTUAL,2009-11-30,,INTERVENTIONAL,,,A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.,Effect of Moderate Liver Impairment on the Pharmacokinetics of Saquinavir After Administration of Saquinavir/Ritonavir 1000/100mg BID in HIV Patients,COMPLETED,,PHASE1,16,ACTUAL,Hoffmann-La Roche,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 02:52:02,2024-10-14 02:52:02,INDUSTRY,,,,,,,Hoffmann-La Roche,Canada|Puerto Rico|United States,Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders
NCT00440297,,2007-02-26,2009-03-24,,2017-03-16,2007-02-26,2007-02-27,ESTIMATED,2009-05-18,2009-07-08,ESTIMATED,,,,2017-03-16,2017-04-13,ACTUAL,2006-12,,2006-12-31,2017-03,2017-03-31,2008-05,ACTUAL,2008-05-31,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,,All vaccinated participants,Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060),"A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process",COMPLETED,,PHASE3,277,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 08:23:13,2024-10-14 08:23:13,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Canada|Italy|Spain|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00440947,,2007-02-23,2011-05-19,2010-05-14,2012-03-15,2007-02-26,2007-02-27,ESTIMATED,2011-07-21,2011-08-17,ESTIMATED,2010-11-18,2010-11-25,ESTIMATED,2012-03-15,2012-03-22,ESTIMATED,2007-03,,2007-03-31,2011-07,2011-07-31,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection,See Detailed Description,COMPLETED,,PHASE3,515,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:07:31,2024-10-13 20:07:31,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Canada|Puerto Rico|United States,"Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00440947,,2007-02-23,2011-05-19,2010-05-14,2012-03-15,2007-02-26,2007-02-27,ESTIMATED,2011-07-21,2011-08-17,ESTIMATED,2010-11-18,2010-11-25,ESTIMATED,2012-03-15,2012-03-22,ESTIMATED,2007-03,,2007-03-31,2011-07,2011-07-31,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection,See Detailed Description,COMPLETED,,PHASE3,515,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:07:31,2024-10-13 20:07:31,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Canada|Puerto Rico|United States,"Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00442962,,2007-03-02,2011-07-13,,2018-09-11,2007-03-02,2007-03-05,ESTIMATED,2011-07-13,2011-08-09,ESTIMATED,,,,2018-09-11,2018-10-12,ACTUAL,2007-05,,2007-05-31,2018-09,2018-09-30,2010-12,ACTUAL,2010-12-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,Nearly Naive,,HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV,"The Effect of Prior Short Course Combination Antiretroviral Therapy Administered for the Prevention of Mother-to-Child Transmission (pMTCT) of HIV-1 on Subsequent Treatment Efficacy in Treatment-""Nearly Naive"" Participants",COMPLETED,,PHASE4,54,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:13:39,2024-10-14 13:13:39,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Peru|Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00443846,,2007-03-05,2017-09-08,,2017-09-08,2007-03-05,2007-03-06,ESTIMATED,2017-09-08,2018-06-20,ACTUAL,,,,2017-09-08,2018-06-20,ACTUAL,2007-02-13,ACTUAL,2007-02-13,2017-09,2017-09-30,2007-10-23,ACTUAL,2007-10-23,2007-09-04,ACTUAL,2007-09-04,,INTERVENTIONAL,,All randomized participants,RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016),"An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants",COMPLETED,,PHASE3,247,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-14 01:31:21,2024-10-14 01:31:21,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Finland,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00444951,,2007-03-07,2011-02-09,,2015-06-16,2007-03-07,2007-03-08,ESTIMATED,2011-02-09,2011-03-04,ESTIMATED,,,,2015-06-16,2015-07-14,ESTIMATED,2007-02,,2007-02-28,2015-06,2015-06-30,2009-02,ACTUAL,2009-02-28,2008-02,ACTUAL,2008-02-29,,INTERVENTIONAL,,,Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia,"Evaluation of the Response to a Single Dose of Menactra® in Adolescents Aged 16 to 19 Years Who Previously Received One Dose of Quadrivalent (A, C, Y, W 135) and at Least One Dose of Bivalent (A, C) Meningococcal Polysaccharide Vaccine in Saudi Arabia.",COMPLETED,,PHASE3,450,ACTUAL,Sanofi,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 03:05:32,2024-10-14 03:05:32,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Saudi Arabia,Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT00445146,,2007-02-28,2016-03-23,,2016-03-23,2007-03-07,2007-03-08,ESTIMATED,2016-03-23,2016-04-25,ESTIMATED,,,,2016-03-23,2016-04-25,ESTIMATED,2007-02,,2007-02-28,2016-03,2016-03-31,2015-03,ACTUAL,2015-03-31,2015-03,ACTUAL,2015-03-31,,INTERVENTIONAL,,Safety Analysis Set: enrolled participants who received at least 1 dose of EVG,Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection,"A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Subjects",COMPLETED,,PHASE2,192,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 13:13:39,2024-10-14 13:13:39,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00448669,,2007-03-16,2015-05-22,,2020-01-24,2007-03-16,2007-03-19,ESTIMATED,2020-01-24,2020-02-05,ACTUAL,,,,2020-01-24,2020-02-05,ACTUAL,2007-03,,2007-03-31,2016-02,2016-02-29,2011-03,ACTUAL,2011-03-31,2011-03,ACTUAL,2011-03-31,,INTERVENTIONAL,TDF2,A total of 1219 underwent randomization. Of the 611 assigned to TDF-FTC: 9 did not start TDF-FTC and 1 was HIV-infected at enrollment. Of the 608 assigned to placebo: 7 did not start placebo and 2 were HIV-infected at enrollment.,Botswana TDF/FTC Oral HIV Prophylaxis Trial,Study of the Safety and Efficacy of Daily Oral Antiretroviral Use for the Prevention of HIV Infection in Heterosexually Active Young Adults in Botswana,COMPLETED,,PHASE2/PHASE3,1219,ACTUAL,Centers for Disease Control and Prevention,"The rates of study completion were lower than predicted because more participants withdrew from the study, mostly due to relocation or conflicting obligations.Findings may not be generalizable to other populations.",2,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,Data sharing will be governed by prevailing CDC data sharing policies.,2024-10-13 13:33:57,2024-10-13 13:33:57,FED,,,,,,,Botswana Ministry of Health|Centers for Disease Control and Prevention|Gilead Sciences,Botswana|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00450437,,2007-03-21,2010-03-19,2009-08-03,2015-01-15,2007-03-21,2007-03-22,ESTIMATED,2010-08-31,2010-09-24,ESTIMATED,2009-08-03,2009-08-10,ESTIMATED,2015-01-15,2015-01-28,ESTIMATED,2007-03,,2007-03-31,2015-01,2015-01-31,2008-01,ACTUAL,2008-01-31,2007-08,ACTUAL,2007-08-31,,INTERVENTIONAL,,,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults,"A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine",COMPLETED,,PHASE3,3539,ACTUAL,Novartis,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 14:07:45,2024-10-14 14:07:45,INDUSTRY,,,,,,,Novartis Vaccines,United States,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00450580,,2007-03-21,2009-07-24,,2012-05-31,2007-03-21,2007-03-22,ESTIMATED,2009-07-24,2009-09-02,ESTIMATED,,,,2012-05-31,2012-06-07,ESTIMATED,2007-03,,2007-03-31,2012-04,2012-04-30,2008-08,ACTUAL,2008-08-31,2008-08,ACTUAL,2008-08-31,,INTERVENTIONAL,,,HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults,"Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.",COMPLETED,,PHASE3,212,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 21:50:37,2024-10-13 21:50:37,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Belgium|France|Germany|Italy|Romania|Russian Federation|Spain|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00450580,,2007-03-21,2009-07-24,,2012-05-31,2007-03-21,2007-03-22,ESTIMATED,2009-07-24,2009-09-02,ESTIMATED,,,,2012-05-31,2012-06-07,ESTIMATED,2007-03,,2007-03-31,2012-04,2012-04-30,2008-08,ACTUAL,2008-08-31,2008-08,ACTUAL,2008-08-31,,INTERVENTIONAL,,,HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults,"Study of Once-Daily Versus Twice-Daily Fosamprenavir Plus Ritonavir, Administered With Abacavir/Lamivudine Once-Daily in Antiretroviral-Naive HIV-1 Infected Adult Subjects.",COMPLETED,,PHASE3,212,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 21:50:37,2024-10-13 21:50:37,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Belgium|France|Germany|Italy|Romania|Russian Federation|Spain|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00452452,,2007-03-23,2010-03-26,2009-01-21,2012-07-06,2007-03-26,2007-03-27,ESTIMATED,2012-07-06,2012-08-15,ESTIMATED,2009-07-31,2009-10-01,ESTIMATED,2012-07-06,2012-08-15,ESTIMATED,2007-07,,2007-07-31,2012-07,2012-07-31,2008-03,ACTUAL,2008-03-31,2008-03,ACTUAL,2008-03-31,,INTERVENTIONAL,,,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children,"A Phase 3 Open-label Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Older Infants and Children Who Are Naive to Previous Vaccination With Pneumococcal Conjugate Vaccine.",COMPLETED,,PHASE3,355,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 13:56:51,2024-10-13 13:56:51,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,Poland,"Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00452790,,2007-03-23,2010-10-13,,2011-03-22,2007-03-26,2007-03-27,ESTIMATED,2010-10-13,2010-11-15,ESTIMATED,,,,2011-03-22,2011-03-24,ESTIMATED,2007-06,,2007-06-30,2011-03,2011-03-31,2010-02,ACTUAL,2010-02-28,2009-10,ACTUAL,2009-10-31,,INTERVENTIONAL,,,Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India,"A Phase 3, Randomised, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Paediatric Vaccinations in India",COMPLETED,,PHASE3,708,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,"Geometric Mean Concentration Outcome Measures were identified as secondary analysis in the study protocol, but are included to maintain consistency with other postings for this program.",2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-15 02:12:28,2024-10-15 02:12:28,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,India,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00453986,,2007-03-28,2012-04-23,2009-09-03,2018-08-27,2007-03-28,2007-03-29,ESTIMATED,2012-04-23,2012-05-22,ESTIMATED,2009-09-03,2009-09-04,ESTIMATED,2018-08-27,2018-09-25,ACTUAL,2007-04-09,,2007-04-09,2016-11,2016-11-30,2008-05-21,ACTUAL,2008-05-21,2007-11-30,ACTUAL,2007-11-30,,INTERVENTIONAL,,,"Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults","Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax™ and Evaluation of the Co-Administration With Fluarix™ of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age",COMPLETED,,PHASE3,1352,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 09:09:30,2024-10-13 09:09:30,INDUSTRY,,,,,,,GlaxoSmithKline,Lebanon|Philippines,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications"
NCT00454181,,2007-03-29,2010-11-09,,2011-09-12,2007-03-29,2007-03-30,ESTIMATED,2010-12-14,2011-01-13,ESTIMATED,,,,2011-09-12,2011-09-16,ESTIMATED,2007-02,,2007-02-28,2011-09,2011-09-30,2009-10,ACTUAL,2009-10-31,2009-09,ACTUAL,2009-09-30,,INTERVENTIONAL,,,Treatment of Oral Warts in HIV+ Patients,Evaluation of Natural Human Interferon Alpha Administered Oromucosally in the Treatment of Oral Warts in HIV-seropositive Subjects Receiving Combination Anti-retroviral Therapy: A Phase 2 Clinical Trial,COMPLETED,,PHASE2,59,ACTUAL,"Ainos, Inc. (f/k/a Amarillo Biosciences Inc.","Only 59 of 80 planned subjects were randomized, so statistical power of the study was limited.",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 01:15:10,2024-10-15 01:15:10,INDUSTRY,,,,,,,"Ainos, Inc. (f/k/a Amarillo Biosciences Inc.",United States,"Gastrointestinal disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT00454909,,2007-03-30,2017-03-01,2009-09-03,2018-05-08,2007-03-30,2007-04-02,ESTIMATED,2017-03-01,2017-04-12,ACTUAL,2009-09-03,2009-09-04,ESTIMATED,2018-05-08,2018-06-08,ACTUAL,2007-04-23,,2007-04-23,2017-04,2017-04-30,2008-04-11,ACTUAL,2008-04-11,2007-10-31,ACTUAL,2007-10-31,,INTERVENTIONAL,,,Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.,"Study to Assess Immunogenicity, Reactogenicity and Safety of 1 Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 vs. 1 Dose of Sanofi-Pasteur's Menactra® in Healthy Subjects 10-25 Years.",COMPLETED,,PHASE2,873,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 08:23:13,2024-10-14 08:23:13,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT00457665,,2007-04-04,2019-05-08,,2019-05-08,2007-04-05,2007-04-06,ESTIMATED,2019-05-08,2019-07-18,ACTUAL,,,,2019-05-08,2019-07-18,ACTUAL,2002-02,,2002-02-28,2019-05,2019-05-31,2014-10,ACTUAL,2014-10-31,2007-10,ACTUAL,2007-10-31,,INTERVENTIONAL,,,Mechanisms of Lipodystrophy in HIV-Infected Pateints,Mecahnisms of Lipodystrophy in HIV-Infected Patients,COMPLETED,,PHASE4,56,ACTUAL,University of Texas Southwestern Medical Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 06:23:59,2024-10-14 06:23:59,OTHER,,,,,,,Bristol-Myers Squibb|GlaxoSmithKline|University of Texas Southwestern Medical Center,United States,Gastrointestinal disorders|Hepatobiliary disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT00458302,,2007-04-06,2010-02-04,,2012-12-14,2007-04-06,2007-04-10,ESTIMATED,2010-02-04,2010-02-26,ESTIMATED,,,,2012-12-14,2012-12-19,ESTIMATED,2007-06,,2007-06-30,2012-12,2012-12-31,2011-01,ACTUAL,2011-01-31,2009-02,ACTUAL,2009-02-28,,INTERVENTIONAL,MONET,,Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir,"A Randomised, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg O.D. vs a Triple Combination Therapy With DRV/r in HIV-1 Infected Patients With Undetectable Plasma HIV-RNA on Their Current Treatments.",COMPLETED,,PHASE3,256,ACTUAL,Janssen-Cilag International NV,This study was not blinded and not designed to demonstrate a safety benefit to stopping nucleoside analogues.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:10:08,2024-10-14 07:10:08,INDUSTRY,,,,,,,Janssen-Cilag International NV,Austria|Belgium|Denmark|Germany|Hungary|Israel|Poland|Portugal|Russian Federation|Spain|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00458393,,2007-04-06,2016-12-27,,2021-10-29,2007-04-06,2007-04-10,ESTIMATED,2018-01-19,2018-01-24,ACTUAL,,,,2021-10-29,2021-11-02,ACTUAL,2007-06,,2007-06-30,2021-10,2021-10-31,2014-02,ACTUAL,2014-02-28,2014-02,ACTUAL,2014-02-28,,INTERVENTIONAL,iPrEx,,Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men,Chemoprophylaxis for HIV Prevention in Men,COMPLETED,,PHASE3,2499,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 16:32:06,2024-10-13 16:32:06,NIH,,,,,,,Bill and Melinda Gates Foundation|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Ecuador|Peru|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00459316,,2007-04-10,2014-03-03,,2021-10-29,2007-04-10,2007-04-11,ESTIMATED,2014-04-14,2014-05-12,ESTIMATED,,,,2021-10-29,2021-11-03,ACTUAL,2007-06,,2007-06-30,2021-10,2021-10-31,2013-03,ACTUAL,2013-03-31,2013-03,ACTUAL,2013-03-31,,INTERVENTIONAL,,All participants who started study treatment.,Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth,Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in HIV-Infected Children and Youth And Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth,COMPLETED,,PHASE1/PHASE2,384,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-12 23:35:36,2024-10-12 23:35:36,NIH,,,,,,,International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00461552,,2007-04-16,2019-01-15,,2019-05-07,2007-04-17,2007-04-18,ESTIMATED,2019-02-28,2019-03-05,ACTUAL,,,,2019-05-07,2019-05-09,ACTUAL,2003-01,,2003-01-31,2019-05,2019-05-31,2014-09,ACTUAL,2014-09-30,2014-09,ACTUAL,2014-09-30,,INTERVENTIONAL,,,Therapeutic Approaches to HAART-Induced Lipodystrophy,Therapeutic Approaches to HAART-Induced Lipodystrophy,COMPLETED,,PHASE2,23,ACTUAL,University of Texas Southwestern Medical Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 03:45:16,2024-10-14 03:45:16,OTHER,,,,,,,"Amylin Pharmaceuticals, LLC.|University of Texas Southwestern Medical Center",United States,Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00464815,,2007-04-23,2017-05-31,2009-09-03,2018-05-08,2007-04-23,2007-04-24,ESTIMATED,2018-03-30,2018-04-02,ACTUAL,2009-09-03,2009-09-04,ESTIMATED,2018-05-08,2018-06-08,ACTUAL,2007-05-02,ACTUAL,2007-05-02,2018-03,2018-03-31,2008-09-10,ACTUAL,2008-09-10,2008-04-16,ACTUAL,2008-04-16,,INTERVENTIONAL,,,Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects,Primary Vaccination Study in Subjects Aged 11-17 Years to Demonstrate the Non-inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Vaccine Versus Mencevax™ ACWY,COMPLETED,,PHASE3,1025,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 09:27:07,2024-10-13 09:27:07,INDUSTRY,,,,,,,GlaxoSmithKline,India|Philippines|Taiwan,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications"
NCT00465816,,2007-04-24,2012-04-23,2009-04-27,2018-05-09,2007-04-24,2007-04-25,ESTIMATED,2012-04-23,2012-05-22,ESTIMATED,2009-10-01,2009-10-02,ESTIMATED,2018-05-09,2018-06-08,ACTUAL,2007-04-11,,2007-04-11,2016-11,2016-11-30,2008-04-28,ACTUAL,2008-04-28,2008-04-28,ACTUAL,2008-04-28,,INTERVENTIONAL,,,Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612,Non-inferiority of GSK Biologicals' Meningococcal Vaccine 134612 Given Concomitantly With GSK Biologicals' Twinrix™ Versus 134612 Alone and Twinrix™ Alone in Healthy Subjects Aged 11 Through 17 Years.,COMPLETED,,PHASE3,611,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 13:03:43,2024-10-13 13:03:43,INDUSTRY,,,,,,,GlaxoSmithKline,Denmark|Sweden,"General disorders|Injury, poisoning and procedural complications|Nervous system disorders|Psychiatric disorders"
NCT00465972,,2007-04-25,2012-12-12,,2013-07-26,2007-04-25,2007-04-27,ESTIMATED,2013-07-26,2013-07-30,ESTIMATED,,,,2013-07-26,2013-07-30,ESTIMATED,2007-03,,2007-03-31,2013-05,2013-05-31,2010-08,ACTUAL,2010-08-31,2010-08,ACTUAL,2010-08-31,,INTERVENTIONAL,,,The Treatment of Insomnia in Patients With HIV Disease,"A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Doxepin and Temazepam in HIV Seropositive Patients With Insomnia.",COMPLETED,,PHASE4,44,ACTUAL,Duke University,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:43:58,2024-10-14 22:43:58,OTHER,,,,,,,Duke University,United States,Nervous system disorders
NCT00466817,,2007-04-26,2013-08-29,2013-01-30,2015-08-13,2007-04-26,2007-04-27,ESTIMATED,2013-08-29,2013-11-13,ESTIMATED,2013-01-30,2013-02-04,ESTIMATED,2015-08-13,2015-08-26,ESTIMATED,2008-06,,2008-06-30,2015-07,2015-07-31,2013-06,ACTUAL,2013-06-30,2011-12,ACTUAL,2011-12-31,,INTERVENTIONAL,,,Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections,"A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)",COMPLETED,,PHASE3,109,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 19:05:55,2024-10-14 19:05:55,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00466947,,2007-04-26,2011-08-25,,2019-07-02,2007-04-26,2007-04-27,ESTIMATED,2013-06-20,2013-09-04,ESTIMATED,,,,2019-07-02,2019-07-16,ACTUAL,2007-06-28,ACTUAL,2007-06-28,2019-07,2019-07-31,2011-07-28,ACTUAL,2011-07-28,2010-08-31,ACTUAL,2010-08-31,,INTERVENTIONAL,,,COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine,COMPAS: A Phase III Study to Demonstrate Efficacy of GSK Biologicals' 10-valent Pneumococcal Vaccine (GSK1024850A) Against Community Acquired Pneumonia and Acute Otitis Media,COMPLETED,,PHASE3,23802,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 22:38:08,2024-10-14 22:38:08,INDUSTRY,,,,,,,GlaxoSmithKline,Argentina|Colombia|Panama,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00467272,,2007-04-26,2020-12-16,,2021-01-12,2007-04-27,2007-04-30,ESTIMATED,2021-01-12,2021-02-08,ACTUAL,,,,2021-01-12,2021-02-08,ACTUAL,2007-03,,2007-03-31,2021-01,2021-01-31,2012-09,ACTUAL,2012-09-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,40 participants were enrolled in the daptomycin arm. The analysis included 38 participants who received Daptomycin: 3 participants were excluded from analysis prior to study entry.,Catheter Related - Gram Positive Bloodstream Infections,"Phase II, Open-Label Study to Evaluate the Safety and Efficacy of Daptomycin in the Treatment of Catheter-Related Gram Positive Bloodstream Infections",COMPLETED,,PHASE2,30,ACTUAL,M.D. Anderson Cancer Center,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 13:56:51,2024-10-13 13:56:51,OTHER,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)|M.D. Anderson Cancer Center",United States,Metabolism and nutrition disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00468104,,2007-04-29,2011-12-18,,2012-04-25,2007-05-01,2007-05-02,ESTIMATED,2012-04-07,2012-04-24,ESTIMATED,,,,2012-04-25,2012-04-30,ESTIMATED,2004-04,,2004-04-30,2012-04,2012-04-30,2009-08,ACTUAL,2009-08-31,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,CPE,,Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas,Response to Instillation of Activase in the Pleural Cavity vs Placebo in the Management of Complicated Pleural Effusion/Empyema,COMPLETED,,NA,100,ACTUAL,Midwest Pulmonary and Critical Care,The sample size for secondary outcomes in the Placebo group is small,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:07:20,2024-10-13 18:07:20,OTHER,,,,,,,"Genentech, Inc.|Midwest Pulmonary and Critical Care",United States,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00468728,,2007-05-01,2011-07-01,2010-08-27,2017-03-23,2007-05-01,2007-05-03,ESTIMATED,2011-07-01,2011-07-29,ESTIMATED,2010-08-27,2010-08-31,ESTIMATED,2017-03-23,2017-04-21,ACTUAL,2006-10-04,ACTUAL,2006-10-04,2017-03,2017-03-31,2009-12-11,ACTUAL,2009-12-11,2009-12-11,ACTUAL,2009-12-11,,INTERVENTIONAL,,,PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD),COMPLETED,,PHASE3,535,ACTUAL,"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 11:45:21,2024-10-14 11:45:21,INDUSTRY,,,,,,,"Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Belgium|Canada|France|Germany|Italy|Spain|Sweden|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00471081,,2007-05-08,2017-03-09,2009-09-03,2019-06-11,2007-05-08,2007-05-09,ESTIMATED,2018-08-16,2018-09-14,ACTUAL,2009-09-03,2009-09-04,ESTIMATED,2019-06-11,2019-06-25,ACTUAL,2007-07-05,ACTUAL,2007-07-05,2019-06,2019-06-30,2008-11-26,ACTUAL,2008-11-26,2008-10-23,ACTUAL,2008-10-23,,INTERVENTIONAL,,,Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.,"Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age",COMPLETED,,PHASE2,385,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 15:29:03,2024-10-14 15:29:03,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00471822,,2007-05-08,2012-10-03,,2013-09-18,2007-05-09,2007-05-10,ESTIMATED,2013-09-18,2013-11-20,ESTIMATED,,,,2013-09-18,2013-11-20,ESTIMATED,2005-07,,2005-07-31,2013-09,2013-09-30,2010-12,ACTUAL,2010-12-31,2010-12,ACTUAL,2010-12-31,,OBSERVATIONAL,,,Nasopharyngeal Streptococcus Pneumoniae Carriage,"An Evaluation of Streptococcus Pneumoniae Serotype Carriage Rate for Nasopharyngeal Carriage in Taiwanese Children Attending Pediatric Clinics in Hospitals, Day Care Centers, or Kindergartens",COMPLETED,,,9707,ACTUAL,Pfizer,,,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 15:17:16,2024-10-14 15:17:16,INDUSTRY,,,,,,,Pfizer,Taiwan,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00474266,,2007-05-15,2017-05-17,2009-09-03,2019-11-15,2007-05-15,2007-05-16,ESTIMATED,2017-05-17,2017-12-15,ACTUAL,2009-09-03,2009-09-04,ESTIMATED,2019-11-15,2019-11-18,ACTUAL,2007-06-05,ACTUAL,2007-06-05,2019-11,2019-11-30,2008-03-26,ACTUAL,2008-03-26,2008-02-26,ACTUAL,2008-02-26,,INTERVENTIONAL,,,Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children,Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children,COMPLETED,,PHASE3,1000,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=248,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 13:38:09,2024-10-14 13:38:09,INDUSTRY,,,,,,,GlaxoSmithKline,Finland,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00474487,,2007-05-16,2010-03-19,2009-08-03,2014-04-01,2007-05-16,2007-05-17,ESTIMATED,2010-07-05,2010-08-04,ESTIMATED,2009-08-03,2009-08-10,ESTIMATED,2014-04-01,2014-04-21,ESTIMATED,2007-05,,2007-05-31,2014-04,2014-04-30,2008-02,ACTUAL,2008-02-29,2007-08,ACTUAL,2007-08-31,,INTERVENTIONAL,,,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults,"A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age.",COMPLETED,,PHASE3,2831,ACTUAL,Novartis,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-12 23:41:00,2024-10-12 23:41:00,INDUSTRY,,,,,,,Novartis Vaccines,Argentina|Colombia,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00478231,,2007-05-22,2011-07-08,,2011-09-01,2007-05-22,2007-05-24,ESTIMATED,2011-07-12,2011-08-08,ESTIMATED,,,,2011-09-01,2011-09-09,ESTIMATED,2007-07,,2007-07-31,2011-09,2011-09-30,2010-09,ACTUAL,2010-09-30,2010-08,ACTUAL,2010-08-31,,INTERVENTIONAL,,,"Multicenter, Safety Study Of Maraviroc","A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc",COMPLETED,,PHASE3,209,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 03:24:11,2024-10-13 03:24:11,INDUSTRY,,,,,,,Pfizer|ViiV Healthcare,Brazil,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00480324,,2007-05-29,2010-03-30,,2019-12-27,2007-05-29,2007-05-30,ESTIMATED,2010-10-21,2010-11-17,ESTIMATED,,,,2019-12-27,2020-01-02,ACTUAL,2007-06-19,ACTUAL,2007-06-19,2019-12,2019-12-31,2009-11-21,ACTUAL,2009-11-21,2009-03-31,ACTUAL,2009-03-31,,INTERVENTIONAL,,,"Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants","Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants",COMPLETED,,PHASE3,765,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=272,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 10:39:45,2024-10-14 10:39:45,INDUSTRY,,,,,,,GlaxoSmithKline,Japan|Sweden|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00481507,,2007-05-30,2011-05-09,,2019-07-03,2007-05-30,2007-06-01,ESTIMATED,2012-02-21,2012-03-26,ESTIMATED,,,,2019-07-03,2019-07-10,ACTUAL,2007-07,,2007-07-31,2019-07,2019-07-31,2008-04,ACTUAL,2008-04-30,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,MILK,,Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK),Measuring the Influence of Kefir on Children's Stools on Antibiotics (MILK),COMPLETED,,NA,125,ACTUAL,Georgetown University,We did not assess or culture stools for the presence of pathogenic organisms. We did not independently examine children; we relied on parental/patient-oriented outcomes. Our population was generally very healthy. We did not assess probiotic dosages.,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,TRUE,,,,,,,,2024-10-13 01:29:17,2024-10-13 01:29:17,OTHER,,,,,,,"Georgetown University|Lifeway Foods, Inc.",United States,Gastrointestinal disorders
NCT00481767,,2007-05-31,2011-02-24,,2020-10-26,2007-06-01,2007-06-04,ESTIMATED,2011-02-24,2011-03-24,ESTIMATED,,,,2020-10-26,2020-11-17,ACTUAL,2007-10-01,ACTUAL,2007-10-01,2020-10,2020-10-31,2010-07-26,ACTUAL,2010-07-26,2010-02-25,ACTUAL,2010-02-25,,INTERVENTIONAL,,,Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.,Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine GSK580299 in Healthy Female Subjects Aged 10-25 Years.,COMPLETED,,PHASE3,676,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 17:09:10,2024-10-14 17:09:10,INDUSTRY,,,,,,,GlaxoSmithKline,Senegal|South Africa|Tanzania,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00485264,,2007-06-11,2014-02-28,,2021-10-29,2007-06-11,2007-06-12,ESTIMATED,2014-12-18,2014-12-22,ESTIMATED,,,,2021-10-29,2021-11-02,ACTUAL,2007-09-17,ACTUAL,2007-09-17,2021-10,2021-10-31,2017-05-18,ACTUAL,2017-05-18,2013-06-03,ACTUAL,2013-06-03,,INTERVENTIONAL,,All Treated Population: All patients exposed to raltegravir (at any dose),Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents,"A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Raltegravir (Isentress, MK-0518) in HIV-1 Infected Children and Adolescents",COMPLETED,,PHASE1/PHASE2,153,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,6,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 14:07:45,2024-10-14 14:07:45,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Botswana|Brazil|Puerto Rico|South Africa|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00485732,,2007-06-12,2009-11-12,,2018-05-24,2007-06-12,2007-06-13,ESTIMATED,2009-11-12,2009-12-17,ESTIMATED,,,,2018-05-24,2018-07-20,ACTUAL,2007-06-11,,2007-06-11,2016-11,2016-11-30,2008-03-30,ACTUAL,2008-03-30,2008-03-30,ACTUAL,2008-03-30,,INTERVENTIONAL,,,A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years,"A Phase IIIb, Double-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV-16/18 L1 VLP AS04 Vaccine, Administered Intramuscularly in Healthy Female Subjects Aged 15 - 25 Years",COMPLETED,,PHASE3,225,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 15:04:55,2024-10-14 15:04:55,INDUSTRY,,,,,,,GlaxoSmithKline,"Korea, Republic of",General disorders|Infections and infestations|Nervous system disorders|Reproductive system and breast disorders
NCT00486330,,2007-06-12,2010-02-25,,2020-04-16,2007-06-13,2007-06-14,ESTIMATED,2012-10-19,2012-11-21,ESTIMATED,,,,2020-04-16,2020-04-20,ACTUAL,2006-05,,2006-05-31,2020-04,2020-04-30,2007-05,ACTUAL,2007-05-31,2007-05,ACTUAL,2007-05-31,,INTERVENTIONAL,BUTI,,Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/Ritonavir,Pharmacokinetic Interactions Between Buprenorphine/Naloxone and Tipranavir/Ritonavir in HIV-Negative Subjects Chronically Receiving Buprenorphine/Naloxone,COMPLETED,,NA,12,ACTUAL,Yale University,"First, the sample size was small. Second, this study utilized a within-subject design with patients acting as their own controls and thereby resulting in less intra-patient variability in the analysis of BUP/NLX.",1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 12:42:42,2024-10-13 12:42:42,OTHER,,,,,,,Boehringer Ingelheim|Yale University,United States,Hepatobiliary disorders|Nervous system disorders
NCT00487188,,2007-06-14,2011-03-22,,2015-07-22,2007-06-14,2007-06-15,ESTIMATED,2011-08-02,2011-09-02,ESTIMATED,,,,2015-07-22,2015-08-13,ESTIMATED,2005-11,,2005-11-30,2015-07,2015-07-31,2008-04,ACTUAL,2008-04-30,2007-11,ACTUAL,2007-11-30,,INTERVENTIONAL,INTENSE,,A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience,"Phase IIIb/IV Randomized, Controlled Study Evaluating an Intensification Treatment Strategy of Adding Enfuvirtide (ENF) to an Oral Highly Active AntiRetroviral Therapy (HAART) in Treatment Experienced Patients",COMPLETED,,PHASE4,47,ACTUAL,Hoffmann-La Roche,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 19:23:54,2024-10-14 19:23:54,INDUSTRY,,,,,,,Hoffmann-La Roche,Canada|France|Germany|Israel|Italy|Mexico|Netherlands|Spain|Switzerland|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00488345,,2007-06-18,2010-09-01,,2012-09-12,2007-06-18,2007-06-20,ESTIMATED,2012-09-12,2012-10-24,ESTIMATED,,,,2012-09-12,2012-10-24,ESTIMATED,2007-12,,2007-12-31,2012-09,2012-09-30,2009-09,ACTUAL,2009-09-30,2009-09,ACTUAL,2009-09-30,,INTERVENTIONAL,,,"Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age","A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections",COMPLETED,,PHASE2,59,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:50:54,2024-10-13 05:50:54,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,Belgium|Mexico|South Africa|Taiwan|Ukraine|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00488345,,2007-06-18,2010-09-01,,2012-09-12,2007-06-18,2007-06-20,ESTIMATED,2012-09-12,2012-10-24,ESTIMATED,,,,2012-09-12,2012-10-24,ESTIMATED,2007-12,,2007-12-31,2012-09,2012-09-30,2009-09,ACTUAL,2009-09-30,2009-09,ACTUAL,2009-09-30,,INTERVENTIONAL,,,"Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age","A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections",COMPLETED,,PHASE2,59,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:50:54,2024-10-13 05:50:54,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,Belgium|Mexico|South Africa|Taiwan|Ukraine|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00488488,,2007-06-18,2011-03-29,,2011-07-20,2007-06-19,2007-06-20,ESTIMATED,2011-06-17,2011-07-18,ESTIMATED,,,,2011-07-20,2011-07-22,ESTIMATED,2006-11,,2006-11-30,2011-06,2011-06-30,2010-03,ACTUAL,2010-03-31,2010-03,ACTUAL,2010-03-31,,OBSERVATIONAL,,,A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting,A Non-Interventional Study To Evaluate The Safety And Effectiveness Of Tygacil In The Treatment Of Patients With Complicated Intra-Abdominal Infections Or Complicated Skin And Skin Structure Infections,COMPLETED,,,1028,ACTUAL,Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:59:07,2024-10-15 02:59:07,INDUSTRY,,,,,,,Pfizer,Germany,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00489554,,2007-06-20,2012-03-15,,2019-12-30,2007-06-20,2007-06-21,ESTIMATED,2012-04-12,2012-05-10,ESTIMATED,,,,2019-12-30,2020-01-13,ACTUAL,2007-07-03,ACTUAL,2007-07-03,2019-12,2019-12-31,2008-03-31,ACTUAL,2008-03-31,2008-03-31,ACTUAL,2008-03-31,,INTERVENTIONAL,,,Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age,"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix",COMPLETED,,PHASE3,230,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=256,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2024-10-13 14:31:53,2024-10-13 14:31:53,INDUSTRY,,,,,,,GlaxoSmithKline,Mexico,"Eye disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00491556,,2007-06-22,2016-03-18,,2017-02-27,2007-06-22,2007-06-26,ESTIMATED,2016-05-16,2016-06-24,ESTIMATED,,,,2017-02-27,2017-03-29,ACTUAL,2007-10,,2007-10-31,2016-05,2016-05-31,2013-06,ACTUAL,2013-06-30,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,,"75 subjects were randomized to the experimental arm, however 2 subjects withdrew from the study at the pre-entry visit. Therefore, only 73 experimental arm subjects were available for the baseline analyses.",Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r),Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r) in Adolescents With CD4 + T Cells > 350 Cells/mm3 Initiating HAART,COMPLETED,,NA,102,ACTUAL,"University of North Carolina, Chapel Hill",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 15:29:03,2024-10-14 15:29:03,OTHER,,,,,,,"International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA)|University of North Carolina, Chapel Hill",Puerto Rico|United States,Gastrointestinal disorders|Hepatobiliary disorders|Investigations|Psychiatric disorders
NCT00492544,,2007-06-26,2009-11-12,2009-08-20,2018-08-30,2007-06-26,2007-06-27,ESTIMATED,2009-11-12,2009-12-21,ESTIMATED,2009-08-20,2009-08-21,ESTIMATED,2018-08-30,2018-09-04,ACTUAL,2007-07-02,ACTUAL,2007-07-02,2018-08,2018-08-31,2008-03-28,ACTUAL,2008-03-28,2008-03-28,ACTUAL,2008-03-28,,INTERVENTIONAL,,,Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age,Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 When Administered as a 3-dose Schedule in Healthy Japanese Pre-adolescent and Adolescent Female Subjects.,COMPLETED,,PHASE3,100,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 21:51:26,2024-10-14 21:51:26,INDUSTRY,,,,,,,GlaxoSmithKline,Japan,Gastrointestinal disorders|General disorders|Infections and infestations|Reproductive system and breast disorders
NCT00492726,,2007-06-26,2010-02-11,,2014-11-03,2007-06-26,2007-06-27,ESTIMATED,2010-02-11,2010-03-03,ESTIMATED,,,,2014-11-03,2014-11-07,ESTIMATED,2006-07,,2006-07-31,2014-11,2014-11-30,2009-02,ACTUAL,2009-02-28,2009-02,ACTUAL,2009-02-28,,INTERVENTIONAL,,,Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem,"A Prospective, Randomized, Double-dummy, Double-blind, Multicenter Trial Comparing the Safety and Efficacy of Intravenous Moxifloxacin 400 mg IV QD 24 Hours to That of Ertapenem 1.0 g IV QD 24 Hours for 5 to 14 Days for the Treatment of Subjects With Complicated Intra-abdominal Infections (PROMISE Study)",COMPLETED,,PHASE3,804,ACTUAL,Bayer,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:59:42,2024-10-14 18:59:42,INDUSTRY,,,,,,,Bayer,Argentina|Belgium|Bulgaria|Estonia|France|Germany|Greece|Israel|Latvia|Lithuania|Romania|Russian Federation|South Africa|Spain,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00493285,,2007-06-26,2012-03-12,,2012-07-13,2007-06-27,2007-06-28,ESTIMATED,2012-03-12,2012-04-09,ESTIMATED,,,,2012-07-13,2012-07-19,ESTIMATED,2007-07,,2007-07-31,2012-07,2012-07-31,2010-04,ACTUAL,2010-04-30,2009-11,ACTUAL,2009-11-30,,INTERVENTIONAL,CP149,,Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy Children 6 to <24 Months of Age",COMPLETED,,PHASE1,49,ACTUAL,MedImmune LLC,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 21:22:01,2024-10-14 21:22:01,INDUSTRY,,,,,,,MedImmune LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00493285,,2007-06-26,2012-03-12,,2012-07-13,2007-06-27,2007-06-28,ESTIMATED,2012-03-12,2012-04-09,ESTIMATED,,,,2012-07-13,2012-07-19,ESTIMATED,2007-07,,2007-07-31,2012-07,2012-07-31,2010-04,ACTUAL,2010-04-30,2009-11,ACTUAL,2009-11-30,,INTERVENTIONAL,CP149,,Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age,"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Viral Shedding of MEDI-534, a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV), in Healthy Children 6 to <24 Months of Age",COMPLETED,,PHASE1,49,ACTUAL,MedImmune LLC,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 21:22:01,2024-10-14 21:22:01,INDUSTRY,,,,,,,MedImmune LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00496015,,2007-07-03,2017-05-11,2009-05-20,2018-08-07,2007-07-03,2007-07-04,ESTIMATED,2018-08-07,2019-01-18,ACTUAL,2009-05-21,2009-09-28,ESTIMATED,2018-08-07,2019-01-18,ACTUAL,2007-07-02,ACTUAL,2007-07-02,2017-05,2017-05-31,2009-02-17,ACTUAL,2009-02-17,2008-03-25,ACTUAL,2008-03-25,,INTERVENTIONAL,,,Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A,Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Vaccine GSK1024850A and DTPa-HBV-IPV/Hib Vaccine (Infanrix Hexa) and Assessment of Impact of Pneumococcal Vaccination on Nasopharyngeal Carriage,COMPLETED,,PHASE3,750,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-15 02:48:17,2024-10-15 02:48:17,INDUSTRY,,,,,,,GlaxoSmithKline,Czechia|Czech Republic,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00496626,,2007-07-03,2010-02-08,,2017-03-20,2007-07-03,2007-07-04,ESTIMATED,2010-06-08,2010-07-09,ESTIMATED,,,,2017-03-20,2017-04-17,ACTUAL,2008-07-20,ACTUAL,2008-07-20,2017-03,2017-03-31,2009-02-28,ACTUAL,2009-02-28,2009-02-28,ACTUAL,2009-02-28,,INTERVENTIONAL,,,An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED),"An Immunogenicity and Safety Study of Quadrivalent HPV (Types 6, 11, 16, 18) Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 45 Years and Male Subjects Aged 9 to 15 Years",COMPLETED,,PHASE3,600,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 15:43:52,2024-10-13 15:43:52,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00497055,,2007-07-05,2012-12-12,,2014-02-05,2007-07-05,2007-07-06,ESTIMATED,2014-02-05,2014-03-24,ESTIMATED,,,,2014-02-05,2014-03-24,ESTIMATED,2009-03,,2009-03-31,2014-02,2014-02-28,2012-03,ACTUAL,2012-03-31,2012-03,ACTUAL,2012-03-31,,INTERVENTIONAL,,,Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals,Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals,COMPLETED,,PHASE2,90,ACTUAL,San Francisco Department of Public Health,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:28:56,2024-10-14 17:28:56,OTHER_GOV,,,,,,,National Institute on Drug Abuse (NIDA)|San Francisco Department of Public Health,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00497081,,2007-07-05,2014-10-07,,2014-12-12,2007-07-05,2007-07-06,ESTIMATED,2014-10-15,2014-10-20,ESTIMATED,,,,2014-12-12,2015-01-05,ESTIMATED,2007-05,,2007-05-31,2014-12,2014-12-31,2010-03,ACTUAL,2010-03-31,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,,Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors,Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors,COMPLETED,,PHASE2,60,ACTUAL,San Francisco Department of Public Health,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-12 23:57:38,2024-10-12 23:57:38,OTHER_GOV,,,,,,,"National Institute on Drug Abuse (NIDA)|Public Health Foundation Enterprises, Inc.|San Francisco Department of Public Health",United States,"Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00497796,,2007-07-05,2015-05-04,,2021-06-02,2007-07-05,2007-07-09,ESTIMATED,2015-05-20,2015-06-04,ESTIMATED,,,,2021-06-02,2021-06-11,ACTUAL,2007-07-23,ACTUAL,2007-07-23,2021-06,2021-06-30,2009-09-14,ACTUAL,2009-09-14,2009-09-14,ACTUAL,2009-09-14,,INTERVENTIONAL,,"The Intent-to-Treat Safety (ITT-S) population, defined as all randomized subjects who received at least one dose of study drug, regardless of whether they had any post-baseline evaluations.",Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients,"A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants",COMPLETED,,PHASE3,307,ACTUAL,Takeda,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:44:30,2024-10-14 07:44:30,INDUSTRY,,,,,,,Shire,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00500266,,2007-07-09,2011-08-11,2010-03-02,2011-08-11,2007-07-10,2007-07-11,ESTIMATED,2011-08-11,2011-09-16,ESTIMATED,2010-03-02,2010-03-03,ESTIMATED,2011-08-11,2011-09-16,ESTIMATED,2008-05,,2008-05-31,2011-08,2011-08-31,2009-05,ACTUAL,2009-05-31,2009-04,ACTUAL,2009-04-30,,INTERVENTIONAL,,,Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects,"A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, & Reactogenicity of a 13vPnC Vaccine in Ambulatory Elderly Adults Aged 68 Years & Older Who Received 1 or More Doses of 23vPS Vaccine at Least 3 Years Before Study Enrollment",COMPLETED,,PHASE3,1053,ACTUAL,Pfizer,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 22:02:15,2024-10-13 22:02:15,INDUSTRY,,,,,,,Pfizer,Germany|Sweden|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00502801,,2007-07-16,2013-02-13,,2013-09-19,2007-07-16,2007-07-18,ESTIMATED,2013-09-19,2013-09-25,ESTIMATED,,,,2013-09-19,2013-09-25,ESTIMATED,2007-08,,2007-08-31,2013-09,2013-09-30,2008-11,ACTUAL,2008-11-30,2008-11,ACTUAL,2008-11-30,,INTERVENTIONAL,,,"An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia",A Phase 2 Study of Doripenem In The Treatment of Nosocomial and Ventilator-Associated Pneumonia In Hospitals,COMPLETED,,PHASE2,185,ACTUAL,"PriCara, Unit of Ortho-McNeil, Inc.",,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 11:28:26,2024-10-14 11:28:26,INDUSTRY,,,,,,,"PriCara, Unit of Ortho-McNeil, Inc.",Argentina|Canada|Chile|Croatia|France|India|Russian Federation|Ukraine|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00502944,,2007-07-16,2012-05-03,,2012-07-16,2007-07-16,2007-07-18,ESTIMATED,2012-06-10,2012-07-13,ESTIMATED,,,,2012-07-16,2012-07-19,ESTIMATED,2007-02,,2007-02-28,2012-07,2012-07-31,2008-07,ACTUAL,2008-07-31,2008-07,ACTUAL,2008-07-31,,INTERVENTIONAL,,,Two Approaches to Routine HIV Testing in a Hospital Emergency Department,Optimizing Strategies for Universal HIV Testing (The USHER Trial),COMPLETED,,NA,4855,ACTUAL,Massachusetts General Hospital,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 03:17:56,2024-10-13 03:17:56,OTHER,,,,,,,Massachusetts General Hospital|National Institute of Mental Health (NIMH),United States,Investigations
NCT00508261,,2007-07-26,2017-05-22,2009-09-03,2018-08-07,2007-07-26,2007-07-27,ESTIMATED,2018-08-07,2019-01-24,ACTUAL,2009-09-03,2009-09-04,ESTIMATED,2018-08-07,2019-01-24,ACTUAL,2007-08-01,,2007-08-01,2017-05,2017-05-31,2008-10-27,ACTUAL,2008-10-27,2008-05-26,ACTUAL,2008-05-26,,INTERVENTIONAL,,,Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine,"Co-Administration of GSK Biologicals' Meningococcal Vaccine GSK134612 With Infanrix Hexa™, Compared to Individual Administration of Each Vaccine, in Healthy 12- Through 23-Month-Old Children",COMPLETED,,PHASE3,793,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 09:21:12,2024-10-13 09:21:12,INDUSTRY,,,,,,,GlaxoSmithKline,Austria|Germany|Greece,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00508742,,2007-07-26,2012-06-12,,2013-05-06,2007-07-27,2007-07-30,ESTIMATED,2012-06-12,2012-07-13,ESTIMATED,,,,2013-05-06,2013-05-10,ESTIMATED,2007-12,,2007-12-31,2013-05,2013-05-31,2011-08,ACTUAL,2011-08-31,2011-08,ACTUAL,2011-08-31,,INTERVENTIONAL,,,Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization,"A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Vaccine Serotypes of Streptococcus Pneumoniae in Healthy Infants in Israel.",COMPLETED,,PHASE3,1866,ACTUAL,Pfizer,"Study designated analysis of effect of 13vPnC on serotypes 6A+19A, changed prior to unblinding, to effect on 6A'+19A. Serotype 6A found to include serotype 6A isolates and isolates of newly identified serotype 6C. Serotype 6A assessed as 6A+6C (6A').",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 06:52:22,2024-10-13 06:52:22,INDUSTRY,,,,,,,Pfizer,Israel,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00510497,,2007-08-01,2016-01-12,,2016-05-12,2007-08-01,2007-08-02,ESTIMATED,2016-03-03,2016-04-04,ESTIMATED,,,,2016-05-12,2016-06-16,ESTIMATED,2007-07,,2007-07-31,2016-05,2016-05-31,2012-09,ACTUAL,2012-09-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,11 particpants were enrolled but one received no study vaccines and was withdrawn and not included in any analyses.,Autologous Dendritic Cell Vaccine in HIV1 Infection,"Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells",COMPLETED,,PHASE1/PHASE2,11,ACTUAL,University of Pittsburgh,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 03:30:58,2024-10-13 03:30:58,OTHER,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|Sharon Riddler,United States,Skin and subcutaneous tissue disorders
NCT00513409,,2007-08-07,2009-03-11,,2018-06-08,2007-08-07,2007-08-08,ESTIMATED,2009-06-25,2009-08-11,ESTIMATED,,,,2018-06-08,2018-12-19,ACTUAL,2007-08-22,,2007-08-22,2018-05,2018-05-31,2008-08-28,ACTUAL,2008-08-28,2008-02-20,ACTUAL,2008-02-20,,INTERVENTIONAL,,,Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule,"Phase II, Observer-blind Follow-up Study to Assess reacto-and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine (GSK1024850A), When Given as Booster in Primed Children or as 2-dose Catch-up in Unprimed Children.",COMPLETED,,PHASE2,163,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 20:42:35,2024-10-13 20:42:35,INDUSTRY,,,,,,,GlaxoSmithKline,Chile,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications"
NCT00513461,,2007-08-06,2017-08-24,,2018-08-09,2007-08-06,2007-08-08,ESTIMATED,2018-08-09,2018-08-10,ACTUAL,,,,2018-08-09,2018-08-10,ACTUAL,2007-10,,2007-10-31,2018-08,2018-08-31,2013-12,ACTUAL,2013-12-31,2012-08,ACTUAL,2012-08-31,,INTERVENTIONAL,,,Liver Cancer Prevention Trial in Patients With Chronic Hep C Infection,"A Phase II, Randomized, Controlled Trial of The Safety and Efficacy of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) in Reducing Serum Alpha-Fetoprotein (AFP) in Patients With Hepatitis C and Moderately Elevated AFP",COMPLETED,,PHASE2,110,ACTUAL,"University of California, Irvine",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 15:19:47,2024-10-13 15:19:47,OTHER,,,,,,,Chao Family Comprehensive Cancer Center|National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00513526,,2007-08-06,2011-06-28,,2023-10-27,2007-08-06,2007-08-08,ESTIMATED,2011-06-28,2011-07-26,ESTIMATED,,,,2023-10-27,2023-11-14,ACTUAL,2007-11,,2007-11-30,2023-10,2023-10-31,2011-10,ACTUAL,2011-10-31,2010-05,ACTUAL,2010-05-31,,INTERVENTIONAL,,,Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection,"A Single-Arm, Open-Label Pilot Trial of the Safety and Immunogenicity of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men",COMPLETED,,PHASE2,112,ACTUAL,AIDS Malignancy Consortium,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 12:52:45,2024-10-13 12:52:45,NETWORK,,,,,,,"AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC",United States,"General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders"
NCT00513799,,2007-08-08,2011-03-02,,2015-07-07,2007-08-08,2007-08-09,ESTIMATED,2011-03-02,2011-03-29,ESTIMATED,,,,2015-07-07,2015-07-30,ESTIMATED,2007-03,,2007-03-31,2015-07,2015-07-31,2010-12,ACTUAL,2010-12-31,2009-06,ACTUAL,2009-06-30,,INTERVENTIONAL,StLStaRS,,The Natural History of Community-Associated MRSA Infections and Decolonization Strategies,The Natural History of Community-Associated Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections and an Evaluation of Decolonization Strategies,COMPLETED,,NA,300,ACTUAL,Washington University School of Medicine,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 19:47:33,2024-10-14 19:47:33,OTHER,,,,,,,Washington University School of Medicine,United States,Skin and subcutaneous tissue disorders
NCT00514904,,2007-08-09,2017-05-11,2009-09-03,2020-10-02,2007-08-09,2007-08-10,ESTIMATED,2017-05-11,2017-10-06,ACTUAL,2009-09-03,2009-09-04,ESTIMATED,2020-10-02,2020-10-27,ACTUAL,2007-09-18,ACTUAL,2007-09-18,2020-09,2020-09-30,2009-01-06,ACTUAL,2009-01-06,2008-09-03,ACTUAL,2008-09-03,,INTERVENTIONAL,,,Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects,Non-inferiority of GSK Biologicals' Meningococcal Vaccine GSK134612 Versus Mencevax™ in Healthy Subjects Aged 2 Through 10 Years of Age,COMPLETED,,PHASE3,1504,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 16:06:18,2024-10-14 16:06:18,INDUSTRY,,,,,,,GlaxoSmithKline,India|Lebanon|Philippines|Saudi Arabia|Tunisia,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00515034,,2007-08-10,2009-11-13,,2019-03-05,2007-08-10,2007-08-13,ESTIMATED,2010-05-20,2010-06-22,ESTIMATED,,,,2019-03-05,2019-03-19,ACTUAL,2007-10,,2007-10-31,2011-05,2011-05-31,2008-11,ACTUAL,2008-11-30,2008-11,ACTUAL,2008-11-30,,INTERVENTIONAL,,,A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia,"A Randomized, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Doripenem Compared With Imipenem in the Treatment of Subjects With Complicated Intra-Abdominal Infections or Ventilator Associated Pneumonia",COMPLETED,,PHASE2,146,ACTUAL,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",open-label study design and limited number of subjects in the comparator group,4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 11:09:57,2024-10-14 11:09:57,INDUSTRY,,,,,,,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",Argentina|Brazil|France|Germany|Russian Federation|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00515827,,2007-08-10,2011-01-25,,2021-11-02,2007-08-10,2007-08-14,ESTIMATED,2011-05-24,2011-06-23,ESTIMATED,,,,2021-11-02,2021-11-04,ACTUAL,2007-11,,2007-11-30,2019-01,2019-01-31,2008-11,ACTUAL,2008-11-30,2008-09,ACTUAL,2008-09-30,,INTERVENTIONAL,,,Effect of Addition of Raltegravir (MK-0518) to PI- or NNRTI-Based ART Regimens in HIV Infected Subjects With Undetectable Viral Load,"A Double-Blind, Randomized, Pilot Study to Measure the Effect of Treatment Intensification With a Potent Integrase Inhibitor, Raltegravir (MK-0518), on the Level of Persistent Plasma Viremia Below 50 Copies/ml in Subjects on Protease Inhibitor- or Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Regimens",COMPLETED,,PHASE2,53,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 07:08:06,2024-10-13 07:08:06,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"General disorders|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00518180,,2007-08-17,2010-03-19,2009-08-12,2016-04-18,2007-08-17,2007-08-20,ESTIMATED,2010-09-15,2010-10-04,ESTIMATED,2009-08-12,2009-08-10,ESTIMATED,2016-04-18,2016-05-18,ESTIMATED,2007-07,,2007-07-31,2016-04,2016-04-30,2008-10,ACTUAL,2008-10-31,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,,,A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents,"A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents",COMPLETED,,PHASE3,1620,ACTUAL,Novartis,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 21:27:39,2024-10-14 21:27:39,INDUSTRY,,,,,,,Novartis Vaccines,Costa Rica,"Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00518336,,2007-08-17,2010-07-12,,2016-10-27,2007-08-17,2007-08-20,ESTIMATED,2011-09-15,2011-10-25,ESTIMATED,,,,2016-10-27,2016-12-09,ESTIMATED,2007-11,,2007-11-30,2016-10,2016-10-31,2010-09,ACTUAL,2010-09-30,2008-07,ACTUAL,2008-07-31,,INTERVENTIONAL,,,Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil,Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil,COMPLETED,,PHASE2,433,ACTUAL,GlaxoSmithKline,Interim analysis at Year 7 and Year 8 are superseded by the final analysis at Year 9.,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 02:34:00,2024-10-14 02:34:00,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil,"Gastrointestinal disorders|Infections and infestations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00527618,,2007-09-07,2012-06-26,,2018-05-04,2007-09-10,2007-09-11,ESTIMATED,2012-06-26,2012-07-31,ESTIMATED,,,,2018-05-04,2018-06-07,ACTUAL,2007-12,,2007-12-31,2018-05,2018-05-31,2011-03,ACTUAL,2011-03-31,2011-03,ACTUAL,2011-03-31,,INTERVENTIONAL,,,Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV,"A Randomized, Open-label, Crossover Trial of the Effect of Dosing of Daily HSV-2 Suppressive Therapy on HSV Reactivation and Plasma HIV-1 Levels Among HIV-1/ HSV-2 Co-infected Persons",COMPLETED,,PHASE4,28,ACTUAL,University of Washington,"Our findings are limited by the high loss to follow up, which is especially problematic in cross-over studies.",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:20:56,2024-10-14 22:20:56,OTHER,,,,,,,GlaxoSmithKline|University of Washington,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00528957,,2007-01-03,2012-02-15,2011-06-08,2018-02-14,2007-09-10,2007-09-14,ESTIMATED,2012-02-15,2012-03-22,ESTIMATED,2011-06-08,2011-06-23,ESTIMATED,2018-02-14,2018-03-14,ACTUAL,2006-12-28,ACTUAL,2006-12-28,2018-02,2018-02-28,2017-08-16,ACTUAL,2017-08-16,2009-04-06,ACTUAL,2009-04-06,,INTERVENTIONAL,,Randomized and Treated Set: participants who were randomized and received at least 1 dose of study drug,Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children,"A Phase III, Randomized, Open-Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate Versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Active Antiretroviral Therapy",COMPLETED,,PHASE3,97,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-15 03:18:24,2024-10-15 03:18:24,INDUSTRY,,,,,,,Gilead Sciences,Panama|Puerto Rico|United Kingdom|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00529243,,2007-09-12,2011-05-09,,2018-07-10,2007-09-13,2007-09-14,ESTIMATED,2011-05-09,2011-06-08,ESTIMATED,,,,2018-07-10,2018-08-07,ACTUAL,2007-09,,2007-09-30,2018-07,2018-07-31,2009-09,ACTUAL,2009-09-30,2008-07,ACTUAL,2008-07-31,,INTERVENTIONAL,CHEER,,Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects,Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen,COMPLETED,,PHASE3,52,ACTUAL,Kaiser Permanente,"A limitation of our study was the lack of a separate control arm. However, patients did serve as their own control by virtue of at least 6 months of HIV-1 ribonucleic acid(RNA)levels below the level of quantification before enrollment in the study.",1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:49:51,2024-10-14 22:49:51,OTHER,,,,,,,Kaiser Permanente|Merck Sharp & Dohme LLC,United States,Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|Hepatobiliary disorders|Nervous system disorders|Renal and urinary disorders
NCT00530777,,2007-09-13,2012-03-22,,2018-11-28,2007-09-14,2007-09-17,ESTIMATED,2012-03-22,2012-04-18,ESTIMATED,,,,2018-11-28,2018-12-19,ACTUAL,2008-04,,2008-04-30,2018-11,2018-11-30,2010-08,ACTUAL,2010-08-31,2010-08,ACTUAL,2010-08-31,,INTERVENTIONAL,VIP,,HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding,HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding,COMPLETED,,PHASE2,148,ACTUAL,University of Washington,Unable to evaluate the effect of valacyclovir on mother-to-child HIV transmission (MTCT) or on change in HIV-1 RNA among women eligible for highly active antiretroviral therapy (HAART); lack power to detect association between treatment and MTCT.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 11:30:46,2024-10-13 11:30:46,OTHER,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Puget Sound Partners for Global Health|Royalty Research Fund - University of Washington|University of Washington,Kenya,Investigations
NCT00530920,,2007-09-17,2009-05-15,,2014-05-27,2007-09-17,2007-09-18,ESTIMATED,2009-05-15,2009-07-08,ESTIMATED,,,,2014-05-27,2014-06-06,ESTIMATED,2007-10,,2007-10-31,2014-05,2014-05-31,,,,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,,"Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment",Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients,"A Multicenter, Randomized, Open Label, Clinical Trial to Evaluate Three Doses of Tipranavir Boosted With Ritonavir (500 mg/200 mg qd, 250 mg/100 mg Bid and 500 mg/100 mg Bid) by Assessing the Steady-state Pharmacokinetics and Short-term Efficacy and Safety in HIV-1 Positive Treatment naïve Patients",COMPLETED,,PHASE2,85,ACTUAL,Boehringer Ingelheim,,,,,FALSE,,,,,,,,,,,,,,,,,2024-10-15 00:47:13,2024-10-15 00:47:13,INDUSTRY,,,,,,,Boehringer Ingelheim,Germany|Italy|Spain,Gastrointestinal disorders|General disorders|Investigations|Nervous system disorders|Psychiatric disorders
NCT00531206,,2007-09-17,2010-01-28,,2014-02-24,2007-09-17,2007-09-18,ESTIMATED,2010-04-21,2010-05-12,ESTIMATED,,,,2014-02-24,2014-04-07,ESTIMATED,2006-08,,2006-08-31,2014-02,2014-02-28,,,,2009-01,ACTUAL,2009-01-31,,OBSERVATIONAL,,,Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.,Observational Non-interventional Study About Antiretroviral Combination Treatment With Aptivus in Combination With Low-dose Ritonavir in HIV Type 1 Infected Patients,COMPLETED,,,65,ACTUAL,Boehringer Ingelheim,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 07:50:54,2024-10-14 07:50:54,INDUSTRY,,,,,,,Boehringer Ingelheim,Germany,Gastrointestinal disorders|General disorders|Investigations|Vascular disorders
NCT00533507,,2007-09-20,2009-06-05,,2018-05-09,2007-09-20,2007-09-21,ESTIMATED,2009-06-05,2009-07-24,ESTIMATED,,,,2018-05-09,2018-06-08,ACTUAL,2007-09-18,,2007-09-18,2016-10,2016-10-31,2008-06-06,ACTUAL,2008-06-06,2008-06-01,ACTUAL,2008-06-01,,INTERVENTIONAL,,,Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age,"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Infanrix Hexa and Rotarix",COMPLETED,,PHASE3,230,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 09:40:26,2024-10-14 09:40:26,INDUSTRY,,,,,,,GlaxoSmithKline,Taiwan,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00534352,,2007-09-21,2009-05-06,,2015-03-26,2007-09-21,2007-09-24,ESTIMATED,2010-03-25,2010-04-12,ESTIMATED,,,,2015-03-26,2015-04-16,ESTIMATED,2008-01,,2008-01-31,2015-03,2015-03-31,2009-03,ACTUAL,2009-03-31,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,,,"A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).",A Multicenter Study to Evaluate the Pharmacokinetic Profile and Safety of TMC125 Plus Tenofovir DF/Emtricitabine All Dosed Once Daily With and Without Darunavir (PREZISTA™)/ Ritonavir Once Daily in Antiretroviral naïve HIV-1 Infected Subjects,COMPLETED,,PHASE2,23,ACTUAL,"Tibotec, Inc",,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 07:32:15,2024-10-13 07:32:15,INDUSTRY,,,,,,,"Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00534638,,2007-09-24,2015-12-17,,2019-10-30,2007-09-24,2007-09-26,ESTIMATED,2015-12-17,2016-01-26,ESTIMATED,,,,2019-10-30,2019-11-15,ACTUAL,2007-10-04,ACTUAL,2007-10-04,2019-10,2019-10-31,2014-12-17,ACTUAL,2014-12-17,2014-12-17,ACTUAL,2014-12-17,,INTERVENTIONAL,,,"Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents",Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents,COMPLETED,,PHASE4,34412,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=4582,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2024-10-14 17:28:56,2024-10-14 17:28:56,INDUSTRY,,,,,,,GlaxoSmithKline,Finland,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00535730,,2007-09-21,2009-01-21,,2017-03-14,2007-09-21,2007-09-26,ESTIMATED,2009-05-12,2009-05-13,ESTIMATED,,,,2017-03-14,2017-04-12,ACTUAL,2007-06,,2007-06-30,2017-03,2017-03-31,2008-02,ACTUAL,2008-02-29,2008-02,ACTUAL,2008-02-29,,INTERVENTIONAL,,,ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED),"A Phase III Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With PNEUMOVAX™ 23 in Subjects 60 Years of Age and Older",COMPLETED,,PHASE3,473,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Germany|Italy|Spain|United Kingdom,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00537394,,2007-09-27,2013-06-14,,2021-11-02,2007-09-27,2007-10-01,ESTIMATED,2014-07-14,2014-08-07,ESTIMATED,,,,2021-11-02,2021-11-04,ACTUAL,2008-01,,2008-01-31,2016-05,2016-05-31,2013-04,ACTUAL,2013-04-30,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,"Everyone randomized (ITT study sample), plus non-randomized group.","Optimizing Treatment for Treatment-Experienced, HIV-Infected People",The Optimized Treatment That Includes or Omits NRTIs Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen,COMPLETED,,PHASE3,517,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,TRUE,,,,,,,,,,,,,,,,,2024-10-15 03:36:43,2024-10-15 03:36:43,NIH,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00539994,,2007-10-04,2009-01-09,,2016-11-02,2007-10-04,2007-10-05,ESTIMATED,2010-07-22,2010-08-20,ESTIMATED,,,,2016-11-02,2016-12-15,ESTIMATED,2007-09,,2007-09-30,2016-11,2016-11-30,2008-01,ACTUAL,2008-01-31,2008-01,ACTUAL,2008-01-31,,INTERVENTIONAL,,,Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus,"Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Efficacy of Retapamulin Ointment, 1% Applied Twice Daily for 3 or 5 Days to the Anterior Nares of Healthy Adult Subjects Nasally Colonized With Staphylococcus Aureus",COMPLETED,,PHASE2,57,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,FALSE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-15 02:53:42,2024-10-15 02:53:42,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00540449,,2007-10-04,2011-06-14,,2016-03-01,2007-10-04,2007-10-08,ESTIMATED,2011-06-14,2011-07-11,ESTIMATED,,,,2016-03-01,2016-03-29,ESTIMATED,2008-05,,2008-05-31,2016-02,2016-02-29,2011-12,ACTUAL,2011-12-31,2010-02,ACTUAL,2010-02-28,,INTERVENTIONAL,,The analysis population included intent to treat (ITT) population defined as all randomized participants who received at least one dose of the study medication.,TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.,"A Phase III, Randomized, Double-blind Trial of TMC278 25 mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Fixed Background Regimen Consisting of Tenofovir Disoproxil Fumarate and Emtricitabine in Antiretroviral-naive HIV-1 Infected Subjects.",COMPLETED,,PHASE3,694,ACTUAL,"Tibotec Pharmaceuticals, Ireland",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 23:44:43,2024-10-13 23:44:43,INDUSTRY,,,,,,,"Tibotec Pharmaceuticals, Ireland",Argentina|Australia|Austria|Brazil|Canada|Denmark|France|India|Mexico|Netherlands|Portugal|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Sweden|Taiwan|Thailand|Uganda|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00541970,,2007-10-09,2012-10-18,,2018-06-28,2007-10-09,2007-10-10,ESTIMATED,2014-03-13,2014-04-17,ESTIMATED,,,,2018-06-28,2018-08-17,ACTUAL,2007-10-17,,2007-10-17,2016-08,2016-08-31,2013-03-18,ACTUAL,2013-03-18,2013-03-18,ACTUAL,2013-03-18,,INTERVENTIONAL,,,Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs,Evaluation of the Safety and Immunogenicity of GSK Biologicals' HPV Vaccine 580299 When Administered in Healthy Females Aged 9 - 25 Years Using an Alternative Schedule and an Alternative Dosing as Compared to the Standard Schedule and Dosing,COMPLETED,,PHASE1,961,ACTUAL,GlaxoSmithKline,"If appropriate, describe significant limitations of the trial. Examples: Early termination leading to small number of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data.",4,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 12:03:14,2024-10-14 12:03:14,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|Germany,"Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00543101,,2007-10-11,2010-04-12,,2017-07-18,2007-10-11,2007-10-12,ESTIMATED,2010-07-22,2010-08-17,ESTIMATED,,,,2017-07-18,2017-07-21,ACTUAL,2007-10,,2007-10-31,2017-07,2017-07-31,2010-02,ACTUAL,2010-02-28,2010-02,ACTUAL,2010-02-28,,INTERVENTIONAL,DVD,,Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors,"A Randomized, Controlled Trial to Evaluate the Efficacy of Substituting Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors in Individuals With Virologic Suppression for at Least 12 Weeks",COMPLETED,,PHASE4,24,ACTUAL,Community Research Initiative of New England,"The foremost problem was the small number of participants enrolled. By the time we were open for enrollment, most clinicians in the community had already switched their patients from dual boosted regimens to darunavir/ritonavir.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:49:25,2024-10-13 15:49:25,OTHER,,,,,,,Community Research Initiative of New England,United States,"Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00543543,,2007-10-12,2014-12-12,,2018-10-30,2007-10-12,2007-10-15,ESTIMATED,2014-12-12,2014-12-19,ESTIMATED,,,,2018-10-30,2018-11-27,ACTUAL,2007-09-24,ACTUAL,2007-09-24,2018-10,2018-10-31,2016-07-07,ACTUAL,2016-07-07,2013-04-10,ACTUAL,2013-04-10,,INTERVENTIONAL,,,Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001),"A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women",COMPLETED,,PHASE3,14840,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 02:41:08,2024-10-13 02:41:08,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Brazil|Canada|Chile|Colombia|Denmark|Hong Kong|Japan|Korea, Republic of|Mexico|New Zealand|Norway|Peru|Puerto Rico|Sweden|Taiwan|Thailand|United States","Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00543725,,2007-10-11,2011-06-14,,2016-03-03,2007-10-11,2007-10-15,ESTIMATED,2011-06-14,2011-07-12,ESTIMATED,,,,2016-03-03,2016-04-01,ESTIMATED,2008-06,,2008-06-30,2016-03,2016-03-31,2012-02,ACTUAL,2012-02-29,2010-01,ACTUAL,2010-01-31,,INTERVENTIONAL,,,TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors,"A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.",COMPLETED,,PHASE3,680,ACTUAL,"Tibotec Pharmaceuticals, Ireland",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 11:46:42,2024-10-13 11:46:42,INDUSTRY,,,,,,,"Tibotec Pharmaceuticals, Ireland",Argentina|Australia|Belgium|Brazil|Canada|Chile|China|Costa Rica|France|Germany|India|Mexico|Panama|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00543803,,2007-10-08,2010-12-17,,2014-05-13,2007-10-12,2007-10-15,ESTIMATED,2010-12-17,2011-01-13,ESTIMATED,,,,2014-05-13,2014-05-20,ESTIMATED,2006-02,,2006-02-28,2014-05,2014-05-31,,,,2009-12,ACTUAL,2009-12-31,,OBSERVATIONAL,,FAS - All patients were considered for the full analysis set.,Observational Non-interventional Study With Viramune® in Combination With Truvada® in HIV-infected Patients,Observational Non-interventional Study Evaluating the Safety and Efficacy of Truvada + Nevirapine,COMPLETED,,,334,ACTUAL,Boehringer Ingelheim,,,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 23:59:37,2024-10-14 23:59:37,INDUSTRY,,,,,,,Boehringer Ingelheim,Germany,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Surgical and medical procedures"
NCT00545623,,2007-10-15,2014-07-25,,2014-08-31,2007-10-16,2007-10-17,ESTIMATED,2014-08-31,2014-09-03,ESTIMATED,,,,2014-08-31,2014-09-03,ESTIMATED,2007-04,,2007-04-30,2014-08,2014-08-31,2010-09,ACTUAL,2010-09-30,2010-09,ACTUAL,2010-09-30,,INTERVENTIONAL,,"A total of 15 patients did not start the intervention after enrollment, 1, 4, 6, and 4 patients in ACUP+RR, SHAM+RR, ACUP+EDU, and SHAM+EDU arms respectively. As such there are a total of 115 patients with baseline data.",Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence,Acupuncture and Relaxation Response for GI Symptoms and HIV Medication Adherence,COMPLETED,,PHASE2,130,ACTUAL,Boston University,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:41:45,2024-10-14 18:41:45,OTHER,,,,,,,Boston University|National Center for Complementary and Integrative Health (NCCIH),United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00546078,,2007-10-17,2009-11-12,,2018-05-24,2007-10-17,2007-10-18,ESTIMATED,2009-11-12,2009-12-15,ESTIMATED,,,,2018-05-24,2018-06-26,ACTUAL,2008-01-14,,2008-01-14,2016-10,2016-10-31,2009-12-01,ACTUAL,2009-12-01,2008-12-22,ACTUAL,2008-12-22,,INTERVENTIONAL,,,Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America,"Safety and Immunogenicity Study of an Additional Dose of HPV Vaccine (580299) in Young, Adult Women in North America.",COMPLETED,,PHASE2,116,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 15:37:58,2024-10-13 15:37:58,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|United States,"General disorders|Hepatobiliary disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00546572,,2007-10-18,2011-04-29,,2011-07-12,2007-10-18,2007-10-19,ESTIMATED,2011-04-29,2011-05-30,ESTIMATED,,,,2011-07-12,2011-07-14,ESTIMATED,2007-11,,2007-11-30,2011-07,2011-07-31,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,"Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)","A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment",COMPLETED,,PHASE3,938,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 11:33:55,2024-10-14 11:33:55,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,Sweden|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00547248,,2007-10-19,2017-05-04,2009-05-20,2018-07-16,2007-10-19,2007-10-22,ESTIMATED,2018-07-16,2019-01-14,ACTUAL,2009-05-21,2009-09-28,ESTIMATED,2018-07-16,2019-01-14,ACTUAL,2007-10-22,ACTUAL,2007-10-22,2017-05,2017-05-31,2008-10-07,ACTUAL,2008-10-07,2008-05-10,ACTUAL,2008-05-10,,INTERVENTIONAL,,,Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines,"Booster Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in Children Who Completed the Primary Vaccination Course in Study 107007",COMPLETED,,PHASE3,756,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 17:58:40,2024-10-14 17:58:40,INDUSTRY,,,,,,,GlaxoSmithKline,Philippines|Poland,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00548041,,2007-10-19,2015-04-20,,2015-10-05,2007-10-22,2007-10-23,ESTIMATED,2015-10-05,2015-11-01,ESTIMATED,,,,2015-10-05,2015-11-01,ESTIMATED,2007-04,,2007-04-30,2015-10,2015-10-31,2009-05,ACTUAL,2009-05-31,2009-05,ACTUAL,2009-05-31,,INTERVENTIONAL,,,Rapid HIV Testing Program in the Emergency Department,Pilot Study to Evaluate a Rapid HIV Testing Program in the Emergency Department,COMPLETED,,NA,100,ACTUAL,Temple University,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 10:42:25,2024-10-13 10:42:25,OTHER,,,,,,,Gilead Sciences|Temple University,United States,Blood and lymphatic system disorders
NCT00549198,,2007-10-24,2010-09-23,,2011-04-07,2007-10-24,2007-10-25,ESTIMATED,2010-09-23,2010-10-15,ESTIMATED,,,,2011-04-07,2011-04-12,ESTIMATED,2007-06,,2007-06-30,2011-04,2011-04-30,2009-12,ACTUAL,2009-12-31,2009-12,ACTUAL,2009-12-31,,INTERVENTIONAL,ASSERT,,"KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects","Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects",COMPLETED,,PHASE4,392,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 07:21:26,2024-10-14 07:21:26,INDUSTRY,,,,,,,GlaxoSmithKline,Austria|Belgium|Denmark|France|Germany|Greece|Ireland|Italy|Latvia|Netherlands|Portugal|Spain|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00549198,,2007-10-24,2010-09-23,,2011-04-07,2007-10-24,2007-10-25,ESTIMATED,2010-09-23,2010-10-15,ESTIMATED,,,,2011-04-07,2011-04-12,ESTIMATED,2007-06,,2007-06-30,2011-04,2011-04-30,2009-12,ACTUAL,2009-12-31,2009-12,ACTUAL,2009-12-31,,INTERVENTIONAL,ASSERT,,"KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects","Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects",COMPLETED,,PHASE4,392,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 07:21:26,2024-10-14 07:21:26,INDUSTRY,,,,,,,GlaxoSmithKline,Austria|Belgium|Denmark|France|Germany|Greece|Ireland|Italy|Latvia|Netherlands|Portugal|Spain|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00549393,,2007-10-24,2015-03-31,,2017-05-19,2007-10-24,2007-10-25,ESTIMATED,2015-09-01,2015-10-02,ESTIMATED,,,,2017-05-19,2017-06-14,ACTUAL,2008-02,,2008-02-29,2017-05,2017-05-31,2012-06,ACTUAL,2012-06-30,2010-12,ACTUAL,2010-12-31,,INTERVENTIONAL,,,Study of Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit,Impact of Daily Bathing With Chlorhexidine Impregnated Cloths on Nosocomial Infections in the Pediatric Intensive Care Unit,COMPLETED,,PHASE2/PHASE3,5659,ACTUAL,Johns Hopkins University,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 19:11:56,2024-10-14 19:11:56,OTHER,,,,,,,"Johns Hopkins University|Sage Products, Inc.",United States,Skin and subcutaneous tissue disorders
NCT00549900,,2007-10-18,2009-11-12,,2018-05-24,2007-10-25,2007-10-26,ESTIMATED,2009-11-12,2009-12-17,ESTIMATED,,,,2018-05-24,2018-07-20,ACTUAL,2007-12-02,,2007-12-02,2016-10,2016-10-31,2008-07-12,ACTUAL,2008-07-12,2008-07-12,ACTUAL,2008-07-12,,INTERVENTIONAL,,,A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females,"Safety and Immunogenicity Study of the HPV Vaccine (GSK-580299) in Healthy, Chinese, Female Subjects",COMPLETED,,PHASE1,30,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 23:41:58,2024-10-14 23:41:58,INDUSTRY,,,,,,,GlaxoSmithKline,China,"General disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
NCT00551031,,2007-10-29,2011-10-13,2010-03-31,2016-04-12,2007-10-29,2007-10-30,ESTIMATED,2011-10-13,2011-11-24,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2016-04-12,2016-05-16,ESTIMATED,2007-10,,2007-10-31,2016-04,2016-04-30,2008-11,ACTUAL,2008-11-30,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,,,"Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects","Immunogenicity and Safety of Two Dosages of the Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in the Elderly Compared With Standard Fluzone® in Adults and Elderly Subjects.",COMPLETED,,PHASE2,2098,ACTUAL,Sanofi,,5,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:32:11,2024-10-14 22:32:11,INDUSTRY,,,,,,,Sanofi,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00552240,,2007-09-28,2011-03-16,,2013-12-09,2007-10-31,2007-11-01,ESTIMATED,2011-04-21,2011-05-23,ESTIMATED,,,,2013-12-09,2014-01-27,ESTIMATED,2007-09,,2007-09-30,2013-12,2013-12-31,,,,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,Full Analysis Set (FAS),Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT),Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone,COMPLETED,,PHASE4,154,ACTUAL,Boehringer Ingelheim,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 18:19:27,2024-10-13 18:19:27,INDUSTRY,,,,,,,Boehringer Ingelheim,United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00552279,,2007-10-30,2010-02-12,2009-08-19,2018-05-24,2007-10-31,2007-11-01,ESTIMATED,2010-02-12,2010-03-05,ESTIMATED,2009-08-19,2009-08-21,ESTIMATED,2018-05-24,2018-06-25,ACTUAL,2007-11-12,,2007-11-12,2017-04,2017-04-30,2009-07-20,ACTUAL,2009-07-20,2009-02-26,ACTUAL,2009-02-26,,INTERVENTIONAL,,,Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age,Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 Administered According to an Alternative Dosing Schedule as Compared to the Standard Dosing Schedule in Young Female Subjects Aged 15-25 Years,COMPLETED,,PHASE3,805,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 21:16:32,2024-10-14 21:16:32,INDUSTRY,,,,,,,GlaxoSmithKline,Italy|Romania|Slovakia,"Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00554996,,2007-11-05,2015-07-16,,2015-09-25,2007-11-06,2007-11-07,ESTIMATED,2015-08-14,2015-09-16,ESTIMATED,,,,2015-09-25,2015-10-16,ESTIMATED,2012-08,,2012-08-31,2015-09,2015-09-30,2014-06,ACTUAL,2014-06-30,2014-06,ACTUAL,2014-06-30,,INTERVENTIONAL,,See Eligibility section.,Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study,Bacterial Interference for Prevention of Catheter-Associated UTI,COMPLETED,,PHASE1,10,ACTUAL,VA Office of Research and Development,Our trial was a small study with no control group.,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 16:49:33,2024-10-13 16:49:33,FED,,,,,,,US Department of Veterans Affairs,United States,Renal and urinary disorders
NCT00555061,,2007-11-06,2009-08-10,,2016-11-04,2007-11-06,2007-11-07,ESTIMATED,2010-04-08,2010-04-30,ESTIMATED,,,,2016-11-04,2016-12-28,ESTIMATED,2007-09,,2007-09-30,2016-11,2016-11-30,2008-08,ACTUAL,2008-08-31,2008-08,ACTUAL,2008-08-31,,INTERVENTIONAL,,,Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.,"An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months",COMPLETED,,PHASE4,60,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,FALSE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 00:26:25,2024-10-13 00:26:25,INDUSTRY,,,,,,,GlaxoSmithKline,Argentina|Chile|Costa Rica|Germany|Mexico|Netherlands|South Africa|Taiwan|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|Immune system disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00557245,,2007-11-08,2014-10-30,,2019-04-16,2007-11-09,2007-11-12,ESTIMATED,2014-11-20,2014-11-27,ESTIMATED,,,,2019-04-16,2019-04-19,ACTUAL,2008-05,,2008-05-31,2019-04,2019-04-30,2013-10,ACTUAL,2013-10-31,2013-10,ACTUAL,2013-10-31,,INTERVENTIONAL,Partners PrEP,"All randomized participants, less those who were found to be ineligible (n=11)",Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples,Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples,COMPLETED,,PHASE3,4758,ACTUAL,University of Washington,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 10:46:20,2024-10-14 10:46:20,OTHER,,,,,,,Bill and Melinda Gates Foundation|University of Washington,Kenya|Uganda,"Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00557245,,2007-11-08,2014-10-30,,2019-04-16,2007-11-09,2007-11-12,ESTIMATED,2014-11-20,2014-11-27,ESTIMATED,,,,2019-04-16,2019-04-19,ACTUAL,2008-05,,2008-05-31,2019-04,2019-04-30,2013-10,ACTUAL,2013-10-31,2013-10,ACTUAL,2013-10-31,,INTERVENTIONAL,Partners PrEP,"All randomized participants, less those who were found to be ineligible (n=11)",Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples,Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples,COMPLETED,,PHASE3,4758,ACTUAL,University of Washington,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 10:46:20,2024-10-14 10:46:20,OTHER,,,,,,,Bill and Melinda Gates Foundation|University of Washington,Kenya|Uganda,"Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00561925,,2007-11-20,2011-12-13,,2014-03-07,2007-11-20,2007-11-21,ESTIMATED,2011-12-13,2012-01-19,ESTIMATED,,,,2014-03-07,2014-04-07,ESTIMATED,2007-11,,2007-11-30,2014-03,2014-03-31,,,,2011-11,ACTUAL,2011-11-30,,INTERVENTIONAL,,,VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients,"A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® in Antiretroviral Therapy naïve HIV-1 Infected Patients (VERxVE)",COMPLETED,,PHASE3,1068,ACTUAL,Boehringer Ingelheim,"For the lead-in-period with NVP IR 200mg QD, MedDRA Version 12.1 was used for AE/SAE reporting.",2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-12 23:46:56,2024-10-12 23:46:56,INDUSTRY,,,,,,,Boehringer Ingelheim,Argentina|Australia|Belgium|Botswana|Canada|France|Germany|Ireland|Italy|Mexico|Netherlands|Peru|Poland|Portugal|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00564447,,2007-11-20,2011-06-27,,2011-09-20,2007-11-27,2007-11-28,ESTIMATED,2011-06-27,2011-07-26,ESTIMATED,,,,2011-09-20,2011-09-22,ESTIMATED,2007-12,,2007-12-31,2011-09,2011-09-30,,,,2007-12,ACTUAL,2007-12-31,,INTERVENTIONAL,,,Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers,"A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration",COMPLETED,,PHASE4,48,ACTUAL,Merck Sharp & Dohme LLC,,8,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 14:49:46,2024-10-13 14:49:46,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Eye disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT00564447,,2007-11-20,2011-06-27,,2011-09-20,2007-11-27,2007-11-28,ESTIMATED,2011-06-27,2011-07-26,ESTIMATED,,,,2011-09-20,2011-09-22,ESTIMATED,2007-12,,2007-12-31,2011-09,2011-09-30,,,,2007-12,ACTUAL,2007-12-31,,INTERVENTIONAL,,,Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers,"A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Conjunctiva of Healthy Volunteers Following a Single Ocular Administration",COMPLETED,,PHASE4,48,ACTUAL,Merck Sharp & Dohme LLC,,8,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 14:49:46,2024-10-13 14:49:46,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Eye disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT00572832,,2007-12-11,2009-09-03,,2010-08-11,2007-12-12,2007-12-13,ESTIMATED,2010-02-11,2010-02-25,ESTIMATED,,,,2010-08-11,2010-08-17,ESTIMATED,2007-09,,2007-09-30,2010-08,2010-08-31,2009-08,ACTUAL,2009-08-31,2009-04,ACTUAL,2009-04-30,,INTERVENTIONAL,,,Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting,Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting,COMPLETED,,NA,200,ACTUAL,University of Pittsburgh,"One participant in the Standard group did not respond to any of the vaccine HPV types. Eleven participants in the Alternate group either did not receive Dose 3 or were out of window, compared with only one participant in the Standard group.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 19:23:54,2024-10-14 19:23:54,OTHER,,,,,,,Merck Sharp & Dohme LLC|University of Pittsburgh,United States,General disorders|Skin and subcutaneous tissue disorders
NCT00572910,,2007-12-11,2011-07-20,,2015-03-16,2007-12-11,2007-12-13,ESTIMATED,2011-07-20,2011-08-15,ESTIMATED,,,,2015-03-16,2015-04-03,ESTIMATED,2008-08,,2008-08-31,2015-03,2015-03-31,2010-01,ACTUAL,2010-01-31,2010-01,ACTUAL,2010-01-31,,INTERVENTIONAL,,,A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED),"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of Merck Staphylococcus Aureus Vaccine (V710) in Adult Patients With End-Stage Renal Disease on Chronic Hemodialysis",COMPLETED,,PHASE2,206,ACTUAL,Merck Sharp & Dohme LLC,,6,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 05:27:40,2024-10-14 05:27:40,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00575094,,2007-12-13,2009-03-31,,2011-06-02,2007-12-13,2007-12-17,ESTIMATED,2009-03-31,2009-05-27,ESTIMATED,,,,2011-06-02,2011-06-03,ESTIMATED,2007-11,,2007-11-30,2011-06,2011-06-30,2008-03,ACTUAL,2008-03-31,2008-03,ACTUAL,2008-03-31,,INTERVENTIONAL,,,Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects,"A Phase 3, Multicenter, Open-label Study Evaluating the Safety and Efficacy of Intravenous Tigecycline to Treat Hospitalized Japanese Subjects With Community-acquired Pneumonia",COMPLETED,,PHASE3,9,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 00:25:50,2024-10-14 00:25:50,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,Japan,Gastrointestinal disorders|Hepatobiliary disorders|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders
NCT00575380,,2007-12-12,2009-06-09,,2011-09-20,2007-12-14,2007-12-18,ESTIMATED,2009-08-11,2009-09-16,ESTIMATED,,,,2011-09-20,2011-09-22,ESTIMATED,2007-12,,2007-12-31,2011-09,2011-09-30,,,,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,,,Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery,"A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery",COMPLETED,,PHASE4,116,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 10:33:41,2024-10-14 10:33:41,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Investigations
NCT00575380,,2007-12-12,2009-06-09,,2011-09-20,2007-12-14,2007-12-18,ESTIMATED,2009-08-11,2009-09-16,ESTIMATED,,,,2011-09-20,2011-09-22,ESTIMATED,2007-12,,2007-12-31,2011-09,2011-09-30,,,,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,,,Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery,"A Multi-Center, Open-Label, Randomized Study of the Pharmacokinetics of Azithromycin Versus Moxifloxacin in Conjunctiva and Aqueous Humor Following Single or Multiple Ocular Administration of AzaSite Ophthalmic Solution, 1% or Vigamox in Subjects Undergoing Routine Cataract Surgery",COMPLETED,,PHASE4,116,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 10:33:41,2024-10-14 10:33:41,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Investigations
NCT00578227,,2007-12-20,2009-11-27,,2018-06-28,2007-12-20,2007-12-21,ESTIMATED,2009-12-03,2010-01-06,ESTIMATED,,,,2018-06-28,2018-08-17,ACTUAL,2007-12-15,,2007-12-15,2016-10,2016-10-31,2009-04-28,ACTUAL,2009-04-28,2008-12-01,ACTUAL,2008-12-01,,INTERVENTIONAL,,,Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects,Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) Co-administered With a Commercially Available Vaccine in Healthy Female Adolescents,COMPLETED,,PHASE3,814,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 11:41:43,2024-10-13 11:41:43,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|Denmark|Hungary|Sweden,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders"
NCT00586339,,2007-12-21,2012-02-16,,2019-12-30,2007-12-21,2008-01-04,ESTIMATED,2012-02-16,2012-03-22,ESTIMATED,,,,2019-12-30,2020-01-03,ACTUAL,2008-01-17,ACTUAL,2008-01-17,2019-12,2019-12-31,2011-07-18,ACTUAL,2011-07-18,2011-07-18,ACTUAL,2011-07-18,,INTERVENTIONAL,,,Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females,Evaluation of the Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in Adult Human Immunodeficiency Virus (HIV) Infected Female Subjects,COMPLETED,,PHASE2,150,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",https://clinicalstudydatarequest.com/Posting.aspx?ID=2198,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 12:14:37,2024-10-13 12:14:37,INDUSTRY,,,,,,,GlaxoSmithKline,South Africa,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00589563,,2007-12-21,2014-07-21,,2014-09-03,2007-12-25,2008-01-09,ESTIMATED,2014-07-21,2014-08-12,ESTIMATED,,,,2014-09-03,2014-09-10,ESTIMATED,2007-05,,2007-05-31,2014-09,2014-09-30,2012-02,ACTUAL,2012-02-29,2012-02,ACTUAL,2012-02-29,,INTERVENTIONAL,,,"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer","A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation",COMPLETED,,PHASE2,32,ACTUAL,City of Hope Medical Center,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 05:22:56,2024-10-13 05:22:56,OTHER,,,,,,,City of Hope Medical Center|National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00592124,,2007-12-31,2017-01-04,,2021-10-15,2007-12-31,2008-01-11,ESTIMATED,2017-01-04,2017-02-27,ACTUAL,,,,2021-10-15,2021-10-19,ACTUAL,2008-06,,2008-06-30,2017-01,2017-01-31,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,The baseline population consists of evaluable enrolled participants.,Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women,Phase 2 Adherence and Pharmacokinetics Study of Oral and Vaginal Preparations of Tenofovir,COMPLETED,,PHASE2,168,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"For a full discussion of the difficulties of sampling and comparing findings in the varied and complex anatomic spaces in this study, please see the primary results publication, listed in the References section (PLoS One 2013;8(1):e55013.)",6,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:48:17,2024-10-15 02:48:17,NIH,,,,,,,Microbicide Trials Network|National Institute of Allergy and Infectious Diseases (NIAID),South Africa|Uganda|United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders"
NCT00594646,,2008-01-07,2015-08-10,,2022-10-04,2008-01-07,2008-01-16,ESTIMATED,2015-08-10,2015-09-10,ESTIMATED,,,,2022-10-04,2022-10-25,ACTUAL,2008-02,,2008-02-29,2022-10,2022-10-31,2010-08,ACTUAL,2010-08-31,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,,HIV Non Occupational Post-Exposure Prophylaxis (PEP),"A Phase IV Open-Label Evaluation of Safety, Tolerability and Patient Acceptance of Raltegravir (MK-0518) Combined With a Fixed-Dose Formulation of Tenofovir Following Potential Exposure to HIV-1",COMPLETED,,PHASE4,100,ACTUAL,Fenway Community Health,"Limitations of the current study included:

1. Reliance on self-reports to measure adherence
2. Study population almost exclusively male (reflecting the demographics of people who call Fenway Health's hotline after an acute sexual exposure)",1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 11:33:55,2024-10-14 11:33:55,OTHER,,,,,,,Fenway Community Health|Merck Sharp & Dohme LLC,United States,Gastrointestinal disorders|General disorders|Nervous system disorders
NCT00594880,,2008-01-04,2013-01-24,,2015-01-28,2008-01-15,2008-01-16,ESTIMATED,2015-01-28,2015-02-10,ESTIMATED,,,,2015-01-28,2015-02-10,ESTIMATED,2008-01,,2008-01-31,2015-01,2015-01-31,2011-05,ACTUAL,2011-05-31,2010-11,ACTUAL,2010-11-30,,INTERVENTIONAL,,,Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection,Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection,COMPLETED,,PHASE2,23,ACTUAL,The Wistar Institute,"The follwing limitations of this study should be noted:

* Small number of participants enrolled
* Lack of a control arm interrupting ART without immunotherapy",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 16:49:33,2024-10-13 16:49:33,OTHER,,,,,,,Hoffmann-La Roche|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)|The Wistar Institute,United States,Blood and lymphatic system disorders|Hepatobiliary disorders|Psychiatric disorders
NCT00596635,,2008-01-08,2010-06-30,,2013-03-19,2008-01-08,2008-01-17,ESTIMATED,2010-09-01,2010-09-23,ESTIMATED,,,,2013-03-19,2013-03-29,ESTIMATED,2007-01,,2007-01-31,2013-03,2013-03-31,2008-08,ACTUAL,2008-08-31,2008-08,ACTUAL,2008-08-31,,INTERVENTIONAL,PACS,,Cranberry for UTI Prevention in Residents of Long Term Care Facilities,Cranberry for UTI Prevention in Residents of Long Term Care Facilities,COMPLETED,,NA,56,ACTUAL,Yale University,The inability to follow all participants for the full six months reflects the vulnerability of the population.,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 19:41:41,2024-10-14 19:41:41,OTHER,,,,,,,Yale University,United States,Gastrointestinal disorders
NCT00600483,,2008-01-02,2021-06-22,,2022-05-04,2008-01-24,2008-01-25,ESTIMATED,2022-05-04,2022-05-05,ACTUAL,,,,2022-05-04,2022-05-05,ACTUAL,2007-12,,2007-12-31,2022-05,2022-05-31,2010-09,ACTUAL,2010-09-30,2010-09,ACTUAL,2010-09-30,,INTERVENTIONAL,,,Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection,"A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection",COMPLETED,,PHASE3,1502,ACTUAL,Innocoll,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 05:06:15,2024-10-13 05:06:15,INDUSTRY,,,,,,,Duke University|Innocoll|Premier Research Group plc,United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00600925,,2008-01-14,2021-06-11,,2021-09-22,2008-01-24,2008-01-25,ESTIMATED,2021-09-22,2021-09-24,ACTUAL,,,,2021-09-22,2021-09-24,ACTUAL,2008-01,,2008-01-31,2021-09,2021-09-30,2010-09,ACTUAL,2010-09-30,2009-03,ACTUAL,2009-03-31,,INTERVENTIONAL,,,A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection,"A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in General Surgical Subjects at Higher Risk for Surgical Wound Infection",COMPLETED,,PHASE3,602,ACTUAL,Innocoll,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 08:10:50,2024-10-14 08:10:50,INDUSTRY,,,,,,,Duke University|Innocoll|Premier Research Group plc,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00603889,,2008-01-17,2011-06-21,,2012-01-18,2008-01-28,2008-01-29,ESTIMATED,2012-01-18,2012-02-23,ESTIMATED,,,,2012-01-18,2012-02-23,ESTIMATED,2008-03,,2008-03-31,2012-01,2012-01-31,2008-05,ACTUAL,2008-05-31,2008-05,ACTUAL,2008-05-31,,INTERVENTIONAL,,,Development of a Skin Test for the Na-ASP-2 Hookworm Antigen,Development of a Skin Test to Detect Immediate-type Hypersensitivity to the Experimental Na-ASP-2 Hookworm Antigen,COMPLETED,,NA,12,ACTUAL,Albert B. Sabin Vaccine Institute,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:11:43,2024-10-13 05:11:43,OTHER,,,,,,,Albert B. Sabin Vaccine Institute,United States,Skin and subcutaneous tissue disorders
NCT00604175,,2008-01-17,2013-07-15,2012-12-11,2021-11-02,2008-01-17,2008-01-30,ESTIMATED,2013-08-06,2013-10-17,ESTIMATED,2012-12-28,2013-01-01,ESTIMATED,2021-11-02,2021-11-04,ACTUAL,2008-02,,2008-02-29,2015-08,2015-08-31,2012-11,ACTUAL,2012-11-30,2012-01,ACTUAL,2012-01-31,,INTERVENTIONAL,,"All participants, except 4: one was found to be ineligible after enrollment (Stratum A) and 3 failed to start intervention (2 in Stratum A, 1 in Stratum C).",Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women,A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females,COMPLETED,,PHASE2,319,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 05:14:37,2024-10-14 05:14:37,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Dental and Craniofacial Research (NIDCR),Brazil|Puerto Rico|South Africa|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00608023,,2008-01-23,2013-11-27,,2022-09-16,2008-01-23,2008-02-06,ESTIMATED,2013-11-27,2014-01-15,ESTIMATED,,,,2022-09-16,2022-09-30,ACTUAL,2007-08,,2007-08-31,2022-09,2022-09-30,2008-10,ACTUAL,2008-10-31,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy,"A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation",COMPLETED,,PHASE3,263,ACTUAL,Theratechnologies,"As this trial was completed in October 2008 hence, the primary Completion Date is prior to January 18, 2017, therefore the Protocol, and Statistical Analysis Plan have not been uploaded to the Document Section.",3,,,FALSE,,,,,,,,,,,,,,,NO,,2024-10-15 00:12:34,2024-10-15 00:12:34,INDUSTRY,,,,,,,Theratechnologies,Belgium|Canada|France|Spain|United Kingdom|United States,"Eye disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00608569,,2008-01-21,2013-09-05,,2018-09-11,2008-01-23,2008-02-06,ESTIMATED,2013-11-14,2013-11-15,ESTIMATED,,,,2018-09-11,2018-10-12,ACTUAL,2009-03,,2009-03-31,2018-09,2018-09-30,2012-09,ACTUAL,2012-09-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,"Five hundred twenty nine subjects including participants and partners entered the study. Among the 529 subjects, 259 were participants, which include two participants with eligibility violations. Only the 257 eligible participants were included in the analysis.",Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults,International Trial of Modified Directly Observed Therapy Versus Self-Administered Therapy for Participants With First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen,COMPLETED,,NA,529,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 01:29:17,2024-10-13 01:29:17,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Brazil|Haiti|Panama|Peru|South Africa|Uganda|Zambia|Zimbabwe,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00608959,,2008-01-23,2009-06-30,,2010-01-22,2008-01-23,2008-02-06,ESTIMATED,2009-12-16,2010-01-25,ESTIMATED,,,,2010-01-22,2010-01-26,ESTIMATED,2008-05,,2008-05-31,2010-01,2010-01-31,2008-06,ACTUAL,2008-06-30,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,,,Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects,"A Single- Center, Open-Label, Study of the Persistence of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects",COMPLETED,,PHASE3,30,ACTUAL,Cadence,FDA reviewer noted that there were multiple endpoints that required multiplicity adjustments to control for the overall type I error rate.Based on feedback the 72 hour endpoint was selected for Part 2 as the primary efficacy endpoint.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 14:31:53,2024-10-13 14:31:53,UNKNOWN,,,,,,,Cadence Pharmaceuticals,United States,General disorders|Nervous system disorders
NCT00609492,,2008-01-25,2016-11-28,2009-09-09,2019-12-30,2008-01-25,2008-02-07,ESTIMATED,2017-03-01,2017-04-12,ACTUAL,2009-09-09,2009-09-10,ESTIMATED,2019-12-30,2020-01-03,ACTUAL,2008-01-03,ACTUAL,2008-01-03,2019-12,2019-12-31,2009-03-30,ACTUAL,2009-03-30,2008-11-10,ACTUAL,2008-11-10,,INTERVENTIONAL,,,Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.,"Safety, Reactogenicity and Immunogenicity Following Booster Dose of GSK Biologicals´ Pneumococcal Conjugate Vaccine When Co-administered With a Booster Dose of Infanrix-IPV/Hib in Preterm Born Children at 16-18 Months of Age",COMPLETED,,PHASE3,245,ACTUAL,GlaxoSmithKline,None reported.,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=255,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 05:06:15,2024-10-13 05:06:15,INDUSTRY,,,,,,,GlaxoSmithKline,Greece|Spain,"General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00613379,,2008-01-30,2013-04-12,,2016-06-16,2008-02-12,2008-02-13,ESTIMATED,2013-04-12,2013-05-31,ESTIMATED,,,,2016-06-16,2016-07-15,ESTIMATED,2007-12,,2007-12-31,2016-06,2016-06-30,2008-08,ACTUAL,2008-08-31,2008-08,ACTUAL,2008-08-31,,INTERVENTIONAL,,,PRO 140 by IV Administration in Adults With HIV-1 Infection,"A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of PRO 140 by Intravenous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection",COMPLETED,,PHASE2,30,ACTUAL,"CytoDyn, Inc.",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:11:05,2024-10-14 18:11:05,INDUSTRY,,,,,,,"CytoDyn, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)",United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT00614614,,2008-01-31,2012-06-15,2011-11-22,2018-08-22,2008-01-31,2008-02-13,ESTIMATED,2012-06-15,2012-07-20,ESTIMATED,2011-11-22,2011-11-23,ESTIMATED,2018-08-22,2018-09-21,ACTUAL,2008-02-13,,2008-02-13,2016-10,2016-10-31,2009-09-17,ACTUAL,2009-09-17,2009-07-31,ACTUAL,2009-07-31,,INTERVENTIONAL,,,"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014",Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Meningococcal Vaccine 134612 Given at 12-15 Months of Age or at 15-18 Months of Age (Co-administered With Infanrix®) in Primed Healthy Toddlers.,COMPLETED,,PHASE3,1558,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 14:08:24,2024-10-13 14:08:24,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00615290,,2008-01-31,2010-02-03,,2014-08-06,2008-02-13,2008-02-14,ESTIMATED,2010-02-03,2010-02-23,ESTIMATED,,,,2014-08-06,2014-08-08,ESTIMATED,2007-06,,2007-06-30,2014-08,2014-08-31,,,,2009-05,ACTUAL,2009-05-31,,OBSERVATIONAL,,All enrolled patients,"Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy","Pharmaco-epidemiological Description of the Patient Population Treated With Aptivus Under Market Conditions, Safety & Efficacy",COMPLETED,,,42,ACTUAL,Boehringer Ingelheim,,,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 00:07:27,2024-10-14 00:07:27,INDUSTRY,,,,,,,Boehringer Ingelheim,France,Hepatobiliary disorders
NCT00616421,,2008-01-31,2011-02-28,2010-08-27,2016-01-19,2008-02-14,2008-02-15,ESTIMATED,2011-05-10,2011-06-09,ESTIMATED,2010-08-27,2010-08-31,ESTIMATED,2016-01-19,2016-02-15,ESTIMATED,2008-03,,2008-03-31,2016-01,2016-01-31,2009-10,ACTUAL,2009-10-31,2009-04,ACTUAL,2009-04-30,,INTERVENTIONAL,,,Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children,"A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age",COMPLETED,,PHASE3,2907,ACTUAL,Novartis,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:32:19,2024-10-14 13:32:19,INDUSTRY,,,,,,,Novartis Vaccines,Canada|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT00618839,,2008-02-07,2009-05-08,,2019-10-11,2008-02-19,2008-02-20,ESTIMATED,2012-08-08,2012-09-10,ESTIMATED,,,,2019-10-11,2019-10-16,ACTUAL,2006-07,,2006-07-31,2018-12,2018-12-31,2008-04,ACTUAL,2008-04-30,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,,,StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects,"Open-Label, Controlled, Randomized, Comparative, Dose Escalation Study Of The Safety, Human Immunology, And Efficacy Of StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects In Patients Undergoing Sequential Skin Reconstruction Procedures",COMPLETED,,PHASE1/PHASE2,15,ACTUAL,Mallinckrodt,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 02:13:30,2024-10-13 02:13:30,INDUSTRY,,,,,,,"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Stratatech, a Mallinckrodt Company",United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00621192,,2008-02-20,2011-10-20,,2023-03-30,2008-02-20,2008-02-22,ESTIMATED,2011-10-20,2011-11-29,ESTIMATED,,,,2023-03-30,2023-04-25,ACTUAL,2008-06,,2008-06-30,2023-03,2023-03-31,2009-10,ACTUAL,2009-10-31,2009-10,ACTUAL,2009-10-31,,INTERVENTIONAL,,,Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections,Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 Days) With Suspected or Complicated Intra-abdominal Infections,COMPLETED,,PHASE1/PHASE2,200,ACTUAL,"The Emmes Company, LLC",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 16:07:16,2024-10-13 16:07:16,INDUSTRY,,,,,,,"The Emmes Company, LLC",United States,"Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00623597,,2008-02-18,2015-12-10,,2016-02-04,2008-02-18,2008-02-26,ESTIMATED,2015-12-10,2016-01-14,ESTIMATED,,,,2016-02-04,2016-03-07,ESTIMATED,2008-06,,2008-06-30,2016-02,2016-02-29,2010-03,ACTUAL,2010-03-31,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,The Safety Analysis Population (SAP) comprised all participants who received at least one dose of study medication. The SAP was used for all efficacy and safety analyses,A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.,A Phase I/II Study of Invirase® Boosted With Ritonavir in HIV Infected Infants and Children 4 Months to Less Than 6 Years Old,COMPLETED,,PHASE2,18,ACTUAL,Hoffmann-La Roche,,1,,,FALSE,,,,FALSE,,,,,,,,,,,YES,,2024-10-14 16:39:05,2024-10-14 16:39:05,INDUSTRY,,,,,,,Hoffmann-La Roche,Argentina|Brazil|Spain|Thailand|United Kingdom,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00624195,,2008-02-15,2013-12-09,,2014-03-21,2008-02-26,2008-02-27,ESTIMATED,2014-03-21,2014-04-23,ESTIMATED,,,,2014-03-21,2014-04-23,ESTIMATED,2007-03,,2007-03-31,2014-03,2014-03-31,2012-06,ACTUAL,2012-06-30,2012-02,ACTUAL,2012-02-29,,INTERVENTIONAL,,,Clinical Trial of CNS-targeted HAART (CIT2),HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-Targeted HAART,COMPLETED,,PHASE2/PHASE3,59,ACTUAL,"University of California, San Diego",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 15:41:07,2024-10-14 15:41:07,OTHER,,,,,,,"National Institute of Mental Health (NIMH)|National Institutes of Health (NIH)|University of California, San Diego",United States,Infections and infestations|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT00624819,,2008-02-15,2017-08-25,2012-07-24,2021-01-11,2008-02-25,2008-02-27,ESTIMATED,2020-03-04,2020-03-18,ACTUAL,2012-07-24,2012-08-02,ESTIMATED,2021-01-11,2021-01-27,ACTUAL,2008-03-03,ACTUAL,2008-03-03,2021-01,2021-01-31,2008-06-02,ACTUAL,2008-06-02,2008-06-02,ACTUAL,2008-06-02,,INTERVENTIONAL,,"The demographic characteristics are presented separately for each Follow-up Period (Year 1, 2 and 4).",Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine,Long-term Follow-up Study to Assess Antibody Persistence in Children Previously Vaccinated With Four Doses of Pneumococcal Conjugate Vaccine in Primary Vaccination Study (105553) and Booster Vaccination Study (107046),COMPLETED,,PHASE3,524,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=2213,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-15 00:18:36,2024-10-15 00:18:36,INDUSTRY,,,,,,,GlaxoSmithKline,Poland,General disorders|Infections and infestations
NCT00625404,,2008-02-19,2013-12-09,,2018-06-28,2008-02-26,2008-02-28,ESTIMATED,2014-03-11,2014-04-16,ESTIMATED,,,,2018-06-28,2018-07-26,ACTUAL,2009-05,,2009-05-31,2018-06,2018-06-30,2013-01,ACTUAL,2013-01-31,2012-08,ACTUAL,2012-08-31,,INTERVENTIONAL,,,FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women,"Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women",COMPLETED,,PHASE3,2120,ACTUAL,FHI 360,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:15:12,2024-10-14 17:15:12,OTHER,,,,,,,FHI 360,Kenya|Malawi|South Africa|Tanzania|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00626327,,2008-02-20,2013-02-12,2011-02-18,2013-04-12,2008-02-28,2008-02-29,ESTIMATED,2013-02-12,2013-03-15,ESTIMATED,2011-02-18,2011-02-25,ESTIMATED,2013-04-12,2013-04-19,ESTIMATED,2008-02,,2008-02-29,2013-04,2013-04-30,2010-10,ACTUAL,2010-10-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers,"A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers",COMPLETED,,PHASE3,1630,ACTUAL,Novartis,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 03:26:59,2024-10-14 03:26:59,INDUSTRY,,,,,,,Novartis Vaccines,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00627393,,2008-02-28,2014-12-02,,2015-04-16,2008-02-28,2008-03-03,ESTIMATED,2014-12-19,2014-12-23,ESTIMATED,,,,2015-04-16,2015-04-17,ESTIMATED,2008-04,,2008-04-30,2014-04,2014-04-30,2013-05,ACTUAL,2013-05-31,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,RING,All randomized subjects.,Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study),High Dose Granulocyte Transfusions for the Treatment of Infection in Neutropenia: The RING Study (Resolving Infection in Neutropenia With Granulocytes),COMPLETED,,PHASE3,114,ACTUAL,Carelon Research,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 03:42:21,2024-10-15 03:42:21,OTHER,,,,,,,"Carelon Research|National Heart, Lung, and Blood Institute (NHLBI)",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00630734,,2008-02-28,2011-09-12,,2014-05-20,2008-03-06,2008-03-07,ESTIMATED,2012-10-15,2012-11-15,ESTIMATED,,,,2014-05-20,2014-05-22,ESTIMATED,2008-02,,2008-02-29,2014-05,2014-05-31,2010-09,ACTUAL,2010-09-30,2009-10,ACTUAL,2009-10-31,,INTERVENTIONAL,,,Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin,Genetic Predictors of Pharmacokinetic Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin: the Role of SLCO1B1 Polymorphisms.,COMPLETED,,PHASE4,32,ACTUAL,"University of Colorado, Denver",The study included only heterozygous carriers of the SLCO1B1 \*15 and \*17 haplotypes. Pravastatin urine concentrations were not measured; therefore the impact of darunavir/ritonavir on pravastatin renal clearance was not assessed in this population.,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 17:32:20,2024-10-13 17:32:20,OTHER,,,,,,,"Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA|University of Colorado, Denver",United States,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders
NCT00631566,,2008-02-27,2017-11-30,,2023-03-01,2008-03-06,2008-03-07,ESTIMATED,2018-07-18,2018-08-16,ACTUAL,,,,2023-03-01,2023-03-03,ACTUAL,2007-05,,2007-05-31,2023-03,2023-03-31,2017-10,ACTUAL,2017-10-31,2017-05,ACTUAL,2017-05-31,,INTERVENTIONAL,MRSA,,Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons,"Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons",COMPLETED,,NA,550,ACTUAL,Henry M. Jackson Foundation for the Advancement of Military Medicine,Low rates of MRSA infections and SSTI during follow-up. Mostly males. Data for counts by arm other than nares for Outcome #2 are estimates from proportions and overall sample as these data were not available when record completed.,3,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,,,2024-10-13 06:08:12,2024-10-13 06:08:12,OTHER,,,,,,,Henry M. Jackson Foundation for the Advancement of Military Medicine|Infectious Diseases Clinical Research Program|National Institute of Allergy and Infectious Diseases (NIAID)|US Military HIV Research Program,United States,Gastrointestinal disorders
NCT00631566,,2008-02-27,2017-11-30,,2023-03-01,2008-03-06,2008-03-07,ESTIMATED,2018-07-18,2018-08-16,ACTUAL,,,,2023-03-01,2023-03-03,ACTUAL,2007-05,,2007-05-31,2023-03,2023-03-31,2017-10,ACTUAL,2017-10-31,2017-05,ACTUAL,2017-05-31,,INTERVENTIONAL,MRSA,,Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons,"Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons",COMPLETED,,NA,550,ACTUAL,Henry M. Jackson Foundation for the Advancement of Military Medicine,Low rates of MRSA infections and SSTI during follow-up. Mostly males. Data for counts by arm other than nares for Outcome #2 are estimates from proportions and overall sample as these data were not available when record completed.,3,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,,,2024-10-13 06:08:12,2024-10-13 06:08:12,OTHER,,,,,,,Henry M. Jackson Foundation for the Advancement of Military Medicine|Infectious Diseases Clinical Research Program|National Institute of Allergy and Infectious Diseases (NIAID)|US Military HIV Research Program,United States,Gastrointestinal disorders
NCT00632463,,2008-03-03,2013-02-22,,2013-03-12,2008-03-07,2008-03-10,ESTIMATED,2013-03-12,2013-04-24,ESTIMATED,,,,2013-03-12,2013-04-24,ESTIMATED,2008-02,,2008-02-29,2013-03,2013-03-31,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,INTERVENTIONAL,,,RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness,RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness,COMPLETED,,PHASE2,21,ACTUAL,"ADMA Biologics, Inc.",Unfortunately enrollment in this study was suspended early due to slow accrual rates.,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 23:55:37,2024-10-13 23:55:37,INDUSTRY,,,,,,,"ADMA Biologics, Inc.",Australia|Canada|New Zealand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00632463,,2008-03-03,2013-02-22,,2013-03-12,2008-03-07,2008-03-10,ESTIMATED,2013-03-12,2013-04-24,ESTIMATED,,,,2013-03-12,2013-04-24,ESTIMATED,2008-02,,2008-02-29,2013-03,2013-03-31,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,INTERVENTIONAL,,,RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness,RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness,COMPLETED,,PHASE2,21,ACTUAL,"ADMA Biologics, Inc.",Unfortunately enrollment in this study was suspended early due to slow accrual rates.,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 23:55:37,2024-10-13 23:55:37,INDUSTRY,,,,,,,"ADMA Biologics, Inc.",Australia|Canada|New Zealand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00633126,,2008-03-03,2012-03-28,,2017-02-02,2008-03-10,2008-03-11,ESTIMATED,2013-02-11,2013-02-12,ESTIMATED,,,,2017-02-02,2017-03-14,ACTUAL,2008-03,,2008-03-31,2017-02,2017-02-28,2009-02,ACTUAL,2009-02-28,2009-02,ACTUAL,2009-02-28,,INTERVENTIONAL,,,Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age,Pharmacokinetics of a Single Dose of Ceftaroline in Subjects 12 to 17 Years of Age Receiving Antibiotic Therapy,COMPLETED,,PHASE1,9,ACTUAL,Forest Laboratories,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:03:40,2024-10-14 22:03:40,INDUSTRY,,,,,,,Forest Laboratories,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Investigations|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders"
NCT00633152,,2008-03-03,2012-07-25,,2017-02-02,2008-03-03,2008-03-11,ESTIMATED,2012-07-31,2012-08-31,ESTIMATED,,,,2017-02-02,2017-03-14,ACTUAL,2008-02,,2008-02-29,2017-02,2017-02-28,2008-07,ACTUAL,2008-07-31,2008-07,ACTUAL,2008-07-31,,INTERVENTIONAL,,,Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections,"A Phase 2, Multicenter, Randomized, Open-label, Comparative Study to Evaluate the Efficacy and Safety of Intramuscular Ceftaroline Versus Intravenous Linezolid in Adult Subjects With Complicated Skin and Skin Structure Infections",COMPLETED,,PHASE2,150,ACTUAL,Forest Laboratories,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 06:47:03,2024-10-14 06:47:03,INDUSTRY,,,,,,,Forest Laboratories,United States,Gastrointestinal disorders|General disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00634049,,2008-03-05,2015-12-02,,2017-12-07,2008-03-11,2008-03-12,ESTIMATED,2016-01-08,2016-01-11,ESTIMATED,,,,2017-12-07,2018-01-02,ACTUAL,2008-04-22,ACTUAL,2008-04-22,2017-12,2017-12-31,2016-05-05,ACTUAL,2016-05-05,2014-01-03,ACTUAL,2014-01-03,,INTERVENTIONAL,VITAL,Intent to Treat Population (ITT),Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi,"Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi",COMPLETED,,PHASE3,149,ACTUAL,Astellas Pharma Inc,Enrollment in the clinical study was suspended in January 2009 pending further characterization of newly identified impurities. After successful study completion resumption of enrollment started in April 2011 for the 9766-CL-0103/WSA-CS-003 study.,1,,,FALSE,,,,TRUE,,,,,,,,,,,YES,Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.,2024-10-13 15:49:25,2024-10-13 15:49:25,INDUSTRY,,,,,,,Astellas Pharma Inc|Basilea Pharmaceutica International Ltd,"Argentina|Australia|Belgium|Brazil|Canada|Chile|China|Egypt|France|Germany|Hungary|India|Israel|Italy|Korea, Republic of|Lebanon|Malaysia|Mexico|New Zealand|Philippines|Poland|Russian Federation|South Africa|Thailand|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00635648,,2008-02-29,2012-04-26,,2017-02-21,2008-03-07,2008-03-14,ESTIMATED,2012-04-26,2012-05-28,ESTIMATED,,,,2017-02-21,2017-03-24,ACTUAL,2008-01,,2008-01-31,2017-02,2017-02-28,2011-05,ACTUAL,2011-05-31,2011-05,ACTUAL,2011-05-31,,INTERVENTIONAL,,,A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066),"A Non-comparative, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate (MK-0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults",COMPLETED,,PHASE3,63,ACTUAL,Merck Sharp & Dohme LLC,This was an open-label non-comparative study with a relatively small sample size.,1,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 09:46:07,2024-10-14 09:46:07,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Investigations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00635830,,2008-03-03,2009-03-17,,2015-10-08,2008-03-07,2008-03-14,ESTIMATED,2009-07-10,2009-08-20,ESTIMATED,,,,2015-10-08,2015-10-09,ESTIMATED,2008-03,,2008-03-31,2015-10,2015-10-31,2008-04,ACTUAL,2008-04-30,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,,,"An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)","An Open-Label, Single-Dose, Safety and Tolerability Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese Female Subjects Aged 9 to 26 Years",COMPLETED,,PHASE1,40,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 11:28:26,2024-10-14 11:28:26,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Eye disorders|Gastrointestinal disorders|General disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00637195,,2008-02-28,2009-11-12,,2019-12-31,2008-03-10,2008-03-17,ESTIMATED,2009-11-12,2009-12-18,ESTIMATED,,,,2019-12-31,2020-01-03,ACTUAL,2008-03-11,ACTUAL,2008-03-11,2019-12,2019-12-31,2009-06-18,ACTUAL,2009-06-18,2008-06-20,ACTUAL,2008-06-20,,INTERVENTIONAL,,,Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299),Evaluation of the Immunogenicity and Safety of a Commercially Available Vaccine When Co-administered With GlaxoSmithKline Biologicals' HPV Vaccine (580299) in Healthy Female Subjects.,COMPLETED,,PHASE3,152,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=211,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 06:40:51,2024-10-13 06:40:51,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium,"Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT00637572,,2008-03-11,2016-01-29,,2017-09-07,2008-03-11,2008-03-18,ESTIMATED,2016-03-18,2016-04-20,ESTIMATED,,,,2017-09-07,2017-10-05,ACTUAL,2004-12,,2004-12-31,2017-09,2017-09-30,2005-06,ACTUAL,2005-06-30,2005-06,ACTUAL,2005-06-30,,INTERVENTIONAL,,Analysis based on Intend to Treat (ITT) population; all randomized subjects who were dispensed medication and had at least one post-randomization visit.,Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss,"A Randomized, Open-labeled, Pilot Study Comparing Weight Gain in Adults With AIDS-related Wasting Given Either Megestrol Acetate Oral Suspension Nanocrystal Dispersion (MA-NCD) or Megestrol Acetate Oral Suspension (Megace)",COMPLETED,,PHASE2,63,ACTUAL,Endo Pharmaceuticals,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-15 00:58:15,2024-10-15 00:58:15,INDUSTRY,,,,,,,"Endo Pharmaceuticals|Quintiles, Inc.",India|South Africa|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00638014,,2008-03-12,2011-02-23,,2011-04-05,2008-03-17,2008-03-18,ESTIMATED,2011-04-05,2011-05-02,ESTIMATED,,,,2011-04-05,2011-05-02,ESTIMATED,2008-03,,2008-03-31,2011-04,2011-04-30,2009-07,ACTUAL,2009-07-31,2009-07,ACTUAL,2009-07-31,,INTERVENTIONAL,TALON,,Rapid Sternal Closure System (TALON),"A Randomized, Controlled, Phase 4 Study of Sternal Plating (Rapid Sternal Closure System, KLS Martin L.P.) in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Complications.",COMPLETED,,PHASE4,51,ACTUAL,Duke University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-12 23:57:38,2024-10-12 23:57:38,OTHER,,,,,,,"Duke University|KLS Martin, L.P.",United States,Renal and urinary disorders|Surgical and medical procedures
NCT00642707,,2008-03-21,2013-04-12,,2015-12-14,2008-03-21,2008-03-25,ESTIMATED,2013-04-12,2013-05-31,ESTIMATED,,,,2015-12-14,2016-01-14,ESTIMATED,2008-03,,2008-03-31,2015-12,2015-12-31,2008-11,ACTUAL,2008-11-30,2008-11,ACTUAL,2008-11-30,,INTERVENTIONAL,,,Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection,"A Phase 2a, Randomized, Double-blind, Placebo Controlled Study of PRO 140 by Subcutaneous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection",COMPLETED,,PHASE2,44,ACTUAL,"CytoDyn, Inc.",,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:43:58,2024-10-14 22:43:58,INDUSTRY,,,,,,,"CytoDyn, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00642707,,2008-03-21,2013-04-12,,2015-12-14,2008-03-21,2008-03-25,ESTIMATED,2013-04-12,2013-05-31,ESTIMATED,,,,2015-12-14,2016-01-14,ESTIMATED,2008-03,,2008-03-31,2015-12,2015-12-31,2008-11,ACTUAL,2008-11-30,2008-11,ACTUAL,2008-11-30,,INTERVENTIONAL,,,Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection,"A Phase 2a, Randomized, Double-blind, Placebo Controlled Study of PRO 140 by Subcutaneous Administration in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection",COMPLETED,,PHASE2,44,ACTUAL,"CytoDyn, Inc.",,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:43:58,2024-10-14 22:43:58,INDUSTRY,,,,,,,"CytoDyn, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00643916,,2008-03-24,2009-09-24,,2014-01-21,2008-03-25,2008-03-26,ESTIMATED,2009-12-04,2010-01-08,ESTIMATED,,,,2014-01-21,2014-02-14,ESTIMATED,2004-12,,2004-12-31,2014-01,2014-01-31,2007-10,ACTUAL,2007-10-31,2006-03,ACTUAL,2006-03-31,,INTERVENTIONAL,,,Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age,"Safety and Immunogenicity of a Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine (TetraMenD) In Toddlers 9 to 18 Months of Age",COMPLETED,,PHASE2,378,ACTUAL,Sanofi,,6,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:03:39,2024-10-13 09:03:39,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00646958,,2008-03-26,2009-03-24,,2014-02-26,2008-03-28,2008-03-31,ESTIMATED,2009-06-25,2009-06-26,ESTIMATED,,,,2014-02-26,2014-03-27,ESTIMATED,2007-12,,2007-12-31,2014-02,2014-02-28,2008-04,ACTUAL,2008-04-30,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,,The intent-to-treat (ITT) population included those patients who were randomized and took at least one (1) dose of study medication.,Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections,"A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection",COMPLETED,,PHASE2,150,ACTUAL,"Melinta Therapeutics, Inc.","This was an unblinded study, which raises the possibility of bias.",3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:37:46,2024-10-13 07:37:46,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",United States,Gastrointestinal disorders|Infections and infestations|Investigations|Nervous system disorders
NCT00646958,,2008-03-26,2009-03-24,,2014-02-26,2008-03-28,2008-03-31,ESTIMATED,2009-06-25,2009-06-26,ESTIMATED,,,,2014-02-26,2014-03-27,ESTIMATED,2007-12,,2007-12-31,2014-02,2014-02-28,2008-04,ACTUAL,2008-04-30,2008-04,ACTUAL,2008-04-30,,INTERVENTIONAL,,The intent-to-treat (ITT) population included those patients who were randomized and took at least one (1) dose of study medication.,Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections,"A Phase 2, Multicenter, Randomized, Open-Label, Comparative Study to Evaluate the Safety and Efficacy of RX-1741 Versus Linezolid in the Outpatient Treatment of Adult Patients With Uncomplicated Skin and Skin Structure Infection",COMPLETED,,PHASE2,150,ACTUAL,"Melinta Therapeutics, Inc.","This was an unblinded study, which raises the possibility of bias.",3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:37:46,2024-10-13 07:37:46,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",United States,Gastrointestinal disorders|Infections and infestations|Investigations|Nervous system disorders
NCT00652938,,2008-03-27,2010-08-04,,2018-06-28,2008-04-01,2008-04-04,ESTIMATED,2010-08-04,2010-08-31,ESTIMATED,,,,2018-06-28,2018-08-17,ACTUAL,2008-04-09,,2008-04-09,2017-04,2017-04-30,2010-01-08,ACTUAL,2010-01-08,2009-08-28,ACTUAL,2009-08-28,,INTERVENTIONAL,,,Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects,Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV Vaccine (580299) Co-administrated With a Commercially Available Vaccine in Healthy Female Adolescents,COMPLETED,,PHASE3,744,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 09:43:00,2024-10-13 09:43:00,INDUSTRY,,,,,,,GlaxoSmithKline,Netherlands|Norway|Sweden,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Renal and urinary disorders|Reproductive system and breast disorders"
NCT00652951,,2008-03-21,2017-09-13,2011-11-17,2019-06-11,2008-04-01,2008-04-04,ESTIMATED,2018-12-13,2018-12-14,ACTUAL,2011-11-17,2011-11-21,ESTIMATED,2019-06-11,2019-06-26,ACTUAL,2008-04-01,ACTUAL,2008-04-01,2019-06,2019-06-30,2010-12-01,ACTUAL,2010-12-01,2009-05-12,ACTUAL,2009-05-12,,INTERVENTIONAL,,,Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib,Non-inferiority of Co-administration of GSK Biologicals'Pneumococcal Conjugate Vaccine GSK1024850A With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib.,COMPLETED,,PHASE3,780,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-15 01:54:09,2024-10-15 01:54:09,INDUSTRY,,,,,,,GlaxoSmithKline,Netherlands,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00654147,,2008-04-02,2015-01-20,,2015-07-11,2008-04-04,2008-04-07,ESTIMATED,2015-07-07,2015-07-13,ESTIMATED,,,,2015-07-11,2015-08-03,ESTIMATED,2008-04,,2008-04-30,2015-07,2015-07-31,2012-01,ACTUAL,2012-01-31,2012-01,ACTUAL,2012-01-31,,INTERVENTIONAL,HIV,,Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects,A Pilot Study to Assess Virologic Suppression and Immune Recovery With Raltegravir and Lopinavir/Ritonavir and Raltegravir and Emtricitabine/Tenofovir in HIV-1 Infected Treatment-naïve Subjects,COMPLETED,,PHASE2,44,ACTUAL,University of Miami,Pilot study with 44 subjects and generalization f results is limited by the small sample size.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 01:34:34,2024-10-13 01:34:34,OTHER,,,,,,,"Margaret A. Fischl, M.D.",United States,Endocrine disorders|Gastrointestinal disorders|Hepatobiliary disorders
NCT00654901,,2008-04-03,2013-05-06,,2016-04-08,2008-04-03,2008-04-09,ESTIMATED,2013-05-06,2013-06-26,ESTIMATED,,,,2016-04-08,2016-05-13,ESTIMATED,2008-03,,2008-03-31,2016-04,2016-04-30,2009-07,ACTUAL,2009-07-31,2009-05,ACTUAL,2009-05-31,,INTERVENTIONAL,,,Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™,"Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican Infants",COMPLETED,,PHASE3,881,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 09:21:12,2024-10-13 09:21:12,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Mexico,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders
NCT00656968,,2008-01-03,2010-08-17,,2015-09-14,2008-04-11,2008-04-14,ESTIMATED,2011-07-05,2011-08-02,ESTIMATED,,,,2015-09-14,2015-09-30,ESTIMATED,2007-05,,2007-05-31,2015-09,2015-09-30,2010-06,ACTUAL,2010-06-30,2010-06,ACTUAL,2010-06-30,,INTERVENTIONAL,960025,,Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection,Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection,COMPLETED,,PHASE4,232,ACTUAL,Kaohsiung Veterans General Hospital.,The trial was performed in a single country,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 10:52:09,2024-10-14 10:52:09,OTHER,,,,,,,Baylor College of Medicine|Kaohsiung Veterans General Hospital.,Taiwan,Gastrointestinal disorders|Nervous system disorders
NCT00659789,,2008-04-14,2015-07-22,,2017-01-05,2008-04-15,2008-04-16,ESTIMATED,2016-11-08,2017-01-05,ESTIMATED,,,,2017-01-05,2017-02-23,ACTUAL,2008-08,,2008-08-31,2016-11,2016-11-30,2011-06,ACTUAL,2011-06-30,2010-06,ACTUAL,2010-06-30,,INTERVENTIONAL,,ITT population,Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV,"A Phase II, Randomized, Double-blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV-1 Who Have Maintained an Adequate Response to ART",COMPLETED,,PHASE2,137,ACTUAL,Bionor Immuno AS,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.,2024-10-13 00:09:32,2024-10-13 00:09:32,INDUSTRY,,,,,,,Bionor Immuno AS,Germany|Italy|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00661557,,2008-04-14,2017-08-25,2009-09-03,2018-06-21,2008-04-15,2008-04-18,ESTIMATED,2018-06-21,2018-12-28,ACTUAL,2009-09-03,2009-09-04,ESTIMATED,2018-06-21,2018-12-28,ACTUAL,2008-05-19,ACTUAL,2008-05-19,2018-06,2018-06-30,2008-12-19,ACTUAL,2008-12-19,2008-12-19,ACTUAL,2008-12-19,,INTERVENTIONAL,,,Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects,Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 Administered in Healthy Subjects Either Previously Primed With Mencevax™ ACWY or naïve to Meningococcal Vaccination.,COMPLETED,,PHASE2,271,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 14:27:14,2024-10-14 14:27:14,INDUSTRY,,,,,,,GlaxoSmithKline,Lebanon,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT00665353,,2008-04-22,2012-06-07,,2018-09-11,2008-04-22,2008-04-23,ESTIMATED,2012-08-14,2012-09-13,ESTIMATED,,,,2018-09-11,2018-10-12,ACTUAL,2009-03,,2009-03-31,2018-09,2018-09-30,2011-12,ACTUAL,2011-12-31,2011-05,ACTUAL,2011-05-31,,INTERVENTIONAL,,,Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance,A Pilot Study of Therapy With Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects With Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy,COMPLETED,,PHASE2,19,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,The study did not fully enroll and the small sample size precluded subgroup analysis.,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:14:24,2024-10-13 06:14:24,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00669955,,2008-04-29,2010-06-21,,2017-02-08,2008-04-30,2008-05-01,ESTIMATED,2010-08-03,2010-08-05,ESTIMATED,,,,2017-02-08,2017-03-16,ACTUAL,2008-06,,2008-06-30,2017-02,2017-02-28,2009-08,ACTUAL,2009-08-31,2009-07,ACTUAL,2009-07-31,,INTERVENTIONAL,,,Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy,"Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days",COMPLETED,,PHASE3,440,ACTUAL,Forest Laboratories,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 07:15:50,2024-10-14 07:15:50,INDUSTRY,,,,,,,Forest Laboratories,United Kingdom,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00674583,,2008-05-07,2017-05-22,2009-09-03,2019-10-29,2008-05-07,2008-05-08,ESTIMATED,2017-05-22,2017-10-19,ACTUAL,2009-09-03,2009-09-04,ESTIMATED,2019-10-29,2019-11-18,ACTUAL,2008-05-09,ACTUAL,2008-05-09,2019-10,2019-10-31,2009-01-08,ACTUAL,2009-01-08,2008-09-02,ACTUAL,2008-09-02,,INTERVENTIONAL,,,Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children,Non-inferiority of GSK Biologicals' Meningococcal Vaccine (GSK134612) Compared to Licensed MenC-CRM197 Conjugate Vaccine in Healthy Children,COMPLETED,,PHASE3,414,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 19:56:46,2024-10-13 19:56:46,INDUSTRY,,,,,,,GlaxoSmithKline,France|Germany,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders"
NCT00678301,,2008-05-13,2017-05-04,2009-09-25,2019-10-29,2008-05-14,2008-05-15,ESTIMATED,2017-05-04,2017-10-27,ACTUAL,2009-09-25,2009-09-28,ESTIMATED,2019-10-29,2019-11-15,ACTUAL,2008-06-18,ACTUAL,2008-06-18,2019-10,2019-10-31,2009-12-10,ACTUAL,2009-12-10,2009-11-09,ACTUAL,2009-11-09,,INTERVENTIONAL,,,"Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™",Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Zilbrix™ Hib and Polio Sabin™,COMPLETED,,PHASE3,365,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=258,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 17:19:39,2024-10-13 17:19:39,INDUSTRY,,,,,,,GlaxoSmithKline,Mali|Nigeria,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00678652,,2008-05-08,2016-11-01,,2017-12-15,2008-05-08,2008-05-15,ESTIMATED,2017-12-15,2017-12-18,ACTUAL,,,,2017-12-15,2017-12-18,ACTUAL,2008-04,,2008-04-30,2017-12,2017-12-31,2009-08,ACTUAL,2009-08-31,2009-08,ACTUAL,2009-08-31,,INTERVENTIONAL,HOPS,,Phase 1 Safety and Immunogenicity of Meningococcal Vaccine,"Ph 1 Dose-Escalation Study of Safety and Immunogenicity of 3 Injections, at 0, 6, 2 Wks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Adm Intramuscularly to Healthy Subjects at 10, 25, 50, 75 μg With Adjuvant",COMPLETED,,PHASE1,36,ACTUAL,U.S. Army Medical Research and Development Command,,4,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,,2024-10-14 05:14:37,2024-10-14 05:14:37,FED,,,,,,,U.S. Army Medical Research and Development Command,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00680914,,2008-05-16,2010-05-13,2009-05-20,2018-05-09,2008-05-19,2008-05-20,ESTIMATED,2010-05-13,2010-06-14,ESTIMATED,2009-09-29,2009-09-30,ESTIMATED,2018-05-09,2018-06-08,ACTUAL,2008-06-10,ACTUAL,2008-06-10,2018-05,2018-05-31,2009-05-08,ACTUAL,2009-05-08,2009-05-08,ACTUAL,2009-05-08,,INTERVENTIONAL,,,Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™,Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A or Prevenar™ Co-administered With Hiberix™,COMPLETED,,PHASE3,503,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 21:10:58,2024-10-14 21:10:58,INDUSTRY,,,,,,,GlaxoSmithKline,"Korea, Republic of",Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders
NCT00683332,,2008-05-21,2011-05-02,,2011-06-09,2008-05-22,2008-05-23,ESTIMATED,2011-06-09,2011-07-08,ESTIMATED,,,,2011-06-09,2011-07-08,ESTIMATED,2007-04,,2007-04-30,2011-06,2011-06-30,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,OBSERVATIONAL,,,Post-Marketing Study Of The Safety Of Tygacil (Tigecycline),"A Prospective, Observational Study To Monitor Safety In Patients Who Were Administered With Tigecycline (Tygacil) 50 mg By Intravenous Injection (An Observational Study for Safety - Monitored Release)",COMPLETED,,,621,ACTUAL,Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 06:29:23,2024-10-14 06:29:23,INDUSTRY,,,,,,,Pfizer,Philippines|United States,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Investigations|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT00683332,,2008-05-21,2011-05-02,,2011-06-09,2008-05-22,2008-05-23,ESTIMATED,2011-06-09,2011-07-08,ESTIMATED,,,,2011-06-09,2011-07-08,ESTIMATED,2007-04,,2007-04-30,2011-06,2011-06-30,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,OBSERVATIONAL,,,Post-Marketing Study Of The Safety Of Tygacil (Tigecycline),"A Prospective, Observational Study To Monitor Safety In Patients Who Were Administered With Tigecycline (Tygacil) 50 mg By Intravenous Injection (An Observational Study for Safety - Monitored Release)",COMPLETED,,,621,ACTUAL,Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 06:29:23,2024-10-14 06:29:23,INDUSTRY,,,,,,,Pfizer,Philippines|United States,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Investigations|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT00684177,,2008-05-22,2010-06-03,,2016-10-11,2008-05-22,2008-05-26,ESTIMATED,2010-07-07,2010-08-04,ESTIMATED,,,,2016-10-11,2016-11-23,ESTIMATED,2008-05,,2008-05-31,2016-10,2016-10-31,2009-10,ACTUAL,2009-10-31,2009-10,ACTUAL,2009-10-31,,INTERVENTIONAL,,,Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL),"A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL",COMPLETED,,PHASE3,508,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 21:56:26,2024-10-13 21:56:26,INDUSTRY,,,,,,,GlaxoSmithKline,Argentina|Brazil|India|Peru|Philippines|South Africa|United States,Cardiac disorders|General disorders|Infections and infestations
NCT00685698,,2008-05-22,2014-12-16,,2014-12-25,2008-05-22,2008-05-28,ESTIMATED,2014-12-25,2015-01-09,ESTIMATED,,,,2014-12-25,2015-01-09,ESTIMATED,2008-06,,2008-06-30,2014-12,2014-12-31,2009-06,ACTUAL,2009-06-30,2009-04,ACTUAL,2009-04-30,,INTERVENTIONAL,,The ITT population consists of all patients from the Enrolled population who took at least one whole dose of study medication (three capsules) and who exhibited at least one Gram-positive pathogen at Baseline (Visit 1) as confirmed by culture of wound tissue by the central (or local) laboratory.,Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections,"An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens",COMPLETED,,PHASE2,40,ACTUAL,"TaiGen Biotechnology Co., Ltd.",,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 17:13:28,2024-10-13 17:13:28,INDUSTRY,,,,,,,"TaiGen Biotechnology Co., Ltd.",South Africa|Taiwan|Thailand|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00686543,,2008-05-27,2010-04-15,,2017-03-09,2008-05-29,2008-05-30,ESTIMATED,2010-04-15,2010-05-14,ESTIMATED,,,,2017-03-09,2017-04-07,ACTUAL,2007-12,,2007-12-31,2017-03,2017-03-31,2009-04,ACTUAL,2009-04-30,2009-04,ACTUAL,2009-04-30,,INTERVENTIONAL,,,Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115),A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection,COMPLETED,,PHASE4,75,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 22:20:01,2024-10-13 22:20:01,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Belgium|Germany|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00686829,,2008-05-27,2020-11-02,,2020-12-02,2008-05-29,2008-05-30,ESTIMATED,2020-12-02,2020-12-03,ACTUAL,,,,2020-12-02,2020-12-03,ACTUAL,2005-06-30,ACTUAL,2005-06-30,2020-12,2020-12-31,2010-10-21,ACTUAL,2010-10-21,2010-10-21,ACTUAL,2010-10-21,,INTERVENTIONAL,,,Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100),Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211,COMPLETED,,PHASE2,79,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 15:04:55,2024-10-14 15:04:55,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00690378,,2008-05-29,2017-09-01,,2018-04-27,2008-06-03,2008-06-04,ESTIMATED,2018-04-27,2018-05-25,ACTUAL,,,,2018-04-27,2018-05-25,ACTUAL,2008-11,,2008-11-30,2018-03,2018-03-31,2010-07,ACTUAL,2010-07-31,2010-06,ACTUAL,2010-06-30,,INTERVENTIONAL,,Safety population included all participants who received at least 1 dose of study drug.,Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections,"Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults",COMPLETED,,PHASE2,137,ACTUAL,Pfizer,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 15:43:52,2024-10-13 15:43:52,INDUSTRY,,,,,,,Pfizer,Jordan|Lebanon|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Vascular disorders"
NCT00696618,,2008-06-04,2016-12-05,,2017-03-20,2008-06-11,2008-06-13,ESTIMATED,2017-03-20,2017-04-28,ACTUAL,,,,2017-03-20,2017-04-28,ACTUAL,2007-07,,2007-07-31,2017-03,2017-03-31,2012-03,ACTUAL,2012-03-31,2009-07,ACTUAL,2009-07-31,,INTERVENTIONAL,,,Enema Use and Acceptability in HIV Negative Men Who Have Sex With Men,"A Randomized, Blinded, Comparative Study of the Mucosal Toxicity, Colorectal Distribution, and Participant Acceptability of Three Different Preparatory Enemas (Hypo-, Iso-, and Hyper-osmolar)",COMPLETED,,NA,9,ACTUAL,Johns Hopkins University,,3,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 12:20:10,2024-10-13 12:20:10,OTHER,,,,,,,"Johns Hopkins University|University of California, Los Angeles",United States,Gastrointestinal disorders|Investigations|Nervous system disorders|Product Issues|Skin and subcutaneous tissue disorders
NCT00700635,,2008-05-07,2010-12-11,2010-09-02,2016-04-12,2008-06-18,2008-06-19,ESTIMATED,2010-12-11,2010-12-23,ESTIMATED,2010-10-04,2010-10-06,ESTIMATED,2016-04-12,2016-04-14,ESTIMATED,2008-06,,2008-06-30,2016-04,2016-04-30,2009-10,ACTUAL,2009-10-31,2009-05,ACTUAL,2009-05-31,,INTERVENTIONAL,,,Dose Comparison Study of Menactra® in US Children,"Exploratory Evaluation of a Two-dose Schedule Versus a One-dose Schedule of Menactra® (Meningococcal [Groups A, C, Y and W 135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) in Children in the US",COMPLETED,,PHASE2,333,ACTUAL,Sanofi,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 19:29:55,2024-10-14 19:29:55,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT00701636,,2008-06-17,2012-03-28,,2016-07-19,2008-06-18,2008-06-19,ESTIMATED,2016-07-19,2016-08-29,ESTIMATED,,,,2016-07-19,2016-08-29,ESTIMATED,2008-07,,2008-07-31,2016-07,2016-07-31,2010-10,ACTUAL,2010-10-31,2010-10,ACTUAL,2010-10-31,,INTERVENTIONAL,,"Our protocol says we will enroll 32 subjects, with the assumption that 2 may not finish the study, have protocol violations, or have data that is corrupt and unusable. Our target was 30 analyzable subjects. Since we had no subjects withdraw from the trial, and no protocol violations or data problems, we halted enrollment at 30 subjects.",Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery,Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery,COMPLETED,,PHASE3,30,ACTUAL,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,Data may be shared upon written request to the principal investigator.,2024-10-15 00:35:58,2024-10-15 00:35:58,OTHER,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)|Hartford Hospital|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|Western University of Health Sciences",United States,Surgical and medical procedures
NCT00701896,,2008-06-17,2020-12-18,,2020-12-18,2008-06-18,2008-06-19,ESTIMATED,2020-12-18,2021-01-15,ACTUAL,,,,2020-12-18,2021-01-15,ACTUAL,2008-10-03,ACTUAL,2008-10-03,2020-12,2020-12-31,2013-06-20,ACTUAL,2013-06-20,2013-04-20,ACTUAL,2013-04-20,,INTERVENTIONAL,,,Smoking Cessation Using Motivational Therapy and Varenicline,Smoking Cessation and the Natural History of HIV-Associated Emphysema,COMPLETED,,NA,294,ACTUAL,Ohio State University,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 13:03:43,2024-10-13 13:03:43,OTHER,,,,,,,"National Heart, Lung, and Blood Institute (NHLBI)|Philip Diaz",United States,Gastrointestinal disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT00705679,,2008-06-24,2016-01-12,2015-05-28,2021-10-15,2008-06-24,2008-06-26,ESTIMATED,2016-01-12,2016-02-10,ESTIMATED,2015-07-02,2015-07-24,ESTIMATED,2021-10-15,2021-10-29,ACTUAL,2009-08,,2009-08-31,2016-02,2016-02-29,2012-08,ACTUAL,2012-08-31,2012-08,ACTUAL,2012-08-31,,INTERVENTIONAL,,Includes all participants enrolled and randomized to a study arm,"Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in Women","Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women",COMPLETED,,PHASE2,5029,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"In September 2011, the oral TDF arm was discontinued for futility; in November 2011, the TFV gel and gel placebo arms were discontinued for futility. The TDF-FTC and oral placebo arms continued follow-up until the end of study in August 2012.",5,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 18:31:10,2024-10-13 18:31:10,NIH,,,,,,,Microbicide Trials Network|National Institute of Allergy and Infectious Diseases (NIAID),Malawi|South Africa|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00706550,,2008-06-24,2013-09-26,,2014-03-27,2008-06-26,2008-06-27,ESTIMATED,2013-09-26,2013-12-12,ESTIMATED,,,,2014-03-27,2014-04-24,ESTIMATED,2008-10,,2008-10-31,2014-03,2014-03-31,2012-09,ACTUAL,2012-09-30,2011-09,ACTUAL,2011-09-30,,INTERVENTIONAL,,,Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects,Immune Responses to Pneumococcal Vaccination Among HIV-Infected Subjects,COMPLETED,,NA,107,ACTUAL,VA Office of Research and Development,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:45:33,2024-10-13 19:45:33,FED,,,,,,,Albert Einstein College of Medicine|Montefiore Medical Center|US Department of Veterans Affairs,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00708110,,2008-06-30,2013-08-22,2009-07-22,2013-11-07,2008-06-30,2008-07-02,ESTIMATED,2013-08-22,2013-10-30,ESTIMATED,2009-07-22,2009-08-10,ESTIMATED,2013-11-07,2013-12-05,ESTIMATED,2008-06,,2008-06-30,2013-08,2013-08-31,2008-08,ACTUAL,2008-08-31,2008-08,ACTUAL,2008-08-31,,INTERVENTIONAL,,,Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults,"A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 Days in HIV-1 Infected Adults (ING111521)",COMPLETED,,PHASE2,35,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 14:01:33,2024-10-14 14:01:33,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00708162,,2008-06-30,2014-10-23,2011-08-23,2016-04-21,2008-06-30,2008-07-02,ESTIMATED,2014-10-30,2014-11-06,ESTIMATED,2011-08-23,2011-08-25,ESTIMATED,2016-04-21,2016-05-30,ESTIMATED,2008-07,,2008-07-31,2016-04,2016-04-30,2015-04,ACTUAL,2015-04-30,2010-12,ACTUAL,2010-12-31,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized and received at least one dose of study drug,"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults",COMPLETED,,PHASE3,724,ACTUAL,Gilead Sciences,10 participants from a single study site were excluded from Intent-to-Treat (ITT) Analysis Set due to critical and multiple protocol violations (elvitegravir arm: n = 3; raltegravir arm: n = 7).,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 05:40:18,2024-10-13 05:40:18,INDUSTRY,,,,,,,Gilead Sciences,Australia|Belgium|Canada|France|Germany|Ireland|Italy|Mexico|Netherlands|Portugal|Puerto Rico|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00709111,,2008-07-01,2011-07-26,,2018-09-11,2008-07-01,2008-07-03,ESTIMATED,2012-01-23,2012-02-24,ESTIMATED,,,,2018-09-11,2018-10-12,ACTUAL,2009-01,,2009-01-31,2018-09,2018-09-30,2010-04,ACTUAL,2010-04-30,2009-10,ACTUAL,2009-10-31,,INTERVENTIONAL,,,Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression,A Pilot Trial of Maraviroc for Treatment of Subjects on Antiretroviral Therapy With Suboptimal CD4 T-cell Count Recovery Despite Sustained Virologic Suppression,COMPLETED,,NA,34,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 19:28:19,2024-10-13 19:28:19,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00710593,,2008-07-02,2013-11-15,,2017-06-01,2008-07-02,2008-07-04,ESTIMATED,2017-04-13,2017-05-22,ACTUAL,,,,2017-06-01,2017-07-02,ACTUAL,2008-02,,2008-02-29,2017-04,2017-04-30,2011-02,ACTUAL,2011-02-28,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,,,Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women,"Immunogenicity, Safety, Tolerability, and Behavioral Consequences of an HPV-6, -11, -16, -18 Vaccine in HIV-Infected Young Women",COMPLETED,,PHASE2,99,ACTUAL,"University of North Carolina, Chapel Hill",The small number of participants (99 started and 79 completed the study) limits generalizability of safety/tolerability data.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 21:57:34,2024-10-14 21:57:34,OTHER,,,,,,,"University of North Carolina, Chapel Hill",Puerto Rico|United States,General disorders
NCT00711009,,2008-07-03,2010-11-16,,2012-02-13,2008-07-03,2008-07-08,ESTIMATED,2011-01-11,2011-02-02,ESTIMATED,,,,2012-02-13,2012-02-14,ESTIMATED,2008-07,,2008-07-31,2012-02,2012-02-29,2010-10,ACTUAL,2010-10-31,2009-11,ACTUAL,2009-11-30,,INTERVENTIONAL,PROGRESS,,Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL),"A Randomized, Open-label Study of Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Co-formulated Emtricitabine/Tenofovir Disoproxil Fumarate 200/300 mg Once Daily Versus Lopinavir/Ritonavir 400/100 mg Tablet Twice Daily + Raltegravir 400 mg Twice Daily in Antiretroviral Naive, HIV-1 Infected Subjects",COMPLETED,,PHASE3,206,ACTUAL,Abbott,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 03:51:52,2024-10-14 03:51:52,INDUSTRY,,,,,,,Abbott|Merck Sharp & Dohme LLC,Canada|France|Italy|Poland|Puerto Rico|Spain|United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00712166,,2008-07-07,2010-09-10,,2010-11-19,2008-07-08,2008-07-09,ESTIMATED,2010-11-19,2010-12-20,ESTIMATED,,,,2010-11-19,2010-12-20,ESTIMATED,2008-05,,2008-05-31,2010-11,2010-11-30,2009-08,ACTUAL,2009-08-31,2009-06,ACTUAL,2009-06-30,,INTERVENTIONAL,AIR-CF4,,"Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa","A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine For Inhalation in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa (AIR-CF4)",COMPLETED,,PHASE3,160,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 11:51:49,2024-10-13 11:51:49,INDUSTRY,,,,,,,Gilead Sciences,Australia|Canada|United States,"Gastrointestinal disorders|General disorders|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00712530,,2008-07-04,2013-02-19,,2013-02-19,2008-07-08,2008-07-10,ESTIMATED,2013-02-19,2013-03-26,ESTIMATED,,,,2013-02-19,2013-03-26,ESTIMATED,2005-01,,2005-01-31,2013-02,2013-02-28,2006-06,ACTUAL,2006-06-30,2006-06,ACTUAL,2006-06-30,,INTERVENTIONAL,GIHU004,,Single DermaVir Immunization in HIV-1 Infected Patients on HAART,"A Phase I Study to Evaluate the Tolerability and Safety of LC002, a DermaVir Vaccine, in HIV-1-infected Subjects Currently Under Treatment With Highly Active Antiretroviral Therapy (HAART)",COMPLETED,,PHASE1,9,ACTUAL,Genetic Immunity,This is a Phase I small sample study that was not powered for the secondary efficacy endpoints.,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 00:30:16,2024-10-15 00:30:16,INDUSTRY,,,,,,,Genetic Immunity,Hungary,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Musculoskeletal and connective tissue disorders|Skin and subcutaneous tissue disorders
NCT00715910,,2008-07-11,2014-04-25,2013-08-22,2014-11-20,2008-07-14,2008-07-15,ESTIMATED,2014-05-01,2014-05-29,ESTIMATED,2013-08-22,2013-08-30,ESTIMATED,2014-11-20,2014-11-27,ESTIMATED,2008-07,,2008-07-31,2014-09,2014-09-30,2013-10,ACTUAL,2013-10-31,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,The overall number of baseline subjects correspond to the subjects at Year 1 persistence phase and another cohort of subjects (naive control group) which was offered a dose of Nimenrix vaccine at Year 5 within the same study.,The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults,Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine Versus Menactra® in Healthy Adolescents/Adults Aged 10-25 Years and Booster Response to MenACWY-TT Vaccine Administered at 5 Years Post-primary Vaccination,COMPLETED,,PHASE2,818,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 01:00:44,2024-10-13 01:00:44,INDUSTRY,,,,,,,GlaxoSmithKline,United States,General disorders|Infections and infestations|Psychiatric disorders
NCT00717067,,2008-07-15,2009-11-16,,2010-11-10,2008-07-15,2008-07-16,ESTIMATED,2009-11-16,2009-12-21,ESTIMATED,,,,2010-11-10,2010-11-19,ESTIMATED,2008-07,,2008-07-31,2010-11,2010-11-30,2008-11,ACTUAL,2008-11-30,2008-11,ACTUAL,2008-11-30,,INTERVENTIONAL,,,"Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function","An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function",COMPLETED,,PHASE4,30,ACTUAL,ViiV Healthcare,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 18:19:27,2024-10-13 18:19:27,INDUSTRY,,,,,,,Pfizer|ViiV Healthcare,Germany,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00717860,,2008-07-16,2011-07-28,,2017-02-20,2008-07-16,2008-07-18,ESTIMATED,2011-07-28,2011-08-26,ESTIMATED,,,,2017-02-20,2017-03-23,ACTUAL,2008-08,,2008-08-31,2017-02,2017-02-28,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED),"A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections",COMPLETED,,PHASE3,121,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 08:37:22,2024-10-13 08:37:22,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00718666,,2008-07-17,2017-09-28,2013-12-05,2019-06-11,2008-07-18,2008-07-21,ESTIMATED,2018-07-26,2018-08-23,ACTUAL,2013-12-05,2013-12-30,ESTIMATED,2019-06-11,2019-06-26,ACTUAL,2008-10-20,ACTUAL,2008-10-20,2019-06,2019-06-30,2014-03-28,ACTUAL,2014-03-28,2013-11-13,ACTUAL,2013-11-13,,INTERVENTIONAL,,Baseline Period for Nimenrix 1 Group and Nimenrix 2 Group is considered Year 1 and Baseline Period for Nimenrix Naive Group is considered Year 5.,The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers,Long Term Antibody Persistence Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered as 1 or 2 Doses to Healthy Toddlers at 9-12 Months of Age and as a Booster Dose at 5 Years Post-primary Vaccination,COMPLETED,,PHASE2,387,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 00:36:58,2024-10-14 00:36:58,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"General disorders|Injury, poisoning and procedural complications"
NCT00719810,,2008-07-18,2010-01-07,,2014-06-30,2008-07-21,2008-07-22,ESTIMATED,2010-01-07,2010-02-03,ESTIMATED,,,,2014-06-30,2014-07-14,ESTIMATED,2008-06,,2008-06-30,2014-06,2014-06-30,2008-10,ACTUAL,2008-10-31,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections,"A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX 3341 Compared With Tigecycline for the Treatment of Complicated Skin and Skin Structure Infections",COMPLETED,,PHASE2,150,ACTUAL,"Melinta Therapeutics, Inc.",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 23:16:28,2024-10-13 23:16:28,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00719810,,2008-07-18,2010-01-07,,2014-06-30,2008-07-21,2008-07-22,ESTIMATED,2010-01-07,2010-02-03,ESTIMATED,,,,2014-06-30,2014-07-14,ESTIMATED,2008-06,,2008-06-30,2014-06,2014-06-30,2008-10,ACTUAL,2008-10-31,2008-10,ACTUAL,2008-10-31,,INTERVENTIONAL,,,Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections,"A Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of RX 3341 Compared With Tigecycline for the Treatment of Complicated Skin and Skin Structure Infections",COMPLETED,,PHASE2,150,ACTUAL,"Melinta Therapeutics, Inc.",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 23:16:28,2024-10-13 23:16:28,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00721396,,2008-07-22,2015-02-18,,2015-03-17,2008-07-23,2008-07-24,ESTIMATED,2015-03-17,2015-03-23,ESTIMATED,,,,2015-03-17,2015-03-23,ESTIMATED,2008-08,,2008-08-31,2015-03,2015-03-31,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,"Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules","A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules.",COMPLETED,,PHASE2,1885,ACTUAL,Novartis,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:59:07,2024-10-15 02:59:07,INDUSTRY,,,,,,,Novartis Vaccines,Belgium|Czech Republic|Germany|Italy|Spain|United Kingdom,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00721578,,2008-07-22,2010-07-28,,2011-01-06,2008-07-23,2008-07-24,ESTIMATED,2010-07-29,2010-08-26,ESTIMATED,,,,2011-01-06,2011-01-10,ESTIMATED,2009-04,,2009-04-30,2011-01,2011-01-31,2009-12,ACTUAL,2009-12-31,2009-12,ACTUAL,2009-12-31,,OBSERVATIONAL,,,A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections,An Observational Study Of Patients Receiving Therapy For Systemic Fungal Infections,COMPLETED,,,23,ACTUAL,Pfizer,"Primary and Secondary outcome measured were arbitrarily defined as they were not defined in the protocol.

This study was terminated prematurely due to slow recruitment rate leading to a small (23) number of subjects analyzed.",,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 23:41:58,2024-10-14 23:41:58,INDUSTRY,,,,,,,Pfizer,India,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00724711,,2008-07-25,2012-03-28,,2012-05-22,2008-07-28,2008-07-29,ESTIMATED,2012-03-28,2012-04-19,ESTIMATED,,,,2012-05-22,2012-05-28,ESTIMATED,2008-07,,2008-07-31,2012-05,2012-05-31,2011-04,ACTUAL,2011-04-30,2011-03,ACTUAL,2011-03-31,,INTERVENTIONAL,SWIFT,,Safety and Efficacy Study of Switching From Epzicom to Truvada,"A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV-1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen",COMPLETED,,PHASE4,312,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 01:17:48,2024-10-13 01:17:48,INDUSTRY,,,,,,,Gilead Sciences,Canada|Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00727597,,2008-07-31,2012-08-28,,2013-06-28,2008-08-01,2008-08-04,ESTIMATED,2013-06-28,2013-07-02,ESTIMATED,,,,2013-06-28,2013-07-02,ESTIMATED,2008-07,,2008-07-31,2013-06,2013-06-30,2011-07,ACTUAL,2011-07-31,2010-08,ACTUAL,2010-08-31,,INTERVENTIONAL,SUPPoRT,,A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT,A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT,COMPLETED,,PHASE3,101,ACTUAL,Georgetown University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:07:17,2024-10-14 13:07:17,OTHER,,,,,,,Georgetown University|GlaxoSmithKline,United States,Cardiac disorders|Endocrine disorders|General disorders|Immune system disorders
NCT00729924,,2008-08-04,2014-05-27,,2015-03-02,2008-08-07,2008-08-08,ESTIMATED,2015-03-02,2015-03-03,ESTIMATED,,,,2015-03-02,2015-03-03,ESTIMATED,2008-08,,2008-08-31,2015-03,2015-03-31,2011-08,ACTUAL,2011-08-31,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,,,Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid,Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid,COMPLETED,,PHASE2/PHASE3,40,ACTUAL,Vanderbilt University,There were no limitations to this trial.,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 02:35:21,2024-10-13 02:35:21,OTHER,,,,,,,Vanderbilt University,United States,Nervous system disorders
NCT00729937,,2008-08-07,2014-04-17,,2015-01-29,2008-08-07,2008-08-08,ESTIMATED,2014-04-24,2014-05-28,ESTIMATED,,,,2015-01-29,2015-02-18,ESTIMATED,2009-04,,2009-04-30,2013-09,2013-09-30,2013-06,ACTUAL,2013-06-30,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,,"The baseline analysis population is the per protocol population. All participants who met enrollment criteria, had none of the exclusion criteria, completed at least 75% of the first 5 days of antimicrobial therapy, and had physical follow-up at the Test of Cure (TOC) visit were included in the per protocol population.","Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus ""STOP MRSA""","Strategies Using Off-Patent Antibiotics for Methicillin-Resistant Staphylococcus Aureus (""STOP MRSA"") - A Phase IIB, Multi-Center, Randomized, Double-Blind Clinical Trial",COMPLETED,,PHASE2/PHASE3,2265,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 13:44:10,2024-10-14 13:44:10,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00730028,,2008-08-07,2016-02-18,,2016-02-18,2008-08-07,2008-08-08,ESTIMATED,2016-02-18,2016-03-17,ESTIMATED,,,,2016-02-18,2016-03-17,ESTIMATED,2009-04,,2009-04-30,2015-04,2015-04-30,2015-02,ACTUAL,2015-02-28,2015-02,ACTUAL,2015-02-28,,INTERVENTIONAL,,All participants enrolled in the protocol are included in the baseline analysis population.,Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus,"Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus",COMPLETED,,PHASE2,1310,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 02:13:30,2024-10-13 02:13:30,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00731783,,2008-08-07,2011-03-02,,2012-04-23,2008-08-07,2008-08-11,ESTIMATED,2011-03-02,2011-03-23,ESTIMATED,,,,2012-04-23,2012-04-30,ESTIMATED,2008-07,,2008-07-31,2012-04,2012-04-30,2010-12,ACTUAL,2010-12-31,2010-01,ACTUAL,2010-01-31,,INTERVENTIONAL,SuDS,,Staphylococcus Aureus Decolonization Study,Household vs. Individual Approach to Decolonization of Community-acquired Methicillin-resistant Staphylococcus Aureus.,COMPLETED,,NA,183,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 09:04:04,2024-10-14 09:04:04,OTHER,,,,,,,Washington University School of Medicine,United States,Skin and subcutaneous tissue disorders
NCT00731783,,2008-08-07,2011-03-02,,2012-04-23,2008-08-07,2008-08-11,ESTIMATED,2011-03-02,2011-03-23,ESTIMATED,,,,2012-04-23,2012-04-30,ESTIMATED,2008-07,,2008-07-31,2012-04,2012-04-30,2010-12,ACTUAL,2010-12-31,2010-01,ACTUAL,2010-01-31,,INTERVENTIONAL,SuDS,,Staphylococcus Aureus Decolonization Study,Household vs. Individual Approach to Decolonization of Community-acquired Methicillin-resistant Staphylococcus Aureus.,COMPLETED,,NA,183,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 09:04:04,2024-10-14 09:04:04,OTHER,,,,,,,Washington University School of Medicine,United States,Skin and subcutaneous tissue disorders
NCT00732238,,2008-08-06,2014-10-28,,2015-01-21,2008-08-08,2008-08-11,ESTIMATED,2014-10-28,2014-11-02,ESTIMATED,,,,2015-01-21,2015-02-16,ESTIMATED,2007-07,,2007-07-31,2015-01,2015-01-31,2012-12,ACTUAL,2012-12-31,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,,,Multifaceted Treatment of Catheter-related Urinary Tract Infection,Multifaceted Treatment of Catheter-related Urinary Tract Infection,COMPLETED,,PHASE2,61,ACTUAL,VA Office of Research and Development,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 02:14:10,2024-10-14 02:14:10,FED,,,,,,,US Department of Veterans Affairs,United States,Gastrointestinal disorders
NCT00734500,,2008-08-13,2011-08-31,,2012-11-16,2008-08-13,2008-08-14,ESTIMATED,2011-11-09,2011-12-14,ESTIMATED,,,,2012-11-16,2012-11-21,ESTIMATED,2008-01,,2008-01-31,2012-11,2012-11-30,2010-06,ACTUAL,2010-06-30,2010-06,ACTUAL,2010-06-30,,INTERVENTIONAL,,,Anidulafungin PK in Infants and Toddlers,Anidulafungin PK in Infants and Toddlers,COMPLETED,,PHASE1,15,ACTUAL,Duke University,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 00:09:32,2024-10-13 00:09:32,OTHER,,,,,,,Michael Cohen-Wolkowiez,United States,Cardiac disorders|Gastrointestinal disorders
NCT00735072,,2008-08-12,2011-06-05,,2020-07-23,2008-08-13,2008-08-14,ESTIMATED,2012-06-13,2012-07-18,ESTIMATED,,,,2020-07-23,2020-08-17,ACTUAL,2008-09,,2008-09-30,2020-07,2020-07-31,2010-07,ACTUAL,2010-07-31,2010-04,ACTUAL,2010-04-30,,INTERVENTIONAL,,,Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure,Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure,COMPLETED,,PHASE4,45,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:58:47,2024-10-14 02:58:47,OTHER,,,,,,,"amfAR, The Foundation for AIDS Research|Case Western Reserve University|Pfizer|Rush University|Stanford University|University of California, San Francisco",United States,Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders
NCT00736242,,2008-07-30,2012-12-21,,2015-02-02,2008-08-14,2008-08-15,ESTIMATED,2013-02-27,2013-04-08,ESTIMATED,,,,2015-02-02,2015-02-19,ESTIMATED,2005-12,,2005-12-31,2015-02,2015-02-28,2011-12,ACTUAL,2011-12-31,2011-12,ACTUAL,2011-12-31,,OBSERVATIONAL,,,Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584),Treatment of Chronic Hepatitis C in HIV-infected Patients With PegIntron Pen and Rebetol According to German Law (§ 67 Abs 6 AMG),COMPLETED,,,232,ACTUAL,Merck Sharp & Dohme LLC,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:26:34,2024-10-13 08:26:34,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT00736476,,2008-08-13,2016-09-30,,2017-01-09,2008-08-13,2008-08-15,ESTIMATED,2017-01-09,2017-02-28,ACTUAL,,,,2017-01-09,2017-02-28,ACTUAL,2008-10,,2008-10-31,2016-09,2016-09-30,2010-04,ACTUAL,2010-04-30,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,,Efficacy and Safety of an H.Pylori Vaccine in H.Pylori-Negative Adults,"Phase I/II, Randomized, Observer-blind, Placebo-controlled, Single-Center Study of the Tolerability, Immunogenicity, and Efficacy of an Novartis' Investigational H. Pylori Vaccine in H. Pylori-Negative Adults",COMPLETED,,PHASE1,63,ACTUAL,Novartis,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 20:47:50,2024-10-14 20:47:50,INDUSTRY,,,,,,,Novartis Vaccines,Germany,General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00736502,,2008-07-07,2012-07-30,,2014-02-03,2008-08-15,2008-08-18,ESTIMATED,2012-07-30,2012-08-31,ESTIMATED,,,,2014-02-03,2014-03-07,ESTIMATED,2008-09,,2008-09-30,2014-02,2014-02-28,,,,2011-07,ACTUAL,2011-07-31,,OBSERVATIONAL,,Treated set,PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.,Longterm Efficacy and Safety of NVP-based HAART in HIV-1 Positive Patients in the Daily Clinical Practice.,COMPLETED,,,280,ACTUAL,Boehringer Ingelheim,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 14:02:53,2024-10-13 14:02:53,INDUSTRY,,,,,,,Boehringer Ingelheim,Austria|Poland,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00740584,,2008-08-21,2012-04-03,,2018-10-01,2008-08-21,2008-08-25,ESTIMATED,2012-07-05,2012-08-14,ESTIMATED,,,,2018-10-01,2018-10-30,ACTUAL,2008-08,,2008-08-31,2018-10,2018-10-31,2009-03,ACTUAL,2009-03-31,2009-03,ACTUAL,2009-03-31,,INTERVENTIONAL,,,Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.,Assessment of Local Retention and Duration of Activity of SPL7013 Following Vaginal Application of 3% SPL7013 Gel (VivaGel) in Healthy Volunteers,COMPLETED,,PHASE1/PHASE2,12,ACTUAL,Starpharma Pty Ltd,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:24:13,2024-10-15 02:24:13,INDUSTRY,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|Starpharma Pty Ltd,Australia,Reproductive system and breast disorders
NCT00743340,,2008-08-26,2018-02-12,,2018-03-28,2008-08-27,2008-08-28,ESTIMATED,2018-03-28,2018-04-26,ACTUAL,,,,2018-03-28,2018-04-26,ACTUAL,2005-11-22,ACTUAL,2005-11-22,2018-03,2018-03-31,2017-02-13,ACTUAL,2017-02-13,2017-02-13,ACTUAL,2017-02-13,,INTERVENTIONAL,,Safety Analysis Set: all enrolled participants who have received at least 1 dose of study drug,Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine,A Rollover Protocol to Provide Subjects Completing the FTC-203 Study in South Africa With Continued Access to Emtricitabine,COMPLETED,,PHASE2,50,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 05:06:15,2024-10-13 05:06:15,INDUSTRY,,,,,,,Gilead Sciences,South Africa,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00744263,,2008-08-27,2014-10-01,,2014-10-01,2008-08-28,2008-08-29,ESTIMATED,2014-10-01,2014-10-06,ESTIMATED,,,,2014-10-01,2014-10-06,ESTIMATED,2008-09,,2008-09-30,2014-10,2014-10-31,2013-10,ACTUAL,2013-10-31,2013-10,ACTUAL,2013-10-31,,INTERVENTIONAL,CAPITA,Safety population included all participants who received study vaccine and who had any safety data.,Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults,"A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease",COMPLETED,,PHASE4,84496,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:59:01,2024-10-13 09:59:01,INDUSTRY,,,,,,,Pfizer,Netherlands,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00750737,,2008-09-10,2015-12-01,,2016-08-22,2008-09-10,2008-09-11,ESTIMATED,2015-12-01,2016-01-06,ESTIMATED,,,,2016-08-22,2016-09-29,ESTIMATED,2008-06,,2008-06-30,2016-01,2016-01-31,2012-06,ACTUAL,2012-06-30,2012-06,ACTUAL,2012-06-30,,INTERVENTIONAL,,,Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC),Phase III Clinical Trial of Oral Posaconazole 3 Times/Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) for Prevention of Invasive Fungal Infections In Patients With Hematologic Malignancies & Hematopoietic Stem Cell Transplant,COMPLETED,,PHASE3,46,ACTUAL,M.D. Anderson Cancer Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:37:13,2024-10-13 20:37:13,OTHER,,,,,,,"Enzon Pharmaceuticals, Inc.|M.D. Anderson Cancer Center",United States,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders
NCT00750893,,2008-09-10,2011-01-28,,2020-02-24,2008-09-10,2008-09-11,ESTIMATED,2011-01-28,2011-02-25,ESTIMATED,,,,2020-02-24,2020-03-03,ACTUAL,2008-09-02,ACTUAL,2008-09-02,2020-02,2020-02-29,2013-06-15,ACTUAL,2013-06-15,2013-06-15,ACTUAL,2013-06-15,,OBSERVATIONAL,,,Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants,"Safety of GlaxoSmithKline Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix or Rotarix Liquid Formulation (Oral Suspension or Prefilled Syringe) When Administered According to the Prescribing Information in Korea",COMPLETED,,,3111,ACTUAL,GlaxoSmithKline,,,1,,FALSE,,,,,,,,,,,,,,,NO,,2024-10-13 10:52:51,2024-10-13 10:52:51,INDUSTRY,,,,,,FALSE,GlaxoSmithKline,"Korea, Republic of","Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00752219,,2008-09-11,2018-05-07,,2018-06-29,2008-09-11,2008-09-15,ESTIMATED,2018-06-29,2018-07-03,ACTUAL,,,,2018-06-29,2018-07-03,ACTUAL,2009-03-31,ACTUAL,2009-03-31,2018-06,2018-06-30,2009-12-31,ACTUAL,2009-12-31,2009-11-30,ACTUAL,2009-11-30,,INTERVENTIONAL,,Safety population included all participants who received at least one dose of study treatment.,Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections,"A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adults",COMPLETED,,PHASE2,204,ACTUAL,Pfizer,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 20:59:15,2024-10-14 20:59:15,INDUSTRY,,,,,,,Pfizer,Bulgaria|France|India|Lebanon|Poland|Romania|Russian Federation|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00752856,,2008-09-13,2020-05-14,,2020-07-13,2008-09-15,2008-09-16,ESTIMATED,2020-06-22,2020-07-07,ACTUAL,,,,2020-07-13,2020-07-22,ACTUAL,2008-08-26,ACTUAL,2008-08-26,2020-07,2020-07-31,2014-02-11,ACTUAL,2014-02-11,2011-05-05,ACTUAL,2011-05-05,,INTERVENTIONAL,,,Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients,Nucleoside-Sparing Combination Therapy With Lopinavir/Ritonavir (LPV/r) + Raltegravir (RAL) vs. Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Patients,COMPLETED,,PHASE2,51,ACTUAL,"University of California, San Diego",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:15:50,2024-10-14 07:15:50,OTHER,,,,,,,"Abbott|California HIV/AIDS Research Program|Merck Sharp & Dohme LLC|University of California, San Diego",United States,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00755274,,2008-09-16,2010-02-01,,2016-04-12,2008-09-16,2008-09-18,ESTIMATED,2010-03-10,2010-04-01,ESTIMATED,,,,2016-04-12,2016-04-14,ESTIMATED,2008-09,,2008-09-30,2016-04,2016-04-30,2009-01,ACTUAL,2009-01-31,2009-01,ACTUAL,2009-01-31,,INTERVENTIONAL,,,Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®,Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2008-2009 Formulation),COMPLETED,,PHASE4,32,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:37:13,2024-10-13 20:37:13,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Gastrointestinal disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00756730,,2008-09-18,2012-02-21,,2017-07-18,2008-09-19,2008-09-22,ESTIMATED,2012-06-08,2012-07-13,ESTIMATED,,,,2017-07-18,2017-08-21,ACTUAL,2008-09,,2008-09-30,2017-07,2017-07-31,2011-06,ACTUAL,2011-06-30,2011-06,ACTUAL,2011-06-30,,INTERVENTIONAL,LARD,,Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r,"Randomized, Open-label Study of Switch From Lopinavir/Ritonavir (LPV/r) or Fosamprenavir/Ritonavir (FPV/r) to Either Once Daily Atazanavir/Ritonavir (ATV/r) or Once Daily Darunavir/Ritonavir (DRV/r) (Plus Background Nucleoside Reverse Transcriptase Inhibitors) in Patients Experiencing Triglyceride Elevations While Receiving LPV/r or FPV/r.",COMPLETED,,PHASE4,49,ACTUAL,Community Research Initiative of New England,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 12:47:38,2024-10-13 12:47:38,OTHER,,,,,,,Community Research Initiative of New England|Tibotec Pharmaceutical Limited,United States,"Gastrointestinal disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00758264,,2008-09-23,2017-04-06,2009-09-09,2018-05-08,2008-09-23,2008-09-25,ESTIMATED,2018-05-08,2018-05-09,ACTUAL,2009-09-09,2009-09-10,ESTIMATED,2018-05-08,2018-05-09,ACTUAL,2008-10-30,,2008-10-30,2017-04,2017-04-30,2009-11-02,ACTUAL,2009-11-02,2009-06-02,ACTUAL,2009-06-02,,INTERVENTIONAL,,,Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration,Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-administered With GSK Biologicals' Pneumococcal Vaccine GSK1024850A in Healthy 12-23-month-old Children Previously Primed With GSK1024850A,COMPLETED,,PHASE3,363,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-15 00:06:20,2024-10-15 00:06:20,INDUSTRY,,,,,,,GlaxoSmithKline,Mexico|Taiwan,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00762320,,2008-09-29,2013-11-14,,2014-02-05,2008-09-29,2008-09-30,ESTIMATED,2014-02-05,2014-03-24,ESTIMATED,,,,2014-02-05,2014-03-24,ESTIMATED,2008-10,,2008-10-31,2014-02,2014-02-28,2011-07,ACTUAL,2011-07-31,2011-07,ACTUAL,2011-07-31,,INTERVENTIONAL,,,Comparison of Liquid Kaletra and Low Dose Kaletra Tablets,Comparison of Liquid Kaletra and Low Dose Kaletra Tablets in HIV-Positive Children,COMPLETED,,NA,8,ACTUAL,Phoenix Children's Hospital,Early termination leading to small number of subjects analyzed.,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:47:40,2024-10-13 08:47:40,OTHER,,,,,,,Abbott|Phoenix Children's Hospital,United States,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Investigations|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders"
NCT00762892,,2008-09-26,2014-12-19,,2014-12-19,2008-09-29,2008-09-30,ESTIMATED,2014-12-19,2015-01-05,ESTIMATED,,,,2014-12-19,2015-01-05,ESTIMATED,2009-01,,2009-01-31,2014-12,2014-12-31,2013-01,ACTUAL,2013-01-31,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,RAN,,Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients,"A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients",COMPLETED,,PHASE4,33,ACTUAL,"The University of Texas Health Science Center, Houston",Limitations are the relatively small sample size and loss to follow-up. Medical records of patients that were lost to follow up was reviewed to ensure that no SAE occurred. We also attempted multiple times to contact patients.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:30:57,2024-10-13 20:30:57,OTHER,,,,,,,"Merck Sharp & Dohme LLC|The University of Texas Health Science Center, Houston",United States,Renal and urinary disorders
NCT00766597,,2008-10-03,2015-11-12,,2021-11-03,2008-10-03,2008-10-06,ESTIMATED,2015-12-28,2016-02-01,ESTIMATED,,,,2021-11-03,2021-11-05,ACTUAL,2009-08,,2009-08-31,2015-12,2015-12-31,2010-08,ACTUAL,2010-08-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,The HIV-1 infected antiretroviral therapy experienced participants With CCR5-tropic virus who started treatment in Step II,Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents,"Phase I/II Open-Label Study to Evaluate the PK, Safety, Tolerability and Antiviral Activity of Vicriviroc, a Novel CCR5 Antagonist in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents",COMPLETED,,PHASE1/PHASE2,9,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"Study was terminated early with Merck's announcement on July 15, 2010 on the discontinuation of the development of Vicriviroc, with 4 participants given study drug and only 1 participant reached Week 24.",1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 18:23:16,2024-10-14 18:23:16,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|South Africa|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00770341,,2008-10-09,2011-05-17,2011-02-16,2017-02-21,2008-10-09,2008-10-10,ESTIMATED,2011-05-17,2011-06-15,ESTIMATED,2011-02-16,2011-03-08,ESTIMATED,2017-02-21,2017-03-24,ACTUAL,2008-09,,2008-09-30,2017-02,2017-02-28,2010-02,ACTUAL,2010-02-28,2010-02,ACTUAL,2010-02-28,,INTERVENTIONAL,,,A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002),"A Phase III Randomized, Open-labeled Clinical Trial of MK-3009 (Daptomycin) in Patients With Skin and Soft Tissue Infections, Septicemia and Right-sided Infective Endocarditis Caused by MRSA",COMPLETED,,PHASE3,122,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 18:42:10,2024-10-13 18:42:10,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00772109,,2008-10-13,2011-07-16,2010-03-31,2016-04-12,2008-10-13,2008-10-15,ESTIMATED,2011-07-16,2011-08-10,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2016-04-12,2016-04-14,ESTIMATED,2008-10,,2008-10-31,2016-04,2016-04-30,2009-07,ACTUAL,2009-07-31,2009-05,ACTUAL,2009-05-31,,INTERVENTIONAL,,,Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults,"Lot Consistency, Immunogenicity, and Safety Study of Three Lots of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® Administered Intramuscularly in Adult Subjects Aged 18 to 64 Years",COMPLETED,,PHASE3,4292,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 01:21:06,2024-10-15 01:21:06,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00772109,,2008-10-13,2011-07-16,2010-03-31,2016-04-12,2008-10-13,2008-10-15,ESTIMATED,2011-07-16,2011-08-10,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2016-04-12,2016-04-14,ESTIMATED,2008-10,,2008-10-31,2016-04,2016-04-30,2009-07,ACTUAL,2009-07-31,2009-05,ACTUAL,2009-05-31,,INTERVENTIONAL,,,Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults,"Lot Consistency, Immunogenicity, and Safety Study of Three Lots of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® Administered Intramuscularly in Adult Subjects Aged 18 to 64 Years",COMPLETED,,PHASE3,4292,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 01:21:06,2024-10-15 01:21:06,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00772369,,2008-10-13,2010-03-15,,2014-01-20,2008-10-13,2008-10-15,ESTIMATED,2010-03-15,2010-04-02,ESTIMATED,,,,2014-01-20,2014-02-14,ESTIMATED,2003-09,,2003-09-30,2014-01,2014-01-31,2005-04,ACTUAL,2005-04-30,2004-04,ACTUAL,2004-04-30,,OBSERVATIONAL,,,Retrospective Survey of Safety of Fourth Dose Pentacel® in Children,Retrospective Safety Survey of Selected Events in the 6 Months Following the 4th Dose of the Pentacel® Vaccination Series in Children,COMPLETED,,,3214,ACTUAL,Sanofi,,,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 23:53:37,2024-10-14 23:53:37,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Canada,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT00772928,,2008-10-13,2009-09-23,,2012-01-30,2008-10-14,2008-10-15,ESTIMATED,2010-01-21,2010-02-12,ESTIMATED,,,,2012-01-30,2012-02-01,ESTIMATED,2003-10,,2003-10-31,2012-01,2012-01-31,2006-11,ACTUAL,2006-11-30,2006-05,ACTUAL,2006-05-31,,INTERVENTIONAL,,,Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™,Immunogenicity Assessment of Pentacel™ (Hybrid CP20/20/5/3DT-mIPV//PRP-T) When Given at Different Times From or Concurrently With a Pneumococcal Conjugate Vaccine,COMPLETED,,PHASE3,1167,ACTUAL,Sanofi,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 11:25:16,2024-10-13 11:25:16,INDUSTRY,,,,,,,Sanofi,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00775450,,2008-10-16,2011-07-14,2010-03-31,2013-12-05,2008-10-16,2008-10-20,ESTIMATED,2011-07-14,2011-08-11,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2013-12-05,2013-12-31,ESTIMATED,2008-10,,2008-10-31,2013-12,2013-12-31,2009-07,ACTUAL,2009-07-31,2009-06,ACTUAL,2009-06-30,,INTERVENTIONAL,,,Influenza Vaccine Revaccination in Ambulatory Elderly Subjects,"Safety and Immunogenicity of Revaccination With Influenza Vaccine in Ambulatory Elderly Subjects Previously Vaccinated With Fluzone ID, Fluzone HD, and Fluzone® IM",COMPLETED,,PHASE2,807,ACTUAL,Sanofi,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:17:21,2024-10-13 19:17:21,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00775450,,2008-10-16,2011-07-14,2010-03-31,2013-12-05,2008-10-16,2008-10-20,ESTIMATED,2011-07-14,2011-08-11,ESTIMATED,2010-03-31,2010-04-02,ESTIMATED,2013-12-05,2013-12-31,ESTIMATED,2008-10,,2008-10-31,2013-12,2013-12-31,2009-07,ACTUAL,2009-07-31,2009-06,ACTUAL,2009-06-30,,INTERVENTIONAL,,,Influenza Vaccine Revaccination in Ambulatory Elderly Subjects,"Safety and Immunogenicity of Revaccination With Influenza Vaccine in Ambulatory Elderly Subjects Previously Vaccinated With Fluzone ID, Fluzone HD, and Fluzone® IM",COMPLETED,,PHASE2,807,ACTUAL,Sanofi,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:17:21,2024-10-13 19:17:21,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00779766,,2008-10-23,2012-04-12,,2019-05-03,2008-10-23,2008-10-24,ESTIMATED,2012-04-12,2012-05-10,ESTIMATED,,,,2019-05-03,2019-06-10,ACTUAL,2008-10-22,ACTUAL,2008-10-22,2019-05,2019-05-31,2016-02-28,ACTUAL,2016-02-28,2011-09-06,ACTUAL,2011-09-06,,INTERVENTIONAL,,,"Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects","Efficacy, Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects",COMPLETED,,PHASE3,6081,ACTUAL,GlaxoSmithKline,"At the time of the event-triggered analysis at Month 24, some safety results remain blinded and are not presented here since the study is still ongoing. These results will be updated once they become available.",2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2024-10-13 07:25:54,2024-10-13 07:25:54,INDUSTRY,,,,,,,GlaxoSmithKline,China,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00779779,,2008-10-23,2010-06-29,,2018-07-02,2008-10-23,2008-10-24,ESTIMATED,2010-06-29,2010-07-30,ESTIMATED,,,,2018-07-02,2018-08-28,ACTUAL,2008-11-22,,2008-11-22,2011-02,2011-02-28,2009-08-26,ACTUAL,2009-08-26,2009-05-25,ACTUAL,2009-05-25,,OBSERVATIONAL,,,Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants,"Reactogenicity and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered in Sri Lankan Infants Aged at Least 6 Weeks at the Time of First Vaccination.",COMPLETED,,,522,ACTUAL,GlaxoSmithKline,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 09:37:59,2024-10-13 09:37:59,INDUSTRY,,,,,,,GlaxoSmithKline,Sri Lanka,General disorders|Nervous system disorders
NCT00792909,,2008-11-17,2017-05-12,2009-09-09,2017-05-12,2008-11-17,2008-11-18,ESTIMATED,2017-05-12,2017-12-14,ACTUAL,2009-09-09,2009-09-10,ESTIMATED,2017-05-12,2017-12-14,ACTUAL,2008-12-02,ACTUAL,2008-12-02,2017-05,2017-05-31,2009-07-02,ACTUAL,2009-07-02,2009-07-02,ACTUAL,2009-07-02,,INTERVENTIONAL,,,Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A,Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children,COMPLETED,,PHASE3,172,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 17:58:40,2024-10-14 17:58:40,INDUSTRY,,,,,,,GlaxoSmithKline,Slovakia|Sweden,"Gastrointestinal disorders|General disorders|Infections and infestations|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT00795145,,2008-11-20,2010-03-02,,2010-05-17,2008-11-20,2008-11-21,ESTIMATED,2010-05-17,2010-06-22,ESTIMATED,,,,2010-05-17,2010-06-22,ESTIMATED,2008-12,,2008-12-31,2010-05,2010-05-31,2009-03,ACTUAL,2009-03-31,2009-03,ACTUAL,2009-03-31,,INTERVENTIONAL,,,A Study To Assess The Effect Of Linezolid On QTc Interval,"Single Dose Safety, Tolerability And Pharmacokinetics Of Escalating Intravenous Doses Of Linezolid Followed By Evaluation Of The Effect Of Single Intravenous Doses Of Linezolid On QTc Interval In Healthy Subjects",COMPLETED,,PHASE1,49,ACTUAL,Pfizer,,7,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 03:24:11,2024-10-13 03:24:11,INDUSTRY,,,,,,,Pfizer,Singapore,Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Nervous system disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders
NCT00795717,,2008-11-19,2013-05-07,,2019-08-30,2008-11-20,2008-11-21,ESTIMATED,2014-12-02,2014-12-08,ESTIMATED,,,,2019-08-30,2019-09-11,ACTUAL,2008-07,,2008-07-31,2019-08,2019-08-31,2010-10,ACTUAL,2010-10-31,2010-10,ACTUAL,2010-10-31,,INTERVENTIONAL,HALO,,"Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial","Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial",COMPLETED,,PHASE4,41,ACTUAL,Tufts University,We had low numbers that may not represent the overall population. There was not an HIV negative control arm. The 4 week wash out was too short and therefore difficult to compare the post-treatment vs true post placebo effects.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 03:33:16,2024-10-14 03:33:16,OTHER,,,,,,,Tufts University,United States,"Cardiac disorders|Gastrointestinal disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00796315,,2008-11-18,2012-12-19,,2013-01-29,2008-11-21,2008-11-24,ESTIMATED,2012-12-19,2013-01-25,ESTIMATED,,,,2013-01-29,2013-02-04,ESTIMATED,2008-12,,2008-12-31,2013-01,2013-01-31,2009-06,ACTUAL,2009-06-30,2009-06,ACTUAL,2009-06-30,,INTERVENTIONAL,,,Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children,"A Single-dose, Open-label, Multi-center Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Ages 2 to < 18 Years",COMPLETED,,PHASE1,41,ACTUAL,Procter and Gamble,"Incidences of mild sedation are consistent with doxylamine's indication as an OTC sleep aid. Conclusive evaluation of sedation couldn't be undertaken in the absence of a control group. Also, children may nap in daytime confounding sedation assessment",1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 21:16:59,2024-10-13 21:16:59,INDUSTRY,,,,,,,Consumer Healthcare Products Association|Procter and Gamble,United States,Infections and infestations|Nervous system disorders
NCT00799058,,2008-11-26,2022-06-28,2017-01-19,2022-10-24,2008-11-26,2008-11-27,ESTIMATED,2022-10-24,2022-10-25,ACTUAL,2017-01-19,2017-01-23,ESTIMATED,2022-10-24,2022-10-25,ACTUAL,2009-07-06,ACTUAL,2009-07-06,2022-10,2022-10-31,2011-01-08,ACTUAL,2011-01-08,2011-01-08,ACTUAL,2011-01-08,,INTERVENTIONAL,,"Healthy, sexually active, HIV-negative women",A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States,"A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL TO EVALUATE THE SAFETY OF DAPIVIRINE GEL 4759, 0.05% 2.5g AND DAPIVIRINE GEL 4789, 0.05% 2.5g FORMULATIONS AS COMPARED TO THE VAGINAL HEC-BASED UNIVERSAL PLACEBO GEL, 2.5g IN HEALTHY HIV-NEGATIVE WOMEN",COMPLETED,,PHASE1/PHASE2,128,ACTUAL,"International Partnership for Microbicides, Inc.","Concluding a general trend in vaginal fluid data is, however, difficult as overall individual fluid levels for the two gel formulations were in the same range and differences based on median values were not consistent across visits.",3,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 13:13:39,2024-10-14 13:13:39,INDUSTRY,,,,,,,"International Partnership for Microbicides, Inc.",United States,"Gastrointestinal disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00799591,,2008-11-26,2011-09-08,,2011-11-15,2008-11-28,2008-12-01,ESTIMATED,2011-11-15,2011-12-19,ESTIMATED,,,,2011-11-15,2011-12-19,ESTIMATED,2008-09,,2008-09-30,2011-09,2011-09-30,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,OBSERVATIONAL,,,French Study In ICU Patients Treated With Tigecycline,French Prospective Observational Study In Intensive Care Unit (ICU) Patients Treated With Tigecycline,COMPLETED,,,156,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 01:54:09,2024-10-15 01:54:09,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,France,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00799825,,2008-11-26,2013-07-18,,2018-06-14,2008-11-26,2008-12-01,ESTIMATED,2013-07-18,2013-09-20,ESTIMATED,,,,2018-06-14,2018-07-12,ACTUAL,2009-01-01,,2009-01-01,2018-06,2018-06-30,2012-08-02,ACTUAL,2012-08-02,2012-08-02,ACTUAL,2012-08-02,,INTERVENTIONAL,,,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female American and Canadian Subjects Who Had Received Control Vaccine in Study 580299/008,COMPLETED,,PHASE3,346,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 13:07:17,2024-10-14 13:07:17,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil|Canada|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Hepatobiliary disorders|Metabolism and nutrition disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders"
NCT00801099,,2008-11-06,2008-11-06,,2015-07-16,2008-12-02,2008-12-03,ESTIMATED,2008-12-02,2008-12-03,ESTIMATED,,,,2015-07-16,2015-08-07,ESTIMATED,2004-12,,2004-12-31,2015-07,2015-07-31,2005-03,ACTUAL,2005-03-31,2005-03,ACTUAL,2005-03-31,,INTERVENTIONAL,SSI2,,Benefit of a Single Preoperative Dose of Antibiotics for the Prevention of Surgical Site Infections,"Benefit of a Single Preoperative Dose of Antibiotics in a Sub-Saharan District Hospital: Minimal Input, Massive Impact",COMPLETED,,NA,276,ACTUAL,Swiss Tropical & Public Health Institute,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 13:07:17,2024-10-14 13:07:17,OTHER,,,,,,,Swiss Academy of Medical Sciences (SAMS)|Swiss Tropical & Public Health Institute,Switzerland,Surgical and medical procedures
NCT00802854,,2008-12-03,2017-05-17,,2018-10-26,2008-12-03,2008-12-05,ESTIMATED,2017-07-05,2017-11-30,ACTUAL,,,,2018-10-26,2018-11-21,ACTUAL,2012-03-02,ACTUAL,2012-03-02,2018-10,2018-10-31,2016-05-20,ACTUAL,2016-05-20,2016-05-20,ACTUAL,2016-05-20,,OBSERVATIONAL,,Safety analysis set included all participants who received at least 1 dose of Eraxis.,Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV,Post Marketing Surveillance Study To Observe Safety And Effectiveness Of Eraxis (Registered) Iv.,COMPLETED,,,244,ACTUAL,Pfizer,,,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,FALSE,Pfizer,"Korea, Republic of","Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00802867,,2008-12-04,2009-09-24,,2016-04-12,2008-12-04,2008-12-05,ESTIMATED,2009-12-08,2010-01-12,ESTIMATED,,,,2016-04-12,2016-04-14,ESTIMATED,2004-02,,2004-02-29,2016-04,2016-04-30,2005-09,ACTUAL,2005-09-30,2005-06,ACTUAL,2005-06-30,,INTERVENTIONAL,,,Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™,Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T),COMPLETED,,PHASE4,989,ACTUAL,Sanofi,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 01:17:29,2024-10-14 01:17:29,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Blood and lymphatic system disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00805545,,2008-12-05,2012-02-03,,2012-03-19,2008-12-05,2008-12-09,ESTIMATED,2012-03-19,2012-04-16,ESTIMATED,,,,2012-03-19,2012-04-16,ESTIMATED,2008-11,,2008-11-30,2012-03,2012-03-31,2009-11,ACTUAL,2009-11-30,2009-11,ACTUAL,2009-11-30,,INTERVENTIONAL,,,Timing of Antibiotic Prophylaxis for Cesarean Deliveries,The Timing of Antibiotic Prophylaxis for Cesarean Delivery,COMPLETED,,NA,400,ACTUAL,University of Florida,There were no limitations to the study. No technical problems occurred during the study.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:25:50,2024-10-14 00:25:50,OTHER,,,,,,,University of Florida,United States,"Pregnancy, puerperium and perinatal conditions"
NCT00806195,,2008-12-09,2013-05-13,2011-05-30,2013-05-13,2008-12-09,2008-12-10,ESTIMATED,2013-05-13,2013-07-09,ESTIMATED,2011-05-30,2011-06-06,ESTIMATED,2013-05-13,2013-07-09,ESTIMATED,2008-12,,2008-12-31,2013-05,2013-05-31,2011-11,ACTUAL,2011-11-30,2011-03,ACTUAL,2011-03-31,,INTERVENTIONAL,,,Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants,"A Phase 3b, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants",COMPLETED,,PHASE3,7744,ACTUAL,Novartis,,6,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 20:01:59,2024-10-13 20:01:59,INDUSTRY,,,,,,,Novartis|Novartis Vaccines,China|Costa Rica|Guatemala|Panama|Peru|Puerto Rico|Taiwan|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00808444,,2008-12-11,2010-10-25,,2018-07-11,2008-12-11,2008-12-15,ESTIMATED,2010-10-25,2010-11-19,ESTIMATED,,,,2018-07-11,2018-08-17,ACTUAL,2009-01-05,,2009-01-05,2016-10,2016-10-31,2009-11-02,ACTUAL,2009-11-02,2009-11-02,ACTUAL,2009-11-02,,INTERVENTIONAL,,,Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age,Non-inferiority of a Commercial Lot of the Pneumococcal Vaccine GSK1024850A Compared to a Clinical Lot.,COMPLETED,,PHASE3,466,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 21:56:26,2024-10-13 21:56:26,INDUSTRY,,,,,,,GlaxoSmithKline,Malaysia|Singapore,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00811642,,2008-12-18,2011-03-31,,2017-03-09,2008-12-18,2008-12-19,ESTIMATED,2011-03-31,2011-04-29,ESTIMATED,,,,2017-03-09,2017-04-07,ACTUAL,2008-11,,2008-11-30,2017-03,2017-03-31,2010-03,ACTUAL,2010-03-31,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,,Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551),"A Multicenter, Open Label Study to Evaluate Safety and Efficacy of Posaconazole Oral Suspension in Treatment of Invasive Fungal Infection",COMPLETED,,PHASE3,63,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 01:11:48,2024-10-13 01:11:48,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00811798,,2008-12-18,2011-09-08,,2016-09-23,2008-12-18,2008-12-19,ESTIMATED,2011-09-08,2011-10-13,ESTIMATED,,,,2016-09-23,2016-10-20,ESTIMATED,2009-05,,2009-05-31,2016-09,2016-09-30,2010-09,ACTUAL,2010-09-30,2010-09,ACTUAL,2010-09-30,,INTERVENTIONAL,,,Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Subjects.,COMPLETED,,PHASE3,92,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 04:03:57,2024-10-13 04:03:57,INDUSTRY,,,,,,,GlaxoSmithKline,Hong Kong,"Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Pregnancy, puerperium and perinatal conditions"
NCT00811954,,2008-12-18,2014-06-23,,2014-09-04,2008-12-18,2008-12-19,ESTIMATED,2014-09-04,2014-09-05,ESTIMATED,,,,2014-09-04,2014-09-05,ESTIMATED,2009-05,,2009-05-31,2014-09,2014-09-30,2013-06,ACTUAL,2013-06-30,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,,Intention to treat: All eligible participants were included in the baseline characteristics.,Comparative Study of Three NNRTI-Sparing HAART Regimens,"The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment",COMPLETED,,PHASE3,1814,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:43:58,2024-10-14 22:43:58,NETWORK,,,,,,,"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|Bristol-Myers Squibb|Gilead Sciences|Merck Sharp & Dohme LLC|National Institute of Allergy and Infectious Diseases (NIAID)|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00814710,,2008-12-23,2010-10-21,,2019-12-31,2008-12-23,2008-12-25,ESTIMATED,2010-10-21,2010-10-29,ESTIMATED,,,,2019-12-31,2020-01-03,ACTUAL,2009-03-07,ACTUAL,2009-03-07,2019-12,2019-12-31,2009-11-13,ACTUAL,2009-11-13,2009-11-13,ACTUAL,2009-11-13,,INTERVENTIONAL,,,Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age,"Primary Vaccination Course in Healthy Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Tritanrix™-HepB/Hib at 6, 10 and 14 Weeks of Age",COMPLETED,,PHASE3,360,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=260,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 22:48:26,2024-10-13 22:48:26,INDUSTRY,,,,,,,GlaxoSmithKline,India,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders"
NCT00814879,,2008-12-18,2015-11-23,,2016-01-04,2008-12-24,2008-12-25,ESTIMATED,2016-01-04,2016-02-04,ESTIMATED,,,,2016-01-04,2016-02-04,ESTIMATED,2009-05,,2009-05-31,2016-01,2016-01-31,2013-11,ACTUAL,2013-11-30,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,,,Pilot Study of a Raltegravir Based NRTI Sparing Regimen,"A Pilot Randomized, Open-Label Study Comparing the Safety and Efficacy of a Raltegravir Based NRTI Sparing Regimen",COMPLETED,,NA,60,ACTUAL,Yale University,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 01:39:59,2024-10-13 01:39:59,OTHER,,,,,,,Bristol-Myers Squibb|Merck Sharp & Dohme LLC|Yale University,United States,"Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00819052,,2009-01-07,2011-12-13,,2014-11-07,2009-01-07,2009-01-08,ESTIMATED,2012-01-23,2012-02-24,ESTIMATED,,,,2014-11-07,2014-11-10,ESTIMATED,2008-12,,2008-12-31,2014-11,2014-11-30,2012-01,ACTUAL,2012-01-31,2012-01,ACTUAL,2012-01-31,,INTERVENTIONAL,,Full Analysis Set (FAS) includes all participants randomized to treatment and confirmed to have taken at least one dose of treatment,Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients,"An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID Based Program",COMPLETED,,PHASE3,445,ACTUAL,Boehringer Ingelheim,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 02:45:55,2024-10-14 02:45:55,INDUSTRY,,,,,,,Boehringer Ingelheim,France|Germany|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00819286,,2009-01-06,2011-12-27,,2018-01-16,2009-01-07,2009-01-08,ESTIMATED,2012-02-11,2012-03-15,ESTIMATED,,,,2018-01-16,2018-02-13,ACTUAL,2008-11,,2008-11-30,2018-01,2018-01-31,2011-12,ACTUAL,2011-12-31,2011-01,ACTUAL,2011-01-31,,INTERVENTIONAL,RESTORE,,Evaluation of Primary Plating in Sternotomy Patients for Osteosynthesis and Pain,"A Prospective, Randomized-Controlled, Multicenter Study Evaluating Primary Plating in High-Risk Median Sternotomy Patients for Osteosynthesis and Pain",COMPLETED,,NA,140,ACTUAL,Zimmer Biomet,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:28:19,2024-10-13 19:28:19,INDUSTRY,,,,,,,Zimmer Biomet,Germany|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT00819390,,2009-01-08,2014-08-26,2013-12-20,2014-10-03,2009-01-08,2009-01-09,ESTIMATED,2014-08-26,2014-09-05,ESTIMATED,2013-12-20,2014-01-28,ESTIMATED,2014-10-03,2014-10-13,ESTIMATED,2009-03,,2009-03-31,2014-10,2014-10-31,2013-05,ACTUAL,2013-05-31,2013-02,ACTUAL,2013-02-28,,INTERVENTIONAL,,"Results are for all participants, off-ART and on-ART, who enrolled in the study.",Chloroquine for Reducing Immune Activation in HIV- Infected Individuals,"A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation",COMPLETED,,PHASE2,70,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:07:20,2024-10-13 18:07:20,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00822692,,2009-01-13,2009-07-29,,2015-12-17,2009-01-13,2009-01-14,ESTIMATED,2009-07-29,2009-09-03,ESTIMATED,,,,2015-12-17,2015-12-21,ESTIMATED,2008-07,,2008-07-31,2015-12,2015-12-31,2009-06,ACTUAL,2009-06-30,2009-06,ACTUAL,2009-06-30,,INTERVENTIONAL,,,Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection,"Prospective Randomized Double Blind, Placebo-Controlled Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection on 30 Day Recurrence Rates.",COMPLETED,,NA,139,ACTUAL,59th Medical Wing,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 13:13:39,2024-10-14 13:13:39,FED,,,,,,,59th Medical Wing|Emergency Medicine Foundation|U.S. Air Force Office of the Surgeon General,United States,Skin and subcutaneous tissue disorders
NCT00827502,,2009-01-21,2010-03-30,,2011-04-25,2009-01-21,2009-01-22,ESTIMATED,2010-05-17,2010-06-09,ESTIMATED,,,,2011-04-25,2011-04-28,ESTIMATED,2009-02,,2009-02-28,2011-04,2011-04-30,2009-07,ACTUAL,2009-07-31,2009-07,ACTUAL,2009-07-31,,OBSERVATIONAL,,,Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections,Trulimax (Azithromycin ) Non-Interventional Study In Acute Bacterial Upper Respiratory Tract Infections,COMPLETED,,,421,ACTUAL,Pfizer,,,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:01:09,2024-10-13 05:01:09,INDUSTRY,,,,,,,Pfizer,India,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders
NCT00827541,,2009-01-20,2011-12-23,,2011-12-23,2009-01-21,2009-01-22,ESTIMATED,2011-12-23,2012-02-01,ESTIMATED,,,,2011-12-23,2012-02-01,ESTIMATED,2008-08,,2008-08-31,2011-12,2011-12-31,2010-12,ACTUAL,2010-12-31,2010-12,ACTUAL,2010-12-31,,OBSERVATIONAL,HORUS,,Post-Authorization Study Evaluating Safety Of Tigecycline,"A Phase IV Pharmacovigilance, Post-Authorization Clinical Trial To Evaluate And Assess The Safety Of Tigecycline In The Approved Indications In The Usual Health Care Setting",COMPLETED,,,115,ACTUAL,Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 09:27:07,2024-10-13 09:27:07,INDUSTRY,,,,,,,Pfizer,Spain,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00827541,,2009-01-20,2011-12-23,,2011-12-23,2009-01-21,2009-01-22,ESTIMATED,2011-12-23,2012-02-01,ESTIMATED,,,,2011-12-23,2012-02-01,ESTIMATED,2008-08,,2008-08-31,2011-12,2011-12-31,2010-12,ACTUAL,2010-12-31,2010-12,ACTUAL,2010-12-31,,OBSERVATIONAL,HORUS,,Post-Authorization Study Evaluating Safety Of Tigecycline,"A Phase IV Pharmacovigilance, Post-Authorization Clinical Trial To Evaluate And Assess The Safety Of Tigecycline In The Approved Indications In The Usual Health Care Setting",COMPLETED,,,115,ACTUAL,Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 09:27:07,2024-10-13 09:27:07,INDUSTRY,,,,,,,Pfizer,Spain,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00829010,,2009-01-22,2012-05-08,,2018-07-11,2009-01-22,2009-01-26,ESTIMATED,2012-05-31,2012-07-06,ESTIMATED,,,,2018-07-11,2018-08-17,ACTUAL,2009-02-17,,2009-02-17,2017-10,2017-10-31,2012-06-27,ACTUAL,2012-06-27,2011-06-13,ACTUAL,2011-06-13,,INTERVENTIONAL,,,"Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.","Primary and Booster Vaccination Course in Human Immunodeficiency Virus (HIV) Infected Infants, HIV Exposed Uninfected Infants and Unexposed Uninfected Infants Receiving the Pneumococcal Vaccine GSK 1024850A.",COMPLETED,,PHASE3,489,ACTUAL,GlaxoSmithKline,"The study aimed to enrol 100 HIV+/+ subjects but succeeded to enrol 83 mainly due to decrease of vertical HIV transmission in South Africa. Some subjects, HIV+ at screening, tested negative at subsequent HIV testing, were reallocated in HIV+/-Group.",5,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 03:20:11,2024-10-14 03:20:11,INDUSTRY,,,,,,,GlaxoSmithKline,South Africa,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00830804,,2009-01-26,2011-09-07,,2018-10-11,2009-01-27,2009-01-28,ESTIMATED,2011-09-07,2011-10-10,ESTIMATED,,,,2018-10-11,2018-11-08,ACTUAL,2009-04,,2009-04-30,2018-10,2018-10-31,2010-09,ACTUAL,2010-09-30,2010-02,ACTUAL,2010-02-28,,INTERVENTIONAL,,,Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults,A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects,COMPLETED,,PHASE2,113,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,This is a single-arm study.,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 01:48:22,2024-10-14 01:48:22,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders"
NCT00833482,,2009-01-30,2012-07-23,,2012-09-24,2009-01-30,2009-02-02,ESTIMATED,2012-09-24,2012-10-25,ESTIMATED,,,,2012-09-24,2012-10-25,ESTIMATED,2009-09,,2009-09-30,2012-09,2012-09-30,2011-02,ACTUAL,2011-02-28,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants,Study to Assess the Pharmacokinetic Drug - Drug Interactions Between Atazanavir Plus Ritonavir Coadministered With Voriconazole in Healthy Subjects,COMPLETED,,PHASE1,185,ACTUAL,Bristol-Myers Squibb,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 15:41:07,2024-10-14 15:41:07,INDUSTRY,,,,,,,Bristol-Myers Squibb,Netherlands|United States,"Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Investigations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00834106,,2009-01-30,2017-09-12,2013-04-25,2019-01-16,2009-01-30,2009-02-03,ESTIMATED,2017-09-12,2017-10-12,ACTUAL,2013-04-25,2013-05-03,ESTIMATED,2019-01-16,2019-02-04,ACTUAL,2008-12-31,ACTUAL,2008-12-31,2019-01,2019-01-31,2016-09-30,ACTUAL,2016-09-30,2012-05-11,ACTUAL,2012-05-11,,INTERVENTIONAL,,All randomized participants,Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041),"A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women",COMPLETED,,PHASE3,3006,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 09:21:12,2024-10-13 09:21:12,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00839254,,2009-02-05,2017-09-29,2013-02-14,2020-11-20,2009-02-05,2009-02-09,ESTIMATED,2020-07-07,2020-07-27,ACTUAL,2013-02-14,2013-02-18,ESTIMATED,2020-11-20,2020-12-17,ACTUAL,2009-02-18,ACTUAL,2009-02-18,2020-11,2020-11-30,2012-01-31,ACTUAL,2012-01-31,2012-01-31,ACTUAL,2012-01-31,,INTERVENTIONAL,,,"Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A","Impact on Nasopharyngeal Carriage, Acute Otitis Media, Immunogenicity and Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A",COMPLETED,,PHASE3,6181,ACTUAL,GlaxoSmithKline,"Number allocation errors were identified for 3 subjects after Dose 1, which GSK assessed as not having significant impact. Lower \& upper respiratory tract infections endpoint results are not presented, being uninterpretable due to low sample size.",8,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=4324,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2024-10-14 12:46:59,2024-10-14 12:46:59,INDUSTRY,,,,,,,GlaxoSmithKline,Finland,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00840658,,2009-02-07,2012-07-02,,2020-04-17,2009-02-09,2009-02-10,ESTIMATED,2012-08-18,2012-09-18,ESTIMATED,,,,2020-04-17,2020-04-30,ACTUAL,2008-10,,2008-10-31,2020-04,2020-04-30,2011-07,ACTUAL,2011-07-31,2011-07,ACTUAL,2011-07-31,,INTERVENTIONAL,FSW-IDU,,Behavioral Intervention to Reduce Sexual and Injection Risks Among Female Sex Workers Who Also Inject Drugs in Mexico,Epidemiologic Study on Changing HIV Risks Among FSW-IDUs on the Mexico-US Border,COMPLETED,,PHASE2,584,ACTUAL,"University of California, San Diego",Observed important site differences at enrollment need to be considered in outcome analysis.,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 09:46:07,2024-10-14 09:46:07,OTHER,,,,,,,"ISSESALUD|National Institute on Drug Abuse (NIDA)|Northeastern University|San Diego State University|Steffanie Strathdee|Universidad Autonoma de Ciudad Juarez|University of California, Los Angeles|University of California, San Diego",Mexico,Social circumstances
NCT00841971,,2009-02-11,2014-12-08,,2014-12-15,2009-02-11,2009-02-12,ESTIMATED,2014-12-15,2014-12-17,ESTIMATED,,,,2014-12-15,2014-12-17,ESTIMATED,2010-02,,2010-02-28,2014-12,2014-12-31,2014-05,ACTUAL,2014-05-31,2013-07,ACTUAL,2013-07-31,,INTERVENTIONAL,,,Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients,"Anidulafungin Versus Fluconazole for the Prevention of Invasive Fungal Infections in High-risk Liver Transplant Recipients: a Randomized, Double-blind Trial",COMPLETED,,PHASE4,200,ACTUAL,University of Pittsburgh,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 02:13:30,2024-10-13 02:13:30,OTHER,,,,,,,University of Pittsburgh,United States,Cardiac disorders|General disorders
NCT00843713,,2009-02-12,2015-01-30,,2018-12-10,2009-02-12,2009-02-13,ESTIMATED,2015-05-26,2015-06-10,ESTIMATED,,,,2018-12-10,2018-12-12,ACTUAL,2009-01,,2009-01-31,2018-12,2018-12-31,2014-02,ACTUAL,2014-02-28,2013-11,ACTUAL,2013-11-30,,INTERVENTIONAL,,,Effect of Raltegravir on Endothelial Function in HIV-Infected Patients,"A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection",COMPLETED,,PHASE4,56,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:46:17,2024-10-13 06:46:17,OTHER,,,,,,,"Merck Sharp & Dohme LLC|National Heart, Lung, and Blood Institute (NHLBI)|University of California, San Francisco",United States,Hepatobiliary disorders|Infections and infestations
NCT00843713,,2009-02-12,2015-01-30,,2018-12-10,2009-02-12,2009-02-13,ESTIMATED,2015-05-26,2015-06-10,ESTIMATED,,,,2018-12-10,2018-12-12,ACTUAL,2009-01,,2009-01-31,2018-12,2018-12-31,2014-02,ACTUAL,2014-02-28,2013-11,ACTUAL,2013-11-30,,INTERVENTIONAL,,,Effect of Raltegravir on Endothelial Function in HIV-Infected Patients,"A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection",COMPLETED,,PHASE4,56,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:46:17,2024-10-13 06:46:17,OTHER,,,,,,,"Merck Sharp & Dohme LLC|National Heart, Lung, and Blood Institute (NHLBI)|University of California, San Francisco",United States,Hepatobiliary disorders|Infections and infestations
NCT00844519,,2009-02-13,2014-05-19,,2014-07-16,2009-02-13,2009-02-16,ESTIMATED,2014-05-19,2014-06-19,ESTIMATED,,,,2014-07-16,2014-07-24,ESTIMATED,2010-01,,2010-01-31,2014-07,2014-07-31,2014-06,ACTUAL,2014-06-30,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,,per protocol,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,,COMPLETED,,PHASE3,52,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 19:53:14,2024-10-14 19:53:14,OTHER,,,,,,,"National Heart, Lung, and Blood Institute (NHLBI)|Pfizer|University of California, San Francisco",United States,Surgical and medical procedures
NCT00844519,,2009-02-13,2014-05-19,,2014-07-16,2009-02-13,2009-02-16,ESTIMATED,2014-05-19,2014-06-19,ESTIMATED,,,,2014-07-16,2014-07-24,ESTIMATED,2010-01,,2010-01-31,2014-07,2014-07-31,2014-06,ACTUAL,2014-06-30,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,,per protocol,Effect of Maraviroc on Endothelial Function in HIV-Infected Patients,,COMPLETED,,PHASE3,52,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 19:53:14,2024-10-14 19:53:14,OTHER,,,,,,,"National Heart, Lung, and Blood Institute (NHLBI)|Pfizer|University of California, San Francisco",United States,Surgical and medical procedures
NCT00845429,,2009-02-13,2012-11-17,,2012-12-13,2009-02-13,2009-02-18,ESTIMATED,2012-11-17,2012-12-17,ESTIMATED,,,,2012-12-13,2012-12-19,ESTIMATED,2007-10,,2007-10-31,2012-12,2012-12-31,2008-11,ACTUAL,2008-11-30,2008-08,ACTUAL,2008-08-31,,INTERVENTIONAL,,,"Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects","Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years",COMPLETED,,PHASE2,729,ACTUAL,Sanofi,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 22:31:13,2024-10-13 22:31:13,INDUSTRY,,,,,,,Sanofi,United States,"General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders"
NCT00845676,,2009-02-17,2013-08-13,,2020-05-14,2009-02-17,2009-02-18,ESTIMATED,2013-08-13,2013-10-17,ESTIMATED,,,,2020-05-14,2020-05-18,ACTUAL,2008-03,,2008-03-31,2020-05,2020-05-31,2013-12,ACTUAL,2013-12-31,2010-12,ACTUAL,2010-12-31,,INTERVENTIONAL,,,Treatment of Acute Hepatitis C Virus in HIV Co-Infection,Treatment of Acute Hepatitis C Virus in HIV Co-Infection,COMPLETED,,PHASE4,21,ACTUAL,"University of California, San Francisco",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:34:55,2024-10-14 17:34:55,OTHER,,,,,,,"California HIV/AIDS Research Program|University of California, San Francisco",United States,Blood and lymphatic system disorders|Infections and infestations
NCT00848211,,2009-02-13,2010-06-12,,2011-02-17,2009-02-19,2009-02-20,ESTIMATED,2011-01-23,2011-02-21,ESTIMATED,,,,2011-02-17,2011-02-24,ESTIMATED,2009-02,,2009-02-28,2011-02,2011-02-28,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,INTERVENTIONAL,THYMON-08001,,Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects,Phase I/IIA Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects,COMPLETED,,PHASE1/PHASE2,24,ACTUAL,"Thymon, LLC",,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 11:14:41,2024-10-13 11:14:41,INDUSTRY,,,,,,,"Thymon, LLC",United States,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT00849381,,2009-02-19,2013-11-27,,2014-09-04,2009-02-19,2009-02-23,ESTIMATED,2014-08-21,2014-08-25,ESTIMATED,,,,2014-09-04,2014-09-12,ESTIMATED,2009-04,,2009-04-30,2014-08,2014-08-31,2012-12,ACTUAL,2012-12-31,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,,,"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand","Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK580299) in Female Brazilian, Taiwanese and Thai Subjects Who Had Received Control Vaccine in Study 580299/008",COMPLETED,,PHASE3,1239,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 05:56:17,2024-10-13 05:56:17,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil|Taiwan|Thailand,"Endocrine disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Vascular disorders"
NCT00850603,,2009-02-24,2009-03-13,,2016-04-12,2009-02-24,2009-02-25,ESTIMATED,2009-03-13,2009-04-30,ESTIMATED,,,,2016-04-12,2016-04-14,ESTIMATED,2002-10,,2002-10-31,2016-04,2016-04-30,2004-11,ACTUAL,2004-11-30,2003-05,ACTUAL,2003-05-31,,INTERVENTIONAL,,,Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®,"Safety and Immunogenicity of Intradermal, and Low-dose Subcutaneous vs Subcutaneous Administration of Menomune® - A/C/Y/W-135",COMPLETED,,PHASE4,170,ACTUAL,Sanofi,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 18:07:20,2024-10-13 18:07:20,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT00851786,,2009-02-25,2012-09-07,,2021-11-02,2009-02-25,2009-02-26,ESTIMATED,2012-09-07,2012-10-10,ESTIMATED,,,,2021-11-02,2021-11-04,ACTUAL,2009-04-29,ACTUAL,2009-04-29,2018-01,2018-01-31,2012-01-03,ACTUAL,2012-01-03,2011-09-22,ACTUAL,2011-09-22,,INTERVENTIONAL,,,Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy,"A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX® (Zoster Vaccine Live) in Human Immunodeficiency Virus (HIV)-1-Infected Adults on Potent Combination ART With Conserved Immune Function",COMPLETED,,PHASE2,395,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:00:12,2024-10-15 02:00:12,NIH,,,,,,,Adult AIDS Clinical Trials Group|Merck Sharp & Dohme LLC|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders"
NCT00851890,,2009-02-24,2014-12-29,2011-08-18,2018-06-01,2009-02-24,2009-02-26,ESTIMATED,2014-12-29,2015-01-08,ESTIMATED,2011-08-18,2011-08-23,ESTIMATED,2018-06-01,2018-07-02,ACTUAL,2009-03,,2009-03-31,2014-12,2014-12-31,2009-07,ACTUAL,2009-07-31,2009-07,ACTUAL,2009-07-31,,INTERVENTIONAL,,Baseline characteristics were summarized by treatment group for all participants who received at least 1 dose of study drug. The treatment groups were compared with 1-way analysis of variance (ANOVA).,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE2,30,ACTUAL,AbbVie,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:49:51,2024-10-14 22:49:51,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00852540,,2009-02-26,2011-07-28,,2017-02-23,2009-02-26,2009-02-27,ESTIMATED,2011-07-28,2011-08-26,ESTIMATED,,,,2017-02-23,2017-03-27,ACTUAL,2009-04,,2009-04-30,2017-02,2017-02-28,2010-09,ACTUAL,2010-09-30,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA,"A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Oral Linezolid in the Treatment of Secondarily-Infected Traumatic Lesions and Impetigo Due to Methicillin-Resistant Staphylococcus Aureus",COMPLETED,,PHASE3,410,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 18:47:54,2024-10-13 18:47:54,INDUSTRY,,,,,,,"GlaxoSmithKline|Stiefel, a GSK Company",United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders"
NCT00854087,,2009-02-26,2014-05-19,,2021-04-28,2009-02-27,2009-03-02,ESTIMATED,2014-05-19,2014-06-18,ESTIMATED,,,,2021-04-28,2021-05-19,ACTUAL,2010-08,,2010-08-31,2021-04,2021-04-30,2013-08,ACTUAL,2013-08-31,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,,Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis,"A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis",COMPLETED,,PHASE2,118,ACTUAL,SCTI Research Foundation,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:19:33,2024-10-13 07:19:33,INDIV,,,,,,,"Shanghai Sundise Traditional Chinese Medicine Co., Ltd.|Tarek Hassanein",United States,"Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00855335,,2009-03-02,2017-06-30,,2018-06-06,2009-03-02,2009-03-04,ESTIMATED,2017-08-15,2017-09-15,ACTUAL,,,,2018-06-06,2018-07-06,ACTUAL,2009-04-09,ACTUAL,2009-04-09,2018-05,2018-05-31,2016-08-11,ACTUAL,2016-08-11,2016-08-11,ACTUAL,2016-08-11,,INTERVENTIONAL,,,"A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women","A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women",COMPLETED,,PHASE3,77,ACTUAL,"Janssen Scientific Affairs, LLC",,5,,,FALSE,,,,FALSE,,FALSE,,,,,,,,,,,2024-10-14 21:16:32,2024-10-14 21:16:32,INDUSTRY,,,,,,,"Janssen Scientific Affairs, LLC",Puerto Rico|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00856323,,2009-03-03,2012-08-27,,2016-08-12,2009-03-04,2009-03-05,ESTIMATED,2012-10-26,2012-11-27,ESTIMATED,,,,2016-08-12,2016-09-20,ESTIMATED,2009-01,,2009-01-31,2016-08,2016-08-31,2010-12,ACTUAL,2010-12-31,2010-12,ACTUAL,2010-12-31,,INTERVENTIONAL,,,Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men,Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM,COMPLETED,,PHASE2,53,ACTUAL,"Friends Research Institute, Inc.",,1,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 22:26:35,2024-10-14 22:26:35,OTHER,,,,,,,"Friends Research Institute, Inc.|University of California, Los Angeles",United States,"Gastrointestinal disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT00858494,,2009-03-05,2010-12-27,,2018-07-23,2009-03-06,2009-03-09,ESTIMATED,2011-03-01,2011-03-03,ESTIMATED,,,,2018-07-23,2018-07-26,ACTUAL,2009-03,,2009-03-31,2018-07,2018-07-31,2009-10,ACTUAL,2009-10-31,2009-10,ACTUAL,2009-10-31,,INTERVENTIONAL,,,Homeopathic Cold Medicine for Children,Homeopathic Cold Medicine for Children,COMPLETED,,NA,50,ACTUAL,University of Washington,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 13:55:50,2024-10-14 13:55:50,OTHER,,,,,,,Standard Homeopathic Company|University of Washington,United States,Gastrointestinal disorders
NCT00860795,,2009-03-10,2010-09-28,,2018-04-29,2009-03-11,2009-03-12,ESTIMATED,2010-10-20,2010-11-17,ESTIMATED,,,,2018-04-29,2018-05-01,ACTUAL,2009-03,,2009-03-31,2018-04,2018-04-30,2009-08,ACTUAL,2009-08-31,2009-08,ACTUAL,2009-08-31,,INTERVENTIONAL,,,Immunologic Effects of Echinacea,Study of the Immunologic Effects of Echinacea Purpurea in Adults,COMPLETED,,NA,20,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 14:14:42,2024-10-14 14:14:42,OTHER,,,,,,,National Center for Complementary and Integrative Health (NCCIH)|University of Washington,United States,"Eye disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00861380,,2009-03-12,2017-04-14,2013-02-14,2020-11-20,2009-03-12,2009-03-13,ESTIMATED,2020-09-04,2020-09-25,ACTUAL,2013-02-14,2013-02-18,ESTIMATED,2020-11-20,2020-12-17,ACTUAL,2009-05-04,ACTUAL,2009-05-04,2020-11,2020-11-30,2013-10-05,ACTUAL,2013-10-05,2012-01-31,ACTUAL,2012-01-31,,INTERVENTIONAL,FinIP,,Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease,Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease,COMPLETED,,PHASE3,41188,ACTUAL,GlaxoSmithKline,,7,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=261,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 01:31:21,2024-10-14 01:31:21,INDUSTRY,,,,,,,GlaxoSmithKline,Finland,"Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00864916,,2009-03-17,2014-03-10,,2014-04-28,2009-03-17,2009-03-19,ESTIMATED,2014-03-10,2014-04-16,ESTIMATED,,,,2014-04-28,2014-05-12,ESTIMATED,2009-03,,2009-03-31,2014-04,2014-04-30,2012-12,ACTUAL,2012-12-31,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,,Completed enrollment visit,Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People,"A Randomized, Placebo-Controlled Trial of Pentoxifylline Plus Combination ART vs. Combination ART Alone to Improve Endothelial Dysfunction in HIV-Infected Patients",COMPLETED,,PHASE2,19,ACTUAL,Indiana University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 01:29:17,2024-10-13 01:29:17,OTHER,,,,,,,"Indiana University|National Heart, Lung, and Blood Institute (NHLBI)",United States,Gastrointestinal disorders
NCT00867048,,2009-03-20,2023-07-19,,2024-02-29,2009-03-20,2009-03-23,ESTIMATED,2023-12-19,2023-12-20,ACTUAL,,,,2024-02-29,2024-03-04,ACTUAL,2009-04-15,ACTUAL,2009-04-15,2024-02,2024-02-29,2022-07-27,ACTUAL,2022-07-27,2022-07-27,ACTUAL,2022-07-27,,INTERVENTIONAL,START,,Strategic Timing of Antiretroviral Treatment,Strategic Timing of AntiRetroviral Treatment,COMPLETED,,PHASE4,4688,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 10:58:04,2024-10-14 10:58:04,OTHER,,,,,,,"Abbott|ANRS, Emerging Infectious Diseases|Bristol-Myers Squibb|Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark|German Federal Ministry of Education and Research|Gilead Sciences|GlaxoSmithKline|Medical Research Council|Merck Sharp & Dohme LLC|National Cancer Institute (NCI)|National Health and Medical Research Council, Australia|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institute of Mental Health (NIMH)|National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)|NEAT - European AIDS Treatment Network|The Kirby Institute for Infection and Immunity in Society|Tibotec Pharmaceutical Limited|University of Minnesota|Washington D.C. Veterans Affairs Medical Center",Argentina|Australia|Austria|Belgium|Brazil|Chile|Czechia|Czech Republic|Denmark|Estonia|Finland|France|Germany|Greece|India|Ireland|Israel|Italy|Luxembourg|Malaysia|Mali|Mexico|Morocco|Nigeria|Norway|Peru|Poland|Portugal|Puerto Rico|Singapore|South Africa|Spain|Sweden|Switzerland|Thailand|Uganda|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00869557,,2009-03-24,2012-09-20,2011-08-23,2014-05-22,2009-03-25,2009-03-26,ESTIMATED,2012-09-20,2012-10-22,ESTIMATED,2011-08-23,2011-08-25,ESTIMATED,2014-05-22,2014-06-04,ESTIMATED,2009-04,,2009-04-30,2014-05,2014-05-31,2013-09,ACTUAL,2013-09-30,2009-11,ACTUAL,2009-11-30,,INTERVENTIONAL,,Safety Analysis Set: participants were randomized and received at least 1 dose of study medication.,"Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Atripla® (Efavirenz 600 mg/Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate 300 mg) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE2,71,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:09:10,2024-10-14 17:09:10,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00870363,,2009-03-25,2017-01-12,,2017-05-24,2009-03-26,2009-03-27,ESTIMATED,2017-02-09,2017-02-10,ACTUAL,,,,2017-05-24,2017-05-30,ACTUAL,2009-04,,2009-04-30,2017-05,2017-05-31,2013-04,ACTUAL,2013-04-30,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,,"A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy","A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy",COMPLETED,,PHASE4,44,ACTUAL,"University of California, Davis",,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 06:30:42,2024-10-13 06:30:42,OTHER,,,,,,,"University of California, Davis",United States,Gastrointestinal disorders|Nervous system disorders
NCT00871234,,2009-03-27,2010-12-07,,2011-01-05,2009-03-27,2009-03-30,ESTIMATED,2010-12-07,2011-01-05,ESTIMATED,,,,2011-01-05,2011-01-07,ESTIMATED,2009-04,,2009-04-30,2010-12,2010-12-31,2010-07,ACTUAL,2010-07-31,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,,Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study,Effects of Etravirine (INTELENCETM) on Endothelial Function in HIV-uninfected Adults: A Pilot Study,COMPLETED,,PHASE1,28,ACTUAL,Indiana University,,,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:41:45,2024-10-14 18:41:45,OTHER,,,,,,,"Indiana University|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA",United States,Gastrointestinal disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00874549,,2009-03-31,2010-03-08,,2013-09-12,2009-03-31,2009-04-02,ESTIMATED,2010-03-08,2010-03-25,ESTIMATED,,,,2013-09-12,2013-09-20,ESTIMATED,2007-10,,2007-10-31,2013-09,2013-09-30,2008-10,ACTUAL,2008-10-31,2008-01,ACTUAL,2008-01-31,,INTERVENTIONAL,,,Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years,"A Safety and Immunogenicity Evaluation of a Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) and a Meningococcal Polysaccharide Vaccine Groups A, C, Y, and W-135 Combined (Menomune® - A/C/Y/W-135) in Subjects 56 Years of Age or Older",COMPLETED,,PHASE1/PHASE2,216,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 10:16:10,2024-10-14 10:16:10,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00874770,,2009-04-02,2015-08-06,,2015-09-23,2009-04-02,2009-04-03,ESTIMATED,2015-09-23,2015-10-23,ESTIMATED,,,,2015-09-23,2015-10-23,ESTIMATED,2009-06,,2009-06-30,2015-09,2015-09-30,2011-01,ACTUAL,2011-01-31,2009-11,ACTUAL,2009-11-30,,INTERVENTIONAL,,The analysis was performed in the treated population defined as all participants who received at least 1 dose of study therapy.,Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin),A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1,COMPLETED,,PHASE2,74,ACTUAL,Bristol-Myers Squibb,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:11:06,2024-10-13 19:11:06,INDUSTRY,,,,,,,Bristol-Myers Squibb,Argentina|France|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00876733,,2009-03-20,2014-12-27,,2015-01-14,2009-04-06,2009-04-07,ESTIMATED,2015-01-14,2015-01-16,ESTIMATED,,,,2015-01-14,2015-01-16,ESTIMATED,2009-03,,2009-03-31,2015-01,2015-01-31,2013-12,ACTUAL,2013-12-31,2013-12,ACTUAL,2013-12-31,,OBSERVATIONAL,,Treated set (TS): This patient set includes all HIV-1 infected patients who were dispensed Viramune® and were documented to have taken at least one dose of Viramune®and of a antiretroviral combination partner.,Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients,Non-Interventional Observational Study With Viramune Plus ARV in HIV Infected Patients,COMPLETED,,,605,ACTUAL,Boehringer Ingelheim,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 06:53:38,2024-10-14 06:53:38,INDUSTRY,,,,,,,Boehringer Ingelheim,Germany,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00877877,,2009-03-26,2011-03-31,,2019-12-31,2009-04-07,2009-04-08,ESTIMATED,2011-03-31,2011-04-27,ESTIMATED,,,,2019-12-31,2020-01-18,ACTUAL,2009-05-07,ACTUAL,2009-05-07,2019-12,2019-12-31,2015-01-06,ACTUAL,2015-01-06,2015-01-06,ACTUAL,2015-01-06,,INTERVENTIONAL,,,Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.,Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of a HPV Vaccine (GSK 580299) in Healthy Female Subjects,COMPLETED,,PHASE3,632,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=3315,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 05:50:54,2024-10-13 05:50:54,INDUSTRY,,,,,,,GlaxoSmithKline,Colombia|Germany|Honduras|Panama|Taiwan,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00880698,,2009-04-10,2015-06-22,2014-10-30,2021-11-03,2009-04-10,2009-04-14,ESTIMATED,2015-07-17,2015-07-22,ESTIMATED,2014-10-30,2014-11-05,ESTIMATED,2021-11-03,2021-11-05,ACTUAL,2009-12,,2009-12-31,2015-07,2015-07-31,2014-01,ACTUAL,2014-01-31,2014-01,ACTUAL,2014-01-31,,INTERVENTIONAL,,Includes all participants 'as randomized',Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers,"Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers",COMPLETED,,PHASE2,202,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),The study was closed to enrollment prematurely so statistical power to detect differences was reduced.,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:53:42,2024-10-15 02:53:42,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Tanzania|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00880698,,2009-04-10,2015-06-22,2014-10-30,2021-11-03,2009-04-10,2009-04-14,ESTIMATED,2015-07-17,2015-07-22,ESTIMATED,2014-10-30,2014-11-05,ESTIMATED,2021-11-03,2021-11-05,ACTUAL,2009-12,,2009-12-31,2015-07,2015-07-31,2014-01,ACTUAL,2014-01-31,2014-01,ACTUAL,2014-01-31,,INTERVENTIONAL,,Includes all participants 'as randomized',Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers,"Safety and Immunogenicity of a Live, Attenuated Rotavirus Vaccine (RotaTeq™) in HIV-1 Infected and Uninfected Children Born to HIV-1-Infected Mothers",COMPLETED,,PHASE2,202,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),The study was closed to enrollment prematurely so statistical power to detect differences was reduced.,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:53:42,2024-10-15 02:53:42,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Tanzania|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00885482,,2009-04-20,2015-02-04,,2015-02-23,2009-04-20,2009-04-22,ESTIMATED,2015-02-04,2015-02-23,ESTIMATED,,,,2015-02-23,2015-03-13,ESTIMATED,2009-05,,2009-05-31,2015-02,2015-02-28,2011-05,ACTUAL,2011-05-31,2010-05,ACTUAL,2010-05-31,,INTERVENTIONAL,AtLaS,,Atazanavir and Lamivudine for Treatment Simplification,Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Atazanavir/Ritonavir + Lamivudine in Patients Stably Treated With Two NRTIs + Atazanavir/Ritonavir With Optimal Virologic Response.,COMPLETED,,PHASE4,40,ACTUAL,Catholic University of the Sacred Heart,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 00:52:43,2024-10-15 00:52:43,OTHER,,,,,,,Catholic University of the Sacred Heart,Italy,Cardiac disorders|Infections and infestations|Renal and urinary disorders|Vascular disorders
NCT00885495,,2009-04-20,2011-03-24,,2022-01-19,2009-04-21,2009-04-22,ESTIMATED,2021-12-20,2022-01-19,ACTUAL,,,,2022-01-19,2022-02-11,ACTUAL,2009-01,,2009-01-31,2022-01,2022-01-31,2010-08,ACTUAL,2010-08-31,2010-04,ACTUAL,2010-04-30,,INTERVENTIONAL,,,Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study,The Effects of Darunavir Plus Ritonavir on the Pharmacokinetics and Pharmacodynamics of Rosuvastatin,COMPLETED,,PHASE1/PHASE2,17,ACTUAL,University of Cincinnati,No clinical outcome data beyond 7 days is available. Cannot necessarily extrapolate directly to persons with HIV.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 11:14:41,2024-10-13 11:14:41,OTHER,,,,,,,University of Cincinnati,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00885664,,2009-04-20,2021-12-20,,2022-07-14,2009-04-21,2009-04-22,ESTIMATED,2022-07-14,2022-08-10,ACTUAL,,,,2022-07-14,2022-08-10,ACTUAL,2005-10,,2005-10-31,2022-07,2022-07-31,2010-03,ACTUAL,2010-03-31,2009-09,ACTUAL,2009-09-30,,INTERVENTIONAL,,,Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection,Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection,COMPLETED,,PHASE4,60,ACTUAL,University of Cincinnati,Small study of 60 subjects. Some subjects did not complete all study visits limiting data available for each time point.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 15:11:22,2024-10-14 15:11:22,OTHER,,,,,,,Abbott|Gilead Sciences|University of Cincinnati,United States,Gastrointestinal disorders|General disorders|Nervous system disorders|Psychiatric disorders
NCT00885703,,2009-04-20,2018-01-11,,2021-11-02,2009-04-20,2009-04-22,ESTIMATED,2018-02-12,2018-03-12,ACTUAL,,,,2021-11-02,2021-11-04,ACTUAL,2010-04-16,ACTUAL,2010-04-16,2018-02,2018-02-28,2017-01-12,ACTUAL,2017-01-12,2017-01-12,ACTUAL,2017-01-12,,INTERVENTIONAL,,,High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals,A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis,COMPLETED,,PHASE1/PHASE2,168,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,7,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 20:30:57,2024-10-13 20:30:57,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),India|Kenya|Peru|South Africa|Thailand|Uganda|United States|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00887653,,2009-04-23,2014-09-19,,2014-10-08,2009-04-23,2009-04-24,ESTIMATED,2014-10-08,2014-10-10,ESTIMATED,,,,2014-10-08,2014-10-10,ESTIMATED,2009-05,,2009-05-31,2014-10,2014-10-31,2014-04,ACTUAL,2014-04-30,2012-06,ACTUAL,2012-06-30,,INTERVENTIONAL,,,Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy,Changes in Lipid Profiles and Safety of Raltegravir Based Antiretroviral Therapy in HIV-1-infected Patients With Hyperlipidemia While on Current Standard Therapy,COMPLETED,,PHASE3,20,ACTUAL,The Miriam Hospital,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 02:59:02,2024-10-13 02:59:02,OTHER,,,,,,,Merck Sharp & Dohme LLC|The Miriam Hospital|Tufts Medical Center,United States,Immune system disorders
NCT00887679,,2009-04-23,2012-11-19,,2014-10-23,2009-04-23,2009-04-24,ESTIMATED,2014-03-07,2014-03-10,ESTIMATED,,,,2014-10-23,2014-10-31,ESTIMATED,2009-05,,2009-05-31,2014-03,2014-03-31,2010-09,ACTUAL,2010-09-30,2009-09,ACTUAL,2009-09-30,,INTERVENTIONAL,,,Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS,"Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder, Adherence to Antiretroviral Therapy,Cognition, and Immune Status Among Patients With HIV and AIDS: A 6-week Open-label, Prospective, Pilot Trial.",COMPLETED,,PHASE3,30,ACTUAL,Duke University,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:11:06,2024-10-13 19:11:06,OTHER,,,,,,,Duke University|Forest Laboratories,United States,Gastrointestinal disorders|Nervous system disorders
NCT00892437,,2009-04-30,2014-10-23,2011-08-23,2016-01-15,2009-05-01,2009-05-04,ESTIMATED,2014-10-23,2014-10-28,ESTIMATED,2011-08-23,2011-08-25,ESTIMATED,2016-01-15,2016-02-15,ESTIMATED,2009-05,,2009-05-31,2016-01,2016-01-31,2015-01,ACTUAL,2015-01-31,2009-12,ACTUAL,2009-12-31,,INTERVENTIONAL,,ITT Analysis Set: participants who were randomized and received at least one dose of study drug.,"Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9350-boosted Atazanavir (ATV/GS-9350) Compared to Ritonavir-boosted Atazanavir (ATV/r) in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE2,85,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 22:25:16,2024-10-13 22:25:16,INDUSTRY,,,,,,,Gilead Sciences,United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00895947,,2009-05-06,2010-11-16,,2011-09-12,2009-05-07,2009-05-08,ESTIMATED,2010-12-14,2011-01-13,ESTIMATED,,,,2011-09-12,2011-09-16,ESTIMATED,2009-04,,2009-04-30,2011-09,2011-09-30,2010-03,ACTUAL,2010-03-31,2010-01,ACTUAL,2010-01-31,,INTERVENTIONAL,,,Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu,"Evaluation of Natural Human Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu in Perth, Western Australia",COMPLETED,,PHASE2,200,ACTUAL,"Ainos, Inc. (f/k/a Amarillo Biosciences Inc.",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 12:09:42,2024-10-14 12:09:42,INDUSTRY,,,,,,,"Ainos, Inc. (f/k/a Amarillo Biosciences Inc.|Department of Health, Western Australia",Australia,"Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT00896051,,2009-05-07,2013-04-10,,2013-09-27,2009-05-07,2009-05-11,ESTIMATED,2013-09-27,2013-09-30,ESTIMATED,,,,2013-09-27,2013-09-30,ESTIMATED,2009-08,,2009-08-31,2013-09,2013-09-30,2012-04,ACTUAL,2012-04-30,2012-04,ACTUAL,2012-04-30,,INTERVENTIONAL,,,"TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients","TMC125-TiDP2-C238: A Randomized, Exploratory, Open-label 48-week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-experienced HIV-1 Infected Subjects",COMPLETED,,PHASE2,50,ACTUAL,Janssen R&D Ireland,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:31:10,2024-10-13 18:31:10,INDUSTRY,,,,,,,Janssen R&D Ireland,Argentina|France|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00896064,,2009-05-07,2017-04-21,2011-11-16,2018-06-25,2009-05-07,2009-05-11,ESTIMATED,2017-04-21,2017-07-19,ACTUAL,2011-11-16,2011-11-21,ESTIMATED,2018-06-25,2018-08-17,ACTUAL,2009-05-18,,2009-05-18,2017-04,2017-04-30,2009-08-05,ACTUAL,2009-08-05,2009-08-05,ACTUAL,2009-08-05,,INTERVENTIONAL,,,Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults,A Study to Evaluate Safety and Immunogenicity of a Booster Dose of Two Formulations of GSK Biologicals' Pneumococcal Candidate Vaccine in Healthy Young Adults,COMPLETED,,PHASE2,43,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 19:53:14,2024-10-14 19:53:14,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium,Gastrointestinal disorders|General disorders|Nervous system disorders
NCT00903682,,2009-05-14,2011-02-10,,2013-01-07,2009-05-14,2009-05-18,ESTIMATED,2011-02-10,2011-03-07,ESTIMATED,,,,2013-01-07,2013-01-14,ESTIMATED,2009-06,,2009-06-30,2013-01,2013-01-31,2011-01,ACTUAL,2011-01-31,2010-02,ACTUAL,2010-02-28,,INTERVENTIONAL,SENSE,,A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients,"A Phase IIb, Multi-centre, Randomised, Double-blind, Active-controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects",COMPLETED,,PHASE2,157,ACTUAL,Janssen-Cilag International NV,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:19:27,2024-10-13 18:19:27,INDUSTRY,,,,,,,Janssen-Cilag International NV,Austria|Denmark|France|Germany|Hungary|Israel|Romania|Russian Federation|Spain|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00905489,,2009-05-06,2013-09-23,,2015-12-02,2009-05-19,2009-05-20,ESTIMATED,2014-04-05,2014-05-07,ESTIMATED,,,,2015-12-02,2016-01-07,ESTIMATED,2009-06,,2009-06-30,2015-12,2015-12-31,2012-09,ACTUAL,2012-09-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,Full analysis set (FAS): All patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.,A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.,"An Open-label, Multiple Dose, Cross-over Study to Evaluate the Steady-state Pharmacokinetic Parameters of Nevirapine Extended Release Tablets in HIV-1 Infected Children, With an Optional Extension Phase",COMPLETED,,PHASE1,85,ACTUAL,Boehringer Ingelheim,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 06:59:11,2024-10-14 06:59:11,INDUSTRY,,,,,,,Boehringer Ingelheim,Argentina|Botswana|Germany|Romania|South Africa|United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00907777,,2009-05-21,2016-11-07,2009-11-10,2020-11-04,2009-05-21,2009-05-25,ESTIMATED,2016-11-07,2017-01-06,ESTIMATED,2009-11-10,2009-11-11,ESTIMATED,2020-11-04,2020-11-23,ACTUAL,2009-06-23,ACTUAL,2009-06-23,2020-11,2020-11-30,2009-10-05,ACTUAL,2009-10-05,2009-10-05,ACTUAL,2009-10-05,,INTERVENTIONAL,,,Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™,Vaccination With the Pneumococcal Vaccine GSK 1024850A or Prevenar™ at Approximately 4 Years of Age in Children Primed With 3 Doses of GSK 1024850A Vaccine or Prevenar™ and Boosted With 23-valent Pneumococcal Plain Polysaccharide Vaccine,COMPLETED,,PHASE3,52,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=472,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 05:01:09,2024-10-13 05:01:09,INDUSTRY,,,,,,,GlaxoSmithKline,Germany,General disorders
NCT00908544,,2009-05-26,2019-03-28,,2019-08-23,2009-05-26,2009-05-27,ESTIMATED,2019-08-23,2019-08-28,ACTUAL,,,,2019-08-23,2019-08-28,ACTUAL,2009-05-15,ACTUAL,2009-05-15,2019-08,2019-08-31,2018-05,ACTUAL,2018-05-31,2018-04-03,ACTUAL,2018-04-03,,INTERVENTIONAL,NewEra,"The safety dataset (safety population) is based on all patients having received at least one dose of study drugs (N=47 pts.); 5 of these patients were excluded.

The efficacy dataset (efficacy population) is based on patients who were enrolled in the study, received at least one dose of study drugs and met the inclusion criteria (N=42 pts.).",New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients,"NEW ERA STUDY - HIV and Eradication: A Multicenter, Open-label, Non-randomized Trial to Evaluate Treatment With Multi-drug Class (MDC) HAART and Its Impact on the Decay Rate of Latently Infected CD4+ T Cells Incl. Amendment 1.0",COMPLETED,,NA,47,ACTUAL,MUC Research GmbH,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 13:44:10,2024-10-14 13:44:10,OTHER,,,,,,,AbbVie|German Center for Infection Research|Merck Sharp & Dohme LLC|MUC Research GmbH|Pfizer,Germany,"Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00911144,,2009-05-28,2011-01-06,,2018-08-21,2009-05-28,2009-06-01,ESTIMATED,2011-01-06,2011-01-19,ESTIMATED,,,,2018-08-21,2018-09-20,ACTUAL,2009-06-11,,2009-06-11,2016-10,2016-10-31,2010-01-11,ACTUAL,2010-01-11,2010-01-11,ACTUAL,2010-01-11,,INTERVENTIONAL,,,Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine,Booster Vaccination With Pneumococcal Vaccine GSK1024850A or Prevenar™ Co-administered With Hiberix™ in Children Primed With the Same Vaccines,COMPLETED,,PHASE3,450,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 02:39:47,2024-10-14 02:39:47,INDUSTRY,,,,,,,GlaxoSmithKline,"Korea, Republic of",General disorders|Infections and infestations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT00915655,,2009-06-04,2011-11-25,,2012-08-28,2009-06-04,2009-06-08,ESTIMATED,2011-11-25,2011-12-28,ESTIMATED,,,,2012-08-28,2012-09-03,ESTIMATED,2009-07,,2009-07-31,2012-08,2012-08-31,2011-03,ACTUAL,2011-03-31,2010-09,ACTUAL,2010-09-30,,INTERVENTIONAL,DIONE,,A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents,"A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years",COMPLETED,,PHASE2,12,ACTUAL,"Tibotec Pharmaceuticals, Ireland",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 00:52:43,2024-10-15 00:52:43,INDUSTRY,,,,,,,"Tibotec Pharmaceutical Limited|Tibotec Pharmaceuticals, Ireland",France|Ireland|Spain|Ukraine|United Kingdom|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00915967,,2009-06-05,2019-01-17,,2019-04-08,2009-06-05,2009-06-08,ESTIMATED,2019-04-08,2019-04-30,ACTUAL,,,,2019-04-08,2019-04-30,ACTUAL,2009-05-13,ACTUAL,2009-05-13,2019-01,2019-01-31,2014-12-19,ACTUAL,2014-12-19,2014-12-19,ACTUAL,2014-12-19,,INTERVENTIONAL,POWI,,Prevention of Neurosurgical Wound Infections,Pilot Project: Prevention of Neurosurgical Wound Infections,COMPLETED,,NA,214,ACTUAL,Oregon Health and Science University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 23:16:28,2024-10-13 23:16:28,OTHER,,,,,,,Oregon Health and Science University,United States,Surgical and medical procedures
NCT00920426,,2009-06-12,2017-07-18,2010-08-12,2017-11-02,2009-06-12,2009-06-15,ESTIMATED,2017-11-02,2017-12-06,ACTUAL,2010-08-12,2010-08-17,ESTIMATED,2017-11-02,2017-12-06,ACTUAL,2009-06-09,ACTUAL,2009-06-09,2017-09,2017-09-30,2009-08-13,ACTUAL,2009-08-13,2009-08-13,ACTUAL,2009-08-13,,INTERVENTIONAL,,,Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929),"A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929)",COMPLETED,,PHASE2,9,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:15:37,2024-10-13 08:15:37,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,United States,Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Vascular disorders
NCT00921024,,2009-06-12,2015-01-09,,2018-09-21,2009-06-12,2009-06-16,ESTIMATED,2015-01-09,2015-01-15,ESTIMATED,,,,2018-09-21,2018-10-18,ACTUAL,2009-06-30,ACTUAL,2009-06-30,2018-09,2018-09-30,2010-03-11,ACTUAL,2010-03-11,2010-02-25,ACTUAL,2010-02-25,,INTERVENTIONAL,,,Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections,"A Multicenter, Double-blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA-101 and Intravenous Ceftazidime in Complicated Urinary Tract Infection, Including Pyelonephritis",COMPLETED,,PHASE2,129,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 19:23:54,2024-10-14 19:23:54,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Germany|Poland|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00921557,,2009-06-12,2016-12-15,,2021-11-03,2009-06-12,2009-06-16,ESTIMATED,2017-02-08,2017-03-28,ACTUAL,,,,2021-11-03,2021-11-05,ACTUAL,2009-11,ACTUAL,2009-11-30,2017-06,2017-06-30,2017-01,ACTUAL,2017-01-31,2016-01,ACTUAL,2016-01-31,,INTERVENTIONAL,,Includes participants who took at least one dose of study treatment (alendronate/placebo),Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents,Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density,COMPLETED,,PHASE2,52,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 14:33:21,2024-10-14 14:33:21,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00924898,,2009-06-17,2017-02-08,,2017-04-06,2009-06-18,2009-06-19,ESTIMATED,2017-04-06,2017-05-16,ACTUAL,,,,2017-04-06,2017-05-16,ACTUAL,2005-01,,2005-01-31,2017-04,2017-04-30,2013-12,ACTUAL,2013-12-31,2013-11,ACTUAL,2013-11-30,,INTERVENTIONAL,,,"Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)","CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis",COMPLETED,,PHASE4,92,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 19:35:45,2024-10-14 19:35:45,OTHER,,,,,,,"Bristol-Myers Squibb|Gilead Sciences|University of North Carolina, Chapel Hill",United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00924898,,2009-06-17,2017-02-08,,2017-04-06,2009-06-18,2009-06-19,ESTIMATED,2017-04-06,2017-05-16,ACTUAL,,,,2017-04-06,2017-05-16,ACTUAL,2005-01,,2005-01-31,2017-04,2017-04-30,2013-12,ACTUAL,2013-12-31,2013-11,ACTUAL,2013-11-30,,INTERVENTIONAL,,,"Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805)","CID 0805 - Treatment of Acute HIV Infection With a Once Daily Regimen of Emtricitabine, Tenofovir and Efavirenz - A Pilot Study of Response to Therapy and HIV Pathogenesis",COMPLETED,,PHASE4,92,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 19:35:45,2024-10-14 19:35:45,OTHER,,,,,,,"Bristol-Myers Squibb|Gilead Sciences|University of North Carolina, Chapel Hill",United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00925756,,2009-06-18,2020-05-13,,2020-08-06,2009-06-19,2009-06-22,ESTIMATED,2020-08-06,2020-08-19,ACTUAL,,,,2020-08-06,2020-08-19,ACTUAL,2008-10-20,ACTUAL,2008-10-20,2020-08,2020-08-31,2014-04-11,ACTUAL,2014-04-11,2012-05-02,ACTUAL,2012-05-02,,INTERVENTIONAL,,,CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery,The Impact of CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery and Gene Expression Profiles in HIV-Infected Patients With Viral Suppression,COMPLETED,,PHASE4,32,ACTUAL,"University of California, San Diego",,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 11:03:59,2024-10-14 11:03:59,OTHER,,,,,,,"California HIV/AIDS Research Program|Pfizer|University of California, Los Angeles|University of California, San Diego|University of Southern California",United States,Psychiatric disorders
NCT00928187,,2009-06-23,2016-07-11,,2017-01-12,2009-06-24,2009-06-25,ESTIMATED,2016-09-21,2016-11-08,ESTIMATED,,,,2017-01-12,2017-02-27,ACTUAL,2009-11,,2009-11-30,2017-01,2017-01-31,2015-12,ACTUAL,2015-12-31,2013-09,ACTUAL,2013-09-30,,INTERVENTIONAL,2LADY,,Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé),"Multicentric, Non-inferiority, Randomized, Non-blinded Phase 3 Trial Comparing Virological Response at 48 Weeks of 3 Antiretroviral Treatment Regimens in HIV-1-infected Patients With Treatment Failure After 1st Line Antiretroviral Therapy (Cameroon, Burkina Faso, Senegal)",COMPLETED,,PHASE3,454,ACTUAL,"ANRS, Emerging Infectious Diseases","Limitations: open label design, random imbalance at baseline. Non-inferiority not shown, results influenced by the hypothesis of 80% viral success (50 copies/mL), not reached (69% in the control group). Therefore, the study power was reduced (80%).",3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:32:11,2024-10-14 22:32:11,OTHER_GOV,,,,,,,"ANRS, Emerging Infectious Diseases|Gilead Sciences|Janssen Pharmaceutica",Burkina Faso|Cameroon|Senegal,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00929526,,2009-06-26,2012-02-16,,2016-09-09,2009-06-26,2009-06-29,ESTIMATED,2012-09-13,2012-10-15,ESTIMATED,,,,2016-09-09,2016-10-20,ESTIMATED,2009-06,,2009-06-30,2016-09,2016-09-30,2011-02,ACTUAL,2011-02-28,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,,,Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study,Long-term Extension Study of the Efficacy of the 580299 Vaccine in the Prevention of HPV-16 and/or HPV-18 Associated Cervical Intraepithelial Neoplasia (CIN) in Japanese Women Vaccinated in the Primary Vaccination Study NCT00316693,COMPLETED,,PHASE3,752,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,GlaxoSmithKline,Japan,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00929643,,2009-06-26,2012-06-27,,2012-08-06,2009-06-26,2009-06-29,ESTIMATED,2012-06-27,2012-08-06,ESTIMATED,,,,2012-08-06,2012-08-10,ESTIMATED,2008-11,,2008-11-30,2012-08,2012-08-31,2010-12,ACTUAL,2010-12-31,2010-12,ACTUAL,2010-12-31,,OBSERVATIONAL,,,Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections,The Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections,COMPLETED,,,203,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:49:29,2024-10-13 00:49:29,INDUSTRY,,,,,,,Pfizer|Wyeth is now a wholly owned subsidiary of Pfizer,Greece,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders"
NCT00931463,,2009-07-01,2013-10-14,,2019-08-25,2009-07-01,2009-07-02,ESTIMATED,2013-12-01,2014-01-17,ESTIMATED,,,,2019-08-25,2019-09-04,ACTUAL,2009-09,,2009-09-30,2019-08,2019-08-31,2013-08,ACTUAL,2013-08-31,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,SECOND-LINE,,A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen,A Randomised Open-label Study Comparing the Safety and Efficacy of Ritonavir Boosted Lopinavir and 2-3N(t)RTI Backbone Versus Ritonavir Boosted Lopinavir and Raltegravir in Participants Virologically Failing First-line NNRTI/2N(t)RTI Therapy,COMPLETED,,PHASE4,558,ACTUAL,Kirby Institute,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 11:03:59,2024-10-14 11:03:59,OTHER_GOV,,,,,,,"Abbott|amfAR, The Foundation for AIDS Research|Kirby Institute|Merck Sharp & Dohme LLC",Argentina|Australia|Chile|China|France|Germany|Hong Kong|India|Ireland|Malaysia|Mexico|New Zealand|Nigeria|Peru|Singapore|South Africa|Taiwan|United Kingdom|Vietnam,"Blood and lymphatic system disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT00936117,,2009-07-07,2015-05-28,,2019-02-05,2009-07-07,2009-07-09,ESTIMATED,2015-08-24,2015-09-24,ESTIMATED,,,,2019-02-05,2019-02-27,ACTUAL,2009-09,,2009-09-30,2019-02,2019-02-28,2013-09,ACTUAL,2013-09-30,2013-09,ACTUAL,2013-09-30,,INTERVENTIONAL,,,Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia,Phase II Study of the Pharmacokinetics of Posaconazole Prophylaxis in Relapsed or Refractory Patients With Acute Leukemia,COMPLETED,,PHASE2,25,ACTUAL,M.D. Anderson Cancer Center,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 01:11:36,2024-10-14 01:11:36,OTHER,,,,,,,M.D. Anderson Cancer Center|Schering-Plough,United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00937521,,2009-06-29,2015-02-13,,2015-03-17,2009-07-10,2009-07-13,ESTIMATED,2015-02-13,2015-03-04,ESTIMATED,,,,2015-03-17,2015-04-07,ESTIMATED,2009-07,,2009-07-31,2015-03,2015-03-31,2012-02,ACTUAL,2012-02-29,2010-11,ACTUAL,2010-11-30,,INTERVENTIONAL,,,Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants,A Phase 2 Partially Observer-Blind Randomized Controlled Multicenter Dose-Ranging and Formulation-Finding Study of a New Novartis Meningococcal B Recombinant Vaccine Evaluating the Safety and Immunogenicity When Given Concomitantly With Routine Vaccines in 2-month-old Infants,COMPLETED,,PHASE2,1507,ACTUAL,Novartis,,8,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 15:43:52,2024-10-13 15:43:52,INDUSTRY,,,,,,,Novartis Vaccines,Argentina|Chile|Czech Republic|Hungary|Italy,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00938327,,2009-07-09,2011-02-17,,2017-12-07,2009-07-09,2009-07-13,ESTIMATED,2011-02-17,2011-03-16,ESTIMATED,,,,2017-12-07,2018-01-02,ACTUAL,2009-08-03,,2009-08-03,2016-02,2016-02-29,2010-04-23,ACTUAL,2010-04-23,2010-02-20,ACTUAL,2010-02-20,,OBSERVATIONAL,,,Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants,"Post Marketing Surveillance to Monitor the Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered According to the Prescribing Information to Indian Infants",COMPLETED,,,332,ACTUAL,GlaxoSmithKline,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 23:50:05,2024-10-13 23:50:05,INDUSTRY,,,,,,,GlaxoSmithKline,India,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00939562,,2009-07-08,2009-11-19,,2009-11-19,2009-07-14,2009-07-15,ESTIMATED,2009-11-19,2009-12-23,ESTIMATED,,,,2009-11-19,2009-12-23,ESTIMATED,2008-11,,2008-11-30,2009-11,2009-11-30,2008-12,ACTUAL,2008-12-31,2008-12,ACTUAL,2008-12-31,,INTERVENTIONAL,,,Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate,"An Open-Label, Two-Treatment, Two-Period, Randomized Cross-Over Study To Assess The Bioequivalence Between Commercial Doxycycline Carragenate And Monohydrate Tablet Formulations In Normal Healthy Male Subjects",COMPLETED,,PHASE4,24,ACTUAL,Pfizer,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:12:28,2024-10-15 02:12:28,INDUSTRY,,,,,,,Pfizer,India,"Blood and lymphatic system disorders|Injury, poisoning and procedural complications|Skin and subcutaneous tissue disorders"
NCT00939874,,2009-07-14,2015-01-13,,2015-05-28,2009-07-14,2009-07-15,ESTIMATED,2015-05-28,2015-06-12,ESTIMATED,,,,2015-05-28,2015-06-12,ESTIMATED,2009-10,,2009-10-31,2015-05,2015-05-31,2014-04,ACTUAL,2014-04-30,2012-06,ACTUAL,2012-06-30,,INTERVENTIONAL,TROP,,Switch From Tenofovir to Raltegravir for Low Bone Mineral Density,Switch From Tenofovir to Raltegravir for Low Bone Mineral Density,COMPLETED,,PHASE4,52,ACTUAL,"St Vincent's Hospital, Sydney",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:15:19,2024-10-13 09:15:19,OTHER,,,,,,,"Holdsworth House Medical Practice|Merck Sharp & Dohme LLC|St Vincent's Hospital, Sydney|The Alfred",Australia,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT00940771,,2009-07-15,2019-03-20,,2020-04-15,2009-07-15,2009-07-16,ESTIMATED,2020-04-15,2020-04-20,ACTUAL,,,,2020-04-15,2020-04-20,ACTUAL,2009-08-26,ACTUAL,2009-08-26,2020-04,2020-04-30,2016-11-23,ACTUAL,2016-11-23,2013-10-16,ACTUAL,2013-10-16,,INTERVENTIONAL,,,Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens,Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens With Other PI's/NNRTI's in HIV+ Children and Adolescents With Elevated Lipid Levels,COMPLETED,,PHASE4,10,ACTUAL,Phoenix Children's Hospital,Small sample size Non fasting lipid levels Large variety of prior treatment regimens,1,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-12 23:52:10,2024-10-12 23:52:10,OTHER,,,,,,,Bristol-Myers Squibb|Phoenix Children's Hospital,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders"
NCT00942305,,2009-07-17,2020-12-09,,2021-06-28,2009-07-17,2009-07-20,ESTIMATED,2021-06-28,2021-07-16,ACTUAL,,,,2021-06-28,2021-07-16,ACTUAL,2009-10,ACTUAL,2009-10-31,2021-06,2021-06-30,2012-01,ACTUAL,2012-01-31,2012-01,ACTUAL,2012-01-31,,INTERVENTIONAL,,"Note: While a total of 239 subjects were enrolled, 1 center was excluded from analysis due to concerns about investigator/site compliance with the study protocol. This center had enrolled 9 subjects: 5 subjects who received brincidofovir (BCV) in Cohort 1, 2 subjects who received placebo in Cohort 1, and 2 subjects who received BCV in Cohort 2.",Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients",COMPLETED,,PHASE2,239,ACTUAL,Chimerix,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 17:32:20,2024-10-13 17:32:20,INDUSTRY,,,,,,,Chimerix,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00943722,,2009-07-21,2014-12-12,,2022-09-22,2009-07-21,2009-07-22,ESTIMATED,2015-01-12,2015-01-13,ESTIMATED,,,,2022-09-22,2022-10-03,ACTUAL,2009-08-27,ACTUAL,2009-08-27,2022-09,2022-09-30,2021-04-22,ACTUAL,2021-04-22,2011-04-30,ACTUAL,2011-04-30,,INTERVENTIONAL,,"Per protocol, baseline characteristics were analyzed in all participants randomized in the base study.",A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002),"A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)",COMPLETED,,PHASE3,3074,ACTUAL,Merck Sharp & Dohme LLC,,5,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 16:26:35,2024-10-13 16:26:35,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Austria|Belgium|Brazil|Chile|Colombia|Costa Rica|Finland|India|Korea, Republic of|Peru|Poland|South Africa|Spain|Sweden|Taiwan|Thailand|United States","Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT00945282,,2009-07-23,2017-08-22,2012-03-08,2018-05-04,2009-07-23,2009-07-24,ESTIMATED,2018-05-04,2018-11-29,ACTUAL,2012-03-08,2012-03-13,ESTIMATED,2018-05-04,2018-11-29,ACTUAL,2009-10-20,ACTUAL,2009-10-20,2017-08,2017-08-31,2009-11-28,ACTUAL,2009-11-28,2009-11-28,ACTUAL,2009-11-28,,INTERVENTIONAL,,,Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.,"A Proof of Concept Study for GSK2248761 (An Extension of NV-05A-002: A Phase I/IIa Double-Blind Study to Evaluate the Safety and Tolerability, Antiretroviral Activity, Pharmacokinetics and Pharmacodynamics of IDX12899 in Antiretroviral Treatment-Naive HIV-1 Infected Subjects, Completed by Idenix)",COMPLETED,,PHASE2,8,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:42:24,2024-10-15 02:42:24,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina,Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Vascular disorders
NCT00947115,,2009-07-16,2011-02-10,,2020-10-02,2009-07-23,2009-07-27,ESTIMATED,2011-03-31,2011-05-02,ESTIMATED,,,,2020-10-02,2020-10-30,ACTUAL,2009-09-22,ACTUAL,2009-09-22,2020-10,2020-10-31,2015-02-03,ACTUAL,2015-02-03,2015-02-03,ACTUAL,2015-02-03,,INTERVENTIONAL,,,Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects,Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects,COMPLETED,,PHASE3,525,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=4512,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-15 01:48:22,2024-10-15 01:48:22,INDUSTRY,,,,,,,GlaxoSmithKline,Germany|Poland,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Reproductive system and breast disorders"
NCT00949234,,2009-07-29,2017-10-02,,2017-12-15,2009-07-29,2009-07-30,ESTIMATED,2017-12-15,2017-12-18,ACTUAL,,,,2017-12-15,2017-12-18,ACTUAL,2010-03,,2010-03-31,2017-12,2017-12-31,2011-08,ACTUAL,2011-08-31,2010-06,ACTUAL,2010-06-30,,INTERVENTIONAL,,,Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV,A Pilot Project to Operationalize the Prevention Strategy of Post Exposure Prophylaxis Following Sexual Exposure to HIV in Combination With Educational Programming and Behavioral Risk Reduction Strategies in Los Angeles County,COMPLETED,,PHASE2,267,ACTUAL,"University of California, Los Angeles",Open label clinical trial of deploying PEP regimens at community based sites. Non-randomized and guidelines have subsequently evolved.,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 14:44:18,2024-10-13 14:44:18,OTHER,,,,,,,"AIDS Project Los Angeles|Los Angeles County Department of Public Health|Los Angeles LGBT Center|The OASIS Clinic|University of California, Los Angeles",United States,Gastrointestinal disorders|General disorders
NCT00950833,,2009-07-30,2017-04-18,2010-12-07,2018-08-21,2009-07-30,2009-08-03,ESTIMATED,2017-04-25,2017-08-07,ACTUAL,2010-12-07,2010-12-10,ESTIMATED,2018-08-21,2018-09-20,ACTUAL,2009-08-10,ACTUAL,2009-08-10,2018-08,2018-08-31,2010-10-27,ACTUAL,2010-10-27,2010-09-16,ACTUAL,2010-09-16,,INTERVENTIONAL,,,Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children,Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children,COMPLETED,,PHASE3,466,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 07:04:43,2024-10-14 07:04:43,INDUSTRY,,,,,,,GlaxoSmithKline,Czechia|Czech Republic,General disorders
NCT00950859,,2009-07-23,2013-08-15,2010-08-12,2015-11-05,2009-07-30,2009-08-03,ESTIMATED,2013-08-15,2013-10-21,ESTIMATED,2010-10-01,2010-10-05,ESTIMATED,2015-11-05,2015-12-04,ESTIMATED,2009-08,,2009-08-31,2015-09,2015-09-30,2015-01,ACTUAL,2015-01-31,2010-11,ACTUAL,2010-11-30,,INTERVENTIONAL,,,A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir,"A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance",COMPLETED,,PHASE2,51,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:15:55,2024-10-13 00:15:55,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Canada|France|Italy|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00951015,,2009-07-30,2013-08-22,2011-03-17,2017-12-14,2009-07-30,2009-08-03,ESTIMATED,2013-08-22,2013-11-11,ESTIMATED,2011-03-17,2011-03-28,ESTIMATED,2017-12-14,2018-01-16,ACTUAL,2009-07-30,,2009-07-30,2017-04,2017-04-30,2016-12-22,ACTUAL,2016-12-22,2010-02-26,ACTUAL,2010-02-26,,INTERVENTIONAL,ING112276,,"A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects",A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects,COMPLETED,,PHASE2,208,ACTUAL,ViiV Healthcare,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 17:02:01,2024-10-13 17:02:01,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,France|Germany|Italy|Russian Federation|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00955682,,2009-08-06,2017-09-11,2012-11-16,2021-02-03,2009-08-06,2009-08-10,ESTIMATED,2019-06-11,2019-08-06,ACTUAL,2012-11-16,2012-11-21,ESTIMATED,2021-02-03,2021-02-26,ACTUAL,2009-08-25,ACTUAL,2009-08-25,2021-02,2021-02-28,2012-09-10,ACTUAL,2012-09-10,2009-12-16,ACTUAL,2009-12-16,,INTERVENTIONAL,,,Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612,Persistence of Antibodies After GSK Biologicals' Meningococcal Vaccine GSK134612 in Toddlers,COMPLETED,,PHASE3,342,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 03:45:16,2024-10-14 03:45:16,INDUSTRY,,,,,,,GlaxoSmithKline,Finland,"General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00955968,,2009-08-07,2017-08-30,,2023-08-10,2009-08-07,2009-08-10,ESTIMATED,2018-01-19,2018-02-19,ACTUAL,,,,2023-08-10,2023-08-14,ACTUAL,2010-01-01,ACTUAL,2010-01-01,2023-08,2023-08-31,2016-08-31,ACTUAL,2016-08-31,2016-08-31,ACTUAL,2016-08-31,,INTERVENTIONAL,,All the participants who were randomized to the study with the exception of one participant who was excluded as she withdrew from the study on the day she was randomized,IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women,IMPAACT 1077HS: HAART Standard Version of the Promoting Maternal and Infant Survival Everywhere (PROMISE) Study,COMPLETED,,PHASE4,1653,ACTUAL,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 16:39:05,2024-10-14 16:39:05,NETWORK,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Botswana|Brazil|China|Haiti|Peru|Puerto Rico|Thailand|United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Surgical and medical procedures|Vascular disorders"
NCT00959699,,2009-07-29,2013-05-08,,2017-03-09,2009-08-14,2009-08-17,ESTIMATED,2013-07-26,2013-08-30,ESTIMATED,,,,2017-03-09,2017-04-07,ACTUAL,2009-11,,2009-11-30,2017-03,2017-03-31,2012-10,ACTUAL,2012-10-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,,"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (Protocol No. P05411)",COMPLETED,,PHASE2,99,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 02:07:38,2024-10-14 02:07:38,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Argentina|Brazil|Canada|France|Germany|Italy|Poland|Portugal|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00959699,,2009-07-29,2013-05-08,,2017-03-09,2009-08-14,2009-08-17,ESTIMATED,2013-07-26,2013-08-30,ESTIMATED,,,,2017-03-09,2017-04-07,ACTUAL,2009-11,,2009-11-30,2017-03,2017-03-31,2012-10,ACTUAL,2012-10-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,,"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (Protocol No. P05411)",COMPLETED,,PHASE2,99,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-14 02:07:38,2024-10-14 02:07:38,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Argentina|Brazil|Canada|France|Germany|Italy|Poland|Portugal|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00959894,,2009-08-14,2015-03-27,,2016-04-29,2009-08-14,2009-08-17,ESTIMATED,2015-05-11,2015-05-13,ESTIMATED,,,,2016-04-29,2016-06-06,ESTIMATED,2009-09,,2009-09-30,2016-04,2016-04-30,2014-05,ACTUAL,2014-05-31,2014-02,ACTUAL,2014-02-28,,INTERVENTIONAL,,All participants who received at least one dose of study medication (etravirine 400 mg given once daily with with one tablet of fixed dose tenofovir/emtricitabine).,Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection,Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection,COMPLETED,,PHASE2,80,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 01:54:24,2024-10-14 01:54:24,OTHER,,,,,,,"Janssen Pharmaceuticals|University of North Carolina, Chapel Hill",United States,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00962780,,2009-08-18,2014-03-17,,2014-11-13,2009-08-19,2009-08-20,ESTIMATED,2014-11-13,2014-11-17,ESTIMATED,,,,2014-11-13,2014-11-17,ESTIMATED,2010-03,,2010-03-31,2014-11,2014-11-30,2013-04,ACTUAL,2013-04-30,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,Safety population included all enrolled participants who received at least 1 dose of investigational product.,Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine,"A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability and Immunogenicity of 2 and 3 Doses of 13vPnC in HIV-Infected Subjects 6 Years of Age and Older Who Have Not Been Previously Immunized With Pneumococcal Vaccine",COMPLETED,,PHASE3,303,ACTUAL,Pfizer,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 03:20:11,2024-10-14 03:20:11,INDUSTRY,,,,,,,Pfizer,Romania|South Africa,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00962780,,2009-08-18,2014-03-17,,2014-11-13,2009-08-19,2009-08-20,ESTIMATED,2014-11-13,2014-11-17,ESTIMATED,,,,2014-11-13,2014-11-17,ESTIMATED,2010-03,,2010-03-31,2014-11,2014-11-30,2013-04,ACTUAL,2013-04-30,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,Safety population included all enrolled participants who received at least 1 dose of investigational product.,Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine,"A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability and Immunogenicity of 2 and 3 Doses of 13vPnC in HIV-Infected Subjects 6 Years of Age and Older Who Have Not Been Previously Immunized With Pneumococcal Vaccine",COMPLETED,,PHASE3,303,ACTUAL,Pfizer,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 03:20:11,2024-10-14 03:20:11,INDUSTRY,,,,,,,Pfizer,Romania|South Africa,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00963235,,2009-08-20,2013-04-17,,2013-04-17,2009-08-20,2009-08-21,ESTIMATED,2013-04-17,2013-06-10,ESTIMATED,,,,2013-04-17,2013-06-10,ESTIMATED,2009-11,,2009-11-30,2013-04,2013-04-30,2012-05,ACTUAL,2012-05-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,Safety population included participants who received at least 1 dose of study vaccine.,Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS,"A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine",COMPLETED,,PHASE3,331,ACTUAL,Pfizer,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 19:47:33,2024-10-14 19:47:33,INDUSTRY,,,,,,,Pfizer,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00963235,,2009-08-20,2013-04-17,,2013-04-17,2009-08-20,2009-08-21,ESTIMATED,2013-04-17,2013-06-10,ESTIMATED,,,,2013-04-17,2013-06-10,ESTIMATED,2009-11,,2009-11-30,2013-04,2013-04-30,2012-05,ACTUAL,2012-05-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,Safety population included participants who received at least 1 dose of study vaccine.,Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS,"A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine",COMPLETED,,PHASE3,331,ACTUAL,Pfizer,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 19:47:33,2024-10-14 19:47:33,INDUSTRY,,,,,,,Pfizer,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT00965185,,2009-08-24,2015-01-30,,2017-11-09,2009-08-24,2009-08-25,ESTIMATED,2015-02-17,2015-02-26,ESTIMATED,,,,2017-11-09,2017-12-11,ACTUAL,2009-09,,2009-09-30,2017-11,2017-11-30,2014-01,ACTUAL,2014-01-31,2014-01,ACTUAL,2014-01-31,,INTERVENTIONAL,,,Statin Therapy to Improve Atherosclerosis in HIV Patients,Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients,COMPLETED,,NA,40,ACTUAL,Massachusetts General Hospital,FDG-PET scan data was interpretable in only a limited subset of participants as a result of technical problems with manual co-registration (outcome 1). We were unable to collect data for endothelial function due to equipment malfunction (outcome 3).,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 08:36:00,2024-10-14 08:36:00,OTHER,,,,,,,"Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)",United States,Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders
NCT00965848,,2009-08-24,2013-03-12,,2013-09-27,2009-08-25,2009-08-26,ESTIMATED,2013-07-25,2013-08-28,ESTIMATED,,,,2013-09-27,2013-10-30,ESTIMATED,2009-06,,2009-06-30,2013-09,2013-09-30,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,"For Baseline characteristics, age and gender, number of participants evaluable was 264.","A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections","A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections",COMPLETED,,PHASE4,270,ACTUAL,"Janssen-Cilag Ltd.,Thailand",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:25:54,2024-10-13 07:25:54,INDUSTRY,,,,,,,"Janssen-Cilag Ltd.,Thailand",Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00965848,,2009-08-24,2013-03-12,,2013-09-27,2009-08-25,2009-08-26,ESTIMATED,2013-07-25,2013-08-28,ESTIMATED,,,,2013-09-27,2013-10-30,ESTIMATED,2009-06,,2009-06-30,2013-09,2013-09-30,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,"For Baseline characteristics, age and gender, number of participants evaluable was 264.","A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections","A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections",COMPLETED,,PHASE4,270,ACTUAL,"Janssen-Cilag Ltd.,Thailand",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:25:54,2024-10-13 07:25:54,INDUSTRY,,,,,,,"Janssen-Cilag Ltd.,Thailand",Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00965848,,2009-08-24,2013-03-12,,2013-09-27,2009-08-25,2009-08-26,ESTIMATED,2013-07-25,2013-08-28,ESTIMATED,,,,2013-09-27,2013-10-30,ESTIMATED,2009-06,,2009-06-30,2013-09,2013-09-30,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,"For Baseline characteristics, age and gender, number of participants evaluable was 264.","A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections","A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections",COMPLETED,,PHASE4,270,ACTUAL,"Janssen-Cilag Ltd.,Thailand",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:25:54,2024-10-13 07:25:54,INDUSTRY,,,,,,,"Janssen-Cilag Ltd.,Thailand",Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00965848,,2009-08-24,2013-03-12,,2013-09-27,2009-08-25,2009-08-26,ESTIMATED,2013-07-25,2013-08-28,ESTIMATED,,,,2013-09-27,2013-10-30,ESTIMATED,2009-06,,2009-06-30,2013-09,2013-09-30,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,"For Baseline characteristics, age and gender, number of participants evaluable was 264.","A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections","A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections",COMPLETED,,PHASE4,270,ACTUAL,"Janssen-Cilag Ltd.,Thailand",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:25:54,2024-10-13 07:25:54,INDUSTRY,,,,,,,"Janssen-Cilag Ltd.,Thailand",Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00965848,,2009-08-24,2013-03-12,,2013-09-27,2009-08-25,2009-08-26,ESTIMATED,2013-07-25,2013-08-28,ESTIMATED,,,,2013-09-27,2013-10-30,ESTIMATED,2009-06,,2009-06-30,2013-09,2013-09-30,2010-07,ACTUAL,2010-07-31,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,"For Baseline characteristics, age and gender, number of participants evaluable was 264.","A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections","A Post Marketing Surveillance Study on the Safety and Effectiveness of Doripenem in the Therapy of Thai Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections",COMPLETED,,PHASE4,270,ACTUAL,"Janssen-Cilag Ltd.,Thailand",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:25:54,2024-10-13 07:25:54,INDUSTRY,,,,,,,"Janssen-Cilag Ltd.,Thailand",Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT00966446,,2009-08-25,2015-12-01,,2019-07-01,2009-08-26,2009-08-27,ESTIMATED,2016-05-20,2016-06-29,ESTIMATED,,,,2019-07-01,2019-07-05,ACTUAL,2009-09,,2009-09-30,2019-07,2019-07-31,2014-12,ACTUAL,2014-12-31,2014-09,ACTUAL,2014-09-30,,INTERVENTIONAL,,,Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community,Epidemiology and Prevention of MRSA Transmission in the Community,COMPLETED,,NA,223,ACTUAL,University of Pennsylvania,,3,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 20:47:50,2024-10-14 20:47:50,OTHER,,,,,,,Children's Hospital of Philadelphia|Milton S. Hershey Medical Center|Pennsylvania Department of Health|University of Pennsylvania,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders"
NCT00969228,,2009-08-20,2011-06-16,,2020-01-03,2009-08-31,2009-09-01,ESTIMATED,2011-10-20,2011-11-28,ESTIMATED,,,,2020-01-03,2020-01-18,ACTUAL,2009-08-25,ACTUAL,2009-08-25,2020-01,2020-01-31,2010-07-23,ACTUAL,2010-07-23,2010-07-23,ACTUAL,2010-07-23,,INTERVENTIONAL,,,"Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants","Immunogenicity, Reactogenicity and Safety Study to Evaluate Two Doses of the Lyophilised Formulation of the Human Rotavirus (HRV) Vaccine When Administered to Healthy Korean Infants Previously Uninfected With HRV",COMPLETED,,PHASE4,684,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=276,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 18:53:55,2024-10-14 18:53:55,INDUSTRY,,,,,,,GlaxoSmithKline,"Korea, Republic of","Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Respiratory, thoracic and mediastinal disorders"
NCT00974493,,2009-09-04,2020-02-24,,2020-06-03,2009-09-09,2009-09-10,ESTIMATED,2020-06-03,2020-06-05,ACTUAL,,,,2020-06-03,2020-06-05,ACTUAL,2010-06,,2010-06-30,2020-06,2020-06-30,2017-02-28,ACTUAL,2017-02-28,2013-03,ACTUAL,2013-03-31,,INTERVENTIONAL,OVIVA,,Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J),Randomized Open Label Study of Oral Versus Intravenous Antibiotic Treatment for Bone and Joint Infections Requiring Prolonged Antibiotic Treatment: Multi-centre Study,COMPLETED,,PHASE4,1054,ACTUAL,Oxford University Hospitals NHS Trust,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:15:50,2024-10-14 07:15:50,OTHER,,,,,,,Oxford University Hospitals NHS Trust,United Kingdom,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00974493,,2009-09-04,2020-02-24,,2020-06-03,2009-09-09,2009-09-10,ESTIMATED,2020-06-03,2020-06-05,ACTUAL,,,,2020-06-03,2020-06-05,ACTUAL,2010-06,,2010-06-30,2020-06,2020-06-30,2017-02-28,ACTUAL,2017-02-28,2013-03,ACTUAL,2013-03-31,,INTERVENTIONAL,OVIVA,,Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J),Randomized Open Label Study of Oral Versus Intravenous Antibiotic Treatment for Bone and Joint Infections Requiring Prolonged Antibiotic Treatment: Multi-centre Study,COMPLETED,,PHASE4,1054,ACTUAL,Oxford University Hospitals NHS Trust,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:15:50,2024-10-14 07:15:50,OTHER,,,,,,,Oxford University Hospitals NHS Trust,United Kingdom,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00975780,,2009-09-10,2013-12-06,,2014-11-07,2009-09-10,2009-09-11,ESTIMATED,2013-12-06,2014-01-21,ESTIMATED,,,,2014-11-07,2014-11-20,ESTIMATED,2009-10,,2009-10-31,2014-11,2014-11-30,2012-12,ACTUAL,2012-12-31,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,PRIDE,,A Trial to Reduce Pneumonia in Nursing Home Residents,A Randomized Controlled Trial to Reduce Pneumonia in Nursing Home Residents,COMPLETED,,PHASE3,834,ACTUAL,Yale University,"Participant flow and outcome information pertains to data collected through 10/25/2012- the official trial termination date.

Serious and Other Adverse Event information pertains to requested surveillance of subjects through 12/10/2012 per the NIA.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 00:03:31,2024-10-13 00:03:31,OTHER,,,,,,,National Institute on Aging (NIA)|Yale University,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00976404,,2009-09-09,2014-09-04,,2014-09-10,2009-09-11,2009-09-14,ESTIMATED,2014-09-10,2014-09-12,ESTIMATED,,,,2014-09-10,2014-09-12,ESTIMATED,2009-11,,2009-11-30,2014-09,2014-09-30,2014-06,ACTUAL,2014-06-30,2013-07,ACTUAL,2013-07-31,,INTERVENTIONAL,EraMune02,,Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir,"Multicenter, Randomized, Non-comparative, Controlled Study of Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients With Long-term Viral Suppression",COMPLETED,,PHASE2,28,ACTUAL,Northwestern University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 00:15:55,2024-10-13 00:15:55,OTHER,,,,,,,Merck Sharp & Dohme LLC|National Institute of Allergy and Infectious Diseases (NIAID)|Objectif Recherche Vaccins SIDA|Pfizer|Robert L. Murphy,United States,Cardiac disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Vascular disorders
NCT00976950,,2009-09-14,2012-05-30,,2014-02-24,2009-09-14,2009-09-15,ESTIMATED,2012-07-09,2012-08-16,ESTIMATED,,,,2014-02-24,2014-03-20,ESTIMATED,2009-09,,2009-09-30,2014-02,2014-02-28,2011-07,ACTUAL,2011-07-31,2011-07,ACTUAL,2011-07-31,,OBSERVATIONAL,,,A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.,A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.,COMPLETED,,,42,ACTUAL,Boehringer Ingelheim,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 00:25:50,2024-10-14 00:25:50,INDUSTRY,,,,,,,Boehringer Ingelheim,Romania,Infections and infestations
NCT00976963,,2009-09-11,2023-04-01,,2023-06-02,2009-09-14,2009-09-15,ESTIMATED,2023-06-02,2023-06-05,ACTUAL,,,,2023-06-02,2023-06-05,ACTUAL,2009-09-17,ACTUAL,2009-09-17,2023-06,2023-06-30,2016-12-27,ACTUAL,2016-12-27,2016-12-27,ACTUAL,2016-12-27,,INTERVENTIONAL,,"Participants who were dispensed the treatment intervention, completed some or all of the treatment intervention and were included in the summary of side effects.",Single Dose Monurol for Treatment of Acute Cystitis,Single Dose Monurol for Treatment of Acute Cystitis,COMPLETED,,NA,300,ACTUAL,University of Washington,The clinicians and participants were not blinded as to the assigned intervention.,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 02:27:29,2024-10-14 02:27:29,OTHER,,,,,,,University of Washington,United States,Gastrointestinal disorders|General disorders
NCT00978068,,2009-09-14,2015-11-18,,2018-12-05,2009-09-15,2009-09-16,ESTIMATED,2018-12-05,2018-12-28,ACTUAL,,,,2018-12-05,2018-12-28,ACTUAL,2009-09,,2009-09-30,2018-12,2018-12-31,2013-01,ACTUAL,2013-01-31,2013-01,ACTUAL,2013-01-31,,INTERVENTIONAL,PROMOTE-PEDS,,HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children,A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children,COMPLETED,,PHASE3,176,ACTUAL,"University of California, San Francisco","The study has limited statistical power for the comparison of uncommon events and limited evaluation of potential cardiotoxic effects, hence future studies of the safety of coadministration of lopinavir-ritonavir and lumefantrine are warranted.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:25:53,2024-10-13 06:25:53,OTHER,,,,,,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, San Francisco",Uganda,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|Hepatobiliary disorders|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00979420,,2009-09-16,2012-05-30,,2014-06-27,2009-09-17,2009-09-18,ESTIMATED,2012-07-10,2012-08-16,ESTIMATED,,,,2014-06-27,2014-06-30,ESTIMATED,2009-08,,2009-08-31,2014-06,2014-06-30,,,,2010-11,ACTUAL,2010-11-30,,OBSERVATIONAL,,Treated set - all patients receiving at least one dose of study medication,Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune,Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune,COMPLETED,,,,,Boehringer Ingelheim,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 16:45:10,2024-10-14 16:45:10,INDUSTRY,,,,,,,Boehringer Ingelheim,Germany,"Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT00980148,,2009-09-17,2015-03-05,,2015-03-05,2009-09-17,2009-09-18,ESTIMATED,2015-03-05,2015-03-18,ESTIMATED,,,,2015-03-05,2015-03-18,ESTIMATED,2009-12,,2009-12-31,2014-06,2014-06-30,2014-05,ACTUAL,2014-05-31,2014-05,ACTUAL,2014-05-31,,INTERVENTIONAL,,The per protocol population is comprised of participants who completed therapy and whose failure status could be established at the day 28 visit. Participants were considered to have completed therapy if they took a single dose of azithromycin or at least 10 of the 14 doses of doxycycline.,Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities,Randomized Clinical Trial Evaluating Treatment Failure Following Recommended Therapy (Azithromycin Versus Doxycycline) for Genital Chlamydial Infection in Males and Females in Youth Correctional Facilities,COMPLETED,,PHASE3,567,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),The analysis of the secondary endpoint Demographical Characteristics and Clinical Parameters to Predict Treatment Outcome was limited by the small number of events and is not presented.,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 22:26:35,2024-10-14 22:26:35,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Gastrointestinal disorders
NCT00980538,,2009-09-18,2021-11-24,,2024-10-08,2009-09-18,2009-09-21,ESTIMATED,2021-11-24,2021-12-21,ACTUAL,,,,2024-10-08,2024-10-10,ESTIMATED,2009-12,ACTUAL,2009-12-31,2024-10,2024-10-31,2032-01,ESTIMATED,2032-01-31,2020-11,ACTUAL,2020-11-30,,INTERVENTIONAL,,,TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants,Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Subjects,ACTIVE_NOT_RECRUITING,,PHASE3,180,ACTUAL,Janssen Sciences Ireland UC,,1,,,FALSE,,,,FALSE,,FALSE,,,,,,,,,,,2024-10-15 04:00:26,2024-10-15 04:00:26,INDUSTRY,,,,,,,Janssen Sciences Ireland UC,Argentina|Brazil|Canada|France|Guatemala|Italy|Panama|Portugal|Puerto Rico|Romania|South Africa|Spain|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00981669,,2009-09-17,2013-02-04,,2013-03-15,2009-09-21,2009-09-22,ESTIMATED,2013-03-15,2013-04-25,ESTIMATED,,,,2013-03-15,2013-04-25,ESTIMATED,2009-03,,2009-03-31,2013-03,2013-03-31,2010-06,ACTUAL,2010-06-30,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,In the vaccine gorup one volunteer was not considered for the final analysis because He received the second dose of the vaccine in an anapropriate interval.,Rotavirus Vaccine Produced by Butantan Institute,"Evaluation of Rotavirus Vaccine Produced by Butantan Institute. Phase I - Safety, Tolerability and Immunogenicity Evaluation",COMPLETED,,PHASE1,80,ACTUAL,Butantan Institute,"The vaccine candidate needs to be evaluated further in larger trials, among the target population.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 15:23:18,2024-10-14 15:23:18,OTHER_GOV,,,,,,,Butantan Institute,Brazil,Gastrointestinal disorders|General disorders|Nervous system disorders
NCT00983853,,2009-09-22,2013-08-02,,2013-08-02,2009-09-23,2009-09-24,ESTIMATED,2013-08-02,2013-10-10,ESTIMATED,,,,2013-08-02,2013-10-10,ESTIMATED,2009-10,,2009-10-31,2013-08,2013-08-31,,,,2012-03,ACTUAL,2012-03-31,,INTERVENTIONAL,,All randomized subjects who received at least 1 dose of study drug,Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV,"A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naïve for Hepatitis C",COMPLETED,,PHASE2,62,ACTUAL,Vertex Pharmaceuticals Incorporated,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 16:56:00,2024-10-13 16:56:00,INDUSTRY,,,,,,,Tibotec Pharmaceutical Limited|Vertex Pharmaceuticals Incorporated,France|Germany|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00985465,,2009-09-24,2017-01-05,2012-11-16,2018-07-30,2009-09-24,2009-09-28,ESTIMATED,2018-07-30,2018-12-14,ACTUAL,2012-11-16,2012-11-21,ESTIMATED,2018-07-30,2018-12-14,ACTUAL,2009-11-12,ACTUAL,2009-11-12,2018-07,2018-07-31,2010-07-26,ACTUAL,2010-07-26,2010-06-26,ACTUAL,2010-06-26,,INTERVENTIONAL,,,Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali,"Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Malian Children",COMPLETED,,PHASE3,218,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-15 02:53:42,2024-10-15 02:53:42,INDUSTRY,,,,,,,GlaxoSmithKline,Mali,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT00985751,,2009-09-24,2017-05-11,2011-04-01,2020-10-15,2009-09-24,2009-09-28,ESTIMATED,2017-05-11,2017-10-06,ACTUAL,2011-04-01,2011-04-11,ESTIMATED,2020-10-15,2020-11-05,ACTUAL,2009-11-24,ACTUAL,2009-11-24,2020-10,2020-10-31,2011-03-02,ACTUAL,2011-03-02,2010-10-12,ACTUAL,2010-10-12,,INTERVENTIONAL,,,Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination,"Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen in Children Aged 12-23 Months at the Time of First Vaccination.",COMPLETED,,PHASE2,257,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=4501,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 09:46:07,2024-10-14 09:46:07,INDUSTRY,,,,,,,GlaxoSmithKline,Czechia|Czech Republic,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00986102,,2009-09-25,2013-01-04,,2013-01-04,2009-09-28,2009-09-29,ESTIMATED,2013-01-04,2013-02-07,ESTIMATED,,,,2013-01-04,2013-02-07,ESTIMATED,2009-07,,2009-07-31,2013-01,2013-01-31,2011-09,ACTUAL,2011-09-30,2011-09,ACTUAL,2011-09-30,,INTERVENTIONAL,,,PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region,A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region,COMPLETED,,PHASE4,216,ACTUAL,Johnson & Johnson Pte Ltd,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 11:25:16,2024-10-13 11:25:16,INDUSTRY,,,,,,,Johnson & Johnson (Hong Kong) Ltd.|Johnson & Johnson Pte Ltd,Hong Kong|Indonesia|Malaysia|Singapore|Vietnam,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00987948,,2009-09-29,2015-01-20,,2017-02-01,2009-09-30,2009-10-01,ESTIMATED,2017-02-01,2017-03-22,ACTUAL,,,,2017-02-01,2017-03-22,ACTUAL,2010-01,,2010-01-31,2017-02,2017-02-28,2013-08,ACTUAL,2013-08-31,2012-11,ACTUAL,2012-11-30,,INTERVENTIONAL,,,Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels,Pilot Study of the Effect of Maraviroc Intensification on Peripheral Blood Monocyte HIV DNA Levels When Given to HIV-Infected Subjects Stable on Highly Active Antiretroviral Therapy With Undetectable Plasma HIV RNA,COMPLETED,,PHASE2,15,ACTUAL,University of Hawaii,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 08:36:00,2024-10-14 08:36:00,OTHER,,,,,,,Pfizer|University of Hawaii,United States,Endocrine disorders
NCT00988884,,2009-10-01,2014-12-12,,2018-11-26,2009-10-01,2009-10-02,ESTIMATED,2015-01-12,2015-01-13,ESTIMATED,,,,2018-11-26,2018-12-14,ACTUAL,2009-10-21,ACTUAL,2009-10-21,2018-11,2018-11-30,2011-02-22,ACTUAL,2011-02-22,2011-02-22,ACTUAL,2011-02-22,,INTERVENTIONAL,,,A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005),A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) Given Concomitantly With Menactra™ and Adacel™ in Preadolescents and Adolescents (11 to 15 Year Olds),COMPLETED,,PHASE3,1241,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 02:36:26,2024-10-15 02:36:26,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Chile|Colombia|Mexico|Peru|Puerto Rico|United States,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT00991289,,2009-10-07,2011-08-29,,2021-11-02,2009-10-07,2009-10-08,ESTIMATED,2011-08-29,2011-09-27,ESTIMATED,,,,2021-11-02,2021-11-04,ACTUAL,2010-01,,2010-01-31,2019-01,2019-01-31,2012-01,ACTUAL,2012-01-31,2010-11,ACTUAL,2010-11-30,,INTERVENTIONAL,,,Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects,The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection,COMPLETED,,PHASE2,68,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:58:40,2024-10-14 17:58:40,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00991289,,2009-10-07,2011-08-29,,2021-11-02,2009-10-07,2009-10-08,ESTIMATED,2011-08-29,2011-09-27,ESTIMATED,,,,2021-11-02,2021-11-04,ACTUAL,2010-01,,2010-01-31,2019-01,2019-01-31,2012-01,ACTUAL,2012-01-31,2010-11,ACTUAL,2010-11-30,,INTERVENTIONAL,,,Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects,The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection,COMPLETED,,PHASE2,68,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:58:40,2024-10-14 17:58:40,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00991302,,2009-10-07,2015-07-29,,2018-02-21,2009-10-07,2009-10-08,ESTIMATED,2015-07-30,2015-08-26,ESTIMATED,,,,2018-02-21,2018-03-20,ACTUAL,2010-01,,2010-01-31,2018-02,2018-02-28,2015-01,ACTUAL,2015-01-31,2015-01,ACTUAL,2015-01-31,,INTERVENTIONAL,DASH,Intention to treat: All eligible participants were included in the baseline characteristics.,Durability of Adherence in Self-Management of HIV,Durability of Adherence in Self-Management of HIV,COMPLETED,,NA,172,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:25:54,2024-10-13 07:25:54,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),India|Peru|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders"
NCT00992017,,2009-10-07,2011-11-07,,2021-11-03,2009-10-07,2009-10-08,ESTIMATED,2012-02-09,2012-03-13,ESTIMATED,,,,2021-11-03,2021-11-05,ACTUAL,2009-10,,2009-10-31,2014-12,2014-12-31,2010-11,ACTUAL,2010-11-30,2010-11,ACTUAL,2010-11-30,,INTERVENTIONAL,,,Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women,A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Monovalent Influenza A (H1N1) Vaccine in HIV-1 Infected Pregnant Women,COMPLETED,,PHASE2,130,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:47:01,2024-10-14 17:47:01,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT00992836,,2009-10-08,2011-08-23,,2021-11-03,2009-10-08,2009-10-09,ESTIMATED,2012-01-05,2012-02-09,ESTIMATED,,,,2021-11-03,2021-11-05,ACTUAL,2009-10,,2009-10-31,2014-12,2014-12-31,2010-08,ACTUAL,2010-08-31,2010-08,ACTUAL,2010-08-31,,INTERVENTIONAL,,,Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth,A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Perinatally Infected Children and Youth,COMPLETED,,PHASE2,155,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 20:04:52,2024-10-14 20:04:52,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT00993031,,2009-10-08,2015-01-05,,2019-04-19,2009-10-08,2009-10-09,ESTIMATED,2017-10-25,2017-12-02,ACTUAL,,,,2019-04-19,2019-05-14,ACTUAL,2009-12-15,ACTUAL,2009-12-15,2019-04,2019-04-30,2013-07,ACTUAL,2013-07-31,2013-07,ACTUAL,2013-07-31,,INTERVENTIONAL,PROMOTE-PIs,,Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women,Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women,COMPLETED,,PHASE3,389,ACTUAL,"University of California, San Francisco","A semi-immune population of adults at relatively low risk for malaria; a high rate of TMP-SMX prophylaxis ; A lower than expected incidence of malaria, resulting in the possibility that the study was underpowered",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 21:10:53,2024-10-13 21:10:53,OTHER,,,,,,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, San Francisco",Uganda,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT00996125,,2009-10-15,2012-05-24,,2018-06-28,2009-10-15,2009-10-16,ESTIMATED,2012-05-24,2012-06-27,ESTIMATED,,,,2018-06-28,2018-08-17,ACTUAL,2009-10-24,,2009-10-24,2016-09,2016-09-30,2010-12-08,ACTUAL,2010-12-08,2010-12-08,ACTUAL,2010-12-08,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects,Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) 580299 Vaccine in Healthy Chinese Female Subjects,COMPLETED,,PHASE3,750,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 15:17:16,2024-10-14 15:17:16,INDUSTRY,,,,,,,GlaxoSmithKline,China,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Reproductive system and breast disorders"
NCT00996736,,2009-10-14,2013-07-26,,2018-07-06,2009-10-15,2009-10-16,ESTIMATED,2013-10-18,2013-12-11,ESTIMATED,,,,2018-07-06,2018-08-01,ACTUAL,2010-04,,2010-04-30,2018-07,2018-07-31,2012-07,ACTUAL,2012-07-31,2012-07,ACTUAL,2012-07-31,,INTERVENTIONAL,MUTT I,,Mycotic Ulcer Treatment Trial I,Mycotic Ulcer Treatment Trial,COMPLETED,,PHASE3,323,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:44:30,2024-10-14 07:44:30,OTHER,,,,,,,"Aravind Eye Hospitals, India|Dartmouth-Hitchcock Medical Center|National Eye Institute (NEI)|University of California, San Francisco",India|United States,Cardiac disorders|Eye disorders
NCT00997035,,2009-10-14,2016-06-09,,2019-02-04,2009-10-15,2009-10-16,ESTIMATED,2017-05-17,2017-06-14,ACTUAL,,,,2019-02-04,2019-02-26,ACTUAL,2010-05,,2010-05-31,2019-02,2019-02-28,2016-03,ACTUAL,2016-03-31,2016-01,ACTUAL,2016-01-31,,INTERVENTIONAL,MUTTII,,The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo,The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo,COMPLETED,,PHASE3,240,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,,2024-10-15 03:18:24,2024-10-15 03:18:24,OTHER,,,,,,,"Aravind Eye Hospitals, India|Bharatpur Eye Hospital|Dartmouth-Hitchcock Medical Center|Lumbini Eye Institute and Hospital|National Eye Institute (NEI)|University of California, San Francisco",India|Nepal|United States,Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Psychiatric disorders
NCT01006629,,2009-11-02,2011-04-29,,2011-06-21,2009-11-02,2009-11-03,ESTIMATED,2011-06-21,2011-07-19,ESTIMATED,,,,2011-06-21,2011-07-19,ESTIMATED,2009-11,,2009-11-30,2011-06,2011-06-30,2010-07,ACTUAL,2010-07-31,2010-04,ACTUAL,2010-04-30,,INTERVENTIONAL,,,Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children,"A Prospective, Multicenter, Open-label, Non-comparative Study of Safety and Efficacy of Synagis in Children at High Risk of Severe Respiratory Syncytial Virus Infection in the Russian Federation",COMPLETED,,PHASE2/PHASE3,100,ACTUAL,Abbott,"This study had no control group; relative comparisons are only possible with current product information for palivizumab. No RSV hospitalizations occurred during the study; therefore, secondary outcome measures could not be evaluated.",1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 19:41:41,2024-10-14 19:41:41,INDUSTRY,,,,,,,Abbott,Russian Federation,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01009619,,2009-11-06,2011-04-21,,2011-08-29,2009-11-06,2009-11-09,ESTIMATED,2011-07-27,2011-08-25,ESTIMATED,,,,2011-08-29,2011-10-03,ESTIMATED,2005-09,,2005-09-30,2011-08,2011-08-31,2009-12,ACTUAL,2009-12-31,2009-12,ACTUAL,2009-12-31,,INTERVENTIONAL,AZI001,,Azithromycin in Bronchiolitis Obliterans Syndrome,Randomized Double-blind Placebo-controlled Prevention Trial of Azithromycin in Lung Transplantation.,COMPLETED,,PHASE4,83,ACTUAL,KU Leuven,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:43:25,2024-10-13 00:43:25,OTHER,,,,,,,"Fund for Scientific Research, Flanders, Belgium|KU Leuven|University Hospital, Gasthuisberg",Belgium,Gastrointestinal disorders
NCT01009814,,2009-11-06,2019-12-13,,2019-12-13,2009-11-06,2009-11-09,ESTIMATED,2019-12-13,2020-01-03,ACTUAL,,,,2019-12-13,2020-01-03,ACTUAL,2009-11-23,ACTUAL,2009-11-23,2019-10,2019-10-31,2010-06-25,ACTUAL,2010-06-25,2010-06-25,ACTUAL,2010-06-25,,INTERVENTIONAL,,,"Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1","Randomized, Open Label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects",COMPLETED,,PHASE2,50,ACTUAL,ViiV Healthcare,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 13:55:50,2024-10-14 13:55:50,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Germany|Poland,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01010399,,2009-11-09,2012-03-26,,2012-03-26,2009-11-09,2009-11-10,ESTIMATED,2012-03-26,2012-04-18,ESTIMATED,,,,2012-03-26,2012-04-18,ESTIMATED,2009-09,,2009-09-30,2012-03,2012-03-31,2010-11,ACTUAL,2010-11-30,2010-11,ACTUAL,2010-11-30,,INTERVENTIONAL,BuLLET,,"Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects","A Pilot, Open-Label Study of Adjunctive Therapy With Lovaza® in Hypertriglyceridemic, HIV-Infected Subjects Who Switched Protease Inhibitor to Once-Daily Lexiva® 1400mg Plus Norvir® 100mg Plus Optimized Background",COMPLETED,,PHASE4,36,ACTUAL,"Felizarta, Franco, M.D.",,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 17:03:12,2024-10-14 17:03:12,INDIV,,,,,,,"Felizarta, Franco, M.D.|GlaxoSmithKline",United States,Gastrointestinal disorders|Infections and infestations|Metabolism and nutrition disorders
NCT01011413,,2009-11-09,2018-02-22,,2020-02-18,2009-11-10,2009-11-11,ESTIMATED,2020-02-18,2020-02-21,ACTUAL,,,,2020-02-18,2020-02-21,ACTUAL,2011-08,,2011-08-31,2020-02,2020-02-29,2014-08,ACTUAL,2014-08-31,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,ENCORE1,,Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.,"A Randomised, Double-blind, Placebo-controlled, Trial to Compare the Safety and Efficacy of Reduced Dose Versus Standard Dose EFV Plus Two Nucleotides (N(t)RTI) in Antiretroviral-naïve HIV-infected Adults Over 96 Weeks",COMPLETED,,PHASE3,636,ACTUAL,Kirby Institute,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 09:51:40,2024-10-14 09:51:40,OTHER_GOV,,,,,,,Kirby Institute,Australia,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01016912,,2009-11-19,2015-08-17,,2015-09-23,2009-11-19,2009-11-20,ESTIMATED,2015-09-23,2015-10-12,ESTIMATED,,,,2015-09-23,2015-10-12,ESTIMATED,2009-12,,2009-12-31,2015-09,2015-09-30,2010-09,ACTUAL,2010-09-30,2010-09,ACTUAL,2010-09-30,,INTERVENTIONAL,,All treated participants who received at least 1 dose of study therapy.,Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients,A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron®) and Ribavirin (Rebetol®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection,COMPLETED,,PHASE2,51,ACTUAL,Bristol-Myers Squibb,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 03:45:16,2024-10-14 03:45:16,INDUSTRY,,,,,,,Bristol-Myers Squibb,Japan,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01017536,,2009-11-18,2014-10-08,,2016-07-25,2009-11-18,2009-11-20,ESTIMATED,2014-10-08,2014-10-13,ESTIMATED,,,,2016-07-25,2016-09-09,ESTIMATED,2009-12,,2009-12-31,2016-07,2016-07-31,2012-05,ACTUAL,2012-05-31,2012-03,ACTUAL,2012-03-31,,INTERVENTIONAL,,,"Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults","Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of AERAS-402 in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3",COMPLETED,,PHASE2,26,ACTUAL,Aeras,,2,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,,2024-10-14 14:21:02,2024-10-14 14:21:02,OTHER,,,,,,,Aeras|Crucell Holland BV,South Africa,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01017575,,2009-11-19,2015-08-13,,2015-08-13,2009-11-19,2009-11-20,ESTIMATED,2015-08-13,2015-09-11,ESTIMATED,,,,2015-08-13,2015-09-11,ESTIMATED,2009-12,,2009-12-31,2015-08,2015-08-31,2011-10,ACTUAL,2011-10-31,2011-10,ACTUAL,2011-10-31,,INTERVENTIONAL,,All treated participants who received at least 1 dose of study therapy.,Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin),A Phase 2a Study of Daclatasvir in Combination With Peginterferon Alfa-2a(Pegasys®) and Ribavirin (Copegus®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection,COMPLETED,,PHASE2,55,ACTUAL,Bristol-Myers Squibb,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 01:57:29,2024-10-13 01:57:29,INDUSTRY,,,,,,,Bristol-Myers Squibb,Japan,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01027845,,2009-12-07,2017-08-31,2012-07-24,2019-11-08,2009-12-07,2009-12-09,ESTIMATED,2019-11-08,2019-11-29,ACTUAL,2012-07-24,2012-08-01,ESTIMATED,2019-11-08,2019-11-29,ACTUAL,2009-12-08,ACTUAL,2009-12-08,2019-11,2019-11-30,2011-09-17,ACTUAL,2011-09-17,2010-08-13,ACTUAL,2010-08-13,,INTERVENTIONAL,,,Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children,"Immunogenicity, Safety and Reactogenicity of GlaxoSmithKline Biologicals' Pneumococcal Vaccine GSK1024850A Following Primary and Booster Vaccination of Healthy Japanese Children",COMPLETED,,PHASE3,360,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=2812,YES,IPD for this study is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 20:10:53,2024-10-14 20:10:53,INDUSTRY,,,,,,,GlaxoSmithKline,Japan,"Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01030822,,2009-12-10,2017-01-09,2012-07-24,2018-08-21,2009-12-10,2009-12-14,ESTIMATED,2017-01-09,2017-02-28,ACTUAL,2012-07-24,2012-08-01,ESTIMATED,2018-08-21,2018-09-20,ACTUAL,2010-04-02,,2010-04-02,2017-01,2017-01-31,2011-08-19,ACTUAL,2011-08-19,2011-08-19,ACTUAL,2011-08-19,,INTERVENTIONAL,,,Booster and Catch-up Vaccination With Vaccine GSK1024850A,Booster Vaccination With Pneumococcal Vaccine GSK1024850A in Primed Children and Catch-up Vaccination in Unprimed Children,COMPLETED,,PHASE3,282,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 22:32:11,2024-10-14 22:32:11,INDUSTRY,,,,,,,GlaxoSmithKline,India,General disorders|Infections and infestations|Nervous system disorders
NCT01031069,,2009-12-10,2017-01-13,,2020-07-13,2009-12-10,2009-12-14,ESTIMATED,2019-05-20,2019-07-24,ACTUAL,,,,2020-07-13,2020-07-21,ACTUAL,2010-10-26,ACTUAL,2010-10-26,2020-07,2020-07-31,2017-04-19,ACTUAL,2017-04-19,2016-01-13,ACTUAL,2016-01-13,,INTERVENTIONAL,,,Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females,Safety and Immunogenicity of Cervarix™ in Human Immunodeficiency Virus Infected Females,COMPLETED,,PHASE4,873,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,FALSE,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20391,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 05:22:56,2024-10-13 05:22:56,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil|Estonia|India|Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01041521,,2009-12-30,2017-03-03,,2020-02-10,2009-12-30,2009-12-31,ESTIMATED,2020-02-10,2020-02-11,ACTUAL,,,,2020-02-10,2020-02-11,ACTUAL,2010-01,,2010-01-31,2020-02,2020-02-29,2015-08,ACTUAL,2015-08-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,HOST,,The Impact of Omega Three Fatty Acids on Vascular Function in HIV,The Impact of Omega Three Fatty Acids on Vascular Function in HIV,COMPLETED,,PHASE4,129,ACTUAL,Tufts University,"PLEASE NOTE THAT THE PRINCIPLE INVESTIGATOR (CHRISTINE WANKE) HAS LEFT TUFTS UNIVERSITY IN RETIREMENT AND CANNOT BE CONTACTED. PLEASE ALSO NOTE THAT THIS IS NOT AN ""APPLICABLE CLINICAL TRIAL"". - 9/3/19",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:37:17,2024-10-15 01:37:17,OTHER,,,,,,,"National Heart, Lung, and Blood Institute (NHLBI)|Tufts University",United States,"Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01043705,,2010-01-05,2015-10-13,,2015-11-20,2010-01-06,2010-01-07,ESTIMATED,2015-11-20,2015-12-24,ESTIMATED,,,,2015-11-20,2015-12-24,ESTIMATED,2010-01,,2010-01-31,2015-10,2015-10-31,2015-05,ACTUAL,2015-05-31,2014-07,ACTUAL,2014-07-31,,OBSERVATIONAL,Centurion,Prospective Population: ICD and CRT replacement implant patients receiving a TYRX Envelope Retrospective Population: CRT Patients receiving a CRT and no TYRX envelope. Patients are site medical charts from just previous to use of TYRX Evelope,TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD,Centurion and Citadel Studies of TYRX™ Anti-Bacterial Envelope and Custom Mesh for Prevention of Infection Following CIED Replacement With a CRT or ICD,COMPLETED,,,1262,ACTUAL,"TYRX, Inc.",This was a non-randomized study and did not have an active comparator.,,5,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 16:57:09,2024-10-14 16:57:09,INDUSTRY,,,,,,,"TYRX, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01048671,,2010-01-12,2013-12-23,,2015-10-29,2010-01-13,2010-01-14,ESTIMATED,2013-12-23,2014-02-14,ESTIMATED,,,,2015-10-29,2015-10-30,ESTIMATED,2010-01,,2010-01-31,2015-10,2015-10-31,2012-12,ACTUAL,2012-12-31,2012-12,ACTUAL,2012-12-31,,OBSERVATIONAL,RACING,,Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138),Collection of Data on the Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including the HIV Integrase Inhibitor Raltegravir,COMPLETED,,,482,ACTUAL,Merck Sharp & Dohme LLC,,,1,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:13:13,2024-10-13 18:13:13,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Korea, Republic of","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01049035,,2010-01-13,2020-05-19,2013-04-16,2022-03-21,2010-01-13,2010-01-14,ESTIMATED,2020-05-19,2020-06-09,ACTUAL,2013-04-16,2013-04-25,ESTIMATED,2022-03-21,2022-03-28,ACTUAL,2009-12-16,ACTUAL,2009-12-16,2022-03,2022-03-31,2012-02-13,ACTUAL,2012-02-13,2012-02-13,ACTUAL,2012-02-13,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers,Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Infants and Toddlers,COMPLETED,,PHASE2,580,ACTUAL,Sanofi,,7,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-13 20:58:47,2024-10-13 20:58:47,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01052545,,2010-01-15,2014-10-20,,2019-02-21,2010-01-15,2010-01-20,ESTIMATED,2014-10-29,2014-11-06,ESTIMATED,,,,2019-02-21,2019-02-25,ACTUAL,2011-07,,2011-07-31,2019-02,2019-02-28,2013-06,ACTUAL,2013-06-30,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,ABU,,Asymptomatic Bacteriuria Guideline Implementation Study,Guideline Implementation to Decrease Inappropriate Bacteriuria Treatment,COMPLETED,,NA,1598,ACTUAL,VA Office of Research and Development,"Modification may be necessary for private sector facilities. We do not know what aspect of our intervention had the biggest impact, and whether the entire bundle is necessary.",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 06:25:53,2024-10-13 06:25:53,FED,,,,,,,VA Office of Research and Development,United States,Renal and urinary disorders
NCT01058239,,2010-01-26,2017-11-03,,2018-01-18,2010-01-27,2010-01-28,ESTIMATED,2018-01-18,2018-02-15,ACTUAL,,,,2018-01-18,2018-02-15,ACTUAL,2011-11,ACTUAL,2011-11-30,2018-01,2018-01-31,2017-11,ACTUAL,2017-11-30,2016-12,ACTUAL,2016-12-31,,INTERVENTIONAL,,,Bortezomib Plus Rituximab for EBV+ PTLD,Bortezomib Plus Rituximab for EBV + Post Transplant Lymphoproliferative Disease (PTLD),COMPLETED,,PHASE2,7,ACTUAL,Massachusetts General Hospital,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:32:11,2024-10-14 22:32:11,OTHER,,,,,,,"Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Massachusetts General Hospital|Millennium Pharmaceuticals, Inc.",United States,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders
NCT01059565,,2010-01-28,2013-03-08,,2014-02-07,2010-01-29,2010-02-01,ESTIMATED,2014-02-07,2014-03-11,ESTIMATED,,,,2014-02-07,2014-03-11,ESTIMATED,2010-02,,2010-02-28,2014-02,2014-02-28,2012-01,ACTUAL,2012-01-31,2011-09,ACTUAL,2011-09-30,,INTERVENTIONAL,,Full Analysis Set: participants were randomized and received at least one dose of study drug.,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection,"Phase 3b Randomized, Double-Blind, Placebo-Controlled Two-Part Trial to Assess the Safety and Efficacy of Continuous Aztreonam for Inhalation Solution (AZLI) in Subjects With Cystic Fibrosis (CF) and Chronic Burkholderia Species Infection",COMPLETED,,PHASE3,102,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:03:39,2024-10-13 09:03:39,INDUSTRY,,,,,,,Gilead Sciences,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01061151,,2010-02-01,2017-09-28,,2022-02-09,2010-02-01,2010-02-02,ESTIMATED,2018-01-12,2018-02-09,ACTUAL,,,,2022-02-09,2022-02-11,ACTUAL,2011-03-01,ACTUAL,2011-03-01,2022-02,2022-02-28,2016-09-30,ACTUAL,2016-09-30,2016-09-30,ACTUAL,2016-09-30,,INTERVENTIONAL,PROMISE,All women in 1077BF/1077FF except those considered ineligible for the analysis after team review.,Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries,Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere),COMPLETED,,PHASE3,3747,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,8,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 12:52:45,2024-10-13 12:52:45,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),India|Malawi|South Africa|Tanzania|Uganda|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01062074,,2010-02-02,2014-02-07,,2017-03-20,2010-02-02,2010-02-04,ESTIMATED,2014-02-07,2014-03-27,ESTIMATED,,,,2017-03-20,2017-04-17,ACTUAL,2007-09-28,ACTUAL,2007-09-28,2017-03,2017-03-31,2013-05-07,ACTUAL,2013-05-07,2013-05-07,ACTUAL,2013-05-07,,OBSERVATIONAL,,,GARDASIL Reexamination Study (V501-059),Re-examination Study for General Vaccine Use to Assess the Safety Profile of GARDASIL in Usual Practice,COMPLETED,,,3605,ACTUAL,Merck Sharp & Dohme LLC,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:25:50,2024-10-14 00:25:50,INDUSTRY,,,,,,FALSE,Merck Sharp & Dohme LLC,"Korea, Republic of",General disorders
NCT01062165,,2010-02-02,2012-12-13,,2016-12-21,2010-02-03,2010-02-04,ESTIMATED,2012-12-13,2013-01-21,ESTIMATED,,,,2016-12-21,2017-02-10,ACTUAL,2010-02,,2010-02-28,2016-12,2016-12-31,2010-12,ACTUAL,2010-12-31,2010-12,ACTUAL,2010-12-31,,INTERVENTIONAL,,,Effect of Weight and/or Obesity on Caspofungin Drug Concentrations,Population Pharmacokinetic Analysis of Caspofungin in Overweight and Obese Volunteers,COMPLETED,,PHASE4,18,ACTUAL,Texas Tech University Health Sciences Center,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 14:44:18,2024-10-13 14:44:18,OTHER,,,,,,,National Center for Research Resources (NCRR)|Texas Tech University Health Sciences Center|University of Texas Southwestern Medical Center,United States,General disorders
NCT01062256,,2010-02-01,2011-02-09,,2013-02-20,2010-02-02,2010-02-04,ESTIMATED,2011-02-09,2011-03-04,ESTIMATED,,,,2013-02-20,2013-02-25,ESTIMATED,2010-01,,2010-01-31,2013-02,2013-02-28,2010-02,ACTUAL,2010-02-28,2010-02,ACTUAL,2010-02-28,,INTERVENTIONAL,,,Study of Count Coughs in Subjects With Acute Upper Respiratory Tract Infections,A Methodology Study to Assess Cough Counts in Subjects With Acute Upper Respiratory Tract Infections,COMPLETED,,NA,265,ACTUAL,Wyeth is now a wholly owned subsidiary of Pfizer,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 08:10:50,2024-10-14 08:10:50,INDUSTRY,,,,,,,Wyeth is now a wholly owned subsidiary of Pfizer,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01069315,,2010-02-16,2017-09-14,,2019-03-15,2010-02-16,2010-02-17,ESTIMATED,2019-03-15,2019-03-18,ACTUAL,,,,2019-03-15,2019-03-18,ACTUAL,2006-07,,2006-07-31,2019-03,2019-03-31,2008-06,ACTUAL,2008-06-30,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,FLOW,,Fluid Lavage of Open Wounds (FLOW): Pilot Trial,"Fluid Lavage of Open Wounds (FLOW): A Multi-Center, Blinded, Factorial Pilot Trial Comparing Alternative Irrigating Solutions and Pressures in Patients With Open Fractures",COMPLETED,,NA,111,ACTUAL,McMaster University,,4,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 16:45:10,2024-10-14 16:45:10,OTHER,,,,,,,McMaster University|Orthopaedic Trauma Association|The Physicians' Services Incorporated Foundation,Canada|India|United States,Surgical and medical procedures
NCT01069705,,2010-02-15,2021-05-06,,2021-05-06,2010-02-16,2010-02-17,ESTIMATED,2021-05-06,2021-06-02,ACTUAL,,,,2021-05-06,2021-06-02,ACTUAL,2010-02-12,ACTUAL,2010-02-12,2021-05,2021-05-31,2012-03-19,ACTUAL,2012-03-19,2012-03-19,ACTUAL,2012-03-19,,INTERVENTIONAL,,"Safety population included all participants who completed their participation in C2303E1, who gave their consent to enter the extension 2 study and who received at least one dose of study drug in the extension 2 study.",Second Open Label Extension to Bridging Study CTBM100C2303,A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Successfully Completed Participation in Study CTBM100C2303E1,COMPLETED,,PHASE3,49,ACTUAL,Novartis,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-15 01:31:57,2024-10-15 01:31:57,INDUSTRY,,,,,,,Novartis Pharmaceuticals,Bulgaria|Estonia|Latvia|Lithuania|Romania|Russian Federation|South Africa,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Respiratory, thoracic and mediastinal disorders"
NCT01069900,,2010-02-15,2015-11-04,,2018-02-22,2010-02-16,2010-02-17,ESTIMATED,2015-11-04,2015-12-08,ESTIMATED,,,,2018-02-22,2018-03-20,ACTUAL,2010-07-21,ACTUAL,2010-07-21,2018-02,2018-02-28,2015-01-21,ACTUAL,2015-01-21,2015-01-21,ACTUAL,2015-01-21,,INTERVENTIONAL,MOXIPEDIA,,Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection,"A Randomized, Double-blind, Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, Oral) Moxifloxacin Versus Comparator in Pediatric Subjects With Complicated Intra-abdominal Infection",COMPLETED,,PHASE3,458,ACTUAL,Bayer,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 00:55:42,2024-10-13 00:55:42,INDUSTRY,,,,,,,Bayer,Argentina|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Czech Republic|Germany|Greece|Hungary|India|Italy|Latvia|Lithuania|Mexico|Peru|Romania|Russian Federation|Serbia|Spain|Ukraine|United Kingdom|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Surgical and medical procedures|Vascular disorders"
NCT01072539,,2010-02-17,2016-04-21,,2023-12-12,2010-02-19,2010-02-22,ESTIMATED,2016-04-21,2016-05-30,ESTIMATED,,,,2023-12-12,2023-12-29,ACTUAL,2010-05,,2010-05-31,2023-12,2023-12-31,2015-04,ACTUAL,2015-04-30,2015-04,ACTUAL,2015-04-30,,OBSERVATIONAL,,Safety Analysis Set: participants who received at least one dose of Tygacil and had related safety endpoints evaluated at least once.,Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment,A Post-marketing Surveillance (Pms) Study Of Safety And Effectiveness In Patients With Tigecycline Treatment,COMPLETED,,,3172,ACTUAL,Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:19:26,2024-10-14 00:19:26,INDUSTRY,,,,,,,Pfizer,"Korea, Republic of","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01072539,,2010-02-17,2016-04-21,,2023-12-12,2010-02-19,2010-02-22,ESTIMATED,2016-04-21,2016-05-30,ESTIMATED,,,,2023-12-12,2023-12-29,ACTUAL,2010-05,,2010-05-31,2023-12,2023-12-31,2015-04,ACTUAL,2015-04-30,2015-04,ACTUAL,2015-04-30,,OBSERVATIONAL,,Safety Analysis Set: participants who received at least one dose of Tygacil and had related safety endpoints evaluated at least once.,Study Evaluating The Safety And Effectiveness In Subjects With Tigecycline Treatment,A Post-marketing Surveillance (Pms) Study Of Safety And Effectiveness In Patients With Tigecycline Treatment,COMPLETED,,,3172,ACTUAL,Pfizer,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:19:26,2024-10-14 00:19:26,INDUSTRY,,,,,,,Pfizer,"Korea, Republic of","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01073293,,2010-02-19,2014-12-12,,2018-10-30,2010-02-19,2010-02-23,ESTIMATED,2014-12-12,2014-12-22,ESTIMATED,,,,2018-10-30,2018-11-27,ACTUAL,2010-04-22,ACTUAL,2010-04-22,2018-10,2018-10-31,2011-06-16,ACTUAL,2011-06-16,2011-06-16,ACTUAL,2011-06-16,,INTERVENTIONAL,,,A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007),"A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds)",COMPLETED,,PHASE3,1054,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 21:51:26,2024-10-14 21:51:26,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Austria|Belgium|Denmark|Finland|Germany|Thailand,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01074008,,2010-02-22,2014-12-29,2012-06-25,2014-12-29,2010-02-22,2010-02-24,ESTIMATED,2014-12-29,2015-01-08,ESTIMATED,2012-06-25,2012-07-02,ESTIMATED,2014-12-29,2015-01-08,ESTIMATED,2010-03,,2010-03-31,2014-12,2014-12-31,2012-01,ACTUAL,2012-01-31,2011-06,ACTUAL,2011-06-30,,INTERVENTIONAL,Champion2,All participants who recieved at least one dose of study drug were included in the baseline characteristic analaysis.,"A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination With Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE2,74,ACTUAL,AbbVie,,9,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 10:46:20,2024-10-14 10:46:20,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Puerto Rico|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01074931,,2010-02-22,2011-05-20,,2011-07-07,2010-02-23,2010-02-24,ESTIMATED,2011-07-07,2011-08-03,ESTIMATED,,,,2011-07-07,2011-08-03,ESTIMATED,2008-04,,2008-04-30,2011-07,2011-07-31,2010-06,ACTUAL,2010-06-30,2010-05,ACTUAL,2010-05-31,,OBSERVATIONAL,,,"Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China","Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China: A Multicenter Post-Marketing Observational Study",COMPLETED,,,98,ACTUAL,Abbott,The location of lipodystrophy was not summarized as there was not a place to record the information on the case report form. Too few participants withdrew from treatment to conduct planned analyses of duration to adverse event(s)/discontinuation.,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:03:40,2024-10-14 22:03:40,INDUSTRY,,,,,,,Abbott,China,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01075152,,2010-02-23,2014-06-27,,2020-06-02,2010-02-23,2010-02-24,ESTIMATED,2014-07-31,2014-08-20,ESTIMATED,,,,2020-06-02,2020-06-09,ACTUAL,2010-11,,2010-11-30,2020-06,2020-06-30,2013-03,ACTUAL,2013-03-31,2012-10,ACTUAL,2012-10-31,,INTERVENTIONAL,COAT,HIV-infected persons not previously receiving HIV therapy with first episode of cryptococcal meningitis diagnosed by CSF culture and/or CSF cryptococcal antigen testing.,Cryptococcal Optimal ART Timing Trial,Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis,COMPLETED,,PHASE4,177,ACTUAL,University of Minnesota,"The differences in mortality in the two arms were of sufficient magnitude that trial enrollment was stopped early by the Data and Safety Monitoring Board. Historically, trials stopped early routinely over-estimate the magnitude of benefit or harm.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 13:39:19,2024-10-13 13:39:19,OTHER,,,,,,,Makerere University|Mbarara University of Science and Technology|National Institute of Allergy and Infectious Diseases (NIAID)|University of Cape Town|University of Minnesota,South Africa|Uganda,Blood and lymphatic system disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders
NCT01075178,,2010-02-23,2011-01-28,,2011-03-18,2010-02-23,2010-02-25,ESTIMATED,2011-01-28,2011-02-24,ESTIMATED,,,,2011-03-18,2011-03-23,ESTIMATED,2006-07,,2006-07-31,2011-03,2011-03-31,2010-01,ACTUAL,2010-01-31,2010-01,ACTUAL,2010-01-31,,OBSERVATIONAL,,,Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease,Palivizumab (Synagis®) Post-marketing Surveillance Cohort Study in Children < 24 Months of Age With Hemodynamically Significant Congenital Heart Disease,COMPLETED,,,2036,ACTUAL,Abbott,"Only serious adverse events of infection and arrhythmia as well as deaths were collected in this study. The criterion for non-inferiority was not met for death, most likely because the reported mortality rates were lower than expected in both groups.",,2,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 22:20:01,2024-10-13 22:20:01,INDUSTRY,,,,,,,Abbott,Austria|Belgium|France|Germany|Italy|Norway|Poland|Slovenia|Spain|United Kingdom,"Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01075204,,2010-02-23,2012-12-20,,2013-02-06,2010-02-23,2010-02-25,ESTIMATED,2012-12-20,2013-01-30,ESTIMATED,,,,2013-02-06,2013-02-12,ESTIMATED,2011-01,,2011-01-31,2013-02,2013-02-28,2012-01,ACTUAL,2012-01-31,2012-01,ACTUAL,2012-01-31,,OBSERVATIONAL,CLOSER,,"Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)","Clarithromycin Modified Release Observational Study for Evaluation of Treatment, Tolerability & Recovery Time in Saudi & Egyptian Clinical Settings (CLOSER)",COMPLETED,,,335,ACTUAL,Abbott,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:56:17,2024-10-13 05:56:17,INDUSTRY,,,,,,,Abbott|Eilaf,Egypt|Saudi Arabia,Gastrointestinal disorders
NCT01075984,,2010-02-24,2013-09-10,,2017-10-11,2010-02-24,2010-02-25,ESTIMATED,2013-09-10,2013-11-15,ESTIMATED,,,,2017-10-11,2017-11-13,ACTUAL,2010-02-23,ACTUAL,2010-02-23,2017-10,2017-10-31,2012-11-20,ACTUAL,2012-11-20,2012-11-20,ACTUAL,2012-11-20,,INTERVENTIONAL,,,"Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)","Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05520)",COMPLETED,,PHASE1,279,ACTUAL,Merck Sharp & Dohme LLC,,5,,,FALSE,,,,TRUE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-15 01:21:06,2024-10-15 01:21:06,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Austria|Belgium|Brazil|Canada|Colombia|Germany|Poland|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01076153,,2010-02-24,2011-04-22,,2011-07-01,2010-02-24,2010-02-26,ESTIMATED,2011-06-03,2011-06-29,ESTIMATED,,,,2011-07-01,2011-07-12,ESTIMATED,2008-12,,2008-12-31,2011-06,2011-06-30,2010-04,ACTUAL,2010-04-30,2010-04,ACTUAL,2010-04-30,,OBSERVATIONAL,,,Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR,"A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR",COMPLETED,,,760,ACTUAL,Abbott,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 17:54:48,2024-10-13 17:54:48,INDUSTRY,,,,,,,Abbott,Thailand,Cardiac disorders|Gastrointestinal disorders|Musculoskeletal and connective tissue disorders
NCT01076166,,2010-02-24,2011-01-07,,2011-04-07,2010-02-24,2010-02-26,ESTIMATED,2011-02-10,2011-03-07,ESTIMATED,,,,2011-04-07,2011-04-11,ESTIMATED,2009-04,,2009-04-30,2011-04,2011-04-30,2010-01,ACTUAL,2010-01-31,2010-01,ACTUAL,2010-01-31,,OBSERVATIONAL,,,Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid® Granules for Oral Suspension.,"A Multi-center, Post-Marketing Observational Study to Identify the Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid Granules for Oral Suspension.",COMPLETED,,,337,ACTUAL,Abbott,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 06:47:03,2024-10-14 06:47:03,INDUSTRY,,,,,,,Abbott,Thailand,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders"
NCT01082367,,2010-03-05,2015-12-22,,2016-06-06,2010-03-05,2010-03-08,ESTIMATED,2016-03-24,2016-04-27,ESTIMATED,,,,2016-06-06,2016-07-15,ESTIMATED,2010-04,,2010-04-30,2016-06,2016-06-30,2015-06,ACTUAL,2015-06-30,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,EARLY,,"Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years","A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years",COMPLETED,,PHASE3,50,ACTUAL,Novartis,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 01:06:01,2024-10-14 01:06:01,INDUSTRY,,,,,,,Novartis Pharmaceuticals,Canada|Egypt|France|Germany|Greece|Hungary|Italy|Poland|Romania|Russian Federation|Switzerland|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01083173,,2010-02-19,2015-10-30,,2016-01-25,2010-03-08,2010-03-09,ESTIMATED,2016-01-25,2016-02-22,ESTIMATED,,,,2016-01-25,2016-02-22,ESTIMATED,2009-10,,2009-10-31,2016-01,2016-01-31,2014-10,ACTUAL,2014-10-31,2014-10,ACTUAL,2014-10-31,,OBSERVATIONAL,,,Surveillance of Kaletra in Korean Patients,"Post-Marketing Surveillance of Safety and Efficacy of Kaletra® Tablet in Korean Patients Under the ""New Drug Re-Examination""",COMPLETED,,,595,ACTUAL,AbbVie,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 02:35:21,2024-10-13 02:35:21,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)","Korea, Republic of","Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01085591,,2010-03-09,2015-04-21,,2018-08-13,2010-03-10,2010-03-12,ESTIMATED,2015-06-12,2015-06-16,ESTIMATED,,,,2018-08-13,2018-09-11,ACTUAL,2010-04-01,ACTUAL,2010-04-01,2018-08,2018-08-31,2011-05-13,ACTUAL,2011-05-13,2011-04-13,ACTUAL,2011-04-13,,INTERVENTIONAL,,All randomized participants who gave proper informed consent.,"Study of CB-183,315 in Participants With Clostridium Difficile Infection","A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection.",COMPLETED,,PHASE2,210,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,3,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 05:11:43,2024-10-13 05:11:43,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01085786,,2010-03-11,2011-04-12,,2015-09-06,2010-03-11,2010-03-12,ESTIMATED,2011-04-12,2011-05-06,ESTIMATED,,,,2015-09-06,2015-09-21,ESTIMATED,2008-08,,2008-08-31,2015-09,2015-09-30,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,INTERVENTIONAL,,,Sequential and Hybrid Therapies for H Pylori Infection,Comparison of 14-day Sequential and Hybrid Therapies for H Pylori Infection,COMPLETED,,PHASE4,240,ACTUAL,Kaohsiung Veterans General Hospital.,The trial was performed in a single country.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 19:22:39,2024-10-13 19:22:39,OTHER,,,,,,,Baylor College of Medicine|Kaohsiung Medical University|Kaohsiung Veterans General Hospital.,Taiwan,Gastrointestinal disorders
NCT01086969,,2010-03-11,2012-01-03,,2012-02-02,2010-03-12,2010-03-15,ESTIMATED,2012-01-03,2012-02-03,ESTIMATED,,,,2012-02-02,2012-02-06,ESTIMATED,2010-06,,2010-06-30,2012-02,2012-02-29,2011-06,ACTUAL,2011-06-30,2011-02,ACTUAL,2011-02-28,,INTERVENTIONAL,,,"A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India","Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects 2-55 Years of Age in India",COMPLETED,,PHASE3,300,ACTUAL,Sanofi,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 10:16:10,2024-10-14 10:16:10,INDUSTRY,,,,,,,Sanofi,India,General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01090102,,2010-03-17,2014-05-20,,2014-08-08,2010-03-18,2010-03-19,ESTIMATED,2014-07-17,2014-08-11,ESTIMATED,,,,2014-08-08,2014-08-13,ESTIMATED,2010-06,,2010-06-30,2014-08,2014-08-31,2012-12,ACTUAL,2012-12-31,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,,,Mesalamine to Reduce T Cell Activation in HIV Infection,Mesalamine to Reduce T Cell Activation in HIV Infection,COMPLETED,,PHASE4,33,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 01:17:29,2024-10-14 01:17:29,OTHER,,,,,,,"Bausch Health Americas, Inc.|California HIV/AIDS Research Program|University of California, San Francisco",United States,General disorders|Hepatobiliary disorders
NCT01090102,,2010-03-17,2014-05-20,,2014-08-08,2010-03-18,2010-03-19,ESTIMATED,2014-07-17,2014-08-11,ESTIMATED,,,,2014-08-08,2014-08-13,ESTIMATED,2010-06,,2010-06-30,2014-08,2014-08-31,2012-12,ACTUAL,2012-12-31,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,,,Mesalamine to Reduce T Cell Activation in HIV Infection,Mesalamine to Reduce T Cell Activation in HIV Infection,COMPLETED,,PHASE4,33,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 01:17:29,2024-10-14 01:17:29,OTHER,,,,,,,"Bausch Health Americas, Inc.|California HIV/AIDS Research Program|University of California, San Francisco",United States,General disorders|Hepatobiliary disorders
NCT01092338,,2010-03-23,2013-01-07,,2013-08-01,2010-03-23,2010-03-24,ESTIMATED,2013-08-01,2013-09-18,ESTIMATED,,,,2013-08-01,2013-09-18,ESTIMATED,2010-01,,2010-01-31,2013-08,2013-08-31,2011-01,ACTUAL,2011-01-31,2011-01,ACTUAL,2011-01-31,,INTERVENTIONAL,,,Vitamin D Dose Finding Study,Safe and Effective Vitamin D Supplementation in HIV,COMPLETED,,PHASE2,44,ACTUAL,Children's Hospital of Philadelphia,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:52:56,2024-10-13 08:52:56,OTHER,,,,,,,Children's Hospital of Philadelphia|National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health (NIH),United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01095796,,2010-03-17,2012-09-20,2011-08-23,2015-10-15,2010-03-26,2010-03-30,ESTIMATED,2012-09-20,2012-10-22,ESTIMATED,2011-08-23,2011-08-25,ESTIMATED,2015-10-15,2015-11-11,ESTIMATED,2010-03,,2010-03-31,2015-10,2015-10-31,2014-09,ACTUAL,2014-09-30,2011-08,ACTUAL,2011-08-31,,INTERVENTIONAL,,Safety Analysis Set: participants were randomized and received at least one dose of study medication.,"Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE3,707,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 13:22:24,2024-10-13 13:22:24,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT01095978,,2010-02-28,2011-05-17,,2011-06-29,2010-03-29,2010-03-30,ESTIMATED,2011-05-17,2011-06-15,ESTIMATED,,,,2011-06-29,2011-07-11,ESTIMATED,2009-08,,2009-08-31,2011-06,2011-06-30,2010-05,ACTUAL,2010-05-31,2010-05,ACTUAL,2010-05-31,,OBSERVATIONAL,KLARAINE,,"Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine","Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine",COMPLETED,,,2822,ACTUAL,Abbott,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 15:59:32,2024-10-14 15:59:32,INDUSTRY,,,,,,,Abbott,Ukraine,Gastrointestinal disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT01096849,,2010-03-12,2018-07-24,2013-07-09,2018-08-20,2010-03-30,2010-03-31,ESTIMATED,2018-08-20,2018-08-22,ACTUAL,2013-07-09,2013-07-12,ESTIMATED,2018-08-20,2018-08-22,ACTUAL,2010-07-13,ACTUAL,2010-07-13,2018-08,2018-08-31,2012-04-03,ACTUAL,2012-04-03,2012-04-03,ACTUAL,2012-04-03,,INTERVENTIONAL,,The intent-to-treat (ITT) population was defined as all randomized patients.,A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP),"A Double-blind, Randomized, Comparator-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of ACHN-490 Injection Administered IV in Patients With Complicated Urinary Tract Infections or Acute Pyelonephritis",COMPLETED,,PHASE2,145,ACTUAL,"Achaogen, Inc.",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:01:28,2024-10-14 00:01:28,INDUSTRY,,,,,,,"Achaogen, Inc.",Chile|Colombia|India|Mexico|United States,"Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Pregnancy, puerperium and perinatal conditions"
NCT01097005,,2010-02-26,2015-06-17,,2022-03-18,2010-03-30,2010-04-01,ESTIMATED,2016-07-28,2016-09-19,ESTIMATED,,,,2022-03-18,2022-03-31,ACTUAL,2009-01,,2009-01-31,2015-03,2015-03-31,2014-03,ACTUAL,2014-03-31,2014-03,ACTUAL,2014-03-31,,OBSERVATIONAL,,,Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections,Special Investigation of Clarith/Klaricid in Patients With Non-tuberculous Mycobacterial Pulmonary Infections,COMPLETED,,,466,ACTUAL,Viatris Inc.,,,1,,FALSE,,,,FALSE,,,,,,,,,,,YES,"Please contact the investigator, and discuss with us.",2024-10-13 00:55:42,2024-10-13 00:55:42,INDUSTRY,,,,,,FALSE,"Mylan Inc.|Taisho Pharmaceutical Co., Ltd.",Japan,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01099579,,2010-04-06,2013-11-14,,2018-04-26,2010-04-06,2010-04-07,ESTIMATED,2014-01-07,2014-02-06,ESTIMATED,,,,2018-04-26,2018-05-24,ACTUAL,2010-10-13,ACTUAL,2010-10-13,2018-04,2018-04-30,2017-09-11,ACTUAL,2017-09-11,2012-10-04,ACTUAL,2012-10-04,,INTERVENTIONAL,PRINCE1,,PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV),"A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Atazanavir (ATV) Powder Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected Pediatric Patients Greater Than or Equal to 3 Months to Less Than 6 Years. (Pediatric Atazanavir International Clinical Evaluation: the PRINCE I Study)",COMPLETED,,PHASE3,82,ACTUAL,Bristol-Myers Squibb,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 16:13:59,2024-10-13 16:13:59,INDUSTRY,,,,,,,Bristol-Myers Squibb,Argentina|Brazil|Chile|Colombia|Italy|Mexico|Peru|Poland|Russian Federation|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT01101542,,2010-04-08,2011-11-10,,2018-05-25,2010-04-08,2010-04-12,ESTIMATED,2011-11-10,2011-12-19,ESTIMATED,,,,2018-05-25,2018-07-23,ACTUAL,2010-07-01,,2010-07-01,2015-10,2015-10-31,2014-02-20,ACTUAL,2014-02-20,2014-02-20,ACTUAL,2014-02-20,,OBSERVATIONAL,,,Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females,"Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix® When Administered to Healthy Females According to the Prescribing Information in Korea",COMPLETED,,,3091,ACTUAL,GlaxoSmithKline,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 11:30:46,2024-10-13 11:30:46,INDUSTRY,,,,,,,GlaxoSmithKline,"Korea, Republic of","Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders"
NCT01102374,,2010-04-11,2016-10-28,,2017-04-18,2010-04-12,2010-04-13,ESTIMATED,2017-04-18,2017-04-21,ACTUAL,,,,2017-04-18,2017-04-21,ACTUAL,2010-05,,2010-05-31,2017-04,2017-04-30,2016-07,ACTUAL,2016-07-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,,,Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents,Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents,COMPLETED,,PHASE2,107,ACTUAL,"University of Colorado, Denver",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 11:45:21,2024-10-14 11:45:21,OTHER,,,,,,,"National Institute on Aging (NIA)|The American Geriatrics Society|University of Colorado, Denver",United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures"
NCT01102972,,2010-04-08,2012-11-28,,2013-10-24,2010-04-12,2010-04-13,ESTIMATED,2012-11-28,2012-12-31,ESTIMATED,,,,2013-10-24,2013-11-19,ESTIMATED,2010-04,,2010-04-30,2013-09,2013-09-30,2012-12,ACTUAL,2012-12-31,2012-06,ACTUAL,2012-06-30,,INTERVENTIONAL,ASSURE,,A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE),"A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying From a Regimen of Atazanavir (ATV) + Ritonavir (RTV) + Tenofovir/Emtricitabine to ATV + Abacavir/Lamivudine Without RTV in Virologically Suppressed, HIV-1 Infected, HLA-B*5701 Negative Subjects",COMPLETED,,PHASE4,297,ACTUAL,ViiV Healthcare,"This study consists of a 35-day Screening Period, a 48-week Treatment Period, and a Follow-up Period (contact \~2-4 weeks after the Week 48/Withdrawal Visit). Data from Week 24 (primary endpoint) and Week 48 (final data) are presented in this summary.",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 05:45:09,2024-10-14 05:45:09,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01105767,,2010-04-14,2014-03-06,,2023-02-01,2010-04-15,2010-04-16,ESTIMATED,2014-11-02,2014-11-04,ESTIMATED,,,,2023-02-01,2023-02-03,ACTUAL,2010-05,,2010-05-31,2023-02,2023-02-28,2012-01,ACTUAL,2012-01-31,2012-01,ACTUAL,2012-01-31,,INTERVENTIONAL,,Participants that developed SSTI.,Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees,Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees,COMPLETED,,NA,30209,ACTUAL,Henry M. Jackson Foundation for the Advancement of Military Medicine,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:43:25,2024-10-13 00:43:25,OTHER,,,,,,,Centers for Disease Control and Prevention|Henry M. Jackson Foundation for the Advancement of Military Medicine,United States,Skin and subcutaneous tissue disorders
NCT01105767,,2010-04-14,2014-03-06,,2023-02-01,2010-04-15,2010-04-16,ESTIMATED,2014-11-02,2014-11-04,ESTIMATED,,,,2023-02-01,2023-02-03,ACTUAL,2010-05,,2010-05-31,2023-02,2023-02-28,2012-01,ACTUAL,2012-01-31,2012-01,ACTUAL,2012-01-31,,INTERVENTIONAL,,Participants that developed SSTI.,Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees,Evaluating Strategies to Prevent Methicillin-resistant Staphylococcus Aureus Skin and Soft Tissue Infections in Military Trainees,COMPLETED,,NA,30209,ACTUAL,Henry M. Jackson Foundation for the Advancement of Military Medicine,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:43:25,2024-10-13 00:43:25,OTHER,,,,,,,Centers for Disease Control and Prevention|Henry M. Jackson Foundation for the Advancement of Military Medicine,United States,Skin and subcutaneous tissue disorders
NCT01106586,,2010-04-14,2012-09-20,2011-08-23,2015-10-09,2010-04-19,2010-04-20,ESTIMATED,2012-09-20,2012-10-22,ESTIMATED,2011-08-23,2011-08-25,ESTIMATED,2015-10-09,2015-11-11,ESTIMATED,2010-04,,2010-04-30,2015-10,2015-10-31,2014-09,ACTUAL,2014-09-30,2011-09,ACTUAL,2011-09-30,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug,"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE3,708,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:13:45,2024-10-13 15:13:45,INDUSTRY,,,,,,,Gilead Sciences,Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Dominican Republic|France|Germany|Italy|Mexico|Netherlands|Portugal|Puerto Rico|Spain|Sweden|Switzerland|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT01107535,,2010-02-20,2012-02-07,,2012-10-26,2010-04-20,2010-04-21,ESTIMATED,2012-03-22,2012-04-23,ESTIMATED,,,,2012-10-26,2012-10-31,ESTIMATED,2007-09,,2007-09-30,2012-10,2012-10-31,2011-02,ACTUAL,2011-02-28,2011-02,ACTUAL,2011-02-28,,OBSERVATIONAL,INSPIRA,,Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection,Observational Study of the Effectiveness of Synagis Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus Infection,COMPLETED,,,82,ACTUAL,Abbott,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 07:32:41,2024-10-14 07:32:41,INDUSTRY,,,,,,,Abbott,Peru,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01108510,,2010-04-20,2014-10-23,2011-08-23,2016-04-15,2010-04-20,2010-04-22,ESTIMATED,2014-10-23,2014-10-28,ESTIMATED,2011-08-23,2011-08-25,ESTIMATED,2016-04-15,2016-05-23,ESTIMATED,2010-04,,2010-04-30,2016-04,2016-04-30,2015-04,ACTUAL,2015-04-30,2011-11,ACTUAL,2011-11-30,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized and received at least on dose of study drug,"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE3,698,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 10:31:45,2024-10-13 10:31:45,INDUSTRY,,,,,,,Gilead Sciences,Argentina|Australia|Austria|Belgium|Brazil|Canada|Denmark|Dominican Republic|France|Germany|Italy|Mexico|Netherlands|Portugal|Puerto Rico|Spain|Sweden|Switzerland|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01111162,,2010-04-13,2016-06-05,,2016-06-07,2010-04-26,2010-04-27,ESTIMATED,2016-06-07,2016-07-12,ESTIMATED,,,,2016-06-07,2016-07-12,ESTIMATED,2009-12,,2009-12-31,2016-06,2016-06-30,2010-12,ACTUAL,2010-12-31,2010-03,ACTUAL,2010-03-31,,INTERVENTIONAL,,,H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients,Evaluating the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Infected Patients,COMPLETED,,PHASE4,120,ACTUAL,University of Pennsylvania,Single Arm Study,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:26:35,2024-10-14 22:26:35,OTHER,,,,,,,University of Pennsylvania,United States,General disorders
NCT01113931,,2010-04-28,2011-11-09,,2011-12-21,2010-04-29,2010-04-30,ESTIMATED,2011-12-21,2012-01-27,ESTIMATED,,,,2011-12-21,2012-01-27,ESTIMATED,2010-04,,2010-04-30,2011-12,2011-12-31,2010-10,ACTUAL,2010-10-31,2010-10,ACTUAL,2010-10-31,,INTERVENTIONAL,,,Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin,"Safety and Efficacy of WC2031 Versus Vibramycin for the Treatment of Uncomplicated Urogenital Chlamydia Trachomatis Infection: A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter Study",COMPLETED,,PHASE3,495,ACTUAL,Warner Chilcott,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 13:22:24,2024-10-13 13:22:24,INDUSTRY,,,,,,,Warner Chilcott,United States,Gastrointestinal disorders|Infections and infestations|Nervous system disorders
NCT01119105,,2010-05-05,2020-10-05,2012-06-05,2020-10-29,2010-05-06,2010-05-07,ESTIMATED,2020-10-05,2020-10-27,ACTUAL,2012-06-25,2012-07-02,ESTIMATED,2020-10-29,2020-11-17,ACTUAL,2010-05,ACTUAL,2010-05-31,2020-10,2020-10-31,2011-02-03,ACTUAL,2011-02-03,2010-12-31,ACTUAL,2010-12-31,,INTERVENTIONAL,,Intent-to-Treat Population,Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),"A Phase II, Multi-center, Randomized, Double-blind Study Comparing the Safety and Efficacy of Two Doses of BC-3781 Versus Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection",COMPLETED,,PHASE2,210,ACTUAL,Nabriva Therapeutics AG,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:19:27,2024-10-13 18:19:27,INDUSTRY,,,,,,,Nabriva Therapeutics AG,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01119105,,2010-05-05,2020-10-05,2012-06-05,2020-10-29,2010-05-06,2010-05-07,ESTIMATED,2020-10-05,2020-10-27,ACTUAL,2012-06-25,2012-07-02,ESTIMATED,2020-10-29,2020-11-17,ACTUAL,2010-05,ACTUAL,2010-05-31,2020-10,2020-10-31,2011-02-03,ACTUAL,2011-02-03,2010-12-31,ACTUAL,2010-12-31,,INTERVENTIONAL,,Intent-to-Treat Population,Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),"A Phase II, Multi-center, Randomized, Double-blind Study Comparing the Safety and Efficacy of Two Doses of BC-3781 Versus Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection",COMPLETED,,PHASE2,210,ACTUAL,Nabriva Therapeutics AG,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:19:27,2024-10-13 18:19:27,INDUSTRY,,,,,,,Nabriva Therapeutics AG,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01119625,,2010-04-22,2012-02-16,2011-04-01,2018-08-21,2010-05-06,2010-05-07,ESTIMATED,2012-02-16,2012-03-22,ESTIMATED,2011-04-01,2011-04-11,ESTIMATED,2018-08-21,2018-09-20,ACTUAL,2010-07-12,,2010-07-12,2016-09,2016-09-30,2011-02-17,ACTUAL,2011-02-17,2011-02-17,ACTUAL,2011-02-17,,INTERVENTIONAL,,,Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose,Evaluation of Immunological Persistence Following 3-dose Priming With GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine in Study NCT00808444 and Safety and Immunogenicity Following a Booster Dose of the Same Vaccine,COMPLETED,,PHASE3,238,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 10:16:10,2024-10-14 10:16:10,INDUSTRY,,,,,,,GlaxoSmithKline,Singapore,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders"
NCT01126268,,2010-04-19,2015-12-14,,2016-01-20,2010-05-18,2010-05-19,ESTIMATED,2016-01-20,2016-02-17,ESTIMATED,,,,2016-01-20,2016-02-17,ESTIMATED,2010-04,,2010-04-30,2016-01,2016-01-31,2012-11,ACTUAL,2012-11-30,2012-11,ACTUAL,2012-11-30,,INTERVENTIONAL,,,Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection,Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection,COMPLETED,,PHASE4,38,ACTUAL,"The University of Texas Health Science Center, Houston",,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 23:36:02,2024-10-14 23:36:02,OTHER,,,,,,,"GlaxoSmithKline|The University of Texas Health Science Center, Houston",United States,General disorders|Infections and infestations|Skin and subcutaneous tissue disorders
NCT01129128,,2010-05-14,2012-05-04,,2012-06-14,2010-05-20,2010-05-24,ESTIMATED,2012-05-04,2012-06-05,ESTIMATED,,,,2012-06-14,2012-06-21,ESTIMATED,2010-05,,2010-05-31,2012-06,2012-06-30,2011-03,ACTUAL,2011-03-31,2011-03,ACTUAL,2011-03-31,,INTERVENTIONAL,,,Three Arm Trial of Immune Effects of Echinacea,3-arm Randomized Controlled Trial Assessing the in Vivo Effect of an Echinacea Purpurea on Immune Markers in Adults,COMPLETED,,NA,67,ACTUAL,University of Washington,"Levels of TNF alpha, IL-6, IL-2 and Interferon gamma varied widely limiting chance of detecting differences.",3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 20:04:52,2024-10-14 20:04:52,OTHER,,,,,,,National Center for Complementary and Integrative Health (NCCIH)|University of Washington,United States,"Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01134939,,2010-06-01,2014-12-31,,2015-01-09,2010-06-01,2010-06-02,ESTIMATED,2015-01-09,2015-01-21,ESTIMATED,,,,2015-01-09,2015-01-21,ESTIMATED,2010-05,,2010-05-31,2015-01,2015-01-31,2013-12,ACTUAL,2013-12-31,2013-12,ACTUAL,2013-12-31,,OBSERVATIONAL,,Treated Set (TS): This patient set includes all HIV-1 infected patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment and of an antiretroviral combination partner.,Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data,Non-interventional Observational Study With Viramune® Plus Antiretroviral Backbone Combination in HIV-infected Women and Male Patients. Gender Specific Evaluation of Data.,COMPLETED,,,265,ACTUAL,Boehringer Ingelheim,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 14:14:42,2024-10-14 14:14:42,INDUSTRY,,,,,,,Boehringer Ingelheim,Germany,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01143883,,2010-03-24,2012-12-10,,2013-06-11,2010-06-11,2010-06-14,ESTIMATED,2013-06-11,2013-06-13,ESTIMATED,,,,2013-06-11,2013-06-13,ESTIMATED,2009-06,,2009-06-30,2013-06,2013-06-30,2010-11,ACTUAL,2010-11-30,2010-09,ACTUAL,2010-09-30,,INTERVENTIONAL,,,Study Looking at the Effect of Silverlon on Post Operative Wound Infections,A Randomized Controlled Clinical Trial Evaluating the Efficacy of Silverlon® in Preventing Surgical Site Infection Following Colorectal Surgery,COMPLETED,,NA,110,ACTUAL,University of South Florida,Members of the surgical team were not blinded to the treatment group.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:49:25,2024-10-13 15:49:25,OTHER,,,,,,,Jorge Marcet,United States,Skin and subcutaneous tissue disorders
NCT01144026,,2010-06-12,2012-12-07,,2013-01-14,2010-06-14,2010-06-15,ESTIMATED,2012-12-07,2013-01-15,ESTIMATED,,,,2013-01-14,2013-01-18,ESTIMATED,2010-09,,2010-09-30,2013-01,2013-01-31,2011-04,ACTUAL,2011-04-30,2011-04,ACTUAL,2011-04-30,,INTERVENTIONAL,THYMON-10001,,Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects,Phase I/IIA Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects,COMPLETED,,PHASE1/PHASE2,15,ACTUAL,"Thymon, LLC",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 09:27:07,2024-10-13 09:27:07,INDUSTRY,,,,,,,"Thymon, LLC",United States,General disorders
NCT01144663,,2010-06-03,2017-09-28,2013-04-11,2020-12-03,2010-06-14,2010-06-15,ESTIMATED,2018-08-29,2019-02-01,ACTUAL,2013-04-11,2013-04-18,ESTIMATED,2020-12-03,2020-12-31,ACTUAL,2010-07-01,ACTUAL,2010-07-01,2020-12,2020-12-31,2013-09-10,ACTUAL,2013-09-10,2012-06-22,ACTUAL,2012-06-22,,INTERVENTIONAL,,,Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines,Immunogenicity and Safety of GSK Biologicals' Meningococcal Vaccine (GSK 134612) When Co-administered With a Pneumococcal Conjugate Vaccine and Infanrix Hexa™ in Healthy Infants,COMPLETED,,PHASE3,2095,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 07:44:30,2024-10-14 07:44:30,INDUSTRY,,,,,,,GlaxoSmithKline,Estonia|Germany|Spain,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01146873,,2010-06-08,2016-02-29,,2017-01-31,2010-06-17,2010-06-22,ESTIMATED,2016-03-31,2016-05-04,ESTIMATED,,,,2017-01-31,2017-03-13,ACTUAL,2010-07,,2010-07-31,2017-01,2017-01-31,2014-12,ACTUAL,2014-12-31,2014-12,ACTUAL,2014-12-31,,INTERVENTIONAL,NEVEREST-III,,Treatment Options for Protease Inhibitor-exposed Children,Treatment Options for Protease Inhibitor-exposed Children,COMPLETED,,PHASE3,300,ACTUAL,Columbia University,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:19:01,2024-10-13 20:19:01,OTHER,,,,,,,"Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Witwatersrand, South Africa",South Africa,Nervous system disorders
NCT01147107,,2010-06-16,2021-07-21,,2021-07-21,2010-06-16,2010-06-22,ESTIMATED,2021-07-21,2021-08-13,ACTUAL,,,,2021-07-21,2021-08-13,ACTUAL,2014-02,ACTUAL,2014-02-28,2021-07,2021-07-31,2021-06-01,ACTUAL,2021-06-01,2016-06-01,ACTUAL,2016-06-01,,INTERVENTIONAL,,,Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection,Hepatic Safety of Raltegravir-based and Efavirenz-based Antiretroviral Regimens in Antiretroviral-Naïve HIV-infected Subjects Co-Infected With Hepatitis C,COMPLETED,,PHASE4,80,ACTUAL,University of Hawaii,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,IPD will be shared with other researchers upon request following the publication of the data. Researchers will contact the PI.,2024-10-14 12:34:19,2024-10-14 12:34:19,OTHER,,,,,,,"Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Oxford University Clinical Research Unit, Vietnam|University of Hawaii|Viet Tiep General Hospital, Hai Phong, Vietnam",Vietnam,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01147640,,2010-06-17,2015-01-09,,2018-09-27,2010-06-17,2010-06-22,ESTIMATED,2015-01-14,2015-01-16,ESTIMATED,,,,2018-09-27,2018-10-25,ACTUAL,2010-06-25,ACTUAL,2010-06-25,2018-09,2018-09-30,2011-03-25,ACTUAL,2011-03-25,2011-02-20,ACTUAL,2011-02-20,,INTERVENTIONAL,,Microbiological Intent-to-Treat,Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections,"A Multicenter, Double-Blind, Randomized, Phase 2 Study to Compare the Safety and Efficacy of Intravenous CXA 101/ Tazobactam and Metronidazole With That of Meropenem in Complicated Intraabdominal Infections",COMPLETED,,PHASE2,122,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 02:41:08,2024-10-13 02:41:08,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Argentina|Georgia|Russian Federation|Serbia|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01151189,,2010-06-24,2015-06-30,,2016-04-25,2010-06-24,2010-06-28,ESTIMATED,2015-07-29,2015-08-26,ESTIMATED,,,,2016-04-25,2016-05-24,ESTIMATED,2011-07,,2011-07-31,2016-04,2016-04-30,2014-09,ACTUAL,2014-09-30,2014-05,ACTUAL,2014-05-31,,INTERVENTIONAL,,"Safety:

All randomized subjects who received a dose of study vaccine, based on actual treatment received.","Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)","A Phase II, Proof of Concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Protective Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in Healthy, HIV-infected Adults",COMPLETED,,PHASE2,650,ACTUAL,Aeras,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-12 23:52:10,2024-10-12 23:52:10,OTHER,,,,,,,Aeras|European and Developing Countries Clinical Trials Partnership (EDCTP)|University of Oxford,Senegal|South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01153269,,2010-02-26,2011-11-16,,2011-11-16,2010-06-28,2010-06-30,ESTIMATED,2011-11-16,2011-12-19,ESTIMATED,,,,2011-11-16,2011-12-19,ESTIMATED,2001-05,,2001-05-31,2011-11,2011-11-30,2010-11,ACTUAL,2010-11-30,2010-11,ACTUAL,2010-11-30,,OBSERVATIONAL,,,Long-term Effectiveness and Safety in Hepatitis-co-infected Patients,Long-term Effectiveness and Safety in Hepatitis-co-infected Patients,COMPLETED,,,33,ACTUAL,Abbott,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 10:04:36,2024-10-13 10:04:36,INDUSTRY,,,,,,,Abbott,Germany,Investigations
NCT01153841,,2010-06-17,2017-01-09,2012-07-23,2019-12-26,2010-06-29,2010-06-30,ESTIMATED,2017-01-09,2017-02-27,ACTUAL,2012-07-23,2012-07-31,ESTIMATED,2019-12-26,2020-01-02,ACTUAL,2011-02-17,ACTUAL,2011-02-17,2019-12,2019-12-31,2011-07-26,ACTUAL,2011-07-26,2011-07-26,ACTUAL,2011-07-26,,INTERVENTIONAL,,,Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam,"Primary Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, in Healthy Infants in Vietnam When Co-administered With GSK Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine",COMPLETED,,PHASE3,300,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=473,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 01:24:19,2024-10-14 01:24:19,INDUSTRY,,,,,,,GlaxoSmithKline,Vietnam,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01153893,,2010-06-29,2012-02-09,,2018-08-21,2010-06-29,2010-06-30,ESTIMATED,2012-02-09,2012-03-15,ESTIMATED,,,,2018-08-21,2018-09-20,ACTUAL,2010-10-04,,2010-10-04,2016-09,2016-09-30,2011-02-16,ACTUAL,2011-02-16,2011-02-16,ACTUAL,2011-02-16,,INTERVENTIONAL,,,Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria,"Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Nigerian Children",COMPLETED,,PHASE3,105,ACTUAL,GlaxoSmithKline,Data were reanalyzed because an issue was discovered with the informed consent obtained for one child after the original statistical analysis. The child's parent requested GlaxoSmithKline not to use the data of their child.,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 01:31:21,2024-10-14 01:31:21,INDUSTRY,,,,,,,GlaxoSmithKline,Nigeria,Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations
NCT01154088,,2010-06-29,2017-03-27,2011-05-27,2018-05-28,2010-06-29,2010-06-30,ESTIMATED,2018-05-28,2018-11-26,ACTUAL,2011-05-27,2011-06-03,ESTIMATED,2018-05-28,2018-11-26,ACTUAL,2010-08-27,,2010-08-27,2018-05,2018-05-31,2010-12-30,ACTUAL,2010-12-30,2010-12-30,ACTUAL,2010-12-30,,INTERVENTIONAL,,,Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds,Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Mencevax™ ACWY in Healthy Subjects Aged 18-25 Years,COMPLETED,,PHASE3,1170,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 15:47:20,2024-10-14 15:47:20,INDUSTRY,,,,,,,GlaxoSmithKline,Panama|Philippines|Thailand,"General disorders|Pregnancy, puerperium and perinatal conditions"
NCT01154296,,2010-06-29,2014-07-29,,2014-09-23,2010-06-29,2010-06-30,ESTIMATED,2014-09-23,2014-09-29,ESTIMATED,,,,2014-09-23,2014-09-29,ESTIMATED,2010-04,,2010-04-30,2014-09,2014-09-30,2012-02,ACTUAL,2012-02-29,2011-07,ACTUAL,2011-07-31,,INTERVENTIONAL,Aware,"6,239 patients approached provided consent to be screened. Of these, 5,028 were eligible (80.6%) and 5012 (99.5% of those eligible) were randomized; 16 screened eligible, but were not randomized due to: decision to decline (3), not returning (11), not testing with HIV/STD battery (1) and not completing baseline activities (1).",HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.,Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032,COMPLETED,,NA,5012,ACTUAL,Columbia University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 15:59:32,2024-10-14 15:59:32,OTHER,,,,,,,"Columbia University|Duke University|Medical University of South Carolina|National Institute on Drug Abuse (NIDA)|Oregon Health and Science University|Research Foundation for Mental Hygiene, Inc.|San Francisco Department of Public Health|The Emmes Company, LLC|University of California|University of California, San Francisco|University of Pittsburgh|Weill Medical College of Cornell University",United States,"Cardiac disorders|General disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
NCT01154673,,2010-06-29,2015-10-26,,2016-03-04,2010-06-29,2010-07-01,ESTIMATED,2016-03-04,2016-04-05,ESTIMATED,,,,2016-03-04,2016-04-05,ESTIMATED,2011-11,,2011-11-30,2016-03,2016-03-31,2014-09,ACTUAL,2014-09-30,2014-09,ACTUAL,2014-09-30,,INTERVENTIONAL,,,Effects of Intensive cART During Acute/Early HIV Infection,"Randomized, Double-blinded, Controlled Trial of Intensive HAART Including Raltegravir, and Maraviroc, on HIV-1 Pro-viral DNA and Reservoir Decay in HIV-1-infected Individuals During the Acute/Early Infection",COMPLETED,,PHASE2/PHASE3,32,ACTUAL,University of Toronto,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 06:04:10,2024-10-14 06:04:10,OTHER,,,,,,,Maple Leaf Research|Unity Health Toronto|University of Toronto,Canada,Blood and lymphatic system disorders
NCT01155193,,2010-03-02,2017-07-12,,2018-02-05,2010-06-30,2010-07-01,ESTIMATED,2018-02-05,2018-10-29,ACTUAL,,,,2018-02-05,2018-10-29,ACTUAL,2002-09-01,ACTUAL,2002-09-01,2017-07,2017-07-31,2016-07-31,ACTUAL,2016-07-31,2016-07-31,ACTUAL,2016-07-31,10 Months,OBSERVATIONAL,,"Evaluable population includes participants who received their first palivizumab injection between 01 September and 31 May of a given season, and who were younger than 2 years at start of immunoprophylaxis. For registry 09/10 - 15/16 only participants who received their first immunoprophylaxis in the corresponding season are included.",Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany,"Prospective, Non-interventional Observation Study for the Use of Palivizumab in High-risk Children in Germany- SYNAGIS",COMPLETED,,,30804,ACTUAL,AbbVie,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 01:37:23,2024-10-14 01:37:23,INDUSTRY,,,,,,TRUE,"AbbVie (prior sponsor, Abbott)",Germany,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01165242,,2010-07-15,2017-05-11,2011-04-13,2018-05-29,2010-07-15,2010-07-19,ESTIMATED,2017-05-11,2017-06-08,ACTUAL,2011-04-13,2011-04-26,ESTIMATED,2018-05-29,2018-06-26,ACTUAL,2010-08-19,,2010-08-19,2018-05,2018-05-31,2011-07-29,ACTUAL,2011-07-29,2011-02-25,ACTUAL,2011-02-25,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults,Immunogenicity and Safety Study of One Dose of GSK Biologicals' Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra® in Healthy Subjects Aged 10-25 Years,COMPLETED,,PHASE2,1013,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 07:10:08,2024-10-14 07:10:08,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|United States,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders"
NCT01170221,,2010-07-23,2014-07-15,2014-04-02,2018-07-31,2010-07-26,2010-07-27,ESTIMATED,2014-08-31,2014-09-03,ESTIMATED,2014-04-02,2014-04-30,ESTIMATED,2018-07-31,2018-08-29,ACTUAL,2010-08-15,ACTUAL,2010-08-15,2018-07,2018-07-31,2011-09-30,ACTUAL,2011-09-30,2011-09-30,ACTUAL,2011-09-30,,INTERVENTIONAL,ABSSSI,All randomized participants,TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.,"A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,667,ACTUAL,"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,2,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 01:37:23,2024-10-14 01:37:23,INDUSTRY,,,,,,,"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Argentina|Brazil|Canada|Czechia|Czech Republic|Germany|Hungary|Latvia|Peru|Slovakia|Ukraine|United States,"Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Skin and subcutaneous tissue disorders"
NCT01171963,,2010-07-28,2013-05-02,,2018-06-18,2010-07-28,2010-07-29,ESTIMATED,2013-05-02,2013-06-24,ESTIMATED,,,,2018-06-18,2018-08-06,ACTUAL,2010-08-29,,2010-08-29,2018-06,2018-06-30,2012-05-12,ACTUAL,2012-05-12,2012-05-12,ACTUAL,2012-05-12,,INTERVENTIONAL,,,"Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants","Efficacy, Immunogenicity and Safety of Two Doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants",COMPLETED,,PHASE3,3340,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 09:04:04,2024-10-14 09:04:04,INDUSTRY,,,,,,,GlaxoSmithKline,China,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01175083,,2010-08-03,2017-09-13,2013-04-11,2019-02-26,2010-08-03,2010-08-04,ESTIMATED,2019-02-26,2019-06-06,ACTUAL,2013-04-11,2013-04-18,ESTIMATED,2019-02-26,2019-06-06,ACTUAL,2011-06-01,ACTUAL,2011-06-01,2019-02,2019-02-28,2013-05-23,ACTUAL,2013-05-23,2013-01-17,ACTUAL,2013-01-17,,INTERVENTIONAL,,,Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A,"Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Pneumococcal Vaccine 1024850A When Administered to Children Between 8 Weeks and 2 Years of Age",COMPLETED,,PHASE3,300,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 00:49:29,2024-10-13 00:49:29,INDUSTRY,,,,,,,GlaxoSmithKline,Burkina Faso,"Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01184872,,2010-02-18,2012-03-22,,2012-07-09,2010-08-18,2010-08-19,ESTIMATED,2012-03-22,2012-04-18,ESTIMATED,,,,2012-07-09,2012-07-13,ESTIMATED,2010-03,,2010-03-31,2012-07,2012-07-31,2011-03,ACTUAL,2011-03-31,2011-03,ACTUAL,2011-03-31,,INTERVENTIONAL,,,Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections,"An Open Label, Multi-center, Randomized, Comparative Phase IIIb Study to Compare Efficacy and Safety of Intravenous (i.v.) Daptomycin With That of Semi-Synthetic Penicillins (SSPs) or Vancomycin in the Treatment of Elderly Patients (Aged ≥ 65 Years) With Complicated Skin and Soft Tissue Infections (cSSTI)",COMPLETED,,PHASE3,120,ACTUAL,Novartis,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 19:23:54,2024-10-14 19:23:54,INDUSTRY,,,,,,,Novartis Pharmaceuticals,Austria|Germany|Italy|Russian Federation|Spain,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01185028,,2010-08-18,2013-03-21,,2021-09-14,2010-08-18,2010-08-19,ESTIMATED,2013-03-21,2013-05-15,ESTIMATED,,,,2021-09-14,2021-10-05,ACTUAL,2010-08,,2010-08-31,2013-05,2013-05-31,2011-10,ACTUAL,2011-10-31,2011-10,ACTUAL,2011-10-31,,INTERVENTIONAL,,,A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures,"An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders",COMPLETED,,PHASE1/PHASE2,8,ACTUAL,National Institutes of Health Clinical Center (CC),,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 11:22:25,2024-10-14 11:22:25,NIH,,,,,,,National Institutes of Health Clinical Center (CC),United States,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01185028,,2010-08-18,2013-03-21,,2021-09-14,2010-08-18,2010-08-19,ESTIMATED,2013-03-21,2013-05-15,ESTIMATED,,,,2021-09-14,2021-10-05,ACTUAL,2010-08,,2010-08-31,2013-05,2013-05-31,2011-10,ACTUAL,2011-10-31,2011-10,ACTUAL,2011-10-31,,INTERVENTIONAL,,,A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures,"An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders",COMPLETED,,PHASE1/PHASE2,8,ACTUAL,National Institutes of Health Clinical Center (CC),,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 11:22:25,2024-10-14 11:22:25,NIH,,,,,,,National Institutes of Health Clinical Center (CC),United States,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01190189,,2010-08-26,2018-11-22,,2019-06-06,2010-08-26,2010-08-27,ESTIMATED,2018-11-22,2018-12-17,ACTUAL,,,,2019-06-06,2019-06-19,ACTUAL,2011-04-01,ACTUAL,2011-04-01,2019-06,2019-06-30,2017-11-23,ACTUAL,2017-11-23,2017-11-23,ACTUAL,2017-11-23,,INTERVENTIONAL,,,Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study,COMPLETED,,PHASE3,137,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 17:34:55,2024-10-14 17:34:55,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01193582,,2010-08-31,2013-09-17,,2013-09-17,2010-08-31,2010-09-02,ESTIMATED,2013-09-17,2013-11-20,ESTIMATED,,,,2013-09-17,2013-11-20,ESTIMATED,2010-09,,2010-09-30,2013-09,2013-09-30,2012-09,ACTUAL,2012-09-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,6114A1-4000-CN,,A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria,"A Phase 4, Open-label Trial to Assess the Safety, Tolerability and Immunogenicity of Prevenar in Older Infants and Young Children in China Who Are Naive to Previous Pneumococcal Vaccination.",COMPLETED,,PHASE4,505,ACTUAL,Pfizer,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 10:31:45,2024-10-13 10:31:45,INDUSTRY,,,,,,,Pfizer,China,"Gastrointestinal disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01193842,,2010-09-01,2018-02-23,,2023-10-31,2010-09-01,2010-09-02,ESTIMATED,2018-06-07,2018-06-12,ACTUAL,,,,2023-10-31,2023-11-21,ACTUAL,2010-10-06,ACTUAL,2010-10-06,2023-10,2023-10-31,2022-05-19,ACTUAL,2022-05-19,2016-11-12,ACTUAL,2016-11-12,,INTERVENTIONAL,,Eligible participants completing at least one cycle of treatment; 3 ineligible participants and 1 participant not completing one cycle of Phase I treatment were not included.,Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma,COMPLETED,,PHASE1/PHASE2,107,ACTUAL,National Cancer Institute (NCI),Experimental Arm C (VR-CHOP) was discontinued early in phase I due to low accrual; only 2 participants received VR-CHOP.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 02:41:08,2024-10-13 02:41:08,NIH,,,,,,,National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01193920,,2010-09-01,2013-12-17,,2014-08-18,2010-09-01,2010-09-02,ESTIMATED,2014-04-03,2014-05-05,ESTIMATED,,,,2014-08-18,2014-08-22,ESTIMATED,2010-10,,2010-10-31,2014-08,2014-08-31,2012-12,ACTUAL,2012-12-31,2011-12,ACTUAL,2011-12-31,,INTERVENTIONAL,,Analysis was done on the all enrolled population.,Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age,"A Phase Ib/II Randomized, Observer-Blind, Controlled, Single Centre Study of a Trivalent Group B Streptococcus Vaccine in Healthy Non-Pregnant Women Leading Into a Dose-Ranging Study in Pregnant Women in South Africa",COMPLETED,,PHASE1/PHASE2,380,ACTUAL,Novartis,,6,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 18:42:10,2024-10-13 18:42:10,INDUSTRY,,,,,,,Novartis Vaccines,South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01195467,,2010-09-03,2014-10-29,,2014-11-13,2010-09-03,2010-09-06,ESTIMATED,2014-10-29,2014-11-04,ESTIMATED,,,,2014-11-13,2014-11-26,ESTIMATED,2010-10,,2010-10-31,2014-11,2014-11-30,2013-06,ACTUAL,2013-06-30,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,SSAT036,,Atripla to Raltegravir Switch Study for CNS Toxicity,"A Phase III, Open-label, Single Centre, Single-arm, Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Raltegravir",COMPLETED,,PHASE3,40,ACTUAL,St Stephens Aids Trust,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:32:15,2024-10-13 07:32:15,OTHER,,,,,,,St Stephens Aids Trust,United Kingdom,Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01198769,,2010-09-09,2012-03-22,,2018-07-02,2010-09-09,2010-09-10,ESTIMATED,2012-03-22,2012-04-17,ESTIMATED,,,,2018-07-02,2018-08-20,ACTUAL,2010-11-11,,2010-11-11,2016-09,2016-09-30,2011-04-18,ACTUAL,2011-04-18,2011-04-18,ACTUAL,2011-04-18,,INTERVENTIONAL,,,Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.,"Immunogenicity, Reactogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.",COMPLETED,,PHASE4,15,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 14:27:14,2024-10-14 14:27:14,INDUSTRY,,,,,,,GlaxoSmithKline,Taiwan,General disorders|Infections and infestations|Skin and subcutaneous tissue disorders
NCT01202279,,2010-09-13,2011-04-04,,2020-12-03,2010-09-13,2010-09-15,ESTIMATED,2012-10-04,2012-11-04,ESTIMATED,,,,2020-12-03,2020-12-30,ACTUAL,2009-10,,2009-10-31,2020-12,2020-12-31,2010-07,ACTUAL,2010-07-31,2010-04,ACTUAL,2010-04-30,,INTERVENTIONAL,Wait and See,,Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Safety and Efficacy of Mucinex D for Symptomatic Therapy in Patients With Acute Upper Respiratory Tract Who Seek Treatment",COMPLETED,,PHASE4,1179,ACTUAL,Reckitt Benckiser LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:56:46,2024-10-13 19:56:46,INDUSTRY,,,,,,,Reckitt Benckiser Inc.,United States,Nervous system disorders|Psychiatric disorders
NCT01204658,,2010-09-16,2016-08-05,2012-11-16,2019-05-17,2010-09-16,2010-09-17,ESTIMATED,2016-08-05,2016-09-28,ESTIMATED,2012-11-16,2012-11-21,ESTIMATED,2019-05-17,2019-05-29,ACTUAL,2010-09-27,ACTUAL,2010-09-27,2019-05,2019-05-31,2012-10-01,ACTUAL,2012-10-01,2011-11-03,ACTUAL,2011-11-03,,INTERVENTIONAL,,,Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants,"Safety, Reactogenicity & Immunogenicity of GSK Biologicals' Pneumococcal Vaccine 2189242A When Co-administered With DTPa-HBV-IPV/Hib Vaccine in Healthy Infants",COMPLETED,,PHASE2,576,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 23:55:37,2024-10-13 23:55:37,INDUSTRY,,,,,,,GlaxoSmithKline,Czechia|Czech Republic|Germany|Poland|Sweden,"Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01204905,,2010-09-16,2018-07-12,,2022-11-09,2010-09-16,2010-09-17,ESTIMATED,2018-09-20,2018-10-18,ACTUAL,,,,2022-11-09,2022-11-14,ACTUAL,2010-09,,2010-09-30,2022-11,2022-11-30,2014-05-16,ACTUAL,2014-05-16,2014-05-16,ACTUAL,2014-05-16,,INTERVENTIONAL,,,R5 Integrase Study in HIV-1 Naive Patients,Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naïve HIV-1 Infected Patients,COMPLETED,,NA,7,ACTUAL,"University of Maryland, Baltimore",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 23:13:29,2024-10-14 23:13:29,OTHER,,,,,,,"Merck Sharp & Dohme LLC|University of Maryland, Baltimore",United States,Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Renal and urinary disorders
NCT01209078,,2010-09-14,2017-09-22,2012-03-29,2017-10-25,2010-09-23,2010-09-24,ESTIMATED,2017-10-25,2017-12-04,ACTUAL,2012-03-29,2012-04-02,ESTIMATED,2017-10-25,2017-12-04,ACTUAL,2010-08-17,ACTUAL,2010-08-17,2017-09,2017-09-30,2011-01-18,ACTUAL,2011-01-18,2011-01-18,ACTUAL,2011-01-18,,INTERVENTIONAL,,,GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection,"A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection",COMPLETED,,PHASE2,84,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-15 01:42:45,2024-10-15 01:42:45,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT01213316,,2010-09-30,2016-03-08,,2016-04-15,2010-09-30,2010-10-04,ESTIMATED,2016-04-15,2016-05-23,ESTIMATED,,,,2016-04-15,2016-05-23,ESTIMATED,2010-10,,2010-10-31,2016-04,2016-04-30,2015-04,ACTUAL,2015-04-30,2015-04,ACTUAL,2015-04-30,,OBSERVATIONAL,WIP,,"A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)",A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany,COMPLETED,,,451,ACTUAL,Merck Sharp & Dohme LLC,,,2,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-12 23:57:38,2024-10-12 23:57:38,INDUSTRY,,,,,,FALSE,Merck Sharp & Dohme LLC,Germany,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT01215188,,2010-10-04,2019-04-08,,2019-04-08,2010-10-05,2010-10-06,ESTIMATED,2019-04-08,2019-04-30,ACTUAL,,,,2019-04-08,2019-04-30,ACTUAL,2010-10-14,ACTUAL,2010-10-14,2019-04,2019-04-30,2012-07-31,ACTUAL,2012-07-31,2012-07-31,ACTUAL,2012-07-31,,INTERVENTIONAL,,,A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003),"A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar 13™ in Healthy Infants",COMPLETED,,PHASE2,1152,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 17:37:34,2024-10-13 17:37:34,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Canada|Finland|Puerto Rico|Spain|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01218802,,2010-10-08,2015-12-11,,2016-03-03,2010-10-08,2010-10-11,ESTIMATED,2016-03-03,2016-03-08,ESTIMATED,,,,2016-03-03,2016-03-08,ESTIMATED,2011-02,,2011-02-28,2016-03,2016-03-31,2014-05,ACTUAL,2014-05-31,2014-05,ACTUAL,2014-05-31,,INTERVENTIONAL,,,Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks,Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation,COMPLETED,,PHASE2,147,ACTUAL,University Hospitals Cleveland Medical Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 19:23:54,2024-10-14 19:23:54,OTHER,,,,,,,AstraZeneca|National Institutes of Health (NIH)|University Hospitals Cleveland Medical Center,United States,Cardiac disorders|Endocrine disorders|Hepatobiliary disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders
NCT01221298,,2010-10-13,2014-12-29,2012-10-18,2014-12-29,2010-10-14,2010-10-15,ESTIMATED,2014-12-29,2015-01-08,ESTIMATED,2012-10-18,2012-10-23,ESTIMATED,2014-12-29,2015-01-08,ESTIMATED,2010-10,,2010-10-31,2014-12,2014-12-31,2012-04,ACTUAL,2012-04-30,2011-05,ACTUAL,2011-05-31,,INTERVENTIONAL,,Baseline analyses included all participants.,"A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)","An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE2,11,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 22:59:32,2024-10-13 22:59:32,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01222585,,2010-10-06,2013-07-23,,2014-01-07,2010-10-15,2010-10-18,ESTIMATED,2013-10-29,2013-12-18,ESTIMATED,,,,2014-01-07,2014-02-06,ESTIMATED,2011-01,,2011-01-31,2014-01,2014-01-31,2011-11,ACTUAL,2011-11-30,2011-11,ACTUAL,2011-11-30,,INTERVENTIONAL,PTN_METRO,,Metronidazole Pharmacokinetics (PK) in Premature Infants,Safety and Pharmacokinetics of Multiple Dose Metronidazole in Premature Infants,COMPLETED,,PHASE1,24,ACTUAL,Duke University,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:19:33,2024-10-13 07:19:33,OTHER,,,,,,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Michael Cohen-Wolkowiez|The Emmes Company, LLC",United States,Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures
NCT01227824,,2010-10-14,2013-08-15,2013-03-21,2018-10-04,2010-10-21,2010-10-25,ESTIMATED,2014-06-19,2014-06-23,ESTIMATED,2013-03-21,2013-04-01,ESTIMATED,2018-10-04,2018-10-09,ACTUAL,2010-10-19,,2010-10-19,2018-10,2018-10-31,2016-12-27,ACTUAL,2016-12-27,2012-02-06,ACTUAL,2012-02-06,,INTERVENTIONAL,SPRING-2,,A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily,"A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects",COMPLETED,,PHASE3,828,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 01:17:48,2024-10-13 01:17:48,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,Australia|Canada|France|Germany|Italy|Russian Federation|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT01228318,,2010-10-23,2018-03-27,,2018-06-21,2010-10-25,2010-10-26,ESTIMATED,2018-06-21,2018-06-26,ACTUAL,,,,2018-06-21,2018-06-26,ACTUAL,2011-01,,2011-01-31,2018-05,2018-05-31,2017-04-13,ACTUAL,2017-04-13,2017-04-13,ACTUAL,2017-04-13,,INTERVENTIONAL,BLIR-HIV,,Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV),Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV),COMPLETED,,PHASE2,63,ACTUAL,Emory University,This single site proof-of-concept phase 2b study had a small sample size \& a 144-week study duration so it could not evaluate the impact of the intervention on long-term bone outcomes. The population enrolled limited the generalization of findings.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-13 17:26:21,2024-10-13 17:26:21,OTHER,,,,,,,Emory University,United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01231516,,2010-10-21,2013-08-15,,2022-03-14,2010-10-28,2010-11-01,ESTIMATED,2013-12-12,2014-01-31,ESTIMATED,,,,2022-03-14,2022-03-15,ACTUAL,2010-10-26,ACTUAL,2010-10-26,2022-03,2022-03-31,2021-02-02,ACTUAL,2021-02-02,2013-02-04,ACTUAL,2013-02-04,,INTERVENTIONAL,SAILING,Four participants from one closed site were removed from the ITT-E Population creating the modified ITT-E Population with 715 participants.,"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults",COMPLETED,,PHASE3,724,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 19:11:06,2024-10-13 19:11:06,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,Argentina|Australia|Belgium|Brazil|Canada|Chile|France|Greece|Hungary|Italy|Mexico|Netherlands|Poland|Romania|Russian Federation|South Africa|Spain|Taiwan|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01231516,,2010-10-21,2013-08-15,,2022-03-14,2010-10-28,2010-11-01,ESTIMATED,2013-12-12,2014-01-31,ESTIMATED,,,,2022-03-14,2022-03-15,ACTUAL,2010-10-26,ACTUAL,2010-10-26,2022-03,2022-03-31,2021-02-02,ACTUAL,2021-02-02,2013-02-04,ACTUAL,2013-02-04,,INTERVENTIONAL,SAILING,Four participants from one closed site were removed from the ITT-E Population creating the modified ITT-E Population with 715 participants.,"A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults",COMPLETED,,PHASE3,724,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 19:11:06,2024-10-13 19:11:06,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,Argentina|Australia|Belgium|Brazil|Canada|Chile|France|Greece|Hungary|Italy|Mexico|Netherlands|Poland|Romania|Russian Federation|South Africa|Spain|Taiwan|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01235546,,2010-11-04,2017-03-13,,2017-06-29,2010-11-04,2010-11-05,ESTIMATED,2017-06-29,2017-07-28,ACTUAL,,,,2017-06-29,2017-07-28,ACTUAL,2011-05,,2011-05-31,2017-06,2017-06-30,2015-12,ACTUAL,2015-12-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,C/SOAP,,Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection,Cesarean Section Optimal Antibiotic Prophylaxis Trial,COMPLETED,,NA,2013,ACTUAL,University of Alabama at Birmingham,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 09:09:30,2024-10-13 09:09:30,OTHER,,,,,,,"Alan Tita|Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Mission Hospital|Ochsner Health System|The University of Texas Health Science Center, Houston|University of Mississippi Medical Center|University of North Carolina|University of Texas|University of Utah",United States,General disorders|Immune system disorders
NCT01235546,,2010-11-04,2017-03-13,,2017-06-29,2010-11-04,2010-11-05,ESTIMATED,2017-06-29,2017-07-28,ACTUAL,,,,2017-06-29,2017-07-28,ACTUAL,2011-05,,2011-05-31,2017-06,2017-06-30,2015-12,ACTUAL,2015-12-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,C/SOAP,,Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection,Cesarean Section Optimal Antibiotic Prophylaxis Trial,COMPLETED,,NA,2013,ACTUAL,University of Alabama at Birmingham,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 09:09:30,2024-10-13 09:09:30,OTHER,,,,,,,"Alan Tita|Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Mission Hospital|Ochsner Health System|The University of Texas Health Science Center, Houston|University of Mississippi Medical Center|University of North Carolina|University of Texas|University of Utah",United States,General disorders|Immune system disorders
NCT01235949,,2010-11-04,2017-09-29,2013-04-11,2019-04-25,2010-11-04,2010-11-07,ESTIMATED,2018-08-17,2019-01-31,ACTUAL,2013-04-11,2013-04-18,ESTIMATED,2019-04-25,2019-05-10,ACTUAL,2010-11-12,ACTUAL,2010-11-12,2019-04,2019-04-30,2012-12-08,ACTUAL,2012-12-08,2012-03-28,ACTUAL,2012-03-28,,INTERVENTIONAL,,,Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment,"Impact of Immediate or Delayed Prophylactic Antipyretic Treatment on the Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline Biologicals' Pneumococcal Vaccine 1024850A and the Co-administered DTPa-combined Vaccines",COMPLETED,,PHASE4,850,ACTUAL,GlaxoSmithKline,,18,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 12:14:37,2024-10-13 12:14:37,INDUSTRY,,,,,,,GlaxoSmithKline,Romania,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01235975,,2010-11-04,2017-03-20,2012-07-23,2018-07-19,2010-11-04,2010-11-07,ESTIMATED,2017-03-20,2017-04-28,ACTUAL,2012-07-23,2012-07-31,ESTIMATED,2018-07-19,2018-08-20,ACTUAL,2010-11-30,ACTUAL,2010-11-30,2018-07,2018-07-31,2011-08-03,ACTUAL,2011-08-03,2011-07-29,ACTUAL,2011-07-29,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years,"Phase IIIb Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Vaccine [GSK 134612] When Given as One Dose to Healthy Subjects Aged 56 Years or Older",COMPLETED,,PHASE3,400,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 10:58:26,2024-10-13 10:58:26,INDUSTRY,,,,,,,GlaxoSmithKline,Lebanon|Saudi Arabia,Nervous system disorders
NCT01239043,,2010-11-08,2012-05-14,,2012-06-18,2010-11-09,2010-11-11,ESTIMATED,2012-05-14,2012-06-19,ESTIMATED,,,,2012-06-18,2012-06-25,ESTIMATED,2010-11,,2010-11-30,2012-06,2012-06-30,2012-02,ACTUAL,2012-02-29,2011-04,ACTUAL,2011-04-30,,INTERVENTIONAL,,,Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination,Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® Vaccine Approximately Three Years Following Initial Vaccination in Adults Who Participated in Trial MTA29,COMPLETED,,PHASE2,139,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 17:48:39,2024-10-13 17:48:39,INDUSTRY,,,,,,,Sanofi,United States,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders"
NCT01241552,,2010-11-12,2016-10-24,,2018-08-06,2010-11-12,2010-11-16,ESTIMATED,2016-10-24,2016-12-15,ESTIMATED,,,,2018-08-06,2018-09-05,ACTUAL,2011-10-10,ACTUAL,2011-10-10,2018-08,2018-08-31,2014-12-09,ACTUAL,2014-12-09,2014-12-09,ACTUAL,2014-12-09,,INTERVENTIONAL,MODIFY I,,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and Toxin B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY I)",COMPLETED,,PHASE3,1452,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 19:22:39,2024-10-13 19:22:39,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Austria|Belgium|Brazil|Canada|Chile|Colombia|Czech Republic|Denmark|Germany|Israel|Italy|Mexico|New Zealand|Portugal|South Africa|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01245764,,2010-11-19,2014-02-04,,2018-10-19,2010-11-19,2010-11-22,ESTIMATED,2014-05-01,2014-06-03,ESTIMATED,,,,2018-10-19,2018-11-14,ACTUAL,2011-03-21,ACTUAL,2011-03-21,2018-10,2018-10-31,2013-04-15,ACTUAL,2013-04-15,2013-04-15,ACTUAL,2013-04-15,,INTERVENTIONAL,,,GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046),Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa,COMPLETED,,PHASE3,250,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 01:06:01,2024-10-14 01:06:01,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Kenya,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders"
NCT01249365,,2010-11-24,2017-12-22,,2019-10-30,2010-11-26,2010-11-29,ESTIMATED,2018-05-31,2018-07-16,ACTUAL,,,,2019-10-30,2019-11-13,ACTUAL,2011-01-24,ACTUAL,2011-01-24,2019-10,2019-10-31,2017-01-10,ACTUAL,2017-01-10,2017-01-10,ACTUAL,2017-01-10,,INTERVENTIONAL,,,The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study,COMPLETED,,PHASE3,199,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=19803,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 11:57:00,2024-10-14 11:57:00,INDUSTRY,,,,,,,GlaxoSmithKline,Australia|Portugal|Russian Federation|Singapore|Thailand,Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders
NCT01249625,,2010-11-29,2019-04-03,,2019-04-03,2010-11-29,2010-11-30,ESTIMATED,2019-04-03,2019-04-25,ACTUAL,,,,2019-04-03,2019-04-25,ACTUAL,2010-12,,2010-12-31,2019-04,2019-04-30,2018-03,ACTUAL,2018-03-31,2018-03,ACTUAL,2018-03-31,,INTERVENTIONAL,ResPECT,,The Respiratory Protection Effectiveness Clinical Trial,Incidence of Respiratory Illness in Outpatient Healthcare Workers Who Wear Respirators or Medical Masks While Caring for Patients,COMPLETED,,NA,2862,ACTUAL,Johns Hopkins University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 05:45:09,2024-10-14 05:45:09,OTHER,,,,,,,"Centers for Disease Control and Prevention|Children's Hospital Colorado|Denver Health and Hospital Authority|Johns Hopkins University|Michael E. DeBakey VA Medical Center|University of Massachusetts, Amherst|US Department of Veterans Affairs|VA Eastern Colorado Health Care System|VA New York Harbor Healthcare System|VA St. Louis Health Care System|Washington D.C. Veterans Affairs Medical Center",United States,Skin and subcutaneous tissue disorders
NCT01251744,,2010-11-30,2017-06-09,,2020-06-12,2010-12-01,2010-12-02,ESTIMATED,2019-12-13,2020-01-02,ACTUAL,,,,2020-06-12,2020-06-29,ACTUAL,2010-12-09,ACTUAL,2010-12-09,2020-05,2020-05-31,2015-06-17,ACTUAL,2015-06-17,2013-11-06,ACTUAL,2013-11-06,,INTERVENTIONAL,,,Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus,Study of Maternal-foetal Cytomegalovirus (CMV) Transmission,COMPLETED,,NA,160,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 02:35:21,2024-10-13 02:35:21,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium,General disorders
NCT01251744,,2010-11-30,2017-06-09,,2020-06-12,2010-12-01,2010-12-02,ESTIMATED,2019-12-13,2020-01-02,ACTUAL,,,,2020-06-12,2020-06-29,ACTUAL,2010-12-09,ACTUAL,2010-12-09,2020-05,2020-05-31,2015-06-17,ACTUAL,2015-06-17,2013-11-06,ACTUAL,2013-11-06,,INTERVENTIONAL,,,Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus,Study of Maternal-foetal Cytomegalovirus (CMV) Transmission,COMPLETED,,NA,160,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 02:35:21,2024-10-13 02:35:21,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium,General disorders
NCT01252719,,2010-12-01,2021-03-08,,2022-07-07,2010-12-01,2010-12-03,ESTIMATED,2022-07-07,2022-08-01,ACTUAL,,,,2022-07-07,2022-08-01,ACTUAL,2010-12,ACTUAL,2010-12-31,2022-07,2022-07-31,2012-11-30,ACTUAL,2012-11-30,2012-10,ACTUAL,2012-10-31,,INTERVENTIONAL,SOLO I,Modified intent to treat (mITT) population consisting of all participants who were randomized into the trial and received any study drug.,Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I),"A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO I)",COMPLETED,,PHASE3,968,ACTUAL,"Melinta Therapeutics, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 11:51:08,2024-10-14 11:51:08,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01252732,,2010-12-01,2021-03-17,,2021-04-12,2010-12-01,2010-12-03,ESTIMATED,2021-03-17,2021-04-13,ACTUAL,,,,2021-04-12,2021-05-05,ACTUAL,2010-12,,2010-12-31,2021-04,2021-04-30,2013-06,ACTUAL,2013-06-30,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,SOLO II,Modified Intent to Treat (mITT) population,Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection,"A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)",COMPLETED,,PHASE3,1019,ACTUAL,"Melinta Therapeutics, Inc.",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 00:37:39,2024-10-13 00:37:39,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01252940,,2010-12-01,2013-03-08,,2015-10-27,2010-12-02,2010-12-03,ESTIMATED,2013-03-08,2013-04-19,ESTIMATED,,,,2015-10-27,2015-12-04,ESTIMATED,2010-11,,2010-11-30,2015-10,2015-10-31,2014-10,ACTUAL,2014-10-31,2012-01,ACTUAL,2012-01-31,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized and received at least one dose of study drug,Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF,"A Phase 3 Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients",COMPLETED,,PHASE3,482,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:34:49,2024-10-13 05:34:49,INDUSTRY,,,,,,,Gilead Sciences,Austria|Belgium|Canada|France|Germany|Italy|Puerto Rico|Spain|United Kingdom|United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01254344,,2010-12-03,2012-10-16,,2017-02-17,2010-12-03,2010-12-06,ESTIMATED,2012-10-16,2012-11-16,ESTIMATED,,,,2017-02-17,2017-03-22,ACTUAL,2010-12,,2010-12-31,2017-02,2017-02-28,2011-12,ACTUAL,2011-12-31,2011-12,ACTUAL,2011-12-31,,INTERVENTIONAL,,,Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056),"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Ceftriaxone Sodium/Metronidazole for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery in Chinese Adults",COMPLETED,,PHASE3,599,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 22:25:16,2024-10-13 22:25:16,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Vascular disorders"
NCT01254344,,2010-12-03,2012-10-16,,2017-02-17,2010-12-03,2010-12-06,ESTIMATED,2012-10-16,2012-11-16,ESTIMATED,,,,2017-02-17,2017-03-22,ACTUAL,2010-12,,2010-12-31,2017-02,2017-02-28,2011-12,ACTUAL,2011-12-31,2011-12,ACTUAL,2011-12-31,,INTERVENTIONAL,,,Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056),"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Ceftriaxone Sodium/Metronidazole for the Prophylaxis of Surgical Site Infection Following Elective Colorectal Surgery in Chinese Adults",COMPLETED,,PHASE3,599,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php",2024-10-13 22:25:16,2024-10-13 22:25:16,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Vascular disorders"
NCT01254643,,2010-12-03,2014-12-12,,2018-10-30,2010-12-03,2010-12-06,ESTIMATED,2014-12-12,2014-12-22,ESTIMATED,,,,2018-10-30,2018-11-28,ACTUAL,2011-01-12,ACTUAL,2011-01-12,2018-10,2018-10-31,2013-08-10,ACTUAL,2013-08-10,2013-08-10,ACTUAL,2013-08-10,,INTERVENTIONAL,,,"A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).","A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls",COMPLETED,,PHASE3,100,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 14:27:14,2024-10-14 14:27:14,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,General disorders|Infections and infestations|Nervous system disorders
NCT01258582,,2010-12-10,2012-05-03,,2012-06-10,2010-12-10,2010-12-13,ESTIMATED,2012-05-03,2012-06-05,ESTIMATED,,,,2012-06-10,2012-06-13,ESTIMATED,2009-05,,2009-05-31,2012-05,2012-05-31,2010-01,ACTUAL,2010-01-31,2010-01,ACTUAL,2010-01-31,,INTERVENTIONAL,USHER,,Two Approaches to Routine HIV Testing in a Hospital Emergency Department,Optimizing Strategies for Universal HIV Testing (The USHER Trial): Phase II,COMPLETED,,NA,1651,ACTUAL,Massachusetts General Hospital,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 03:41:50,2024-10-13 03:41:50,OTHER,,,,,,,Massachusetts General Hospital|National Institute of Mental Health (NIMH),United States,Investigations
NCT01259726,,2010-12-09,2015-01-20,,2021-05-30,2010-12-10,2010-12-14,ESTIMATED,2015-02-11,2015-02-12,ESTIMATED,,,,2021-05-30,2021-06-10,ACTUAL,2011-06-27,ACTUAL,2011-06-27,2021-05,2021-05-31,2013-06-11,ACTUAL,2013-06-11,2013-06-11,ACTUAL,2013-06-11,,INTERVENTIONAL,,Intent-to-Treat-Safety (ITT-S) population was defined as all randomized participants who received at least 1 dose of study drug.,Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI",COMPLETED,,PHASE2,173,ACTUAL,Takeda,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:58:56,2024-10-13 18:58:56,INDUSTRY,,,,,,,Shire,Belgium|Canada|Germany|Spain|Switzerland|United States,"Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01260350,,2010-12-13,2014-11-07,2014-05-28,2014-11-07,2010-12-13,2010-12-15,ESTIMATED,2014-11-07,2014-11-17,ESTIMATED,2014-05-28,2014-06-02,ESTIMATED,2014-11-07,2014-11-17,ESTIMATED,2010-12,,2010-12-31,2014-11,2014-11-30,2013-12,ACTUAL,2013-12-31,2013-10,ACTUAL,2013-10-31,,INTERVENTIONAL,,Safety Analysis Set: participants were randomized and received at least one dose of study medication.,Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3,"A Multi-center, Open-Labeled Exploratory Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 400 mg and Ribavirin for 12 Weeks With and Without Pegylated Interferon in Treatment-Naïve Patients With Chronic HCV Infection Genotype 2 or Genotype 3",COMPLETED,,PHASE2,292,ACTUAL,Gilead Sciences,,22,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,,Gilead Sciences,New Zealand,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01262846,,2010-12-16,2016-12-08,,2017-03-01,2010-12-16,2010-12-17,ESTIMATED,2017-03-01,2017-04-13,ACTUAL,,,,2017-03-01,2017-04-13,ACTUAL,2010-11,,2010-11-30,2017-03,2017-03-31,2011-04,ACTUAL,2011-04-30,2011-04,ACTUAL,2011-04-30,,INTERVENTIONAL,,,Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals,Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals,COMPLETED,,PHASE4,195,ACTUAL,University of Pennsylvania,Caution The trial was not powered to determine clinical efficacy or to detect differences in the occurrence of less common adverse events.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 21:10:53,2024-10-13 21:10:53,OTHER,,,,,,,University of Pennsylvania,United States,Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Skin and subcutaneous tissue disorders
NCT01262872,,2010-12-02,2014-03-13,2013-04-11,2019-06-06,2010-12-16,2010-12-17,ESTIMATED,2014-03-13,2014-04-21,ESTIMATED,2013-04-11,2013-04-18,ESTIMATED,2019-06-06,2019-06-19,ACTUAL,2011-02-09,ACTUAL,2011-02-09,2019-06,2019-06-30,2013-03-18,ACTUAL,2013-03-18,2013-03-18,ACTUAL,2013-03-18,,INTERVENTIONAL,,,"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety and Immunogenicity When Co-administered With Routine EPI Vaccines in Infants Following Safety Assessment in Children Aged 2-4 Years in The Gambia",COMPLETED,,PHASE2,1320,ACTUAL,GlaxoSmithKline,,8,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-14 13:38:09,2024-10-14 13:38:09,INDUSTRY,,,,,,,"Department of State for Health and Social Welfare, The Gambia|GlaxoSmithKline|London School of Hygiene and Tropical Medicine|Medical Research Council Unit, The Gambia|PATH",Gambia,"General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01263015,,2010-12-16,2013-08-15,2012-11-15,2018-03-08,2010-12-16,2010-12-20,ESTIMATED,2014-05-29,2014-07-02,ESTIMATED,2012-11-15,2012-11-21,ESTIMATED,2018-03-08,2018-04-04,ACTUAL,2011-02-01,,2011-02-01,2018-03,2018-03-31,2015-12-03,ACTUAL,2015-12-03,2012-05-14,ACTUAL,2012-05-14,,INTERVENTIONAL,,,A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial),"A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects",COMPLETED,,PHASE3,844,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:26:41,2024-10-15 01:26:41,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,Australia|Belgium|Canada|Denmark|France|Germany|Italy|Netherlands|Poland|Romania|South Africa|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01263691,,2010-12-17,2014-01-17,,2024-03-14,2010-12-20,2010-12-21,ESTIMATED,2014-08-01,2014-08-20,ESTIMATED,,,,2024-03-14,2024-03-18,ACTUAL,2010-12,,2010-12-31,2024-03,2024-03-31,2012-06,ACTUAL,2012-06-30,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,,"Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults","A Parallel-arm, Double-blind, Randomized, Placebo-controlled, Dose-ranging Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of AV7909 in Healthy Adults",COMPLETED,,PHASE1,105,ACTUAL,Emergent BioSolutions,,6,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 00:07:27,2024-10-14 00:07:27,INDUSTRY,,,,,,,Department of Health and Human Services|Emergent BioSolutions|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Social circumstances"
NCT01265511,,2010-11-23,2014-10-22,,2017-07-18,2010-12-22,2010-12-23,ESTIMATED,2017-07-18,2017-08-18,ACTUAL,,,,2017-07-18,2017-08-18,ACTUAL,2010-11,,2010-11-30,2017-07,2017-07-31,2011-10,ACTUAL,2011-10-31,2011-10,ACTUAL,2011-10-31,,INTERVENTIONAL,,,"Study of SCY-635, Pegasys and Copegus in Hepatitis C",A Phase 2a Study of SCY-635 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Hepatitis C Infection,COMPLETED,,PHASE2,10,ACTUAL,"Scynexis, Inc.",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 03:12:53,2024-10-14 03:12:53,INDUSTRY,,,,,,,"Scynexis, Inc.",Puerto Rico|United States,"Blood and lymphatic system disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01265784,,2010-12-21,2015-08-04,,2021-12-16,2010-12-22,2010-12-23,ESTIMATED,2015-08-04,2015-09-04,ESTIMATED,,,,2021-12-16,2022-01-06,ACTUAL,2011-01,,2011-01-31,2021-12,2021-12-31,2012-05,ACTUAL,2012-05-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,All randomized participants.,Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections,"A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety, and PK of 2 Dose Regimens of TP-434 Compared With Ertapenem in Adult Community-Acquired Complicated Intra-abdominal Infections",COMPLETED,,PHASE2,143,ACTUAL,La Jolla Pharmaceutical Company,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:50:54,2024-10-14 07:50:54,INDUSTRY,,,,,,,"Tetraphase Pharmaceuticals, Inc.",Bulgaria|India|Latvia|Lithuania|Romania|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01266850,,2010-12-23,2014-10-09,,2014-10-23,2010-12-23,2010-12-24,ESTIMATED,2014-10-23,2014-10-28,ESTIMATED,,,,2014-10-23,2014-10-28,ESTIMATED,2011-03,,2011-03-31,2014-09,2014-09-30,2014-03,ACTUAL,2014-03-31,2013-10,ACTUAL,2013-10-31,,INTERVENTIONAL,,"Population for baseline analysis includes all participants who were enrolled, randomized, and received at least the first vaccination.",Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules,Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®,COMPLETED,,PHASE4,1384,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 09:03:39,2024-10-13 09:03:39,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01266902,,2010-12-23,2021-02-10,,2021-02-10,2010-12-23,2010-12-24,ESTIMATED,2021-02-10,2021-03-04,ACTUAL,,,,2021-02-10,2021-03-04,ACTUAL,2011-02,ACTUAL,2011-02-28,2021-02,2021-02-28,2020-02,ACTUAL,2020-02-29,2020-02,ACTUAL,2020-02-29,,INTERVENTIONAL,,,A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1,An Open-label Trial With TMC278 25 mg q.d. in Combination With a Background Regimen Containing 2 N(t)RTI's in HIV-1 Infected Subjects Who Participated in TMC278 Clinical Trials and Were Still Benefitting From Treatment With TMC278,COMPLETED,,PHASE3,482,ACTUAL,Janssen R&D Ireland,"Not all Adverse Events (AEs) were collected; AEs considered related to rilpivirine (RPV), leading to discontinuations, serious adverse events (SAEs), or grade 3/4 events of rash regardless of causality were collected; discontinuation rate was greater than (\>) 90 percent which makes interpretation of results difficult.",1,,,TRUE,,,,FALSE,,FALSE,,,,,,,,,,,2024-10-14 10:03:49,2024-10-14 10:03:49,INDUSTRY,,NCT03847376,APPROVED_FOR_MARKETING,,,,Janssen R&D Ireland,Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|Denmark|France|Germany|Mexico|Netherlands|Panama|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Sweden|Taiwan|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01266993,,2010-12-16,2017-08-25,2014-05-29,2020-11-04,2010-12-23,2010-12-24,ESTIMATED,2018-08-28,2019-01-31,ACTUAL,2014-05-29,2014-06-02,ESTIMATED,2020-11-04,2020-11-23,ACTUAL,2011-01-03,ACTUAL,2011-01-03,2020-11,2020-11-30,2014-05-17,ACTUAL,2014-05-17,2014-03-31,ACTUAL,2014-03-31,,INTERVENTIONAL,,,Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children,Persistence of Antibodies After Vaccination With a Dose of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Children and Safety and Immunogenicity of a Booster Dose at 68 Months Post-primary Vaccination,COMPLETED,,PHASE3,271,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-13 10:42:25,2024-10-13 10:42:25,INDUSTRY,,,,,,,GlaxoSmithKline,France|Germany,Gastrointestinal disorders|General disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT01277042,,2011-01-13,2012-09-06,,2018-06-28,2011-01-13,2011-01-14,ESTIMATED,2013-10-04,2013-12-03,ESTIMATED,,,,2018-06-28,2018-08-17,ACTUAL,2011-02-17,,2011-02-17,2016-08,2016-08-31,2012-02-28,ACTUAL,2012-02-28,2011-09-26,ACTUAL,2011-09-26,,INTERVENTIONAL,,,Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years),Immunogenicity and Safety Study of GSK Biologicals' HPV Vaccine (GSK 580299) in Healthy Adult Chinese Female Subjects,COMPLETED,,PHASE3,1212,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 01:51:42,2024-10-13 01:51:42,INDUSTRY,,,,,,,GlaxoSmithKline,China,"Cardiac disorders|Congenital, familial and genetic disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT01279044,,2011-01-18,2014-03-18,,2014-09-30,2011-01-18,2011-01-19,ESTIMATED,2014-09-30,2014-10-07,ESTIMATED,,,,2014-09-30,2014-10-07,ESTIMATED,2007-09,,2007-09-30,2014-09,2014-09-30,2012-11,ACTUAL,2012-11-30,2012-11,ACTUAL,2012-11-30,,INTERVENTIONAL,,"There were no significant differences between the two study arms on baseline demographics, HIV testing, and substance use. The mean age was 33.6 years; 49% were white and 51% non-white including 26% Latino/Hispanic, 11% Asian and Pacific Islander, 10% black/African American, and 6% mixed/other race.",Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM),Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM): Adaptation of the Personalized Cognitive Counseling (PCC) Intervention,COMPLETED,,PHASE1/PHASE2,385,ACTUAL,San Francisco Department of Public Health,Self-report data subject to recall bias Sample is San Francisco SUMSM; may not be generalizable to other locations 42% screened as substance-dependent per SDS Inclusion of dependent MSM reduced ability to detect significant intervention effects,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:49:51,2024-10-14 22:49:51,OTHER_GOV,,,,,,,Centers for Disease Control and Prevention|San Francisco Department of Public Health,United States,Psychiatric disorders
NCT01281813,,2010-12-30,2022-06-29,,2022-10-06,2011-01-20,2011-01-24,ESTIMATED,2022-10-06,2022-10-31,ACTUAL,,,,2022-10-06,2022-10-31,ACTUAL,2011-08-08,ACTUAL,2011-08-08,2022-10,2022-10-31,2021-07-29,ACTUAL,2021-07-29,2021-07-29,ACTUAL,2021-07-29,,INTERVENTIONAL,,,"TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV","Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above",COMPLETED,,PHASE3,145,ACTUAL,Janssen Sciences Ireland UC,,1,,,FALSE,,,,FALSE,,FALSE,,,,,,,,,,,2024-10-13 12:31:22,2024-10-13 12:31:22,INDUSTRY,,,,,,,Janssen Sciences Ireland UC,Australia|Brazil|Costa Rica|Guatemala|Malaysia|Mexico|Panama|South Africa|Thailand|Ukraine,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01283581,,2011-01-24,2013-08-23,,2019-09-25,2011-01-25,2011-01-26,ESTIMATED,2013-08-23,2013-10-29,ESTIMATED,,,,2019-09-25,2019-10-16,ACTUAL,2011-01,,2011-01-31,2019-09,2019-09-30,2011-11,ACTUAL,2011-11-30,2011-11,ACTUAL,2011-11-30,,INTERVENTIONAL,,"ITT (intent-to-treat) population, defined as all subjects who were randomized.",A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections,"A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid",COMPLETED,,PHASE2,256,ACTUAL,"Melinta Therapeutics, Inc.",,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 23:39:05,2024-10-13 23:39:05,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",United States,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01285050,,2011-01-26,2016-08-15,,2016-10-06,2011-01-26,2011-01-27,ESTIMATED,2016-10-06,2016-11-29,ESTIMATED,,,,2016-10-06,2016-11-29,ESTIMATED,2011-01,,2011-01-31,2016-10,2016-10-31,2015-04,ACTUAL,2015-04-30,2015-04,ACTUAL,2015-04-30,,INTERVENTIONAL,,,Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds,Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy,COMPLETED,,PHASE4,20,ACTUAL,Johns Hopkins University,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 18:58:56,2024-10-13 18:58:56,OTHER,,,,,,,Johns Hopkins University|National Institute on Drug Abuse (NIDA),United States,"Injury, poisoning and procedural complications"
NCT01286740,,2011-01-27,2013-03-08,2012-12-12,2013-04-19,2011-01-27,2011-01-31,ESTIMATED,2013-03-08,2013-04-19,ESTIMATED,2012-12-13,2012-12-18,ESTIMATED,2013-04-19,2013-04-26,ESTIMATED,2011-01,,2011-01-31,2013-04,2013-04-30,2012-03,ACTUAL,2012-03-31,2011-07,ACTUAL,2011-07-31,,INTERVENTIONAL,,Safety Analysis Set: participants who enrolled and received at least one dose of study drug,Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR,"A Phase 2B Open Label Pilot Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV 1 Infected Subjects",COMPLETED,,PHASE2,50,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:24:13,2024-10-15 02:24:13,INDUSTRY,,,,,,,Gilead Sciences,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01295515,,2011-02-11,2018-12-19,,2019-04-01,2011-02-11,2011-02-14,ESTIMATED,2019-04-01,2019-04-23,ACTUAL,,,,2019-04-01,2019-04-23,ACTUAL,2011-02-11,ACTUAL,2011-02-11,2019-04,2019-04-30,2017-05-31,ACTUAL,2017-05-31,2017-05-31,ACTUAL,2017-05-31,,INTERVENTIONAL,,HIV-infected individuals undergoing antiretroviral therapy,Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy,Effect of Interferon Alpha 2b Intensification on HIV-1 Residual Viremia in Individuals Suppressed on Antiretroviral Therapy,COMPLETED,,PHASE1/PHASE2,7,ACTUAL,National Institutes of Health Clinical Center (CC),,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 06:08:12,2024-10-13 06:08:12,NIH,,,,,,,National Cancer Institute (NCI)|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01296152,,2011-02-14,2015-09-28,,2015-11-18,2011-02-14,2011-02-15,ESTIMATED,2015-11-18,2015-12-22,ESTIMATED,,,,2015-11-18,2015-12-22,ESTIMATED,2011-05,,2011-05-31,2015-11,2015-11-30,2012-10,ACTUAL,2012-10-31,2012-10,ACTUAL,2012-10-31,,INTERVENTIONAL,,All participants enrolled.,Pharmacokinetic Interactions Between DMPA and LPV/r Among HIV-Infected Women,"An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA) and Lopinavir/Ritonavir (LPV/r) and of the Effects of DMPA on Cellular Immunity and Regulation in HIV-Infected Women",COMPLETED,,PHASE2,25,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 06:29:23,2024-10-14 06:29:23,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,General disorders|Investigations|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders
NCT01297504,,2011-02-15,2014-08-22,,2014-09-19,2011-02-15,2011-02-16,ESTIMATED,2014-08-22,2014-09-03,ESTIMATED,,,,2014-09-19,2014-10-01,ESTIMATED,2011-02,,2011-02-28,2014-09,2014-09-30,2013-08,ACTUAL,2013-08-31,2013-08,ACTUAL,2013-08-31,,OBSERVATIONAL,,Participants Studied,A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America,A One-Year Observational Study of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America,COMPLETED,,,464,ACTUAL,AbbVie,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 09:57:35,2024-10-14 09:57:35,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)|Fundasamin (Argentina)",Argentina|Chile|Colombia|Ecuador|Mexico|Peru|Uruguay,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01297959,,2011-02-11,2020-12-22,,2021-01-21,2011-02-15,2011-02-17,ESTIMATED,2020-12-22,2021-01-19,ACTUAL,,,,2021-01-21,2021-02-10,ACTUAL,2013-01-10,ACTUAL,2013-01-10,2021-01,2021-01-31,2015-10-14,ACTUAL,2015-10-14,2015-10-14,ACTUAL,2015-10-14,,INTERVENTIONAL,Triple IN,Safety analysis set included all participants randomized to treatment and exposed to any quantity of study drug.,Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery,Phase 3 Study of Efficacy and Safety of Topical E-101 Solution to Prevent Incisional Infections Among Colorectal Surgery Patients (Triple IN Study --Inhibition of Incisional Infections),COMPLETED,,PHASE3,503,ACTUAL,"Excited States, LLC",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 09:03:39,2024-10-13 09:03:39,INDUSTRY,,,,,,,"Biotec Services International Ltd|CBR International Corp.|Eurofins|Excited States, LLC|Veristat, Inc.",Czech Republic|Estonia|France|Germany|India|Israel|Latvia|Lithuania|Romania|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01302847,,2011-02-15,2022-01-11,,2024-05-30,2011-02-22,2011-02-24,ESTIMATED,2022-02-23,2022-03-22,ACTUAL,,,,2024-05-30,2024-06-12,ACTUAL,2011-04-20,ACTUAL,2011-04-20,2024-05,2024-05-31,2023-10-18,ACTUAL,2023-10-18,2021-01-20,ACTUAL,2021-01-20,,INTERVENTIONAL,,Participants who received at least one dose of DTG.,"Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents","Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents",COMPLETED,,PHASE1/PHASE2,181,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,8,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 11:16:14,2024-10-14 11:16:14,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Botswana|Brazil|Kenya|Puerto Rico|South Africa|Tanzania|Thailand|Uganda|United States|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01306617,,2011-02-28,2014-12-29,2012-11-16,2014-12-29,2011-02-28,2011-03-02,ESTIMATED,2014-12-29,2015-01-08,ESTIMATED,2012-11-16,2012-11-21,ESTIMATED,2014-12-29,2015-01-08,ESTIMATED,2011-02,,2011-02-28,2014-12,2014-12-31,2012-10,ACTUAL,2012-10-31,2011-11,ACTUAL,2011-11-30,,INTERVENTIONAL,,Baseline analyses included all participants.,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE2,50,ACTUAL,AbbVie,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:19:33,2024-10-13 07:19:33,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01307449,,2011-03-01,2018-08-24,,2018-09-28,2011-03-01,2011-03-03,ESTIMATED,2018-09-28,2018-10-02,ACTUAL,,,,2018-09-28,2018-10-02,ACTUAL,2014-04,ACTUAL,2014-04-30,2018-09,2018-09-30,2017-07,ACTUAL,2017-07-31,2017-07,ACTUAL,2017-07-31,,INTERVENTIONAL,,,Systems Biology of PNEUMOVAX®23 and PREVNAR 13®,Systems Biology of 23 Valent Pneumococcal Polysaccharide Vaccine (PNEUMOVAX®23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR 13®),COMPLETED,,NA,88,ACTUAL,Emory University,,4,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-14 22:03:40,2024-10-14 22:03:40,OTHER,,,,,,,Emory University|National Institute of Allergy and Infectious Diseases (NIAID),United States,Cardiac disorders|Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders
NCT01307579,,2011-03-01,2019-06-11,,2021-03-26,2011-03-01,2011-03-03,ESTIMATED,2019-08-28,2019-09-17,ACTUAL,,,,2021-03-26,2021-03-30,ACTUAL,2011-04-04,ACTUAL,2011-04-04,2019-06,2019-06-30,2020-06-30,ACTUAL,2020-06-30,2018-06-30,ACTUAL,2018-06-30,,INTERVENTIONAL,,,Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia,A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML),COMPLETED,,PHASE3,517,ACTUAL,Children's Oncology Group,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 17:42:56,2024-10-13 17:42:56,NETWORK,,,,,,,Children's Oncology Group|National Cancer Institute (NCI),Australia|Canada|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01309243,,2011-03-03,2013-09-25,,2015-02-03,2011-03-03,2011-03-07,ESTIMATED,2013-09-25,2013-11-27,ESTIMATED,,,,2015-02-03,2015-02-25,ESTIMATED,2011-02,,2011-02-28,2015-02,2015-02-28,2014-02,ACTUAL,2014-02-28,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,Participants in the Safety Analysis Set (randomized and received at least 1 dose of study drug) were analyzed for baseline characteristics.,"Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","A Phase 3B, Randomized, Open-label Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE3,799,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 16:13:59,2024-10-13 16:13:59,INDUSTRY,,,,,,,Gilead Sciences,Australia|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Portugal|Puerto Rico|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01313182,,2011-02-11,2014-02-21,,2020-01-03,2011-03-10,2011-03-11,ESTIMATED,2014-04-24,2014-05-19,ESTIMATED,,,,2020-01-03,2020-01-14,ACTUAL,2011-03,,2011-03-31,2020-01,2020-01-31,2012-09,ACTUAL,2012-09-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,arthroplasty or spine fusion surgery patients,Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin,Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine,COMPLETED,,PHASE4,1874,ACTUAL,3M,"Study failed to achieve target enrollment. The small sample size precluded a multivariate analysis. Nasal culture alone was used as a screen for S. aureus colonization, which has a sensitivity of only 48% to 66%.",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 10:47:40,2024-10-13 10:47:40,INDUSTRY,,,,,,,3M|New York University,United States,General disorders|Vascular disorders
NCT01314261,,2011-03-11,2014-12-29,2013-01-11,2018-06-01,2011-03-11,2011-03-14,ESTIMATED,2015-01-21,2015-01-26,ESTIMATED,2013-01-11,2013-01-21,ESTIMATED,2018-06-01,2018-07-02,ACTUAL,2011-03,,2011-03-31,2015-01,2015-01-31,2013-02,ACTUAL,2013-02-28,2012-01,ACTUAL,2012-01-31,,INTERVENTIONAL,,All 37 participants enrolled in the study received at least 1 dose of study drug and were included in the intent-to-treat population for efficacy and safety analyses.,Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects,"A Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE2,37,ACTUAL,AbbVie,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 03:26:59,2024-10-14 03:26:59,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01315236,,2011-03-11,2019-04-03,2016-09-29,2019-08-06,2011-03-13,2011-03-15,ESTIMATED,2019-08-06,2019-08-21,ACTUAL,2016-09-29,2016-10-03,ESTIMATED,2019-08-06,2019-08-21,ACTUAL,2012-04-19,ACTUAL,2012-04-19,2019-08,2019-08-31,2015-06-18,ACTUAL,2015-06-18,2014-08-18,ACTUAL,2014-08-18,,INTERVENTIONAL,,Double-blind Phase,Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria,"A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease",COMPLETED,,PHASE2,90,ACTUAL,Insmed Incorporated,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 02:02:46,2024-10-13 02:02:46,INDUSTRY,,,,,,,Insmed Incorporated|National Institute of Allergy and Infectious Diseases (NIAID),Canada|United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01315353,,2011-03-14,2018-02-01,,2018-05-10,2011-03-14,2011-03-15,ESTIMATED,2018-05-10,2018-05-11,ACTUAL,,,,2018-05-10,2018-05-11,ACTUAL,2012-04-04,ACTUAL,2012-04-04,2018-05,2018-05-31,2017-02-01,ACTUAL,2017-02-01,2017-02-01,ACTUAL,2017-02-01,,INTERVENTIONAL,,Intent to treat: All eligible participants were included in the analysis.,HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women,A Randomized Trial To Compare An HPV Test-And-Treat Strategy To A Cytology-Based Strategy For Prevention Of CIN 2+ In HIV-Infected Women,COMPLETED,,NA,467,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:19:27,2024-10-13 18:19:27,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Haiti|India|Malawi|Peru|South Africa|Zambia|Zimbabwe,"Gastrointestinal disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders"
NCT01315678,,2011-03-14,2019-04-03,2015-02-12,2020-05-28,2011-03-14,2011-03-15,ESTIMATED,2019-06-20,2019-06-24,ACTUAL,2015-02-12,2015-03-03,ESTIMATED,2020-05-28,2020-06-16,ACTUAL,2012-02-29,ACTUAL,2012-02-29,2020-05,2020-05-31,2013-09-18,ACTUAL,2013-09-18,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,,,Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections,"Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa",COMPLETED,,PHASE3,302,ACTUAL,Insmed Incorporated,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 04:03:57,2024-10-13 04:03:57,INDUSTRY,,,,,,,Insmed Incorporated,Austria|Belgium|Bulgaria|Canada|Denmark|France|Germany|Greece|Hungary|Ireland|Italy|Netherlands|Poland|Serbia|Slovakia|Spain|Sweden|United Kingdom,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01317160,,2011-03-16,2016-01-18,,2024-03-05,2011-03-16,2011-03-17,ESTIMATED,2016-02-15,2016-03-15,ESTIMATED,,,,2024-03-05,2024-03-07,ACTUAL,2011-03,,2011-03-31,2024-03,2024-03-31,2018-09,ACTUAL,2018-09-30,2015-08,ACTUAL,2015-08-31,,INTERVENTIONAL,,,Compression Treatment Effects on Complications and Healing of Achilles Tendon Rupture,Intermittent Pneumatic Compression Effects on Venous Thromboembolism Incidence and Healing of Achilles Tendon Rupture,COMPLETED,,NA,150,ACTUAL,Karolinska University Hospital,,2,,,FALSE,,,,FALSE,,,,,,,,Starting 12 months after publication the data will be available for 10 years after the study is published.,Contact PI.,,YES,Plan to share data on primary outcome (DVT),2024-10-13 03:46:56,2024-10-13 03:46:56,OTHER,,,,,,,DJO Incorporated|Karolinska University Hospital|Region Stockholm,Sweden,Infections and infestations|Surgical and medical procedures
NCT01318356,,2011-03-15,2021-03-09,,2021-06-22,2011-03-17,2011-03-18,ESTIMATED,2021-06-22,2021-06-23,ACTUAL,,,,2021-06-22,2021-06-23,ACTUAL,2011-04,,2011-04-30,2021-06,2021-06-30,2015-09,ACTUAL,2015-09-30,2015-09,ACTUAL,2015-09-30,,INTERVENTIONAL,Qure,,The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment,The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment,COMPLETED,,PHASE4,156,ACTUAL,Radboud University Medical Center,"It was not designed to compare doxycycline and CBT directly, due to the limited number of available patients.

As masking for CBT was not possible, this trial was partly blinded. CBT was directly compared to placebo plus usual care.

Due to the maximum number of vailable patients, it was not possible to include a control group without any form of treatment.

Finally, it is unclear whether the detected effects will be sustained over time.",3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 14:25:50,2024-10-13 14:25:50,OTHER,,,,,,,Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development,Netherlands,Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01319383,,2011-03-17,2017-02-09,,2017-05-30,2011-03-18,2011-03-21,ESTIMATED,2017-05-30,2017-06-29,ACTUAL,,,,2017-05-30,2017-06-29,ACTUAL,2011-02,,2011-02-28,2017-04,2017-04-30,2016-03-31,ACTUAL,2016-03-31,2016-03-31,ACTUAL,2016-03-31,,INTERVENTIONAL,,,The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART,A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy,COMPLETED,,PHASE1/PHASE2,25,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 09:04:04,2024-10-14 09:04:04,OTHER,,,,,,,"Merck Sharp & Dohme LLC|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)|University of North Carolina, Chapel Hill",United States,"Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01321879,,2011-03-17,2019-12-12,,2019-12-12,2011-03-22,2011-03-24,ESTIMATED,2019-12-12,2019-12-27,ACTUAL,,,,2019-12-12,2019-12-27,ACTUAL,2011-03,,2011-03-31,2019-12,2019-12-31,2016-12,ACTUAL,2016-12-31,2016-12,ACTUAL,2016-12-31,,INTERVENTIONAL,,,Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients,"Phase II, Open-Label Pilot Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients",COMPLETED,,PHASE2,40,ACTUAL,M.D. Anderson Cancer Center,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 14:01:33,2024-10-14 14:01:33,OTHER,,,,,,,M.D. Anderson Cancer Center|Theravance Biopharma,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01327547,,2011-03-22,2014-04-09,,2017-11-02,2011-03-31,2011-04-01,ESTIMATED,2014-11-13,2014-11-14,ESTIMATED,,,,2017-11-02,2017-12-06,ACTUAL,2011-05-18,ACTUAL,2011-05-18,2017-11,2017-11-30,2015-03-24,ACTUAL,2015-03-24,2013-04-23,ACTUAL,2013-04-23,,INTERVENTIONAL,,A participant was included in the FAS if the participant had taken at least one dose of study drug.,A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B,"A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus",COMPLETED,,PHASE4,138,ACTUAL,ViiV Healthcare,The median time to development of Grade 3 and 4 ALT abnormalities was not estimable due to too few events reported under each treatment group.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 11:04:01,2024-10-13 11:04:01,INDUSTRY,,,,,,,Pfizer|ViiV Healthcare,Czechia|Czech Republic|France|Germany|Hungary|Poland|Puerto Rico|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT01327651,,2010-12-01,2017-01-05,,2022-08-25,2011-03-31,2011-04-01,ESTIMATED,2017-03-30,2017-05-12,ACTUAL,,,,2022-08-25,2022-09-21,ACTUAL,2011-08,,2011-08-31,2022-08,2022-08-31,2014-12,ACTUAL,2014-12-31,2014-12,ACTUAL,2014-12-31,,INTERVENTIONAL,ADAPT,"For daily dosing arm in Cape Town, we dropped one participant from analysis, since retrospective test of HIV infection in central lab shows that this participant was seroconverted on week 6(randomization week), so she was not eligible to be randomized. Because of this, total baseline population dropped from 536 to 535.",The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP),"The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)",COMPLETED,,PHASE2,622,ACTUAL,HIV Prevention Trials Network,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 21:39:34,2024-10-13 21:39:34,NETWORK,,,,,,,HIV Prevention Trials Network,South Africa|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT01328041,,2011-03-31,2013-08-15,,2015-12-07,2011-03-31,2011-04-04,ESTIMATED,2014-07-17,2014-07-21,ESTIMATED,,,,2015-12-07,2016-01-07,ESTIMATED,2011-05,,2011-05-31,2015-12,2015-12-31,2015-05,ACTUAL,2015-05-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,VIKING-3,,A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.,A Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.,COMPLETED,,PHASE3,183,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 00:30:16,2024-10-15 00:30:16,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,Belgium|Canada|France|Italy|Portugal|Spain|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01328158,,2011-04-01,2014-12-12,,2014-12-12,2011-04-01,2011-04-04,ESTIMATED,2014-12-12,2014-12-22,ESTIMATED,,,,2014-12-12,2014-12-22,ESTIMATED,2011-06,,2011-06-30,2014-12,2014-12-31,2013-12,ACTUAL,2013-12-31,2013-12,ACTUAL,2013-12-31,,OBSERVATIONAL,,All participants who received Lopinavir/Ritonavir for the treatment of HIV infection in institutions participating in the HRD Cooperative Survey during the registration period.,Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection,"Drug Use Investigation of Kaletra Tablets (Quaque Die, QD) on Patients With HIV-infection",COMPLETED,,,236,ACTUAL,AbbVie,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 23:50:05,2024-10-13 23:50:05,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Japan,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01335191,,2011-04-12,2012-12-07,,2013-01-14,2011-04-13,2011-04-14,ESTIMATED,2013-01-14,2013-02-15,ESTIMATED,,,,2013-01-14,2013-02-15,ESTIMATED,2011-06,,2011-06-30,2013-01,2013-01-31,2012-06,ACTUAL,2012-06-30,2012-06,ACTUAL,2012-06-30,,INTERVENTIONAL,,,Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001),"Clinical Study of TUTI-16 in Asymptomatic, HIV-1 Infected Subjects Effectively Controlled by Antiretroviral Therapy and the Effects on Viral Load During a Structured Treatment Interruption",COMPLETED,,PHASE1/PHASE2,27,ACTUAL,"Thymon, LLC",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 03:41:50,2024-10-13 03:41:50,INDUSTRY,,,,,,,"Thymon, LLC",United States,General disorders
NCT01337167,,2011-04-15,2016-02-18,,2018-10-19,2011-04-15,2011-04-18,ESTIMATED,2016-02-18,2016-03-16,ESTIMATED,,,,2018-10-19,2018-11-15,ACTUAL,2011-04-19,ACTUAL,2011-04-19,2018-10,2018-10-31,2013-05-09,ACTUAL,2013-05-09,2013-05-09,ACTUAL,2013-05-09,,INTERVENTIONAL,,,"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","A Phase III Randomized, Open-Label, Active-Comparator Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq™",COMPLETED,,PHASE3,1473,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 01:06:01,2024-10-14 01:06:01,INDUSTRY,,,,,,,MCM Vaccines B.V.|Merck Sharp & Dohme LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01339091,,2011-04-18,2013-11-07,,2013-12-26,2011-04-19,2011-04-20,ESTIMATED,2013-11-07,2013-12-25,ESTIMATED,,,,2013-12-26,2014-01-31,ESTIMATED,2011-03,,2011-03-31,2013-12,2013-12-31,2012-11,ACTUAL,2012-11-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,573,ACTUAL,"Durata Therapeutics Inc., an affiliate of Allergan plc",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 21:16:32,2024-10-14 21:16:32,INDUSTRY,,,,,,,"Durata Therapeutics Inc., an affiliate of Allergan plc",Canada|Croatia|Georgia|Germany|Poland|Russian Federation|Ukraine|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01339091,,2011-04-18,2013-11-07,,2013-12-26,2011-04-19,2011-04-20,ESTIMATED,2013-11-07,2013-12-25,ESTIMATED,,,,2013-12-26,2014-01-31,ESTIMATED,2011-03,,2011-03-31,2013-12,2013-12-31,2012-11,ACTUAL,2012-11-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,573,ACTUAL,"Durata Therapeutics Inc., an affiliate of Allergan plc",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 21:16:32,2024-10-14 21:16:32,INDUSTRY,,,,,,,"Durata Therapeutics Inc., an affiliate of Allergan plc",Canada|Croatia|Georgia|Germany|Poland|Russian Federation|Ukraine|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01340196,,2011-04-20,2015-07-03,,2015-07-03,2011-04-21,2011-04-22,ESTIMATED,2015-07-03,2015-07-31,ESTIMATED,,,,2015-07-03,2015-07-31,ESTIMATED,2011-04,,2011-04-30,2015-07,2015-07-31,,,,2011-06,ACTUAL,2011-06-30,,INTERVENTIONAL,,,Drug Drug Interaction of BI 201335 and Tenofovir,Effect of Multiple Dosing With 240 mg BID BI 201335 on the Steady State Pharmacokinetics of 300mg QD Tenofovir and Effect of Multiple Dosing With 300mg QD Tenofovir on Steady State BI 201335 Pharmacokinetics in Healthy Male and Female Volunteers,COMPLETED,,PHASE1,16,ACTUAL,Boehringer Ingelheim,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 18:47:54,2024-10-13 18:47:54,INDUSTRY,,,,,,,Boehringer Ingelheim,United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01340898,,2011-04-14,2017-09-11,2015-03-12,2019-06-11,2011-04-21,2011-04-25,ESTIMATED,2019-06-11,2019-08-06,ACTUAL,2015-03-12,2015-04-01,ESTIMATED,2019-06-11,2019-08-06,ACTUAL,2012-01-27,ACTUAL,2012-01-27,2019-06,2019-06-30,2015-10-19,ACTUAL,2015-10-19,2014-08-04,ACTUAL,2014-08-04,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK 134612) When Co-administered With Routine Vaccines in Healthy Infants and Toddlers,COMPLETED,,PHASE3,753,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-13 04:03:57,2024-10-13 04:03:57,INDUSTRY,,,,,,,GlaxoSmithKline,Lebanon|Mexico|Pakistan|Saudi Arabia|Turkey,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01340937,,2011-04-21,2016-02-18,,2018-10-19,2011-04-22,2011-04-25,ESTIMATED,2016-03-29,2016-05-02,ESTIMATED,,,,2018-10-19,2018-11-15,ACTUAL,2011-05-10,ACTUAL,2011-05-10,2018-10,2018-10-31,2013-07-26,ACTUAL,2013-07-26,2012-12-18,ACTUAL,2012-12-18,,INTERVENTIONAL,,,A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006),"A Phase III Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 6 Months Concomitantly With Prevnar 13™ and RotaTeq ™",COMPLETED,,PHASE3,2808,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-15 00:18:36,2024-10-15 00:18:36,INDUSTRY,,,,,,,MCM Vaccines B.V.|Merck Sharp & Dohme LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01341639,,2011-04-22,2019-01-28,,2019-04-29,2011-04-22,2011-04-26,ESTIMATED,2019-03-18,2019-04-10,ACTUAL,,,,2019-04-29,2019-04-30,ACTUAL,2011-05-26,ACTUAL,2011-05-26,2019-04,2019-04-30,2013-03-13,ACTUAL,2013-03-13,2013-03-13,ACTUAL,2013-03-13,,INTERVENTIONAL,,All randomized participants excluding participants from site 0048.,"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months (V419-007-03)",COMPLETED,,PHASE3,1250,ACTUAL,MCM Vaccines B.V.,,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 07:27:07,2024-10-14 07:27:07,INDUSTRY,,,,,,,MCM Vaccines B.V.|Merck Sharp & Dohme LLC,Belgium|Finland|Germany,"Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01345929,,2011-04-28,2015-01-09,,2018-09-27,2011-04-29,2011-05-02,ESTIMATED,2015-01-09,2015-01-15,ESTIMATED,,,,2018-09-27,2018-10-25,ACTUAL,2011-06-20,ACTUAL,2011-06-20,2018-09,2018-09-30,2013-09-04,ACTUAL,2013-09-04,2013-08-11,ACTUAL,2013-08-11,,INTERVENTIONAL,,,"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis","A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis",COMPLETED,,PHASE3,558,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","Two identical P3 protocols were initiated (NCT01345929 and NCT01345955) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. These analyses are presented here.",2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 22:15:13,2024-10-14 22:15:13,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","Brazil|Colombia|Estonia|Georgia|Germany|Hungary|Israel|Latvia|Mexico|Moldova, Republic of|Romania|Russian Federation|Serbia|Slovakia|South Africa|Thailand|United States","Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01346774,,2011-04-29,2015-04-28,,2015-05-26,2011-05-02,2011-05-03,ESTIMATED,2015-05-26,2015-06-10,ESTIMATED,,,,2015-05-26,2015-06-10,ESTIMATED,2011-06,,2011-06-30,2015-05,2015-05-31,2013-10,ACTUAL,2013-10-31,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,PUPS,,Preventing Urinary Tract Infection Post-Surgery,Phase II Efficacy of Cranberry Powder in Preventing Catheter-associated Urinary Tract Infection Post Elective Gynecological Surgery,COMPLETED,,PHASE2,200,ACTUAL,University of Michigan,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 12:09:42,2024-10-14 12:09:42,OTHER,,,,,,,Betsy Foxman|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Michigan,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT01351025,,2010-11-08,2015-05-01,,2021-07-31,2011-05-09,2011-05-10,ESTIMATED,2015-07-07,2015-08-04,ESTIMATED,,,,2021-07-31,2021-08-03,ACTUAL,2011-04-14,ACTUAL,2011-04-14,2021-07,2021-07-31,2014-05,ACTUAL,2014-05-31,2014-05,ACTUAL,2014-05-31,,INTERVENTIONAL,,Participants who started study treatment are included,"Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells","A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL",COMPLETED,,PHASE2,98,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 10:31:45,2024-10-13 10:31:45,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID)|Pfizer,Puerto Rico|United States,"General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01351740,,2011-05-09,2017-10-24,,2017-10-24,2011-05-10,2011-05-11,ESTIMATED,2017-10-24,2018-07-30,ACTUAL,,,,2017-10-24,2018-07-30,ACTUAL,2011-07,,2011-07-31,2017-10,2017-10-31,2015-12,ACTUAL,2015-12-31,2015-01,ACTUAL,2015-01-31,,INTERVENTIONAL,SUAT,,Switch to Unboosted Atazanavir With Tenofovir Study,Switch to Unboosted Atazanavir With Tenofovir (SUAT) Study,COMPLETED,,PHASE4,50,ACTUAL,University of British Columbia,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:48:16,2024-10-13 07:48:16,OTHER,,,,,,,University of British Columbia,Canada,Gastrointestinal disorders|Renal and urinary disorders
NCT01352117,,2011-03-03,2017-03-17,,2019-11-01,2011-05-10,2011-05-11,ESTIMATED,2017-05-12,2017-07-31,ACTUAL,,,,2019-11-01,2019-11-14,ACTUAL,2011-11-18,ACTUAL,2011-11-18,2019-11,2019-11-30,2018-11-29,ACTUAL,2018-11-29,2016-03-16,ACTUAL,2016-03-16,,INTERVENTIONAL,REACT-KS,All eligible participants who initiated study treatment.,Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma,A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067,COMPLETED,,PHASE3,192,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,,2024-10-15 03:05:50,2024-10-15 03:05:50,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Kenya|Malawi|Peru|South Africa|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01352715,,2011-01-12,2015-10-29,,2021-08-03,2011-05-11,2011-05-12,ESTIMATED,2015-12-02,2016-01-06,ESTIMATED,,,,2021-08-03,2021-08-05,ACTUAL,2012-03-13,ACTUAL,2012-03-13,2021-08,2021-08-31,2014-10-29,ACTUAL,2014-10-29,2014-10-29,ACTUAL,2014-10-29,,INTERVENTIONAL,SELECT,Intention to treat: All 512 participants without a major eligibility violation.,Study of Options for Second-Line Effective Combination Therapy (SELECT),Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT),COMPLETED,,PHASE3,515,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-12 23:46:56,2024-10-12 23:46:56,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|India|Kenya|Malawi|Peru|South Africa|Tanzania|Thailand|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01353339,,2011-05-11,2022-11-17,,2023-10-11,2011-05-12,2011-05-13,ESTIMATED,2023-10-11,2024-04-05,ACTUAL,,,,2023-10-11,2024-04-05,ACTUAL,2011-12-01,ACTUAL,2011-12-01,2014-10,2014-10-31,2014-02-25,ACTUAL,2014-02-25,2014-02-25,ACTUAL,2014-02-25,,INTERVENTIONAL,,All participants were randomized in the study and included in baseline analysis,Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study,Quinolone Prophylaxis for the Prevention of BK Virus Infection in Kidney Transplantation: A Pilot Study,COMPLETED,,PHASE4,154,ACTUAL,Ottawa Hospital Research Institute,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:48:16,2024-10-13 07:48:16,OTHER,,,,,,,"Canadian Institutes of Health Research (CIHR)|Dalhousie University|London Health Sciences Centre|McGill University Health Centre/Research Institute of the McGill University Health Centre|Ottawa Hospital Research Institute|St. Joseph's Healthcare Hamilton|St. Paul's Hospital, Canada|Unity Health Toronto|University Health Network, Toronto|University of Alberta|University of Manitoba|Vancouver General Hospital",Canada,Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders
NCT01357720,,2011-05-19,2013-03-27,,2013-08-29,2011-05-20,2011-05-23,ESTIMATED,2013-03-27,2013-05-22,ESTIMATED,,,,2013-08-29,2013-09-09,ESTIMATED,2011-05,,2011-05-31,2013-08,2013-08-31,2011-09,ACTUAL,2011-09-30,2011-09,ACTUAL,2011-09-30,,INTERVENTIONAL,,,Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination,"A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age",COMPLETED,,PHASE4,400,ACTUAL,Crucell Holland BV,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 02:45:55,2024-10-14 02:45:55,INDUSTRY,,,,,,,Crucell Holland BV,Philippines,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders"
NCT01359046,,2011-05-20,2019-04-04,,2019-04-25,2011-05-23,2011-05-24,ESTIMATED,2019-04-04,2019-04-26,ACTUAL,,,,2019-04-25,2019-05-09,ACTUAL,2011-07,,2011-07-31,2019-04,2019-04-30,2018-03-09,ACTUAL,2018-03-09,2018-03-02,ACTUAL,2018-03-02,,INTERVENTIONAL,,,Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology,Randomized Control Trial of Silver-alloy Impregnated Suprapubic Catheters in Urogynecology Patients,COMPLETED,,NA,288,ACTUAL,Mayo Clinic,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:59:41,2024-10-14 00:59:41,OTHER,,,,,,,Mayo Clinic,United States,General disorders|Surgical and medical procedures
NCT01359046,,2011-05-20,2019-04-04,,2019-04-25,2011-05-23,2011-05-24,ESTIMATED,2019-04-04,2019-04-26,ACTUAL,,,,2019-04-25,2019-05-09,ACTUAL,2011-07,,2011-07-31,2019-04,2019-04-30,2018-03-09,ACTUAL,2018-03-09,2018-03-02,ACTUAL,2018-03-02,,INTERVENTIONAL,,,Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology,Randomized Control Trial of Silver-alloy Impregnated Suprapubic Catheters in Urogynecology Patients,COMPLETED,,NA,288,ACTUAL,Mayo Clinic,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:59:41,2024-10-14 00:59:41,OTHER,,,,,,,Mayo Clinic,United States,General disorders|Surgical and medical procedures
NCT01359449,,2011-05-23,2013-04-04,,2016-07-20,2011-05-23,2011-05-24,ESTIMATED,2013-04-04,2013-05-24,ESTIMATED,,,,2016-07-20,2016-08-19,ESTIMATED,2011-05,,2011-05-31,2016-07,2016-07-31,2012-11,ACTUAL,2012-11-30,2012-07,ACTUAL,2012-07-31,,INTERVENTIONAL,,,Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations,"Safety and Immunogenicity of Two Doses of Menactra® (Meningococcal [Groups A, C, Y, and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) or One Dose of Monovalent Meningococcal Group C Conjugate Vaccine Administered Concomitantly With Routine Immunizations Between 12 and 18 Months of Age in Canada",COMPLETED,,PHASE3,123,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:50:54,2024-10-13 05:50:54,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Canada,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01360762,,2011-05-24,2018-02-09,,2018-10-05,2011-05-25,2011-05-26,ESTIMATED,2018-10-05,2019-02-15,ACTUAL,,,,2018-10-05,2019-02-15,ACTUAL,2011-11,,2011-11-30,2018-10,2018-10-31,2015-11,ACTUAL,2015-11-30,2015-11,ACTUAL,2015-11-30,,INTERVENTIONAL,,,Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study,Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study,COMPLETED,,PHASE3,74,ACTUAL,"Institute of Tropical Medicine, Belgium",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 01:11:36,2024-10-14 01:11:36,OTHER,,,,,,,"Addis Ababa University|Amhara Regional Health Bureau, Amhara Region|Drugs for Neglected Diseases|Institute of Tropical Medicine, Belgium|Leishmania East Africa Platform (LEAP)|Medecins Sans Frontieres, Netherlands|Tigray Regional Health Bureau, Tigray Region|University of Gondar",Ethiopia,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01362517,,2011-05-26,2013-03-27,,2013-08-29,2011-05-27,2011-05-30,ESTIMATED,2013-05-15,2013-06-24,ESTIMATED,,,,2013-08-29,2013-09-09,ESTIMATED,2010-04,,2010-04-30,2013-08,2013-08-31,2011-04,ACTUAL,2011-04-30,2010-07,ACTUAL,2010-07-31,,INTERVENTIONAL,,,"Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B","Assessment of the Immunogenicity and Safety of Quinvaxem Vaccine (DTwP-HepB-Hib) Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by H. Influenzae Among Healthy Vietnamese Children",COMPLETED,,PHASE3,131,ACTUAL,Crucell Holland BV,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 16:39:05,2024-10-14 16:39:05,INDUSTRY,,,,,,,Crucell Holland BV,Vietnam,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01363011,,2011-05-11,2014-10-27,2014-01-10,2016-03-29,2011-05-27,2011-06-01,ESTIMATED,2014-10-27,2014-10-31,ESTIMATED,2014-01-10,2014-02-10,ESTIMATED,2016-03-29,2016-05-02,ESTIMATED,2011-05,,2011-05-31,2016-03,2016-03-31,2015-02,ACTUAL,2015-02-28,2013-01,ACTUAL,2013-01-31,,INTERVENTIONAL,,Safety Analysis Set: participants were randomized and received at least one dose of study drug,Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment,COMPLETED,,PHASE3,106,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 10:46:20,2024-10-14 10:46:20,INDUSTRY,,,,,,,Gilead Sciences,Australia|Austria|Canada|Dominican Republic|Germany|Mexico|Puerto Rico|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01370616,,2011-06-08,2014-11-24,,2018-07-27,2011-06-09,2011-06-10,ESTIMATED,2014-11-24,2014-12-02,ESTIMATED,,,,2018-07-27,2018-08-27,ACTUAL,2011-09-02,ACTUAL,2011-09-02,2018-07,2018-07-31,2013-12-18,ACTUAL,2013-12-18,2013-12-08,ACTUAL,2013-12-08,,INTERVENTIONAL,,All Randomized Participants,Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061),"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults",COMPLETED,,PHASE3,565,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 17:34:55,2024-10-14 17:34:55,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01371656,,2011-06-04,2018-05-25,,2020-11-23,2011-06-10,2011-06-13,ESTIMATED,2018-05-25,2018-06-26,ACTUAL,,,,2020-11-23,2020-12-07,ACTUAL,2011-09,ACTUAL,2011-09-30,2018-06,2018-06-30,2017-06,ACTUAL,2017-06-30,2017-06,ACTUAL,2017-06-30,,INTERVENTIONAL,,,Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation,A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT),COMPLETED,,PHASE3,624,ACTUAL,Children's Oncology Group,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:46:17,2024-10-13 06:46:17,NETWORK,,,,,,,Children's Oncology Group|National Cancer Institute (NCI),Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01371656,,2011-06-04,2018-05-25,,2020-11-23,2011-06-10,2011-06-13,ESTIMATED,2018-05-25,2018-06-26,ACTUAL,,,,2020-11-23,2020-12-07,ACTUAL,2011-09,ACTUAL,2011-09-30,2018-06,2018-06-30,2017-06,ACTUAL,2017-06-30,2017-06,ACTUAL,2017-06-30,,INTERVENTIONAL,,,Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation,A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT),COMPLETED,,PHASE3,624,ACTUAL,Children's Oncology Group,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:46:17,2024-10-13 06:46:17,NETWORK,,,,,,,Children's Oncology Group|National Cancer Institute (NCI),Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01371838,,2011-04-27,2014-05-28,,2017-09-01,2011-06-10,2011-06-13,ESTIMATED,2014-09-22,2014-09-23,ESTIMATED,,,,2017-09-01,2017-09-06,ACTUAL,2011-12,,2011-12-31,2017-09,2017-09-30,2013-05,ACTUAL,2013-05-31,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,,All randomized subjects who were intended to receive study treatment and were of PORT risk class III and IV. There was one patient with PORT risk class II who was not included in baseline analysis population.,A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia,"A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia",COMPLETED,,PHASE3,848,ACTUAL,Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 23:39:05,2024-10-13 23:39:05,INDUSTRY,,,,,,,Forest Laboratories|Pfizer,"China|India|Korea, Republic of|Philippines|Taiwan|Vietnam","Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01374802,,2011-06-08,2015-07-03,,2015-07-03,2011-06-15,2011-06-16,ESTIMATED,2015-07-03,2015-07-31,ESTIMATED,,,,2015-07-03,2015-07-31,ESTIMATED,2011-06,,2011-06-30,2015-07,2015-07-31,,,,2011-07,ACTUAL,2011-07-31,,INTERVENTIONAL,,"The study was performed as an open-label, multiple-dose, single-group, fixed-sequence study in 14 healthy volunteers.",Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers,"Effect of Multiple Dosing With 240 mg QD BI 201335 on the Steady-state Pharmacokinetics of 800 mg QD Darunavir Coadministered With 100 mg QD Ritonavir (DRV/r) in Healthy Male and Female Volunteers (an Open-label, Multiple-dose, Single Group, Single Fixed Sequence Phase I Study)",COMPLETED,,PHASE1,14,ACTUAL,Boehringer Ingelheim,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 10:09:34,2024-10-13 10:09:34,INDUSTRY,,,,,,,Boehringer Ingelheim,Germany,Eye disorders|Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Vascular disorders
NCT01376778,,2011-06-15,2022-10-21,,2023-01-17,2011-06-16,2011-06-20,ESTIMATED,2023-01-17,2023-02-02,ACTUAL,,,,2023-01-17,2023-02-02,ACTUAL,2012-04,,2012-04-30,2023-01,2023-01-31,2021-06-30,ACTUAL,2021-06-30,2019-10,ACTUAL,2019-10-31,,INTERVENTIONAL,CMV,,A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV),A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV),COMPLETED,,PHASE3,399,ACTUAL,The George Washington University Biostatistics Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.,2024-10-13 20:01:59,2024-10-13 20:01:59,OTHER,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The George Washington University Biostatistics Center,United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|General disorders|Infections and infestations|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01376778,,2011-06-15,2022-10-21,,2023-01-17,2011-06-16,2011-06-20,ESTIMATED,2023-01-17,2023-02-02,ACTUAL,,,,2023-01-17,2023-02-02,ACTUAL,2012-04,,2012-04-30,2023-01,2023-01-31,2021-06-30,ACTUAL,2021-06-30,2019-10,ACTUAL,2019-10-31,,INTERVENTIONAL,CMV,,A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV),A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV),COMPLETED,,PHASE3,399,ACTUAL,The George Washington University Biostatistics Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.,2024-10-13 20:01:59,2024-10-13 20:01:59,OTHER,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The George Washington University Biostatistics Center,United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|General disorders|Infections and infestations|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01376804,,2011-06-17,2014-03-27,,2017-06-15,2011-06-17,2011-06-20,ESTIMATED,2014-03-27,2014-04-28,ESTIMATED,,,,2017-06-15,2017-07-11,ACTUAL,2011-07-31,ACTUAL,2011-07-31,2017-06,2017-06-30,2013-05-31,ACTUAL,2013-05-31,2013-05-31,ACTUAL,2013-05-31,,INTERVENTIONAL,,Baseline measures were based on the Intent-to-treat population that included all enrolled patients who had taken at least one dose of study drug.,A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients,Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients,COMPLETED,,PHASE4,57,ACTUAL,Hoffmann-La Roche,,1,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-13 00:26:25,2024-10-13 00:26:25,INDUSTRY,,,,,,,Hoffmann-La Roche,Australia|Brazil|France|Germany|Mexico|Spain|Sweden|United Kingdom|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01380080,,2011-06-22,2016-01-26,,2021-01-08,2011-06-22,2011-06-27,ESTIMATED,2016-01-26,2016-02-23,ESTIMATED,,,,2021-01-08,2021-01-29,ACTUAL,2011-10,ACTUAL,2011-10-31,2021-01,2021-01-31,2016-04,ACTUAL,2016-04-30,2015-01,ACTUAL,2015-01-31,,INTERVENTIONAL,REMEMBER,Intent to treat: All eligible participants were included in the baseline characteristics.,REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment,Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER),COMPLETED,,PHASE4,851,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 22:31:13,2024-10-13 22:31:13,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Haiti|India|Kenya|Malawi|Peru|South Africa|Tanzania|Uganda|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01381575,,2011-06-17,2013-06-28,,2020-05-19,2011-06-23,2011-06-27,ESTIMATED,2013-10-04,2013-12-05,ESTIMATED,,,,2020-05-19,2020-06-09,ACTUAL,2011-06-29,ACTUAL,2011-06-29,2020-05,2020-05-31,2014-11-13,ACTUAL,2014-11-13,2012-06-28,ACTUAL,2012-06-28,,INTERVENTIONAL,,,Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls,Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine When Administered According to Alternative 2-dose Schedules in 9 - 14 Year Old Females,COMPLETED,,PHASE3,1447,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=4511,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 16:43:39,2024-10-13 16:43:39,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|Germany|Italy|Taiwan|Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT01383005,,2011-05-31,2012-12-28,,2013-04-30,2011-06-24,2011-06-28,ESTIMATED,2013-03-07,2013-04-22,ESTIMATED,,,,2013-04-30,2013-05-06,ESTIMATED,2011-06,,2011-06-30,2013-04,2013-04-30,2011-12,ACTUAL,2011-12-31,2011-12,ACTUAL,2011-12-31,,OBSERVATIONAL,QD-Kapital,,Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets),Treatment Perception of QD Dosed Kaletra (Tablets) Based Treatment in HIV Infected Patients. Observational Cross-Sectional Study (QD-KAPITAL),COMPLETED,,,97,ACTUAL,AbbVie,,,2,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:15:13,2024-10-14 22:15:13,INDUSTRY,,,,,,FALSE,"AbbVie (prior sponsor, Abbott)|Triaca Magna, SA",Spain,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders
NCT01384734,,2011-06-23,2018-08-16,,2018-10-16,2011-06-28,2011-06-29,ESTIMATED,2018-10-16,2018-11-14,ACTUAL,,,,2018-10-16,2018-11-14,ACTUAL,2011-07-26,ACTUAL,2011-07-26,2018-08,2018-08-31,2017-05-12,ACTUAL,2017-05-12,2013-02-18,ACTUAL,2013-02-18,,INTERVENTIONAL,,,HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections,"A Phase IIb Randomized, Controlled, Partially-Blinded Trial to Investigate Safety, Efficacy and Dose-Response of BMS-663068 in Treatment-experienced HIV-1 Subjects, Followed by an Open-Label Period on the Recommended Dose",COMPLETED,,PHASE2,254,ACTUAL,ViiV Healthcare,,5,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:42:24,2024-10-15 02:42:24,INDUSTRY,,,,,,,ViiV Healthcare,Argentina|Colombia|Germany|Mexico|Peru|Romania|Russian Federation|South Africa|Spain|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01385189,,2011-06-28,2017-01-13,,2017-05-30,2011-06-28,2011-06-30,ESTIMATED,2017-03-10,2017-04-20,ACTUAL,,,,2017-05-30,2017-06-22,ACTUAL,2012-05,,2012-05-31,2017-03,2017-03-31,2015-06,ACTUAL,2015-06-30,2015-01,ACTUAL,2015-01-31,,INTERVENTIONAL,,,Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant,Phase I Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel® With Different Doses of the Novel Immunostimulant GLA-AF in Healthy Adults,COMPLETED,,PHASE1,40,ACTUAL,Baylor College of Medicine,,5,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:49:54,2024-10-14 13:49:54,OTHER,,,,,,,Baylor College of Medicine|Children's National Research Institute|George Washington University,United States,Gastrointestinal disorders|General disorders|Immune system disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders
NCT01391793,,2011-07-08,2019-03-28,,2019-06-24,2011-07-11,2011-07-12,ESTIMATED,2019-06-24,2019-07-02,ACTUAL,,,,2019-06-24,2019-07-02,ACTUAL,2011-09,,2011-09-30,2019-06,2019-06-30,2018-03-30,ACTUAL,2018-03-30,2018-03-30,ACTUAL,2018-03-30,,INTERVENTIONAL,STARRS,546 children were randomized; 271 to Adjuvant Dexamethasone and 275 to Placebo. 3 of the 271 were found ineligible post randomization \& were withdrawn by the PI. 71 \& 87 participants in the respective groups had negative/indeterminate cultures. The remaining 197 \& 188 participants had positive urine cultures \& were the basis for the analysis.,Corticosteroids for Children With Febrile Urinary Tract Infections,Corticosteroids for Children With Febrile Urinary Tract Infections,COMPLETED,,PHASE3,546,ACTUAL,University of Pittsburgh,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 08:52:59,2024-10-14 08:52:59,OTHER,,,,,,,Nader Shaikh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),United States,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01391793,,2011-07-08,2019-03-28,,2019-06-24,2011-07-11,2011-07-12,ESTIMATED,2019-06-24,2019-07-02,ACTUAL,,,,2019-06-24,2019-07-02,ACTUAL,2011-09,,2011-09-30,2019-06,2019-06-30,2018-03-30,ACTUAL,2018-03-30,2018-03-30,ACTUAL,2018-03-30,,INTERVENTIONAL,STARRS,546 children were randomized; 271 to Adjuvant Dexamethasone and 275 to Placebo. 3 of the 271 were found ineligible post randomization \& were withdrawn by the PI. 71 \& 87 participants in the respective groups had negative/indeterminate cultures. The remaining 197 \& 188 participants had positive urine cultures \& were the basis for the analysis.,Corticosteroids for Children With Febrile Urinary Tract Infections,Corticosteroids for Children With Febrile Urinary Tract Infections,COMPLETED,,PHASE3,546,ACTUAL,University of Pittsburgh,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 08:52:59,2024-10-14 08:52:59,OTHER,,,,,,,Nader Shaikh|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),United States,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01400412,,2011-07-21,2015-06-17,,2021-07-31,2011-07-21,2011-07-22,ESTIMATED,2015-06-17,2015-07-15,ESTIMATED,,,,2021-07-31,2021-08-03,ACTUAL,2012-01-17,ACTUAL,2012-01-17,2018-01,2018-01-31,2014-06,ACTUAL,2014-06-30,2014-06,ACTUAL,2014-06-30,,INTERVENTIONAL,,Participants who started study treatment,"Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen","A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1",COMPLETED,,PHASE2,262,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:15:10,2024-10-15 01:15:10,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01403051,,2011-07-25,2014-02-05,,2018-09-11,2011-07-25,2011-07-27,ESTIMATED,2014-02-05,2014-03-19,ESTIMATED,,,,2018-09-11,2018-10-12,ACTUAL,2011-09,,2011-09-30,2018-09,2018-09-30,2013-02,ACTUAL,2013-02-28,2013-02,ACTUAL,2013-02-28,,INTERVENTIONAL,,Includes only subjects who did not have eligibility violations,High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART,"A Prospective, Randomized, Double-Blind Phase II Trial of High-Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART)",COMPLETED,,PHASE2,167,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 14:07:45,2024-10-14 14:07:45,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01404312,,2011-07-26,2018-11-14,,2021-11-02,2011-07-26,2011-07-28,ESTIMATED,2018-11-14,2018-12-06,ACTUAL,,,,2021-11-02,2021-11-04,ACTUAL,2012-05-23,ACTUAL,2012-05-23,2020-12,2020-12-31,2017-11-14,ACTUAL,2017-11-14,2017-11-14,ACTUAL,2017-11-14,,INTERVENTIONAL,,All enrolled participants,Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB),Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection,COMPLETED,,PHASE3,3000,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:05:26,2024-10-13 08:05:26,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Brazil|Haiti|India|Kenya|Malawi|Peru|Puerto Rico|South Africa|Tanzania|Thailand|Uganda|United States|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01412801,,2011-08-08,2014-06-20,,2014-09-05,2011-08-08,2011-08-09,ESTIMATED,2014-09-05,2014-09-12,ESTIMATED,,,,2014-09-05,2014-09-12,ESTIMATED,2011-09,,2011-09-30,2014-09,2014-09-30,2012-12,ACTUAL,2012-12-31,2012-10,ACTUAL,2012-10-31,,INTERVENTIONAL,,,Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings,"A Phase II Open-Label, Multi-Center Study of a Group B Streptococcus Vaccine in HIV Positive and HIV Negative Pregnant Women",COMPLETED,,PHASE2,270,ACTUAL,Novartis,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 09:27:07,2024-10-13 09:27:07,INDUSTRY,,,,,,,Novartis Vaccines,Malawi|South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01412801,,2011-08-08,2014-06-20,,2014-09-05,2011-08-08,2011-08-09,ESTIMATED,2014-09-05,2014-09-12,ESTIMATED,,,,2014-09-05,2014-09-12,ESTIMATED,2011-09,,2011-09-30,2014-09,2014-09-30,2012-12,ACTUAL,2012-12-31,2012-10,ACTUAL,2012-10-31,,INTERVENTIONAL,,,Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings,"A Phase II Open-Label, Multi-Center Study of a Group B Streptococcus Vaccine in HIV Positive and HIV Negative Pregnant Women",COMPLETED,,PHASE2,270,ACTUAL,Novartis,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 09:27:07,2024-10-13 09:27:07,INDUSTRY,,,,,,,Novartis Vaccines,Malawi|South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01412801,,2011-08-08,2014-06-20,,2014-09-05,2011-08-08,2011-08-09,ESTIMATED,2014-09-05,2014-09-12,ESTIMATED,,,,2014-09-05,2014-09-12,ESTIMATED,2011-09,,2011-09-30,2014-09,2014-09-30,2012-12,ACTUAL,2012-12-31,2012-10,ACTUAL,2012-10-31,,INTERVENTIONAL,,,Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings,"A Phase II Open-Label, Multi-Center Study of a Group B Streptococcus Vaccine in HIV Positive and HIV Negative Pregnant Women",COMPLETED,,PHASE2,270,ACTUAL,Novartis,,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 09:27:07,2024-10-13 09:27:07,INDUSTRY,,,,,,,Novartis Vaccines,Malawi|South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01416025,,2011-08-11,2016-04-15,,2016-07-18,2011-08-11,2011-08-12,ESTIMATED,2016-04-15,2016-05-23,ESTIMATED,,,,2016-07-18,2016-08-18,ESTIMATED,2012-01,,2012-01-31,2016-07,2016-07-31,2014-12,ACTUAL,2014-12-31,2014-12,ACTUAL,2014-12-31,,INTERVENTIONAL,VoriTDM,,A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing,"A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing",COMPLETED,,PHASE4,29,ACTUAL,Johns Hopkins University,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 22:15:13,2024-10-14 22:15:13,OTHER,,,,,,,Johns Hopkins University|Pfizer,Canada|United States,"Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01417780,,2011-08-11,2021-04-19,2021-01-26,2021-07-26,2011-08-15,2011-08-16,ESTIMATED,2021-07-26,2021-08-18,ACTUAL,2021-01-26,2021-01-28,ACTUAL,2021-07-26,2021-08-18,ACTUAL,2011-12,ACTUAL,2011-12-31,2021-07,2021-07-31,2012-09,ACTUAL,2012-09-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,"Data are from the modified intent-to-treat (mITT) population. The mITT population consisted of all randomized patients who received the proper study drug (AB103 or placebo) and dose, had a definitive surgical diagnosis of NSTI, and did not have a CD4 count \<200 cells/mm3.","Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients","Evaluation of Safety, Pharmacokinetics and Immunomodulatory Effects of AB103, a CD28 Co-stimulatory Receptor Antagonist, in Patients Diagnosed With Necrotizing Soft Tissue Infections",COMPLETED,,PHASE2,43,ACTUAL,Atox Bio Ltd,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 23:27:20,2024-10-13 23:27:20,INDUSTRY,,,,,,,Atox Bio Ltd,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01418937,,2011-08-12,2015-07-27,,2018-06-14,2011-08-16,2011-08-17,ESTIMATED,2015-07-27,2015-08-21,ESTIMATED,,,,2018-06-14,2018-07-12,ACTUAL,2012-05-29,,2012-05-29,2018-06,2018-06-30,2015-01-09,ACTUAL,2015-01-09,2015-01-09,ACTUAL,2015-01-09,,INTERVENTIONAL,,,Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study,Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study,COMPLETED,,PHASE3,164,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 06:40:51,2024-10-13 06:40:51,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil,Psychiatric disorders
NCT01419184,,2011-08-16,2015-04-23,,2018-08-06,2011-08-17,2011-08-18,ESTIMATED,2015-06-12,2015-07-08,ESTIMATED,,,,2018-08-06,2018-09-05,ACTUAL,2011-09-09,ACTUAL,2011-09-09,2018-08,2018-08-31,2012-10-05,ACTUAL,2012-10-05,2012-09-01,ACTUAL,2012-09-01,,INTERVENTIONAL,DAPHEOR1006,"Baseline analysis population is drawn from the subset of the entire sample of participants that received at least 1 dose of study drug and that had complete data for calculating the primary outcome, infection-related length of stay (IRLOS).",Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA,"A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA)",COMPLETED,,PHASE4,250,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 14:08:24,2024-10-13 14:08:24,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|General disorders|Immune system disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT01421511,,2011-08-19,2014-07-15,2014-04-02,2018-07-31,2011-08-19,2011-08-22,ESTIMATED,2014-08-31,2014-09-08,ESTIMATED,2014-04-02,2014-04-30,ESTIMATED,2018-07-31,2018-08-29,ACTUAL,2011-09-15,ACTUAL,2011-09-15,2018-07,2018-07-31,2013-01-10,ACTUAL,2013-01-10,2013-01-10,ACTUAL,2013-01-10,,INTERVENTIONAL,,All randomized participants,TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of IV to Oral 6-Day TR-701 Free Acid and IV to Oral 10-Day Linezolid for the Treatment of ABSSSI",COMPLETED,,PHASE3,666,ACTUAL,"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","Analyses for this study were conducted using 2 statistical plans, 1 for the US FDA and 1 for the EMA, to address differing guidance on the development of antibacterials. These differences are reflected in the EudraCT and clinicaltrials.gov records.",2,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 12:53:49,2024-10-14 12:53:49,INDUSTRY,,,,,,,"Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Argentina|Australia|Brazil|Germany|Mexico|New Zealand|Poland|Russian Federation|South Africa|Spain|United States,Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Vascular disorders
NCT01426217,,2011-08-29,2018-08-20,,2018-09-20,2011-08-30,2011-08-31,ESTIMATED,2018-09-20,2018-10-18,ACTUAL,,,,2018-09-20,2018-10-18,ACTUAL,2011-08,,2011-08-31,2018-08,2018-08-31,2011-11,ACTUAL,2011-11-30,2011-11,ACTUAL,2011-11-30,,INTERVENTIONAL,,,Reduction in IV Associated Contamination,"Reduction in Intraoperative Lumen Contamination of Standard 3-Way Open Lumen Stopcock Sets Through Use of a Novel, Passive Bundle",COMPLETED,,NA,594,ACTUAL,Dartmouth-Hitchcock Medical Center,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 14:49:46,2024-10-13 14:49:46,OTHER,,,,,,,Dartmouth-Hitchcock Medical Center|PSI Medical,United States,Infections and infestations|Vascular disorders
NCT01426438,,2011-08-30,2014-10-15,,2016-01-04,2011-08-30,2011-08-31,ESTIMATED,2014-10-15,2014-10-21,ESTIMATED,,,,2016-01-04,2016-02-03,ESTIMATED,2011-11,,2011-11-30,2016-01,2016-01-31,2013-10,ACTUAL,2013-10-31,2013-10,ACTUAL,2013-10-31,,INTERVENTIONAL,,,"Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate","Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate",COMPLETED,,PHASE2,99,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 02:52:51,2024-10-13 02:52:51,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,Gastrointestinal disorders|General disorders|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT01427738,,2010-11-03,2015-01-06,,2015-02-12,2011-09-01,2011-09-02,ESTIMATED,2015-02-12,2015-02-16,ESTIMATED,,,,2015-02-12,2015-02-16,ESTIMATED,2011-06,,2011-06-30,2015-02,2015-02-28,2014-01,ACTUAL,2014-01-31,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,All participants who enrolled.,Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis,"A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Gentian Violet Oral Solution to That of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings",COMPLETED,,PHASE3,221,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:49:25,2024-10-13 15:49:25,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|India|Kenya|Malawi|South Africa|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01428063,,2011-09-01,2015-08-19,,2016-04-21,2011-09-01,2011-09-02,ESTIMATED,2016-04-21,2016-05-27,ESTIMATED,,,,2016-04-21,2016-05-27,ESTIMATED,2011-09,,2011-09-30,2016-04,2016-04-30,2014-12,ACTUAL,2014-12-31,2014-09,ACTUAL,2014-09-30,,INTERVENTIONAL,,All participants who received at least 1 dose of study drug,"Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials","An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C",COMPLETED,,PHASE2,276,ACTUAL,Bristol-Myers Squibb,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 23:44:43,2024-10-13 23:44:43,INDUSTRY,,,,,,,Bristol-Myers Squibb,"Argentina|Australia|Austria|Brazil|Canada|Denmark|France|Germany|Greece|Ireland|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Puerto Rico|Singapore|Spain|Sweden|Taiwan|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01429259,,2011-09-02,2015-03-17,,2018-02-20,2011-09-06,2011-09-07,ESTIMATED,2015-03-26,2015-03-27,ESTIMATED,,,,2018-02-20,2018-03-20,ACTUAL,2012-02,,2012-02-29,2018-02,2018-02-28,2014-01,ACTUAL,2014-01-31,2014-01,ACTUAL,2014-01-31,,INTERVENTIONAL,,Enrolled participants receiving at least 3 doses of meropenem as a 3 hour prolonged infusion.,Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children,"An Open Label Study to Assess the Population Pharmacokinetics, Safety, and Practicality of Administering Meropenem as a Prolonged Infusion to Cystic Fibrosis Children Admitted With an Acute Pulmonary Exacerbation",COMPLETED,,PHASE4,30,ACTUAL,Hartford Hospital,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:15:37,2024-10-13 08:15:37,OTHER,,,,,,,Joseph Kuti|Thrasher Research Fund,United States,Blood and lymphatic system disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Skin and subcutaneous tissue disorders
NCT01431339,,2011-09-08,2013-12-27,,2013-12-27,2011-09-08,2011-09-09,ESTIMATED,2013-12-27,2014-02-12,ESTIMATED,,,,2013-12-27,2014-02-12,ESTIMATED,2011-07,,2011-07-31,2013-12,2013-12-31,2012-12,ACTUAL,2012-12-31,2012-11,ACTUAL,2012-11-30,,INTERVENTIONAL,,,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,739,ACTUAL,"Durata Therapeutics Inc., an affiliate of Allergan plc",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:11:05,2024-10-14 18:11:05,INDUSTRY,,,,,,,"Durata Therapeutics Inc., an affiliate of Allergan plc","Bulgaria|Estonia|Hungary|Israel|Korea, Republic of|Latvia|Lithuania|Poland|Romania|Russian Federation|Slovakia|South Africa|Taiwan|Ukraine|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01431339,,2011-09-08,2013-12-27,,2013-12-27,2011-09-08,2011-09-09,ESTIMATED,2013-12-27,2014-02-12,ESTIMATED,,,,2013-12-27,2014-02-12,ESTIMATED,2011-07,,2011-07-31,2013-12,2013-12-31,2012-12,ACTUAL,2012-12-31,2012-11,ACTUAL,2012-11-30,,INTERVENTIONAL,,,Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regimen (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,739,ACTUAL,"Durata Therapeutics Inc., an affiliate of Allergan plc",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:11:05,2024-10-14 18:11:05,INDUSTRY,,,,,,,"Durata Therapeutics Inc., an affiliate of Allergan plc","Bulgaria|Estonia|Hungary|Israel|Korea, Republic of|Latvia|Lithuania|Poland|Romania|Russian Federation|Slovakia|South Africa|Taiwan|Ukraine|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01431989,,2011-09-08,2012-01-05,,2018-06-18,2011-09-08,2011-09-12,ESTIMATED,2012-01-05,2012-02-07,ESTIMATED,,,,2018-06-18,2018-06-20,ACTUAL,2011-05-27,ACTUAL,2011-05-27,2018-06,2018-06-30,2011-06-11,ACTUAL,2011-06-11,2011-06-11,ACTUAL,2011-06-11,,INTERVENTIONAL,,,Amoxicillin Bioequivalence Study Brazil - Fast,"Evaluation of Pharmaceutical Bioequivalence of Amoxicillin Trihydrate - Clamoxyl 500mg/5mL (Glaxo Wellcome Production.) in the Form Powder for Oral Suspension Versus Amoxil ® 500mg/5mL (GlaxoSmithKline Mexico SA) in the Form of Powder for Oral Suspension in Healthy Volunteers and Fasting, Using Techniques of Liquid Chromatography",COMPLETED,,PHASE1,28,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 03:24:11,2024-10-13 03:24:11,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil,Blood and lymphatic system disorders|General disorders|Hepatobiliary disorders|Renal and urinary disorders
NCT01432262,,2011-06-22,2012-12-04,,2013-01-18,2011-09-08,2011-09-12,ESTIMATED,2012-12-04,2013-01-08,ESTIMATED,,,,2013-01-18,2013-01-25,ESTIMATED,2011-07,,2011-07-31,2013-01,2013-01-31,2011-12,ACTUAL,2011-12-31,2011-12,ACTUAL,2011-12-31,,INTERVENTIONAL,,,13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico,"A Phase 3, Open Label, Single Arm, Multicenter, Trial to Assess The Safety, Tolerability And Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine In Healthy Adults Aged => 50 Years of Age Who Are Naive To 23-Valent Pneumococcal Polysaccharide Vaccine in Mexico.",COMPLETED,,PHASE3,324,ACTUAL,Pfizer,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:25:50,2024-10-14 00:25:50,INDUSTRY,,,,,,,Pfizer,Mexico,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01433289,,2011-09-09,2022-01-20,,2023-04-26,2011-09-12,2011-09-13,ESTIMATED,2023-04-26,2023-05-19,ACTUAL,,,,2023-04-26,2023-05-19,ACTUAL,2010-12,,2010-12-31,2023-04,2023-04-30,2015-07,ACTUAL,2015-07-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,,,Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals,"Placebo-Controlled, Dose-Blinded, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Polyphenon E (EGCG) 14 Day Monotherapy in Antiretroviral Naïve and Experienced, HIV-1-Infected Subjects",COMPLETED,,PHASE1,23,ACTUAL,Baylor College of Medicine,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 01:06:01,2024-10-13 01:06:01,OTHER,,,,,,,Baylor College of Medicine|National Center for Complementary and Integrative Health (NCCIH),United States,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01435018,,2011-09-14,2019-03-13,,2021-09-24,2011-09-14,2011-09-15,ESTIMATED,2019-03-13,2019-04-08,ACTUAL,,,,2021-09-24,2021-10-20,ACTUAL,2013-10-01,ACTUAL,2013-10-01,2021-09,2021-09-30,2019-08-29,ACTUAL,2019-08-29,2018-03-13,ACTUAL,2018-03-13,,INTERVENTIONAL,,All randomized participants who were eligible for the study and who started their randomized chemotherapy.,Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS,A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings,COMPLETED,,PHASE3,334,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 15:17:16,2024-10-14 15:17:16,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|AIDS Malignancy Consortium|National Cancer Institute (NCI)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Dental and Craniofacial Research (NIDCR),Brazil|Kenya|Malawi|South Africa|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01440569,,2011-09-22,2014-10-23,2013-11-17,2016-10-26,2011-09-23,2011-09-26,ESTIMATED,2014-10-23,2014-10-28,ESTIMATED,2013-11-17,2013-12-12,ESTIMATED,2016-10-26,2016-12-14,ESTIMATED,2011-09,,2011-09-30,2016-10,2016-10-31,2015-10,ACTUAL,2015-10-31,2012-08,ACTUAL,2012-08-31,,INTERVENTIONAL,,Full Analysis Set: participants who were enrolled into the study and received at least one dose of study drug.,Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults,"A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV-1 Infected, Antiretroviral Treatment-Naïve and -Experienced Adults With No Darunavir Resistance-associated Mutations",COMPLETED,,PHASE3,314,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 16:51:07,2024-10-14 16:51:07,INDUSTRY,,,,,,,"Gilead Sciences|Janssen Research & Development, LLC",Belgium|France|Germany|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01442675,,2011-09-26,2014-11-11,2012-12-03,2014-11-17,2011-09-27,2011-09-28,ESTIMATED,2014-11-17,2014-11-18,ESTIMATED,2012-12-03,2012-12-05,ESTIMATED,2014-11-17,2014-11-18,ESTIMATED,2011-09,,2011-09-30,2014-11,2014-11-30,2012-12,ACTUAL,2012-12-31,2012-06,ACTUAL,2012-06-30,,INTERVENTIONAL,,,Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine,Safety and Immunogenicity of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine,COMPLETED,,PHASE2,834,ACTUAL,Sanofi,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:01:09,2024-10-13 05:01:09,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01443728,,2011-09-27,2024-07-13,2016-10-10,2024-07-13,2011-09-28,2011-09-30,ESTIMATED,2024-07-13,2024-08-09,ACTUAL,2016-10-10,2016-10-12,ESTIMATED,2024-07-13,2024-08-09,ACTUAL,2011-12-13,ACTUAL,2011-12-13,2024-07,2024-07-31,2015-02-15,ACTUAL,2015-02-15,2013-06-20,ACTUAL,2013-06-20,,INTERVENTIONAL,,,Vitamin D for Sickle-cell Respiratory Complications,Vitamin D for Sickle-cell Respiratory Complications,COMPLETED,,PHASE2,70,ACTUAL,Columbia University,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 13:38:09,2024-10-14 13:38:09,OTHER,,,,,,,"Gary M Brittenham, MD",United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01445678,,2011-09-26,2015-01-09,,2018-10-18,2011-10-03,2011-10-04,ESTIMATED,2015-01-09,2015-01-15,ESTIMATED,,,,2018-10-18,2018-11-16,ACTUAL,2011-12-23,ACTUAL,2011-12-23,2018-10,2018-10-31,2013-10-15,ACTUAL,2013-10-15,2013-10-03,ACTUAL,2013-10-03,,INTERVENTIONAL,,,Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections,"A Multicenter, Double-Blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA-201 With That of Meropenem in Complicated Intraabdominal Infections",COMPLETED,,PHASE3,494,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","Two identical P3 protocols were initiated (NCT01445678 and NCT01445665) subsequently, Cubist and FDA agreed that integrated data from the 2 protocols could be analyzed and reported in a single Clinical Study Report. These analyses are presented here.",2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 21:05:07,2024-10-13 21:05:07,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","Argentina|Bulgaria|Chile|Croatia|Estonia|Germany|Hungary|India|Israel|Korea, Republic of|Latvia|Lithuania|Moldova, Republic of|Poland|Serbia|United States","Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01446289,,2011-09-27,2014-06-20,,2014-09-05,2011-10-03,2011-10-05,ESTIMATED,2014-09-05,2014-09-08,ESTIMATED,,,,2014-09-05,2014-09-08,ESTIMATED,2011-09,,2011-09-30,2014-09,2014-09-30,2013-10,ACTUAL,2013-10-31,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,All enrolled population,Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings,"A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",COMPLETED,,PHASE2,86,ACTUAL,Novartis,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 03:52:04,2024-10-13 03:52:04,INDUSTRY,,,,,,,Novartis|Novartis Vaccines,Belgium|Canada,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT01446289,,2011-09-27,2014-06-20,,2014-09-05,2011-10-03,2011-10-05,ESTIMATED,2014-09-05,2014-09-08,ESTIMATED,,,,2014-09-05,2014-09-08,ESTIMATED,2011-09,,2011-09-30,2014-09,2014-09-30,2013-10,ACTUAL,2013-10-31,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,All enrolled population,Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings,"A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",COMPLETED,,PHASE2,86,ACTUAL,Novartis,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 03:52:04,2024-10-13 03:52:04,INDUSTRY,,,,,,,Novartis|Novartis Vaccines,Belgium|Canada,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT01446289,,2011-09-27,2014-06-20,,2014-09-05,2011-10-03,2011-10-05,ESTIMATED,2014-09-05,2014-09-08,ESTIMATED,,,,2014-09-05,2014-09-08,ESTIMATED,2011-09,,2011-09-30,2014-09,2014-09-30,2013-10,ACTUAL,2013-10-31,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,All enrolled population,Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings,"A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",COMPLETED,,PHASE2,86,ACTUAL,Novartis,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 03:52:04,2024-10-13 03:52:04,INDUSTRY,,,,,,,Novartis|Novartis Vaccines,Belgium|Canada,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT01447407,,2011-10-03,2020-01-28,,2020-02-20,2011-10-04,2011-10-06,ESTIMATED,2020-02-20,2020-03-04,ACTUAL,,,,2020-02-20,2020-03-04,ACTUAL,2011-09,,2011-09-30,2020-02,2020-02-29,2012-12,ACTUAL,2012-12-31,2012-03,ACTUAL,2012-03-31,,INTERVENTIONAL,,,Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine,Phase 1b Study to Evaluate the Safety and Immunogenicity of NDV-3 Formulated With or Without Alum (AlOH) and Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults,COMPLETED,,PHASE1,164,ACTUAL,"NovaDigm Therapeutics, Inc.",,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:41:45,2024-10-14 18:41:45,INDUSTRY,,,,,,,"NovaDigm Therapeutics, Inc.|United States Department of Defense",United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01447407,,2011-10-03,2020-01-28,,2020-02-20,2011-10-04,2011-10-06,ESTIMATED,2020-02-20,2020-03-04,ACTUAL,,,,2020-02-20,2020-03-04,ACTUAL,2011-09,,2011-09-30,2020-02,2020-02-29,2012-12,ACTUAL,2012-12-31,2012-03,ACTUAL,2012-03-31,,INTERVENTIONAL,,,Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine,Phase 1b Study to Evaluate the Safety and Immunogenicity of NDV-3 Formulated With or Without Alum (AlOH) and Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults,COMPLETED,,PHASE1,164,ACTUAL,"NovaDigm Therapeutics, Inc.",,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:41:45,2024-10-14 18:41:45,INDUSTRY,,,,,,,"NovaDigm Therapeutics, Inc.|United States Department of Defense",United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01448057,,2011-10-05,2016-08-16,,2017-01-18,2011-10-06,2011-10-07,ESTIMATED,2016-11-17,2017-01-13,ESTIMATED,,,,2017-01-18,2017-03-03,ACTUAL,2013-07,,2013-07-31,2017-01,2017-01-31,2015-08,ACTUAL,2015-08-31,2015-08,ACTUAL,2015-08-31,,INTERVENTIONAL,,,"Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu","A Prospective, Randomized, Investigator-Blind Study to Compare Three Days of Treatment With Paracetamol (500 mg) / Dimethindene Maleate (1 mg) / Phenylephrine Hydrochloride (10 mg) Tablets Versus Paracetamol 500 mg Alone in the Treatment of Nasal Congestion and Other Symptoms Due to Cold and Flu",COMPLETED,,PHASE3,341,ACTUAL,Novartis,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 08:42:04,2024-10-14 08:42:04,INDUSTRY,,,,,,,Novartis,Brazil,Gastrointestinal disorders|Nervous system disorders
NCT01448707,,2011-06-02,2015-10-30,,2017-10-23,2011-10-06,2011-10-07,ESTIMATED,2015-10-30,2015-12-03,ESTIMATED,,,,2017-10-23,2017-11-27,ACTUAL,2012-03-15,ACTUAL,2012-03-15,2017-10,2017-10-31,2015-03-18,ACTUAL,2015-03-18,2014-06-11,ACTUAL,2014-06-11,,INTERVENTIONAL,PROTEA,Baseline characteristics were analyzed for all participants who were treated.,A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment,PROTEAse Inhibitor (DRV/Rtv) in Mono- or Triple Therapy in Suppressed HIV-1 Infected Subjects,COMPLETED,,PHASE3,274,ACTUAL,Janssen-Cilag International NV,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 01:48:22,2024-10-14 01:48:22,INDUSTRY,,,,,,,Janssen-Cilag International NV,Austria|Belgium|Denmark|France|Germany|Hungary|Ireland|Israel|Netherlands|Poland|Spain|Sweden|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT01449929,,2011-10-06,2013-12-12,,2017-12-14,2011-10-06,2011-10-10,ESTIMATED,2014-02-27,2014-03-27,ESTIMATED,,,,2017-12-14,2018-01-16,ACTUAL,2011-10-31,ACTUAL,2011-10-31,2017-10,2017-10-31,2016-12-26,ACTUAL,2016-12-26,2013-04-22,ACTUAL,2013-04-22,,INTERVENTIONAL,FLAMINGO,,"Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily Compared to Darunavir/Ritonavir (DRV/r) 800 mg/100 mg Once Daily Each Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral naïve Adult Subjects",COMPLETED,,PHASE3,488,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,TRUE,,,,,,,,,,,,2024-10-13 11:14:41,2024-10-13 11:14:41,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,France|Germany|Italy|Puerto Rico|Romania|Russian Federation|Spain|Switzerland|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT01450631,,2011-10-10,2014-07-03,,2022-07-29,2011-10-11,2011-10-12,ESTIMATED,2014-07-03,2014-08-01,ESTIMATED,,,,2022-07-29,2022-08-01,ACTUAL,2012-02,,2012-02-29,2022-07,2022-07-31,2013-12,ACTUAL,2013-12-31,2013-12,ACTUAL,2013-12-31,,INTERVENTIONAL,,,The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions,"A Prospective, Randomized, Evaluation of the Prevena™ Incision Management System on Closed Incisions in Obese Subjects Undergoing Cesarean Section Surgery",COMPLETED,,NA,92,ACTUAL,3M,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 05:08:02,2024-10-14 05:08:02,INDUSTRY,,,,,,,3M,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01450631,,2011-10-10,2014-07-03,,2022-07-29,2011-10-11,2011-10-12,ESTIMATED,2014-07-03,2014-08-01,ESTIMATED,,,,2022-07-29,2022-08-01,ACTUAL,2012-02,,2012-02-29,2022-07,2022-07-31,2013-12,ACTUAL,2013-12-31,2013-12,ACTUAL,2013-12-31,,INTERVENTIONAL,,,The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions,"A Prospective, Randomized, Evaluation of the Prevena™ Incision Management System on Closed Incisions in Obese Subjects Undergoing Cesarean Section Surgery",COMPLETED,,NA,92,ACTUAL,3M,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 05:08:02,2024-10-14 05:08:02,INDUSTRY,,,,,,,3M,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01454947,,2011-08-04,2015-07-20,,2024-05-22,2011-10-14,2011-10-19,ESTIMATED,2017-03-30,2017-06-20,ACTUAL,,,,2024-05-22,2024-05-23,ACTUAL,2011-08,,2011-08-31,2024-05,2024-05-31,2014-09,ACTUAL,2014-09-30,2014-04,ACTUAL,2014-04-30,,INTERVENTIONAL,BEARI,Enrolled Clinicians,Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study),Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study),COMPLETED,,NA,248,ACTUAL,University of Southern California,,8,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 05:45:47,2024-10-13 05:45:47,OTHER,,,,,,,National Institute on Aging (NIA)|University of Southern California,United States,Infections and infestations
NCT01461096,,2011-10-26,2016-12-14,,2021-10-29,2011-10-26,2011-10-27,ESTIMATED,2016-12-14,2017-02-07,ESTIMATED,,,,2021-10-29,2021-11-02,ACTUAL,2012-03,,2012-03-31,2021-10,2021-10-31,2016-01,ACTUAL,2016-01-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,,All participants randomized who had results for the respective baseline measure available. The numbers of participants for each measure are shown below.,Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women,"A Randomized, Double-Blinded, Placebo-Controlled, Phase III Trial of the Quadrivalent HPV Vaccine to Prevent Anal Human Papillomavirus Infection in HIV-Infected Men and Women",COMPLETED,,PHASE3,575,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:25:54,2024-10-13 07:25:54,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT01462357,,2011-10-27,2014-08-11,,2019-10-30,2011-10-27,2011-10-31,ESTIMATED,2016-02-25,2016-03-28,ESTIMATED,,,,2019-10-30,2019-11-15,ACTUAL,2011-11-21,ACTUAL,2011-11-21,2019-10,2019-10-31,2015-10-27,ACTUAL,2015-10-27,2015-10-27,ACTUAL,2015-10-27,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females,Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' HPV-16/18 L1 AS04 Vaccine and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females,COMPLETED,,PHASE3,1079,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=4513,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below).,2024-10-13 06:35:41,2024-10-13 06:35:41,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil|France|Hong Kong|Singapore|Sweden,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01466062,,2011-09-12,2013-04-25,,2013-06-13,2011-11-04,2011-11-06,ESTIMATED,2013-06-13,2013-06-17,ESTIMATED,,,,2013-06-13,2013-06-17,ESTIMATED,2011-08,,2011-08-31,2013-06,2013-06-30,2012-04,ACTUAL,2012-04-30,2012-04,ACTUAL,2012-04-30,,INTERVENTIONAL,,,"Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions","Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions",COMPLETED,,PHASE3,28,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 02:39:47,2024-10-14 02:39:47,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Japan,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01466595,,2011-10-06,2013-09-03,,2018-08-10,2011-11-04,2011-11-08,ESTIMATED,2013-09-03,2013-11-07,ESTIMATED,,,,2018-08-10,2018-09-10,ACTUAL,2011-09,,2011-09-30,2018-08,2018-08-31,2012-11,ACTUAL,2012-11-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,,Rifaximin as a Modulator of Microbial Translocation and Immune Activation,A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy,COMPLETED,,PHASE2,73,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 01:57:29,2024-10-13 01:57:29,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,Gastrointestinal disorders|General disorders|Investigations|Metabolism and nutrition disorders|Nervous system disorders
NCT01466985,,2011-11-04,2018-09-24,,2018-09-24,2011-11-04,2011-11-08,ESTIMATED,2018-09-24,2019-02-15,ACTUAL,,,,2018-09-24,2019-02-15,ACTUAL,2011-10-21,ACTUAL,2011-10-21,2018-09,2018-09-30,2012-04-10,ACTUAL,2012-04-10,2012-04-10,ACTUAL,2012-04-10,,INTERVENTIONAL,,,A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005),"A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-1439 in HIV-1 Infected Patients",COMPLETED,,PHASE1,18,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 09:33:05,2024-10-13 09:33:05,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany,"Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01471444,,2011-11-10,2021-09-21,,2021-11-18,2011-11-14,2011-11-15,ESTIMATED,2021-11-18,2021-12-16,ACTUAL,,,,2021-11-18,2021-12-16,ACTUAL,2011-11-02,ACTUAL,2011-11-02,2021-09,2021-09-30,2020-12-14,ACTUAL,2020-12-14,2020-12-14,ACTUAL,2020-12-14,,INTERVENTIONAL,,,Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS),A Randomized Study of Once Daily Fludarabine-Clofarabine Versus Fludarabine Alone Combined With Intervenous Busulfan Followed by Allogeneic Hemopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS),COMPLETED,,PHASE3,256,ACTUAL,M.D. Anderson Cancer Center,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 17:34:55,2024-10-14 17:34:55,OTHER,,,,,,,M.D. Anderson Cancer Center|Sanofi,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01472549,,2011-09-20,2018-04-03,,2018-07-12,2011-11-10,2011-11-16,ESTIMATED,2018-07-12,2018-08-08,ACTUAL,,,,2018-07-12,2018-08-08,ACTUAL,2011-09,,2011-09-30,2018-07,2018-07-31,2015-06,ACTUAL,2015-06-30,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,,,The Skin Prep Study,Antiseptic Skin Preparation for Preventing Surgical Site Infection at Cesarean Delivery: a Randomized Comparative Effectiveness Trial,COMPLETED,,NA,1147,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 17:42:56,2024-10-13 17:42:56,OTHER,,,,,,,Washington University School of Medicine,United States,Skin and subcutaneous tissue disorders
NCT01472965,,2011-11-14,2017-08-18,,2017-10-12,2011-11-16,2011-11-17,ESTIMATED,2017-10-12,2017-11-13,ACTUAL,,,,2017-10-12,2017-11-13,ACTUAL,2011-12-29,ACTUAL,2011-12-29,2017-08,2017-08-31,2016-11-11,ACTUAL,2016-11-11,2016-11-11,ACTUAL,2016-11-11,,INTERVENTIONAL,,,Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line-Associated Bloodstream Infection,"A Double-Blind, Randomized, Placebo-Controlled, Trial of Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line Associated Bloodstream Infection (CLABSI) in Children and Adolescents",COMPLETED,,PHASE3,95,ACTUAL,St. Jude Children's Research Hospital,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 16:25:58,2024-10-14 16:25:58,OTHER,,,,,,,St. Jude Children's Research Hospital,Australia|United States,"General disorders|Product Issues|Respiratory, thoracic and mediastinal disorders"
NCT01473836,,2011-10-11,2013-10-10,,2013-12-18,2011-11-14,2011-11-17,ESTIMATED,2013-10-10,2013-12-10,ESTIMATED,,,,2013-12-18,2014-01-24,ESTIMATED,2011-11,,2011-11-30,2013-12,2013-12-31,2012-10,ACTUAL,2012-10-31,2012-10,ACTUAL,2012-10-31,,INTERVENTIONAL,,,A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection,"A Phase 3, Multicenter, Unblind, Non-Comparative Study To Confirm Efficacy And Safety Of Intravenous Metronidazole In Patients With Intrabdominal Infection In Combination With Intravenous Ceftriaxone",COMPLETED,,PHASE3,38,ACTUAL,Pfizer,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:01:09,2024-10-13 05:01:09,INDUSTRY,,,,,,,Pfizer,Japan,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01475838,,2011-11-17,2015-01-08,2014-08-25,2016-05-06,2011-11-18,2011-11-21,ESTIMATED,2015-01-22,2015-01-26,ESTIMATED,2014-08-25,2014-08-27,ESTIMATED,2016-05-06,2016-06-08,ESTIMATED,2011-11,,2011-11-30,2016-05,2016-05-31,2014-12,ACTUAL,2014-12-31,2013-11,ACTUAL,2013-11-30,,INTERVENTIONAL,,Safety Analysis Set: participants were randomized and received at least one dose of study medication.,"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","A Phase 3b Randomized, Open-Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI + RTV) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically-Suppressed, HIV-1 Infected Patients",COMPLETED,,PHASE3,438,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 07:57:22,2024-10-14 07:57:22,INDUSTRY,,,,,,,Gilead Sciences,Austria|Belgium|Canada|France|Germany|Italy|Portugal|Puerto Rico|Spain|Switzerland|United Kingdom|United States,"Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01478620,,2011-11-21,2014-08-27,,2019-02-05,2011-11-21,2011-11-23,ESTIMATED,2014-10-10,2014-10-13,ESTIMATED,,,,2019-02-05,2019-02-27,ACTUAL,2011-10,,2011-10-31,2019-02,2019-02-28,2012-08,ACTUAL,2012-08-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,,Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI),"An Open-label, Non-randomized, Multicenter, Interventional Study to Investigate the Safety and Efficacy of Canephron® N in the Management of Uncomplicated Urinary Tract Infections (uUTI)",COMPLETED,,PHASE3,125,ACTUAL,Bionorica SE,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 07:38:23,2024-10-14 07:38:23,INDUSTRY,,,,,,,Bionorica SE,Russian Federation|Ukraine,Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Investigations|Nervous system disorders|Psychiatric disorders|Vascular disorders
NCT01479478,,2011-11-22,2018-07-18,,2018-08-14,2011-11-23,2011-11-24,ESTIMATED,2018-08-14,2018-08-20,ACTUAL,,,,2018-08-14,2018-08-20,ACTUAL,2011-11,,2011-11-30,2018-08,2018-08-31,2017-07-26,ACTUAL,2017-07-26,2017-07-26,ACTUAL,2017-07-26,,INTERVENTIONAL,,,Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy,Oral Probiotic Supplementation and Group B Streptococcus Rectovaginal Colonization in Pregnant Women: a Randomized Double-blind Placebo-controlled Trial.,COMPLETED,,NA,251,ACTUAL,Stanford University,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 03:11:24,2024-10-13 03:11:24,OTHER,,,,,,,Stanford University,United States,"Pregnancy, puerperium and perinatal conditions"
NCT01480258,,2011-11-23,2019-03-11,,2019-03-11,2011-11-23,2011-11-28,ESTIMATED,2019-03-11,2019-04-02,ACTUAL,,,,2019-03-11,2019-04-02,ACTUAL,2011-11-23,ACTUAL,2011-11-23,2019-03,2019-03-31,2013-10-09,ACTUAL,2013-10-09,2013-10-09,ACTUAL,2013-10-09,,INTERVENTIONAL,,,"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months",COMPLETED,,PHASE3,1315,ACTUAL,MCM Vaccines B.V.,,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 14:14:19,2024-10-13 14:14:19,INDUSTRY,,,,,,,MCM Vaccines B.V.|Merck Sharp & Dohme LLC,Finland|Italy|Sweden,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01482767,,2011-11-28,2016-04-05,,2021-11-02,2011-11-28,2011-12-01,ESTIMATED,2016-04-05,2016-05-10,ESTIMATED,,,,2021-11-02,2021-11-04,ACTUAL,2012-04,,2012-04-30,2016-06,2016-06-30,2015-04,ACTUAL,2015-04-30,2015-04,ACTUAL,2015-04-30,,INTERVENTIONAL,,"All eligible participants enrolled (Group B participants who were found ineligible after enrollment, n=5, were excluded).","Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection","A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects",COMPLETED,,PHASE3,262,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:46:17,2024-10-13 06:46:17,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01489358,,2011-12-07,2016-03-11,,2016-06-09,2011-12-08,2011-12-09,ESTIMATED,2016-03-11,2016-04-12,ESTIMATED,,,,2016-06-09,2016-07-25,ESTIMATED,2011-12,,2011-12-31,2016-03,2016-03-31,2013-04,ACTUAL,2013-04-30,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,All enrolled participants,Chikungunya Virus Vaccine Trial in Healthy Adults,"VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults",COMPLETED,,PHASE1,25,ACTUAL,National Institutes of Health Clinical Center (CC),,3,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 20:35:44,2024-10-14 20:35:44,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Surgical and medical procedures|Vascular disorders"
NCT01489527,,2011-12-08,2015-01-05,,2015-01-21,2011-12-08,2011-12-09,ESTIMATED,2015-01-05,2015-01-12,ESTIMATED,,,,2015-01-21,2015-02-06,ESTIMATED,2012-09,,2012-09-30,2015-01,2015-01-31,2014-12,ACTUAL,2014-12-31,2014-04,ACTUAL,2014-04-30,,INTERVENTIONAL,,All treated participants,Preparedness Study - HPV Vaccine,Preparedness Study: Efficacy of HPV Vaccine to Reduce HIV Infection,COMPLETED,,NA,406,ACTUAL,H. Lee Moffitt Cancer Center and Research Institute,"The EVRI Trial had a short duration with limited follow-up time; therefore, clinical efficacy in reducing HIV acquisition cannot be assessed.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:37:13,2024-10-13 20:37:13,OTHER,,,,,,,H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme LLC,South Africa|United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01492582,,2011-12-12,2020-02-06,,2021-10-07,2011-12-13,2011-12-15,ESTIMATED,2020-04-17,2020-04-30,ACTUAL,,,,2021-10-07,2021-10-27,ACTUAL,2012-07,,2012-07-31,2021-10,2021-10-31,2020-07-20,ACTUAL,2020-07-20,2019-02-08,ACTUAL,2019-02-08,,INTERVENTIONAL,,Participants who consented to the study.,Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors,Quadrivalent Human Papillomavirus (qHPV) Vaccine in Cancer Survivors: Cross Sectional Survey and Phase II Open-Label Vaccine Trial,COMPLETED,,PHASE2,1499,ACTUAL,University of Alabama at Birmingham,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 06:47:03,2024-10-14 06:47:03,OTHER,,,,,,,Merck Sharp & Dohme LLC|National Cancer Institute (NCI)|University of Alabama at Birmingham,United States,"Endocrine disorders|Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Skin and subcutaneous tissue disorders"
NCT01494038,,2011-12-14,2018-09-06,,2021-11-03,2011-12-14,2011-12-16,ESTIMATED,2018-10-22,2018-11-20,ACTUAL,,,,2021-11-03,2021-11-05,ACTUAL,2014-08-19,ACTUAL,2014-08-19,2018-10,2018-10-31,2017-09-06,ACTUAL,2017-09-06,2017-09-06,ACTUAL,2017-09-06,,INTERVENTIONAL,,All women in study.,Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women,A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Settings,COMPLETED,,PHASE4,956,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 23:16:28,2024-10-13 23:16:28,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Haiti|India|South Africa|Tanzania|Thailand|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01495702,,2011-12-14,2014-12-31,2014-08-25,2015-12-01,2011-12-16,2011-12-20,ESTIMATED,2015-01-22,2015-01-26,ESTIMATED,2014-08-25,2014-08-27,ESTIMATED,2015-12-01,2016-01-07,ESTIMATED,2011-12,,2011-12-31,2015-12,2015-12-31,2014-12,ACTUAL,2014-12-31,2013-11,ACTUAL,2013-11-30,,INTERVENTIONAL,,Safety Analysis Set: participants were randomized and received at least one dose of study drug,"Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","A Phase 3b Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Plus Emtricitabine (FTC) and Tenofovir DF (TDF) to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (EVG/COBI/FTC/TDF) in Virologically Suppressed, HIV 1 Infected Patients",COMPLETED,,PHASE3,439,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 13:38:09,2024-10-14 13:38:09,INDUSTRY,,,,,,,Gilead Sciences,Australia|Austria|Belgium|Canada|France|Germany|Italy|Portugal|Puerto Rico|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01496352,,2011-12-15,2014-08-15,,2014-08-15,2011-12-19,2011-12-21,ESTIMATED,2014-08-15,2014-09-01,ESTIMATED,,,,2014-08-15,2014-09-01,ESTIMATED,2012-02,,2012-02-29,2014-08,2014-08-31,2013-06,ACTUAL,2013-06-30,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,,DFA-02 in Patients Undergoing Colorectal Surgery,"A Randomized, Double-blind, Placebo Controlled, Safety, Tolerability, and Pharmacokinetic Dose Escalation Study of DFA-02 in Patients Undergoing Colorectal Surgery",COMPLETED,,PHASE1/PHASE2,30,ACTUAL,Dr. Reddy's Laboratories Limited,"Protocol specified cohorts of 10, 20, 30 or 40 mL to be placed after closure of the fascia and prior to skin closure. Experience with 20 and 30 mL dose levels showed that even largest patients would not accommodate 40 mL so that arm was not done.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:05:26,2024-10-13 08:05:26,INDUSTRY,,,,,,,Dr. Reddy's Laboratories Limited|Duke Clinical Research Institute,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01497899,,2011-12-14,2015-12-04,2013-10-21,2018-10-19,2011-12-22,2011-12-23,ESTIMATED,2015-12-04,2016-01-08,ESTIMATED,2013-10-21,2013-11-11,ESTIMATED,2018-10-19,2018-11-19,ACTUAL,2011-12-28,ACTUAL,2011-12-28,2017-08,2017-08-31,2016-08-22,ACTUAL,2016-08-22,2012-10-17,ACTUAL,2012-10-17,,INTERVENTIONAL,,"E/C/F/TAF and E/C/F/TDF arms: participants who were randomized to the Double-Blind Phase and received at least 1 dose of study drug.

D/C/F/TAF to E/C/F/TAF and DRV+COBI+TVD to E/C/F/TAF arms: participants who enrolled from Gilead-sponsored Study GS-US-299-0102 in the Open-Label Extension Phase and received at least 1 dose of open-label E/C/F/TAF","Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE2,279,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 03:05:32,2024-10-14 03:05:32,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01499199,,2011-12-15,2013-08-15,,2015-01-15,2011-12-21,2011-12-26,ESTIMATED,2013-09-19,2013-11-25,ESTIMATED,,,,2015-01-15,2015-02-25,ESTIMATED,2012-01,,2012-01-31,2015-01,2015-01-31,2014-05,ACTUAL,2014-05-31,2012-10,ACTUAL,2012-10-31,,INTERVENTIONAL,,,A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects,"A Single-arm Study of the Safety, Efficacy and Central Nervous System and Plasma PK of GSK1349572 (Dolutegravir, DTG) 50 mg Once Daily in Combination With the Abacavir/Lamivudine Fixed Dose Combination Tablet Over 96 Weeks in HIV-1 Infected Antiretroviral Naive Adult Subjects",COMPLETED,,PHASE3,13,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 12:58:07,2024-10-13 12:58:07,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01499277,,2011-12-16,2015-06-23,,2017-09-01,2011-12-22,2011-12-26,ESTIMATED,2015-10-07,2015-11-09,ESTIMATED,,,,2017-09-01,2017-09-06,ACTUAL,2012-05,,2012-05-31,2017-09,2017-09-30,2015-01,ACTUAL,2015-01-31,2014-06,ACTUAL,2014-06-30,,INTERVENTIONAL,,"761 randomized patients who received any amount of study therapy. there are 11 patients who are randomized , but didn't receive any study therapy.",Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections,"A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities",COMPLETED,,PHASE3,802,ACTUAL,Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 00:43:25,2024-10-13 00:43:25,INDUSTRY,,,,,,,Forest Laboratories|Pfizer,"Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Chile|China|Colombia|Croatia|Czechia|Czech Republic|France|Germany|Greece|Hong Kong|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|Peru|Philippines|Poland|Romania|Russian Federation|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01499290,,2011-12-19,2015-11-06,,2017-08-31,2011-12-22,2011-12-26,ESTIMATED,2016-01-29,2016-03-01,ESTIMATED,,,,2017-08-31,2017-09-06,ACTUAL,2012-03,,2012-03-31,2017-08,2017-08-31,2014-04,ACTUAL,2014-04-30,2014-04,ACTUAL,2014-04-30,,INTERVENTIONAL,,The MITT analysis set includes all patients who met the disease definition for cIAI and received at least 1 dose of study drug. 15 patients excluded received at least one dose of study drug but failed the minimum disease criteria.,Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections,"A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults",COMPLETED,,PHASE3,493,ACTUAL,Pfizer,This summary describes data collected from two identical CSPs (D4280C00001 and D4280C00005). With agreement from the EMA and the FDA the data have been combined into a single study database.,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 22:08:13,2024-10-13 22:08:13,INDUSTRY,,,,,,,Forest Laboratories|Pfizer,Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|Croatia|Czechia|Czech Republic|France|Germany|Greece|Hungary|India|Israel|Italy|Latvia|Lithuania|Malaysia|Mexico|Netherlands|Peru|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01502072,,2011-12-22,2021-01-21,,2021-01-21,2011-12-29,2011-12-30,ESTIMATED,2021-01-21,2021-02-15,ACTUAL,,,,2021-01-21,2021-02-15,ACTUAL,2011-12-28,ACTUAL,2011-12-28,2021-01,2021-01-31,2020-02-01,ACTUAL,2020-02-01,2020-02-01,ACTUAL,2020-02-01,,INTERVENTIONAL,,One patient from the Oral ribavarin group withdrew consent.,Respiratory Syncytial Virus - RSV Protocol,An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant,COMPLETED,,PHASE2,48,ACTUAL,M.D. Anderson Cancer Center,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 20:53:21,2024-10-14 20:53:21,OTHER,,,,,,,M.D. Anderson Cancer Center,United States,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01502072,,2011-12-22,2021-01-21,,2021-01-21,2011-12-29,2011-12-30,ESTIMATED,2021-01-21,2021-02-15,ACTUAL,,,,2021-01-21,2021-02-15,ACTUAL,2011-12-28,ACTUAL,2011-12-28,2021-01,2021-01-31,2020-02-01,ACTUAL,2020-02-01,2020-02-01,ACTUAL,2020-02-01,,INTERVENTIONAL,,One patient from the Oral ribavarin group withdrew consent.,Respiratory Syncytial Virus - RSV Protocol,An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant,COMPLETED,,PHASE2,48,ACTUAL,M.D. Anderson Cancer Center,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 20:53:21,2024-10-14 20:53:21,OTHER,,,,,,,M.D. Anderson Cancer Center,United States,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01502072,,2011-12-22,2021-01-21,,2021-01-21,2011-12-29,2011-12-30,ESTIMATED,2021-01-21,2021-02-15,ACTUAL,,,,2021-01-21,2021-02-15,ACTUAL,2011-12-28,ACTUAL,2011-12-28,2021-01,2021-01-31,2020-02-01,ACTUAL,2020-02-01,2020-02-01,ACTUAL,2020-02-01,,INTERVENTIONAL,,One patient from the Oral ribavarin group withdrew consent.,Respiratory Syncytial Virus - RSV Protocol,An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant,COMPLETED,,PHASE2,48,ACTUAL,M.D. Anderson Cancer Center,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 20:53:21,2024-10-14 20:53:21,OTHER,,,,,,,M.D. Anderson Cancer Center,United States,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01503515,,2012-01-01,2020-12-10,,2022-01-24,2012-01-01,2012-01-04,ESTIMATED,2021-01-05,2021-01-07,ACTUAL,,,,2022-01-24,2022-01-31,ACTUAL,2013-03-21,ACTUAL,2013-03-21,2022-01,2022-01-31,2021-09-30,ACTUAL,2021-09-30,2019-12-31,ACTUAL,2019-12-31,,INTERVENTIONAL,,,"Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant",A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT),COMPLETED,,PHASE3,292,ACTUAL,Children's Oncology Group,,2,,,FALSE,,,,TRUE,TRUE,,,,TRUE,,,,,,,,2024-10-14 20:35:44,2024-10-14 20:35:44,NETWORK,,,,,,,Children's Oncology Group|National Cancer Institute (NCI),Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01504841,,2011-12-30,2019-07-16,,2021-10-29,2012-01-03,2012-01-05,ESTIMATED,2019-08-27,2019-09-17,ACTUAL,,,,2021-10-29,2021-11-02,ACTUAL,2013-03-14,ACTUAL,2013-03-14,2021-10,2021-10-31,2020-08-26,ACTUAL,2020-08-26,2018-07-17,ACTUAL,2018-07-17,,INTERVENTIONAL,,"Analysis population is defined as having been treated exclusively on the dose determined to be optimal for a given cohort and having either completed 48 weeks of exposure to the study drug or having been classified as a safety failure, due to a study drug related adverse event occurring during the first 48 weeks of treatment.",Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children,"A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years",COMPLETED,,PHASE1/PHASE2,26,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"Due to the slow rate of accrual and the challenging accrual into the youngest cohort, enrollment was stopped early.",3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:06:14,2024-10-15 02:06:14,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Brazil|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01505114,,2012-01-04,2017-05-16,,2021-11-03,2012-01-04,2012-01-06,ESTIMATED,2017-06-20,2017-07-18,ACTUAL,,,,2021-11-03,2021-11-05,ACTUAL,2012-06,ACTUAL,2012-06-30,2017-06,2017-06-30,2015-11,ACTUAL,2015-11-30,2015-11,ACTUAL,2015-11-30,,INTERVENTIONAL,,,Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women,"A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex With Men and in At-Risk Women",COMPLETED,,PHASE2,594,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 02:01:23,2024-10-14 02:01:23,NIH,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|HIV Prevention Trials Network|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01505634,,2012-01-04,2019-04-26,,2019-04-26,2012-01-05,2012-01-06,ESTIMATED,2019-04-26,2019-05-24,ACTUAL,,,,2019-04-26,2019-05-24,ACTUAL,2012-05-16,ACTUAL,2012-05-16,2019-04,2019-04-30,2015-07-28,ACTUAL,2015-07-28,2015-07-28,ACTUAL,2015-07-28,,INTERVENTIONAL,,,"Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)","A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Urinary Tract Infection (cUTI)",COMPLETED,,PHASE2,302,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 20:19:01,2024-10-13 20:19:01,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Argentina|Brazil|Bulgaria|Canada|Chile|Colombia|Greece|Guatemala|Korea, Republic of|Latvia|Peru|Poland|Romania|Russian Federation|Spain|Taiwan|Turkey|Ukraine|United States","Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders"
NCT01506271,,2012-01-05,2019-04-26,,2019-06-07,2012-01-06,2012-01-09,ESTIMATED,2019-06-07,2019-06-10,ACTUAL,,,,2019-06-07,2019-06-10,ACTUAL,2012-06-01,ACTUAL,2012-06-01,2019-06,2019-06-30,2014-08-12,ACTUAL,2014-08-12,2014-08-12,ACTUAL,2014-08-12,,INTERVENTIONAL,,,"Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)","A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Intra-Abdominal Infection [cIAI]",COMPLETED,,PHASE2,351,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 03:24:24,2024-10-15 03:24:24,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Argentina|Brazil|Bulgaria|Chile|Colombia|Estonia|Germany|Greece|Korea, Republic of|Latvia|Lithuania|Mexico|Peru|Poland|Portugal|Romania|Russian Federation|South Africa|Spain|Taiwan|Turkey|Ukraine|United States","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01511809,,2012-01-13,2014-11-07,,2024-02-07,2012-01-18,2012-01-19,ESTIMATED,2014-11-17,2014-11-24,ESTIMATED,,,,2024-02-07,2024-02-09,ACTUAL,2010-09,,2010-09-30,2024-02,2024-02-29,2015-05,ACTUAL,2015-05-31,2013-07,ACTUAL,2013-07-31,,INTERVENTIONAL,,,Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression,"Efficacy of Atazanavir / Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression. Randomized, Open Label Non Inferiority Trial. A Phase 3 Study.",COMPLETED,,PHASE3,117,ACTUAL,IRCCS San Raffaele,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 00:58:15,2024-10-15 00:58:15,OTHER,,,,,,,Bristol-Myers Squibb|IRCCS San Raffaele,Italy,"Cardiac disorders|Hepatobiliary disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01513239,,2012-01-16,2016-10-24,,2018-08-06,2012-01-19,2012-01-20,ESTIMATED,2016-10-24,2016-12-15,ESTIMATED,,,,2018-08-06,2018-09-05,ACTUAL,2012-02-01,ACTUAL,2012-02-01,2018-08,2018-08-31,2015-05-22,ACTUAL,2015-05-22,2015-05-22,ACTUAL,2015-05-22,,INTERVENTIONAL,MODIFY II,All Randomized Participants,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for Clostridium Difficile Infection (MODIFY II)",COMPLETED,,PHASE3,1203,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 09:46:07,2024-10-14 09:46:07,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Argentina|Canada|Czech Republic|Finland|France|Germany|Israel|Japan|Korea, Republic of|Poland|Russian Federation|Spain|Sweden|Switzerland|Taiwan|Turkey|United States","Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01513551,,2011-12-27,2018-11-26,,2018-11-26,2012-01-16,2012-01-20,ESTIMATED,2018-11-26,2018-12-13,ACTUAL,,,,2018-11-26,2018-12-13,ACTUAL,2012-03-13,ACTUAL,2012-03-13,2018-11,2018-11-30,2013-02-15,ACTUAL,2013-02-15,2013-02-15,ACTUAL,2013-02-15,,INTERVENTIONAL,,The baseline analysis population consisted of all randomized participants who received study vaccine.,"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and PREVNAR 13® (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older",COMPLETED,,PHASE2,692,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 07:50:54,2024-10-14 07:50:54,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Canada|Israel|Norway|Poland|Spain|Sweden|United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders"
NCT01519661,,2012-01-24,2014-12-17,,2015-02-08,2012-01-26,2012-01-27,ESTIMATED,2015-02-08,2015-02-10,ESTIMATED,,,,2015-02-08,2015-02-10,ESTIMATED,2012-01,,2012-01-31,2015-02,2015-02-28,2014-01,ACTUAL,2014-01-31,2014-01,ACTUAL,2014-01-31,,INTERVENTIONAL,,,Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis,"A Single Arm, Open-label, Multicenter, Phase IV Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis",COMPLETED,,PHASE4,157,ACTUAL,Novartis,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 08:58:16,2024-10-14 08:58:16,INDUSTRY,,,,,,,Novartis Pharmaceuticals,Argentina|Australia|Brazil|Canada|France|Germany|Hungary|Italy|Mexico|Spain|United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT01519713,,2012-01-20,2013-04-04,,2013-05-22,2012-01-24,2012-01-27,ESTIMATED,2013-05-22,2013-05-28,ESTIMATED,,,,2013-05-22,2013-05-28,ESTIMATED,2012-01,,2012-01-31,2013-05,2013-05-31,2012-12,ACTUAL,2012-12-31,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,,Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects,"Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects",COMPLETED,,PHASE3,200,ACTUAL,Sanofi,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:32:07,2024-10-13 08:32:07,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Japan,Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders
NCT01524900,,2012-01-17,2015-05-15,,2015-06-01,2012-01-31,2012-02-02,ESTIMATED,2015-06-01,2015-06-02,ESTIMATED,,,,2015-06-01,2015-06-02,ESTIMATED,2012-03,,2012-03-31,2015-06,2015-06-30,2014-05,ACTUAL,2014-05-31,2014-05,ACTUAL,2014-05-31,,OBSERVATIONAL,,Patients from the Treated Set (TS): This patient set includes all HIV-1 infected patients who were dispensed Viramune® and were documented to have taken at least one dose of Viramune®and of a antiretroviral combination partner.,Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice,"Observational Study Assessing the Safety, Efficacy and Treatment Adherence of Nevirapine Extended Release (Combined With Other Antiretroviral Drugs) in HIV Infected Patients in Daily Clinical Practice",COMPLETED,,,398,ACTUAL,Boehringer Ingelheim,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 03:12:53,2024-10-14 03:12:53,INDUSTRY,,,,,,,Boehringer Ingelheim,Austria|Poland|Romania,Cardiac disorders|Gastrointestinal disorders
NCT01528969,,2012-01-24,2015-03-30,,2015-07-14,2012-02-05,2012-02-08,ESTIMATED,2015-07-14,2015-08-10,ESTIMATED,,,,2015-07-14,2015-08-10,ESTIMATED,2012-03,,2012-03-31,2015-07,2015-07-31,2012-05,ACTUAL,2012-05-31,2012-04,ACTUAL,2012-04-30,,INTERVENTIONAL,,,Effect of Xylitol on Oral Microbiota in Children,The Effect of the Frequent Xylitol Chewing Gum Use on the Oral Microbiota in Children With High MS Counts,COMPLETED,,PHASE1/PHASE2,122,ACTUAL,Kuwait University,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:15:55,2024-10-13 00:15:55,OTHER,,,,,,,Kuwait University|University of Michigan|University of Turku,Kuwait,Gastrointestinal disorders
NCT01529749,,2012-02-08,2018-04-17,,2019-06-07,2012-02-08,2012-02-09,ESTIMATED,2019-06-07,2019-08-02,ACTUAL,,,,2019-06-07,2019-08-02,ACTUAL,2012-02,,2012-02-29,2019-06,2019-06-30,2016-02,ACTUAL,2016-02-29,2012-03,ACTUAL,2012-03-31,,INTERVENTIONAL,,,"Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation Mediators, Cardiovascular Risk and Neurocognitive Disorders in HIV Infected Patients Previously Effectively Treated",Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation,COMPLETED,,PHASE4,48,ACTUAL,Hospital Clinic of Barcelona,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 06:17:57,2024-10-14 06:17:57,OTHER,,,,,,,Felipe Garcia,Spain,Endocrine disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT01533259,,2012-02-02,2015-01-16,2013-11-19,2015-01-16,2012-02-10,2012-02-15,ESTIMATED,2015-01-16,2015-01-26,ESTIMATED,2013-11-19,2013-12-13,ESTIMATED,2015-01-16,2015-01-26,ESTIMATED,2012-01,,2012-01-31,2015-01,2015-01-31,2013-07,ACTUAL,2013-07-31,2012-11,ACTUAL,2012-11-30,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least one dose of study drug.,"Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","A Phase 3B Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (FTC/TDF) to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF) Single-Tablet Regimen (STR) in Virologically Suppressed, HIV-1 Infected Patients",COMPLETED,,PHASE3,48,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 19:47:33,2024-10-14 19:47:33,INDUSTRY,,,,,,,Gilead Sciences,United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01537081,,2012-02-16,2013-07-03,,2013-10-22,2012-02-16,2012-02-22,ESTIMATED,2013-07-03,2013-09-12,ESTIMATED,,,,2013-10-22,2013-11-14,ESTIMATED,2011-09,,2011-09-30,2013-10,2013-10-31,2012-07,ACTUAL,2012-07-31,2012-03,ACTUAL,2012-03-31,,INTERVENTIONAL,,"Based on the Safety population, defined as all patients who received at least one dose of the study medication, excluding patients who later return all the dispensed study medication to the site unused.",Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract Infections,"Randomized, Double-Blind, Double Dummy, Placebo-Controlled Study of the Safety and Efficacy Mucinex (2400 mg/d) and Immediate-Release Guaifenesin (800 mg/d) in the Treatment of Symptoms of Acute Upper Respiratory Tract Infections For 7 Days",COMPLETED,,PHASE2/PHASE3,2810,ACTUAL,Reckitt Benckiser LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 00:35:58,2024-10-15 00:35:58,INDUSTRY,,,,,,,Reckitt Benckiser LLC,United States,Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders
NCT01537198,,2011-12-15,2015-06-18,,2015-06-18,2012-02-17,2012-02-23,ESTIMATED,2015-06-18,2015-07-10,ESTIMATED,,,,2015-06-18,2015-07-10,ESTIMATED,2012-01,,2012-01-31,2015-06,2015-06-30,2014-06,ACTUAL,2014-06-30,2014-06,ACTUAL,2014-06-30,,OBSERVATIONAL,,,Surveillance of Synagis in Korean Pediatric Patients,"Post-Marketing Surveillance of Synagis in Korean Pediatric Patients Under the ""New Drug Re-Examination""",COMPLETED,,,618,ACTUAL,AbbVie,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:07:31,2024-10-13 20:07:31,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)","Korea, Republic of","Cardiac disorders|Eye disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01539226,,2012-02-21,2022-06-23,2018-03-14,2022-09-26,2012-02-24,2012-02-27,ESTIMATED,2022-09-26,2022-10-19,ACTUAL,2018-03-14,2018-03-16,ACTUAL,2022-09-26,2022-10-19,ACTUAL,2012-03-27,ACTUAL,2012-03-27,2022-07,2022-07-31,2016-12-13,ACTUAL,2016-12-13,2016-12-13,ACTUAL,2016-12-13,,INTERVENTIONAL,,,Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women,"A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women",COMPLETED,,NA,1959,ACTUAL,"International Partnership for Microbicides, Inc.","Dapivirine residual levels in used rings and dapivirine plasma concentrations are two objective measures of adherence to DVR ring use; however, they were found to be an imperfect measure of adherence as they cannot distinguish different patterns of use during the month. In addition, self-reported adherence based on the adherence questionnaires was also considered to have limitations.",2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 07:08:06,2024-10-13 07:08:06,INDUSTRY,,,,,,,"International Partnership for Microbicides, Inc.",Rwanda|South Africa|Uganda,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01539980,,2012-02-17,2015-03-10,,2015-04-01,2012-02-22,2012-02-28,ESTIMATED,2015-04-01,2015-04-02,ESTIMATED,,,,2015-04-01,2015-04-02,ESTIMATED,2012-08,,2012-08-31,2015-04,2015-04-30,2014-04,ACTUAL,2014-04-30,2014-03,ACTUAL,2014-03-31,,INTERVENTIONAL,,,Clinical Study on Silk Sericin Wound Dressing for Split-thickness Skin Graft Donor Sites Treatment,Clinical Efficacy of Wound Dressing Containing Silk Sericin for Split-thickness Skin Graft Donor Site Treatment,COMPLETED,,PHASE1/PHASE2,30,ACTUAL,Chulalongkorn University,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 21:44:55,2024-10-13 21:44:55,OTHER,,,,,,,Chulalongkorn University,Thailand,Skin and subcutaneous tissue disorders
NCT01540162,,2012-02-16,2015-08-12,,2015-08-12,2012-02-22,2012-02-28,ESTIMATED,2015-08-12,2015-09-10,ESTIMATED,,,,2015-08-12,2015-09-10,ESTIMATED,2011-03,,2011-03-31,2015-08,2015-08-31,2012-12,ACTUAL,2012-12-31,2012-07,ACTUAL,2012-07-31,,OBSERVATIONAL,EMSUP,,Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement,"Open-labelled, Controlled, Parallel Group Study to Assess the Efficacy and Safety of MUTAFLOR in 3 Weeks Treatment for Immunity Improvement in Preterm Infants With 1 Year Follow-up Period",COMPLETED,,,62,ACTUAL,Odessa National Medical University,,,2,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 16:26:35,2024-10-13 16:26:35,OTHER,,,,,,,Odessa National Medical University,Ukraine,"Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01543087,,2012-02-17,2018-12-14,,2020-03-26,2012-02-27,2012-03-02,ESTIMATED,2020-03-26,2020-03-27,ACTUAL,,,,2020-03-26,2020-03-27,ACTUAL,2012-09-07,ACTUAL,2012-09-07,2020-02,2020-02-29,2018-01-05,ACTUAL,2018-01-05,2018-01-05,ACTUAL,2018-01-05,,INTERVENTIONAL,,"Full analysis set included all participants enrolled in this study from primary studies B1971010, B1971012, and B1971015.",Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose,"A PHASE 3 STUDY TO ASSESS THE PERSISTENCE OF HSBA RESPONSE UP TO 48 MONTHS AFTER COMPLETION OF A PRIMARY SERIES OF BIVALENT RLP2086, AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF BIVALENT RLP2086",COMPLETED,,PHASE3,698,ACTUAL,Pfizer,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 20:58:47,2024-10-13 20:58:47,INDUSTRY,,,,,,,Pfizer,Czechia|Czech Republic|Denmark|Finland|Germany|Poland|Sweden|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01543958,,2012-02-29,2013-09-23,,2018-09-11,2012-02-29,2012-03-05,ESTIMATED,2013-09-23,2013-11-25,ESTIMATED,,,,2018-09-11,2018-10-11,ACTUAL,2011-11,,2011-11-30,2018-09,2018-09-30,2012-11,ACTUAL,2012-11-30,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,,Sevelamer for Reducing Endotoxemia and Immune Activation,Sevelamer Carbonate for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study,COMPLETED,,PHASE2,40,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 03:17:56,2024-10-13 03:17:56,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Eye disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations"
NCT01545375,,2012-03-01,2017-07-11,,2019-12-17,2012-03-01,2012-03-06,ESTIMATED,2017-08-11,2017-09-12,ACTUAL,,,,2019-12-17,2019-12-27,ACTUAL,2012-05-21,ACTUAL,2012-05-21,2019-12,2019-12-31,2016-07-26,ACTUAL,2016-07-26,2016-07-26,ACTUAL,2016-07-26,,INTERVENTIONAL,,,Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children,Study to Determine Protective Efficacy Against Otitis Media and Assess Safety of an Investigational Pneumococcal Vaccine 2189242A in Healthy Infants,COMPLETED,,PHASE2,1806,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 05:27:40,2024-10-14 05:27:40,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01549613,,2012-02-08,2014-07-07,,2014-07-07,2012-03-06,2012-03-09,ESTIMATED,2014-07-07,2014-08-01,ESTIMATED,,,,2014-07-07,2014-08-01,ESTIMATED,2012-05,,2012-05-31,2014-07,2014-07-31,2013-07,ACTUAL,2013-07-31,2013-07,ACTUAL,2013-07-31,,INTERVENTIONAL,,"161 patients were screened;104 were initially enrolled. 3 patients were withdrawn prior to randomization; 1 patient was transferred to OR, 1 patient was admitted prior to randomization, 1 patient was prescribed a different antibiotic;1 patient was withdrawn not meet inclusion criteria. 39 patients in each treatment group completed follow-up.",Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections,Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections,COMPLETED,,PHASE4,104,ACTUAL,University of Cincinnati,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:47:40,2024-10-13 08:47:40,OTHER,,,,,,,University of Cincinnati,United States,"General disorders|Investigations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01552369,,2012-03-02,2019-06-13,,2021-07-29,2012-03-08,2012-03-13,ESTIMATED,2019-06-13,2019-07-02,ACTUAL,,,,2021-07-29,2021-08-26,ACTUAL,2012-10-29,ACTUAL,2012-10-29,2018-03-22,2018-03-22,2018-06-22,ACTUAL,2018-06-22,2018-06-22,ACTUAL,2018-06-22,,INTERVENTIONAL,,,"CMV Antiviral Prevention Strategies in D+R-Liver Transplants (""CAPSIL"")",Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients,COMPLETED,,PHASE4,205,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 10:58:04,2024-10-14 10:58:04,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Blood and lymphatic system disorders|Cardiac disorders|Renal and urinary disorders
NCT01553279,,2012-03-07,2019-01-30,,2019-03-06,2012-03-09,2012-03-14,ESTIMATED,2019-03-06,2019-03-28,ACTUAL,,,,2019-03-06,2019-03-28,ACTUAL,2012-03-30,ACTUAL,2012-03-30,2019-03,2019-03-31,2013-09-27,ACTUAL,2013-09-27,2013-09-27,ACTUAL,2013-09-27,,INTERVENTIONAL,,,Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011),"A Phase III Open-label Randomised Study, to Evaluate the Immunogenicity and Safety of the Concomitant Administration of V419 (PR5I) Given at 2, 3 and 4 Months of Age With Two Types of Meningococcal Serogroup C Conjugate (MCC) Vaccines Given at 3 and 4 Months of Age, and Followed by the Administration at 12 Months of Age of a Combined Haemophilus Influenzae Type b-MCC Vaccine",COMPLETED,,PHASE3,284,ACTUAL,MCM Vaccines B.V.,,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 12:09:42,2024-10-14 12:09:42,INDUSTRY,,,,,,,MCM Vaccines B.V.,United Kingdom,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01563536,,2012-01-27,2014-12-29,2013-04-25,2018-06-01,2012-03-23,2012-03-27,ESTIMATED,2014-12-29,2015-01-08,ESTIMATED,2013-04-25,2013-05-03,ESTIMATED,2018-06-01,2018-07-02,ACTUAL,2012-02,,2012-02-29,2014-12,2014-12-31,2013-06,ACTUAL,2013-06-30,2012-04,ACTUAL,2012-04-30,,INTERVENTIONAL,,,"Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects","An Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects",COMPLETED,,PHASE2,12,ACTUAL,AbbVie,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01565850,,2012-03-27,2016-03-11,2013-11-25,2016-03-11,2012-03-27,2012-03-29,ESTIMATED,2016-03-11,2016-04-11,ESTIMATED,2013-11-25,2013-12-19,ESTIMATED,2016-03-11,2016-04-11,ESTIMATED,2012-04,,2012-04-30,2016-03,2016-03-31,2014-02,ACTUAL,2014-02-28,2013-01,ACTUAL,2013-01-31,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized and received at least one dose of study drug,"D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults","A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults",COMPLETED,,PHASE2,153,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 12:15:54,2024-10-14 12:15:54,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01568892,,2012-03-29,2013-08-15,,2018-06-14,2012-03-29,2012-04-02,ESTIMATED,2014-01-02,2014-02-19,ESTIMATED,,,,2018-06-14,2018-07-02,ACTUAL,2012-04-18,ACTUAL,2012-04-18,2018-06,2018-06-30,2013-12-16,ACTUAL,2013-12-16,2012-10-31,ACTUAL,2012-10-31,,INTERVENTIONAL,VIKING-4,,Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir,"A Phase III Randomized, Double-blind Study to Demonstrate the Antiviral Activity of Dolutegravir (DTG) 50 mg Twice Daily Versus Placebo Both Co-Administered With a Failing Antiretroviral Regimen Over Seven Days, Followed by an Open Label Phase With All Subjects Receiving DTG 50 mg Twice Daily Co-administered With an Optimised Background Regimen (OBR) in HIV-1 Infected, Integrase Inhibitor Therapy-Experienced and Resistant, Adults",COMPLETED,,PHASE3,30,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 14:33:21,2024-10-14 14:33:21,INDUSTRY,,,,,,,GlaxoSmithKline|Shionogi|ViiV Healthcare,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01570283,,2012-03-27,2018-12-03,2016-01-21,2019-05-09,2012-04-02,2012-04-04,ESTIMATED,2019-05-09,2019-05-30,ACTUAL,2016-01-21,2016-02-15,ESTIMATED,2019-05-09,2019-05-30,ACTUAL,2012-09,,2012-09-30,2019-04,2019-04-30,2017-09,ACTUAL,2017-09-30,2016-08,ACTUAL,2016-08-31,,INTERVENTIONAL,ARMS,Eligible patients who received multivirus-specific T cells per protocol.,"ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus","ARMS - Administration Of Rapidly Generated Multivirus-Specific Cytotoxic T-Lymphocytes For The Prophylaxis And Treatment Of EBV, CMV, Adenovirus, HHV6, And BK Virus Infections Post Allogeneic Stem Cell Transplant",COMPLETED,,PHASE1/PHASE2,21,ACTUAL,AlloVir,,6,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 11:57:00,2024-10-14 11:57:00,INDUSTRY,,,,,,,"AlloVir|Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01576003,,2012-04-10,2020-03-19,,2020-06-08,2012-04-11,2012-04-12,ESTIMATED,2020-06-08,2020-06-11,ACTUAL,,,,2020-06-08,2020-06-11,ACTUAL,2012-04,,2012-04-30,2020-06,2020-06-30,2015-06,ACTUAL,2015-06-30,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,,1 Participant withdrew in the screening phase and did not randomize.,Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants,Efficacy of Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants,COMPLETED,,NA,10,ACTUAL,"Children's Hospital Medical Center, Cincinnati",Recruitment was low due to the improvement in care from the use of ethanol lock therapy and improved techniques related to line care. Early termination of participants lead to small number of subjects analyzed and inability to analyze all study aims.,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:09:10,2024-10-14 17:09:10,OTHER,,,,,,,"Children's Hospital Medical Center, Cincinnati|Emmaus Medical, Inc.|Emory University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Colorado, Denver|University of Michigan",United States,Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Skin and subcutaneous tissue disorders
NCT01576809,,2012-03-29,2013-04-17,,2013-10-18,2012-04-11,2012-04-12,ESTIMATED,2013-10-18,2013-11-11,ESTIMATED,,,,2013-10-18,2013-11-11,ESTIMATED,2012-03,,2012-03-31,2013-10,2013-10-31,2012-05,ACTUAL,2012-05-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,,"Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)","An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection",COMPLETED,,PHASE3,51,ACTUAL,Novartis,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:15:55,2024-10-13 00:15:55,INDUSTRY,,,,,,,Novartis|Novartis Consumer Health,Canada,General disorders
NCT01586962,,2012-04-23,2013-04-25,,2013-08-06,2012-04-25,2012-04-27,ESTIMATED,2013-08-06,2013-08-07,ESTIMATED,,,,2013-08-06,2013-08-07,ESTIMATED,2012-05,,2012-05-31,2013-04,2013-04-30,2012-05,ACTUAL,2012-05-31,2012-05,ACTUAL,2012-05-31,,INTERVENTIONAL,,,"Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI","An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection",COMPLETED,,PHASE3,56,ACTUAL,Novartis,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 02:20:45,2024-10-14 02:20:45,INDUSTRY,,,,,,,Novartis|Novartis Consumer Health,Canada,Nervous system disorders
NCT01590758,,2012-04-27,2017-04-14,,2017-05-19,2012-05-02,2012-05-03,ESTIMATED,2017-05-19,2017-06-14,ACTUAL,,,,2017-05-19,2017-06-14,ACTUAL,2014-06,,2014-06-30,2017-04,2017-04-30,2016-08,ACTUAL,2016-08-31,2016-08,ACTUAL,2016-08-31,,INTERVENTIONAL,OneStep-1,,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,"A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers",COMPLETED,,PHASE3,189,ACTUAL,"Dipexium Pharmaceuticals, Inc.",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 01:00:44,2024-10-13 01:00:44,INDUSTRY,,,,,,,"Dipexium Pharmaceuticals, Inc.",United States,Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01593592,,2012-05-05,2015-03-07,,2015-07-19,2012-05-07,2012-05-08,ESTIMATED,2015-07-19,2015-08-17,ESTIMATED,,,,2015-07-19,2015-08-17,ESTIMATED,2012-06,,2012-06-30,2015-07,2015-07-31,,,,2013-01,ACTUAL,2013-01-31,,INTERVENTIONAL,,All were dyspeptic patients,Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients,Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients: a Double Blind Placebo Controlled Randomized Clinical Trial,COMPLETED,,NA,70,ACTUAL,Zagazig University,no limitations,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:12:28,2024-10-15 02:12:28,OTHER_GOV,,,,,,,BioGaia AB|Zagazig University,Egypt,Gastrointestinal disorders|Reproductive system and breast disorders
NCT01593761,,2012-05-06,2013-04-11,,2022-08-17,2012-05-06,2012-05-08,ESTIMATED,2022-06-12,2022-07-06,ACTUAL,,,,2022-08-17,2022-09-10,ACTUAL,2012-06,,2012-06-30,2022-08,2022-08-31,2012-10,ACTUAL,2012-10-31,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,CG400549,,Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus,"Phase 2a, Repeated-dose, Open-label, Single-arm Study of CG400549 for the Treatment of Complicated Acute Bacterial Skin and Skin Structure Infection (cABSSSI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)",COMPLETED,,PHASE2,20,ACTUAL,"CrystalGenomics, Inc.",,1,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-14 05:21:07,2024-10-14 05:21:07,INDUSTRY,,,,,,,"CrystalGenomics, Inc.",United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01594762,,2012-05-07,2017-04-14,,2017-05-19,2012-05-08,2012-05-09,ESTIMATED,2017-05-19,2017-06-14,ACTUAL,,,,2017-05-19,2017-06-14,ACTUAL,2014-06,,2014-06-30,2017-04,2017-04-30,2016-07,ACTUAL,2016-07-31,2016-07,ACTUAL,2016-07-31,,INTERVENTIONAL,OneStep-2,,Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers,"A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers",COMPLETED,,PHASE3,200,ACTUAL,"Dipexium Pharmaceuticals, Inc.",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 03:52:04,2024-10-13 03:52:04,INDUSTRY,,,,,,,"Dipexium Pharmaceuticals, Inc.",United States,"Cardiac disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT01595438,,2012-04-27,2015-10-28,,2017-08-31,2012-05-08,2012-05-10,ESTIMATED,2016-03-08,2016-03-09,ESTIMATED,,,,2017-08-31,2017-09-06,ACTUAL,2012-10,,2012-10-31,2017-08,2017-08-31,2014-08,ACTUAL,2014-08-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,,Safety analysis set,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),"A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults",COMPLETED,,PHASE3,598,ACTUAL,Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 01:06:01,2024-10-14 01:06:01,INDUSTRY,,,,,,,Forest Laboratories|Pfizer,"Argentina|Belgium|Brazil|Bulgaria|Canada|Croatia|Czechia|Czech Republic|France|Germany|Greece|Hungary|India|Israel|Japan|Korea, Republic of|Mexico|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Serbia|Slovakia|Taiwan|Turkey|Ukraine|United States","Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01595529,,2012-05-08,2020-06-25,,2020-07-23,2012-05-08,2012-05-10,ESTIMATED,2020-06-25,2020-07-13,ACTUAL,,,,2020-07-23,2020-08-06,ACTUAL,2012-05-18,ACTUAL,2012-05-18,2013-10-22,2013-10-22,2019-08-12,ACTUAL,2019-08-12,2019-06-30,ACTUAL,2019-06-30,,INTERVENTIONAL,,"Of the 677 treated patients, only 664 were able to be evaluated for the primary endpoint.

Subject noncompliant: 4 Consent withdrawn: 3 Admin/Inv decision: 2 AE concomitant infection: 2 Lost to follow-up: 1 Protocol violation/deviation: 1","The SCOUT Study: ""Short Course Therapy for Urinary Tract Infections in Children""","Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance The SCOUT Study: ""Short Course Therapy for Urinary Tract Infections in Children""",COMPLETED,,PHASE2,717,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 22:49:51,2024-10-14 22:49:51,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01597505,,2012-05-10,2018-01-18,,2019-07-15,2012-05-11,2012-05-14,ESTIMATED,2018-02-26,2018-02-28,ACTUAL,,,,2019-07-15,2019-07-23,ACTUAL,2012-05-16,ACTUAL,2012-05-16,2019-07,2019-07-31,2015-03-20,ACTUAL,2015-03-20,2015-03-20,ACTUAL,2015-03-20,,INTERVENTIONAL,,,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)","A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea",COMPLETED,,PHASE3,606,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 10:20:44,2024-10-13 10:20:44,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",Austria|Belgium|Canada|Czech Republic|France|Germany|Hungary|Israel|Italy|Poland|Spain|Sweden|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01597973,,2012-05-08,2021-08-09,,2022-11-10,2012-05-10,2012-05-15,ESTIMATED,2021-11-03,2021-11-30,ACTUAL,,,,2022-11-10,2022-11-14,ACTUAL,2012-10-06,ACTUAL,2012-10-06,2022-11,2022-11-30,2020-08-09,ACTUAL,2020-08-09,2020-08-09,ACTUAL,2020-08-09,,INTERVENTIONAL,,,Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME),Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME),COMPLETED,,PHASE3,467,ACTUAL,University of Michigan,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:38:09,2024-10-14 13:38:09,OTHER,,,,,,,University of Michigan,Bulgaria|Greece|Israel|Italy|Taiwan|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT01598311,,2012-05-10,2018-01-31,,2022-08-19,2012-05-11,2012-05-15,ESTIMATED,2018-01-31,2018-02-27,ACTUAL,,,,2022-08-19,2022-08-22,ACTUAL,2012-05-16,ACTUAL,2012-05-16,2022-08,2022-08-31,2015-08-25,ACTUAL,2015-08-25,2015-07-26,ACTUAL,2015-07-26,,INTERVENTIONAL,,The baseline analysis population includes all randomized and treated participants with a confirmed CDAD diagnosis (microbiological modified intent-to-treat \[mMITT\] population).,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)","A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea",COMPLETED,,PHASE3,608,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 18:13:13,2024-10-13 18:13:13,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","Argentina|Australia|Belgium|Canada|Chile|Korea, Republic of|New Zealand|Peru|Taiwan|United States","Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01599806,,2012-05-15,2015-11-04,,2017-08-31,2012-05-15,2012-05-16,ESTIMATED,2016-02-03,2016-03-02,ESTIMATED,,,,2017-08-31,2017-09-06,ACTUAL,2012-10,,2012-10-31,2017-08,2017-08-31,2014-08,ACTUAL,2014-08-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,,Safety analysis set,Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections),"A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults",COMPLETED,,PHASE3,641,ACTUAL,Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 01:31:21,2024-10-14 01:31:21,INDUSTRY,,,,,,,Forest Laboratories|Pfizer,"Argentina|Belgium|Brazil|Bulgaria|Canada|Chile|Croatia|Czechia|Czech Republic|France|Germany|Greece|India|Israel|Italy|Korea, Republic of|Mexico|Peru|Poland|Puerto Rico|Romania|Russian Federation|Serbia|Spain|Taiwan|Ukraine|United Kingdom|United States","Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01605890,,2012-05-22,2017-03-10,,2017-09-20,2012-05-23,2012-05-25,ESTIMATED,2017-09-20,2018-07-20,ACTUAL,,,,2017-09-20,2018-07-20,ACTUAL,2012-07,,2012-07-31,2017-09,2017-09-30,2015-12,ACTUAL,2015-12-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,VIH-2,,"Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients","ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients",COMPLETED,,PHASE2,30,ACTUAL,"ANRS, Emerging Infectious Diseases",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:14:10,2024-10-14 02:14:10,OTHER_GOV,,,,,,,"ANRS, Emerging Infectious Diseases|Gilead Sciences|Merck Sharp & Dohme LLC",France,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01608815,,2012-05-28,2014-03-07,,2014-04-15,2012-05-28,2012-05-31,ESTIMATED,2014-04-15,2014-05-12,ESTIMATED,,,,2014-04-15,2014-05-12,ESTIMATED,2012-05,,2012-05-31,2014-04,2014-04-30,2012-12,ACTUAL,2012-12-31,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,,Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects,Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects,COMPLETED,,PHASE3,200,ACTUAL,Sanofi,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 16:25:58,2024-10-14 16:25:58,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Japan,Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01608815,,2012-05-28,2014-03-07,,2014-04-15,2012-05-28,2012-05-31,ESTIMATED,2014-04-15,2014-05-12,ESTIMATED,,,,2014-04-15,2014-05-12,ESTIMATED,2012-05,,2012-05-31,2014-04,2014-04-30,2012-12,ACTUAL,2012-12-31,2012-09,ACTUAL,2012-09-30,,INTERVENTIONAL,,,Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects,Immunogenicity and Safety of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine Given in Japanese Subjects,COMPLETED,,PHASE3,200,ACTUAL,Sanofi,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 16:25:58,2024-10-14 16:25:58,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Japan,Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01609257,,2012-05-25,2015-12-08,,2019-01-08,2012-05-29,2012-05-31,ESTIMATED,2016-07-18,2016-08-15,ESTIMATED,,,,2019-01-08,2019-01-09,ACTUAL,2012-07-16,ACTUAL,2012-07-16,2019-01,2019-01-31,2014-03-18,ACTUAL,2014-03-18,2014-03-01,ACTUAL,2014-03-01,,INTERVENTIONAL,,,Norovirus Bivalent-Vaccine Efficacy Study,"Phase 1-2, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Safety, Immunogenicity, and Efficacy Study in Healthy Adults of Intramuscular Norovirus Bivalent Virus-like Particle Vaccine in Experimental Human Norovirus GII.4 Disease",COMPLETED,,PHASE1/PHASE2,132,ACTUAL,Takeda,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 09:40:26,2024-10-14 09:40:26,INDUSTRY,,,,,,,Takeda,United States,"Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders"
NCT01612858,,2012-06-04,2016-05-12,,2016-05-12,2012-06-05,2012-06-06,ESTIMATED,2016-05-12,2016-06-20,ESTIMATED,,,,2016-05-12,2016-06-20,ESTIMATED,2011-06,,2011-06-30,2016-05,2016-05-31,2014-11,ACTUAL,2014-11-30,2014-11,ACTUAL,2014-11-30,,INTERVENTIONAL,,,Metabolic Abnormalities in HIV-infected Persons,Metabolic Abnormalities in HIV-infected Persons,COMPLETED,,PHASE4,20,ACTUAL,Tufts Medical Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 02:59:02,2024-10-13 02:59:02,OTHER,,,,,,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Tufts Medical Center,United States,Gastrointestinal disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders
NCT01616459,,2012-06-07,2014-04-10,2013-08-22,2019-07-02,2012-06-07,2012-06-11,ESTIMATED,2014-05-15,2014-06-16,ESTIMATED,2013-08-22,2013-08-30,ESTIMATED,2019-07-02,2019-07-16,ACTUAL,2012-07-11,ACTUAL,2012-07-11,2019-07,2019-07-31,2014-01-22,ACTUAL,2014-01-22,2013-04-25,ACTUAL,2013-04-25,,INTERVENTIONAL,,,Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants,Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants,COMPLETED,,PHASE2,953,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,FALSE,,,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site,2024-10-13 13:22:24,2024-10-13 13:22:24,INDUSTRY,,,,,,,GlaxoSmithKline,Czechia|Czech Republic|Germany|Poland|Spain,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01617096,,2012-06-08,2022-06-29,2017-02-02,2022-12-19,2012-06-11,2012-06-12,ESTIMATED,2022-11-21,2022-12-16,ACTUAL,2017-02-02,2017-02-03,ESTIMATED,2022-12-19,2022-12-21,ACTUAL,2012-07-24,ACTUAL,2012-07-24,2022-12,2022-12-31,2015-12,ACTUAL,2015-12-31,2015-07-03,ACTUAL,2015-07-03,,INTERVENTIONAL,ASPIRE,Primary safety cohort,Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women",COMPLETED,,PHASE3,2629,ACTUAL,"International Partnership for Microbicides, Inc.","Dapivirine residual levels in used rings and dapivirine plasma concentrations are two objective measures of adherence to DVR ring use; however, they were found to be an imperfect measure of adherence as they cannot distinguish different patterns of use during the month. In addition, self-reported adherence based on the adherence questionnaires was also considered to have limitations.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 10:09:42,2024-10-14 10:09:42,INDUSTRY,,,,,,,"International Partnership for Microbicides, Inc.|National Institute of Allergy and Infectious Diseases (NIAID)",Malawi|South Africa|Uganda|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders"
NCT01618305,,2012-06-06,2019-12-10,,2020-01-14,2012-06-11,2012-06-13,ESTIMATED,2019-12-10,2019-12-26,ACTUAL,,,,2020-01-14,2020-01-30,ACTUAL,2013-09-05,ACTUAL,2013-09-05,2020-01,2020-01-31,2018-12-11,ACTUAL,2018-12-11,2018-12-11,ACTUAL,2018-12-11,,INTERVENTIONAL,,"All women randomized to NICHD P1081 were eligible for inclusion in this summary. Additionally, the 14 women who were randomized under IMPAACT P1081 to one of the two continuing arms in NICHD P1081 were also eligible for inclusion.","Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission",A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Two Different Potent Regimens in HIV Infected Women Initiating Triple Antiretroviral Regimens Between 20 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child Transmission: NICHD P1081,COMPLETED,,PHASE4,408,ACTUAL,Westat,,4,,,FALSE,,,,TRUE,,,,,,,,Beginning 9 months following publication and available throughout period of funding of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) by NIH.,"With whom? Researchers whose proposed use of the data is approved by the NICHD Data and Specimen Hub (DASH) Data Access Committee as scientifically and ethically appropriate and does not conflict with constraints or informed consent limitations.

For what types of analyses? To achieve aims in the approved proposal. By what mechanism will data be made available? To gain access, data requestors will need to create a free NICHD DASH account, submit a data access proposal, and if approved, sign a data access agreement. Information regarding creating a NICHD DASH account and accessing data may be found at https://dash.nichd.nih.gov/",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-14 07:15:50,2024-10-14 07:15:50,OTHER,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|Westat,Argentina|Brazil|Kenya|Puerto Rico|South Africa|Tanzania|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT01623154,,2012-06-15,2014-04-29,,2015-02-02,2012-06-18,2012-06-19,ESTIMATED,2015-01-09,2015-01-13,ESTIMATED,,,,2015-02-02,2015-02-23,ESTIMATED,2012-07,,2012-07-31,2015-01,2015-01-31,2013-04,ACTUAL,2013-04-30,2013-03,ACTUAL,2013-03-31,,INTERVENTIONAL,,95 evaluable subjects for initial diagnosis- each patient received the BreathTek UBT test. Collected breath samples were analyzed on both the UBiT-IR300 and the POC-one.,POCone-UBiT-IR300 Pediatric Comparison Study,"A Prospective, Multi-Center, Open-Label Study to Compare the POCone® With the UBiT®-IR300 in Measurement of 13CO2/12CO2 Ratio in Breath Samples Collected From Pediatric Subjects Ages 3 to 17 Years With Upper Gastrointestinal Signs and Symptoms",COMPLETED,,PHASE4,99,ACTUAL,Otsuka America Pharmaceutical,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 20:59:15,2024-10-14 20:59:15,INDUSTRY,,,,,,,Otsuka America Pharmaceutical,United States,"Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01624948,,2012-06-15,2016-04-12,,2016-07-01,2012-06-18,2012-06-21,ESTIMATED,2016-07-01,2016-08-15,ESTIMATED,,,,2016-07-01,2016-08-15,ESTIMATED,2012-09,,2012-09-30,2016-07,2016-07-31,2015-11,ACTUAL,2015-11-30,2015-02,ACTUAL,2015-02-28,,INTERVENTIONAL,,,Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients,Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection,COMPLETED,,PHASE4,40,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 09:43:00,2024-10-13 09:43:00,OTHER,,,,,,,"University of California, San Francisco",United States,Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01625091,,2012-06-12,2017-07-06,,2018-06-12,2012-06-18,2012-06-21,ESTIMATED,2017-07-06,2017-08-02,ACTUAL,,,,2018-06-12,2018-07-10,ACTUAL,2012-12,ACTUAL,2012-12-31,2018-06,2018-06-30,2016-07,ACTUAL,2016-07-31,2016-07,ACTUAL,2016-07-31,,INTERVENTIONAL,WHATIF,,Clinical Trial to Reduce Drinking in Women With HIV,Pharmacotherapy for Alcohol Consumption in HIV Infected Women: Randomized Trial,COMPLETED,,PHASE3,194,ACTUAL,University of Florida,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 13:26:27,2024-10-14 13:26:27,OTHER,,,,,,,Florida International University|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Rush University|University of Florida|University of Miami,United States,Gastrointestinal disorders|General disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT01627561,,2012-06-14,2015-04-23,,2020-03-19,2012-06-21,2012-06-26,ESTIMATED,2015-04-23,2015-05-08,ESTIMATED,,,,2020-03-19,2020-04-10,ACTUAL,2012-10-15,ACTUAL,2012-10-15,2020-03,2020-03-31,2016-10-06,ACTUAL,2016-10-06,2014-04-23,ACTUAL,2014-04-23,,INTERVENTIONAL,,,Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old,Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old,COMPLETED,,PHASE3,148,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=16039,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 13:45:03,2024-10-13 13:45:03,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil|Colombia|Mexico|Panama,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01632345,,2012-06-28,2017-11-16,,2019-07-04,2012-06-28,2012-07-02,ESTIMATED,2017-11-16,2017-12-13,ACTUAL,,,,2019-07-04,2019-07-18,ACTUAL,2012-10-12,ACTUAL,2012-10-12,2019-07,2019-07-31,2016-03-21,ACTUAL,2016-03-21,2014-12-03,ACTUAL,2014-12-03,,INTERVENTIONAL,,All Treated participants randomized to doravirine or efavirenz using an interactive voice response system (IVRS),A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007),"Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients",COMPLETED,,PHASE2,342,ACTUAL,Merck Sharp & Dohme LLC,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 03:26:59,2024-10-14 03:26:59,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Belgium|Canada|France|Germany|Netherlands|Poland|Puerto Rico|Romania|Russian Federation|Spain|United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01632891,,2012-06-29,2018-12-12,2017-04-14,2019-07-23,2012-06-29,2012-07-03,ESTIMATED,2019-01-08,2019-02-04,ACTUAL,2017-04-14,2017-04-20,ACTUAL,2019-07-23,2019-08-06,ACTUAL,2014-01-10,ACTUAL,2014-01-10,2019-07,2019-07-31,2016-06-19,ACTUAL,2016-06-19,2016-06-19,ACTUAL,2016-06-19,,INTERVENTIONAL,,All participants,Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected,"An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3",COMPLETED,,PHASE1/PHASE2,52,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:52:22,2024-10-13 06:52:22,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Kenya|Malawi|Uganda,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders
NCT01632995,,2012-06-29,2016-11-16,,2021-11-03,2012-06-29,2012-07-04,ESTIMATED,2017-01-30,2017-03-21,ACTUAL,,,,2021-11-03,2021-11-05,ACTUAL,2012-10,,2012-10-31,2016-07,2016-07-31,2015-02,ACTUAL,2015-02-28,2015-02,ACTUAL,2015-02-28,,INTERVENTIONAL,,,Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics,Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project,COMPLETED,,NA,557,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 20:19:01,2024-10-13 20:19:01,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Injury, poisoning and procedural complications|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders"
NCT01637870,,2012-07-06,2015-05-26,,2018-03-19,2012-07-10,2012-07-11,ESTIMATED,2018-03-19,2018-04-18,ACTUAL,,,,2018-03-19,2018-04-18,ACTUAL,2012-08,,2012-08-31,2018-03,2018-03-31,2013-02,ACTUAL,2013-02-28,2013-02,ACTUAL,2013-02-28,,INTERVENTIONAL,,,Negative Pressure Wound Therapy After Cesarean Delivery,Negative Pressure Wound Therapy to Prevent Post Operative Wound Complications Following Cesarean Delivery in Women at High Risk for Wound Complications,COMPLETED,,NA,110,ACTUAL,University of Iowa,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 01:24:19,2024-10-14 01:24:19,OTHER,,,,,,,"Abbey Hardy-Fairbanks|Kinetic Concepts, Inc.",United States,Skin and subcutaneous tissue disorders
NCT01637870,,2012-07-06,2015-05-26,,2018-03-19,2012-07-10,2012-07-11,ESTIMATED,2018-03-19,2018-04-18,ACTUAL,,,,2018-03-19,2018-04-18,ACTUAL,2012-08,,2012-08-31,2018-03,2018-03-31,2013-02,ACTUAL,2013-02-28,2013-02,ACTUAL,2013-02-28,,INTERVENTIONAL,,,Negative Pressure Wound Therapy After Cesarean Delivery,Negative Pressure Wound Therapy to Prevent Post Operative Wound Complications Following Cesarean Delivery in Women at High Risk for Wound Complications,COMPLETED,,NA,110,ACTUAL,University of Iowa,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 01:24:19,2024-10-14 01:24:19,OTHER,,,,,,,"Abbey Hardy-Fairbanks|Kinetic Concepts, Inc.",United States,Skin and subcutaneous tissue disorders
NCT01640925,,2012-07-05,2015-04-15,,2018-03-27,2012-07-13,2012-07-16,ESTIMATED,2015-05-04,2015-05-22,ESTIMATED,,,,2018-03-27,2018-04-27,ACTUAL,2012-07,,2012-07-31,2018-03,2018-03-31,2014-09,ACTUAL,2014-09-30,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,,,Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit,Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit,COMPLETED,,NA,350,ACTUAL,The Methodist Hospital Research Institute,,2,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,Plan to share data to be determined.,2024-10-14 00:19:26,2024-10-14 00:19:26,OTHER,,,,,,,Joshua Swan|Texas Southern University|The Methodist Hospital Research Institute,United States,Skin and subcutaneous tissue disorders
NCT01640925,,2012-07-05,2015-04-15,,2018-03-27,2012-07-13,2012-07-16,ESTIMATED,2015-05-04,2015-05-22,ESTIMATED,,,,2018-03-27,2018-04-27,ACTUAL,2012-07,,2012-07-31,2018-03,2018-03-31,2014-09,ACTUAL,2014-09-30,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,,,Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit,Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit,COMPLETED,,NA,350,ACTUAL,The Methodist Hospital Research Institute,,2,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,Plan to share data to be determined.,2024-10-14 00:19:26,2024-10-14 00:19:26,OTHER,,,,,,,Joshua Swan|Texas Southern University|The Methodist Hospital Research Institute,United States,Skin and subcutaneous tissue disorders
NCT01640925,,2012-07-05,2015-04-15,,2018-03-27,2012-07-13,2012-07-16,ESTIMATED,2015-05-04,2015-05-22,ESTIMATED,,,,2018-03-27,2018-04-27,ACTUAL,2012-07,,2012-07-31,2018-03,2018-03-31,2014-09,ACTUAL,2014-09-30,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,,,Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit,Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit,COMPLETED,,NA,350,ACTUAL,The Methodist Hospital Research Institute,,2,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,Plan to share data to be determined.,2024-10-14 00:19:26,2024-10-14 00:19:26,OTHER,,,,,,,Joshua Swan|Texas Southern University|The Methodist Hospital Research Institute,United States,Skin and subcutaneous tissue disorders
NCT01640925,,2012-07-05,2015-04-15,,2018-03-27,2012-07-13,2012-07-16,ESTIMATED,2015-05-04,2015-05-22,ESTIMATED,,,,2018-03-27,2018-04-27,ACTUAL,2012-07,,2012-07-31,2018-03,2018-03-31,2014-09,ACTUAL,2014-09-30,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,,,Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit,Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit,COMPLETED,,NA,350,ACTUAL,The Methodist Hospital Research Institute,,2,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,Plan to share data to be determined.,2024-10-14 00:19:26,2024-10-14 00:19:26,OTHER,,,,,,,Joshua Swan|Texas Southern University|The Methodist Hospital Research Institute,United States,Skin and subcutaneous tissue disorders
NCT01641042,,2012-07-12,2017-09-21,2015-03-12,2017-09-21,2012-07-12,2012-07-16,ESTIMATED,2017-09-21,2017-10-18,ACTUAL,2015-03-12,2015-04-01,ESTIMATED,2017-09-21,2017-10-18,ACTUAL,2012-09-10,,2012-09-10,2017-03,2017-03-31,2015-03-03,ACTUAL,2015-03-03,2014-10-10,ACTUAL,2014-10-10,,INTERVENTIONAL,,,Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered to at Risk Subjects From 1 to Less Than 18 Years,COMPLETED,,PHASE3,86,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 19:29:55,2024-10-14 19:29:55,INDUSTRY,,,,,,,GlaxoSmithKline,Czechia|Czech Republic|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT01641133,,2012-07-12,2017-01-09,2013-08-22,2021-02-08,2012-07-12,2012-07-16,ESTIMATED,2017-01-09,2017-02-27,ACTUAL,2013-08-22,2013-08-30,ESTIMATED,2021-02-08,2021-03-02,ACTUAL,2012-09-04,ACTUAL,2012-09-04,2021-02,2021-02-28,2014-05-07,ACTUAL,2014-05-07,2013-07-15,ACTUAL,2013-07-15,,INTERVENTIONAL,,,Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™,Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™,COMPLETED,,PHASE3,457,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20769,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-14 11:45:21,2024-10-14 11:45:21,INDUSTRY,,,,,,,GlaxoSmithKline,Mexico,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01641367,,2012-06-28,2017-11-20,,2019-03-14,2012-07-12,2012-07-16,ESTIMATED,2018-01-22,2018-02-20,ACTUAL,,,,2019-03-14,2019-03-15,ACTUAL,2013-02-22,ACTUAL,2013-02-22,2019-03,2019-03-31,2018-12-31,ACTUAL,2018-12-31,2016-11-23,ACTUAL,2016-11-23,,INTERVENTIONAL,MULTI-OCTAVE,All enrolled participants.,A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure,Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE),COMPLETED,,PHASE4,545,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,6,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:08:06,2024-10-13 07:08:06,NETWORK,,,,,,,AbbVie|Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|Dimagi Inc.|Gilead Sciences|Janssen Pharmaceuticals|Merck Sharp & Dohme LLC|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Haiti|India|Kenya|Malawi|Peru|South Africa|Thailand|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01641809,,2012-06-28,2020-01-21,2014-03-13,2020-01-21,2012-07-12,2012-07-17,ESTIMATED,2020-01-21,2020-01-30,ACTUAL,2014-03-13,2014-04-11,ESTIMATED,2020-01-21,2020-01-30,ACTUAL,2012-08-06,ACTUAL,2012-08-06,2020-01,2020-01-31,2019-01-15,ACTUAL,2019-01-15,2013-10-10,ACTUAL,2013-10-10,,INTERVENTIONAL,,,Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine,"A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral GSK1265744 is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects",COMPLETED,,PHASE2,244,ACTUAL,ViiV Healthcare,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:11:06,2024-10-13 19:11:06,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01641809,,2012-06-28,2020-01-21,2014-03-13,2020-01-21,2012-07-12,2012-07-17,ESTIMATED,2020-01-21,2020-01-30,ACTUAL,2014-03-13,2014-04-11,ESTIMATED,2020-01-21,2020-01-30,ACTUAL,2012-08-06,ACTUAL,2012-08-06,2020-01,2020-01-31,2019-01-15,ACTUAL,2019-01-15,2013-10-10,ACTUAL,2013-10-10,,INTERVENTIONAL,,,Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine,"A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral GSK1265744 is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects",COMPLETED,,PHASE2,244,ACTUAL,ViiV Healthcare,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:11:06,2024-10-13 19:11:06,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01644565,,2012-07-11,2016-11-30,,2021-02-10,2012-07-16,2012-07-19,ESTIMATED,2019-04-19,2019-07-08,ACTUAL,,,,2021-02-10,2021-02-12,ACTUAL,2012-08,ACTUAL,2012-08-31,2021-02,2021-02-28,2015-06,ACTUAL,2015-06-30,2014-06,ACTUAL,2014-06-30,,INTERVENTIONAL,,Demographics within Final Clinical Study Report were not broken out by groups or cohorts. No randomization was presented to detail which subject was in which group or cohort. Data is presented as it was detailed in the FCSR. No explanation was given as to why groups were combined to report demographic data.,Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea,A Phase 1 Dose Escalating Study of Two Enterotoxigenic Escherichia Coli Prototype Adhesin-based Vaccines With or Without Modified Heat-labile Enterotoxin by Intradermal or Transcutaneous Immunization,COMPLETED,,PHASE1,57,ACTUAL,U.S. Army Medical Research and Development Command,,9,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,,2024-10-13 03:46:56,2024-10-13 03:46:56,FED,,,,,,,U.S. Army Medical Research and Development Command,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01644643,,2012-06-28,2015-09-28,,2017-08-31,2012-07-18,2012-07-19,ESTIMATED,2015-11-10,2015-12-14,ESTIMATED,,,,2017-08-31,2017-09-29,ACTUAL,2013-01,,2013-01-31,2017-08,2017-08-31,2014-09,ACTUAL,2014-09-30,2014-09,ACTUAL,2014-09-30,,INTERVENTIONAL,,Microbiological modified intent to treat: all patients who have a diagnosis of cIAI or cUTI with a ceftazidime-resistant Gram-negative pathogen on the study-qualifying culture and who received at least 1 dose of study therapy.,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,"An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens",COMPLETED,,PHASE3,345,ACTUAL,Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 22:15:13,2024-10-14 22:15:13,INDUSTRY,,,,,,,Forest Laboratories|Pfizer,"Argentina|Australia|Belgium|Brazil|Bulgaria|Chile|China|Croatia|Czechia|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Peru|Philippines|Poland|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01644643,,2012-06-28,2015-09-28,,2017-08-31,2012-07-18,2012-07-19,ESTIMATED,2015-11-10,2015-12-14,ESTIMATED,,,,2017-08-31,2017-09-29,ACTUAL,2013-01,,2013-01-31,2017-08,2017-08-31,2014-09,ACTUAL,2014-09-30,2014-09,ACTUAL,2014-09-30,,INTERVENTIONAL,,Microbiological modified intent to treat: all patients who have a diagnosis of cIAI or cUTI with a ceftazidime-resistant Gram-negative pathogen on the study-qualifying culture and who received at least 1 dose of study therapy.,Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens,"An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens",COMPLETED,,PHASE3,345,ACTUAL,Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 22:15:13,2024-10-14 22:15:13,INDUSTRY,,,,,,,Forest Laboratories|Pfizer,"Argentina|Australia|Belgium|Brazil|Bulgaria|Chile|China|Croatia|Czechia|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Mexico|Peru|Philippines|Poland|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Taiwan|Turkey|Ukraine|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01645735,,2012-07-09,2014-09-29,,2015-12-24,2012-07-18,2012-07-20,ESTIMATED,2015-12-24,2016-02-01,ESTIMATED,,,,2015-12-24,2016-02-01,ESTIMATED,2012-10,,2012-10-31,2015-12,2015-12-31,2013-12,ACTUAL,2013-12-31,2013-12,ACTUAL,2013-12-31,,INTERVENTIONAL,,"* Safety: all randomized who received any amount of study drug
* MITT: all randomized who received any amount of IV study drug \& had a confirmed CABP w/risk factors for MRSA (excluding those w/sole atypical pathogen)
* mMITT: MITT subset, including subjects w/at least 1 typical bacterial pathogen identified from adequate micro specimen at baseline",Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus,"A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus",COMPLETED,,PHASE4,49,ACTUAL,Forest Laboratories,Small number of subjects enrolled,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 23:24:26,2024-10-14 23:24:26,INDUSTRY,,,,,,,AstraZeneca|Forest Laboratories,Georgia|Hungary|Poland|Romania|Russian Federation|Spain|Ukraine|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Vascular disorders"
NCT01649869,,2012-07-20,2020-12-23,,2021-05-06,2012-07-24,2012-07-25,ESTIMATED,2021-05-06,2021-06-02,ACTUAL,,,,2021-05-06,2021-06-02,ACTUAL,2015-02-24,ACTUAL,2015-02-24,2018-03-22,2018-03-22,2019-12-24,ACTUAL,2019-12-24,2019-12-24,ACTUAL,2019-12-24,,INTERVENTIONAL,,,Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss,A Phase II Randomized and Controlled Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss,COMPLETED,,PHASE2,54,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-15 01:15:10,2024-10-15 01:15:10,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United Kingdom|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01654263,,2012-07-19,2016-08-11,,2017-02-23,2012-07-26,2012-07-31,ESTIMATED,2016-11-23,2017-01-23,ESTIMATED,,,,2017-02-23,2017-03-27,ACTUAL,2012-10-10,ACTUAL,2012-10-10,2016-04-15,2016-04-15,2015-08-21,ACTUAL,2015-08-21,2015-08-21,ACTUAL,2015-08-21,,INTERVENTIONAL,,All participants are included in the baseline analysis population.,"A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine","A Phase IIb, Open-Label, Dose-Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine",COMPLETED,,PHASE2,884,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,6,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 17:28:56,2024-10-14 17:28:56,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01654289,,2012-07-19,2018-05-29,,2018-10-09,2012-07-30,2012-07-31,ESTIMATED,2018-10-09,2018-11-07,ACTUAL,,,,2018-10-09,2018-11-07,ACTUAL,2012-07,,2012-07-31,2018-10,2018-10-31,2016-06,ACTUAL,2016-06-30,2016-06,ACTUAL,2016-06-30,,INTERVENTIONAL,MEPARI-2,,University of Wisconsin Meditation & Exercise Cold Study,Meditation or Exercise for Preventing Acute Respiratory Infection (MEPARI-2),COMPLETED,,PHASE2,413,ACTUAL,"University of Wisconsin, Madison",,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 14:55:33,2024-10-13 14:55:33,OTHER,,,,,,,"National Center for Complementary and Integrative Health (NCCIH)|University of Wisconsin, Madison",United States,Cardiac disorders|General disorders|Musculoskeletal and connective tissue disorders
NCT01659996,,2012-08-02,2015-09-29,,2015-11-10,2012-08-03,2012-08-08,ESTIMATED,2015-11-10,2015-12-15,ESTIMATED,,,,2015-11-10,2015-12-15,ESTIMATED,2012-07,,2012-07-31,2015-11,2015-11-30,2015-09,ACTUAL,2015-09-30,2014-11,ACTUAL,2014-11-30,,INTERVENTIONAL,,The demographic and baseline characteristics are in the safety analysis set (SafAS),Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age,"An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.",COMPLETED,,PHASE4,1394,ACTUAL,Sanofi,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 23:41:58,2024-10-14 23:41:58,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01662336,,2012-08-08,2017-06-19,,2017-06-19,2012-08-09,2012-08-10,ESTIMATED,2017-06-19,2018-01-29,ACTUAL,,,,2017-06-19,2018-01-29,ACTUAL,2012-06,,2012-06-30,2017-06,2017-06-30,2016-06,ACTUAL,2016-06-30,2016-06,ACTUAL,2016-06-30,,OBSERVATIONAL,,,Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program,Real-Life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program: A Prospective Observational Cohort Study (KASA PMOS),COMPLETED,,,173,ACTUAL,AbbVie,,,1,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 12:58:07,2024-10-13 12:58:07,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Canada,Cardiac disorders|General disorders|Psychiatric disorders
NCT01663740,,2012-08-09,2017-10-02,,2018-08-01,2012-08-09,2012-08-13,ESTIMATED,2018-08-01,2018-08-31,ACTUAL,,,,2018-08-01,2018-08-31,ACTUAL,2012-01-30,ACTUAL,2012-01-30,2018-07,2018-07-31,2016-12-30,ACTUAL,2016-12-30,2015-09-29,ACTUAL,2015-09-29,,INTERVENTIONAL,,"Safety population included all participants assigned to a cohort. One participant who was considered for inclusion in the study but did not participate, was excluded from baseline analysis.",A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls,A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls,COMPLETED,,PHASE4,59,ACTUAL,Hoffmann-La Roche,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 23:11:12,2024-10-13 23:11:12,INDUSTRY,,,,,,,Hoffmann-La Roche,Mexico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT01666782,,2012-08-14,2016-01-29,,2016-05-23,2012-08-14,2012-08-16,ESTIMATED,2016-04-15,2016-05-24,ESTIMATED,,,,2016-05-23,2016-06-24,ESTIMATED,2012-08,,2012-08-31,2016-05,2016-05-31,2015-12,ACTUAL,2015-12-31,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,IMMUNE,,Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy,A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy,COMPLETED,,PHASE2,105,ACTUAL,Rochester General Hospital,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 03:41:50,2024-10-13 03:41:50,OTHER,,,,,,,Saad Jamshed MD|Sanofi,United States,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01672983,,2012-07-27,2015-10-27,,2018-04-30,2012-08-23,2012-08-27,ESTIMATED,2015-10-27,2015-11-26,ESTIMATED,,,,2018-04-30,2018-05-30,ACTUAL,2012-07,,2012-07-31,2015-10,2015-10-31,2014-05,ACTUAL,2014-05-31,2014-05,ACTUAL,2014-05-31,,INTERVENTIONAL,,Baseline characteristics were summarized by treatment arm for all participants who received at least 1 dose of study drug.,A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection,"A Phase 2 Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection",COMPLETED,,PHASE2,110,ACTUAL,AbbVie,,6,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 11:14:41,2024-10-13 11:14:41,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Japan,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01674725,,2012-07-27,2014-12-23,,2021-07-08,2012-08-27,2012-08-29,ESTIMATED,2014-12-23,2015-01-06,ESTIMATED,,,,2021-07-08,2021-07-12,ACTUAL,2012-08,,2012-08-31,2021-07,2021-07-31,2014-10,ACTUAL,2014-10-31,2014-01,ACTUAL,2014-01-31,,INTERVENTIONAL,PEARL-II,All participants who received at least 1 dose of study drug.,A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C,"A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin in Treatment-Experienced Subjects With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-II)",COMPLETED,,PHASE3,187,ACTUAL,AbbVie,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:59:42,2024-10-14 18:59:42,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Austria|Belgium|Italy|Netherlands|Portugal|Puerto Rico|Sweden|Switzerland|Turkey|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01682876,,2012-09-07,2014-06-06,,2019-06-13,2012-09-07,2012-09-11,ESTIMATED,2014-09-29,2014-10-06,ESTIMATED,,,,2019-06-13,2019-06-14,ACTUAL,2012-10-07,ACTUAL,2012-10-07,2019-06,2019-06-30,2014-05-30,ACTUAL,2014-05-30,2013-07-02,ACTUAL,2013-07-02,,INTERVENTIONAL,,,"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","A Phase 3b, Randomized, Observer-Blind, Placebo-Controlled Multi-Center Study Comparing Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, Administered to Healthy Children 2 to 10 Years of Age.",COMPLETED,,PHASE3,715,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 04:04:40,2024-10-14 04:04:40,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01689207,,2012-09-12,2015-12-14,,2017-08-31,2012-09-20,2012-09-21,ESTIMATED,2016-09-06,2016-10-26,ESTIMATED,,,,2017-08-31,2017-09-06,ACTUAL,2012-09,,2012-09-30,2017-08,2017-08-31,2014-12,ACTUAL,2014-12-31,2014-12,ACTUAL,2014-12-31,,INTERVENTIONAL,,All randomised subjects,To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI),"A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI)",COMPLETED,,PHASE1,222,ACTUAL,Pfizer,"No formal statistical hypothesis testing was performed. The analyses of safety, tolerability, and pharmacokinetic data were summarised descriptively including tables, listings, and graphs, as appropriate.",4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 23:55:37,2024-10-13 23:55:37,INDUSTRY,,,,,,,Pfizer,United Kingdom,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01689207,,2012-09-12,2015-12-14,,2017-08-31,2012-09-20,2012-09-21,ESTIMATED,2016-09-06,2016-10-26,ESTIMATED,,,,2017-08-31,2017-09-06,ACTUAL,2012-09,,2012-09-30,2017-08,2017-08-31,2014-12,ACTUAL,2014-12-31,2014-12,ACTUAL,2014-12-31,,INTERVENTIONAL,,All randomised subjects,To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI),"A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI)",COMPLETED,,PHASE1,222,ACTUAL,Pfizer,"No formal statistical hypothesis testing was performed. The analyses of safety, tolerability, and pharmacokinetic data were summarised descriptively including tables, listings, and graphs, as appropriate.",4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 23:55:37,2024-10-13 23:55:37,INDUSTRY,,,,,,,Pfizer,United Kingdom,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01693783,,2012-09-21,2022-06-28,,2022-10-17,2012-09-25,2012-09-26,ESTIMATED,2022-10-17,2022-11-08,ACTUAL,,,,2022-10-17,2022-11-08,ACTUAL,2012-12-03,ACTUAL,2012-12-03,2022-10,2022-10-31,2021-11-24,ACTUAL,2021-11-24,2021-03-18,ACTUAL,2021-03-18,,INTERVENTIONAL,,,Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer,A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies,COMPLETED,,PHASE2,42,ACTUAL,National Cancer Institute (NCI),The primary limitation of the trial was the single-arm design. This was a phase 1/2 trial assessing ipilimumab monotherapy with no control arm.,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:27:07,2024-10-14 07:27:07,NIH,,,,,,,National Cancer Institute (NCI),Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01697748,,2012-09-19,2018-08-06,,2019-10-25,2012-09-27,2012-10-02,ESTIMATED,2018-08-27,2018-09-26,ACTUAL,,,,2019-10-25,2019-11-14,ACTUAL,2013-09,,2013-09-30,2012-12,2012-12-31,2018-05,ACTUAL,2018-05-31,2016-08,ACTUAL,2016-08-31,,INTERVENTIONAL,,,Prospective Study on Cesarean Wound Outcomes,A Prospective Randomized Study Assessing Post Operative Wound Infections Along With Cosmetic Outcomes Using Silver Impregnated Dressings Compared to Conventional Dressings on Cesarean Section Incisions,COMPLETED,,NA,660,ACTUAL,University of South Florida,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 14:21:02,2024-10-14 14:21:02,OTHER,,,,,,,University of South Florida,United States,Skin and subcutaneous tissue disorders
NCT01700179,,2012-10-02,2014-09-30,,2023-08-07,2012-10-02,2012-10-04,ESTIMATED,2014-09-30,2014-10-03,ESTIMATED,,,,2023-08-07,2023-08-29,ACTUAL,2012-09,,2012-09-30,2023-08,2023-08-31,2013-09,ACTUAL,2013-09-30,2013-09,ACTUAL,2013-09-30,,INTERVENTIONAL,,The analysis population for baseline characteristics was all enrolled participants.,"Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants","A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment-naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b",COMPLETED,,PHASE1,8,ACTUAL,"Alexion Pharmaceuticals, Inc.",,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:19:33,2024-10-13 07:19:33,INDUSTRY,,,,,,,"Achillion, a wholly owned subsidiary of Alexion|Alexion Pharmaceuticals, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01704755,,2012-09-28,2014-12-23,,2021-07-08,2012-10-10,2012-10-11,ESTIMATED,2014-12-23,2015-01-06,ESTIMATED,,,,2021-07-08,2021-07-12,ACTUAL,2012-10,,2012-10-31,2021-07,2021-07-31,2014-09,ACTUAL,2014-09-30,2014-01,ACTUAL,2014-01-31,,INTERVENTIONAL,TURQUOISE-II,All participants who received at least 1 dose of study drug.,A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)",COMPLETED,,PHASE3,381,ACTUAL,AbbVie,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:35:34,2024-10-14 18:35:34,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Belgium|Canada|France|Germany|Italy|Puerto Rico|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01704781,,2012-09-11,2017-01-16,,2017-01-16,2012-10-10,2012-10-11,ESTIMATED,2017-01-16,2017-03-08,ACTUAL,,,,2017-01-16,2017-03-08,ACTUAL,2012-09,,2012-09-30,2014-10,2014-10-31,2014-08,ACTUAL,2014-08-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,IMID,,Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART),A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).,COMPLETED,,PHASE1/PHASE2,36,ACTUAL,Bionor Immuno AS,,3,,,FALSE,,,,TRUE,,,,,,,,,,,NO,Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.,2024-10-13 23:27:20,2024-10-13 23:27:20,INDUSTRY,,,,,,,Bionor Immuno AS|Celgene Corporation,Germany,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01705574,,2012-10-10,2016-02-11,,2019-09-05,2012-10-11,2012-10-12,ESTIMATED,2016-02-11,2016-03-10,ESTIMATED,,,,2019-09-05,2019-09-20,ACTUAL,2012-10-24,ACTUAL,2012-10-24,2019-09,2019-09-30,2018-09-06,ACTUAL,2018-09-06,2015-02-09,ACTUAL,2015-02-09,,INTERVENTIONAL,WAVES,Safety Analysis Set included participants who were randomized and received at least one dose of study drug.,"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women",COMPLETED,,PHASE3,583,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 08:58:16,2024-10-14 08:58:16,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Brazil|Dominican Republic|France|Italy|Mexico|Portugal|Puerto Rico|Russian Federation|Thailand|Uganda|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01707472,,2012-09-11,2019-09-19,2015-11-17,2019-10-22,2012-10-12,2012-10-16,ESTIMATED,2019-09-19,2019-10-09,ACTUAL,2015-11-17,2015-12-16,ESTIMATED,2019-10-22,2019-11-05,ACTUAL,2012-10-04,ACTUAL,2012-10-04,2019-10,2019-10-31,2014-10-17,ACTUAL,2014-10-17,2014-10-17,ACTUAL,2014-10-17,,INTERVENTIONAL,,The Safety Analysis Set included participants who received at least one dose of study drug.,Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis,A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis,COMPLETED,,PHASE2,18,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 20:37:13,2024-10-13 20:37:13,INDUSTRY,,,,,,,Gilead Sciences|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01709084,,2012-10-16,2016-10-05,,2021-01-22,2012-10-16,2012-10-17,ESTIMATED,2016-11-04,2017-01-05,ESTIMATED,,,,2021-01-22,2021-02-11,ACTUAL,2013-10-02,ACTUAL,2013-10-02,2021-01,2021-01-31,2020-07-02,ACTUAL,2020-07-02,2015-10-22,ACTUAL,2015-10-22,,INTERVENTIONAL,SALIF,,A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment,"A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF)",COMPLETED,,PHASE3,426,ACTUAL,Janssen-Cilag International NV,It was an open label switch study with a significant number of patients (55%) on the Efavirenz (EFV) arm who did not switch their Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NNRTI) unlike in the Rilpivirine (RPV) arm where 100% switched.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-12 23:57:38,2024-10-12 23:57:38,INDUSTRY,,,,,,,Janssen-Cilag International NV,Cameroon|Ghana|Kenya|Senegal|South Africa|Thailand|Uganda,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01712256,,2012-10-16,2017-01-11,,2017-01-11,2012-10-19,2012-10-23,ESTIMATED,2017-01-11,2017-03-06,ACTUAL,,,,2017-01-11,2017-03-06,ACTUAL,2012-12,,2012-12-31,2017-01,2017-01-31,2014-01,ACTUAL,2014-01-31,2014-01,ACTUAL,2014-01-31,,INTERVENTIONAL,Re-boost,,Re-boosting of HIV-1 Infected Subjects With Vacc-4x,"Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART",COMPLETED,,PHASE2,33,ACTUAL,Bionor Immuno AS,,1,,,FALSE,,,,TRUE,,,,,,,,,,,NO,Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.,2024-10-13 06:20:43,2024-10-13 06:20:43,INDUSTRY,,,,,,,Bionor Immuno AS,Germany|Italy|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01715415,,2012-10-25,2014-12-23,,2021-07-29,2012-10-25,2012-10-29,ESTIMATED,2014-12-23,2015-01-06,ESTIMATED,,,,2021-07-29,2021-08-02,ACTUAL,2012-11,,2012-11-30,2021-07,2021-07-31,2014-10,ACTUAL,2014-10-31,2013-11,ACTUAL,2013-11-30,,INTERVENTIONAL,,Safety population: all randomized participants who received at least 1 dose of blinded study drug.,A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)",COMPLETED,,PHASE3,395,ACTUAL,AbbVie,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 06:23:59,2024-10-14 06:23:59,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Australia|Canada|Czech Republic|Denmark|France|Germany|Ireland|Italy|Mexico|Netherlands|Portugal|Puerto Rico|Russian Federation|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01716585,,2012-10-18,2014-12-23,,2021-07-08,2012-10-26,2012-10-30,ESTIMATED,2014-12-23,2015-01-06,ESTIMATED,,,,2021-07-08,2021-07-12,ACTUAL,2012-11,,2012-11-30,2021-07,2021-07-31,2014-10,ACTUAL,2014-10-31,2013-10,ACTUAL,2013-10-31,,INTERVENTIONAL,,Safety population: all randomized participants who received at least 1 dose of blinded study drug,A Study to Evaluate Chronic Hepatitis C Infection,"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)",COMPLETED,,PHASE3,636,ACTUAL,AbbVie,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 03:20:11,2024-10-14 03:20:11,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Australia|Austria|Canada|France|Germany|Hungary|Italy|New Zealand|Spain|Sweden|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01717287,,2012-10-26,2014-06-30,,2018-07-23,2012-10-26,2012-10-30,ESTIMATED,2014-06-30,2014-07-29,ESTIMATED,,,,2018-07-23,2018-08-21,ACTUAL,2012-11-16,ACTUAL,2012-11-16,2018-07,2018-07-31,2013-12-11,ACTUAL,2013-12-11,2013-12-11,ACTUAL,2013-12-11,,INTERVENTIONAL,,,"A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)","A Phase II, Multicenter, Open-Label, Noncomparative Study of Raltegravir (MK-0518) in Two Oral Formulations in Combination With Other Antiretroviral Agents to Evaluate the Safety, Tolerability, and Antiretroviral Activity in HIV-1 Infected Russian Children and Adolescents",COMPLETED,,PHASE2,32,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 19:51:18,2024-10-13 19:51:18,INDUSTRY,,,,,,,Covance|Merck Sharp & Dohme LLC,Russian Federation,Gastrointestinal disorders|Infections and infestations
NCT01721109,,2012-11-01,2017-02-24,2016-08-17,2018-07-20,2012-11-01,2012-11-04,ESTIMATED,2017-02-24,2017-04-10,ACTUAL,2016-08-18,2016-08-19,ESTIMATED,2018-07-20,2018-08-17,ACTUAL,2012-12-06,ACTUAL,2012-12-06,2018-07,2018-07-31,2018-01-29,ACTUAL,2018-01-29,2015-10-22,ACTUAL,2015-10-22,,INTERVENTIONAL,,Safety Analysis Set: all participants who received at least 1 dose of study drug.,"Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents","A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents",COMPLETED,,PHASE2/PHASE3,50,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 14:31:53,2024-10-13 14:31:53,INDUSTRY,,,,,,,Gilead Sciences,Mexico|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01721408,,2012-10-31,2016-09-29,,2017-09-14,2012-11-01,2012-11-04,ESTIMATED,2017-09-14,2018-04-09,ACTUAL,,,,2017-09-14,2018-04-09,ACTUAL,2012-11,ACTUAL,2012-11-30,2017-09,2017-09-30,2015-10,ACTUAL,2015-10-31,2015-10,ACTUAL,2015-10-31,,INTERVENTIONAL,,,A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection,"A Multicenter, Double-blind, Randomized, Comparison Study Of The Efficacy And Safety Of Tigecycline To Imipenem/Cilastatin To Treat Complicated Intra-abdominal Infections In Hospitalized Subjects.",COMPLETED,,PHASE4,470,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 23:33:16,2024-10-13 23:33:16,INDUSTRY,,,,,,,Pfizer,China,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT01726023,,2012-11-05,2016-02-01,,2017-09-01,2012-11-09,2012-11-14,ESTIMATED,2016-03-16,2016-04-14,ESTIMATED,,,,2017-09-01,2017-09-06,ACTUAL,2013-01,,2013-01-31,2017-09,2017-09-30,2015-03,ACTUAL,2015-03-31,2015-03,ACTUAL,2015-03-31,,INTERVENTIONAL,RECLAIM3,"Baseline analysis population is MITT ; Randomized patients who received any amount of study therapy, excluding patients who received both study therapies. 9 patients were randomized but not treated, and one patient received doses of both treatments.",Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections,"A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults",COMPLETED,,PHASE3,486,ACTUAL,Pfizer,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 12:14:37,2024-10-13 12:14:37,INDUSTRY,,,,,,,Pfizer,"China|Korea, Republic of|Vietnam","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT01732627,,2012-11-13,2020-05-19,2013-11-11,2022-03-24,2012-11-19,2012-11-26,ESTIMATED,2020-05-19,2020-06-09,ACTUAL,2013-11-11,2013-12-04,ESTIMATED,2022-03-24,2022-04-04,ACTUAL,2012-11-12,ACTUAL,2012-11-12,2022-03,2022-03-31,2013-01-17,ACTUAL,2013-01-17,2013-01-17,ACTUAL,2013-01-17,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older,Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Subjects 56 Years of Age and Older,COMPLETED,,PHASE2,301,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-13 15:25:43,2024-10-13 15:25:43,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01744730,,2012-12-05,2016-02-10,,2016-11-21,2012-12-05,2012-12-07,ESTIMATED,2016-10-18,2016-10-19,ESTIMATED,,,,2016-11-21,2016-11-29,ESTIMATED,2013-06,,2013-06-30,2016-10,2016-10-31,2014-08,ACTUAL,2014-08-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,CLIN01,,Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile,Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (NICHD): CLIN01,COMPLETED,,PHASE1,22,ACTUAL,Duke University,Data from 3 different studies was included to increase the robustness of the population PK model developed and leverage all available clindamycin PK data.,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:42:57,2024-10-13 07:42:57,OTHER,,,,,,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Phillip Brian Smith|The Emmes Company, LLC",United States,"Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01745822,,2012-12-06,2020-04-28,,2021-02-12,2012-12-07,2012-12-10,ESTIMATED,2021-02-12,2021-03-05,ACTUAL,,,,2021-02-12,2021-03-05,ACTUAL,2013-01,,2013-01-31,2021-02,2021-02-28,2018-10,ACTUAL,2018-10-31,2016-12,ACTUAL,2016-12-31,,INTERVENTIONAL,iTAP,Mothers only,Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand,"Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization.",COMPLETED,,PHASE3,654,ACTUAL,Institut de Recherche pour le Developpement,,2,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,Pending completion of analysis planned in the protocol,2024-10-13 00:49:29,2024-10-13 00:49:29,OTHER_GOV,,,,,,,Centers for Disease Control and Prevention|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Gilead Sciences|Institut de Recherche pour le Developpement,Thailand,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT01746108,,2012-11-28,2016-11-08,2015-10-08,2019-06-26,2012-12-06,2012-12-10,ESTIMATED,2016-11-08,2017-01-09,ESTIMATED,2015-10-08,2015-11-01,ESTIMATED,2019-06-26,2019-07-09,ACTUAL,2013-06-18,ACTUAL,2013-06-18,2019-06,2019-06-30,2015-06-29,ACTUAL,2015-06-29,2015-06-29,ACTUAL,2015-06-29,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection,"Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection",COMPLETED,,PHASE3,52,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 15:43:52,2024-10-13 15:43:52,INDUSTRY,,,,,,,GlaxoSmithKline,Poland|Russian Federation,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01751568,,2012-12-14,2020-11-24,,2021-11-03,2012-12-14,2012-12-18,ESTIMATED,2020-11-24,2020-12-21,ACTUAL,,,,2021-11-03,2021-11-05,ACTUAL,2014-11-12,ACTUAL,2014-11-12,2020-11,2020-11-30,2019-11-27,ACTUAL,2019-11-27,2019-11-27,ACTUAL,2019-11-27,,INTERVENTIONAL,,Includes all participants who enrolled and received raltegravir.,"Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB","Phase I/II Dose-Finding, Safety, Tolerance, and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Infants and Children",COMPLETED,,PHASE1/PHASE2,40,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:42:57,2024-10-13 07:42:57,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01751646,,2012-12-14,2017-10-18,,2019-03-25,2012-12-14,2012-12-18,ESTIMATED,2018-11-19,2019-03-11,ACTUAL,,,,2019-03-25,2019-03-27,ACTUAL,2012-10,,2012-10-31,2018-11,2018-11-30,2016-06,ACTUAL,2016-06-30,2016-06,ACTUAL,2016-06-30,,INTERVENTIONAL,,"The baseline analysis population includes all participants randomized to Group A or Group B who received the intervention, with the exception of two participants (one in each group) who were later determined to have been inadvertent enrollments who did not meet eligibility criteria.",Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART,"A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU Every 4 Weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth With HIV Infection Being Treated With Tenofovir-Containing Combination Antiretroviral Therapy (cART)",COMPLETED,,NA,214,ACTUAL,"University of North Carolina, Chapel Hill","The analysis by efavirenz use and ritonavir use after baseline do not adjust for treatment group (secondary outcome measures 68, 69, 71, and 72). Results post-baseline may differ based on treatment group.",2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,,,2024-10-13 23:21:52,2024-10-13 23:21:52,OTHER,,,,,,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA)|University of North Carolina, Chapel Hill",Puerto Rico|United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01755026,,2011-06-29,2013-06-12,,2013-06-12,2012-12-18,2012-12-21,ESTIMATED,2013-06-12,2013-08-21,ESTIMATED,,,,2013-06-12,2013-08-21,ESTIMATED,2010-11,,2010-11-30,2013-06,2013-06-30,2012-11,ACTUAL,2012-11-30,2011-07,ACTUAL,2011-07-31,,INTERVENTIONAL,,,Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery,Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery Receiving Two Differing Doses of Pre-operative Cefazolin.,COMPLETED,,PHASE4,23,ACTUAL,West Virginia University,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 01:11:48,2024-10-13 01:11:48,OTHER,,,,,,,Michael Stitely,United States,Skin and subcutaneous tissue disorders
NCT01755689,,2012-12-13,2017-06-16,2015-04-27,2018-01-10,2012-12-19,2012-12-24,ESTIMATED,2018-01-10,2018-07-03,ACTUAL,2015-04-27,2015-05-13,ESTIMATED,2018-01-10,2018-07-03,ACTUAL,2013-01-11,ACTUAL,2013-01-11,2017-11,2017-11-30,2014-04-29,ACTUAL,2014-04-29,2014-04-29,ACTUAL,2014-04-29,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults,Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine 134612 With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults at 9-25 Years of Age,COMPLETED,,PHASE3,1300,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 11:04:01,2024-10-13 11:04:01,INDUSTRY,,,,,,,GlaxoSmithKline,Brazil|Dominican Republic|Estonia|Thailand,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01764256,,2013-01-07,2018-08-08,,2019-02-19,2013-01-08,2013-01-09,ESTIMATED,2018-09-26,2019-02-15,ACTUAL,,,,2019-02-19,2019-03-12,ACTUAL,2012-12,,2012-12-31,2019-02,2019-02-28,2013-09,ACTUAL,2013-09-30,2013-06,ACTUAL,2013-06-30,,INTERVENTIONAL,,,A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine,"A Phase 1 Double Blinded, Randomized, Placebo-controlled Dose Escalation Study to Examine the Safety, Reactogenicity, Tolerability and Immunogenicity of the P2-VP8 Subunit Rotavirus Vaccine in Healthy Adult Volunteers",COMPLETED,,PHASE1,48,ACTUAL,PATH,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 00:48:07,2024-10-14 00:48:07,OTHER,,,,,,,PATH,United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01765920,,2013-01-09,2020-08-17,,2020-12-10,2013-01-09,2013-01-10,ESTIMATED,2020-11-17,2020-12-11,ACTUAL,,,,2020-12-10,2021-01-05,ACTUAL,2012-12,,2012-12-31,2019-01,2019-01-31,2015-04,ACTUAL,2015-04-30,2014-12,ACTUAL,2014-12-31,,INTERVENTIONAL,,,Clinical Trial of Safety and Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adults,Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients,COMPLETED,,PHASE3,342,ACTUAL,Materia Medica Holding,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:30:57,2024-10-13 20:30:57,INDUSTRY,,,,,,,Materia Medica Holding,Russian Federation,"Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01767116,,2012-11-30,2014-12-23,,2021-07-08,2013-01-10,2013-01-14,ESTIMATED,2014-12-23,2015-01-06,ESTIMATED,,,,2021-07-08,2021-07-12,ACTUAL,2012-12,,2012-12-31,2021-07,2021-07-31,2014-08,ACTUAL,2014-08-31,2013-12,ACTUAL,2013-12-31,,INTERVENTIONAL,PEARL-III,All randomized participants who received at least 1 dose of study drug,A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection,"A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)",COMPLETED,,PHASE3,419,ACTUAL,AbbVie,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:15:37,2024-10-13 08:15:37,INDUSTRY,,,,,,,"AbbVie (prior sponsor, Abbott)",Austria|Belgium|Hungary|Israel|Italy|Poland|Portugal|Romania|Russian Federation|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01767376,,2012-12-21,2017-08-03,2014-05-29,2017-08-03,2013-01-10,2013-01-14,ESTIMATED,2017-08-03,2017-09-06,ACTUAL,2014-05-29,2014-06-02,ESTIMATED,2017-08-03,2017-09-06,ACTUAL,2013-01-10,ACTUAL,2013-01-10,2017-08,2017-08-31,2014-01-16,ACTUAL,2014-01-16,2014-01-16,ACTUAL,2014-01-16,,INTERVENTIONAL,,,Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age,"Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Healthy Adolescents and Young Adults Between 11 and 25 Years of Age",COMPLETED,,PHASE3,692,ACTUAL,GlaxoSmithKline,"Due to late availability of the serology results, only safety results were posted by the initial due date.",3,,,FALSE,,,,,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-13 15:07:24,2024-10-13 15:07:24,INDUSTRY,,,,,,,GlaxoSmithKline,"Dominican Republic|Germany|Korea, Republic of",Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT01769365,,2013-01-14,2015-09-06,,2017-10-17,2013-01-14,2013-01-16,ESTIMATED,2015-09-06,2015-10-06,ESTIMATED,,,,2017-10-17,2017-11-17,ACTUAL,2010-07,,2010-07-31,2015-09,2015-09-30,2013-10,ACTUAL,2013-10-31,2013-10,ACTUAL,2013-10-31,,INTERVENTIONAL,,,"Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection","Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan",COMPLETED,,PHASE4,307,ACTUAL,Kaohsiung Veterans General Hospital.,The trial was performed in a single country,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 20:24:02,2024-10-14 20:24:02,OTHER,,,,,,,Kaohsiung Veterans General Hospital.,Taiwan,Gastrointestinal disorders
NCT01769456,,2013-01-14,2017-10-06,,2018-01-12,2013-01-14,2013-01-16,ESTIMATED,2017-11-08,2017-11-13,ACTUAL,,,,2018-01-12,2018-01-17,ACTUAL,2013-03,,2013-03-31,2017-11,2017-11-30,2016-11,ACTUAL,2016-11-30,2015-11,ACTUAL,2015-11-30,,INTERVENTIONAL,,,An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM),Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) in the United States,COMPLETED,,PHASE2,78,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 13:07:17,2024-10-14 13:07:17,OTHER,,,,,,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Gilead Sciences|University of North Carolina, Chapel Hill",United States,Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders
NCT01771107,,2013-01-16,2022-10-26,,2024-08-08,2013-01-16,2013-01-18,ESTIMATED,2023-02-01,2023-03-03,ACTUAL,,,,2024-08-08,2024-08-09,ACTUAL,2013-03-07,ACTUAL,2013-03-07,2024-04,2024-04-30,2025-02-28,ESTIMATED,2025-02-28,2021-10-15,ACTUAL,2021-10-15,,INTERVENTIONAL,,Participant enrolled on the study,Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma,A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma,ACTIVE_NOT_RECRUITING,,PHASE1/PHASE2,41,ACTUAL,National Cancer Institute (NCI),,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 18:07:20,2024-10-13 18:07:20,NIH,,,,,,,National Cancer Institute (NCI)|The Lymphoma Academic Research Organisation,France|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01772823,,2012-12-21,2017-10-13,,2018-01-12,2013-01-17,2013-01-21,ESTIMATED,2017-12-20,2017-12-21,ACTUAL,,,,2018-01-12,2018-01-17,ACTUAL,2012-11,,2012-11-30,2017-12,2017-12-31,2015-11,ACTUAL,2015-11-30,2015-11,ACTUAL,2015-11-30,,INTERVENTIONAL,,,An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis,Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among Young Men Who Have Sex With Men (YMSM) in the United States,COMPLETED,,PHASE2,200,ACTUAL,"University of North Carolina, Chapel Hill",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 16:26:35,2024-10-13 16:26:35,OTHER,,,,,,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|University of North Carolina, Chapel Hill",United States,"Gastrointestinal disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT01777308,,2013-01-24,2017-09-29,,2018-08-09,2013-01-24,2013-01-28,ESTIMATED,2018-08-09,2019-01-25,ACTUAL,,,,2018-08-09,2019-01-25,ACTUAL,2013-05-03,,2013-05-03,2017-09,2017-09-30,2016-04-20,ACTUAL,2016-04-20,2014-07-03,ACTUAL,2014-07-03,,INTERVENTIONAL,,,"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination",The Vaccine Response and Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine (GSK134612) Administered as One Dose at 6 Years Post-MenC Primary Vaccination in Healthy Subjects Aged 12-18 Months at Primary Vaccination,COMPLETED,,PHASE3,156,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-15 03:30:49,2024-10-15 03:30:49,INDUSTRY,,,,,,,GlaxoSmithKline,Australia,Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT01777997,,2013-01-10,2017-10-31,2016-11-14,2021-07-31,2013-01-28,2013-01-29,ESTIMATED,2017-12-12,2018-01-12,ACTUAL,2016-12-15,2017-01-11,ESTIMATED,2021-07-31,2021-08-03,ACTUAL,2013-04-25,ACTUAL,2013-04-25,2017-12,2017-12-31,2017-02-07,ACTUAL,2017-02-07,2016-02-19,ACTUAL,2016-02-19,,INTERVENTIONAL,,Participants who were on intervention (ART) for at least 24 weeks,"FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir","A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers",COMPLETED,,PHASE4,38,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 07:19:33,2024-10-13 07:19:33,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01778634,,2013-01-22,2018-03-02,,2020-11-03,2013-01-24,2013-01-29,ESTIMATED,2018-04-18,2018-05-17,ACTUAL,,,,2020-11-03,2020-11-30,ACTUAL,2013-07,,2013-07-31,2020-11,2020-11-30,2020-11-03,ACTUAL,2020-11-03,2016-12,ACTUAL,2016-12-31,,INTERVENTIONAL,AZIPIII,,Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants,"A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants",COMPLETED,,PHASE2,121,ACTUAL,"University of Maryland, Baltimore",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:38:09,2024-10-14 13:38:09,OTHER,,,,,,,"Christiana Care Health Services|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Johns Hopkins University|Mercy Medical Center|University of Alabama at Birmingham|University of Maryland, Baltimore|University of Virginia",United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01780506,,2013-01-16,2015-12-04,2014-06-24,2018-10-19,2013-01-29,2013-01-31,ESTIMATED,2015-12-04,2016-01-08,ESTIMATED,2014-06-24,2014-06-26,ESTIMATED,2018-10-19,2018-11-19,ACTUAL,2012-12-26,ACTUAL,2012-12-26,2018-08,2018-08-31,2017-09-06,ACTUAL,2017-09-06,2014-08-26,ACTUAL,2014-08-26,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults",COMPLETED,,PHASE3,872,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 00:03:31,2024-10-13 00:03:31,INDUSTRY,,,,,,,Gilead Sciences,Australia|Austria|Belgium|Brazil|Canada|Dominican Republic|France|Germany|Italy|Japan|Mexico|Netherlands|Poland|Portugal|Puerto Rico|Russian Federation|Spain|Sweden|Switzerland|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01780831,,2013-01-29,2020-06-02,,2021-11-04,2013-01-29,2013-01-31,ESTIMATED,2020-07-01,2020-07-17,ACTUAL,,,,2021-11-04,2021-11-05,ACTUAL,2014-01-28,ACTUAL,2014-01-28,2020-07,2020-07-31,2018-04-20,ACTUAL,2018-04-20,2017-12-14,ACTUAL,2017-12-14,,INTERVENTIONAL,,All enrolled infants.,Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection,A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection,COMPLETED,,PHASE1,52,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-13 20:58:47,2024-10-13 20:58:47,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Argentina|Brazil|Puerto Rico|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01782131,,2013-01-30,2020-07-16,2020-06-15,2024-01-16,2013-01-30,2013-02-01,ESTIMATED,2020-08-06,2020-08-21,ACTUAL,2020-06-15,2020-06-17,ACTUAL,2024-01-16,2024-01-18,ACTUAL,2013-09-25,ACTUAL,2013-09-25,2024-01,2024-01-31,2019-09-10,ACTUAL,2019-09-10,2019-07-10,ACTUAL,2019-07-10,,INTERVENTIONAL,,The analysis population included all participants who received at least one dose of study treatment.,A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069),A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069),COMPLETED,,PHASE3,585,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 08:15:37,2024-10-13 08:15:37,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Argentina|Australia|Belgium|Brazil|Canada|Chile|China|Colombia|Croatia|Czechia|Estonia|France|Germany|Greece|Guatemala|Hungary|Israel|Italy|Korea, Republic of|Lithuania|Malaysia|Mexico|Peru|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Spain|Switzerland|Taiwan|Turkey|United States","Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01782495,,2013-01-22,2017-10-09,,2017-10-09,2013-01-31,2013-02-04,ESTIMATED,2017-10-09,2017-11-07,ACTUAL,,,,2017-10-09,2017-11-07,ACTUAL,2013-02-25,ACTUAL,2013-02-25,2017-10,2017-10-31,2017-07-13,ACTUAL,2017-07-13,2016-11-02,ACTUAL,2016-11-02,,INTERVENTIONAL,CORAL-I,,A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients,"Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)",COMPLETED,,PHASE2,129,ACTUAL,AbbVie,,11,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 05:11:43,2024-10-13 05:11:43,INDUSTRY,,,,,,,AbbVie,Australia|France|Germany|Puerto Rico|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01789203,,2013-02-07,2019-04-02,,2019-10-25,2013-02-11,2013-02-12,ESTIMATED,2019-10-25,2019-11-13,ACTUAL,,,,2019-10-25,2019-11-13,ACTUAL,2013-01,ACTUAL,2013-01-31,2019-10,2019-10-31,2017-10,ACTUAL,2017-10-31,2017-04,ACTUAL,2017-04-30,,INTERVENTIONAL,,Analysis performed on IIT patients (all randomized patients),Ciprofloxacin for Prevention of BK Infection,Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients,COMPLETED,,PHASE4,200,ACTUAL,The Methodist Hospital Research Institute,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,UNDECIDED,,2024-10-13 11:46:42,2024-10-13 11:46:42,OTHER,,,,,,,The Methodist Hospital Research Institute,United States,Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Surgical and medical procedures|Vascular disorders
NCT01797445,,2013-02-20,2015-12-04,2015-07-28,2020-02-18,2013-02-20,2013-02-22,ESTIMATED,2015-12-04,2016-01-08,ESTIMATED,2015-07-28,2015-08-18,ESTIMATED,2020-02-18,2020-03-02,ACTUAL,2013-03-12,ACTUAL,2013-03-12,2019-10,2019-10-31,2018-10-03,ACTUAL,2018-10-03,2014-09-19,ACTUAL,2014-09-19,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.,"Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults",COMPLETED,,PHASE3,872,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-14 01:17:29,2024-10-14 01:17:29,INDUSTRY,,,,,,,Gilead Sciences,Australia|Austria|Belgium|Brazil|Canada|Dominican Republic|France|Germany|Italy|Mexico|Netherlands|Portugal|Puerto Rico|Spain|Sweden|Switzerland|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01803074,,2013-03-01,2019-01-28,,2019-11-04,2013-03-01,2013-03-04,ESTIMATED,2019-11-04,2019-11-25,ACTUAL,,,,2019-11-04,2019-11-25,ACTUAL,2013-04-04,ACTUAL,2013-04-04,2019-11,2019-11-30,2014-11-29,ACTUAL,2014-11-29,2014-11-29,ACTUAL,2014-11-29,,INTERVENTIONAL,,,Study to Evaluate a HIV Drug for the Treatment of HIV Infection,"Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects",COMPLETED,,PHASE2,107,ACTUAL,ViiV Healthcare,,13,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 09:15:19,2024-10-13 09:15:19,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Germany|South Africa,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01803074,,2013-03-01,2019-01-28,,2019-11-04,2013-03-01,2013-03-04,ESTIMATED,2019-11-04,2019-11-25,ACTUAL,,,,2019-11-04,2019-11-25,ACTUAL,2013-04-04,ACTUAL,2013-04-04,2019-11,2019-11-30,2014-11-29,ACTUAL,2014-11-29,2014-11-29,ACTUAL,2014-11-29,,INTERVENTIONAL,,,Study to Evaluate a HIV Drug for the Treatment of HIV Infection,"Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects",COMPLETED,,PHASE2,107,ACTUAL,ViiV Healthcare,,13,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 09:15:19,2024-10-13 09:15:19,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Germany|South Africa,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01808456,,2013-03-04,2021-04-28,,2022-07-20,2013-03-07,2013-03-11,ESTIMATED,2022-07-20,2022-07-22,ACTUAL,,,,2022-07-20,2022-07-22,ACTUAL,2013-10,,2013-10-31,2022-07,2022-07-31,2016-12,ACTUAL,2016-12-31,2016-12,ACTUAL,2016-12-31,,INTERVENTIONAL,,,Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.,"Phase IV, Pilot, Randomized, Investigator-blinded, Study to Evaluate the Reactogenicity and Immunogenicity of Standard-dose Versus High-dose Inactivated Influenza Vaccine After Kidney, Heart and Lung Transplantation.",COMPLETED,,PHASE4,62,ACTUAL,Inova Health Care Services,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-12 23:52:10,2024-10-12 23:52:10,OTHER,,,,,,,Inova Health Care Services,United States,General disorders|Musculoskeletal and connective tissue disorders
NCT01811732,,2013-03-08,2017-07-25,2015-06-22,2017-08-29,2013-03-14,2013-03-15,ESTIMATED,2017-07-25,2017-08-24,ACTUAL,2015-06-22,2015-07-15,ESTIMATED,2017-08-29,2017-09-27,ACTUAL,2013-04,ACTUAL,2013-04-30,2017-08,2017-08-31,2014-07,ACTUAL,2014-07-31,2014-07,ACTUAL,2014-07-31,,INTERVENTIONAL,,Intent-to-Treat (ITT) Population included all patients who were randomly assigned to treatment.,Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,660,ACTUAL,"Melinta Therapeutics, Inc.",,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 18:59:42,2024-10-14 18:59:42,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",Croatia|Israel|Latvia|Russian Federation|Spain|Ukraine|United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01814371,,2013-03-15,2018-04-09,,2019-02-04,2013-03-15,2013-03-19,ESTIMATED,2018-09-25,2018-10-26,ACTUAL,,,,2019-02-04,2019-02-21,ACTUAL,2013-04,,2013-04-30,2019-02,2019-02-28,2017-11-28,ACTUAL,2017-11-28,2017-02-26,ACTUAL,2017-02-26,,INTERVENTIONAL,HOME2DS,,Individualized vs. Household MRSA Decolonization,Individualized vs. Household Eradication of MRSA in Households With Children,COMPLETED,,NA,474,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:52:56,2024-10-13 08:52:56,OTHER,,,,,,,Washington University School of Medicine,United States,General disorders
NCT01814371,,2013-03-15,2018-04-09,,2019-02-04,2013-03-15,2013-03-19,ESTIMATED,2018-09-25,2018-10-26,ACTUAL,,,,2019-02-04,2019-02-21,ACTUAL,2013-04,,2013-04-30,2019-02,2019-02-28,2017-11-28,ACTUAL,2017-11-28,2017-02-26,ACTUAL,2017-02-26,,INTERVENTIONAL,HOME2DS,,Individualized vs. Household MRSA Decolonization,Individualized vs. Household Eradication of MRSA in Households With Children,COMPLETED,,NA,474,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:52:56,2024-10-13 08:52:56,OTHER,,,,,,,Washington University School of Medicine,United States,General disorders
NCT01815736,,2013-03-19,2016-03-15,2014-10-30,2021-03-22,2013-03-19,2013-03-21,ESTIMATED,2016-03-15,2016-04-14,ESTIMATED,2014-10-30,2014-11-05,ESTIMATED,2021-03-22,2021-04-13,ACTUAL,2013-03-27,ACTUAL,2013-03-27,2021-03,2021-03-31,2020-04-01,ACTUAL,2020-04-01,2015-03-16,ACTUAL,2015-03-16,,INTERVENTIONAL,,Safety Analysis Set included participants who were randomized and received at least one dose of study drug.,"Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants","A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects",COMPLETED,,PHASE3,1443,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",2024-10-13 11:04:01,2024-10-13 11:04:01,INDUSTRY,,,,,,,Gilead Sciences,Australia|Austria|Belgium|Brazil|Canada|Denmark|Dominican Republic|France|Germany|Italy|Mexico|Netherlands|Portugal|Puerto Rico|Spain|Sweden|Switzerland|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT01817075,,2013-03-20,2020-03-25,,2021-06-18,2013-03-20,2013-03-22,ESTIMATED,2020-03-25,2020-04-08,ACTUAL,,,,2021-06-18,2021-06-22,ACTUAL,2013-11-04,ACTUAL,2013-11-04,2020-03,2020-03-31,2020-03-31,ACTUAL,2020-03-31,2019-03-31,ACTUAL,2019-03-31,,INTERVENTIONAL,,,Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant,Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT),COMPLETED,,PHASE3,177,ACTUAL,Children's Oncology Group,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:35:34,2024-10-14 18:35:34,NETWORK,,,,,,,Children's Oncology Group|National Cancer Institute (NCI),Canada|Puerto Rico|United States,Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Skin and subcutaneous tissue disorders
NCT01817075,,2013-03-20,2020-03-25,,2021-06-18,2013-03-20,2013-03-22,ESTIMATED,2020-03-25,2020-04-08,ACTUAL,,,,2021-06-18,2021-06-22,ACTUAL,2013-11-04,ACTUAL,2013-11-04,2020-03,2020-03-31,2020-03-31,ACTUAL,2020-03-31,2019-03-31,ACTUAL,2019-03-31,,INTERVENTIONAL,,,Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant,Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT),COMPLETED,,PHASE3,177,ACTUAL,Children's Oncology Group,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:35:34,2024-10-14 18:35:34,NETWORK,,,,,,,Children's Oncology Group|National Cancer Institute (NCI),Canada|Puerto Rico|United States,Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Skin and subcutaneous tissue disorders
NCT01818596,,2013-03-22,2015-12-04,2014-09-16,2020-02-18,2013-03-22,2013-03-26,ESTIMATED,2016-01-21,2016-02-18,ESTIMATED,2014-09-16,2014-09-29,ESTIMATED,2020-02-18,2020-03-02,ACTUAL,2013-03-27,ACTUAL,2013-03-27,2019-06,2019-06-30,2018-07-18,ACTUAL,2018-07-18,2014-07-31,ACTUAL,2014-07-31,,INTERVENTIONAL,,Safety Analysis Set: participants were enrolled and received at least 1 dose of study drug,Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment,A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment,COMPLETED,,PHASE3,252,ACTUAL,Gilead Sciences,"Enrollment in Cohort 2 (treatment-naive) was low, which affects the interpretation of the data.",1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-15 02:24:13,2024-10-15 02:24:13,INDUSTRY,,,,,,,Gilead Sciences,Australia|Austria|Belgium|Brazil|Canada|Dominican Republic|France|Germany|Italy|Mexico|Netherlands|Puerto Rico|Spain|Sweden|Switzerland|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01822522,,2013-04-01,2022-08-25,,2022-12-14,2013-04-01,2013-04-02,ESTIMATED,2022-12-14,2023-01-10,ACTUAL,,,,2022-12-14,2023-01-10,ACTUAL,2013-06-21,ACTUAL,2013-06-21,2022-12,2022-12-31,2021-05-12,ACTUAL,2021-05-12,2019-05-22,ACTUAL,2019-05-22,,INTERVENTIONAL,,Patients who enrolled on the study and whose antiretroviral regimen met the requirements for the appropriate stratum,Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus,Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection,COMPLETED,,PHASE1,36,ACTUAL,National Cancer Institute (NCI),,6,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:22:39,2024-10-13 19:22:39,NIH,,,,,,,National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01827358,,2013-04-04,2017-06-01,,2017-06-29,2013-04-04,2013-04-09,ESTIMATED,2017-06-29,2017-07-07,ACTUAL,,,,2017-06-29,2017-07-07,ACTUAL,2014-04-30,,2014-04-30,2016-04-13,2016-04-13,2016-06-21,ACTUAL,2016-06-21,2016-06-07,ACTUAL,2016-06-07,,INTERVENTIONAL,,,Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants,"Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial",COMPLETED,,PHASE2,155,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-13 01:51:42,2024-10-13 01:51:42,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01828073,,2013-04-05,2019-04-23,,2021-11-04,2013-04-05,2013-04-10,ESTIMATED,2019-04-23,2019-05-15,ACTUAL,,,,2021-11-04,2021-11-08,ACTUAL,2011-05-19,,2011-05-19,2020-02,2020-02-29,2018-04-23,ACTUAL,2018-04-23,2018-04-23,ACTUAL,2018-04-23,,OBSERVATIONAL,,All infants,Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants,Raltegravir Pharmacokinetics and Safety in Neonates,COMPLETED,,,40,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,,2,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 18:25:33,2024-10-13 18:25:33,NIH,,,,,,FALSE,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Puerto Rico|South Africa|Tanzania|Thailand|United States,"Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01830595,,2013-04-10,2018-05-30,,2018-09-21,2013-04-11,2013-04-12,ESTIMATED,2018-09-14,2018-09-18,ACTUAL,,,,2018-09-21,2018-10-18,ACTUAL,2014-09,ACTUAL,2014-09-30,2018-09,2018-09-30,2018-01,ACTUAL,2018-01-31,2017-07,ACTUAL,2017-07-31,,INTERVENTIONAL,,,Lactoferrin Treatment in HIV Patients,Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients,COMPLETED,,PHASE2,55,ACTUAL,Hennepin Healthcare Research Institute,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:37:59,2024-10-13 09:37:59,OTHER,,,,,,,Jason Baker|Ventria Bioscience,United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01831154,,2013-04-09,2016-04-27,,2017-03-13,2013-04-10,2013-04-15,ESTIMATED,2017-03-13,2017-04-24,ACTUAL,,,,2017-03-13,2017-04-24,ACTUAL,2010-05,,2010-05-31,2017-03,2017-03-31,2011-10,ACTUAL,2011-10-31,2011-07,ACTUAL,2011-07-31,,INTERVENTIONAL,,,The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery,The Effect of Intraoperative Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery,COMPLETED,,NA,37,ACTUAL,James A. Haley Veterans Administration Hospital,This study was conducted in a single center and homogenous sample. Statistical power was not sufficient to draw conclusion on the effect of tight glycemic control on postoperative outcomes.,3,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,,2024-10-13 05:56:17,2024-10-13 05:56:17,FED,,,,,,,James A. Haley Veterans Administration Hospital|University of South Florida,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01833533,,2013-02-27,2014-12-23,,2021-07-08,2013-04-13,2013-04-17,ESTIMATED,2014-12-23,2015-01-06,ESTIMATED,,,,2021-07-08,2021-07-12,ACTUAL,2013-03,,2013-03-31,2021-07,2021-07-31,2014-09,ACTUAL,2014-09-30,2013-12,ACTUAL,2013-12-31,,INTERVENTIONAL,PEARL-IV,,A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection,"A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)",COMPLETED,,PHASE3,305,ACTUAL,AbbVie,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 11:51:08,2024-10-14 11:51:08,INDUSTRY,,,,,,,AbbVie,Canada|United Kingdom|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01839188,,2013-04-19,2019-01-28,,2019-02-21,2013-04-19,2013-04-24,ESTIMATED,2019-02-21,2019-02-25,ACTUAL,,,,2019-02-21,2019-02-25,ACTUAL,2013-05-01,ACTUAL,2013-05-01,2019-02,2019-02-28,2014-03-19,ACTUAL,2014-03-19,2014-03-19,ACTUAL,2014-03-19,,INTERVENTIONAL,,All participants receiving ≥1 dose of study vaccination.,Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010),A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age.,COMPLETED,,PHASE3,385,ACTUAL,MCM Vaccines B.V.,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 23:50:05,2024-10-13 23:50:05,INDUSTRY,,,,,,,"MCM Vaccines B.V.|Merck Sharp & Dohme LLC|Sanofi Pasteur, a Sanofi Company",Spain,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01843842,,2013-04-26,2017-05-10,,2018-11-28,2013-04-26,2013-05-01,ESTIMATED,2017-10-30,2018-08-03,ACTUAL,,,,2018-11-28,2018-11-29,ACTUAL,2013-04,,2013-04-30,2018-11,2018-11-30,2015-03,ACTUAL,2015-03-31,2015-03,ACTUAL,2015-03-31,,INTERVENTIONAL,,,Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children,Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children,COMPLETED,,PHASE3,306,ACTUAL,Materia Medica Holding,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:51:18,2024-10-13 19:51:18,INDUSTRY,,,,,,,Materia Medica Holding,Russian Federation,Ear and labyrinth disorders|Gastrointestinal disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT01844856,,2013-04-29,2016-01-26,,2021-12-21,2013-04-29,2013-05-01,ESTIMATED,2016-02-29,2016-03-21,ESTIMATED,,,,2021-12-21,2022-01-11,ACTUAL,2013-08,,2013-08-31,2021-12,2021-12-31,2014-08,ACTUAL,2014-08-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,IGNITE1,All randomized participants (Intent-to-treat \[ITT\] population),Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections,"A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections",COMPLETED,,PHASE3,541,ACTUAL,La Jolla Pharmaceutical Company,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 12:40:41,2024-10-14 12:40:41,INDUSTRY,,,,,,,"Tetraphase Pharmaceuticals, Inc.",Argentina|Bulgaria|Czechia|Czech Republic|Estonia|France|Germany|India|Latvia|Lithuania|Romania|Russian Federation|South Africa|Ukraine|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT01846455,,2013-05-01,2015-08-07,,2016-09-09,2013-05-02,2013-05-03,ESTIMATED,2016-09-09,2016-10-24,ESTIMATED,,,,2016-09-09,2016-10-24,ESTIMATED,2012-09,,2012-09-30,2016-09,2016-09-30,2013-05,ACTUAL,2013-05-31,2013-04,ACTUAL,2013-04-30,,INTERVENTIONAL,,Safety population,Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects,"Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers",COMPLETED,,PHASE4,43,ACTUAL,Indivior Inc.,,5,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 22:02:15,2024-10-13 22:02:15,INDUSTRY,,,,,,,Indivior Inc.,United States,Gastrointestinal disorders|General disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT01852942,,2012-02-20,2020-07-16,,2020-11-16,2013-05-09,2013-05-14,ESTIMATED,2020-11-16,2020-12-11,ACTUAL,,,,2020-11-16,2020-12-11,ACTUAL,2014-09,ACTUAL,2014-09-30,2020-11,2020-11-30,2019-07-16,ACTUAL,2019-07-16,2019-07-16,ACTUAL,2019-07-16,,INTERVENTIONAL,,,Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV,Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV,COMPLETED,,PHASE2,52,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:08:12,2024-10-13 06:08:12,OTHER,,,,,,,Merck Sharp & Dohme LLC|National Institute of Allergy and Infectious Diseases (NIAID)|University of Minnesota,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01852942,,2012-02-20,2020-07-16,,2020-11-16,2013-05-09,2013-05-14,ESTIMATED,2020-11-16,2020-12-11,ACTUAL,,,,2020-11-16,2020-12-11,ACTUAL,2014-09,ACTUAL,2014-09-30,2020-11,2020-11-30,2019-07-16,ACTUAL,2019-07-16,2019-07-16,ACTUAL,2019-07-16,,INTERVENTIONAL,,,Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV,Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV,COMPLETED,,PHASE2,52,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:08:12,2024-10-13 06:08:12,OTHER,,,,,,,Merck Sharp & Dohme LLC|National Institute of Allergy and Infectious Diseases (NIAID)|University of Minnesota,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01854138,,2013-05-12,2018-04-04,,2018-06-11,2013-05-14,2013-05-15,ESTIMATED,2018-06-11,2018-07-12,ACTUAL,,,,2018-06-11,2018-07-12,ACTUAL,2014-01,,2014-01-31,2018-06,2018-06-30,2015-04,ACTUAL,2015-04-30,2015-03,ACTUAL,2015-03-31,,INTERVENTIONAL,,,Evaluating Advantages of Prevena After Hip and Knee Arthroplasty,Evaluating the Efficacy of the Prevena Incision Management System in Patients Undergoing Total Knee and Hip Arthroplasty,COMPLETED,,NA,248,ACTUAL,ProMedica Health System,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 17:37:34,2024-10-13 17:37:34,OTHER,,,,,,,ProMedica Health System,United States,Skin and subcutaneous tissue disorders
NCT01854528,,2013-05-13,2015-11-24,,2018-05-02,2013-05-14,2013-05-15,ESTIMATED,2016-01-14,2016-02-11,ESTIMATED,,,,2018-05-02,2018-06-06,ACTUAL,2013-06,,2013-06-30,2016-06,2016-06-30,2015-07,ACTUAL,2015-07-31,2014-11,ACTUAL,2014-11-30,,INTERVENTIONAL,MALACHITE II,All randomized participants who received at least 1 dose of study drug (ITT population) were included in baseline analysis population.,A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults,"A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon a-2a and Ribavirin in Treatment-Experienced Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE-II)",COMPLETED,,PHASE3,148,ACTUAL,AbbVie,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 21:57:34,2024-10-14 21:57:34,INDUSTRY,,,,,,,AbbVie,Argentina|Australia|Chile|Finland|Hungary|Poland|Romania|Slovakia,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01854697,,2013-04-08,2015-11-04,,2018-05-02,2013-05-13,2013-05-15,ESTIMATED,2016-01-25,2016-02-22,ESTIMATED,,,,2018-05-02,2018-06-06,ACTUAL,2013-03,,2013-03-31,2016-07,2016-07-31,2015-07,ACTUAL,2015-07-31,2014-11,ACTUAL,2014-11-30,,INTERVENTIONAL,MALACHITE 1,,A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before,"A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)",COMPLETED,,PHASE3,311,ACTUAL,AbbVie,,5,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:11:05,2024-10-14 18:11:05,INDUSTRY,,,,,,,AbbVie,Argentina|Australia|Canada|Chile|Finland|Hungary|Norway|Poland|Romania|Slovakia,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01854775,,2013-05-03,2021-04-29,,2024-02-26,2013-05-13,2013-05-16,ESTIMATED,2021-04-29,2021-05-24,ACTUAL,,,,2024-02-26,2024-02-28,ACTUAL,2013-05-06,ACTUAL,2013-05-06,2024-02,2024-02-29,2024-12,ESTIMATED,2024-12-31,2020-05-11,ACTUAL,2020-05-11,,INTERVENTIONAL,,The Safety Analysis Set included all participants who received at least 1 dose of study drug.,"Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children","A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children",ACTIVE_NOT_RECRUITING,,PHASE2/PHASE3,129,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 06:14:24,2024-10-13 06:14:24,INDUSTRY,,,,,,,Gilead Sciences,Mexico|South Africa|Thailand|Uganda|United States|Zimbabwe,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01860807,,2013-05-20,2019-01-06,,2019-01-06,2013-05-22,2013-05-23,ESTIMATED,2019-01-06,2019-01-30,ACTUAL,,,,2019-01-06,2019-01-30,ACTUAL,2013-07,,2013-07-31,2019-01,2019-01-31,2017-12-31,ACTUAL,2017-12-31,2017-12-31,ACTUAL,2017-12-31,,INTERVENTIONAL,IBUD ph II,,Trial of Ibudilast for Methamphetamine Dependence,Randomized Trial of Ibudilast for Methamphetamine Dependence,COMPLETED,,PHASE2,125,ACTUAL,"University of California, Los Angeles",Study did not determine if ibudilast may help patients who have stopped methamphetamine use prior to starting medication,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 15:55:21,2024-10-13 15:55:21,OTHER,,,,,,,"National Institute on Drug Abuse (NIDA)|University of California, Los Angeles",United States,Cardiac disorders|Gastrointestinal disorders|Nervous system disorders|Psychiatric disorders
NCT01862874,,2013-05-22,2018-07-30,,2019-03-25,2013-05-22,2013-05-27,ESTIMATED,2018-07-30,2018-08-31,ACTUAL,,,,2019-03-25,2019-04-02,ACTUAL,2013-06-27,ACTUAL,2013-06-27,2019-03,2019-03-31,2017-08-30,ACTUAL,2017-08-30,2017-08-30,ACTUAL,2017-08-30,,INTERVENTIONAL,,,Efficacy and Tolerability Study of V501 in Japanese Males (V501-122),"A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men",COMPLETED,,PHASE3,1124,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 03:41:50,2024-10-13 03:41:50,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,General disorders|Psychiatric disorders
NCT01870583,,2013-06-03,2017-05-19,,2017-09-02,2013-06-03,2013-06-06,ESTIMATED,2017-05-19,2017-06-19,ACTUAL,,,,2017-09-02,2017-10-02,ACTUAL,2013-02,,2013-02-28,2017-09,2017-09-30,2014-07,ACTUAL,2014-07-31,2014-07,ACTUAL,2014-07-31,,INTERVENTIONAL,,,Comparison of Surgical Skin Preps During Cesarean Deliveries,Comparison of Surgical Skin Preps During Cesarean Deliveries,COMPLETED,,NA,1404,ACTUAL,Montefiore Medical Center,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 06:25:53,2024-10-13 06:25:53,OTHER,,,,,,,Montefiore Medical Center,United States,Infections and infestations
NCT01883427,,2013-04-23,2015-04-16,,2015-12-07,2013-06-20,2013-06-21,ESTIMATED,2015-12-07,2016-01-11,ESTIMATED,,,,2015-12-07,2016-01-11,ESTIMATED,2012-10,,2012-10-31,2015-12,2015-12-31,2013-06,ACTUAL,2013-06-30,2013-05,ACTUAL,2013-05-31,,INTERVENTIONAL,,Pre-school children,Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children,"Placebo Controlled Study Among Children Below Four Years of Age, Investigating Whether a Glucose Oxidase Nasal Spray Can Reduce Days With Upper Respiratory Tract Infection Symptoms",COMPLETED,,PHASE2,40,ACTUAL,Umeå University,"We wanted 200 Children but only 40 fulfilled the study, which make the results hard to evaluate.",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 06:30:42,2024-10-13 06:30:42,OTHER,,,,,,,Krister Tano,Sweden,"Respiratory, thoracic and mediastinal disorders"
NCT01888367,,2013-06-25,2016-03-23,,2016-08-17,2013-06-26,2013-06-27,ESTIMATED,2016-08-17,2016-10-11,ESTIMATED,,,,2016-08-17,2016-10-11,ESTIMATED,2013-10,,2013-10-31,2016-08,2016-08-31,2015-02,ACTUAL,2015-02-28,2015-02,ACTUAL,2015-02-28,,INTERVENTIONAL,,,"Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery","A Randomized, Blinded, Placebo and Standard of Care Controlled Efficacy, Safety, and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery",COMPLETED,,PHASE2,445,ACTUAL,Dr. Reddy's Laboratories Limited,The number of culture positive SSIs were too small to draw any conclusions on antibiotic resistance.,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:58:47,2024-10-14 02:58:47,INDUSTRY,,,,,,,Dr. Reddy's Laboratories Limited|Duke Clinical Research Institute,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01890759,,2013-06-27,2017-07-18,,2022-03-24,2013-06-27,2013-07-02,ESTIMATED,2017-07-21,2017-08-21,ACTUAL,,,,2022-03-24,2022-04-19,ACTUAL,2013-06-25,ACTUAL,2013-06-25,2022-03,2022-03-31,2016-04-12,ACTUAL,2016-04-12,2016-04-12,ACTUAL,2016-04-12,,INTERVENTIONAL,,,Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation,"Immunogenicity and Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Subjects Aged 9 to 23 Months in India and in the Russian Federation",COMPLETED,,PHASE3,300,ACTUAL,Sanofi,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 18:04:38,2024-10-14 18:04:38,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",India|Russian Federation,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders
NCT01893346,,2013-06-26,2015-04-09,,2017-09-01,2013-07-02,2013-07-09,ESTIMATED,2015-05-06,2015-05-27,ESTIMATED,,,,2017-09-01,2017-09-06,ACTUAL,2013-07,,2013-07-31,2017-09,2017-09-30,2014-10,ACTUAL,2014-10-31,2014-10,ACTUAL,2014-10-31,,INTERVENTIONAL,,Baseline characteristics are shown for safety analysis set. The safety analysis set included all patients who received any amount of IV study dose of CAZ AVI.,Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections,"A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection",COMPLETED,,PHASE1,35,ACTUAL,Pfizer,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:07:17,2024-10-14 13:07:17,INDUSTRY,,,,,,,Forest Laboratories|Pfizer,United States,"Cardiac disorders|Gastrointestinal disorders|Injury, poisoning and procedural complications|Investigations"
NCT01894776,,2013-06-19,2019-12-20,,2020-02-25,2013-07-03,2013-07-10,ESTIMATED,2020-02-25,2020-03-10,ACTUAL,,,,2020-02-25,2020-03-10,ACTUAL,2013-06,,2013-06-30,2020-02,2020-02-29,2015-02,ACTUAL,2015-02-28,2013-12,ACTUAL,2013-12-31,,INTERVENTIONAL,RIFAMARA,A single participant dropped out due to Nausea. This resulted in 14 participants Data only being analyzed.,A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc,A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc,COMPLETED,,PHASE1,15,ACTUAL,Ottawa Hospital Research Institute,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:27:29,2024-10-14 02:27:29,OTHER,,,,,,,Ottawa Hospital Research Institute|Pfizer,Canada,General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01894776,,2013-06-19,2019-12-20,,2020-02-25,2013-07-03,2013-07-10,ESTIMATED,2020-02-25,2020-03-10,ACTUAL,,,,2020-02-25,2020-03-10,ACTUAL,2013-06,,2013-06-30,2020-02,2020-02-29,2015-02,ACTUAL,2015-02-28,2013-12,ACTUAL,2013-12-31,,INTERVENTIONAL,RIFAMARA,A single participant dropped out due to Nausea. This resulted in 14 participants Data only being analyzed.,A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc,A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc,COMPLETED,,PHASE1,15,ACTUAL,Ottawa Hospital Research Institute,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:27:29,2024-10-14 02:27:29,OTHER,,,,,,,Ottawa Hospital Research Institute|Pfizer,Canada,General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01897402,,2013-07-09,2015-03-26,,2015-04-16,2013-07-11,2013-07-12,ESTIMATED,2015-04-16,2015-04-23,ESTIMATED,,,,2015-04-16,2015-04-23,ESTIMATED,2013-07,,2013-07-31,2015-04,2015-04-30,2014-12,ACTUAL,2014-12-31,2014-05,ACTUAL,2014-05-31,,INTERVENTIONAL,,"Population contains all randomized subjects. Two randomized subjects could not be vaccinated. Three subjects, one female and 3 males received incorrect vaccine. They are listed according to randomized treatment in the baseline population, but were analyzed according to the actual vaccine received in the safety population (secondary outcomes).","Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine","A Phase 2 Double Blind Study to Evaluate Safety and Immunogenicity of Meningococcal Meningitis Serogroups A, C, Y & W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT™) Compared With a Licensed Vaccine",COMPLETED,,PHASE2,525,ACTUAL,JN-International Medical Corporation,"Three subjects, 1 female and 2 males, received incorrect vaccine. They are listed according to randomized treatment in the baseline population, but were analyzed according to the actual vaccine received in the safety population (outcomes 2 and 3).",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:01:09,2024-10-13 05:01:09,INDUSTRY,,,,,,,JN-International Medical Corporation,United States,Gastrointestinal disorders|General disorders|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01898208,,2013-07-08,2015-12-02,,2016-02-17,2013-07-11,2013-07-12,ESTIMATED,2016-02-17,2016-03-15,ESTIMATED,,,,2016-02-17,2016-03-15,ESTIMATED,2013-08,,2013-08-31,2016-02,2016-02-29,2014-08,ACTUAL,2014-08-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,,"Randomized subjects were excluded if they had a positive blood culture in the prior week, had not provided the state research authorization, previously enrolled in the study, died or transitioned to comfort care within 24 hours of enrollment, or had a negative Gram stain. Only non-excluded subjects were included in the baseline characteristics.",Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures,Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles - A Quality Improvement Theragnostic Stewardship Project,COMPLETED,,NA,743,ACTUAL,Mayo Clinic,,3,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 02:46:59,2024-10-13 02:46:59,OTHER,,,,,,,Mayo Clinic|National Center for Advancing Translational Sciences (NCATS)|National Institute of Allergy and Infectious Diseases (NIAID),United States,Cardiac disorders|Hepatobiliary disorders|Immune system disorders|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01898494,,2013-07-10,2022-08-31,,2024-03-06,2013-07-10,2013-07-12,ESTIMATED,2022-08-31,2022-09-28,ACTUAL,,,,2024-03-06,2024-03-08,ACTUAL,2014-01-22,ACTUAL,2014-01-22,2024-03,2024-03-31,2024-12,ESTIMATED,2024-12-31,2020-11-30,ACTUAL,2020-11-30,,INTERVENTIONAL,,Eligible and treated patients,Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer,ACTIVE_NOT_RECRUITING,,PHASE2,519,ACTUAL,Eastern Cooperative Oncology Group,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,YES,Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.,2024-10-13 02:08:09,2024-10-13 02:08:09,NETWORK,,,,,,,ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT01900899,,2013-06-27,2018-04-30,,2019-03-13,2013-07-12,2013-07-17,ESTIMATED,2019-03-13,2019-06-17,ACTUAL,,,,2019-03-13,2019-06-17,ACTUAL,2013-07,ACTUAL,2013-07-31,2019-03,2019-03-31,2017-11,ACTUAL,2017-11-30,2017-11,ACTUAL,2017-11-30,,INTERVENTIONAL,,All eligible participants who received primary and booster vaccination with MenACWY-TT or Meningitec vaccine in studies MENACWY-TT-039 and MENACWY-TT-048 EXT and had available assay results for at least 1 tested antigen.,Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children,"A PHASE III, OPEN, MULTI-CENTRE, CONTROLLED STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 2, 3, 4, 5 AND 6 YEARS AFTER A BOOSTER DOSE OF MENINGOCOCCAL SEROGROUP A, C, W-135, Y- TETANUS TOXOID CONJUGATE VACCINE (MENACWY-TT) OR MENINGITEC (REGISTERED) ADMINISTERED IN HEALTHY 5-YEAR-OLD CHILDREN IN STUDY MENACWY-TT-048 EXT: 039 Y2, 3, 4, 5 (112036), WHO WERE PRIMED WITH THE SAME VACCINE IN STUDY MENACWY-TT-039 (109670) AT 12 THROUGH 23 MONTHS OF AGE.",COMPLETED,,PHASE3,184,ACTUAL,Pfizer,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-14 17:15:12,2024-10-14 17:15:12,INDUSTRY,,,,,,,Pfizer,Finland,Musculoskeletal and connective tissue disorders
NCT01903031,,2013-07-16,2017-12-01,2017-06-30,2018-05-03,2013-07-18,2013-07-19,ESTIMATED,2018-01-03,2018-01-04,ACTUAL,2017-06-30,2017-07-05,ACTUAL,2018-05-03,2018-06-06,ACTUAL,2014-12-30,ACTUAL,2014-12-30,2018-05,2018-05-31,2016-10-10,ACTUAL,2016-10-10,2016-10-03,ACTUAL,2016-10-03,,INTERVENTIONAL,,All participants enrolled.,Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART,Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART),COMPLETED,,PHASE2,84,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 02:52:51,2024-10-13 02:52:51,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Brazil|Kenya|Peru|Puerto Rico|South Africa|Thailand|United States|Zimbabwe,Infections and infestations|Investigations|Psychiatric disorders|Reproductive system and breast disorders
NCT01910402,,2013-07-25,2016-07-25,,2024-02-14,2013-07-26,2013-07-29,ESTIMATED,2016-09-13,2016-10-31,ESTIMATED,,,,2024-02-14,2024-02-20,ACTUAL,2013-08-22,ACTUAL,2013-08-22,2024-02,2024-02-29,2022-08-18,ACTUAL,2022-08-18,2015-09-22,ACTUAL,2015-09-22,,INTERVENTIONAL,,Baseline Characteristic data are reported for members of the ITT-E Population which comprised of all randomized participants who received at least one dose of study treatment.,A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA),"A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women",COMPLETED,,PHASE3,499,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-15 02:36:26,2024-10-15 02:36:26,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Canada|France|Italy|Mexico|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|Thailand|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01910402,,2013-07-25,2016-07-25,,2024-02-14,2013-07-26,2013-07-29,ESTIMATED,2016-09-13,2016-10-31,ESTIMATED,,,,2024-02-14,2024-02-20,ACTUAL,2013-08-22,ACTUAL,2013-08-22,2024-02,2024-02-29,2022-08-18,ACTUAL,2022-08-18,2015-09-22,ACTUAL,2015-09-22,,INTERVENTIONAL,,Baseline Characteristic data are reported for members of the ITT-E Population which comprised of all randomized participants who received at least one dose of study treatment.,A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA),"A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women",COMPLETED,,PHASE3,499,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-15 02:36:26,2024-10-15 02:36:26,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Canada|France|Italy|Mexico|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|Thailand|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01911845,,2013-05-13,2014-12-23,,2018-04-30,2013-07-29,2013-07-30,ESTIMATED,2014-12-23,2015-01-06,ESTIMATED,,,,2018-04-30,2018-05-30,ACTUAL,2013-04,,2013-04-30,2015-08,2015-08-31,2014-09,ACTUAL,2014-09-30,2013-12,ACTUAL,2013-12-31,,INTERVENTIONAL,,All participants who received at least 1 dose of study drug.,"An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine","An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine",COMPLETED,,PHASE2,38,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:36:58,2024-10-14 00:36:58,INDUSTRY,,,,,,,AbbVie,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01925417,,2013-08-15,2015-05-28,,2019-10-30,2013-08-15,2013-08-19,ESTIMATED,2015-06-30,2015-07-01,ESTIMATED,,,,2019-10-30,2019-11-13,ACTUAL,2013-08,,2013-08-31,2018-09,2018-09-30,2014-07,ACTUAL,2014-07-31,2014-03,ACTUAL,2014-03-31,,INTERVENTIONAL,PUNCH CD,,Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea,A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study,COMPLETED,,PHASE2,34,ACTUAL,Rebiotix Inc.,Small sample size (n=34) limits extrapolation of results to a larger population.,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 19:29:55,2024-10-14 19:29:55,INDUSTRY,,,,,,,Rebiotix Inc.,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT01928433,,2013-07-17,2016-12-20,,2017-04-06,2013-08-20,2013-08-26,ESTIMATED,2017-04-06,2017-06-20,ACTUAL,,,,2017-04-06,2017-06-20,ACTUAL,2012-12,,2012-12-31,2017-04,2017-04-30,2015-10,ACTUAL,2015-10-31,2014-06,ACTUAL,2014-06-30,,INTERVENTIONAL,,Subjects that received at least one dose of study medication (safety set).,Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis,"A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation.",COMPLETED,,PHASE2,225,ACTUAL,MerLion Pharmaceuticals GmbH,,3,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 21:33:25,2024-10-14 21:33:25,INDUSTRY,,,,,,,MerLion Pharmaceuticals GmbH,Germany,Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT01928927,,2013-08-22,2017-03-01,,2021-07-31,2013-08-22,2013-08-27,ESTIMATED,2017-03-01,2017-04-12,ACTUAL,,,,2021-07-31,2021-08-03,ACTUAL,2014-01,ACTUAL,2014-01-31,2020-06,2020-06-30,2016-03,ACTUAL,2016-03-31,2016-03,ACTUAL,2016-03-31,,INTERVENTIONAL,TRAFIC,All Step 2 randomized participants with data available for specific measures.,Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study),Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy,COMPLETED,,PHASE2,58,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 02:06:14,2024-10-15 02:06:14,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01930045,,2013-08-23,2014-10-29,,2018-07-25,2013-08-23,2013-08-28,ESTIMATED,2014-10-29,2014-11-02,ESTIMATED,,,,2018-07-25,2018-08-24,ACTUAL,2013-10-01,ACTUAL,2013-10-01,2018-07,2018-07-31,2013-12-10,ACTUAL,2013-12-10,2013-12-10,ACTUAL,2013-12-10,,INTERVENTIONAL,,,A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295),A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen,COMPLETED,,PHASE1,18,ACTUAL,Merck Sharp & Dohme LLC,,6,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 12:25:40,2024-10-13 12:25:40,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT01932697,,2013-08-27,2019-08-28,,2023-09-18,2013-08-27,2013-08-30,ESTIMATED,2019-08-28,2019-09-18,ACTUAL,,,,2023-09-18,2023-09-21,ACTUAL,2013-09-04,ACTUAL,2013-09-04,2023-09,2023-09-30,2021-12-28,ACTUAL,2021-12-28,2016-10-20,ACTUAL,2016-10-20,,INTERVENTIONAL,,,Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer,Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer,COMPLETED,,PHASE2,81,ACTUAL,Mayo Clinic,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:29:07,2024-10-14 18:29:07,OTHER,,,,,,,Mayo Clinic|National Cancer Institute (NCI),United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01933594,,2013-08-28,2019-04-03,,2021-10-28,2013-08-28,2013-09-02,ESTIMATED,2019-05-01,2019-05-23,ACTUAL,,,,2021-10-28,2021-11-01,ACTUAL,2014-05-05,ACTUAL,2014-05-05,2021-10,2021-10-31,2018-04-16,ACTUAL,2018-04-16,2018-04-16,ACTUAL,2018-04-16,,INTERVENTIONAL,,All enrolled participants. The placebo arms of Cohorts 1-3 were combined for the Baseline Characteristics.,Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load,"A Phase I/II Study of Romidepsin in HIV-Infected Adults With Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression",COMPLETED,,PHASE1/PHASE2,59,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,8,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 19:23:54,2024-10-14 19:23:54,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01934140,,2013-08-22,2019-07-16,2018-11-15,2019-07-16,2013-08-29,2013-09-04,ESTIMATED,2019-07-16,2019-08-28,ACTUAL,2018-11-15,2018-11-26,ACTUAL,2019-07-16,2019-08-28,ACTUAL,2014-04,ACTUAL,2014-04-30,2019-07,2019-07-31,2018-08,ACTUAL,2018-08-31,2018-02,ACTUAL,2018-02-28,,INTERVENTIONAL,,Baseline analysis population included all the participants enrolled in the study.,Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination,"A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 11-55 YEAR OLD SUBJECTS WITH MENACWY-TT OR MENCEVAX (REGISTERED) ACWY.",COMPLETED,,PHASE3,311,ACTUAL,Pfizer,"Enrollment for this study (MENACWY-TT-99) started at Year 6. However, Study visit for Year 6 was not done because approval was not obtained from the authorities until after the end of the Year 6. Hence, no planned activities were done for Year 6.",2,,,FALSE,,,,,FALSE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 21:50:37,2024-10-13 21:50:37,INDUSTRY,,,,,,,Pfizer,Philippines,Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders
NCT01935089,,2013-08-27,2023-06-07,,2023-07-05,2013-08-29,2013-09-04,ESTIMATED,2023-07-05,2023-07-06,ACTUAL,,,,2023-07-05,2023-07-06,ACTUAL,2013-08-07,,2013-08-07,2023-07,2023-07-31,2016-05-02,ACTUAL,2016-05-02,2015-03-25,ACTUAL,2015-03-25,,INTERVENTIONAL,,,Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV,"Pilot Study: Single Arm, Multi-site, Open-label Study to Assess the Effectiveness of Peg-IFN-a2b in Decreasing the Levels of Cell-associated Integrated Viral DNA in HIV Chronic Infection",COMPLETED,,PHASE2,20,ACTUAL,The Wistar Institute,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:29:07,2024-10-14 18:29:07,OTHER,,,,,,,Merck Sharp & Dohme LLC|The Wistar Institute|University of Pennsylvania,United States,Blood and lymphatic system disorders|Nervous system disorders
NCT01938430,,2013-09-05,2016-03-16,2015-11-04,2018-10-19,2013-09-05,2013-09-10,ESTIMATED,2016-03-16,2016-04-15,ESTIMATED,2015-11-04,2015-12-01,ESTIMATED,2018-10-19,2018-11-16,ACTUAL,2013-09,,2013-09-30,2016-03,2016-03-31,2015-03,ACTUAL,2015-03-31,2015-01,ACTUAL,2015-01-31,,INTERVENTIONAL,,Safety Analysis Set: participants who were enrolled and received at least one dose of study drug,Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant,"A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant",COMPLETED,,PHASE2,339,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,14,,,FALSE,,,,TRUE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 15:29:03,2024-10-14 15:29:03,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01939145,,2013-09-03,2016-01-07,,2016-11-08,2013-09-05,2013-09-11,ESTIMATED,2016-01-07,2016-02-08,ESTIMATED,,,,2016-11-08,2016-12-29,ESTIMATED,2013-09,,2013-09-30,2016-11,2016-11-30,2016-07,ACTUAL,2016-07-31,2014-07,ACTUAL,2014-07-31,,INTERVENTIONAL,,,Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation,A Prospective Randomized Trial Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation,COMPLETED,,PHASE4,100,ACTUAL,Georgetown University,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,Data collected has not been approved for use beyond the scope of this trial and will not be made available.,2024-10-14 21:45:37,2024-10-14 21:45:37,OTHER,,,,,,,Georgetown University,United States,Cardiac disorders|Infections and infestations|Surgical and medical procedures
NCT01939158,,2013-08-29,2021-09-07,2020-09-23,2021-09-07,2013-09-05,2013-09-11,ESTIMATED,2021-09-07,2021-10-05,ACTUAL,2020-09-23,2020-09-30,ACTUAL,2021-09-07,2021-10-05,ACTUAL,2013-10-02,ACTUAL,2013-10-02,2021-09,2021-09-30,2019-12-05,ACTUAL,2019-12-05,2019-12-05,ACTUAL,2019-12-05,,INTERVENTIONAL,,"Analysis was performed on participants, who received at least one dose of study drug.","Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","A PHASE III, RANDOMISED, OPEN, CONTROLLED, MULTICENTRE, PRIMARY VACCINATION STUDY TO EVALUATE THE IMMUNOGENICITY AND PERSISTENCE OF 1 AND 2 DOSES OF MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT IN TODDLERS (AFTER 1 MONTH AND UP TO 5 YEARS) AND TO DEMONSTRATE NON-INFERIORITY OF CO-ADMINISTRATION OF MENACWY-TT AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE PREVENAR 13(REGISTERED) VERSUS SEPARATE ADMINISTRATION OF THE 2 VACCINES",COMPLETED,,PHASE3,803,ACTUAL,Pfizer,,4,,,FALSE,,,,,TRUE,FALSE,,,TRUE,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 11:46:42,2024-10-13 11:46:42,INDUSTRY,,,,,,,Pfizer,Australia|Canada|Czechia|Czech Republic|Panama|South Africa|Turkey,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01939197,,2013-09-06,2017-07-20,,2021-07-08,2013-09-06,2013-09-11,ESTIMATED,2017-10-13,2017-11-17,ACTUAL,,,,2021-07-08,2021-07-12,ACTUAL,2013-08-30,,2013-08-30,2021-07,2021-07-31,2016-10-25,ACTUAL,2016-10-25,2016-07-21,ACTUAL,2016-07-21,,INTERVENTIONAL,TURQUOISE-I,,"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)",COMPLETED,,PHASE2/PHASE3,318,ACTUAL,AbbVie,,12,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:27:07,2024-10-14 07:27:07,INDUSTRY,,,,,,,AbbVie,Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|Russian Federation|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01939197,,2013-09-06,2017-07-20,,2021-07-08,2013-09-06,2013-09-11,ESTIMATED,2017-10-13,2017-11-17,ACTUAL,,,,2021-07-08,2021-07-12,ACTUAL,2013-08-30,,2013-08-30,2021-07,2021-07-31,2016-10-25,ACTUAL,2016-10-25,2016-07-21,ACTUAL,2016-07-21,,INTERVENTIONAL,TURQUOISE-I,,"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)",COMPLETED,,PHASE2/PHASE3,318,ACTUAL,AbbVie,,12,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:27:07,2024-10-14 07:27:07,INDUSTRY,,,,,,,AbbVie,Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|Russian Federation|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01943799,,2013-09-12,2019-10-03,2015-01-16,2019-10-30,2013-09-12,2013-09-17,ESTIMATED,2019-10-30,2019-11-01,ACTUAL,2015-01-16,2015-01-28,ESTIMATED,2019-10-30,2019-11-01,ACTUAL,2013-09-13,ACTUAL,2013-09-13,2019-10,2019-10-31,2015-03-03,ACTUAL,2015-03-03,2014-09-09,ACTUAL,2014-09-09,,INTERVENTIONAL,,"Safety Analysis Set: participants who had a Group A Baseline visit or received at least 1 dose of GS-4774 for Group B, C, and D. For each participant, the average of non-missing doses were calculated and participants were assigned based on the average: Group A = 0 YU, Group B = \> 0 and ≤ 6 YU, Group C = \> 6 YU and ≤ 25 YU, or Group D = \> 25 YU.",Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B,"A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B",COMPLETED,,PHASE2,178,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 12:37:24,2024-10-13 12:37:24,INDUSTRY,,,,,,,Gilead Sciences,New Zealand|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01944319,,2013-07-02,2015-10-18,,2016-01-28,2013-09-12,2013-09-17,ESTIMATED,2016-01-28,2016-02-25,ESTIMATED,,,,2016-01-28,2016-02-25,ESTIMATED,2013-07,,2013-07-31,2016-01,2016-01-31,2015-10,ACTUAL,2015-10-31,2015-10,ACTUAL,2015-10-31,,INTERVENTIONAL,,,Meropenem Dosage Strategy Based on PPK Model,Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients,COMPLETED,,PHASE4,79,ACTUAL,Peking University Third Hospital,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 12:47:38,2024-10-13 12:47:38,OTHER,,,,,,,Qingtao Zhou,China,Vascular disorders
NCT01946139,,2013-09-17,2022-06-28,,2023-10-24,2013-09-17,2013-09-19,ESTIMATED,2022-09-21,2022-09-30,ACTUAL,,,,2023-10-24,2023-11-07,ACTUAL,2013-12-04,ACTUAL,2013-12-04,2023-04,2023-04-30,2018-10-31,ACTUAL,2018-10-31,2018-10-31,ACTUAL,2018-10-31,,INTERVENTIONAL,,Participants who were entered into the AMC084 study,Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV,Screening HIV-Infected Women for Anal Cancer Precursors,COMPLETED,,NA,276,ACTUAL,AIDS Malignancy Consortium,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:48:17,2024-10-15 02:48:17,NETWORK,,,,,,,AIDS Malignancy Consortium|National Cancer Institute (NCI),Puerto Rico|United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT01946139,,2013-09-17,2022-06-28,,2023-10-24,2013-09-17,2013-09-19,ESTIMATED,2022-09-21,2022-09-30,ACTUAL,,,,2023-10-24,2023-11-07,ACTUAL,2013-12-04,ACTUAL,2013-12-04,2023-04,2023-04-30,2018-10-31,ACTUAL,2018-10-31,2018-10-31,ACTUAL,2018-10-31,,INTERVENTIONAL,,Participants who were entered into the AMC084 study,Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV,Screening HIV-Infected Women for Anal Cancer Precursors,COMPLETED,,NA,276,ACTUAL,AIDS Malignancy Consortium,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:48:17,2024-10-15 02:48:17,NETWORK,,,,,,,AIDS Malignancy Consortium|National Cancer Institute (NCI),Puerto Rico|United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT01948193,,2013-09-18,2015-08-26,,2015-09-29,2013-09-18,2013-09-23,ESTIMATED,2015-08-26,2015-09-25,ESTIMATED,,,,2015-09-29,2015-10-20,ESTIMATED,2014-02,,2014-02-28,2015-09,2015-09-30,2015-06,ACTUAL,2015-06-30,2014-12,ACTUAL,2014-12-31,,INTERVENTIONAL,,,Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth,"Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given at 6, 10 and 14 Weeks of Age in Infants From India Who Previously Received a Dose of Hepatitis B Vaccine at Birth",COMPLETED,,PHASE3,177,ACTUAL,Sanofi,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 15:04:55,2024-10-14 15:04:55,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",India,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders
NCT01949116,,2013-09-19,2017-12-04,,2021-10-28,2013-09-20,2013-09-24,ESTIMATED,2018-01-09,2018-01-10,ACTUAL,,,,2021-10-28,2021-11-01,ACTUAL,2014-01-31,ACTUAL,2014-01-31,2021-10,2021-10-31,2016-12-08,ACTUAL,2016-12-08,2016-12-08,ACTUAL,2016-12-08,,INTERVENTIONAL,,Intent-to-treat (ITT) population consists of all eligible participants who were randomized for the study.,Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications,Effect of Reducing Inflammation With Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection,COMPLETED,,PHASE2,176,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 10:52:09,2024-10-14 10:52:09,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT01952470,,2013-08-31,2019-01-29,,2019-07-22,2013-09-27,2013-09-30,ESTIMATED,2019-07-22,2019-08-28,ACTUAL,,,,2019-07-22,2019-08-28,ACTUAL,2013-10-31,ACTUAL,2013-10-31,2019-07,2019-07-31,2017-08-23,ACTUAL,2017-08-23,2017-08-23,ACTUAL,2017-08-23,,INTERVENTIONAL,,,Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.,Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation.,COMPLETED,,PHASE2,32,ACTUAL,The Alfred,Pre-existing/new diagnoses CLAD +/- LRTI; Participants deviating from protocol; Potential for performance bias; Infection control excluded viral LRTI; Single center trial; Participants were \>2 months post-tx.,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 02:08:09,2024-10-13 02:08:09,OTHER,,,,,,,Dr Carey Denholm and Laura Denholm|The Alfred|The Alfred Research Trusts Small Project Grant.,Australia,"Gastrointestinal disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01952470,,2013-08-31,2019-01-29,,2019-07-22,2013-09-27,2013-09-30,ESTIMATED,2019-07-22,2019-08-28,ACTUAL,,,,2019-07-22,2019-08-28,ACTUAL,2013-10-31,ACTUAL,2013-10-31,2019-07,2019-07-31,2017-08-23,ACTUAL,2017-08-23,2017-08-23,ACTUAL,2017-08-23,,INTERVENTIONAL,,,Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.,Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation.,COMPLETED,,PHASE2,32,ACTUAL,The Alfred,Pre-existing/new diagnoses CLAD +/- LRTI; Participants deviating from protocol; Potential for performance bias; Infection control excluded viral LRTI; Single center trial; Participants were \>2 months post-tx.,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 02:08:09,2024-10-13 02:08:09,OTHER,,,,,,,Dr Carey Denholm and Laura Denholm|The Alfred|The Alfred Research Trusts Small Project Grant.,Australia,"Gastrointestinal disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01958281,,2013-10-06,2018-07-13,,2018-07-13,2013-10-06,2013-10-09,ESTIMATED,2018-07-13,2018-08-08,ACTUAL,,,,2018-07-13,2018-08-08,ACTUAL,2013-10-07,ACTUAL,2013-10-07,2018-07,2018-07-31,2017-10-19,ACTUAL,2017-10-19,2017-07-18,ACTUAL,2017-07-18,,INTERVENTIONAL,,Safety Analysis Set: participants who took at least 1 dose of study drug.,"Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency","A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 Weeks in Genotype 1 or 4 HCV Infected Subjects With Renal Insufficiency",COMPLETED,,PHASE2,38,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 07:32:41,2024-10-14 07:32:41,INDUSTRY,,,,,,,Gilead Sciences,Argentina|Austria|Germany|Netherlands|New Zealand|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01962207,,2013-09-26,2019-03-04,2018-10-30,2019-03-04,2013-10-10,2013-10-14,ESTIMATED,2019-03-04,2019-06-07,ACTUAL,2018-10-30,2018-11-02,ACTUAL,2019-03-04,2019-06-07,ACTUAL,2013-10,ACTUAL,2013-10-31,2019-03,2019-03-31,2018-06,ACTUAL,2018-06-30,2017-12,ACTUAL,2017-12-31,,INTERVENTIONAL,,Baseline analysis population included all the participants enrolled in the study.,The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination,"A PHASE IIIB, OPEN, MULTI-CENTER STUDY TO EVALUATE THE LONG-TERM ANTIBODY PERSISTENCE AT 6, 7, 8, 9 AND 10 YEARS AFTER THE ADMINISTRATION OF ONE DOSE OF THE MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT VERSUS ONE DOSE OF MENINGITEC(REGISTERED) VACCINE OR ONE DOSE OF THE MENINGOCOCCAL POLYSACCHARIDE VACCINE MENCEVAX(REGISTERED) ACWY, AND TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A BOOSTER DOSE OF MENACWY-TT VACCINE ADMINISTERED 10 YEARS AFTER PRIMARY VACCINATION OF 1-10 YEAR OLD SUBJECTS WITH MENACWY-TT, MENINGITEC(REGISTERED) OR MENCEVAX(REGISTERED) ACWY.",COMPLETED,,PHASE3,243,ACTUAL,Pfizer,,4,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 05:11:43,2024-10-13 05:11:43,INDUSTRY,,,,,,,Pfizer,Finland,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01965535,,2013-10-16,2015-08-27,,2018-10-19,2013-10-16,2013-10-18,ESTIMATED,2015-08-27,2015-09-28,ESTIMATED,,,,2018-10-19,2018-11-16,ACTUAL,2013-10,,2013-10-31,2016-06,2016-06-30,2014-11,ACTUAL,2014-11-30,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug,Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks With Ribavirin or for 24 Weeks Without Ribavirin in Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection",COMPLETED,,PHASE2,155,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,TRUE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 07:10:08,2024-10-14 07:10:08,INDUSTRY,,,,,,,Gilead Sciences,France,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01966900,,2013-10-15,2019-08-06,,2019-10-18,2013-10-17,2013-10-22,ESTIMATED,2019-10-18,2019-11-07,ACTUAL,,,,2019-10-18,2019-11-07,ACTUAL,2013-10,,2013-10-31,2019-10,2019-10-31,2015-11,ACTUAL,2015-11-30,2015-11,ACTUAL,2015-11-30,,INTERVENTIONAL,,,The Safety and Immunogenicity of a Potential HIV Vaccine,"A Phase 1 Open-Labelled Trial to Evaluate the Safety and Immunogenicity of CN54gp140 in HIV-Uninfected, Healthy Volunteers",COMPLETED,,PHASE1,14,ACTUAL,Imperial College London,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 03:52:04,2024-10-13 03:52:04,OTHER,,,,,,,"Imperial College London|National Institute for Health Research, United Kingdom|Wellcome Trust",United Kingdom,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT01967940,,2013-10-18,2017-05-09,,2018-10-19,2013-10-18,2013-10-23,ESTIMATED,2017-05-09,2017-06-12,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2013-10-25,ACTUAL,2013-10-25,2018-07,2018-07-31,2017-07-31,ACTUAL,2017-07-31,2015-05-21,ACTUAL,2015-05-21,,INTERVENTIONAL,,Full Analysis Set: participants who enrolled into Part 1 of the study and received at least one dose of study drug in Part 1.,"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults","A Phase 3, Two-Part Study to Evaluate the Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults",COMPLETED,,PHASE3,55,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-12 23:57:38,2024-10-12 23:57:38,INDUSTRY,,,,,,,Gilead Sciences,Australia|Canada|Dominican Republic|Germany|Poland|Russian Federation|Thailand|Uganda|United Kingdom|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01968434,,2013-10-17,2015-05-14,,2018-01-25,2013-10-19,2013-10-24,ESTIMATED,2015-10-05,2015-11-01,ESTIMATED,,,,2018-01-25,2018-02-23,ACTUAL,2013-12,,2013-12-31,2018-01,2018-01-31,2014-04,ACTUAL,2014-04-30,2014-03,ACTUAL,2014-03-31,,INTERVENTIONAL,URTI,"Enrolled patients had a minimum cough intensity both day and night, according to questionnaire, had not received any cough medicine the day before enrollment and fulfilled all inclusion criteria.",Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.,"Randomized, Single Blind, Multicenter Study to Evaluate the Efficacy and Tolerability of Syr. Grintuss Pediatric and Syr. Mucolit in Cough Due to Upper Respiratory Tract Infection in Children",COMPLETED,,PHASE4,150,ACTUAL,Clalit Health Services,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 07:42:57,2024-10-13 07:42:57,OTHER,,,,,,,Aboca Spa Societa' Agricola|Clalit Health Services,Israel,Gastrointestinal disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT01968551,,2013-09-26,2016-07-20,2015-04-16,2018-10-19,2013-10-18,2013-10-24,ESTIMATED,2016-09-14,2016-11-01,ESTIMATED,2015-04-16,2015-05-06,ESTIMATED,2018-10-19,2018-11-16,ACTUAL,2013-09-03,ACTUAL,2013-09-03,2017-07,2017-07-31,2016-07-09,ACTUAL,2016-07-09,2015-07-21,ACTUAL,2015-07-21,,INTERVENTIONAL,,"Safety analysis set included:

* Cohort 1: participants who (1) were enrolled into Cohort 1 and (2) received at least 1 dose of study drug during the OL Phase or the Extension Phase
* Cohort 2: participants who (1) were randomized into Cohort 2 and (2) received at least 1 dose of study drug during the OL Phase or the Extension Phase",Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults,A Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults,COMPLETED,,PHASE3,158,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 09:57:35,2024-10-14 09:57:35,INDUSTRY,,,,,,,Gilead Sciences,Canada|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01969058,,2013-08-21,2017-08-04,,2021-07-31,2013-10-21,2013-10-25,ESTIMATED,2017-08-04,2017-09-05,ACTUAL,,,,2021-07-31,2021-08-03,ACTUAL,2014-07-02,ACTUAL,2014-07-02,2019-03,2019-03-31,2016-11,ACTUAL,2016-11-30,2016-08,ACTUAL,2016-08-31,,INTERVENTIONAL,,All enrolled participants,Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery,A Prospective Randomized Controlled Study to Evaluate the Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery on Suppressive Antiretroviral Therapy (ART),COMPLETED,,PHASE2,76,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:21:42,2024-10-14 17:21:42,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Infections and infestations|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01970371,,2013-10-23,2018-07-24,,2018-09-19,2013-10-23,2013-10-28,ESTIMATED,2018-09-19,2018-10-16,ACTUAL,,,,2018-09-19,2018-10-16,ACTUAL,2014-09-16,ACTUAL,2014-09-16,2018-09,2018-09-30,2016-09-15,ACTUAL,2016-09-15,2016-08-18,ACTUAL,2016-08-18,,INTERVENTIONAL,CARE,The intent-to-treat (ITT) population includes all randomized patients in Cohort 1 and all enrolled patients in Cohort 2.,A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE),"A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)",COMPLETED,,PHASE3,69,ACTUAL,"Achaogen, Inc.",,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 20:04:52,2024-10-14 20:04:52,INDUSTRY,,,,,,,"Achaogen, Inc.|Department of Health and Human Services",Argentina|Brazil|Colombia|France|Germany|Greece|Israel|Italy|Mexico|Spain|Turkey|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01970371,,2013-10-23,2018-07-24,,2018-09-19,2013-10-23,2013-10-28,ESTIMATED,2018-09-19,2018-10-16,ACTUAL,,,,2018-09-19,2018-10-16,ACTUAL,2014-09-16,ACTUAL,2014-09-16,2018-09,2018-09-30,2016-09-15,ACTUAL,2016-09-15,2016-08-18,ACTUAL,2016-08-18,,INTERVENTIONAL,CARE,The intent-to-treat (ITT) population includes all randomized patients in Cohort 1 and all enrolled patients in Cohort 2.,A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE),"A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)",COMPLETED,,PHASE3,69,ACTUAL,"Achaogen, Inc.",,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 20:04:52,2024-10-14 20:04:52,INDUSTRY,,,,,,,"Achaogen, Inc.|Department of Health and Human Services",Argentina|Brazil|Colombia|France|Germany|Greece|Israel|Italy|Mexico|Spain|Turkey|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01972035,,2013-10-10,2022-02-17,,2022-03-17,2013-10-23,2013-10-30,ESTIMATED,2022-02-17,2022-03-16,ACTUAL,,,,2022-03-17,2022-04-12,ACTUAL,2014-08-01,ACTUAL,2014-08-01,2022-03,2022-03-31,2021-02-28,ACTUAL,2021-02-28,2021-02-28,ACTUAL,2021-02-28,,INTERVENTIONAL,,,ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation,ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation,COMPLETED,,PHASE2,137,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 11:33:55,2024-10-14 11:33:55,OTHER,,,,,,,University of Minnesota,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01972035,,2013-10-10,2022-02-17,,2022-03-17,2013-10-23,2013-10-30,ESTIMATED,2022-02-17,2022-03-16,ACTUAL,,,,2022-03-17,2022-04-12,ACTUAL,2014-08-01,ACTUAL,2014-08-01,2022-03,2022-03-31,2021-02-28,ACTUAL,2021-02-28,2021-02-28,ACTUAL,2021-02-28,,INTERVENTIONAL,,,ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation,ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation,COMPLETED,,PHASE2,137,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 11:33:55,2024-10-14 11:33:55,OTHER,,,,,,,University of Minnesota,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01972035,,2013-10-10,2022-02-17,,2022-03-17,2013-10-23,2013-10-30,ESTIMATED,2022-02-17,2022-03-16,ACTUAL,,,,2022-03-17,2022-04-12,ACTUAL,2014-08-01,ACTUAL,2014-08-01,2022-03,2022-03-31,2021-02-28,ACTUAL,2021-02-28,2021-02-28,ACTUAL,2021-02-28,,INTERVENTIONAL,,,ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation,ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation,COMPLETED,,PHASE2,137,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 11:33:55,2024-10-14 11:33:55,OTHER,,,,,,,University of Minnesota,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01973439,,2013-10-25,2013-12-04,,2014-02-03,2013-10-25,2013-10-31,ESTIMATED,2014-02-03,2014-03-20,ESTIMATED,,,,2014-02-03,2014-03-20,ESTIMATED,2006-07,,2006-07-31,2014-02,2014-02-28,2009-06,ACTUAL,2009-06-30,2008-06,ACTUAL,2008-06-30,,INTERVENTIONAL,PENTA15,,PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months,PENTA15: Plasma Pharmacokinetic Study of Once Versus Twice Daily Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV-1 Infection Aged 3 Months to <36 Months,COMPLETED,,PHASE1,23,ACTUAL,PENTA Foundation,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 14:52:00,2024-10-14 14:52:00,NETWORK,,,,,,,PENTA Foundation,France|Germany|Italy|Spain|United Kingdom,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications"
NCT01975675,,2013-10-29,2015-06-04,,2018-10-19,2013-10-29,2013-11-05,ESTIMATED,2015-06-04,2015-06-26,ESTIMATED,,,,2018-10-19,2018-11-16,ACTUAL,2013-10,,2013-10-31,2015-06,2015-06-30,2014-08,ACTUAL,2014-08-31,2014-06,ACTUAL,2014-06-30,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug,Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection,"A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection",COMPLETED,,PHASE3,341,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,FALSE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 02:27:29,2024-10-14 02:27:29,INDUSTRY,,,,,,,Gilead Sciences,Japan,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT01980095,,2013-11-04,2016-11-13,,2019-09-15,2013-11-04,2013-11-08,ESTIMATED,2016-11-13,2017-01-10,ESTIMATED,,,,2019-09-15,2019-09-24,ACTUAL,2013-11,,2013-11-30,2019-09,2019-09-30,2015-08,ACTUAL,2015-08-31,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,ERADICATE Hp,,ERADICATE Hp - Treating Helicobacter Pylori With RHB-105,A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients,COMPLETED,,PHASE3,119,ACTUAL,RedHill Biopharma Limited,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:48:17,2024-10-15 02:48:17,INDUSTRY,,,,,,,RedHill Biopharma Limited,United States,Blood and lymphatic system disorders|Gastrointestinal disorders|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT01983683,,2013-11-07,2018-03-09,,2018-04-26,2013-11-13,2013-11-14,ESTIMATED,2018-04-09,2018-04-13,ACTUAL,,,,2018-04-26,2018-05-24,ACTUAL,2013-12-12,ACTUAL,2013-12-12,2018-04,2018-04-30,2017-05-02,ACTUAL,2017-05-02,2017-03-09,ACTUAL,2017-03-09,,INTERVENTIONAL,,"The modified-intent-to-treat population (mITT) was used: all subjects who have received at least one dose of the study drug and had a confirmed diagnosis of CDAD, and excluding 22 randomized subjects due to potential data integrity issues.",Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea,"A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD).",COMPLETED,,PHASE3,631,ACTUAL,Actelion,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 02:20:45,2024-10-14 02:20:45,INDUSTRY,,,,,,,Actelion,"Argentina|Belgium|Brazil|Canada|Chile|Croatia|Czechia|Czech Republic|Greece|Hungary|Israel|Korea, Republic of|Puerto Rico|Romania|Slovakia|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT01984294,,2013-11-08,2015-04-30,,2018-10-19,2013-11-08,2013-11-14,ESTIMATED,2015-04-30,2015-05-21,ESTIMATED,,,,2018-10-19,2018-11-19,ACTUAL,2013-10,,2013-10-31,2015-04,2015-04-30,2014-07,ACTUAL,2014-07-31,2014-04,ACTUAL,2014-04-30,,INTERVENTIONAL,,Safety Analysis Set: participants were randomized and received at least one dose of study drug.,Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection,"A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naive or Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection",COMPLETED,,PHASE2,101,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,FALSE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 02:45:55,2024-10-14 02:45:55,INDUSTRY,,,,,,,Gilead Sciences,United States,Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT01984684,,2013-11-08,2017-07-26,2016-11-12,2017-11-13,2013-11-14,2013-11-15,ESTIMATED,2017-07-26,2017-08-28,ACTUAL,2016-11-14,2016-11-15,ESTIMATED,2017-11-13,2017-11-17,ACTUAL,2014-05,ACTUAL,2014-05-31,2017-11,2017-11-30,2016-01,ACTUAL,2016-01-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,,Intent-to-Treat (ITT) Population included all patients who were randomly assigned to treatment.,Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",COMPLETED,,PHASE3,850,ACTUAL,"Melinta Therapeutics, Inc.",,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 09:37:59,2024-10-13 09:37:59,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.","Argentina|Brazil|Bulgaria|Chile|Estonia|Georgia|Hungary|Korea, Republic of|Latvia|Mexico|Moldova, Republic of|Peru|Romania|Slovakia|Taiwan|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01984684,,2013-11-08,2017-07-26,2016-11-12,2017-11-13,2013-11-14,2013-11-15,ESTIMATED,2017-07-26,2017-08-28,ACTUAL,2016-11-14,2016-11-15,ESTIMATED,2017-11-13,2017-11-17,ACTUAL,2014-05,ACTUAL,2014-05-31,2017-11,2017-11-30,2016-01,ACTUAL,2016-01-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,,Intent-to-Treat (ITT) Population included all patients who were randomly assigned to treatment.,Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",COMPLETED,,PHASE3,850,ACTUAL,"Melinta Therapeutics, Inc.",,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 09:37:59,2024-10-13 09:37:59,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.","Argentina|Brazil|Bulgaria|Chile|Estonia|Georgia|Hungary|Korea, Republic of|Latvia|Mexico|Moldova, Republic of|Peru|Romania|Slovakia|Taiwan|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01984697,,2013-11-08,2016-03-23,,2018-07-12,2013-11-14,2013-11-15,ESTIMATED,2016-03-23,2016-04-26,ESTIMATED,,,,2018-07-12,2018-08-08,ACTUAL,2013-12-12,ACTUAL,2013-12-12,2018-07,2018-07-31,2017-07-24,ACTUAL,2017-07-24,2015-06-19,ACTUAL,2015-06-19,,INTERVENTIONAL,,,"A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)","A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)",COMPLETED,,PHASE3,1518,ACTUAL,Merck Sharp & Dohme LLC,,5,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 09:15:19,2024-10-13 09:15:19,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Canada|Chile|Colombia|Czech Republic|Denmark|Israel|Korea, Republic of|Malaysia|Norway|South Africa|Spain|Thailand|Turkey|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01986010,,2013-11-11,2021-09-30,,2021-09-30,2013-11-11,2013-11-18,ESTIMATED,2021-09-30,2021-11-01,ACTUAL,,,,2021-09-30,2021-11-01,ACTUAL,2013-11-25,ACTUAL,2013-11-25,2021-09,2021-09-30,2017-03-14,ACTUAL,2017-03-14,2016-04-19,ACTUAL,2016-04-19,,INTERVENTIONAL,,,"Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)","A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults",COMPLETED,,PHASE1,190,ACTUAL,Merck Sharp & Dohme LLC,,17,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 12:22:18,2024-10-14 12:22:18,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01987453,,2013-11-12,2016-11-11,,2018-10-19,2013-11-12,2013-11-19,ESTIMATED,2016-11-11,2017-01-10,ESTIMATED,,,,2018-10-19,2018-11-19,ACTUAL,2014-07,,2014-07-31,2016-11,2016-11-30,2015-11,ACTUAL,2015-11-30,2015-11,ACTUAL,2015-11-30,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug,Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study,"An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study",COMPLETED,,PHASE2,100,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,3,,,FALSE,,,,FALSE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 00:03:31,2024-10-13 00:03:31,INDUSTRY,,,,,,,Gilead Sciences,Australia|France|New Zealand|Puerto Rico|Spain|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT01987895,,2013-11-07,2018-02-23,,2018-05-03,2013-11-13,2013-11-20,ESTIMATED,2018-05-03,2018-05-04,ACTUAL,,,,2018-05-03,2018-05-04,ACTUAL,2014-03-27,ACTUAL,2014-03-27,2018-05,2018-05-31,2017-03-24,ACTUAL,2017-03-24,2017-02-26,ACTUAL,2017-02-26,,INTERVENTIONAL,,The baseline characteristics were defined using the modified intent-to-treat analysis set (mITT) including all randomized subjects who have received at least one dose of the study drug and had a confirmed diagnosis of CDAD,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,"A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",COMPLETED,,PHASE3,632,ACTUAL,Actelion,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 16:56:00,2024-10-13 16:56:00,INDUSTRY,,,,,,,Actelion,Australia|Brazil|Canada|France|Germany|Italy|Netherlands|Peru|Poland|Romania|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT01989910,,2013-10-22,2018-10-22,,2018-10-22,2013-11-14,2013-11-21,ESTIMATED,2018-10-22,2019-02-25,ACTUAL,,,,2018-10-22,2019-02-25,ACTUAL,2013-09,,2013-09-30,2018-10,2018-10-31,2017-12,ACTUAL,2017-12-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,,,Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients,"An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-naïve Patients With HIV-1 Infection",COMPLETED,,PHASE4,107,ACTUAL,"Taipei Veterans General Hospital, Taiwan",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 12:31:22,2024-10-13 12:31:22,OTHER_GOV,,,,,,,"Taipei Veterans General Hospital, Taiwan",Taiwan,Blood and lymphatic system disorders|Gastrointestinal disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT01994538,,2013-11-19,2020-10-02,,2021-05-13,2013-11-19,2013-11-25,ESTIMATED,2020-10-02,2020-10-28,ACTUAL,,,,2021-05-13,2021-06-02,ACTUAL,2014-04-24,ACTUAL,2014-04-24,2021-05,2021-05-31,2019-12-31,ACTUAL,2019-12-31,2019-12-31,ACTUAL,2019-12-31,,INTERVENTIONAL,,,Seven vs. 14 Days Treatment for Male Urinary Tract Infection,Seven Versus Fourteen Day Treatment for Male Urinary Tract Infection,COMPLETED,,NA,273,ACTUAL,VA Office of Research and Development,Goal enrollment was 290; actual enrollment of 273 slightly reduces power to detect minimally clinically significant difference.,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,FALSE,,,Anticipate will share data for 2 years after publication of the primary result manuscript,Requests will be handled on a case-by-case basis with input from the local privacy officer and IRB.,,YES,No formal plan submitted at time of grant. Will handle such requests on a case-by-case basis with input from local privacy officer and institutional review board.,2024-10-13 15:25:43,2024-10-13 15:25:43,FED,,,,,,,VA Office of Research and Development,United States,General disorders
NCT01994993,,2013-11-18,2018-01-15,,2019-05-28,2013-11-25,2013-11-26,ESTIMATED,2018-02-26,2018-02-27,ACTUAL,,,,2019-05-28,2019-05-30,ACTUAL,2013-12,,2013-12-31,2019-05,2019-05-31,2017-04-20,ACTUAL,2017-04-20,2017-01-15,ACTUAL,2017-01-15,,INTERVENTIONAL,SCAMP,"count of participants

Note: the overall numbers above were based on ""Per protocol population"", defined as participants who received at least 1 study dose of each study drug of the enrolled treatment group.",Antibiotic Safety (SCAMP),Antibiotic Safety in Infants With Complicated Intra-Abdominal Infections (SCAMP Trial),COMPLETED,,PHASE2/PHASE3,260,ACTUAL,Duke University,,5,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 00:52:43,2024-10-15 00:52:43,OTHER,,,,,,,"Michael Cohen-Wolkowiez|The Emmes Company, LLC",Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT01998633,,2013-10-29,2018-03-29,,2022-12-06,2013-11-25,2013-12-02,ESTIMATED,2018-05-01,2018-06-01,ACTUAL,,,,2022-12-06,2022-12-08,ACTUAL,2013-12,ACTUAL,2013-12-31,2022-12,2022-12-31,2016-12,ACTUAL,2016-12-31,2016-09-23,ACTUAL,2016-09-23,,INTERVENTIONAL,RICHI,,Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204),Reduced-Intensity Conditioning for Children and Adults With Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI) (BMT CTN #1204),COMPLETED,,PHASE2,47,ACTUAL,Medical College of Wisconsin,,1,,,FALSE,,,,TRUE,,,,,,,,Within 6 months of official study closure at participating sites.,Available to the public.,https://biolincc.nhlbi.nih.gov/home/,YES,Findings will be published in a manuscript.,2024-10-13 05:56:17,2024-10-13 05:56:17,OTHER,,,,,,,"Blood and Marrow Transplant Clinical Trials Network|Medical College of Wisconsin|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)|National Marrow Donor Program",Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|General disorders|Immune system disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02010255,,2013-12-09,2016-05-11,,2018-10-19,2013-12-09,2013-12-12,ESTIMATED,2016-05-11,2016-06-20,ESTIMATED,,,,2018-10-19,2018-11-19,ACTUAL,2014-01,,2014-01-31,2016-05,2016-05-31,2015-08,ACTUAL,2015-08-31,2015-05,ACTUAL,2015-05-31,,INTERVENTIONAL,,Safety Analysis Set: participants who were enrolled and received at least one dose of study drug,Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant,"A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant",COMPLETED,,PHASE2,334,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,14,,,FALSE,,,,TRUE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 10:46:20,2024-10-14 10:46:20,INDUSTRY,,,,,,,Gilead Sciences,Australia|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|New Zealand|Spain|Switzerland|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02016690,,2013-12-11,2016-12-16,,2017-02-10,2013-12-16,2013-12-20,ESTIMATED,2016-12-16,2017-02-08,ESTIMATED,,,,2017-02-10,2017-03-20,ACTUAL,2013-12,,2013-12-31,2017-02,2017-02-28,2015-12,ACTUAL,2015-12-31,2015-12,ACTUAL,2015-12-31,,OBSERVATIONAL,,Participants enrolled via consecutive enrollment method who had a completed CRF. Participants were excluded if there was enrollment at a non-contracting institution or beyond the contracted number; duplicate enrollment; no palivizumab administration; or if palivizumab administration began outside of the investigation period.,"Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®","Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®",COMPLETED,,,312,ACTUAL,AbbVie,"The study population was a very specific, defined group, observed in the context of daily practice.The results of this study of the safety and effectiveness of palivizumab may not be applicable to the general population of healthy infants in Japan.",,1,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 16:07:16,2024-10-13 16:07:16,INDUSTRY,,,,,,,AbbVie,Japan,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02021643,,2013-11-26,2017-08-11,,2017-08-11,2013-12-20,2013-12-27,ESTIMATED,2017-08-11,2018-02-20,ACTUAL,,,,2017-08-11,2018-02-20,ACTUAL,2013-12-10,ACTUAL,2013-12-10,2017-08,2017-08-31,2016-11-03,ACTUAL,2016-11-03,2016-08-12,ACTUAL,2016-08-12,,INTERVENTIONAL,,Safety Analysis Set: participants who were enrolled and received at least one dose of study drug.,Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection,"A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection",COMPLETED,,PHASE3,687,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,FALSE,,FALSE,,,,,,,,,,,2024-10-15 02:30:25,2024-10-15 02:30:25,INDUSTRY,,,,,,,Gilead Sciences,"China|Hong Kong|Korea, Republic of|Taiwan|Vietnam","Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02021656,,2013-12-20,2018-07-03,,2020-02-18,2013-12-20,2013-12-27,ESTIMATED,2018-07-03,2018-12-28,ACTUAL,,,,2020-02-18,2020-03-05,ACTUAL,2013-12-10,ACTUAL,2013-12-10,2019-01,2019-01-31,2017-09-29,ACTUAL,2017-09-29,2017-07-08,ACTUAL,2017-07-08,,INTERVENTIONAL,,Safety Analysis Set: participants who were enrolled and received at least 1 dose of study,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection,"A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection",COMPLETED,,PHASE3,384,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 01:45:43,2024-10-13 01:45:43,INDUSTRY,,,,,,,Gilead Sciences,"China|Korea, Republic of|Taiwan","Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02023099,,2013-12-23,2015-10-27,,2018-05-02,2013-12-23,2013-12-30,ESTIMATED,2015-10-27,2015-11-26,ESTIMATED,,,,2018-05-02,2018-06-06,ACTUAL,2013-12,,2013-12-31,2016-09,2016-09-30,2015-10,ACTUAL,2015-10-31,2014-10,ACTUAL,2014-10-31,,INTERVENTIONAL,GIFT I,,Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection,"A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)",COMPLETED,,PHASE3,363,ACTUAL,AbbVie,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 14:55:33,2024-10-13 14:55:33,INDUSTRY,,,,,,,AbbVie,Japan,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02034162,,2014-01-09,2016-07-21,,2016-09-16,2014-01-09,2014-01-13,ESTIMATED,2016-09-16,2016-11-04,ESTIMATED,,,,2016-09-16,2016-11-04,ESTIMATED,2014-12,,2014-12-31,2016-09,2016-09-30,2015-09,ACTUAL,2015-09-30,2015-09,ACTUAL,2015-09-30,,INTERVENTIONAL,,,A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants,"A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects",COMPLETED,,PHASE3,295,ACTUAL,"Janssen Research & Development, LLC",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 16:37:52,2024-10-13 16:37:52,INDUSTRY,,,,,,,"Janssen Research & Development, LLC",Ethiopia|Rwanda,"Eye disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02037984,,2014-01-14,2019-01-24,,2019-06-10,2014-01-14,2014-01-16,ESTIMATED,2019-04-11,2019-04-30,ACTUAL,,,,2019-06-10,2019-06-24,ACTUAL,2014-01-28,ACTUAL,2014-01-28,2019-06,2019-06-30,2016-07-01,ACTUAL,2016-07-01,2016-07-01,ACTUAL,2016-07-01,,INTERVENTIONAL,,All randomized and treated participants are included. One participant in the Infant V114: 0.5x:0.5x:2x arm was enrolled and randomized but did not receive any study treatment.,"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants",COMPLETED,,PHASE1/PHASE2,341,ACTUAL,Merck Sharp & Dohme LLC,,8,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 20:35:44,2024-10-14 20:35:44,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02037984,,2014-01-14,2019-01-24,,2019-06-10,2014-01-14,2014-01-16,ESTIMATED,2019-04-11,2019-04-30,ACTUAL,,,,2019-06-10,2019-06-24,ACTUAL,2014-01-28,ACTUAL,2014-01-28,2019-06,2019-06-30,2016-07-01,ACTUAL,2016-07-01,2016-07-01,ACTUAL,2016-07-01,,INTERVENTIONAL,,All randomized and treated participants are included. One participant in the Infant V114: 0.5x:0.5x:2x arm was enrolled and randomized but did not receive any study treatment.,"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants",COMPLETED,,PHASE1/PHASE2,341,ACTUAL,Merck Sharp & Dohme LLC,,8,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 20:35:44,2024-10-14 20:35:44,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02045797,,2014-01-23,2017-06-27,2015-10-12,2017-10-16,2014-01-23,2014-01-27,ESTIMATED,2017-08-24,2017-09-21,ACTUAL,2015-10-12,2015-11-05,ESTIMATED,2017-10-16,2017-11-17,ACTUAL,2014-03-24,ACTUAL,2014-03-24,2017-10,2017-10-31,2015-06-29,ACTUAL,2015-06-29,2015-06-29,ACTUAL,2015-06-29,,INTERVENTIONAL,,mITT population: those participants who received study treatment,Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections,"A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE2,126,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,TRUE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-13 06:01:52,2024-10-13 06:01:52,INDUSTRY,,,,,,,GlaxoSmithKline,United States,Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT02049437,,2014-01-28,2020-10-28,,2024-08-02,2014-01-28,2014-01-30,ESTIMATED,2020-11-19,2020-12-17,ACTUAL,,,,2024-08-02,2024-08-06,ACTUAL,2014-08,,2014-08-31,2024-08,2024-08-31,2017-09-11,ACTUAL,2017-09-11,2017-09-11,ACTUAL,2017-09-11,,INTERVENTIONAL,IL-6,,AIDS 347: IL-6 Blockade in Treated HIV Infection,AIDS 347: IL-6 Blockade in Treated HIV Infection,COMPLETED,,PHASE1/PHASE2,34,ACTUAL,Case Western Reserve University,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 11:36:27,2024-10-13 11:36:27,OTHER,,,,,,,Case Western Reserve University,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02061358,,2014-02-06,2016-07-20,,2024-03-14,2014-02-11,2014-02-12,ESTIMATED,2016-07-20,2016-09-01,ESTIMATED,,,,2024-03-14,2024-03-18,ACTUAL,2014-07,,2014-07-31,2024-03,2024-03-31,2015-09,ACTUAL,2015-09-30,2015-07,ACTUAL,2015-07-31,,INTERVENTIONAL,UV,Total number of randomized subjects in each cohort,"Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects","Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects",COMPLETED,,PHASE1,64,ACTUAL,Emergent BioSolutions,,8,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 10:33:41,2024-10-14 10:33:41,INDUSTRY,,,,,,,"Emergent BioSolutions|Quintiles, Inc.|Unither Virology",United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02062294,,2014-02-12,2016-01-14,,2017-06-13,2014-02-12,2014-02-13,ESTIMATED,2016-01-14,2016-02-11,ESTIMATED,,,,2017-06-13,2017-07-05,ACTUAL,2010-07-31,ACTUAL,2010-07-31,2017-05,2017-05-31,2011-09-30,ACTUAL,2011-09-30,2011-09-30,ACTUAL,2011-09-30,,OBSERVATIONAL,,,An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients,Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program,COMPLETED,,,14,ACTUAL,Hoffmann-La Roche,,,1,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 12:15:54,2024-10-14 12:15:54,INDUSTRY,,,,,,,Hoffmann-La Roche,Switzerland,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02063867,,2014-02-12,2019-04-29,,2019-06-14,2014-02-12,2014-02-14,ESTIMATED,2019-06-14,2019-07-12,ACTUAL,,,,2019-06-14,2019-07-12,ACTUAL,2014-04,,2014-04-30,2019-06,2019-06-30,2019-02,ACTUAL,2019-02-28,2019-02,ACTUAL,2019-02-28,,INTERVENTIONAL,ABATE,These numbers reflect the number of participants in the baseline period across all participating facilities enrolled.,Active Bathing to Eliminate Infection (ABATE Infection) Trial,Cluster-Randomized Controlled Trial of Hospitals to Reduce Healthcare-Associated Infections and Readmissions Through Routine Bathing With Antiseptic Soap and Targeted Use of Nasal Antibiotic Ointment (ABATE Infection Trial),COMPLETED,,NA,53,ACTUAL,"University of California, Irvine",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 23:29:48,2024-10-14 23:29:48,OTHER,,,,,,,"Centers for Disease Control and Prevention|Cook County Health|Harvard Medical School (HMS and HSDM)|Harvard Pilgrim Health Care|Hospital Corporation of America (HCA)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)|Rush University|University of California, Irvine",United States,Skin and subcutaneous tissue disorders
NCT02066402,,2014-02-17,2017-02-15,,2017-05-05,2014-02-17,2014-02-19,ESTIMATED,2017-05-05,2017-06-07,ACTUAL,,,,2017-05-05,2017-06-07,ACTUAL,2014-03-04,ACTUAL,2014-03-04,2017-05,2017-05-31,2016-04-18,ACTUAL,2016-04-18,2016-03-06,ACTUAL,2016-03-06,,INTERVENTIONAL,,,Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI),"A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,598,ACTUAL,Bayer,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 10:04:36,2024-10-13 10:04:36,INDUSTRY,,,,,,,Bayer|Merck Sharp & Dohme LLC,China|Philippines|Taiwan|United States,Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT02067676,,2014-02-18,2017-03-29,,2018-01-29,2014-02-19,2014-02-20,ESTIMATED,2017-06-19,2018-01-25,ACTUAL,,,,2018-01-29,2018-02-23,ACTUAL,2014-04-21,ACTUAL,2014-04-21,2018-01,2018-01-31,2016-01-22,ACTUAL,2016-01-22,2014-09-24,ACTUAL,2014-09-24,,INTERVENTIONAL,CJCV1-01,,Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea,Safety and Immunogenicity Evaluation of an Intramuscular Capsule-Conjugate Campylobacter Vaccine (CJCV1),COMPLETED,,PHASE1,48,ACTUAL,U.S. Army Medical Research and Development Command,,6,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,WRAIR,2024-10-13 00:31:48,2024-10-13 00:31:48,FED,,,,,,,U.S. Army Medical Research and Development Command|Walter Reed Army Institute of Research (WRAIR),United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02071095,,2014-02-21,2017-12-21,,2018-02-13,2014-02-24,2014-02-25,ESTIMATED,2018-02-13,2018-03-13,ACTUAL,,,,2018-02-13,2018-03-13,ACTUAL,2014-04,,2014-04-30,2018-02,2018-02-28,2016-07-26,ACTUAL,2016-07-26,2016-07-26,ACTUAL,2016-07-26,,INTERVENTIONAL,Poly-ICLC,,Enhancement by Poly-ICLC During HIV-1 Infection,Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection,COMPLETED,,PHASE1/PHASE2,15,ACTUAL,Icahn School of Medicine at Mount Sinai,"Small sample size, gender homogeneity, and exclusion of older individuals (\>55 years) and common comorbidities such as cardiovascular disease and diabetes limit the generalizability of the safety findings in the HIV-infected population as a whole.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 11:04:01,2024-10-13 11:04:01,OTHER,,,,,,,"National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)|Nina Bhardwaj|Oncovir, Inc.|The Campbell Foundation",United States,Blood and lymphatic system disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Surgical and medical procedures
NCT02072174,,2014-02-14,2019-04-04,,2019-07-11,2014-02-24,2014-02-26,ESTIMATED,2019-07-11,2019-07-12,ACTUAL,,,,2019-07-11,2019-07-12,ACTUAL,2014-10-08,ACTUAL,2014-10-08,2019-07,2019-07-31,2018-04-16,ACTUAL,2018-04-16,2018-04-16,ACTUAL,2018-04-16,,INTERVENTIONAL,,,Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children,International Multicenter Double-blind Placebo-controlled Randomized Parallel Group Clinical Trial of Efficacy of Anaferon for Children in the Treatment of Influenza and Acute Respiratory Viral Infections in Children,COMPLETED,,PHASE4,569,ACTUAL,Materia Medica Holding,,2,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-14 06:29:23,2024-10-14 06:29:23,INDUSTRY,,,,,,,Materia Medica Holding,Belarus|Russian Federation|Ukraine,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02074514,,2014-02-26,2016-09-02,,2016-09-02,2014-02-26,2014-02-28,ESTIMATED,2016-09-02,2016-10-25,ESTIMATED,,,,2016-09-02,2016-10-25,ESTIMATED,2014-03,,2014-03-31,2016-09,2016-09-30,2015-11,ACTUAL,2015-11-30,2015-09,ACTUAL,2015-09-30,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least one dose of study drug.,Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection,"A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection",COMPLETED,,PHASE3,117,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:47:46,2024-10-14 18:47:46,INDUSTRY,,,,,,,Gilead Sciences,India,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02075593,,2014-02-27,2022-01-25,2020-08-05,2022-09-09,2014-02-27,2014-03-03,ESTIMATED,2022-01-25,2022-02-18,ACTUAL,2020-08-13,2020-08-27,ACTUAL,2022-09-09,2022-10-06,ACTUAL,2014-12-17,ACTUAL,2014-12-17,2022-08,2022-08-31,2021-09-15,ACTUAL,2021-09-15,2018-10-22,ACTUAL,2018-10-22,,INTERVENTIONAL,,"Baseline Characteristics data was collected only in pregnant women (enrolled population/study participants) and not in infants, as infants were not considered as enrolled per study design.","ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection","ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women",COMPLETED,,PHASE3,4,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:53:50,2024-10-13 07:53:50,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Russian Federation|Spain|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02075593,,2014-02-27,2022-01-25,2020-08-05,2022-09-09,2014-02-27,2014-03-03,ESTIMATED,2022-01-25,2022-02-18,ACTUAL,2020-08-13,2020-08-27,ACTUAL,2022-09-09,2022-10-06,ACTUAL,2014-12-17,ACTUAL,2014-12-17,2022-08,2022-08-31,2021-09-15,ACTUAL,2021-09-15,2018-10-22,ACTUAL,2018-10-22,,INTERVENTIONAL,,"Baseline Characteristics data was collected only in pregnant women (enrolled population/study participants) and not in infants, as infants were not considered as enrolled per study design.","ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection","ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women",COMPLETED,,PHASE3,4,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:53:50,2024-10-13 07:53:50,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Russian Federation|Spain|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02076100,,2014-02-27,2018-04-16,,2018-12-03,2014-02-27,2014-03-03,ESTIMATED,2018-11-26,2018-11-28,ACTUAL,,,,2018-12-03,2018-12-24,ACTUAL,2014-03-27,ACTUAL,2014-03-27,2018-12,2018-12-31,2015-11-15,ACTUAL,2015-11-15,2015-11-15,ACTUAL,2015-11-15,,INTERVENTIONAL,,,"Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)","A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects With Hepatitis C Infection",COMPLETED,,PHASE1,22,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 19:23:54,2024-10-14 19:23:54,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Germany|Moldova, Republic of|Netherlands|New Zealand","Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02076178,,2014-02-27,2017-09-28,2015-09-10,2017-12-13,2014-02-27,2014-03-03,ESTIMATED,2017-12-13,2017-12-15,ACTUAL,2015-09-10,2015-09-29,ESTIMATED,2017-12-13,2017-12-15,ACTUAL,2014-03-27,ACTUAL,2014-03-27,2017-10,2017-10-31,2016-02-23,ACTUAL,2016-02-23,2015-05-15,ACTUAL,2015-05-15,,INTERVENTIONAL,,,"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)","A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)",COMPLETED,,PHASE2,127,ACTUAL,ViiV Healthcare,The results are presented till Week 41 with cutoff date 15-May-2015.,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 18:42:10,2024-10-13 18:42:10,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02087306,,2014-03-12,2020-12-09,,2021-07-21,2014-03-13,2014-03-14,ESTIMATED,2021-07-21,2021-08-13,ACTUAL,,,,2021-07-21,2021-08-13,ACTUAL,2014-03,ACTUAL,2014-03-31,2021-07,2021-07-31,2016-08,ACTUAL,2016-08-31,2016-06,ACTUAL,2016-06-30,,INTERVENTIONAL,,,Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection,"A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection",COMPLETED,,PHASE3,201,ACTUAL,Chimerix,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 12:09:05,2024-10-13 12:09:05,INDUSTRY,,,,,,,Chimerix,United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02089659,,2014-03-14,2018-07-03,,2018-07-03,2014-03-14,2014-03-18,ESTIMATED,2018-07-03,2018-12-28,ACTUAL,,,,2018-07-03,2018-12-28,ACTUAL,2014-03-26,ACTUAL,2014-03-26,2018-07,2018-07-31,2014-05-12,ACTUAL,2014-05-12,2014-05-12,ACTUAL,2014-05-12,,INTERVENTIONAL,,All enrolled participants,A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019),"A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439",COMPLETED,,PHASE1,16,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://www.merck.com/clinicaltrials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf,2024-10-14 13:38:09,2024-10-14 13:38:09,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT02092116,,2014-03-03,2016-11-08,,2017-01-11,2014-03-17,2014-03-19,ESTIMATED,2017-01-11,2017-03-01,ACTUAL,,,,2017-01-11,2017-03-01,ACTUAL,2014-03,,2014-03-31,2017-01,2017-01-31,2015-12,ACTUAL,2015-12-31,2015-08,ACTUAL,2015-08-31,,INTERVENTIONAL,REDUC,,Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir,An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART,COMPLETED,,PHASE1/PHASE2,26,ACTUAL,Bionor Immuno AS,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.,2024-10-13 13:15:50,2024-10-13 13:15:50,INDUSTRY,,,,,,,Bionor Immuno AS|Celgene Corporation,Denmark,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT02097108,,2014-03-24,2016-06-15,,2016-07-26,2014-03-24,2014-03-26,ESTIMATED,2016-07-26,2016-09-13,ESTIMATED,,,,2016-07-26,2016-09-13,ESTIMATED,2014-05,,2014-05-31,2016-07,2016-07-31,2015-12,ACTUAL,2015-12-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,,,Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir,"One Arm, Open Label, Interventional, Non-comparative Study to Assess Changes in Lipids and Lipoproteins in HIV Infected Women With Hyperlipidemia After Switch From Boosted Protease Inhibitor to Raltegravir",COMPLETED,,PHASE2,11,ACTUAL,Arbeitsgemeinschaft medikamentoese Tumortherapie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:42:20,2024-10-13 08:42:20,OTHER,,,,,,,Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme LLC,Austria,"Gastrointestinal disorders|General disorders|Investigations|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02102724,,2014-03-31,2018-08-13,,2019-03-25,2014-04-02,2014-04-03,ESTIMATED,2019-03-25,2019-03-26,ACTUAL,,,,2019-03-25,2019-03-26,ACTUAL,2014-04,,2014-04-30,2019-03,2019-03-31,2015-12,ACTUAL,2015-12-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,,,Fish Oil for HIV-Related Inflamm-aging and Immune Senescence,Fish Oil for HIV-Related Inflamm-aging and Immune Senescence,COMPLETED,,NA,37,ACTUAL,Rush University Medical Center,Small sample size; only single dose tested; duration may be too short to detect effects,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 14:08:24,2024-10-13 14:08:24,OTHER,,,,,,,Rush University Medical Center,United States,Blood and lymphatic system disorders|Gastrointestinal disorders|Nervous system disorders
NCT02103439,,2014-04-01,2015-05-21,,2018-07-13,2014-04-01,2014-04-03,ESTIMATED,2015-07-17,2015-07-21,ESTIMATED,,,,2018-07-13,2018-08-09,ACTUAL,2013-06-06,ACTUAL,2013-06-06,2018-07,2018-07-31,2015-08-26,ACTUAL,2015-08-26,2015-08-26,ACTUAL,2015-08-26,,INTERVENTIONAL,,,An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients,"Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC ""BIOCAD"", Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients",COMPLETED,,PHASE3,140,ACTUAL,Biocad,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 08:10:23,2024-10-13 08:10:23,INDUSTRY,,,,,,,Biocad,Russian Federation,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02105701,,2014-04-02,2016-02-03,,2021-01-15,2014-04-02,2014-04-07,ESTIMATED,2016-02-03,2016-03-04,ESTIMATED,,,,2021-01-15,2021-02-05,ACTUAL,2014-06-05,ACTUAL,2014-06-05,2021-01,2021-01-31,2015-06-19,ACTUAL,2015-06-19,2015-03-24,ACTUAL,2015-03-24,,INTERVENTIONAL,,,"Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)","A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects Who Have Failed Prior Treatment With Pegylated Interferon and Ribavirin (P/R) With Chronic HCV GT1, GT4, and GT6 Infection",COMPLETED,,PHASE3,420,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 10:16:10,2024-10-14 10:16:10,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Australia|Canada|Denmark|Finland|France|Israel|Korea, Republic of|Malaysia|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Taiwan|United States","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02105987,,2014-04-03,2015-12-10,,2016-11-07,2014-04-03,2014-04-07,ESTIMATED,2016-01-28,2016-02-25,ESTIMATED,,,,2016-11-07,2017-01-04,ESTIMATED,2014-04,,2014-04-30,2016-11,2016-11-30,2015-12,ACTUAL,2015-12-31,2015-04,ACTUAL,2015-04-30,,INTERVENTIONAL,,,"A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen","201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.",COMPLETED,,PHASE3,555,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 14:21:02,2024-10-14 14:21:02,INDUSTRY,,,,,,,"GlaxoSmithKline|PPD DEVELOPMENT, LP|ViiV Healthcare",Canada|Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Social circumstances|Vascular disorders"
NCT02106390,,2014-02-14,2017-10-06,,2018-06-14,2014-04-03,2014-04-08,ESTIMATED,2018-06-14,2018-08-22,ACTUAL,,,,2018-06-14,2018-08-22,ACTUAL,2014-06-05,ACTUAL,2014-06-05,2018-01,2018-01-31,2016-10-14,ACTUAL,2016-10-14,2016-10-14,ACTUAL,2016-10-14,,INTERVENTIONAL,,,Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants,"A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants",COMPLETED,,PHASE3,750,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-13 00:31:48,2024-10-13 00:31:48,INDUSTRY,,,,,,,GlaxoSmithKline,Argentina|Mexico,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02108522,,2014-04-07,2021-05-10,2019-05-10,2021-07-16,2014-04-08,2014-04-09,ESTIMATED,2021-06-28,2021-07-19,ACTUAL,2019-05-20,2019-05-29,ACTUAL,2021-07-16,2021-07-20,ACTUAL,2014-06,,2014-06-30,2021-07,2021-07-31,2019-12,ACTUAL,2019-12-31,2018-12,ACTUAL,2018-12-31,,INTERVENTIONAL,CHARMS,"Investigational product was administered to 58 unique patients, however one patient was enrolled twice for two separate infections. An additional 24 patients were screened but did not receive investigational product.",Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant,"Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus Infections Post Allogeneic Stem Cell Transplant",COMPLETED,,NA,82,ACTUAL,AlloVir,Limited information is available regarding patients who were screened for the study but were not administered investigational product. Data are preliminary and unaudited.,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:20:45,2024-10-14 02:20:45,INDUSTRY,,,,,,,"AlloVir|Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02114151,,2014-04-02,2016-01-21,,2016-03-07,2014-04-11,2014-04-15,ESTIMATED,2016-03-07,2016-04-04,ESTIMATED,,,,2016-03-07,2016-04-04,ESTIMATED,2014-04,,2014-04-30,2016-03,2016-03-31,2015-04,ACTUAL,2015-04-30,2015-01,ACTUAL,2015-01-31,,INTERVENTIONAL,,,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis,"A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis",COMPLETED,,PHASE3,103,ACTUAL,Janssen Infectious Diseases BVBA,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:09:30,2024-10-13 09:09:30,INDUSTRY,,,,,,,Janssen Infectious Diseases BVBA,Canada|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders"
NCT02114177,,2014-04-02,2016-01-19,,2016-03-14,2014-04-11,2014-04-15,ESTIMATED,2016-03-14,2016-04-12,ESTIMATED,,,,2016-03-14,2016-04-12,ESTIMATED,2014-04,,2014-04-30,2016-03,2016-03-31,2015-04,ACTUAL,2015-04-30,2015-01,ACTUAL,2015-01-31,,INTERVENTIONAL,,,Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis,"A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve and -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection Without Cirrhosis",COMPLETED,,PHASE3,310,ACTUAL,Janssen Infectious Diseases BVBA,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:15:13,2024-10-14 22:15:13,INDUSTRY,,,,,,,Janssen Infectious Diseases BVBA,Canada|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02114268,,2014-04-03,2016-07-26,,2016-10-05,2014-04-11,2014-04-15,ESTIMATED,2016-10-05,2016-11-28,ESTIMATED,,,,2016-10-05,2016-11-28,ESTIMATED,2014-04,,2014-04-30,2016-10,2016-10-31,2015-06,ACTUAL,2015-06-30,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,,The As-treated Population included participants who receive any study investigational product.,"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults","A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults",COMPLETED,,PHASE1,342,ACTUAL,MedImmune LLC,Physical examination parameters of participants were not evaluated.,6,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 20:13:23,2024-10-13 20:13:23,INDUSTRY,,,,,,,MedImmune LLC,United States,"Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02114385,,2014-04-08,2017-08-03,,2018-02-20,2014-04-11,2014-04-15,ESTIMATED,2018-02-20,2018-11-01,ACTUAL,,,,2018-02-20,2018-11-01,ACTUAL,2014-03-24,,2014-03-24,2018-02,2018-02-28,2015-04-22,ACTUAL,2015-04-22,2015-04-22,ACTUAL,2015-04-22,,INTERVENTIONAL,,Randomized participants,A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020),"A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men",COMPLETED,,PHASE3,500,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 13:07:17,2024-10-14 13:07:17,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Belgium|Germany|Netherlands,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders"
NCT02120300,,2014-04-18,2016-08-16,,2016-10-13,2014-04-18,2014-04-22,ESTIMATED,2016-10-13,2016-12-06,ESTIMATED,,,,2016-10-13,2016-12-06,ESTIMATED,2014-04,,2014-04-30,2016-10,2016-10-31,2015-08,ACTUAL,2015-08-31,2015-08,ACTUAL,2015-08-31,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug.,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders,"A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders",COMPLETED,,PHASE2,122,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 23:36:02,2024-10-14 23:36:02,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT02120352,,2014-04-17,2020-06-15,2015-12-10,2024-06-11,2014-04-21,2014-04-22,ESTIMATED,2020-08-14,2020-08-31,ACTUAL,2015-12-10,2016-01-13,ESTIMATED,2024-06-11,2024-06-12,ACTUAL,2014-04-28,ACTUAL,2014-04-28,2024-06,2024-06-30,2023-04-20,ACTUAL,2023-04-20,2015-08-13,ACTUAL,2015-08-13,,INTERVENTIONAL,,309 participants are valid only for the Induction Phase of the study (Weeks -20 to Day 1). Participants (n=286) were randomized at Day 1 of the Maintenance Phase.,"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects",COMPLETED,,PHASE2,309,ACTUAL,ViiV Healthcare,,7,,,FALSE,,,,TRUE,,,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 01:31:21,2024-10-14 01:31:21,INDUSTRY,,,,,,,GlaxoSmithKline|Janssen Pharmaceuticals|ViiV Healthcare,Canada|France|Germany|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02120352,,2014-04-17,2020-06-15,2015-12-10,2024-06-11,2014-04-21,2014-04-22,ESTIMATED,2020-08-14,2020-08-31,ACTUAL,2015-12-10,2016-01-13,ESTIMATED,2024-06-11,2024-06-12,ACTUAL,2014-04-28,ACTUAL,2014-04-28,2024-06,2024-06-30,2023-04-20,ACTUAL,2023-04-20,2015-08-13,ACTUAL,2015-08-13,,INTERVENTIONAL,,309 participants are valid only for the Induction Phase of the study (Weeks -20 to Day 1). Participants (n=286) were randomized at Day 1 of the Maintenance Phase.,"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects",COMPLETED,,PHASE2,309,ACTUAL,ViiV Healthcare,,7,,,FALSE,,,,TRUE,,,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 01:31:21,2024-10-14 01:31:21,INDUSTRY,,,,,,,GlaxoSmithKline|Janssen Pharmaceuticals|ViiV Healthcare,Canada|France|Germany|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02121756,,2014-04-21,2018-11-02,,2019-03-20,2014-04-22,2014-04-23,ESTIMATED,2019-03-20,2019-04-11,ACTUAL,,,,2019-03-20,2019-04-11,ACTUAL,2014-07,,2014-07-31,2019-03,2019-03-31,2017-11,ACTUAL,2017-11-30,2017-10,ACTUAL,2017-10-31,,INTERVENTIONAL,,"40 HIV-1-infected, ART-treated adults 18 years of age and older with HIV-1 RNA less than 50 copies/mL were enrolled and randomized. Of these 40 participants, 35 participants were included in the as-treated (AT) analysis (17 Dipyridamole, 18 placebo).",Dipyridamole for Immune Activation in HIV,A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987,COMPLETED,,PHASE1/PHASE2,40,ACTUAL,University of Pittsburgh,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 00:13:26,2024-10-14 00:13:26,OTHER,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|Sharon Riddler,United States,"Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02121795,,2014-04-22,2016-08-11,,2020-02-28,2014-04-22,2014-04-24,ESTIMATED,2016-10-07,2016-11-30,ESTIMATED,,,,2020-02-28,2020-03-12,ACTUAL,2014-05-06,ACTUAL,2014-05-06,2020-02,2020-02-29,2019-03-01,ACTUAL,2019-03-01,2015-08-12,ACTUAL,2015-08-12,,INTERVENTIONAL,,The Safety Analysis Set included all randomized participants who received at least one dose of study drug.,Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF,"A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF",COMPLETED,,PHASE3,668,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",2024-10-14 18:53:55,2024-10-14 18:53:55,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Canada|France|Italy|Puerto Rico|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02127281,,2014-04-29,2017-08-17,,2018-08-21,2014-04-29,2014-04-30,ESTIMATED,2018-03-22,2018-03-26,ACTUAL,,,,2018-08-21,2018-09-19,ACTUAL,2014-05,,2014-05-31,2018-08,2018-08-31,2017-06-30,ACTUAL,2017-06-30,2017-04-24,ACTUAL,2017-04-24,,INTERVENTIONAL,,,Evaluation of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Revision Arthroplasty.,Randomized Controlled Trial of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Knee and Hip Revision Arthroplasty.,COMPLETED,,NA,160,ACTUAL,The Cleveland Clinic,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 08:36:00,2024-10-14 08:36:00,OTHER,,,,,,,"KCI USA, Inc|The Cleveland Clinic",United States,"Blood and lymphatic system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02127970,,2014-04-25,2018-07-18,2016-05-11,2018-08-31,2014-04-29,2014-05-01,ESTIMATED,2018-07-18,2018-08-14,ACTUAL,2016-05-11,2016-06-02,ESTIMATED,2018-08-31,2018-09-28,ACTUAL,2014-04-18,ACTUAL,2014-04-18,2018-08,2018-08-31,2015-03-11,ACTUAL,2015-03-11,2015-03-11,ACTUAL,2015-03-11,,INTERVENTIONAL,,Intent-to-treat (ITT) Population included all randomized participants.,Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,698,ACTUAL,"Durata Therapeutics Inc., an affiliate of Allergan plc",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 03:12:53,2024-10-14 03:12:53,INDUSTRY,,,,,,,"Durata Therapeutics Inc., an affiliate of Allergan plc",Bulgaria|Croatia|Estonia|Georgia|Hungary|Latvia|Romania|Russian Federation|Serbia|South Africa|Ukraine|United States,"Eye disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02127970,,2014-04-25,2018-07-18,2016-05-11,2018-08-31,2014-04-29,2014-05-01,ESTIMATED,2018-07-18,2018-08-14,ACTUAL,2016-05-11,2016-06-02,ESTIMATED,2018-08-31,2018-09-28,ACTUAL,2014-04-18,ACTUAL,2014-04-18,2018-08,2018-08-31,2015-03-11,ACTUAL,2015-03-11,2015-03-11,ACTUAL,2015-03-11,,INTERVENTIONAL,,Intent-to-treat (ITT) Population included all randomized participants.,Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections,"A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,698,ACTUAL,"Durata Therapeutics Inc., an affiliate of Allergan plc",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 03:12:53,2024-10-14 03:12:53,INDUSTRY,,,,,,,"Durata Therapeutics Inc., an affiliate of Allergan plc",Bulgaria|Croatia|Estonia|Georgia|Hungary|Latvia|Romania|Russian Federation|Serbia|South Africa|Ukraine|United States,"Eye disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02128217,,2014-04-29,2018-02-28,,2018-03-29,2014-04-29,2014-05-01,ESTIMATED,2018-02-28,2018-03-30,ACTUAL,,,,2018-03-29,2018-04-27,ACTUAL,2014-05-30,ACTUAL,2014-05-30,2018-03,2018-03-31,2017-05-09,ACTUAL,2017-05-09,2017-02-28,ACTUAL,2017-02-28,,INTERVENTIONAL,SWIFT-C,Participants who enrolled and started first dose of study treatment.,Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection,Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C),COMPLETED,,PHASE1,44,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 11:51:08,2024-10-14 11:51:08,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Cardiac disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02128542,,2014-04-29,2016-06-21,,2016-06-21,2014-04-29,2014-05-01,ESTIMATED,2016-06-21,2016-08-03,ESTIMATED,,,,2016-06-21,2016-08-03,ESTIMATED,2014-06,,2014-06-30,2016-06,2016-06-30,2015-06,ACTUAL,2015-06-30,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,VALOR-HCV,Safety analysis set: participants who received at least 1 dose of study drug,Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis,"A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV",COMPLETED,,PHASE4,66,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 18:19:27,2024-10-13 18:19:27,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02130986,,2014-05-01,2018-12-02,,2019-01-14,2014-05-01,2014-05-06,ESTIMATED,2019-01-14,2019-01-15,ACTUAL,,,,2019-01-14,2019-01-15,ACTUAL,2014-11-03,ACTUAL,2014-11-03,2019-01,2019-01-31,2017-07-21,ACTUAL,2017-07-21,2017-07-21,ACTUAL,2017-07-21,,INTERVENTIONAL,ProACT,Only excluded 4 patients in each group for a total of 8 subjects. These 8 subjects withdrew all consent for participation.,Procalcitonin Antibiotic Consensus Trial (ProACT),Procalcitonin Antibiotic Consensus Trial (ProACT),COMPLETED,,NA,1664,ACTUAL,University of Pittsburgh,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 00:41:27,2024-10-15 00:41:27,OTHER,,,,,,,BioMérieux|National Institute of General Medical Sciences (NIGMS)|University of Pittsburgh,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02131233,,2014-05-02,2016-09-07,,2019-01-11,2014-05-02,2014-05-06,ESTIMATED,2016-09-07,2016-10-31,ESTIMATED,,,,2019-01-11,2019-01-30,ACTUAL,2014-05-23,ACTUAL,2014-05-23,2019-01,2019-01-31,2016-12-19,ACTUAL,2016-12-19,2015-12-21,ACTUAL,2015-12-21,,INTERVENTIONAL,onceMRK,All Treated Participants,"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects",COMPLETED,,PHASE3,802,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 17:40:56,2024-10-14 17:40:56,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Argentina|Australia|Belgium|Canada|Chile|Colombia|France|Germany|Guatemala|Ireland|Israel|Italy|Korea, Republic of|Malaysia|Peru|Philippines|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|Switzerland|Taiwan|Thailand|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02134184,,2014-05-07,2016-12-16,,2023-04-17,2014-05-07,2014-05-09,ESTIMATED,2016-12-16,2016-12-26,ESTIMATED,,,,2023-04-17,2023-04-19,ACTUAL,2012-10,,2012-10-31,2023-04,2023-04-30,2012-12,ACTUAL,2012-12-31,2012-12,ACTUAL,2012-12-31,,INTERVENTIONAL,SLVP025,,The Influence of Chronic CMV Infection on Influenza Vaccine Responses,The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses,COMPLETED,,PHASE4,78,ACTUAL,Stanford University,,3,,,FALSE,,,,FALSE,,,,,,,,,,,YES,The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique ID code and the volunteer identity (except for age) will not be disclosed.,2024-10-14 21:51:26,2024-10-14 21:51:26,OTHER,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|Stanford University,United States,"Respiratory, thoracic and mediastinal disorders"
NCT02135419,,2014-05-08,2022-07-25,,2024-07-18,2014-05-08,2014-05-12,ESTIMATED,2022-11-08,2022-12-02,ACTUAL,,,,2024-07-18,2024-07-26,ACTUAL,2014-09-24,ACTUAL,2014-09-24,2024-07,2024-07-31,2024-03-31,ACTUAL,2024-03-31,2021-08-06,ACTUAL,2021-08-06,,INTERVENTIONAL,ANCHOR,Participants who were randomized and received assigned intervention,Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions,ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study,COMPLETED,,PHASE3,4446,ACTUAL,AIDS Malignancy Consortium,,2,,,FALSE,,,,TRUE,TRUE,TRUE,,,FALSE,,,"IPD will only be shared with external investigators following conclusion of all participant data collection and the acceptance of a manuscript(s) that addresses all trial objectives, via release of the data to a public data repository, anticipated to occur on or after August 2025. Data will be available according to the archival terms of the AMC Data Commons.","Qualified researchers with plans approved by the AMC Executive Committee who have entered into a Data Use Agreement (DUA) with the AMC will be granted data access. Research plans may include, but are not limited to, research on HIV/AIDS, anal HSIL screening and/or treatment, HPV-associated malignancies, anal cancer, and associated conditions.",,YES,"A CDISC-mapped, de-identified version of the study data with appropriate documentation (data dictionary, annotated static copies of electronic case report forms, clinical protocol, informed consent document) of the data elements will be made available via a public data repository: the AIDS Malignancy Consortium (AMC) Data Commons.",2024-10-13 15:07:24,2024-10-13 15:07:24,NETWORK,,,,,,,"AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arizona|University of Arkansas|University of California, San Francisco",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02135419,,2014-05-08,2022-07-25,,2024-07-18,2014-05-08,2014-05-12,ESTIMATED,2022-11-08,2022-12-02,ACTUAL,,,,2024-07-18,2024-07-26,ACTUAL,2014-09-24,ACTUAL,2014-09-24,2024-07,2024-07-31,2024-03-31,ACTUAL,2024-03-31,2021-08-06,ACTUAL,2021-08-06,,INTERVENTIONAL,ANCHOR,Participants who were randomized and received assigned intervention,Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions,ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study,COMPLETED,,PHASE3,4446,ACTUAL,AIDS Malignancy Consortium,,2,,,FALSE,,,,TRUE,TRUE,TRUE,,,FALSE,,,"IPD will only be shared with external investigators following conclusion of all participant data collection and the acceptance of a manuscript(s) that addresses all trial objectives, via release of the data to a public data repository, anticipated to occur on or after August 2025. Data will be available according to the archival terms of the AMC Data Commons.","Qualified researchers with plans approved by the AMC Executive Committee who have entered into a Data Use Agreement (DUA) with the AMC will be granted data access. Research plans may include, but are not limited to, research on HIV/AIDS, anal HSIL screening and/or treatment, HPV-associated malignancies, anal cancer, and associated conditions.",,YES,"A CDISC-mapped, de-identified version of the study data with appropriate documentation (data dictionary, annotated static copies of electronic case report forms, clinical protocol, informed consent document) of the data elements will be made available via a public data repository: the AIDS Malignancy Consortium (AMC) Data Commons.",2024-10-13 15:07:24,2024-10-13 15:07:24,NETWORK,,,,,,,"AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC|University of Arizona|University of Arkansas|University of California, San Francisco",Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02135614,,2014-05-08,2018-03-27,2017-11-15,2018-08-24,2014-05-08,2014-05-12,ESTIMATED,2018-05-10,2018-05-11,ACTUAL,2017-11-15,2017-11-17,ACTUAL,2018-08-24,2018-09-24,ACTUAL,2014-06-09,ACTUAL,2014-06-09,2018-05,2018-05-31,2017-04-12,ACTUAL,2017-04-12,2017-03-27,ACTUAL,2017-03-27,,INTERVENTIONAL,,Safety Analysis Set: all participants who received 1 dose of study drug.,"Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection","A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection",COMPLETED,,PHASE2,189,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 13:44:10,2024-10-14 13:44:10,INDUSTRY,,,,,,,Gilead Sciences,"Australia|Belgium|Canada|France|Hong Kong|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|United Kingdom|United States","Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Product Issues|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT02137772,,2014-05-12,2017-10-16,,2019-08-29,2014-05-12,2014-05-14,ESTIMATED,2017-10-16,2017-11-17,ACTUAL,,,,2019-08-29,2019-09-11,ACTUAL,2014-06-06,ACTUAL,2014-06-06,2019-08,2019-08-31,2016-11-21,ACTUAL,2016-11-21,2016-08-08,ACTUAL,2016-08-08,,INTERVENTIONAL,,Randomized participants,"Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)","A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients",COMPLETED,,PHASE3,570,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 23:44:43,2024-10-13 23:44:43,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Austria|Belgium|Brazil|Canada|Finland|France|Germany|Italy|Japan|Korea, Republic of|Lithuania|New Zealand|Peru|Poland|Romania|Spain|Sweden|Turkey|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02141217,,2014-05-15,2014-08-14,,2017-08-25,2014-05-15,2014-05-19,ESTIMATED,2014-08-14,2014-08-28,ESTIMATED,,,,2017-08-25,2017-09-25,ACTUAL,2013-03-21,ACTUAL,2013-03-21,2017-08,2017-08-31,2013-12-28,ACTUAL,2013-12-28,2013-12-28,ACTUAL,2013-12-28,,INTERVENTIONAL,AUGDENT,,AUGMENTIN™ in Dental Infections,"Efficacy, Safety and Tolerability of Amoxicillin + Clavulanic Acid (875mg/125mg) Two Times a Day Compared to Clindamycin (150mg) Four Times a Day for 5-7 Days in Treatment of Acute Odontogenic Infection With or Without Abscess",COMPLETED,,PHASE4,472,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,,,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 01:17:29,2024-10-14 01:17:29,INDUSTRY,,,,,,,GlaxoSmithKline,Malaysia|Philippines|Thailand|Vietnam,Gastrointestinal disorders|Investigations|Metabolism and nutrition disorders|Nervous system disorders
NCT02147288,,2014-05-21,2016-08-11,,2016-12-06,2014-05-21,2014-05-26,ESTIMATED,2016-12-06,2017-01-30,ESTIMATED,,,,2016-12-06,2017-01-30,ESTIMATED,2012-01,,2012-01-31,2016-12,2016-12-31,2014-06,ACTUAL,2014-06-30,2014-06,ACTUAL,2014-06-30,,INTERVENTIONAL,,,Prevention of Seroma Formation and Wound Complications Using NPWT Devices,Prevention of Seroma Formation and Wound Complications Using NPWT Devices,COMPLETED,,NA,46,ACTUAL,Yale University,,10,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 01:54:09,2024-10-15 01:54:09,OTHER,,,,,,,"Smith & Nephew, Inc.|Yale University",United States,Skin and subcutaneous tissue disorders
NCT02155985,,2014-06-03,2016-05-27,,2017-05-08,2014-06-03,2014-06-04,ESTIMATED,2016-05-27,2016-07-07,ESTIMATED,,,,2017-05-08,2017-06-12,ACTUAL,2014-08,,2014-08-31,2017-05,2017-05-31,2015-07,ACTUAL,2015-07-31,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,,"121 randomized participants, all of which did initiate study treatment.",Modulation of Immune Activation by Aspirin,Modulation of Immune Activation by Aspirin,COMPLETED,,PHASE2,121,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 18:17:09,2024-10-14 18:17:09,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,Infections and infestations|Investigations
NCT02158442,,2014-04-11,2016-06-22,,2016-08-23,2014-06-05,2014-06-06,ESTIMATED,2016-06-22,2016-08-03,ESTIMATED,,,,2016-08-23,2016-09-30,ESTIMATED,2013-10,,2013-10-31,2016-08,2016-08-31,2015-03,ACTUAL,2015-03-31,2015-02,ACTUAL,2015-02-28,,INTERVENTIONAL,,,Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients,Randomized Study Comparing Clinical and Microbiological Efficacy of Timentin Delivered Via Percutaneous Isolated Limb Perfusion (PILP) or Intravenous Infusion in Diabetic Subjects With Moderate to Severe Lower Limb Infection,COMPLETED,,PHASE2,15,ACTUAL,"Osprey Medical, Inc",,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-12 23:46:56,2024-10-12 23:46:56,INDUSTRY,,,,,,,"Osprey Medical, Inc",Australia,Cardiac disorders
NCT02159976,,2014-06-03,2016-05-05,,2019-02-08,2014-06-06,2014-06-10,ESTIMATED,2019-02-08,2019-05-13,ACTUAL,,,,2019-02-08,2019-05-13,ACTUAL,2014-07,,2014-07-31,2019-02,2019-02-28,2016-04,ACTUAL,2016-04-30,2015-05,ACTUAL,2015-05-31,,INTERVENTIONAL,,,Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea,"A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea",COMPLETED,,NA,390,ACTUAL,Seoul National University Bundang Hospital,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:06:14,2024-10-15 02:06:14,OTHER,,,,,,,"Chong Kun Dang Pharmaceutical|Green Cross Corporation|HK inno.N Corporation|Seoul National University Bundang Hospital|SK Chemicals Co., Ltd.","Korea, Republic of",Gastrointestinal disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT02163824,,2014-06-12,2020-11-25,2016-06-30,2021-01-06,2014-06-12,2014-06-16,ESTIMATED,2020-11-25,2020-12-22,ACTUAL,2016-06-30,2016-07-04,ESTIMATED,2021-01-06,2021-01-29,ACTUAL,2014-05,,2014-05-31,2021-01,2021-01-31,2014-12,ACTUAL,2014-12-31,2014-12,ACTUAL,2014-12-31,,INTERVENTIONAL,Hawaii-1,,Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation,"A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation",COMPLETED,,PHASE3,380,ACTUAL,"Kala Pharmaceuticals, Inc.",,4,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-15 02:18:46,2024-10-15 02:18:46,INDUSTRY,,,,,,,"Kala Pharmaceuticals, Inc.",United States,Cardiac disorders|Eye disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Nervous system disorders
NCT02166476,,2014-06-16,2017-04-18,2016-12-01,2018-05-11,2014-06-16,2014-06-18,ESTIMATED,2017-09-27,2017-10-26,ACTUAL,2016-12-01,2016-12-05,ESTIMATED,2018-05-11,2018-06-11,ACTUAL,2014-11-20,ACTUAL,2014-11-20,2018-04,2018-04-30,2016-04-28,ACTUAL,2016-04-28,2016-04-28,ACTUAL,2016-04-28,,INTERVENTIONAL,,All randomized participants who received at least 1 dose of study drug (MITT population).,Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP,"Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis",COMPLETED,,PHASE3,550,ACTUAL,"Melinta Therapeutics, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 16:37:52,2024-10-13 16:37:52,INDUSTRY,,,,,,,"Department of Health and Human Services|Melinta Therapeutics, Inc.","Belarus|Brazil|Bulgaria|Czechia|Czech Republic|Greece|Hungary|Italy|Korea, Republic of|Peru|Poland|Romania|Slovakia|Slovenia|Spain|Taiwan|Ukraine|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02167945,,2014-06-18,2022-03-11,,2022-06-27,2014-06-18,2014-06-19,ESTIMATED,2022-03-11,2022-04-06,ACTUAL,,,,2022-06-27,2022-07-19,ACTUAL,2014-06-12,ACTUAL,2014-06-12,2022-06,2022-06-30,2021-05-13,ACTUAL,2021-05-13,2021-05-13,ACTUAL,2021-05-13,,INTERVENTIONAL,TOPAZ-II,Safety population: All participants enrolled in this study (M14-222; TOPAZ-II) who received at least one dose of study drug,A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection,"An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)",COMPLETED,,PHASE3,615,ACTUAL,AbbVie,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,"For details on when studies are available for sharing, please refer to the link below.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.",https://vivli.org/ourmember/abbvie/,YES,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2024-10-13 21:22:54,2024-10-13 21:22:54,INDUSTRY,,,,,,,AbbVie,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02168946,,2014-06-18,2018-09-27,,2019-02-28,2014-06-18,2014-06-20,ESTIMATED,2018-11-26,2018-12-11,ACTUAL,,,,2019-02-28,2019-03-04,ACTUAL,2014-07,,2014-07-31,2019-02,2019-02-28,2017-07-21,ACTUAL,2017-07-21,2017-07-21,ACTUAL,2017-07-21,,INTERVENTIONAL,,All randomized subjects who received at least one dose of study drug (MITT and Safety Population),"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults","A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)",COMPLETED,,PHASE3,77,ACTUAL,"Melinta Therapeutics, Inc.",Enrollment Challenges required the Sponsor to terminate the study early which led to a smaller number of patients being enrolled.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 23:21:52,2024-10-13 23:21:52,INDUSTRY,,,,,,,"Department of Health and Human Services|Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",Argentina|Brazil|Colombia|Greece|Israel|Italy|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02168946,,2014-06-18,2018-09-27,,2019-02-28,2014-06-18,2014-06-20,ESTIMATED,2018-11-26,2018-12-11,ACTUAL,,,,2019-02-28,2019-03-04,ACTUAL,2014-07,,2014-07-31,2019-02,2019-02-28,2017-07-21,ACTUAL,2017-07-21,2017-07-21,ACTUAL,2017-07-21,,INTERVENTIONAL,,All randomized subjects who received at least one dose of study drug (MITT and Safety Population),"Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults","A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)",COMPLETED,,PHASE3,77,ACTUAL,"Melinta Therapeutics, Inc.",Enrollment Challenges required the Sponsor to terminate the study early which led to a smaller number of patients being enrolled.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 23:21:52,2024-10-13 23:21:52,INDUSTRY,,,,,,,"Department of Health and Human Services|Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)",Argentina|Brazil|Colombia|Greece|Israel|Italy|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02171819,,2014-06-20,2018-11-11,,2018-11-11,2014-06-20,2014-06-24,ESTIMATED,2018-11-11,2019-03-14,ACTUAL,,,,2018-11-11,2019-03-14,ACTUAL,2014-06,,2014-06-30,2018-11,2018-11-30,2014-08,ACTUAL,2014-08-31,2014-08,ACTUAL,2014-08-31,,INTERVENTIONAL,,,Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1,"A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC in Healthy Adult Volunteers in Vietnam",COMPLETED,,PHASE1,75,ACTUAL,"Institute of Vaccines and Medical Biologicals, Vietnam",,3,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 01:37:23,2024-10-14 01:37:23,INDUSTRY,,,,,,,"Department of Health and Human Services|Institute of Vaccines and Medical Biologicals, Vietnam|Institut Pasteur|PATH|World Health Organization",Vietnam,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02173704,,2014-06-05,2017-02-20,2016-01-04,2020-08-13,2014-06-23,2014-06-25,ESTIMATED,2018-06-14,2018-06-15,ACTUAL,2016-01-04,2016-02-03,ESTIMATED,2020-08-13,2020-08-25,ACTUAL,2014-09-11,ACTUAL,2014-09-11,2020-08,2020-08-31,2016-06-17,ACTUAL,2016-06-17,2015-12-25,ACTUAL,2015-12-25,,INTERVENTIONAL,,,"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants in Taiwan.",COMPLETED,,PHASE3,225,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 08:04:12,2024-10-14 08:04:12,INDUSTRY,,,,,,,GlaxoSmithKline|Novartis Vaccines,Taiwan,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02175758,,2014-06-24,2019-02-28,,2019-04-05,2014-06-24,2014-06-26,ESTIMATED,2019-04-05,2019-04-30,ACTUAL,,,,2019-04-05,2019-04-30,ACTUAL,2014-07-07,ACTUAL,2014-07-07,2019-04,2019-04-30,2018-09-13,ACTUAL,2018-09-13,2018-06-21,ACTUAL,2018-06-21,,INTERVENTIONAL,,Safety Analysis Set included all participants who took at least 1 dose of study drug.,Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection,"A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection",COMPLETED,,PHASE2,106,ACTUAL,Gilead Sciences,,6,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 20:41:55,2024-10-14 20:41:55,INDUSTRY,,,,,,,Gilead Sciences,Australia|Belgium|Germany|India|Italy|New Zealand|Russian Federation|United Kingdom|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Product Issues|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT02177032,,2014-06-24,2016-08-18,,2017-02-21,2014-06-26,2014-06-27,ESTIMATED,2017-02-21,2017-04-07,ACTUAL,,,,2017-02-21,2017-04-07,ACTUAL,2014-06,,2014-06-30,2017-02,2017-02-28,2015-08,ACTUAL,2015-08-31,2014-10,ACTUAL,2014-10-31,,INTERVENTIONAL,,,Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age,"Phase 3, Randomized, Stratified, Open Label, Multicenter, Controlled Clinical Study to Evaluate Safety and Immunogenicity of a Rabies Vaccine Administered, With and Without Human Rabies Immunoglobulin, Using the New ""4-sites, 1-week"" Intradermal Regimen for Postexposure Prophylaxis Compared to the Currently Recommended ""2-sites, TRC"" Intradermal Regimen in Children and Adults Subjects.",COMPLETED,,PHASE3,885,ACTUAL,Novartis,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-12 23:46:56,2024-10-12 23:46:56,INDUSTRY,,,,,,,Novartis|Novartis Vaccines,Philippines|Thailand,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02178592,,2014-06-26,2018-10-05,,2020-12-18,2014-06-26,2014-07-01,ESTIMATED,2018-10-05,2019-02-21,ACTUAL,,,,2020-12-18,2021-01-12,ACTUAL,2015-01-23,ACTUAL,2015-01-23,2020-12,2020-12-31,2020-03-06,ACTUAL,2020-03-06,2017-11-02,ACTUAL,2017-11-02,,INTERVENTIONAL,,,Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection,"ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naïve Adults Starting Treatment for Rifampicin-sensitive Tuberculosis",COMPLETED,,PHASE3,113,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-14 02:45:55,2024-10-14 02:45:55,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Brazil|Mexico|Peru|Russian Federation|South Africa|Thailand,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02178592,,2014-06-26,2018-10-05,,2020-12-18,2014-06-26,2014-07-01,ESTIMATED,2018-10-05,2019-02-21,ACTUAL,,,,2020-12-18,2021-01-12,ACTUAL,2015-01-23,ACTUAL,2015-01-23,2020-12,2020-12-31,2020-03-06,ACTUAL,2020-03-06,2017-11-02,ACTUAL,2017-11-02,,INTERVENTIONAL,,,Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection,"ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naïve Adults Starting Treatment for Rifampicin-sensitive Tuberculosis",COMPLETED,,PHASE3,113,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-14 02:45:55,2024-10-14 02:45:55,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Brazil|Mexico|Peru|Russian Federation|South Africa|Thailand,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02178800,,2014-06-27,2018-04-30,,2021-10-14,2014-06-27,2014-07-01,ESTIMATED,2018-06-05,2018-07-05,ACTUAL,,,,2021-10-14,2021-10-18,ACTUAL,2015-02,,2015-02-28,2021-10,2021-10-31,2018-07-13,ACTUAL,2018-07-13,2017-04-05,ACTUAL,2017-04-05,,INTERVENTIONAL,,,"Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults","A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women",COMPLETED,,PHASE2,199,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:09:19,2024-10-14 22:09:19,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Malawi|South Africa|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02180438,,2014-05-29,2018-04-07,,2018-06-30,2014-07-01,2014-07-02,ESTIMATED,2018-04-07,2018-05-08,ACTUAL,,,,2018-06-30,2018-07-26,ACTUAL,2014-09,ACTUAL,2014-09-30,2018-06,2018-06-30,2017-01,ACTUAL,2017-01-31,2017-01,ACTUAL,2017-01-31,,INTERVENTIONAL,Stribild HIV-2,,"An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal","An Open Label Trial of STRIBILD™ (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) for ARV-naïve HIV-2 Infected Adults in Dakar, Senegal",COMPLETED,,PHASE4,30,ACTUAL,University of Washington,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-13 09:59:01,2024-10-13 09:59:01,OTHER,,,,,,,"Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann|Gilead Sciences|University of Washington",Senegal,Nervous system disorders
NCT02182115,,2014-07-01,2017-10-19,,2019-11-04,2014-07-03,2014-07-08,ESTIMATED,2017-10-19,2017-11-17,ACTUAL,,,,2019-11-04,2019-11-05,ACTUAL,2014-07,,2014-07-31,2019-11,2019-11-30,2016-08,ACTUAL,2016-08-31,2016-08,ACTUAL,2016-08-31,,INTERVENTIONAL,,,S. Aureus Screening and Decolonization,Effectiveness of Screening and Decolonization of S. Aureus in Surgery Outpatients,COMPLETED,,PHASE4,110,ACTUAL,University of Minnesota,Limitations include the small number of participants with methicillin resistant SA (MRSA) and with SA carriage at non-nares sites. We were unable to assess the decolonization bundle's efficacy for MRSA and for sites other than nares and perianal.,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,Aggregate data will be reported once the study has been completed.,2024-10-14 14:45:38,2024-10-14 14:45:38,OTHER,,,,,,,Agency for Healthcare Research and Quality (AHRQ)|University of Minnesota,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02182115,,2014-07-01,2017-10-19,,2019-11-04,2014-07-03,2014-07-08,ESTIMATED,2017-10-19,2017-11-17,ACTUAL,,,,2019-11-04,2019-11-05,ACTUAL,2014-07,,2014-07-31,2019-11,2019-11-30,2016-08,ACTUAL,2016-08-31,2016-08,ACTUAL,2016-08-31,,INTERVENTIONAL,,,S. Aureus Screening and Decolonization,Effectiveness of Screening and Decolonization of S. Aureus in Surgery Outpatients,COMPLETED,,PHASE4,110,ACTUAL,University of Minnesota,Limitations include the small number of participants with methicillin resistant SA (MRSA) and with SA carriage at non-nares sites. We were unable to assess the decolonization bundle's efficacy for MRSA and for sites other than nares and perianal.,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,Aggregate data will be reported once the study has been completed.,2024-10-14 14:45:38,2024-10-14 14:45:38,OTHER,,,,,,,Agency for Healthcare Research and Quality (AHRQ)|University of Minnesota,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02185794,,2014-07-07,2020-08-06,,2020-08-28,2014-07-07,2014-07-10,ESTIMATED,2020-08-06,2020-08-21,ACTUAL,,,,2020-08-28,2020-09-17,ACTUAL,2014-06-13,ACTUAL,2014-06-13,2020-08,2020-08-31,2015-09-28,ACTUAL,2015-09-28,2014-12-22,ACTUAL,2014-12-22,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug (voxilaprevir or placebo).,"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection","Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection",COMPLETED,,PHASE1,101,ACTUAL,Gilead Sciences,,16,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 13:45:03,2024-10-13 13:45:03,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT02199691,,2014-07-23,2020-05-19,2015-09-29,2022-03-24,2014-07-23,2014-07-24,ESTIMATED,2020-05-19,2020-06-09,ACTUAL,2015-09-29,2015-10-20,ESTIMATED,2022-03-24,2022-04-04,ACTUAL,2014-07-22,ACTUAL,2014-07-22,2022-03,2022-03-31,2015-10-02,ACTUAL,2015-10-02,2015-10-02,ACTUAL,2015-10-02,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents,A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents,COMPLETED,,PHASE2,1715,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-13 07:48:16,2024-10-13 07:48:16,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02201901,,2014-07-24,2016-08-24,,2018-10-19,2014-07-24,2014-07-28,ESTIMATED,2016-10-24,2016-12-14,ESTIMATED,,,,2018-10-19,2018-11-15,ACTUAL,2014-07,,2014-07-31,2016-10,2016-10-31,2015-11,ACTUAL,2015-11-30,2015-08,ACTUAL,2015-08-31,,INTERVENTIONAL,ASTRAL-4,Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug.,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis,"A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis",COMPLETED,,PHASE3,268,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,3,,,FALSE,,,,TRUE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 16:26:35,2024-10-13 16:26:35,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02201940,,2014-07-24,2016-07-27,2016-04-08,2018-10-19,2014-07-24,2014-07-28,ESTIMATED,2016-07-27,2016-09-16,ESTIMATED,2016-04-08,2016-05-05,ESTIMATED,2018-10-19,2018-11-15,ACTUAL,2014-07,,2014-07-31,2016-07,2016-07-31,2015-09,ACTUAL,2015-09-30,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,ASTRAL-1,Safety Analysis Set: participants who received at least 1 dose of study drug.,Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV",COMPLETED,,PHASE3,741,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 22:48:26,2024-10-13 22:48:26,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Canada|China|France|Germany|Italy|Puerto Rico|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02201953,,2014-07-24,2016-09-01,,2018-10-19,2014-07-24,2014-07-28,ESTIMATED,2016-09-01,2016-10-26,ESTIMATED,,,,2018-10-19,2018-11-16,ACTUAL,2014-07,,2014-07-31,2016-09,2016-09-30,2015-12,ACTUAL,2015-12-31,2015-09,ACTUAL,2015-09-30,,INTERVENTIONAL,ASTRAL-3,Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug.,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection,"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Subjects With Chronic Genotype 3 HCV Infection",COMPLETED,,PHASE3,558,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-12 23:52:10,2024-10-12 23:52:10,INDUSTRY,,,,,,,Gilead Sciences,Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02212379,,2014-07-30,2020-04-20,,2021-03-31,2014-08-06,2014-08-08,ESTIMATED,2021-01-11,2021-02-05,ACTUAL,,,,2021-03-31,2021-04-27,ACTUAL,2015-01,,2015-01-31,2021-03,2021-03-31,2018-04,ACTUAL,2018-04-30,2017-10,ACTUAL,2017-10-31,,INTERVENTIONAL,,,Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL,Dual Therapy Combining Raltegravir With Etravirine Maintains a High Level of Viral Suppression Over 96 Weeks in Long-term Experienced HIV-infected Individuals Over 45 Years on a PI-based Regimen: Results From the Phase II ANRS 163 ETRAL Study,COMPLETED,,PHASE2,170,ACTUAL,"ANRS, Emerging Infectious Diseases","The absence of a comparator arm, which in terms of impact on fat, bone density and inflammation/activation markers may limit the interpretation of the observed changes over time. One limitation is the small number of women.",1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:01:13,2024-10-14 13:01:13,OTHER_GOV,,,,,,,"ANRS, Emerging Infectious Diseases|Janssen-Cilag Ltd.|Merck Sharp & Dohme LLC",France|Spain,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Reproductive system and breast disorders|Surgical and medical procedures"
NCT02212457,,2014-08-06,2017-03-02,2015-05-29,2019-06-13,2014-08-06,2014-08-08,ESTIMATED,2017-06-22,2017-07-21,ACTUAL,2015-05-29,2015-06-26,ESTIMATED,2019-06-13,2019-06-27,ACTUAL,2014-08-21,ACTUAL,2014-08-21,2019-06,2019-06-30,2016-03-03,ACTUAL,2016-03-03,2015-05-22,ACTUAL,2015-05-22,,INTERVENTIONAL,,,Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents,"A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Meningococcal Group B Vaccine, in Healthy Adolescents",COMPLETED,,PHASE2,1063,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 10:22:11,2024-10-14 10:22:11,INDUSTRY,,,,,,,GlaxoSmithKline,Finland|Poland|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT02213328,,2014-08-07,2018-03-19,,2023-06-14,2014-08-07,2014-08-11,ESTIMATED,2023-06-14,2023-07-03,ACTUAL,,,,2023-06-14,2023-07-03,ACTUAL,2015-04,,2015-04-30,2023-06,2023-06-30,2017-03-06,ACTUAL,2017-03-06,2017-03-06,ACTUAL,2017-03-06,,INTERVENTIONAL,,All participants are adolescent male and female 15-19 years old,"Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents",CHAMPS: Choices For Adolescent Prevention Methods For South Africa. Pilot Study B: 'PlusPills',COMPLETED,,PHASE2,148,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 10:09:34,2024-10-13 10:09:34,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),South Africa,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Injury, poisoning and procedural complications|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT02216422,,2014-08-12,2016-05-23,,2016-05-23,2014-08-12,2014-08-15,ESTIMATED,2016-05-23,2016-06-29,ESTIMATED,,,,2016-05-23,2016-06-29,ESTIMATED,2014-09,,2014-09-30,2016-05,2016-05-31,2015-12,ACTUAL,2015-12-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,Turquoise-IV,Baseline analyses included all participants.,A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection,"An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (Turquoise-IV)",COMPLETED,,PHASE3,36,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 11:14:41,2024-10-13 11:14:41,INDUSTRY,,,,,,,AbbVie,Belarus|Russian Federation,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02219490,,2014-08-15,2022-03-11,,2022-06-27,2014-08-15,2014-08-19,ESTIMATED,2022-06-27,2023-04-07,ACTUAL,,,,2022-06-27,2023-04-07,ACTUAL,2014-10-30,ACTUAL,2014-10-30,2022-06,2022-06-30,2021-05-13,ACTUAL,2021-05-13,2021-05-13,ACTUAL,2021-05-13,,INTERVENTIONAL,TOPAZ-I,Safety population: All participants enrolled in this study (M14-423; TOPAZ-I) who received at least one dose of study drug,A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection,"An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)",COMPLETED,,PHASE3,1596,ACTUAL,AbbVie,,1,,,FALSE,,,,TRUE,FALSE,FALSE,,,FALSE,,,"For details on when studies are available for sharing, please refer to the link below.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.",https://vivli.org/ourmember/abbvie/,YES,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications",2024-10-13 11:46:42,2024-10-13 11:46:42,INDUSTRY,,,,,,,AbbVie,Algeria|Australia|Austria|Belgium|Bulgaria|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Mexico|Netherlands|Norway|Poland|Portugal|Qatar|Romania|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|Turkey|United Arab Emirates|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02219503,,2014-08-15,2016-05-23,,2021-07-08,2014-08-15,2014-08-19,ESTIMATED,2016-05-23,2016-06-29,ESTIMATED,,,,2021-07-08,2021-07-12,ACTUAL,2014-09,,2014-09-30,2021-07,2021-07-31,2015-09,ACTUAL,2015-09-30,2015-06,ACTUAL,2015-06-30,,INTERVENTIONAL,TURQUOISE-III,Baseline analyses included all participants.,A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis,"An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)",COMPLETED,,PHASE3,60,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 01:21:06,2024-10-15 01:21:06,INDUSTRY,,,,,,,AbbVie,Belgium|Canada|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02219685,,2014-08-15,2016-08-02,,2018-10-19,2014-08-15,2014-08-19,ESTIMATED,2016-10-07,2016-11-30,ESTIMATED,,,,2018-10-19,2018-11-16,ACTUAL,2014-08,,2014-08-31,2016-10,2016-10-31,2016-04,ACTUAL,2016-04-30,2015-08,ACTUAL,2015-08-31,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug.,Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection,"A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Effect of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection",COMPLETED,,PHASE2,40,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 18:23:16,2024-10-14 18:23:16,INDUSTRY,,,,,,,Gilead Sciences,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT02220998,,2014-08-18,2016-07-27,2016-04-08,2018-10-19,2014-08-18,2014-08-20,ESTIMATED,2016-09-26,2016-11-15,ESTIMATED,2016-04-08,2016-05-05,ESTIMATED,2018-10-19,2018-11-15,ACTUAL,2014-09,,2014-09-30,2016-09,2016-09-30,2015-09,ACTUAL,2015-09-30,2015-07,ACTUAL,2015-07-31,,INTERVENTIONAL,ASTRAL-2,Safety Analysis Set: participants who received at least 1 dose of study drug.,Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection,"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection",COMPLETED,,PHASE3,269,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 01:39:59,2024-10-13 01:39:59,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT02223520,,2014-08-21,2020-03-02,,2022-01-07,2014-08-21,2014-08-22,ESTIMATED,2020-03-02,2020-03-16,ACTUAL,,,,2022-01-07,2022-01-11,ACTUAL,2014-11,ACTUAL,2014-11-30,2020-03,2020-03-31,2019-10-31,ACTUAL,2019-10-31,2019-10-31,ACTUAL,2019-10-31,,INTERVENTIONAL,TREAT PARENTS,,Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial,Treating Parents to Reduce Neonatal Intensive Care Unit (NICU) Transmission of Staphylococcus Aureus,COMPLETED,,NA,307,ACTUAL,Johns Hopkins University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 05:21:07,2024-10-14 05:21:07,OTHER,,,,,,,Agency for Healthcare Research and Quality (AHRQ)|Johns Hopkins University,United States,"Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02225587,,2014-08-22,2019-11-26,2016-06-16,2021-10-25,2014-08-22,2014-08-26,ESTIMATED,2020-01-28,2020-02-05,ACTUAL,2016-06-16,2016-07-11,ESTIMATED,2021-10-25,2021-11-02,ACTUAL,2014-08-28,ACTUAL,2014-08-28,2021-10,2021-10-31,2015-07-06,ACTUAL,2015-07-06,2015-07-06,ACTUAL,2015-07-06,,INTERVENTIONAL,,,Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029),Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Subjects 50 Years of Age and Older,COMPLETED,,PHASE3,400,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 19:35:45,2024-10-14 19:35:45,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02226549,,2014-08-25,2016-02-05,,2018-10-19,2014-08-25,2014-08-27,ESTIMATED,2016-02-05,2016-03-04,ESTIMATED,,,,2018-10-19,2018-11-16,ACTUAL,2014-07,,2014-07-31,2016-02,2016-02-29,2015-02,ACTUAL,2015-02-28,2015-02,ACTUAL,2015-02-28,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug.,Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis,"A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis",COMPLETED,,PHASE2,47,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,2,,,FALSE,,,,FALSE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-15 00:47:13,2024-10-15 00:47:13,INDUSTRY,,,,,,,Gilead Sciences,United States,"General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02227238,,2014-08-25,2018-07-25,,2023-02-09,2014-08-25,2014-08-28,ESTIMATED,2019-04-24,2019-07-12,ACTUAL,,,,2023-02-09,2023-03-13,ACTUAL,2014-12-11,ACTUAL,2014-12-11,2023-01,2023-01-31,2022-02-14,ACTUAL,2022-02-14,2017-08-02,ACTUAL,2017-08-02,,INTERVENTIONAL,,Baseline Characteristic data are reported for members of the ITT-E Population which comprised of all participants who received at least one dose of study medication.,Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment,"A Phase 3b, Randomized, Open-label Study of the Antiviral Activity and Safety of Dolutegravir Compared to Lopinavir/Ritonavir Both Administered With Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1 Infected Adult Subjects With Treatment Failure on First Line Therapy",COMPLETED,,PHASE3,627,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-14 10:03:49,2024-10-14 10:03:49,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Brazil|Chile|China|Colombia|Kenya|Mexico|Peru|Romania|Russian Federation|South Africa|Thailand|Ukraine,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02227446,,2014-08-21,2020-07-23,,2021-05-06,2014-08-26,2014-08-28,ESTIMATED,2021-05-06,2021-06-01,ACTUAL,,,,2021-05-06,2021-06-01,ACTUAL,2014-10,,2014-10-31,2021-05,2021-05-31,2019-11,ACTUAL,2019-11-30,2018-06,ACTUAL,2018-06-30,,INTERVENTIONAL,VANCO,,"Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)","Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)",COMPLETED,,PHASE3,1036,ACTUAL,Major Extremity Trauma Research Consortium,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:07:17,2024-10-14 13:07:17,OTHER,,,,,,,Major Extremity Trauma Research Consortium,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders"
NCT02231879,,2014-09-03,2021-12-23,,2023-04-06,2014-09-03,2014-09-04,ESTIMATED,2023-04-06,2023-04-07,ACTUAL,,,,2023-04-06,2023-04-07,ACTUAL,2014-10-14,ACTUAL,2014-10-14,2021-03,2021-03-31,2021-02-24,ACTUAL,2021-02-24,2020-10-08,ACTUAL,2020-10-08,,INTERVENTIONAL,,,Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome,A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.,COMPLETED,,PHASE2/PHASE3,20,ACTUAL,National Institutes of Health Clinical Center (CC),"1. Highly variable disease phenotypic expression made crossover design optimal but a placebo arm was not included due to infection risk of severe neutropenia
2. Prophylactic supplemental immunoglobulin and antibiotics were allowed
3. Tolerance of G-CSF was insured prior to randomization but plerixafor was never used before randomization in 17/19 patients,
4. Non-inferiority analysis of primary endpoint was not planned because there were no defined equivalence margins",2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:34:55,2024-10-14 15:34:55,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT02246998,,2014-09-19,2017-01-20,,2017-12-01,2014-09-19,2014-09-23,ESTIMATED,2017-12-01,2018-01-03,ACTUAL,,,,2017-12-01,2018-01-03,ACTUAL,2014-12-15,ACTUAL,2014-12-15,2017-12,2017-12-31,2016-02-17,ACTUAL,2016-02-17,2016-01-20,ACTUAL,2016-01-20,,INTERVENTIONAL,,"Safety Analysis Set: all randomized participants who received at least 1 dose of study drug, excluding iohexol",Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults,"A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or Other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF) Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults With eGFR ≥70 mL/Min",COMPLETED,,PHASE4,72,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-13 08:15:37,2024-10-13 08:15:37,INDUSTRY,,,,,,,Gilead Sciences,Belgium|France|Ireland|Spain|United Kingdom,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02247401,,2014-09-19,2017-06-28,,2021-07-28,2014-09-22,2014-09-25,ESTIMATED,2017-06-28,2017-07-27,ACTUAL,,,,2021-07-28,2021-07-30,ACTUAL,2014-11-04,,2014-11-04,2021-07,2021-07-31,2016-08-01,ACTUAL,2016-08-01,2016-08-01,ACTUAL,2016-08-01,,INTERVENTIONAL,,,Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt,An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt,COMPLETED,,PHASE3,160,ACTUAL,AbbVie,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:59:41,2024-10-14 00:59:41,INDUSTRY,,,,,,,AbbVie,Egypt,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02247440,,2014-09-09,2018-03-16,,2019-02-22,2014-09-19,2014-09-25,ESTIMATED,2019-02-22,2019-06-03,ACTUAL,,,,2019-02-22,2019-06-03,ACTUAL,2014-08,,2014-08-31,2019-02,2019-02-28,2018-01,ACTUAL,2018-01-31,2017-05,ACTUAL,2017-05-31,,INTERVENTIONAL,,,HCV-HIV Co-infected Patient Cohort in Thailand,"Response to Peg-interferon and Ribavirin for the Treatment of HCV Infection in HIV Co-infected Patients, Implemented in Public Hospitals in Thailand",COMPLETED,,PHASE4,18,ACTUAL,Institut de Recherche pour le Developpement,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 15:53:27,2024-10-14 15:53:27,OTHER_GOV,,,,,,,"Institut de Recherche pour le Developpement|Ministry of Health, Thailand",Thailand,Blood and lymphatic system disorders|Gastrointestinal disorders
NCT02249182,,2014-09-23,2019-02-15,,2020-02-18,2014-09-23,2014-09-25,ESTIMATED,2019-03-29,2019-04-24,ACTUAL,,,,2020-02-18,2020-03-02,ACTUAL,2014-11-05,ACTUAL,2014-11-05,2019-03,2019-03-31,2018-08-24,ACTUAL,2018-08-24,2018-06-15,ACTUAL,2018-06-15,,INTERVENTIONAL,,Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug.,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection,"A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection",COMPLETED,,PHASE2,226,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-15 01:37:17,2024-10-15 01:37:17,INDUSTRY,,,,,,,Gilead Sciences,Australia|New Zealand|United Kingdom|United States,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Product Issues|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02251717,,2014-09-25,2017-03-22,,2018-10-19,2014-09-25,2014-09-29,ESTIMATED,2017-11-06,2017-11-17,ACTUAL,,,,2018-10-19,2018-11-19,ACTUAL,2014-10-14,ACTUAL,2014-10-14,2017-11,2017-11-30,2016-06-16,ACTUAL,2016-06-16,2016-03-24,ACTUAL,2016-03-24,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug,Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection,"A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection",COMPLETED,,PHASE2,114,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-15 00:24:31,2024-10-15 00:24:31,INDUSTRY,,,,,,,Gilead Sciences,Austria|France|Germany|Italy,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT02254421,,2014-09-29,2018-03-27,,2018-08-24,2014-09-29,2014-10-01,ESTIMATED,2018-05-10,2018-05-11,ACTUAL,,,,2018-08-24,2018-09-24,ACTUAL,2015-01-31,ACTUAL,2015-01-31,2018-05,2018-05-31,2017-04-17,ACTUAL,2017-04-17,2017-04-17,ACTUAL,2017-04-17,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 full dose of study drug.,Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract,"A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract",COMPLETED,,PHASE2,60,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 10:09:34,2024-10-13 10:09:34,INDUSTRY,,,,,,,Gilead Sciences,"Australia|France|Germany|Israel|Korea, Republic of|Netherlands|Sweden|Switzerland|Taiwan|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02256631,,2014-10-01,2021-06-14,,2023-01-12,2014-10-01,2014-10-03,ESTIMATED,2021-07-27,2021-08-23,ACTUAL,,,,2023-01-12,2023-02-08,ACTUAL,2015-06-30,ACTUAL,2015-06-30,2023-01,2023-01-31,2021-12-16,ACTUAL,2021-12-16,2020-06-17,ACTUAL,2020-06-17,,INTERVENTIONAL,,Baseline characteristics were collected only for infants.,"Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants","Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants",COMPLETED,,PHASE1,83,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,7,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 03:37:02,2024-10-13 03:37:02,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|South Africa|United States|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02258659,,2014-09-19,2020-12-14,,2024-09-09,2014-10-02,2014-10-07,ESTIMATED,2020-12-14,2021-01-08,ACTUAL,,,,2024-09-09,2024-09-24,ACTUAL,2014-09-22,ACTUAL,2014-09-22,2024-09,2024-09-30,2024-09-06,ACTUAL,2024-09-06,2024-09-06,ACTUAL,2024-09-06,,INTERVENTIONAL,OPTIMA,,Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer,An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial,COMPLETED,,PHASE2,62,ACTUAL,University of Chicago,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 17:58:40,2024-10-14 17:58:40,OTHER,,,,,,,National Cancer Institute (NCI)|University of Chicago,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02260882,,2014-10-06,2016-01-19,,2018-10-01,2014-10-06,2014-10-09,ESTIMATED,2016-01-19,2016-02-17,ESTIMATED,,,,2018-10-01,2018-10-30,ACTUAL,2014-10-31,ACTUAL,2014-10-31,2018-10,2018-10-31,2015-04-09,ACTUAL,2015-04-09,2015-04-09,ACTUAL,2015-04-09,,INTERVENTIONAL,,One participant in the Primary Vaccination Group was withdrawn from the study before vaccination because of a protocol violation. Baseline Characteristics are based on the Full Analysis Set: participants who received at least one vaccination.,Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902),A Study Evaluating the Safety and Immunogenicity of Revaccination With 23-Valent Pneumococcal Polysaccharide Vaccine in Older Japanese Adults,COMPLETED,,PHASE4,243,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 18:53:36,2024-10-13 18:53:36,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders"
NCT02263326,,2014-10-06,2018-08-24,,2019-10-10,2014-10-08,2014-10-13,ESTIMATED,2018-11-08,2018-11-13,ACTUAL,,,,2019-10-10,2019-10-14,ACTUAL,2014-12,,2014-12-31,2019-10,2019-10-31,2017-09,ACTUAL,2017-09-30,2017-07,ACTUAL,2017-07-31,,INTERVENTIONAL,ASPIRE,,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure,Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study,COMPLETED,,PHASE3,89,ACTUAL,Northwestern University,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 23:07:13,2024-10-14 23:07:13,OTHER,,,,,,,Babafemi Taiwo|ViiV Healthcare,United States,Cardiac disorders|Hepatobiliary disorders|Infections and infestations
NCT02266706,,2014-09-22,2018-04-04,,2019-08-29,2014-10-14,2014-10-17,ESTIMATED,2018-09-27,2019-02-15,ACTUAL,,,,2019-08-29,2019-09-11,ACTUAL,2014-09-17,ACTUAL,2014-09-17,2019-08,2019-08-31,2017-06-15,ACTUAL,2017-06-15,2017-06-08,ACTUAL,2017-06-08,,INTERVENTIONAL,,All enrolled participants,Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010),"A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/Tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis",COMPLETED,,PHASE1,43,ACTUAL,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,6,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 07:10:08,2024-10-14 07:10:08,INDUSTRY,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02270944,,2014-10-08,2016-09-19,2015-04-29,2019-11-19,2014-10-21,2014-10-22,ESTIMATED,2017-06-30,2017-07-28,ACTUAL,2015-04-29,2015-05-18,ESTIMATED,2019-11-19,2019-12-05,ACTUAL,2014-11-20,ACTUAL,2014-11-20,2019-11,2019-11-30,2015-09-22,ACTUAL,2015-09-22,2015-04-23,ACTUAL,2015-04-23,,INTERVENTIONAL,,,Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine,"A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women Aged 18 to 40 Years",COMPLETED,,PHASE2,1053,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 01:11:48,2024-10-13 01:11:48,INDUSTRY,,,,,,,GlaxoSmithKline|Novartis Vaccines,Belgium|Czechia|Czech Republic|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders"
NCT02270944,,2014-10-08,2016-09-19,2015-04-29,2019-11-19,2014-10-21,2014-10-22,ESTIMATED,2017-06-30,2017-07-28,ACTUAL,2015-04-29,2015-05-18,ESTIMATED,2019-11-19,2019-12-05,ACTUAL,2014-11-20,ACTUAL,2014-11-20,2019-11,2019-11-30,2015-09-22,ACTUAL,2015-09-22,2015-04-23,ACTUAL,2015-04-23,,INTERVENTIONAL,,,Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine,"A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women Aged 18 to 40 Years",COMPLETED,,PHASE2,1053,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-13 01:11:48,2024-10-13 01:11:48,INDUSTRY,,,,,,,GlaxoSmithKline|Novartis Vaccines,Belgium|Czechia|Czech Republic|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Reproductive system and breast disorders"
NCT02275065,,2014-10-23,2020-09-08,,2020-10-16,2014-10-23,2014-10-27,ESTIMATED,2020-09-14,2020-10-08,ACTUAL,,,,2020-10-16,2020-11-09,ACTUAL,2014-10-24,ACTUAL,2014-10-24,2020-10,2020-10-31,2015-01-29,ACTUAL,2015-01-29,2015-01-23,ACTUAL,2015-01-23,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of bictegravir or matched placebo.,"Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants","A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects",COMPLETED,,PHASE1,23,ACTUAL,Gilead Sciences,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 09:03:39,2024-10-13 09:03:39,INDUSTRY,,,,,,,Gilead Sciences,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT02277990,,2014-10-22,2019-10-02,,2019-10-23,2014-10-27,2014-10-29,ESTIMATED,2019-10-02,2019-10-24,ACTUAL,,,,2019-10-23,2019-11-05,ACTUAL,2015-01,ACTUAL,2015-01-31,2019-10,2019-10-31,2018-09,ACTUAL,2018-09-30,2018-09,ACTUAL,2018-09-30,,INTERVENTIONAL,WRAP-IT,,World-wide Randomized Antibiotic Envelope Infection Prevention Trial,Cardiac Implantable Electronic Device (CIED) Antibiotic Envelope Infection Prevention Trial,COMPLETED,,PHASE4,7075,ACTUAL,Medtronic Cardiac Rhythm and Heart Failure,,2,,,FALSE,,,,TRUE,FALSE,TRUE,,,TRUE,,,,,,,,2024-10-13 09:48:07,2024-10-13 09:48:07,INDUSTRY,,,,,,,Medtronic Cardiac Rhythm and Heart Failure|The Cleveland Clinic,Austria|Belgium|Canada|Chile|China|Denmark|Finland|France|Germany|Greece|Israel|Italy|Malaysia|Netherlands|Norway|Poland|Portugal|Saudi Arabia|Singapore|Slovakia|Spain|Sweden|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT02282605,,2014-10-21,2016-02-29,,2016-09-12,2014-11-03,2014-11-04,ESTIMATED,2016-09-12,2016-10-07,ESTIMATED,,,,2016-09-12,2016-10-07,ESTIMATED,2014-09,,2014-09-30,2016-06,2016-06-30,2014-11,ACTUAL,2014-11-30,2014-11,ACTUAL,2014-11-30,,INTERVENTIONAL,,,Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects,"A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects.",COMPLETED,,PHASE1/PHASE2,60,ACTUAL,Destiny Pharma Plc,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 00:21:11,2024-10-13 00:21:11,INDUSTRY,,,,,,,Destiny Pharma Plc,United Kingdom,"Gastrointestinal disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02284126,,2014-11-03,2020-11-30,,2021-03-01,2014-11-04,2014-11-05,ESTIMATED,2021-01-22,2021-01-25,ACTUAL,,,,2021-03-01,2021-03-23,ACTUAL,2014-10,,2014-10-31,2021-03,2021-03-31,2021-06,ESTIMATED,2021-06-30,2019-11,ACTUAL,2019-11-30,,INTERVENTIONAL,Vanguard,"Out of 1103 enrolled subjects, only 973 subjects completed the study and their data have been analyzed and presented here.",Topical Vancomycin for Neurosurgery Wound Prophylaxis,Topical Vancomycin for the Reduction of Surgical Site Infections in Neurosurgery,UNKNOWN,ACTIVE_NOT_RECRUITING,PHASE3,1103,ACTUAL,Columbia University,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 20:37:13,2024-10-13 20:37:13,OTHER,,,,,,,Agency for Healthcare Research and Quality (AHRQ)|Columbia University|Cornell University|Icahn School of Medicine at Mount Sinai,United States,"Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02292719,,2014-11-13,2018-06-07,,2021-07-08,2014-11-13,2014-11-17,ESTIMATED,2018-06-07,2018-07-06,ACTUAL,,,,2021-07-08,2021-07-12,ACTUAL,2014-12-19,ACTUAL,2014-12-19,2021-07,2021-07-31,2017-07-14,ACTUAL,2017-07-14,2017-07-14,ACTUAL,2017-07-14,,INTERVENTIONAL,Quartz II/III,All subjects who received at least 1 dose of study drug were included in the intent-to-treat (ITT) population; the safety population is the same as the ITT population.,A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection,"A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis",COMPLETED,,PHASE2,70,ACTUAL,AbbVie,,6,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-15 02:24:13,2024-10-15 02:24:13,INDUSTRY,,,,,,,AbbVie,Australia|Canada|New Zealand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02300103,,2014-11-20,2017-06-30,,2018-10-19,2014-11-20,2014-11-24,ESTIMATED,2017-06-30,2017-07-28,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2014-12-01,ACTUAL,2014-12-01,2017-06,2017-06-30,2016-09-15,ACTUAL,2016-09-15,2016-07-02,ACTUAL,2016-07-02,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug,Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study,An Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study,COMPLETED,,PHASE2,69,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 09:40:26,2024-10-14 09:40:26,INDUSTRY,,,,,,,Gilead Sciences,Australia|New Zealand|Puerto Rico|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02301936,,2014-11-24,2017-04-18,,2018-10-19,2014-11-24,2014-11-26,ESTIMATED,2017-04-18,2017-05-25,ACTUAL,,,,2018-10-19,2018-11-19,ACTUAL,2015-03-02,ACTUAL,2015-03-02,2017-04,2017-04-30,2016-04-18,ACTUAL,2016-04-18,2016-04-18,ACTUAL,2016-04-18,,INTERVENTIONAL,,Safety Analysis Set: participants who took at least 1 dose of study drug.,Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease,An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Subjects With Sickle Cell Disease,COMPLETED,,PHASE2,10,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 19:11:06,2024-10-13 19:11:06,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT02308007,,2014-12-01,2020-06-23,2018-06-26,2020-07-21,2014-12-02,2014-12-04,ESTIMATED,2020-07-21,2020-08-04,ACTUAL,2018-06-27,2018-06-29,ACTUAL,2020-07-21,2020-08-04,ACTUAL,2015-06,,2015-06-30,2020-07,2020-07-31,2018-06,ACTUAL,2018-06-30,2018-06,ACTUAL,2018-06-30,,INTERVENTIONAL,SMART GIVES,"modified intent-to-treat (mITT) population includes all subjects randomized to treatment and administered at least one dose of study drug. In addition, subjects must have a Nugent score of 4 or more on Baseline visit Gram stain slide and a Baseline visit yeast culture positive for Candida species.",Multi-Center Study of New Medications to Treat Vaginal Infections,Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety,COMPLETED,,PHASE3,475,ACTUAL,"Curatek Pharmaceuticals, LLC",,3,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 19:11:06,2024-10-13 19:11:06,INDUSTRY,,,,,,,"Curatek Pharmaceuticals, LLC",United States,Metabolism and nutrition disorders|Reproductive system and breast disorders
NCT02308033,,2014-12-01,2020-06-18,2018-06-26,2020-07-09,2014-12-02,2014-12-04,ESTIMATED,2020-07-09,2020-07-27,ACTUAL,2018-06-27,2018-06-29,ACTUAL,2020-07-09,2020-07-27,ACTUAL,2015-06,ACTUAL,2015-06-30,2020-07,2020-07-31,2017-06,ACTUAL,2017-06-30,2017-06,ACTUAL,2017-06-30,,INTERVENTIONAL,SMART GIVES,"modified intent-to-treat (mITT) population includes all subjects randomized to treatment and administered at least one dose of study drug. In addition, subjects must have a Nugent score of 4 or more on Baseline visit Gram stain slide.",Multi-Center Study of New Medications to Treat Vaginal Infections,Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety,COMPLETED,,PHASE3,204,ACTUAL,"Curatek Pharmaceuticals, LLC",,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 08:10:23,2024-10-13 08:10:23,INDUSTRY,,,,,,,"Curatek Pharmaceuticals, LLC",United States,Infections and infestations|Nervous system disorders|Reproductive system and breast disorders
NCT02308046,,2014-12-01,2020-06-18,2018-06-26,2020-07-09,2014-12-02,2014-12-04,ESTIMATED,2020-07-09,2020-07-27,ACTUAL,2018-06-26,2018-06-27,ACTUAL,2020-07-09,2020-07-27,ACTUAL,2015-06,ACTUAL,2015-06-30,2020-07,2020-07-31,2017-06,ACTUAL,2017-06-30,2017-06,ACTUAL,2017-06-30,,INTERVENTIONAL,SMART GIVES,"modified intent-to-treat (mITT) population includes all subjects randomized to treatment and administered at least one dose of study drug. In addition, subjects must have a positive baseline vaginal fungal culture for Candida species.",Multi-Center Study of New Medications to Treat Vaginal Infections,Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety,COMPLETED,,PHASE3,212,ACTUAL,"Curatek Pharmaceuticals, LLC",,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 18:47:46,2024-10-14 18:47:46,INDUSTRY,,,,,,,"Curatek Pharmaceuticals, LLC",United States,Infections and infestations|Reproductive system and breast disorders
NCT02321800,,2014-11-11,2019-11-20,2017-07-11,2019-11-20,2014-12-16,2014-12-22,ESTIMATED,2019-11-20,2019-12-12,ACTUAL,2017-07-11,2017-07-13,ACTUAL,2019-11-20,2019-12-12,ACTUAL,2015-02-05,ACTUAL,2015-02-05,2019-11,2019-11-30,2016-08-16,ACTUAL,2016-08-16,2016-07-26,ACTUAL,2016-07-26,,INTERVENTIONAL,APEKS-cUTI,Modified intent-to-treat population includes all randomly assigned participants who received at least one dose of study drug and had qualifying Gram-negative uropathogen (≥1 × 10⁵ colony forming unit (CFU)/mL),A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections,"A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin",COMPLETED,,PHASE2,452,ACTUAL,Shionogi Inc.,,2,,,TRUE,,,,TRUE,,,,,,,,,,,,,2024-10-13 03:41:50,2024-10-13 03:41:50,INDUSTRY,,NCT03780140,APPROVED_FOR_MARKETING,,,,Shionogi,Bulgaria|Croatia|Czechia|Czech Republic|Georgia|Germany|Hungary|Italy|Japan|Latvia|Poland|Romania|Russian Federation|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT02325791,,2014-12-21,2018-07-05,,2018-10-08,2014-12-21,2014-12-25,ESTIMATED,2018-10-08,2018-11-06,ACTUAL,,,,2018-10-08,2018-11-06,ACTUAL,2015-07-21,,2015-07-21,2018-10,2018-10-31,2017-09-26,ACTUAL,2017-09-26,2017-07-05,ACTUAL,2017-07-05,,INTERVENTIONAL,,,Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants",COMPLETED,,PHASE3,1177,ACTUAL,Regeneron Pharmaceuticals,,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 01:34:34,2024-10-13 01:34:34,INDUSTRY,,,,,,,Regeneron Pharmaceuticals,Argentina|Australia|Bulgaria|Canada|Chile|Denmark|Finland|Germany|Hungary|Netherlands|New Zealand|Panama|Puerto Rico|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT02326467,,2014-06-25,2020-07-17,,2021-07-06,2014-12-22,2014-12-29,ESTIMATED,2021-07-06,2021-07-27,ACTUAL,,,,2021-07-06,2021-07-27,ACTUAL,2016-02,ACTUAL,2016-02-29,2021-07,2021-07-31,2019-07-01,ACTUAL,2019-07-01,2018-09-13,ACTUAL,2018-09-13,,INTERVENTIONAL,,,Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age,Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age,COMPLETED,,PHASE1,10,ACTUAL,Boston Children's Hospital,The study was stopped early due to the unknown risks associated with CHG levels in relation to CHG bathing.,1,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 00:36:58,2024-10-14 00:36:58,OTHER,,,,,,,Celeste Chandonnet,United States,Blood and lymphatic system disorders
NCT02335905,,2014-12-31,2021-05-03,,2021-10-05,2015-01-07,2015-01-12,ESTIMATED,2021-10-05,2021-11-02,ACTUAL,,,,2021-10-05,2021-11-02,ACTUAL,2015-06-03,ACTUAL,2015-06-03,2021-10,2021-10-31,2020-06-16,ACTUAL,2020-06-16,2020-06-16,ACTUAL,2020-06-16,,INTERVENTIONAL,,,Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children,Phase 1/2 Trial of Ceftaroline for the Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children,COMPLETED,,PHASE1/PHASE2,11,ACTUAL,Baylor College of Medicine,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 16:43:39,2024-10-13 16:43:39,OTHER,,,,,,,Allergan|Baylor College of Medicine,United States,Infections and infestations
NCT02339155,,2015-01-12,2017-12-12,,2024-03-14,2015-01-12,2015-01-15,ESTIMATED,2017-12-12,2018-01-09,ACTUAL,,,,2024-03-14,2024-03-18,ACTUAL,2015-02-24,ACTUAL,2015-02-24,2024-03,2024-03-31,2017-06-06,ACTUAL,2017-06-06,2017-01-03,ACTUAL,2017-01-03,,INTERVENTIONAL,,The Intent to Treat (ITT) Population comprised of all randomized participants,Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed,"A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483)",COMPLETED,,PHASE4,573,ACTUAL,Emergent BioSolutions,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 16:25:58,2024-10-14 16:25:58,INDUSTRY,,,,,,,Emergent BioSolutions|GlaxoSmithKline,United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02339415,,2015-01-12,2019-02-17,,2019-08-15,2015-01-14,2015-01-15,ESTIMATED,2019-08-15,2019-09-06,ACTUAL,,,,2019-08-15,2019-09-06,ACTUAL,2015-07,ACTUAL,2015-07-31,2019-08,2019-08-31,2018-09,ACTUAL,2018-09-30,2018-09,ACTUAL,2018-09-30,,INTERVENTIONAL,TACTICAL-HIV,,Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease,Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease,COMPLETED,,PHASE2,44,ACTUAL,Hennepin Healthcare Research Institute,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 10:58:04,2024-10-14 10:58:04,OTHER,,,,,,,Hennepin Healthcare Research Institute,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders|Surgical and medical procedures"
NCT02344004,,2015-01-09,2018-10-25,,2020-04-22,2015-01-16,2015-01-22,ESTIMATED,2018-10-25,2018-11-20,ACTUAL,,,,2020-04-22,2020-05-07,ACTUAL,2015-05-27,ACTUAL,2015-05-27,2020-02,2020-02-29,2019-04-03,ACTUAL,2019-04-03,2018-07-03,ACTUAL,2018-07-03,,INTERVENTIONAL,CONVERT,,Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone,"A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment",COMPLETED,,PHASE3,336,ACTUAL,Insmed Incorporated,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 18:42:10,2024-10-13 18:42:10,INDUSTRY,,,,,,,Insmed Incorporated,"Australia|Austria|Canada|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Poland|Spain|Sweden|Taiwan|Thailand|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02345226,,2015-01-19,2017-09-21,2017-02-14,2019-12-16,2015-01-19,2015-01-26,ESTIMATED,2017-09-21,2017-10-19,ACTUAL,2017-02-14,2017-02-16,ACTUAL,2019-12-16,2020-01-02,ACTUAL,2015-01-26,ACTUAL,2015-01-26,2019-12,2019-12-31,2019-01-02,ACTUAL,2019-01-02,2016-06-29,ACTUAL,2016-06-29,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.,"Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults","A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects",COMPLETED,,PHASE3,881,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and transparency",2024-10-13 02:52:51,2024-10-13 02:52:51,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Canada|France|Germany|Italy|Netherlands|Puerto Rico|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02345252,,2015-01-19,2017-09-20,2017-02-14,2019-12-16,2015-01-19,2015-01-26,ESTIMATED,2017-11-07,2017-12-08,ACTUAL,2017-02-14,2017-02-16,ACTUAL,2019-12-16,2020-01-02,ACTUAL,2015-01-26,ACTUAL,2015-01-26,2019-12,2019-12-31,2019-01-09,ACTUAL,2019-01-09,2016-06-22,ACTUAL,2016-06-22,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.,Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF),"A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)",COMPLETED,,PHASE3,632,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 00:19:26,2024-10-14 00:19:26,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Canada|France|Germany|Italy|Netherlands|Puerto Rico|Spain|Sweden|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT02346721,,2015-01-21,2017-03-23,,2018-10-19,2015-01-21,2015-01-27,ESTIMATED,2017-03-23,2017-05-03,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2015-02-23,ACTUAL,2015-02-23,2017-03,2017-03-31,2016-06-15,ACTUAL,2016-06-15,2016-03-23,ACTUAL,2016-03-23,,INTERVENTIONAL,,Safety Analysis Set included participants who took at least 1 dose of study drug.,Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection,An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection,COMPLETED,,PHASE3,111,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 00:15:55,2024-10-13 00:15:55,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Canada|China|France|Germany|Hong Kong|Italy|Puerto Rico|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02350569,,2015-01-26,2017-03-27,,2018-10-19,2015-01-26,2015-01-29,ESTIMATED,2017-03-27,2017-05-05,ACTUAL,,,,2018-10-19,2018-11-19,ACTUAL,2015-05-22,ACTUAL,2015-05-22,2017-03,2017-03-31,2016-04-22,ACTUAL,2016-04-22,2016-03-28,ACTUAL,2016-03-28,,INTERVENTIONAL,,Safety Analysis Set: participants who were enrolled into the study and received at least 1 dose of study drug during the Main Study,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting,"A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic HCV for Use in the Peri-Operative Liver Transplantation Setting",COMPLETED,,PHASE2,17,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 02:29:56,2024-10-13 02:29:56,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02351180,,2015-01-26,2022-01-18,,2022-02-08,2015-01-26,2015-01-30,ESTIMATED,2022-02-08,2022-03-03,ACTUAL,,,,2022-02-08,2022-03-03,ACTUAL,2017-02-01,ACTUAL,2017-02-01,2022-01,2022-01-31,2021-01-31,ACTUAL,2021-01-31,2021-01-31,ACTUAL,2021-01-31,,INTERVENTIONAL,,,Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients,A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients,COMPLETED,,PHASE1/PHASE2,16,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,NO,There is no plan to share IPD,2024-10-13 12:09:05,2024-10-13 12:09:05,OTHER,,,,,,,Washington University School of Medicine,United States,"Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02356562,,2015-02-02,2017-10-19,,2017-11-22,2015-02-02,2015-02-05,ESTIMATED,2017-10-19,2017-11-24,ACTUAL,,,,2017-11-22,2017-12-20,ACTUAL,2015-02-03,ACTUAL,2015-02-03,2017-10,2017-10-31,2017-07-07,ACTUAL,2017-07-07,2016-10-28,ACTUAL,2016-10-28,,INTERVENTIONAL,,,A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection,"An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With or Without Sofosbuvir (SOF) and Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE2,29,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 21:10:53,2024-10-13 21:10:53,INDUSTRY,,,,,,,AbbVie,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02358993,,2015-02-03,2021-09-24,,2022-02-03,2015-02-06,2015-02-09,ESTIMATED,2022-02-03,2022-02-25,ACTUAL,,,,2022-02-03,2022-02-25,ACTUAL,2014-12,ACTUAL,2014-12-31,2022-02,2022-02-28,2020-09-30,ACTUAL,2020-09-30,2020-09-30,ACTUAL,2020-09-30,,INTERVENTIONAL,NO-UTI,,Short-course Methenamine Hippurate for Prevention of Post-operative UTI,The Efficacy and Cost-effectiveness of a 24-hour Course of metheNamine Hippurate for Preventing Post-Operative Urinary Tract Infection,COMPLETED,,NA,201,ACTUAL,University of Pennsylvania,,2,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-14 22:49:51,2024-10-14 22:49:51,OTHER,,,,,,,University of Pennsylvania,United States,Gastrointestinal disorders|Musculoskeletal and connective tissue disorders
NCT02358993,,2015-02-03,2021-09-24,,2022-02-03,2015-02-06,2015-02-09,ESTIMATED,2022-02-03,2022-02-25,ACTUAL,,,,2022-02-03,2022-02-25,ACTUAL,2014-12,ACTUAL,2014-12-31,2022-02,2022-02-28,2020-09-30,ACTUAL,2020-09-30,2020-09-30,ACTUAL,2020-09-30,,INTERVENTIONAL,NO-UTI,,Short-course Methenamine Hippurate for Prevention of Post-operative UTI,The Efficacy and Cost-effectiveness of a 24-hour Course of metheNamine Hippurate for Preventing Post-Operative Urinary Tract Infection,COMPLETED,,NA,201,ACTUAL,University of Pennsylvania,,2,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-14 22:49:51,2024-10-14 22:49:51,OTHER,,,,,,,University of Pennsylvania,United States,Gastrointestinal disorders|Musculoskeletal and connective tissue disorders
NCT02359435,,2015-01-25,2016-01-11,,2017-03-21,2015-02-04,2015-02-10,ESTIMATED,2016-01-11,2016-02-10,ESTIMATED,,,,2017-03-21,2017-04-18,ACTUAL,2012-10,,2012-10-31,2017-03,2017-03-31,2015-02,ACTUAL,2015-02-28,2015-02,ACTUAL,2015-02-28,,INTERVENTIONAL,REHYTRI,,Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection,Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study),COMPLETED,,NA,440,ACTUAL,Kaohsiung Veterans General Hospital.,The trial was performed in a single country,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 12:09:05,2024-10-13 12:09:05,OTHER,,,,,,,Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Veterans General Hospital.,Taiwan,Gastrointestinal disorders|Nervous system disorders
NCT02360475,,2015-01-29,2016-11-29,,2018-05-31,2015-02-05,2015-02-10,ESTIMATED,2017-07-14,2017-08-16,ACTUAL,,,,2018-05-31,2018-07-03,ACTUAL,2015-03-20,ACTUAL,2015-03-20,2018-05,2018-05-31,2016-06-21,ACTUAL,2016-06-21,2015-07-02,ACTUAL,2015-07-02,,INTERVENTIONAL,,,"Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women","An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women",COMPLETED,,PHASE2,507,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 16:39:05,2024-10-14 16:39:05,INDUSTRY,,,,,,,GlaxoSmithKline,Australia|Czechia|Czech Republic|Germany|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02362503,,2015-02-09,2018-08-02,,2024-07-11,2015-02-12,2015-02-13,ESTIMATED,2018-08-20,2018-09-18,ACTUAL,,,,2024-07-11,2024-07-23,ACTUAL,2015-02-23,ACTUAL,2015-02-23,2024-07,2024-07-31,2026-12-31,ESTIMATED,2026-12-31,2016-08-18,ACTUAL,2016-08-18,,INTERVENTIONAL,,,Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients,"A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)",ACTIVE_NOT_RECRUITING,,PHASE3,371,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 21:10:53,2024-10-13 21:10:53,INDUSTRY,,,,,,,ViiV Healthcare,Argentina|Australia|Belgium|Brazil|Canada|Chile|Colombia|France|Germany|Greece|Ireland|Italy|Mexico|Netherlands|Peru|Poland|Portugal|Puerto Rico|Romania|Russian Federation|South Africa|Spain|Taiwan|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02363322,,2015-02-13,2018-08-07,,2019-05-23,2015-02-13,2015-02-16,ESTIMATED,2019-04-19,2019-05-14,ACTUAL,,,,2019-05-23,2019-06-05,ACTUAL,2015-03-13,ACTUAL,2015-03-13,2018-06,2018-06-30,2017-12-31,ACTUAL,2017-12-31,2017-12-31,ACTUAL,2017-12-31,,INTERVENTIONAL,,,Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection,A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection,COMPLETED,,PHASE1/PHASE2,72,ACTUAL,National Institutes of Health Clinical Center (CC),Due to the severity of the underlying illness (Ebola infection) only infusion-related adverse events were captured.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 03:05:32,2024-10-14 03:05:32,NIH,,,,,,,"Institut National de la Santé Et de la Recherche Médicale, France|Ministry of Health and Sanitation, Sierra Leone|National Institute of Allergy and Infectious Diseases (NIAID)|The Ministry of Health and Public Hygiene, Guinea|The Ministry of Health and Social Welfare, Liberia",Guinea|Liberia|Sierra Leone|United States,"Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02367885,,2015-02-13,2016-03-08,,2016-03-08,2015-02-13,2015-02-20,ESTIMATED,2016-03-08,2016-04-07,ESTIMATED,,,,2016-03-08,2016-04-07,ESTIMATED,2015-02,,2015-02-28,2016-03,2016-03-31,2015-05,ACTUAL,2015-05-31,2015-05,ACTUAL,2015-05-31,,INTERVENTIONAL,,Safety analysis set included all participants who received at least 1 dose of study vaccination.,Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants,"An Open-label, Multi-center, Phase 1/2 Study to Evaluate the Safety and Immunogenicity of an Intramuscular Injection of TAK-850 in Healthy Pediatric Subjects",COMPLETED,,PHASE1/PHASE2,99,ACTUAL,Takeda,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 21:05:16,2024-10-14 21:05:16,INDUSTRY,,,,,,,Takeda,Japan,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02378480,,2015-02-19,2019-01-09,,2019-03-20,2015-02-26,2015-03-04,ESTIMATED,2019-03-20,2019-03-21,ACTUAL,,,,2019-03-20,2019-03-21,ACTUAL,2015-06,,2015-06-30,2019-03,2019-03-31,2016-05,ACTUAL,2016-05-31,2016-04,ACTUAL,2016-04-30,,INTERVENTIONAL,,Safety Population: all randomized participants who received test article,Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23),"A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",COMPLETED,,PHASE3,655,ACTUAL,Paratek Pharmaceuticals Inc,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:03:40,2024-10-14 22:03:40,INDUSTRY,,,,,,,Paratek Pharmaceuticals Inc,Bulgaria|Croatia|Greece|Hungary|Israel|Latvia|Peru|Poland|Romania|South Africa|Spain|Turkey|Ukraine|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02378480,,2015-02-19,2019-01-09,,2019-03-20,2015-02-26,2015-03-04,ESTIMATED,2019-03-20,2019-03-21,ACTUAL,,,,2019-03-20,2019-03-21,ACTUAL,2015-06,,2015-06-30,2019-03,2019-03-31,2016-05,ACTUAL,2016-05-31,2016-04,ACTUAL,2016-04-30,,INTERVENTIONAL,,Safety Population: all randomized participants who received test article,Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23),"A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",COMPLETED,,PHASE3,655,ACTUAL,Paratek Pharmaceuticals Inc,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 22:03:40,2024-10-14 22:03:40,INDUSTRY,,,,,,,Paratek Pharmaceuticals Inc,Bulgaria|Croatia|Greece|Hungary|Israel|Latvia|Peru|Poland|Romania|South Africa|Spain|Turkey|Ukraine|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02378935,,2015-02-27,2017-08-16,2016-05-23,2020-02-18,2015-02-27,2015-03-04,ESTIMATED,2017-11-06,2017-12-08,ACTUAL,2016-05-23,2016-06-06,ESTIMATED,2020-02-18,2020-03-06,ACTUAL,2015-02-17,ACTUAL,2015-02-17,2017-11,2017-11-30,2016-04-12,ACTUAL,2016-04-12,2016-02-01,ACTUAL,2016-02-01,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug,Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection,"A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection",COMPLETED,,PHASE2,205,ACTUAL,Gilead Sciences,,10,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-14 09:22:22,2024-10-14 09:22:22,INDUSTRY,,,,,,,Gilead Sciences,New Zealand|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02378961,,2015-02-27,2017-08-16,2016-05-23,2020-02-18,2015-02-27,2015-03-04,ESTIMATED,2017-08-16,2017-09-15,ACTUAL,2016-05-23,2016-06-06,ESTIMATED,2020-02-18,2020-03-03,ACTUAL,2015-02-16,ACTUAL,2015-02-16,2017-10,2017-10-31,2016-01-26,ACTUAL,2016-01-26,2015-09-21,ACTUAL,2015-09-21,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug.,Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection,"A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Non-Genotype 1 HCV Infection",COMPLETED,,PHASE2,128,ACTUAL,Gilead Sciences,,7,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 03:24:11,2024-10-13 03:24:11,INDUSTRY,,,,,,,Gilead Sciences,New Zealand|Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02384395,,2015-03-04,2021-09-28,,2021-10-22,2015-03-04,2015-03-10,ESTIMATED,2021-10-22,2021-11-22,ACTUAL,,,,2021-10-22,2021-11-22,ACTUAL,2015-09,,2015-09-30,2021-10,2021-10-31,2021-09-17,ACTUAL,2021-09-17,2020-03-06,ACTUAL,2020-03-06,,INTERVENTIONAL,PHI-05,,Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection,IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect,COMPLETED,,NA,40,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 01:11:36,2024-10-14 01:11:36,OTHER,,,,,,,"University of North Carolina, Chapel Hill|ViiV Healthcare",United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT02385708,,2015-03-05,2019-04-02,,2019-04-23,2015-03-10,2015-03-11,ESTIMATED,2019-04-02,2019-04-24,ACTUAL,,,,2019-04-23,2019-04-30,ACTUAL,2015-08,ACTUAL,2015-08-31,2019-04,2019-04-30,2018-06-21,ACTUAL,2018-06-21,2018-06-21,ACTUAL,2018-06-21,,INTERVENTIONAL,,,Use of 2% Chlorhexidine Cloths Reduce Surgical Site Infections,A Randomized Controlled Trial of 2% Chlorhexidine Gluconate Skin Preparation Cloths for the Prevention of Post-Operative Surgical Site Infections in Colorectal Patients,COMPLETED,,NA,163,ACTUAL,Vanderbilt University Medical Center,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 09:46:07,2024-10-14 09:46:07,OTHER,,,,,,,Vanderbilt University,United States,Cardiac disorders|Gastrointestinal disorders|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT02387983,,2015-03-09,2017-04-20,,2018-09-10,2015-03-09,2015-03-13,ESTIMATED,2017-04-20,2017-07-14,ACTUAL,,,,2018-09-10,2018-10-09,ACTUAL,2015-05-06,ACTUAL,2015-05-06,2018-09,2018-09-30,2016-05-02,ACTUAL,2016-05-02,2016-05-02,ACTUAL,2016-05-02,,INTERVENTIONAL,,,Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117),"Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections",COMPLETED,,PHASE1,65,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 12:15:54,2024-10-14 12:15:54,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02396134,,2015-03-12,2023-06-20,,2024-02-14,2015-03-23,2015-03-24,ESTIMATED,2023-06-20,2023-07-12,ACTUAL,,,,2024-02-14,2024-02-20,ACTUAL,2015-05-21,ACTUAL,2015-05-21,2024-02,2024-02-29,2024-12-31,ESTIMATED,2024-12-31,2018-03-04,ACTUAL,2018-03-04,,INTERVENTIONAL,,,Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant,"A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant",ACTIVE_NOT_RECRUITING,,PHASE2,61,ACTUAL,City of Hope Medical Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:13:23,2024-10-13 20:13:23,OTHER,,,,,,,City of Hope Medical Center|National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02397096,,2015-03-18,2019-02-04,,2024-08-22,2015-03-18,2015-03-24,ESTIMATED,2019-03-13,2019-04-03,ACTUAL,,,,2024-08-22,2024-09-19,ACTUAL,2015-06-09,ACTUAL,2015-06-09,2024-08,2024-08-31,2023-09-05,ACTUAL,2023-09-05,2018-02-22,ACTUAL,2018-02-22,,INTERVENTIONAL,DRIVE-SHIFT,,"Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)","A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)",COMPLETED,,PHASE3,673,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 04:00:26,2024-10-15 04:00:26,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Argentina|Australia|Austria|Belgium|Canada|Colombia|Denmark|France|Germany|Guatemala|Israel|Italy|Korea, Republic of|Mexico|New Zealand|Peru|Poland|Puerto Rico|Russian Federation|Spain|Switzerland|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02397694,,2015-03-20,2018-02-27,2016-08-22,2020-03-25,2015-03-20,2015-03-25,ESTIMATED,2018-02-27,2018-03-27,ACTUAL,2016-08-22,2016-08-24,ESTIMATED,2020-03-25,2020-04-07,ACTUAL,2015-03-23,ACTUAL,2015-03-23,2020-03,2020-03-31,2019-02-27,ACTUAL,2019-02-27,2015-11-30,ACTUAL,2015-11-30,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.,"Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE2,98,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 00:31:18,2024-10-14 00:31:18,INDUSTRY,,,,,,,Gilead Sciences,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02397707,,2015-03-20,2020-03-04,,2020-04-02,2015-03-20,2015-03-25,ESTIMATED,2020-03-04,2020-03-20,ACTUAL,,,,2020-04-02,2020-04-09,ACTUAL,2015-03-24,ACTUAL,2015-03-24,2020-04,2020-04-30,2016-03-04,ACTUAL,2016-03-04,2016-03-04,ACTUAL,2016-03-04,,INTERVENTIONAL,,Safety Analysis Set included all participants who took at least 1 dose of study drug.,Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment,"A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment",COMPLETED,,PHASE1,33,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,Gilead Sciences,Germany|New Zealand|United States,Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT02399345,,2015-03-23,2016-10-19,,2016-10-19,2015-03-23,2015-03-26,ESTIMATED,2016-10-19,2016-12-12,ESTIMATED,,,,2016-10-19,2016-12-12,ESTIMATED,2015-03,,2015-03-31,2016-10,2016-10-31,2015-11,ACTUAL,2015-11-30,2015-11,ACTUAL,2015-11-30,,INTERVENTIONAL,,,Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults,"An Open-Label, Treatment Duration-Ranging Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/ Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE3,10,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 03:39:24,2024-10-14 03:39:24,INDUSTRY,,,,,,,AbbVie,Australia|Canada|New Zealand,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT02402218,,2015-03-18,2019-07-08,,2020-04-10,2015-03-24,2015-03-30,ESTIMATED,2019-08-13,2019-09-06,ACTUAL,,,,2020-04-10,2020-04-14,ACTUAL,2015-08,ACTUAL,2015-08-31,2020-04,2020-04-30,2017-06-21,ACTUAL,2017-06-21,2017-01-04,ACTUAL,2017-01-04,,INTERVENTIONAL,CHAMPS,,CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS,CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS,COMPLETED,,NA,144,ACTUAL,Johns Hopkins University,,3,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 23:55:37,2024-10-13 23:55:37,OTHER,,,,,,,Johns Hopkins University|National Institute on Drug Abuse (NIDA)|National Institutes of Health (NIH),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Social circumstances"
NCT02402452,,2015-03-25,2020-03-04,,2020-03-04,2015-03-25,2015-03-30,ESTIMATED,2020-03-04,2020-03-20,ACTUAL,,,,2020-03-04,2020-03-20,ACTUAL,2015-05-05,ACTUAL,2015-05-05,2020-03,2020-03-31,2015-09-28,ACTUAL,2015-09-28,2015-09-28,ACTUAL,2015-09-28,,INTERVENTIONAL,,Safety Analysis Set included all participants who took at least 1 dose of study drug.,Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment,"A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Renal Function and Severe Renal Impairment",COMPLETED,,PHASE1,20,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 07:13:49,2024-10-13 07:13:49,INDUSTRY,,,,,,,Gilead Sciences,Germany|New Zealand|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02404311,,2015-03-17,2020-09-21,,2021-11-03,2015-03-26,2015-03-31,ESTIMATED,2020-09-21,2020-10-19,ACTUAL,,,,2021-11-03,2021-11-05,ACTUAL,2015-02-02,ACTUAL,2015-02-02,2020-07,2020-07-31,2018-08-07,ACTUAL,2018-08-07,2018-08-07,ACTUAL,2018-08-07,,INTERVENTIONAL,,,A Safety and Immune Response Study of 2 Experimental HIV Vaccines,"A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in HIV-uninfected Adults at Low Risk of HIV Infection",COMPLETED,,PHASE1/PHASE2,252,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 06:57:59,2024-10-13 06:57:59,NIH,,,,,,,"Bill and Melinda Gates Foundation|GlaxoSmithKline|HIV Vaccine Trials Network|Medical Research Council|National Institute of Allergy and Infectious Diseases (NIAID)|Sanofi Pasteur, a Sanofi Company",South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02411539,,2015-04-02,2017-03-17,,2021-11-04,2015-04-06,2015-04-08,ESTIMATED,2017-05-03,2017-07-31,ACTUAL,,,,2021-11-04,2021-11-05,ACTUAL,2015-08-25,ACTUAL,2015-08-25,2018-06,2018-06-30,2016-09-29,ACTUAL,2016-09-29,2016-04-15,ACTUAL,2016-04-15,,INTERVENTIONAL,,All participants enrolled,"Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)","A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults",COMPLETED,,PHASE1,40,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:24:49,2024-10-13 20:24:49,NIH,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02412436,,2015-03-17,2018-08-27,2018-03-20,2019-06-13,2015-04-06,2015-04-09,ESTIMATED,2018-08-27,2018-09-25,ACTUAL,2018-03-20,2018-03-22,ACTUAL,2019-06-13,2019-07-01,ACTUAL,2015-11-03,ACTUAL,2015-11-03,2019-06,2019-06-30,2017-06-15,ACTUAL,2017-06-15,2017-06-15,ACTUAL,2017-06-15,,INTERVENTIONAL,PRIDE-HT,All enrolled participants.,PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB,"An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-infected With Human Immunodeficiency Virus (HIV) and Tuberculosis (TB)",COMPLETED,,PHASE2,62,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,,,2024-10-14 21:05:16,2024-10-14 21:05:16,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Kenya|South Africa|Zimbabwe,Blood and lymphatic system disorders|Investigations
NCT02413593,,2015-04-07,2016-12-22,,2018-10-19,2015-04-07,2015-04-10,ESTIMATED,2016-12-22,2017-02-14,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2015-04,,2015-04-30,2016-12,2016-12-31,2016-01,ACTUAL,2016-01-31,2015-12,ACTUAL,2015-12-31,,INTERVENTIONAL,,Safety Analysis Set: all enrolled participants who received at least 1 dose of study drug.,Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection,A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection,COMPLETED,,PHASE2,111,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 15:37:58,2024-10-13 15:37:58,INDUSTRY,,,,,,,Gilead Sciences,Canada,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02414399,,2015-03-31,2021-10-18,,2023-11-30,2015-04-07,2015-04-10,ESTIMATED,2023-11-30,2023-12-04,ACTUAL,,,,2023-11-30,2023-12-04,ACTUAL,2016-06-28,ACTUAL,2016-06-28,2023-11,2023-11-30,2025-12-28,ESTIMATED,2025-12-28,2020-05-04,ACTUAL,2020-05-04,,INTERVENTIONAL,Toto Bora,,Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children,Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children,ACTIVE_NOT_RECRUITING,,PHASE4,1400,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,With publication of primary manuscript (Sep 2021),Open Access,https://doi.org/10.7910/DVN/YTMFOJ,YES,De-identified data for the primary analysis is available,2024-10-13 20:01:59,2024-10-13 20:01:59,OTHER,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Kenya Medical Research Institute|University of Washington,Kenya,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02421120,,2015-04-13,2017-02-28,,2020-07-27,2015-04-17,2015-04-20,ESTIMATED,2017-02-28,2017-04-13,ACTUAL,,,,2020-07-27,2020-08-04,ACTUAL,2015-09,,2015-09-30,2020-07,2020-07-31,2016-10,ACTUAL,2016-10-31,2016-03,ACTUAL,2016-03-31,,INTERVENTIONAL,,,Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients,"A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation",COMPLETED,,PHASE4,21,ACTUAL,Hartford Hospital,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 23:27:20,2024-10-13 23:27:20,OTHER,,,,,,,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)|Indiana University Health|Joseph L. Kuti, PharmD|St. Christopher's Hospital for Children|University of North Carolina",United States,"General disorders|Hepatobiliary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02422797,,2015-04-09,2017-07-27,,2024-08-26,2015-04-20,2015-04-21,ESTIMATED,2017-09-22,2017-10-24,ACTUAL,,,,2024-08-26,2024-09-03,ACTUAL,2015-04-21,ACTUAL,2015-04-21,2024-08,2024-08-31,2023-05-25,ACTUAL,2023-05-25,2016-09-16,ACTUAL,2016-09-16,,INTERVENTIONAL,,,Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2),"A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed",COMPLETED,,PHASE3,518,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 13:55:50,2024-10-14 13:55:50,INDUSTRY,,,,,,,GlaxoSmithKline|Janssen Pharmaceuticals|ViiV Healthcare,Argentina|Australia|Canada|France|Germany|Italy|Russian Federation|Spain|Taiwan|United Kingdom|United States,"Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02426918,,2015-04-22,2019-10-24,2017-08-21,2019-10-24,2015-04-22,2015-04-27,ESTIMATED,2019-10-24,2019-11-13,ACTUAL,2017-08-25,2017-08-28,ACTUAL,2019-10-24,2019-11-13,ACTUAL,2015-05,,2015-05-31,2019-10,2019-10-31,2016-09,ACTUAL,2016-09-30,2016-08,ACTUAL,2016-08-31,,INTERVENTIONAL,,Intent-to-Treat Population (ITT) population included all randomized participants.,Study of Debio 1450 for Bacterial Skin Infections,"A Phase 2, Randomized, Double-Blind, Multicenter Study of Safety, Tolerability, and Efficacy of Debio 1450 vs Vancomycin (IV)/Linezolid (Oral) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococcus Sensitive or Resistant to Methicillin",COMPLETED,,PHASE2,330,ACTUAL,Debiopharm International SA,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 09:57:35,2024-10-14 09:57:35,INDUSTRY,,,,,,,Debiopharm International SA,United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders"
NCT02427802,,2015-04-17,2021-05-28,,2021-08-02,2015-04-27,2015-04-28,ESTIMATED,2021-08-02,2021-08-25,ACTUAL,,,,2021-08-02,2021-08-25,ACTUAL,2015-05,,2015-05-31,2021-08,2021-08-31,2016-10,ACTUAL,2016-10-31,2016-10,ACTUAL,2016-10-31,,INTERVENTIONAL,COACT-1,,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer",COMPLETED,,PHASE3,612,ACTUAL,Innocoll,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 16:51:07,2024-10-14 16:51:07,INDUSTRY,,,,,,,Innocoll,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02429791,,2015-04-09,2017-07-27,,2024-08-26,2015-04-23,2015-04-29,ESTIMATED,2017-10-26,2017-12-02,ACTUAL,,,,2024-08-26,2024-09-03,ACTUAL,2015-04-14,ACTUAL,2015-04-14,2024-08,2024-08-31,2023-05-30,ACTUAL,2023-05-30,2016-09-16,ACTUAL,2016-09-16,,INTERVENTIONAL,,,Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1),"A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults Who Are Virologically Suppressed",COMPLETED,,PHASE3,510,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,TRUE,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-15 01:37:17,2024-10-15 01:37:17,INDUSTRY,,,,,,,GlaxoSmithKline|Janssen Pharmaceuticals|ViiV Healthcare,Argentina|Australia|Belgium|Canada|France|Germany|Italy|Netherlands|Russian Federation|Spain|Taiwan|United Kingdom|United States,"Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02430181,,2015-04-21,2022-11-03,,2022-11-03,2015-04-25,2015-04-30,ESTIMATED,2022-11-03,2022-11-29,ACTUAL,,,,2022-11-03,2022-11-29,ACTUAL,2014-11,,2014-11-30,2022-11,2022-11-30,2015-11,ACTUAL,2015-11-30,2015-09,ACTUAL,2015-09-30,,INTERVENTIONAL,LOWR-1,"Patients aged 18-65 years with documented HBsAg, anti-delta positivity for at least 6 months, and compensated liver disease were eligible after evaluation for other forms of chronic liver disease. Patients were required to have detectable HDV-RNA levels at screening, platelet counts \>/= 100,000/mm3, absolute neutrophil count \>/= 1,500 /mm3, and international normalized ratio \<1.5. Patients with hepatocellular carcinoma were excluded.",Lonafarnib With and Without Ritonavir in HDV (LOWR-1),"An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)",COMPLETED,,PHASE2,21,ACTUAL,Eiger BioPharmaceuticals,,7,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-13 11:41:43,2024-10-13 11:41:43,INDUSTRY,,,,,,,Eiger BioPharmaceuticals,Turkey,Gastrointestinal disorders|General disorders|Investigations
NCT02430194,,2015-04-21,2023-01-24,,2023-03-01,2015-04-25,2015-04-30,ESTIMATED,2023-01-24,2023-02-21,ACTUAL,,,,2023-03-01,2023-03-03,ACTUAL,2014-12,ACTUAL,2014-12-31,2023-03,2023-03-31,2017-06-15,ACTUAL,2017-06-15,2017-04-18,ACTUAL,2017-04-18,,INTERVENTIONAL,LOWR-2,"18-year-old to 65-year-old patients with chronic HDV infection, documented by a positive anti-HDV test of at least 6 month duration and detectable HDV RNA by PCR within 3 months to study entry, were included. All patients were required to be HDV RNA-positive at baseline and have compensated liver disease. Platelet and white blood cell counts had to be ≥100,000 (×10\^9/L) and 3000 (×10\^9/L), respectively.",Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2),"An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting +/- Peginterferon Alfa-2a in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)",COMPLETED,,PHASE2,55,ACTUAL,Eiger BioPharmaceuticals,,10,,,TRUE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,NCT03895528,APPROVED_FOR_MARKETING,,,,Ankara University|Eiger BioPharmaceuticals,Turkey,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Investigations|Nervous system disorders
NCT02436876,,2015-04-28,2021-08-02,,2021-09-29,2015-05-06,2015-05-07,ESTIMATED,2021-09-29,2021-09-30,ACTUAL,,,,2021-09-29,2021-09-30,ACTUAL,2016-05-24,ACTUAL,2016-05-24,2021-09,2021-09-30,2018-07-26,ACTUAL,2018-07-26,2017-10-27,ACTUAL,2017-10-27,,INTERVENTIONAL,,,Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites,"Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites",COMPLETED,,PHASE2,29,ACTUAL,Microbion Corporation,,3,,,FALSE,,,,TRUE,TRUE,,,,,,,,,,,,2024-10-13 20:47:42,2024-10-13 20:47:42,INDUSTRY,,,,,,,"Congressionally Directed Medical Research Programs|Medpace, Inc.|Microbion Corporation|University of California, San Francisco|University of Pennsylvania",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Product Issues|Renal and urinary disorders"
NCT02440789,,2015-04-06,2019-12-12,2018-09-10,2021-07-30,2015-05-08,2015-05-12,ESTIMATED,2019-12-12,2019-12-30,ACTUAL,2018-09-10,2018-09-18,ACTUAL,2021-07-30,2021-08-03,ACTUAL,2015-12-21,ACTUAL,2015-12-21,2019-12,2019-12-31,2018-02-01,ACTUAL,2018-02-01,2017-11-02,ACTUAL,2017-11-02,,INTERVENTIONAL,,Participants who initiated Sirolimus,Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART),Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy,COMPLETED,,PHASE1/PHASE2,32,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 01:15:10,2024-10-15 01:15:10,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02442271,,2015-05-11,2017-06-29,,2017-07-05,2015-05-11,2015-05-13,ESTIMATED,2017-07-05,2017-08-01,ACTUAL,,,,2017-07-05,2017-08-01,ACTUAL,2015-04-27,ACTUAL,2015-04-27,2017-07,2017-07-31,2016-09-26,ACTUAL,2016-09-26,2016-07-04,ACTUAL,2016-07-04,,INTERVENTIONAL,,,"A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil","An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve or Treatment-Experienced Adults in Brazil With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ III)",COMPLETED,,PHASE3,222,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 11:39:25,2024-10-14 11:39:25,INDUSTRY,,,,,,,AbbVie,Brazil,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02445859,,2015-05-13,2019-06-03,,2019-10-08,2015-05-14,2015-05-15,ESTIMATED,2019-08-07,2019-09-12,ACTUAL,,,,2019-10-08,2019-10-10,ACTUAL,2015-08,ACTUAL,2015-08-31,2019-10,2019-10-31,2017-05,ACTUAL,2017-05-31,2017-05,ACTUAL,2017-05-31,,INTERVENTIONAL,Colo-Pro,The analysis population was on an intention to treat basis,Continuous Antibiotic Prophylaxis in Colorectal Surgery,Colo-Pro Pilot: A Pilot Study to Compare Standard Single Dose Antibiotic Prophylaxis to Bolus-continuous Infusion Dosed Antibiotic Prophylaxis for the Prevention of Infections After Colorectal Surgery,COMPLETED,,PHASE2,90,ACTUAL,University of Leeds,"These patients are expected to have multiple adverse events. We only formally collected all serious adverse events, plus specific events e.g. C.difficile. As a pilot trial we have learned about the collection of adverse events in this patient group.",2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 17:21:42,2024-10-14 17:21:42,OTHER,,,,,,,University of Leeds,United Kingdom,Gastrointestinal disorders
NCT02446691,,2015-05-13,2018-12-20,,2019-06-13,2015-05-15,2015-05-18,ESTIMATED,2018-12-20,2019-04-01,ACTUAL,,,,2019-06-13,2019-06-27,ACTUAL,2015-07-13,ACTUAL,2015-07-13,2019-06,2019-06-30,2017-12-28,ACTUAL,2017-12-28,2017-12-28,ACTUAL,2017-12-28,,INTERVENTIONAL,,,Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations,"A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea",COMPLETED,,PHASE4,128,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-14 18:35:34,2024-10-14 18:35:34,INDUSTRY,,,,,,,GlaxoSmithKline,"Korea, Republic of","Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02446743,,2015-05-06,2017-09-19,,2018-10-08,2015-05-13,2015-05-18,ESTIMATED,2017-11-14,2017-12-13,ACTUAL,,,,2018-10-08,2018-11-08,ACTUAL,2015-11-17,ACTUAL,2015-11-17,2018-04,2018-04-30,2016-09-23,ACTUAL,2016-09-23,2016-09-23,ACTUAL,2016-09-23,,INTERVENTIONAL,,,Combined Study - Phase 3b MenB Long Term Persistence in Adolescents,"A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects Who Previously Participated in Parent Studies V72_41 (NCT01423084) and V72P10 (NCT00661713), Compared to Naïve Healthy Controls",COMPLETED,,PHASE3,531,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-13 01:57:29,2024-10-13 01:57:29,INDUSTRY,,,,,,,GlaxoSmithKline,Australia|Canada|Chile,Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT02446847,,2015-03-17,2020-06-03,2018-04-13,2020-07-08,2015-05-13,2015-05-18,ESTIMATED,2020-07-08,2020-07-23,ACTUAL,2018-04-19,2018-04-24,ACTUAL,2020-07-08,2020-07-23,ACTUAL,2015-03-11,ACTUAL,2015-03-11,2020-07,2020-07-31,2017-03-25,ACTUAL,2017-03-25,2017-03-25,ACTUAL,2017-03-25,,INTERVENTIONAL,,,3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption,"A Phase 2, Open Label Study of the Safety, Antiretroviral Activity and Pharmacokinetics of 3BNC117 During a Short Analytical Treatment Interruption in HIV-infected Subjects",COMPLETED,,PHASE2,16,ACTUAL,Rockefeller University,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 17:52:48,2024-10-14 17:52:48,OTHER,,,,,,,Rockefeller University,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02447172,,2015-05-14,2021-06-01,,2021-09-02,2015-05-15,2015-05-18,ESTIMATED,2021-08-04,2021-08-27,ACTUAL,,,,2021-09-02,2021-09-29,ACTUAL,2015-06,,2015-06-30,2021-09,2021-09-30,2016-09,ACTUAL,2016-09-30,2016-09,ACTUAL,2016-09-30,,INTERVENTIONAL,COACT-2,,Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers,"A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer",COMPLETED,,PHASE3,524,ACTUAL,Innocoll,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 18:13:13,2024-10-13 18:13:13,INDUSTRY,,,,,,,Innocoll,Australia|Austria|Belgium|Czechia|Czech Republic|Denmark|Germany|Hungary|Ireland|Italy|Netherlands|Poland|Slovakia|Spain|Sweden|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02447432,,2015-05-07,2017-01-23,,2018-06-14,2015-05-14,2015-05-18,ESTIMATED,2017-01-23,2017-03-16,ACTUAL,,,,2018-06-14,2018-08-02,ACTUAL,2015-06-11,,2015-06-11,2018-06,2018-06-30,2016-05-22,ACTUAL,2016-05-22,2016-01-23,ACTUAL,2016-01-23,,INTERVENTIONAL,,,A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants,Study to Compare Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants,COMPLETED,,PHASE3,320,ACTUAL,GlaxoSmithKline,None reported.,2,,,FALSE,,,,TRUE,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 16:01:13,2024-10-13 16:01:13,INDUSTRY,,,,,,,GlaxoSmithKline,Bangladesh,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders"
NCT02451514,,2015-05-04,2017-05-24,2016-11-18,2020-06-24,2015-05-21,2015-05-22,ESTIMATED,2020-06-24,2020-07-09,ACTUAL,2016-11-18,2016-12-19,ESTIMATED,2020-06-24,2020-07-09,ACTUAL,2015-06-30,ACTUAL,2015-06-30,2020-06,2020-06-30,2015-12-10,ACTUAL,2015-12-10,2015-11-14,ACTUAL,2015-11-14,,INTERVENTIONAL,,,A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158),"A Phase 2, Open-label, Controlled, Multi-center Extension Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)",COMPLETED,,PHASE2,129,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-15 02:12:28,2024-10-15 02:12:28,INDUSTRY,,,,,,,GlaxoSmithKline,Chile|Colombia|Panama,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT02452047,,2015-05-20,2018-07-24,,2018-10-18,2015-05-20,2015-05-22,ESTIMATED,2018-10-18,2018-10-19,ACTUAL,,,,2018-10-18,2018-10-19,ACTUAL,2015-08-21,ACTUAL,2015-08-21,2018-10,2018-10-31,2017-09-18,ACTUAL,2017-09-18,2017-09-18,ACTUAL,2017-09-18,,INTERVENTIONAL,RESTORE-IMI 1,,Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013),"A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects With Imipenem-Resistant Bacterial Infection",COMPLETED,,PHASE3,50,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 19:05:55,2024-10-14 19:05:55,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Brazil|Colombia|Estonia|Germany|Greece|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Mexico|Peru|Romania|South Africa|Turkey|Ukraine|United States","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02452918,,2015-05-13,2023-11-08,,2023-12-18,2015-05-20,2015-05-25,ESTIMATED,2023-12-18,2023-12-20,ACTUAL,,,,2023-12-18,2023-12-20,ACTUAL,2015-09-29,ACTUAL,2015-09-29,2023-12,2023-12-31,2016-07-05,ACTUAL,2016-07-05,2016-07-05,ACTUAL,2016-07-05,,INTERVENTIONAL,,Intent-to-treat population included all participants who were screened and enrolled,A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI),An Open-Label Study to Evaluate the Safety of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) in Subjects on Concomitant Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI),COMPLETED,,PHASE4,17,ACTUAL,The Medicines Company,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 12:58:07,2024-10-13 12:58:07,INDUSTRY,,,,,,,The Medicines Company,United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications"
NCT02457611,,2015-05-27,2017-01-06,,2018-10-19,2015-05-27,2015-05-29,ESTIMATED,2017-01-06,2017-02-28,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2015-06,,2015-06-30,2017-01,2017-01-31,2016-01,ACTUAL,2016-01-31,2016-01,ACTUAL,2016-01-31,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug,Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection,Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection,COMPLETED,,PHASE2,26,ACTUAL,Gilead Sciences,There were no limitations affecting the analysis or results.,1,,,FALSE,,,,FALSE,,,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 10:58:04,2024-10-14 10:58:04,INDUSTRY,,,,,,,Gilead Sciences,Germany|United Kingdom,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02459262,,2015-05-22,2020-11-30,,2021-01-12,2015-05-28,2015-06-02,ESTIMATED,2021-01-12,2021-01-14,ACTUAL,,,,2021-01-12,2021-01-14,ACTUAL,2015-05,,2015-05-31,2020-11,2020-11-30,2017-04-21,ACTUAL,2017-04-21,2017-04-12,ACTUAL,2017-04-12,,INTERVENTIONAL,MVX13211,,Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.,"A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.",COMPLETED,,PHASE1,240,ACTUAL,Minervax ApS,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 09:03:39,2024-10-13 09:03:39,OTHER,,,,,,,Minervax ApS,United Kingdom,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02461563,,2015-06-01,2018-04-13,,2018-04-13,2015-06-01,2015-06-03,ESTIMATED,2018-04-13,2018-11-13,ACTUAL,,,,2018-04-13,2018-11-13,ACTUAL,2015-06-23,ACTUAL,2015-06-23,2018-04,2018-04-30,2015-12-23,ACTUAL,2015-12-23,2015-12-23,ACTUAL,2015-12-23,,INTERVENTIONAL,,,A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004),"A Multiple-Dose Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of MK-1075 in GT3 and GT1 HCV Infected Patients",COMPLETED,,PHASE1,12,ACTUAL,Merck Sharp & Dohme LLC,,6,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:28:33,2024-10-13 05:28:33,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Belgium|Moldova, Republic of","Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02463227,,2015-05-29,2017-03-09,,2021-10-15,2015-06-02,2015-06-04,ESTIMATED,2017-03-09,2017-04-20,ACTUAL,,,,2021-10-15,2021-10-19,ACTUAL,2015-08,ACTUAL,2015-08-31,2017-03,2017-03-31,2016-10,ACTUAL,2016-10-31,2016-03,ACTUAL,2016-03-31,,INTERVENTIONAL,,All participants enrolled.,"Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption","A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption",COMPLETED,,PHASE1,14,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 02:27:29,2024-10-14 02:27:29,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"General disorders|Infections and infestations|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02469246,,2015-06-09,2018-03-29,,2019-10-14,2015-06-09,2015-06-11,ESTIMATED,2018-05-11,2018-06-11,ACTUAL,,,,2019-10-14,2019-10-25,ACTUAL,2015-06-29,ACTUAL,2015-06-29,2019-10,2019-10-31,2019-03-13,ACTUAL,2019-03-13,2017-12-11,ACTUAL,2017-12-11,,INTERVENTIONAL,,The Safety Analysis Set included all randomized participants who received at least one dose of study drug. Participants were grouped according to the treatment they actually received.,Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC,"A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC",COMPLETED,,PHASE3,567,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 22:53:54,2024-10-13 22:53:54,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Canada|Denmark|France|Germany|Ireland|Italy|Puerto Rico|Spain|Sweden|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT02469857,,2015-06-06,2021-09-03,2021-01-25,2021-10-02,2015-06-11,2015-06-12,ESTIMATED,2021-10-02,2021-10-05,ACTUAL,2021-01-25,2021-01-27,ACTUAL,2021-10-02,2021-10-05,ACTUAL,2015-12-01,ACTUAL,2015-12-01,2021-10,2021-10-31,2019-10-18,ACTUAL,2019-10-18,2019-08-18,ACTUAL,2019-08-18,,INTERVENTIONAL,ACCUTE,"This analysis population (As Treated/Safety Analysis Set) included all randomized patients who were exposed to study drug (reltecimod or placebo), with patients analyzed according to the treatment actually received.",Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections,"Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)",COMPLETED,,PHASE3,290,ACTUAL,Atox Bio Ltd,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 19:41:41,2024-10-14 19:41:41,INDUSTRY,,,,,,,Atox Bio Ltd|Biomedical Advanced Research and Development Authority,France|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02471430,,2015-06-11,2024-01-05,,2024-02-01,2015-06-11,2015-06-15,ESTIMATED,2024-02-01,2024-02-28,ACTUAL,,,,2024-02-01,2024-02-28,ACTUAL,2016-05,ACTUAL,2016-05-31,2024-02,2024-02-29,2023-12,ACTUAL,2023-12-31,2022-08,ACTUAL,2022-08-31,,INTERVENTIONAL,ACTIVATE,,Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy,A Phase I-II Pilot Study to Assess the Safety and Efficacy of Combined Administration With Pegylated Interferon-alpha2a and the Histone Deacetylase Inhibitor (HDACi) Panobinostat for Reducing the Residual Reservoir of HIV-1 Infected Cells in cART-Treated HIV-1 Positive Individuals,COMPLETED,,PHASE1/PHASE2,17,ACTUAL,Massachusetts General Hospital,,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 05:01:09,2024-10-13 05:01:09,OTHER,,,,,,,"Genentech, Inc.|Massachusetts General Hospital|Novartis",United States,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT02472886,,2015-06-12,2017-03-30,,2018-10-19,2015-06-12,2015-06-16,ESTIMATED,2017-03-30,2017-05-10,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2015-06-17,ACTUAL,2015-06-17,2017-03,2017-03-31,2016-06-30,ACTUAL,2016-06-30,2016-03-30,ACTUAL,2016-03-30,,INTERVENTIONAL,,Safety Analysis Set included all participants who received at least 1 dose of study drug.,Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection,"A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection",COMPLETED,,PHASE3,153,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 18:17:09,2024-10-14 18:17:09,INDUSTRY,,,,,,,Gilead Sciences,Estonia|Russian Federation,Gastrointestinal disorders|General disorders|Investigations|Nervous system disorders|Psychiatric disorders
NCT02473367,,2015-06-12,2016-07-19,,2018-07-27,2015-06-12,2015-06-16,ESTIMATED,2016-07-19,2016-09-01,ESTIMATED,,,,2018-07-27,2018-08-27,ACTUAL,2015-06-23,ACTUAL,2015-06-23,2018-07,2018-07-31,2015-10-09,ACTUAL,2015-10-09,2015-08-29,ACTUAL,2015-08-29,,INTERVENTIONAL,,,The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824),A Study to Evaluate the Influence of Metal Cation-Containing Antacids on MK-0518 Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen,COMPLETED,,PHASE1,20,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-15 02:12:28,2024-10-15 02:12:28,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02475655,,2015-06-16,2019-02-14,,2021-11-02,2015-06-16,2015-06-19,ESTIMATED,2019-03-28,2019-04-18,ACTUAL,,,,2021-11-02,2021-11-04,ACTUAL,2016-05-16,ACTUAL,2016-05-16,2020-07,2020-07-31,2018-04-04,ACTUAL,2018-04-04,2018-02-18,ACTUAL,2018-02-18,,INTERVENTIONAL,,All enrolled participants.,Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults,"A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults",COMPLETED,,PHASE2,60,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 21:16:59,2024-10-13 21:16:59,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02475733,,2015-05-25,2018-07-12,,2018-07-12,2015-06-16,2015-06-19,ESTIMATED,2018-07-12,2018-08-09,ACTUAL,,,,2018-07-12,2018-08-09,ACTUAL,2015-08-01,ACTUAL,2015-08-01,2018-07,2018-07-31,2017-06-01,ACTUAL,2017-06-01,2017-06-01,ACTUAL,2017-06-01,,INTERVENTIONAL,,Intent-to-treat (ITT) analysis set included all participants who had been assigned a randomized treatment.,"Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).","A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam When Given In Combination With Metronidazole, Compared With Meropenem, In Children From 3 Months To Less Than 18 Years Of Age With Complicated Intra-abdominal Infections (cIAIs)",COMPLETED,,PHASE2,83,ACTUAL,Pfizer,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-13 15:19:47,2024-10-13 15:19:47,INDUSTRY,,,,,,,Pfizer,Argentina|Chile|Czechia|Czech Republic|Greece|Hungary|Poland|Romania|Russian Federation|Spain|Taiwan|Turkey|United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02478463,,2015-06-18,2020-06-02,,2020-06-02,2015-06-18,2015-06-23,ESTIMATED,2020-06-02,2020-06-22,ACTUAL,,,,2020-06-02,2020-06-22,ACTUAL,2017-02-27,ACTUAL,2017-02-27,2020-06,2020-06-30,2019-07-25,ACTUAL,2019-07-25,2019-07-25,ACTUAL,2019-07-25,,INTERVENTIONAL,,,Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers,"A Phase 1, Multicompartmental Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers",COMPLETED,,PHASE1,19,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-15 02:36:26,2024-10-15 02:36:26,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02478463,,2015-06-18,2020-06-02,,2020-06-02,2015-06-18,2015-06-23,ESTIMATED,2020-06-02,2020-06-22,ACTUAL,,,,2020-06-02,2020-06-22,ACTUAL,2017-02-27,ACTUAL,2017-02-27,2020-06,2020-06-30,2019-07-25,ACTUAL,2019-07-25,2019-07-25,ACTUAL,2019-07-25,,INTERVENTIONAL,,,Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers,"A Phase 1, Multicompartmental Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers",COMPLETED,,PHASE1,19,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-15 02:36:26,2024-10-15 02:36:26,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02480712,,2015-06-22,2017-04-26,,2018-10-19,2015-06-22,2015-06-24,ESTIMATED,2017-04-26,2017-06-01,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2015-07-01,ACTUAL,2015-07-01,2017-04,2017-04-30,2016-06-22,ACTUAL,2016-06-22,2016-04-29,ACTUAL,2016-04-29,,INTERVENTIONAL,ASTRAL-5,Safety Analysis Set: Participants who received at least one dose of study drug.,Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection,"A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection",COMPLETED,,PHASE3,107,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 02:02:46,2024-10-13 02:02:46,INDUSTRY,,,,,,,Gilead Sciences,United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02481375,,2015-06-10,2018-03-14,,2019-04-30,2015-06-24,2015-06-25,ESTIMATED,2018-03-14,2018-10-24,ACTUAL,,,,2019-04-30,2019-05-14,ACTUAL,2015-07,,2015-07-31,2019-04,2019-04-30,2016-01,ACTUAL,2016-01-31,2016-01,ACTUAL,2016-01-31,,INTERVENTIONAL,,,Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?,Is Iron Deficiency the Cause of Anemia Among Women of Reproductive Age in Cambodia? A 2 x 2 Factorial Double Blind Randomized Controlled Trial of Oral Iron and Multiple Micronutrient Supplementation,COMPLETED,,NA,809,ACTUAL,University of British Columbia,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 09:59:01,2024-10-13 09:59:01,OTHER,,,,,,,"Canadian Institutes of Health Research (CIHR)|DSM Nutritional Products, Inc.|Helen Keller International|International Development Research Centre, Canada|Micronutrient Initiative|University of British Columbia",Cambodia,Gastrointestinal disorders
NCT02486406,,2015-06-17,2021-09-07,,2021-09-07,2015-06-29,2015-07-01,ESTIMATED,2021-09-07,2021-10-05,ACTUAL,,,,2021-09-07,2021-10-05,ACTUAL,2015-10-28,ACTUAL,2015-10-28,2021-09,2021-09-30,2020-11-19,ACTUAL,2020-11-19,2020-11-19,ACTUAL,2020-11-19,,INTERVENTIONAL,ZIRCON,Intention-to-treat population: all participants who received at least one dose of study drug in Part 1 or Part 2,A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects,"An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)",COMPLETED,,PHASE2/PHASE3,64,ACTUAL,AbbVie,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.",https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html,YES,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2024-10-13 07:37:46,2024-10-13 07:37:46,INDUSTRY,,,,,,,AbbVie,Belgium|Canada|Germany|Puerto Rico|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02486627,,2015-06-25,2018-07-24,,2018-07-24,2015-06-29,2015-07-01,ESTIMATED,2018-07-24,2018-08-23,ACTUAL,,,,2018-07-24,2018-08-23,ACTUAL,2016-01-11,ACTUAL,2016-01-11,2018-07,2018-07-31,2016-09-22,ACTUAL,2016-09-22,2016-09-22,ACTUAL,2016-09-22,,INTERVENTIONAL,EPIC,The intent-to-treat (ITT) population includes all randomized patients.,A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP),"A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults",COMPLETED,,PHASE3,609,ACTUAL,"Achaogen, Inc.",,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 02:08:09,2024-10-13 02:08:09,INDUSTRY,,,,,,,"Achaogen, Inc.",Bulgaria|Estonia|Georgia|Hungary|Latvia|Poland|Romania|Russian Federation|Serbia|Ukraine|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Renal and urinary disorders"
NCT02486653,,2015-06-25,2019-04-04,,2019-09-20,2015-06-26,2015-07-01,ESTIMATED,2019-04-04,2019-04-23,ACTUAL,,,,2019-09-20,2019-09-25,ACTUAL,2015-08,ACTUAL,2015-08-31,2019-09,2019-09-30,2018-05-02,ACTUAL,2018-05-02,2018-04-01,ACTUAL,2018-04-01,,INTERVENTIONAL,POUR,"76 subjects randomized to Tamsulosin; 4 surgery cancelled, 1 withdrew prior to starting study drug, 1 had intraoperative urethral injury precluding ability to collect outcome data, therefore analysis population was 70 subjects. 75 randomized to Placebo; 3 withdrew prior to starting study drug, 1 surgery cancelled, therefore analysis pop. was 71",Prevention of Post-operative Urinary Retention,"Pre-operative Tamsulosin for the Prevention of Post-operative Urinary Retention: a Randomized, Double-blind, Placebo-controlled Trial",COMPLETED,,PHASE3,158,ACTUAL,"University of Wisconsin, Madison",,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 19:56:46,2024-10-13 19:56:46,OTHER,,,,,,,"University of Wisconsin, Madison",United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02487030,,2015-06-27,2017-11-09,,2018-10-19,2015-06-27,2015-07-01,ESTIMATED,2017-11-09,2017-12-14,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2015-09-07,ACTUAL,2015-09-07,2017-11,2017-11-30,2017-02-04,ACTUAL,2017-02-04,2016-11-11,ACTUAL,2016-11-11,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized or enrolled and received at least 1 dose of study drug,"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection","A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection",COMPLETED,,PHASE3,255,ACTUAL,Gilead Sciences,,7,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-15 01:42:45,2024-10-15 01:42:45,INDUSTRY,,,,,,,Gilead Sciences,Egypt,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Vascular disorders"
NCT02491463,,2015-06-29,2017-04-05,,2018-06-11,2015-07-02,2015-07-08,ESTIMATED,2018-06-11,2018-08-20,ACTUAL,,,,2018-06-11,2018-08-20,ACTUAL,2015-07-23,ACTUAL,2015-07-23,2018-05,2018-05-31,2017-01-26,ACTUAL,2017-01-26,2016-04-08,ACTUAL,2016-04-08,,INTERVENTIONAL,,,"A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults","A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Healthy Adults",COMPLETED,,PHASE1,73,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 03:58:09,2024-10-14 03:58:09,INDUSTRY,,,,,,,GlaxoSmithKline,United Kingdom,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02492958,,2015-05-29,2017-08-15,,2018-07-27,2015-07-06,2015-07-09,ESTIMATED,2018-07-27,2018-07-30,ACTUAL,,,,2018-07-27,2018-07-30,ACTUAL,2015-06,ACTUAL,2015-06-30,2018-07,2018-07-31,2016-09,ACTUAL,2016-09-30,2016-09,ACTUAL,2016-09-30,,INTERVENTIONAL,,Safety population included all participants who received at least 1 dose of investigational product and had safety data available after vaccination.,"SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults","A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults",COMPLETED,,PHASE2,136,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 07:38:23,2024-10-14 07:38:23,INDUSTRY,,,,,,,Pfizer,Japan,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT02497781,,2015-06-16,2018-03-12,,2018-06-13,2015-07-10,2015-07-15,ESTIMATED,2018-03-12,2018-04-10,ACTUAL,,,,2018-06-13,2018-07-11,ACTUAL,2015-09-24,ACTUAL,2015-09-24,2018-06,2018-06-30,2017-09-15,ACTUAL,2017-09-15,2017-09-15,ACTUAL,2017-09-15,,INTERVENTIONAL,,Safety analysis set included all randomized participants who received any amount of IV study medication.,"Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)","A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With Complicated Urinary Tract Infections (Cutis)",COMPLETED,,PHASE2,97,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 07:15:50,2024-10-14 07:15:50,INDUSTRY,,,,,,,Pfizer|PRA Health Sciences,"Czechia|Czech Republic|Greece|Hungary|Korea, Republic of|Poland|Romania|Russian Federation|Taiwan|Turkey|United States",Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT02503202,,2015-07-17,2018-09-07,,2018-10-09,2015-07-17,2015-07-20,ESTIMATED,2018-10-09,2018-10-12,ACTUAL,,,,2018-10-09,2018-10-12,ACTUAL,2015-08-17,ACTUAL,2015-08-17,2018-10,2018-10-31,2017-09-29,ACTUAL,2017-09-29,2016-05-02,ACTUAL,2016-05-02,,INTERVENTIONAL,,All randomized participants,Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012),"A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults",COMPLETED,,PHASE3,1197,ACTUAL,Merck Sharp & Dohme LLC,,5,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-13 12:20:10,2024-10-13 12:20:10,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Canada|Spain|United States,"Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02503982,,2015-07-14,2016-05-23,,2017-03-05,2015-07-20,2015-07-21,ESTIMATED,2016-05-23,2016-06-30,ESTIMATED,,,,2017-03-05,2017-04-04,ACTUAL,2014-12,,2014-12-31,2016-04,2016-04-30,2015-08,ACTUAL,2015-08-31,2015-08,ACTUAL,2015-08-31,,INTERVENTIONAL,,,Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients,Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients - a Prospective Study,COMPLETED,,PHASE4,13,ACTUAL,Rabin Medical Center,,1,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 16:01:13,2024-10-13 16:01:13,OTHER,,,,,,,Rabin Medical Center,Israel,Blood and lymphatic system disorders
NCT02506933,,2015-07-21,2023-03-21,,2024-03-13,2015-07-21,2015-07-23,ESTIMATED,2023-03-21,2023-04-14,ACTUAL,,,,2024-03-13,2024-03-15,ACTUAL,2015-11-05,ACTUAL,2015-11-05,2024-03,2024-03-31,2024-12-30,ESTIMATED,2024-12-30,2018-01-25,ACTUAL,2018-01-25,,INTERVENTIONAL,,,Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant,"A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant",ACTIVE_NOT_RECRUITING,,PHASE2,102,ACTUAL,City of Hope Medical Center,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 08:29:25,2024-10-14 08:29:25,OTHER,,,,,,,City of Hope Medical Center|Diavax Biosciences|National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02509260,,2015-07-24,2022-10-20,,2022-10-20,2015-07-24,2015-07-27,ESTIMATED,2022-10-20,2022-11-14,ACTUAL,,,,2022-10-20,2022-11-14,ACTUAL,2015-07,,2015-07-31,2022-10,2022-10-31,2021-02-19,ACTUAL,2021-02-19,2021-02-19,ACTUAL,2021-02-19,,INTERVENTIONAL,,,Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery,A Randomized Controlled Trial of Prevena™ Incisional Negative Pressure Wound Therapy to Reduce Surgical Site Infection in Re-operative Colorectal Surgery,COMPLETED,,NA,298,ACTUAL,The Cleveland Clinic,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 10:03:49,2024-10-14 10:03:49,OTHER,,,,,,,The Cleveland Clinic,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02513771,,2015-07-13,2017-11-06,,2018-05-18,2015-07-30,2015-08-03,ESTIMATED,2017-12-05,2018-01-05,ACTUAL,,,,2018-05-18,2018-06-18,ACTUAL,2015-09,,2015-09-30,2018-05,2018-05-31,2017-01-10,ACTUAL,2017-01-10,2016-12-13,ACTUAL,2016-12-13,,INTERVENTIONAL,,,Sitagliptin for Reducing Inflammation and Immune Activation,"A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)",COMPLETED,,PHASE2,90,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 01:06:01,2024-10-14 01:06:01,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Respiratory, thoracic and mediastinal disorders"
NCT02519777,,2015-08-06,2021-12-17,2020-01-15,2022-04-20,2015-08-06,2015-08-11,ESTIMATED,2022-02-04,2022-03-02,ACTUAL,2020-01-15,2020-02-05,ACTUAL,2022-04-20,2022-04-22,ACTUAL,2016-04-21,ACTUAL,2016-04-21,2022-04,2022-04-30,2021-01-05,ACTUAL,2021-01-05,2019-12-02,ACTUAL,2019-12-02,,INTERVENTIONAL,,All participants were included in the analysis.,Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND),"A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV",COMPLETED,,PHASE4,191,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 03:12:53,2024-10-14 03:12:53,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Puerto Rico|South Africa|Thailand|United States,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02528721,,2015-08-17,2016-11-16,,2022-12-19,2015-08-18,2015-08-19,ESTIMATED,2017-01-12,2017-03-03,ACTUAL,,,,2022-12-19,2022-12-20,ACTUAL,2015-10,,2015-10-31,2022-12,2022-12-31,2016-07,ACTUAL,2016-07-31,2016-06,ACTUAL,2016-06-30,,INTERVENTIONAL,,,Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection,Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the BreathID® Hp Lab System Compared to Biopsy Results,COMPLETED,,PHASE3,282,ACTUAL,"Meridian Bioscience, Inc.",,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 01:51:42,2024-10-13 01:51:42,INDUSTRY,,,,,,,"Meridian Bioscience, Inc.",Israel|United States,Gastrointestinal disorders|General disorders
NCT02531373,,2015-08-20,2018-03-16,,2019-03-21,2015-08-20,2015-08-24,ESTIMATED,2018-03-16,2018-04-17,ACTUAL,,,,2019-03-21,2019-04-02,ACTUAL,2015-09-15,ACTUAL,2015-09-15,2019-03,2019-03-31,2017-04-14,ACTUAL,2017-04-14,2017-04-14,ACTUAL,2017-04-14,,INTERVENTIONAL,,All participants who received at least one study vaccination,"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants",COMPLETED,,PHASE1/PHASE2,338,ACTUAL,Merck Sharp & Dohme LLC,,9,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 00:07:27,2024-10-14 00:07:27,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02531438,,2015-07-14,2018-11-02,2018-02-09,2019-01-03,2015-08-20,2015-08-24,ESTIMATED,2018-11-02,2018-11-29,ACTUAL,2018-02-09,2018-02-14,ACTUAL,2019-01-03,2019-01-16,ACTUAL,2015-11,ACTUAL,2015-11-30,2019-01,2019-01-31,2017-03-10,ACTUAL,2017-03-10,2017-02-05,ACTUAL,2017-02-05,,INTERVENTIONAL,,,Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13),"A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia",COMPLETED,,PHASE3,774,ACTUAL,Paratek Pharmaceuticals Inc,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 11:14:41,2024-10-13 11:14:41,INDUSTRY,,,,,,,Paratek Pharmaceuticals Inc,"Belgium|Brazil|Bulgaria|Croatia|Czechia|Czech Republic|Georgia|Germany|Greece|Hungary|Israel|Korea, Republic of|Latvia|Mexico|Peru|Philippines|Poland|Romania|Russian Federation|Slovakia|South Africa|Spain|Taiwan|Turkey|Ukraine|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02531698,,2015-08-20,2018-02-28,,2020-10-22,2015-08-20,2015-08-24,ESTIMATED,2018-02-28,2018-03-27,ACTUAL,,,,2020-10-22,2020-10-26,ACTUAL,2015-08,ACTUAL,2015-08-31,2020-10,2020-10-31,2017-03,ACTUAL,2017-03-31,2017-03,ACTUAL,2017-03-31,,INTERVENTIONAL,,"Safety population included all participants who received at least 1 dose of the investigational product (rLP2086, HAV vaccine or saline) and had safety data available.","A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years","A Phase 2, Randomized, Controlled, Observer-blinded Study To Describe The Immunogenicity, Safety, And Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) In Healthy Subjects Aged >/= 24 Months To <10 Years",COMPLETED,,PHASE2,400,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 05:45:09,2024-10-14 05:45:09,INDUSTRY,,,,,,,Pfizer,Finland|Poland,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02533427,,2015-08-24,2020-08-17,,2020-08-17,2015-08-24,2015-08-26,ESTIMATED,2020-08-17,2020-09-02,ACTUAL,,,,2020-08-17,2020-09-02,ACTUAL,2015-10-29,ACTUAL,2015-10-29,2020-08,2020-08-31,2016-03-18,ACTUAL,2016-03-18,2016-03-18,ACTUAL,2016-03-18,,INTERVENTIONAL,,The Safety Analysis Set included all enrolled participants who took at least 1 dose of study drug.,"Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol","A Phase 1, Open-Label, Drug Interaction Study Evaluating the Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol",COMPLETED,,PHASE1,15,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",2024-10-13 05:17:37,2024-10-13 05:17:37,INDUSTRY,,,,,,,Gilead Sciences,New Zealand,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT02536313,,2015-08-27,2017-08-16,2016-05-23,2019-02-08,2015-08-27,2015-08-31,ESTIMATED,2017-08-16,2017-09-14,ACTUAL,2016-05-23,2016-06-06,ESTIMATED,2019-02-08,2019-02-25,ACTUAL,2015-07-29,ACTUAL,2015-07-29,2017-08,2017-08-31,2016-06-28,ACTUAL,2016-06-28,2016-03-28,ACTUAL,2016-03-28,,INTERVENTIONAL,,Safety Analysis Set: participants who took at least 1 dose of study drug,Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen,"A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS-5816/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Subjects With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen",COMPLETED,,PHASE2,49,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/about/ethics-and-code-of-conduct/policies,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.",2024-10-13 20:01:59,2024-10-13 20:01:59,INDUSTRY,,,,,,,Gilead Sciences,United States,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations
NCT02542462,,2015-06-24,2018-05-29,,2018-07-11,2015-09-03,2015-09-07,ESTIMATED,2018-07-11,2018-07-12,ACTUAL,,,,2018-07-11,2018-07-12,ACTUAL,2015-11,ACTUAL,2015-11-30,2018-07,2018-07-31,2017-05,ACTUAL,2017-05-31,2017-05,ACTUAL,2017-05-31,,INTERVENTIONAL,,,Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study,Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study,COMPLETED,,PHASE4,144,ACTUAL,"Children's Hospital Medical Center, Cincinnati",This was a pilot study to assess the feasibility of conducting the outlined study and was not powered to detect differences in the anatomy pre-versus post immunization.,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 10:09:42,2024-10-14 10:09:42,OTHER,,,,,,,"Centers for Disease Control and Prevention|Children's Hospital Medical Center, Cincinnati",United States,Gastrointestinal disorders|Infections and infestations|Nervous system disorders
NCT02547012,,2015-09-06,2017-10-20,,2019-03-13,2015-09-09,2015-09-11,ESTIMATED,2019-03-13,2019-03-14,ACTUAL,,,,2019-03-13,2019-03-14,ACTUAL,2013-11,,2013-11-30,2019-03,2019-03-31,2017-10,ACTUAL,2017-10-31,2017-07,ACTUAL,2017-07-31,,INTERVENTIONAL,,,Comparison of Two Rescue Therapies for Helicobacter Pylori Infection,Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial,COMPLETED,,NA,51,ACTUAL,Kaohsiung Veterans General Hospital.,The trial was performed in a single country,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 14:21:02,2024-10-14 14:21:02,OTHER,,,,,,,Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Veterans General Hospital.,Taiwan,Gastrointestinal disorders|Nervous system disorders
NCT02547038,,2015-09-06,2018-10-30,,2019-03-11,2015-09-09,2015-09-11,ESTIMATED,2019-03-11,2019-06-10,ACTUAL,,,,2019-03-11,2019-06-10,ACTUAL,2015-02,,2015-02-28,2019-03,2019-03-31,2018-10,ACTUAL,2018-10-31,2018-10,ACTUAL,2018-10-31,,INTERVENTIONAL,,,Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy,Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication,COMPLETED,,NA,352,ACTUAL,Kaohsiung Veterans General Hospital.,The trial was performed in a single country,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 23:29:48,2024-10-14 23:29:48,OTHER,,,,,,,Kaohsiung Veterans General Hospital.,Taiwan,Gastrointestinal disorders|General disorders
NCT02547649,,2015-09-10,2019-03-08,,2019-04-09,2015-09-10,2015-09-11,ESTIMATED,2019-03-08,2019-04-02,ACTUAL,,,,2019-04-09,2019-04-16,ACTUAL,2015-10-08,ACTUAL,2015-10-08,2019-04,2019-04-30,2016-01-20,ACTUAL,2016-01-20,2016-01-20,ACTUAL,2016-01-20,,INTERVENTIONAL,,The Baseline Analysis Population consists of all vaccinated participants.,"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older",COMPLETED,,PHASE2,690,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 05:11:43,2024-10-13 05:11:43,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Cardiac disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT02554383,,2015-09-08,2023-03-28,,2023-06-13,2015-09-17,2015-09-18,ESTIMATED,2023-05-11,2023-06-08,ACTUAL,,,,2023-06-13,2023-06-29,ACTUAL,2016-02,ACTUAL,2016-02-29,2023-06,2023-06-30,2023-03-09,ACTUAL,2023-03-09,2022-03-31,ACTUAL,2022-03-31,,INTERVENTIONAL,,"515 children underwent randomization; 257 were randomized to the amoxicillin-clavulanate group and 258 to the placebo group. 3 and 2, respectively, were found ineligible after randomization. The remaining 254 and 256 participants, respectively, were the basis for analysis.",Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?,Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?,COMPLETED,,PHASE3,515,ACTUAL,University of Pittsburgh,,2,,,FALSE,,,,TRUE,,,,,,,,,,,YES,,2024-10-13 15:55:21,2024-10-13 15:55:21,OTHER,,,,,,,Nader Shaikh|National Institute of Allergy and Infectious Diseases (NIAID),United States,Gastrointestinal disorders
NCT02562482,,2015-09-21,2019-03-05,,2020-10-20,2015-09-28,2015-09-29,ESTIMATED,2019-04-25,2019-05-14,ACTUAL,,,,2020-10-20,2020-10-22,ACTUAL,2015-11-18,ACTUAL,2015-11-18,2020-10,2020-10-31,2018-03-06,ACTUAL,2018-03-06,2018-03-06,ACTUAL,2018-03-06,,INTERVENTIONAL,,Population includes all enrolled subjects.,"Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults","Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults",COMPLETED,,PHASE2,400,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),Exploratory immunogenicity analyses (to evaluate humoral and cellular responses to VRC-CHKVLP059-00-VP at additional time points by antibody assays that include antigen-specific ELISA and neutralization assay) were not completed and are not reported.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 11:39:25,2024-10-14 11:39:25,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Dominican Republic|Guadeloupe|Haiti|Martinique|Puerto Rico,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Surgical and medical procedures"
NCT02563106,,2015-09-28,2018-02-12,,2018-10-31,2015-09-28,2015-09-29,ESTIMATED,2018-02-12,2018-03-12,ACTUAL,,,,2018-10-31,2018-11-27,ACTUAL,2015-10,,2015-10-31,2018-10,2018-10-31,2016-11,ACTUAL,2016-11-30,2016-11,ACTUAL,2016-11-30,,INTERVENTIONAL,,"One subject in the placebo group was randomized but never dosed. The subject withdrew consent prior to dosing, therefore they are not included in the analysis population.",A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI,"A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection",COMPLETED,,PHASE2,413,ACTUAL,"Theriva Biologics, Inc.","A safety assessment conducted by an independent third party to evaluate SAEs and fatal events confirmed that they were related to the subjects' underlying health, medical history, and comorbidities and not to study drug administration.",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 12:22:18,2024-10-14 12:22:18,INDUSTRY,,,,,,,"Theriva Biologics, Inc.",Bulgaria|Canada|Hungary|Poland|Romania|Serbia|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02568215,,2015-10-01,2021-11-30,,2022-02-08,2015-10-01,2015-10-05,ESTIMATED,2022-01-12,2022-02-08,ACTUAL,,,,2022-02-08,2022-02-23,ACTUAL,2016-05,ACTUAL,2016-05-31,2022-02,2022-02-28,2021-03-03,ACTUAL,2021-03-03,2021-03-03,ACTUAL,2021-03-03,,INTERVENTIONAL,,Safety Population,Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women,A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa,COMPLETED,,PHASE2,1924,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 13:39:19,2024-10-13 13:39:19,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Kenya|Malawi|Mozambique|South Africa|Tanzania|United States|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT02569541,,2015-10-05,2020-01-09,,2020-01-21,2015-10-05,2015-10-06,ESTIMATED,2020-01-21,2020-01-30,ACTUAL,,,,2020-01-21,2020-01-30,ACTUAL,2015-12,,2015-12-31,2020-01,2020-01-31,2019-02-21,ACTUAL,2019-02-21,2017-10-17,ACTUAL,2017-10-17,,INTERVENTIONAL,,"Intent-to-Treat (ITT) Population included all subjects who provided informed consent, met all eligibility criteria, and were enrolled in the study.",Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections,"An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated",COMPLETED,,PHASE2/PHASE3,30,ACTUAL,Arrevus Inc.,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 10:39:45,2024-10-14 10:39:45,INDUSTRY,,,,,,,Arrevus Inc.,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02569632,,2015-09-30,2017-05-10,,2021-02-01,2015-10-06,2015-10-07,ESTIMATED,2021-02-01,2021-02-02,ACTUAL,,,,2021-02-01,2021-02-02,ACTUAL,2015-01,ACTUAL,2015-01-31,2021-02,2021-02-28,2016-12,ACTUAL,2016-12-31,2016-12,ACTUAL,2016-12-31,,INTERVENTIONAL,,The data from one subject enrolled in the study were excluded due to a diagnosis of cancer after dose 2.,Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba),Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure,COMPLETED,,PHASE4,18,ACTUAL,UCSF Benioff Children's Hospital Oakland,,1,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 16:32:06,2024-10-13 16:32:06,OTHER,,,,,,,"UCSF Benioff Children's Hospital Oakland|University of Massachusetts, Worcester",United States,Skin and subcutaneous tissue disorders
NCT02572817,,2015-10-07,2019-04-24,,2019-06-14,2015-10-07,2015-10-09,ESTIMATED,2019-05-24,2019-06-14,ACTUAL,,,,2019-06-14,2019-06-25,ACTUAL,2015-11,,2015-11-30,2019-06,2019-06-30,2018-05-18,ACTUAL,2018-05-18,2018-04-26,ACTUAL,2018-04-26,,INTERVENTIONAL,,,Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A,"A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A",COMPLETED,,PHASE3,138,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 10:26:13,2024-10-13 10:26:13,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02573181,,2015-10-08,2019-07-26,,2019-07-26,2015-10-08,2015-10-09,ESTIMATED,2019-07-26,2019-08-14,ACTUAL,,,,2019-07-26,2019-08-14,ACTUAL,2015-10-30,ACTUAL,2015-10-30,2019-07,2019-07-31,2016-01-28,ACTUAL,2016-01-28,2016-01-28,ACTUAL,2016-01-28,,INTERVENTIONAL,,,"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine",COMPLETED,,PHASE2,253,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 14:39:19,2024-10-14 14:39:19,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Cardiac disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders"
NCT02575079,,2015-10-12,2019-03-29,,2019-06-06,2015-10-12,2015-10-14,ESTIMATED,2019-06-06,2019-06-25,ACTUAL,,,,2019-06-06,2019-06-25,ACTUAL,2015-03,,2015-03-31,2019-06,2019-06-30,2018-03-29,ACTUAL,2018-03-29,2018-03-29,ACTUAL,2018-03-29,,INTERVENTIONAL,,,Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT,Parafilm Application to Prevent Central Line Associated Bloodstream Infections in Pediatric Patients Undergoing Hematopoietic Cell Transplantation,COMPLETED,,NA,119,ACTUAL,Emory University,Assessing feasibility of outpatient parafilm use was limited by difficulty collecting parafilm compliance calendars from caretakers and observed variability of compliance in the outpatient setting.,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 00:01:28,2024-10-14 00:01:28,OTHER,,,,,,,Emory University,United States,"Immune system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02576054,,2015-10-13,2019-07-24,,2019-11-13,2015-10-13,2015-10-15,ESTIMATED,2019-07-24,2019-09-06,ACTUAL,,,,2019-11-13,2019-11-25,ACTUAL,2015-11-20,ACTUAL,2015-11-20,2019-11,2019-11-30,2018-08-08,ACTUAL,2018-08-08,2018-08-08,ACTUAL,2018-08-08,,INTERVENTIONAL,,,Safety and Tolerability Study of V501 in Japanese Boys (V501-200),"A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys",COMPLETED,,PHASE3,101,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 06:35:12,2024-10-14 06:35:12,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,General disorders|Infections and infestations
NCT02577718,,2015-10-13,2017-06-22,,2017-10-02,2015-10-14,2015-10-16,ESTIMATED,2017-10-02,2017-11-06,ACTUAL,,,,2017-10-02,2017-11-06,ACTUAL,2015-11,,2015-11-30,2017-10,2017-10-31,2016-10,ACTUAL,2016-10-31,2016-06-22,ACTUAL,2016-06-22,,INTERVENTIONAL,,,Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution,"Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients",COMPLETED,,PHASE1/PHASE2,60,ACTUAL,"Novel Anti-Infective Technologies, LLC",,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 00:03:31,2024-10-13 00:03:31,INDUSTRY,,,,,,,"M.D. Anderson Cancer Center|Novel Anti-Infective Technologies, LLC",United States,Nervous system disorders|Skin and subcutaneous tissue disorders
NCT02577718,,2015-10-13,2017-06-22,,2017-10-02,2015-10-14,2015-10-16,ESTIMATED,2017-10-02,2017-11-06,ACTUAL,,,,2017-10-02,2017-11-06,ACTUAL,2015-11,,2015-11-30,2017-10,2017-10-31,2016-10,ACTUAL,2016-10-31,2016-06-22,ACTUAL,2016-06-22,,INTERVENTIONAL,,,Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution,"Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients",COMPLETED,,PHASE1/PHASE2,60,ACTUAL,"Novel Anti-Infective Technologies, LLC",,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 00:03:31,2024-10-13 00:03:31,INDUSTRY,,,,,,,"M.D. Anderson Cancer Center|Novel Anti-Infective Technologies, LLC",United States,Nervous system disorders|Skin and subcutaneous tissue disorders
NCT02578706,,2015-10-15,2017-10-23,,2018-01-29,2015-10-16,2015-10-19,ESTIMATED,2018-01-29,2018-02-28,ACTUAL,,,,2018-01-29,2018-02-28,ACTUAL,2015-10,,2015-10-31,2018-01,2018-01-31,2016-11,ACTUAL,2016-11-30,2016-11,ACTUAL,2016-11-30,,INTERVENTIONAL,,,Targeting Platelets in Chronic HIV Infection,Targeting Platelets in Chronic HIV Infection,COMPLETED,,PHASE2,27,ACTUAL,Icahn School of Medicine at Mount Sinai,"This study was powered assuming that 40 study participants would be assigned per arm, however less than 10 participants were assigned per arm, therefore more participants would be needed to observe significant differences.",3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 00:09:32,2024-10-13 00:09:32,OTHER,,,,,,,"Icahn School of Medicine at Mount Sinai|National Heart, Lung, and Blood Institute (NHLBI)",United States,Infections and infestations
NCT02578745,,2015-10-09,2018-04-02,,2019-11-14,2015-10-14,2015-10-19,ESTIMATED,2019-10-03,2019-10-22,ACTUAL,,,,2019-11-14,2019-11-27,ACTUAL,2015-10,,2015-10-31,2019-11,2019-11-30,2016-03,ACTUAL,2016-03-31,2016-03,ACTUAL,2016-03-31,,INTERVENTIONAL,PICO-C,,Prophylactic Incisional Care in Obese Women at Cesarean,Prophylactic Negative Pressure Wound Therapy in Obese Women After Cesarean: a Pilot Randomized Trial,COMPLETED,,NA,120,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 10:33:41,2024-10-14 10:33:41,OTHER,,,,,,,Washington University School of Medicine,United States,Skin and subcutaneous tissue disorders
NCT02581202,,2015-10-19,2018-05-23,,2019-05-22,2015-10-19,2015-10-20,ESTIMATED,2018-12-20,2019-03-29,ACTUAL,,,,2019-05-22,2019-06-06,ACTUAL,2015-12-21,,2015-12-21,2018-05,2018-05-31,2017-05-27,ACTUAL,2017-05-27,2017-05-27,ACTUAL,2017-05-27,,OBSERVATIONAL,SIMPLE,,The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation,"ProSpective, MultI-Center, Observational PrograM to Assess the Effectiveness of Dual TheraPy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Routine Clinical Settings of the Russian Federation (SIMPLE)",COMPLETED,,,216,ACTUAL,AbbVie,,,1,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-13 20:24:49,2024-10-13 20:24:49,INDUSTRY,,,,,,,AbbVie,Russian Federation,Gastrointestinal disorders|General disorders|Investigations
NCT02582632,,2015-10-20,2017-11-16,,2021-07-28,2015-10-20,2015-10-21,ESTIMATED,2017-11-16,2017-12-13,ACTUAL,,,,2021-07-28,2021-07-30,ACTUAL,2015-11-24,,2015-11-24,2021-07,2021-07-31,2016-12-01,ACTUAL,2016-12-01,2016-08-24,ACTUAL,2016-08-24,,INTERVENTIONAL,GARNET,,A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults,"An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)",COMPLETED,,PHASE3,166,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 20:24:02,2024-10-14 20:24:02,INDUSTRY,,,,,,,AbbVie,Australia|Canada|France|Germany|Israel|Italy|Spain|United Kingdom,Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT02582684,,2015-10-20,2018-02-28,,2018-04-10,2015-10-20,2015-10-21,ESTIMATED,2018-02-28,2018-03-30,ACTUAL,,,,2018-04-10,2018-05-09,ACTUAL,2015-12-08,ACTUAL,2015-12-08,2018-04,2018-04-30,2017-09-26,ACTUAL,2017-09-26,2017-02-28,ACTUAL,2017-02-28,,INTERVENTIONAL,,All eligible participants enrolled.,Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients,A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants,COMPLETED,,PHASE2,122,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 15:23:18,2024-10-14 15:23:18,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,Infections and infestations|Investigations|Psychiatric disorders
NCT02582983,,2015-10-08,2016-05-25,,2016-05-25,2015-10-20,2015-10-21,ESTIMATED,2016-05-25,2016-07-06,ESTIMATED,,,,2016-05-25,2016-07-06,ESTIMATED,2004-02,,2004-02-29,2016-05,2016-05-31,2009-12,ACTUAL,2009-12-31,2009-12,ACTUAL,2009-12-31,,INTERVENTIONAL,,,A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection,"An Open-Label Safety Trial of Enfuvirtide (T-20/RO 29-9800, HIV-1 Fusion Inhibitor) in Combination With Free Choice Antiviral Regimen in Thai Patients With Advanced HIV Infection",COMPLETED,,PHASE4,23,ACTUAL,Hoffmann-La Roche,,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 03:24:11,2024-10-13 03:24:11,INDUSTRY,,,,,,,Hoffmann-La Roche,Thailand,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02583048,,2015-10-20,2020-01-03,,2022-01-20,2015-10-20,2015-10-21,ESTIMATED,2020-01-16,2020-01-29,ACTUAL,,,,2022-01-20,2022-01-27,ACTUAL,2016-08-15,ACTUAL,2016-08-15,2022-01,2022-01-31,2021-02-04,ACTUAL,2021-02-04,2019-01-07,ACTUAL,2019-01-07,,INTERVENTIONAL,,All randomized participants.,"Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis","A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, Among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis",COMPLETED,,PHASE2,84,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 10:16:10,2024-10-14 10:16:10,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Peru|South Africa,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02588586,,2015-10-26,2021-03-31,2019-04-16,2021-05-21,2015-10-27,2015-10-28,ESTIMATED,2021-05-21,2021-06-16,ACTUAL,2019-04-24,2019-04-30,ACTUAL,2021-05-21,2021-06-16,ACTUAL,2015-10,,2015-10-31,2021-05,2021-05-31,2018-04,ACTUAL,2018-04-30,2018-02,ACTUAL,2018-02-28,,INTERVENTIONAL,,Adults living with HIV and on suppressive antiretroviral therapy,A Study of the Safety and Antiretroviral Activity of 3BNC117,"An Open Label, Phase 2 Study of the Safety and Antiretroviral Activity of 3BNC117 in HIV-Infected Individuals on Combination Antiretroviral Therapy",COMPLETED,,PHASE2,17,ACTUAL,Rockefeller University,This study was an exploratory open label study with a small sample size.,1,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 17:52:48,2024-10-14 17:52:48,OTHER,,,,,,,Bill and Melinda Gates Foundation|Montefiore Medical Center|National Institute of Allergy and Infectious Diseases (NIAID)|Rockefeller University|Weill Medical College of Cornell University,United States,Gastrointestinal disorders|General disorders|Psychiatric disorders
NCT02589847,,2015-10-26,2020-04-28,,2021-03-25,2015-10-27,2015-10-28,ESTIMATED,2020-04-28,2020-05-11,ACTUAL,,,,2021-03-25,2021-03-26,ACTUAL,2015-10,ACTUAL,2015-10-31,2021-02,2021-02-28,2019-03,ACTUAL,2019-03-31,2017-06,ACTUAL,2017-06-30,,INTERVENTIONAL,,Full Analysis Set included participants who received at least one dose of study drug.,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection,COMPLETED,,PHASE2,272,ACTUAL,Rebiotix Inc.,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 18:35:34,2024-10-14 18:35:34,INDUSTRY,,,,,,,Rebiotix Inc.,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT02590354,,2015-10-14,2019-08-05,,2019-09-23,2015-10-27,2015-10-29,ESTIMATED,2019-09-23,2019-09-24,ACTUAL,,,,2019-09-23,2019-09-24,ACTUAL,2016-01-25,ACTUAL,2016-01-25,2019-09,2019-09-30,2018-06-22,ACTUAL,2018-06-22,2018-06-22,ACTUAL,2018-06-22,,INTERVENTIONAL,ISALA,114 participants were included in phase 1 of the study. 16 of those continued to phase 2 (treatment interruption).,Analytical Treatment Interruption in HIV Positive Patients,Analytical Treatment Interruption in HIV Positive Patients With Low Viral Reservoir to Evaluate the Potential of a Functional Cure,COMPLETED,,NA,114,ACTUAL,"Institute of Tropical Medicine, Belgium",,1,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 08:37:22,2024-10-13 08:37:22,OTHER,,,,,,,"Agentschap voor Innovatie door Wetenschap en Technologie|Institute of Tropical Medicine, Belgium|Saint-Pierre University Hospital|Universitair Ziekenhuis Brussel|University Hospital, Ghent",Belgium,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02591290,,2015-10-27,2017-10-05,,2017-10-05,2015-10-27,2015-10-29,ESTIMATED,2017-10-05,2017-11-06,ACTUAL,,,,2017-10-05,2017-11-06,ACTUAL,2015-10-20,ACTUAL,2015-10-20,2017-10,2017-10-31,2016-03-16,ACTUAL,2016-03-16,2016-03-16,ACTUAL,2016-03-16,,INTERVENTIONAL,,,Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects,"Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects",COMPLETED,,PHASE4,60,ACTUAL,Sanofi,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 03:37:02,2024-10-13 03:37:02,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Japan,General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT02595866,,2015-11-03,2024-05-10,,2024-07-16,2015-11-03,2015-11-04,ESTIMATED,2024-06-25,2024-07-16,ACTUAL,,,,2024-07-16,2024-08-09,ACTUAL,2016-04-04,ACTUAL,2016-04-04,2024-05,2024-05-31,2024-03-25,ACTUAL,2024-03-25,2023-10-04,ACTUAL,2023-10-04,,INTERVENTIONAL,,Participants do not have to complete the study in order to be included in the analysis population for the primary outcome measure.,Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer,Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm,COMPLETED,,PHASE1,58,ACTUAL,National Cancer Institute (NCI),,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 23:01:29,2024-10-14 23:01:29,NIH,,,,,,,National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02600611,,2015-11-05,2018-03-20,,2018-05-19,2015-11-06,2015-11-09,ESTIMATED,2018-05-19,2018-06-19,ACTUAL,,,,2018-05-19,2018-06-19,ACTUAL,2015-11-01,ACTUAL,2015-11-01,2018-04,2018-04-30,2017-01-30,ACTUAL,2017-01-30,2017-01-30,ACTUAL,2017-01-30,,INTERVENTIONAL,REVIVE-1,Intent to Treat Population (all patients randomized),Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1,"A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1",COMPLETED,,PHASE3,600,ACTUAL,Motif Bio,,2,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-14 18:17:09,2024-10-14 18:17:09,INDUSTRY,,,,,,,Motif Bio,Bulgaria|Chile|Colombia|Germany|Latvia|Peru|Poland|Puerto Rico|Ukraine|United States,Product Issues|Renal and urinary disorders
NCT02600819,,2015-11-06,2018-09-21,,2020-10-13,2015-11-06,2015-11-09,ESTIMATED,2018-09-21,2018-10-16,ACTUAL,,,,2020-10-13,2020-11-05,ACTUAL,2015-12-14,ACTUAL,2015-12-14,2020-10,2020-10-31,2019-10-15,ACTUAL,2019-10-15,2017-09-29,ACTUAL,2017-09-29,,INTERVENTIONAL,,The GEN Safety Analysis Set included all participants who received at least 1 dose of GEN.,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis","A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis",COMPLETED,,PHASE3,55,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 01:11:48,2024-10-13 01:11:48,INDUSTRY,,,,,,,Gilead Sciences,Austria|France|Germany|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02600871,,2015-11-05,2018-01-22,,2018-10-01,2015-11-05,2015-11-09,ESTIMATED,2018-02-26,2018-03-27,ACTUAL,,,,2018-10-01,2018-10-30,ACTUAL,2015-12,ACTUAL,2015-12-31,2018-02,2018-02-28,2017-05-30,ACTUAL,2017-05-30,2017-04-30,ACTUAL,2017-04-30,,INTERVENTIONAL,,,Skin and Soft Tissue Infection (SSTI) Study,Skin and Soft Tissue Infection (SSTI) Study,COMPLETED,,PHASE4,101,ACTUAL,The University of Texas Health Science Center at San Antonio,"The low sample size of subjects was insufficient to perform a power calculation. Not all patients were compliant with hand washing and Provodine use. The 30-day follow phone call was self-reported, and not all subjects could be contacted.",2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 01:17:48,2024-10-13 01:17:48,OTHER,,,,,,,The University of Texas Health Science Center at San Antonio,United States,"Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02603107,,2015-11-10,2018-05-03,,2020-12-07,2015-11-10,2015-11-11,ESTIMATED,2018-05-03,2018-06-06,ACTUAL,,,,2020-12-07,2020-12-29,ACTUAL,2015-11-20,ACTUAL,2015-11-20,2020-12,2020-12-31,2019-12-23,ACTUAL,2019-12-23,2017-05-15,ACTUAL,2017-05-15,,INTERVENTIONAL,,Safety Analysis Set: all randomized participants who received at least 1 dose of study drug.,Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults,"A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults",COMPLETED,,PHASE3,578,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-14 17:09:10,2024-10-14 17:09:10,INDUSTRY,,,,,,,Gilead Sciences,Australia|Belgium|Canada|Dominican Republic|France|Germany|Italy|Puerto Rico|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT02603120,,2015-11-10,2018-05-01,,2020-10-22,2015-11-10,2015-11-11,ESTIMATED,2018-06-25,2018-07-23,ACTUAL,,,,2020-10-22,2020-11-12,ACTUAL,2015-11-11,ACTUAL,2015-11-11,2020-10,2020-10-31,2019-10-23,ACTUAL,2019-10-23,2017-05-09,ACTUAL,2017-05-09,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized into the study and received at least 1 dose of study drug.,Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed",COMPLETED,,PHASE3,567,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 20:07:31,2024-10-13 20:07:31,INDUSTRY,,,,,,,Gilead Sciences,Australia|Belgium|Canada|France|Germany|Italy|Puerto Rico|Spain|United Kingdom|United States,"Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02605954,,2015-11-13,2018-06-13,,2018-10-19,2015-11-13,2015-11-17,ESTIMATED,2018-06-13,2018-07-13,ACTUAL,,,,2018-10-19,2018-11-14,ACTUAL,2015-11-18,ACTUAL,2015-11-18,2018-06,2018-06-30,2018-01-24,ACTUAL,2018-01-24,2017-06-14,ACTUAL,2017-06-14,,INTERVENTIONAL,,Safety Analysis Set: participants who took at least 1 dose of E/C/F/TAF or ABC/3TC+3rd Agent (on or after Day 1).,Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults,"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adult Subjects",COMPLETED,,PHASE3,275,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,,Gilead Sciences,France|Germany|Italy|Spain|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Product Issues|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02607618,,2015-11-13,2018-06-14,,2018-07-10,2015-11-16,2015-11-18,ESTIMATED,2018-06-14,2018-07-11,ACTUAL,,,,2018-07-10,2018-08-07,ACTUAL,2015-11,,2015-11-30,2018-06,2018-06-30,2017-08-08,ACTUAL,2017-08-08,2017-08-08,ACTUAL,2017-08-08,,INTERVENTIONAL,REVIVE-2,,Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2,"A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2",COMPLETED,,PHASE3,613,ACTUAL,Motif Bio,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 02:36:26,2024-10-15 02:36:26,INDUSTRY,,,,,,,Motif Bio,Argentina|Belgium|Croatia|Czechia|Czech Republic|Estonia|Hungary|Portugal|Romania|Turkey|United States,Renal and urinary disorders
NCT02607930,,2015-11-10,2018-05-02,,2022-02-07,2015-11-16,2015-11-18,ESTIMATED,2018-06-25,2018-07-23,ACTUAL,,,,2022-02-07,2022-03-02,ACTUAL,2015-11-13,ACTUAL,2015-11-13,2022-02,2022-02-28,2021-07-02,ACTUAL,2021-07-02,2017-05-09,ACTUAL,2017-05-09,,INTERVENTIONAL,,Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study drug.,"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE3,631,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gileadclinicaltrials.com/transparency-policy/,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/",2024-10-13 03:04:59,2024-10-13 03:04:59,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Canada|Dominican Republic|France|Germany|Italy|Puerto Rico|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT02607956,,2015-11-10,2018-05-03,,2022-02-10,2015-11-16,2015-11-18,ESTIMATED,2018-05-03,2018-06-06,ACTUAL,,,,2022-02-10,2022-03-07,ACTUAL,2015-11-11,ACTUAL,2015-11-11,2022-02,2022-02-28,2021-07-05,ACTUAL,2021-07-05,2017-05-12,ACTUAL,2017-05-12,,INTERVENTIONAL,,Safety Analysis Set included participants who were randomized into the study and received at least 1 dose of the study drug.,"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults",COMPLETED,,PHASE3,657,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",2024-10-13 14:25:50,2024-10-13 14:25:50,INDUSTRY,,,,,,,Gilead Sciences,Australia|Belgium|Canada|Dominican Republic|France|Gabon|Germany|Italy|Puerto Rico|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02613871,,2015-11-23,2018-01-03,,2020-02-18,2015-11-23,2015-11-25,ESTIMATED,2018-02-12,2018-02-13,ACTUAL,,,,2020-02-18,2020-03-06,ACTUAL,2015-12-22,ACTUAL,2015-12-22,2019-11,2019-11-30,2018-11-07,ACTUAL,2018-11-07,2017-01-04,ACTUAL,2017-01-04,,INTERVENTIONAL,,Safety Analysis Set included participants who received at least 1 dose of study drug.,Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection,A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection,COMPLETED,,PHASE3,111,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 12:47:38,2024-10-13 12:47:38,INDUSTRY,,,,,,,Gilead Sciences,Taiwan,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders"
NCT02616029,,2015-11-24,2019-10-10,,2020-07-09,2015-11-24,2015-11-26,ESTIMATED,2019-10-10,2019-11-04,ACTUAL,,,,2020-07-09,2020-07-23,ACTUAL,2015-12-17,ACTUAL,2015-12-17,2020-07,2020-07-31,2019-07-11,ACTUAL,2019-07-11,2018-10-11,ACTUAL,2018-10-11,,INTERVENTIONAL,,The Safety Analysis Set included all participants who received at least 1 dose of study drug.,Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I,A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I,COMPLETED,,PHASE3,66,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 23:11:12,2024-10-13 23:11:12,INDUSTRY,,,,,,,Gilead Sciences,France|Germany|Italy|Spain|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02616783,,2015-11-23,2019-01-31,,2020-02-18,2015-11-27,2015-11-30,ESTIMATED,2019-01-31,2019-02-19,ACTUAL,,,,2020-02-18,2020-03-04,ACTUAL,2015-12-22,ACTUAL,2015-12-22,2019-01,2019-01-31,2018-03-21,ACTUAL,2018-03-21,2018-02-21,ACTUAL,2018-02-21,,INTERVENTIONAL,,Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study drug.,"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","A Phase 3b, Randomized, Open-Label Study to Evaluate Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years",COMPLETED,,PHASE3,167,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-14 18:29:07,2024-10-14 18:29:07,INDUSTRY,,,,,,,Gilead Sciences,Belgium|France|Italy|Spain|United Kingdom,"Cardiac disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02620774,,2015-12-01,2017-10-27,,2018-07-31,2015-12-01,2015-12-03,ESTIMATED,2018-07-31,2019-01-15,ACTUAL,,,,2018-07-31,2019-01-15,ACTUAL,2016-02-19,ACTUAL,2016-02-19,2017-10,2017-10-31,2017-04,ACTUAL,2017-04-30,2017-04,ACTUAL,2017-04-30,,INTERVENTIONAL,,,Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections,,COMPLETED,,PHASE1,16,ACTUAL,Hartford Hospital,No clinical or microbiological outcome data were collected; patient and volunteers were not matched based on demographic data; interference with the plasma assay was observed in two patients.,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-15 03:54:19,2024-10-15 03:54:19,OTHER,,,,,,,Hartford Hospital|Merck Sharp & Dohme LLC,United States,Nervous system disorders
NCT02620787,,2015-12-01,2017-09-28,,2018-07-31,2015-12-01,2015-12-03,ESTIMATED,2018-07-31,2019-01-15,ACTUAL,,,,2018-07-31,2019-01-15,ACTUAL,2016-02-23,ACTUAL,2016-02-23,2018-07,2018-07-31,2017-03-01,ACTUAL,2017-03-01,2017-03-01,ACTUAL,2017-03-01,,INTERVENTIONAL,,,Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis,Comparative Assessment of Tedizolid Tissue Penetration and Pharmacokinetic Profile Between Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis,COMPLETED,,PHASE1,18,ACTUAL,Hartford Hospital,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-14 18:23:16,2024-10-14 18:23:16,OTHER,,,,,,,Hartford Hospital|Merck Sharp & Dohme LLC,United States,Gastrointestinal disorders|General disorders|Nervous system disorders
NCT02628600,,2015-12-08,2019-10-15,,2020-01-21,2015-12-10,2015-12-11,ESTIMATED,2019-11-15,2019-11-19,ACTUAL,,,,2020-01-21,2020-02-10,ACTUAL,2016-02-05,ACTUAL,2016-02-05,2020-01,2020-01-31,2018-10-17,ACTUAL,2018-10-17,2018-10-17,ACTUAL,2018-10-17,,INTERVENTIONAL,,"Safety population, defined as participants who received at least 1 dose of LAI.",Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212,An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment,COMPLETED,,PHASE3,163,ACTUAL,Insmed Incorporated,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 23:07:13,2024-10-14 23:07:13,INDUSTRY,,,,,,,Insmed Incorporated,Australia|Canada|Germany|Japan|Netherlands|New Zealand|Spain|United Kingdom|United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02629822,,2015-12-10,2019-11-14,,2021-10-07,2015-12-10,2015-12-14,ESTIMATED,2019-12-12,2019-12-26,ACTUAL,,,,2021-10-07,2021-10-26,ACTUAL,2016-01-14,ACTUAL,2016-01-14,2021-10,2021-10-31,2020-10-28,ACTUAL,2020-10-28,2018-11-28,ACTUAL,2018-11-28,,INTERVENTIONAL,DRIVE BEYOND,,"Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)","A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects With Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations",COMPLETED,,PHASE2,10,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 02:12:28,2024-10-15 02:12:28,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Canada|France|Germany|Italy|Spain|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02631746,,2015-12-15,2019-02-06,,2023-11-30,2015-12-15,2015-12-16,ESTIMATED,2019-02-06,2019-03-01,ACTUAL,,,,2023-11-30,2023-12-21,ACTUAL,2017-02-21,ACTUAL,2017-02-21,2019-09,2019-09-30,2018-03-30,ACTUAL,2018-03-30,2017-11-30,ACTUAL,2017-11-30,,INTERVENTIONAL,,,Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma,Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma,COMPLETED,,PHASE2,3,ACTUAL,National Cancer Institute (NCI),,1,,,,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 16:45:10,2024-10-14 16:45:10,NIH,,,,,,,National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02631954,,2015-12-13,2020-02-12,,2020-03-11,2015-12-15,2015-12-16,ESTIMATED,2020-03-11,2020-03-18,ACTUAL,,,,2020-03-11,2020-03-18,ACTUAL,2015-09,,2015-09-30,2016-01,2016-01-31,2015-11,ACTUAL,2015-11-30,2015-10,ACTUAL,2015-10-31,,INTERVENTIONAL,,24 subejcts were used for baseline analysis.,Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers,,COMPLETED,,PHASE1,24,ACTUAL,Chong Kun Dang Pharmaceutical,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:40:18,2024-10-13 05:40:18,INDUSTRY,,,,,,,Chong Kun Dang Pharmaceutical,"Korea, Republic of","Eye disorders|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02631954,,2015-12-13,2020-02-12,,2020-03-11,2015-12-15,2015-12-16,ESTIMATED,2020-03-11,2020-03-18,ACTUAL,,,,2020-03-11,2020-03-18,ACTUAL,2015-09,,2015-09-30,2016-01,2016-01-31,2015-11,ACTUAL,2015-11-30,2015-10,ACTUAL,2015-10-31,,INTERVENTIONAL,,24 subejcts were used for baseline analysis.,Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers,,COMPLETED,,PHASE1,24,ACTUAL,Chong Kun Dang Pharmaceutical,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:40:18,2024-10-13 05:40:18,INDUSTRY,,,,,,,Chong Kun Dang Pharmaceutical,"Korea, Republic of","Eye disorders|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02631954,,2015-12-13,2020-02-12,,2020-03-11,2015-12-15,2015-12-16,ESTIMATED,2020-03-11,2020-03-18,ACTUAL,,,,2020-03-11,2020-03-18,ACTUAL,2015-09,,2015-09-30,2016-01,2016-01-31,2015-11,ACTUAL,2015-11-30,2015-10,ACTUAL,2015-10-31,,INTERVENTIONAL,,24 subejcts were used for baseline analysis.,Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers,,COMPLETED,,PHASE1,24,ACTUAL,Chong Kun Dang Pharmaceutical,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 05:40:18,2024-10-13 05:40:18,INDUSTRY,,,,,,,Chong Kun Dang Pharmaceutical,"Korea, Republic of","Eye disorders|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02634073,,2015-12-14,2016-10-28,,2017-05-03,2015-12-14,2015-12-17,ESTIMATED,2017-05-03,2017-05-15,ACTUAL,,,,2017-05-03,2017-05-15,ACTUAL,2016-01-01,,2016-01-01,2017-02,2017-02-28,2016-03-11,ACTUAL,2016-03-11,2016-03-01,ACTUAL,2016-03-01,,INTERVENTIONAL,,,"A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers","An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects",COMPLETED,,PHASE4,16,ACTUAL,ViiV Healthcare,,4,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 18:47:46,2024-10-14 18:47:46,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,United States,General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT02639247,,2015-12-21,2017-10-04,,2019-02-08,2015-12-21,2015-12-24,ESTIMATED,2017-10-04,2017-11-06,ACTUAL,,,,2019-02-08,2019-03-05,ACTUAL,2015-12-23,ACTUAL,2015-12-23,2017-10,2017-10-31,2017-01-18,ACTUAL,2017-01-18,2016-10-05,ACTUAL,2016-10-05,,INTERVENTIONAL,POLARIS-4,Safety Analysis Set: all randomized or enrolled participants who received at least 1 dose of study drug,Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor,"A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor",COMPLETED,,PHASE3,333,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/about/ethics-and-code-of-conduct/policies,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.",2024-10-14 22:32:11,2024-10-14 22:32:11,INDUSTRY,,,,,,,Gilead Sciences,Australia|Canada|France|Germany|New Zealand|Puerto Rico|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders"
NCT02639338,,2015-12-21,2017-10-10,,2019-02-08,2015-12-21,2015-12-24,ESTIMATED,2017-10-10,2017-11-14,ACTUAL,,,,2019-02-08,2019-03-05,ACTUAL,2015-12-23,ACTUAL,2015-12-23,2017-11,2017-11-30,2017-01-02,ACTUAL,2017-01-02,2016-10-12,ACTUAL,2016-10-12,,INTERVENTIONAL,POLARIS-3,Safety Analysis Set: all participants who received at least 1 dose of study drug,Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis,"A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis",COMPLETED,,PHASE3,220,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/about/ethics-and-code-of-conduct/policies,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.",2024-10-15 00:35:58,2024-10-15 00:35:58,INDUSTRY,,,,,,,Gilead Sciences,Australia|Canada|France|Germany|New Zealand|Puerto Rico|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Vascular disorders"
NCT02639351,,2015-12-21,2018-08-21,,2019-06-13,2015-12-21,2015-12-24,ESTIMATED,2019-03-05,2019-06-07,ACTUAL,,,,2019-06-13,2019-06-28,ACTUAL,2016-03-01,ACTUAL,2016-03-01,2019-06,2019-06-30,2017-08-31,ACTUAL,2017-08-31,2017-08-31,ACTUAL,2017-08-31,,INTERVENTIONAL,,,Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine,"A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 Years of Age).",COMPLETED,,PHASE1,80,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 22:02:15,2024-10-13 22:02:15,INDUSTRY,,,,,,,GlaxoSmithKline,Germany,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02640404,,2015-12-22,2017-12-06,,2017-12-06,2015-12-22,2015-12-29,ESTIMATED,2017-12-06,2018-01-08,ACTUAL,,,,2017-12-06,2018-01-08,ACTUAL,2016-06-06,,2016-06-06,2017-12,2017-12-31,2016-12-05,ACTUAL,2016-12-05,2016-12-05,ACTUAL,2016-12-05,,INTERVENTIONAL,,Safety analysis set included all participants who received at least 1 dose of study vaccine.,"Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam","Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects Aged 9 Months to 55 Years in Vietnam",COMPLETED,,PHASE2,224,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-14 15:34:55,2024-10-14 15:34:55,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Vietnam,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT02640482,,2015-12-18,2017-08-17,2016-10-21,2021-07-14,2015-12-22,2015-12-29,ESTIMATED,2017-08-17,2017-09-18,ACTUAL,2016-10-21,2016-10-24,ESTIMATED,2021-07-14,2021-07-16,ACTUAL,2015-11,ACTUAL,2015-11-30,2021-07,2021-07-31,2017-02,ACTUAL,2017-02-28,2016-09,ACTUAL,2016-09-30,,INTERVENTIONAL,ENDURANCE-2,Safety population: All participants who received at least one dose of study drug.,A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection,"A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)",COMPLETED,,PHASE3,304,ACTUAL,AbbVie,,3,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 14:27:14,2024-10-14 14:27:14,INDUSTRY,,,,,,,AbbVie,"Belgium|France|Italy|Korea, Republic of|Lithuania|Portugal|Taiwan|United States","Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02642432,,2015-12-28,2017-08-17,2017-02-10,2021-07-09,2015-12-28,2015-12-30,ESTIMATED,2017-08-29,2017-09-26,ACTUAL,2017-02-10,2017-02-13,ACTUAL,2021-07-09,2021-07-13,ACTUAL,2015-12-07,ACTUAL,2015-12-07,2021-07,2021-07-31,2017-02-10,ACTUAL,2017-02-10,2016-10-27,ACTUAL,2016-10-27,,INTERVENTIONAL,EXPEDITION-1,,"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis","A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)",COMPLETED,,PHASE3,146,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 06:20:43,2024-10-13 06:20:43,INDUSTRY,,,,,,,AbbVie,Belgium|Canada|Germany|South Africa|Spain|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02646332,,2016-01-04,2020-11-01,,2020-11-01,2016-01-04,2016-01-05,ESTIMATED,2020-11-01,2020-11-24,ACTUAL,,,,2020-11-01,2020-11-24,ACTUAL,2015-12,,2015-12-31,2020-11,2020-11-30,2020-08-31,ACTUAL,2020-08-31,2020-07-31,ACTUAL,2020-07-31,,INTERVENTIONAL,,,Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy,Comparing the Efficacy and Impact on Gastrointestinal Microbiota of Reverse Hybrid Therapy and Concomitant Therapy in Helicobacter Pylori Eradication,COMPLETED,,NA,248,ACTUAL,Kaohsiung Veterans General Hospital.,The trial was performed in a single country,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 03:05:32,2024-10-14 03:05:32,OTHER,,,,,,,Kaohsiung Veterans General Hospital.,Taiwan,Gastrointestinal disorders|Skin and subcutaneous tissue disorders
NCT02651194,,2016-01-07,2017-08-17,2017-01-31,2017-09-14,2016-01-07,2016-01-08,ESTIMATED,2017-09-14,2017-10-16,ACTUAL,2017-01-31,2017-02-01,ESTIMATED,2017-09-14,2017-10-16,ACTUAL,2015-12,ACTUAL,2015-12-31,2017-09,2017-09-30,2017-01,ACTUAL,2017-01-31,2016-10,ACTUAL,2016-10-31,,INTERVENTIONAL,EXPEDITION-4,All participants who received at least 1 dose of study drug (ITT population).,A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection,"A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)",COMPLETED,,PHASE3,104,ACTUAL,AbbVie,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 00:07:27,2024-10-14 00:07:27,INDUSTRY,,,,,,,AbbVie,Australia|Belgium|Canada|France|Greece|Italy|New Zealand|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02651428,,2016-01-07,2021-04-28,2020-08-04,2021-08-05,2016-01-07,2016-01-11,ESTIMATED,2021-08-05,2021-08-31,ACTUAL,2020-08-04,2020-08-07,ACTUAL,2021-08-05,2021-08-31,ACTUAL,2015-12,,2015-12-31,2021-08,2021-08-31,2018-10,ACTUAL,2018-10-31,2018-10,ACTUAL,2018-10-31,,INTERVENTIONAL,,All randomized subjects,Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection,"Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease",COMPLETED,,PHASE3,806,ACTUAL,CorMedix,,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 21:39:34,2024-10-13 21:39:34,INDUSTRY,,,,,,,"CorMedix|Davita Clinical Research|Frenova Renal Research|JMI Laboratories|PPD DEVELOPMENT, LP|Spectra Clinical Research",United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02652624,,2016-01-08,2018-10-02,,2020-02-18,2016-01-08,2016-01-12,ESTIMATED,2018-10-02,2018-11-02,ACTUAL,,,,2020-02-18,2020-03-04,ACTUAL,2016-02-19,ACTUAL,2016-02-19,2019-11,2019-11-30,2018-11-26,ACTUAL,2018-11-26,2017-10-09,ACTUAL,2017-10-09,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.,"Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women","A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women",COMPLETED,,PHASE3,472,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 07:13:49,2024-10-13 07:13:49,INDUSTRY,,,,,,,Gilead Sciences,Dominican Republic|Puerto Rico|Russian Federation|Thailand|Uganda|United States,"Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Social circumstances|Vascular disorders"
NCT02655419,,2015-12-01,2018-10-24,,2020-03-31,2016-01-12,2016-01-14,ESTIMATED,2018-10-25,2019-03-04,ACTUAL,,,,2020-03-31,2020-04-02,ACTUAL,2016-05-19,ACTUAL,2016-05-19,2020-03,2020-03-31,2017-10-26,ACTUAL,2017-10-26,2017-10-26,ACTUAL,2017-10-26,,INTERVENTIONAL,,The modified intent-to-treat (MITT) population included all enrolled participants who received any amount of study drug.,Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE),"A PHASE IIA PROSPECTIVE, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE PHARMACOKINETICS (PK) AND SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAIS) IN HOSPITALIZED ADULTS",COMPLETED,,PHASE2,40,ACTUAL,Pfizer,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-14 17:03:12,2024-10-14 17:03:12,INDUSTRY,,,,,,,Innovative Medicines Initiative (IMI) COMBACTE-CARE|Pfizer,France|Germany|Spain,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02660489,,2016-01-12,2019-12-10,,2021-02-09,2016-01-20,2016-01-21,ESTIMATED,2021-02-09,2021-02-26,ACTUAL,,,,2021-02-09,2021-02-26,ACTUAL,2015-01,ACTUAL,2015-01-31,2021-02,2021-02-28,2018-02,ACTUAL,2018-02-28,2018-02,ACTUAL,2018-02-28,,INTERVENTIONAL,,Participants who completed the study and had confirmed rhinovirus infection,Effect of OC459 on the Response to Rhinovirus Challenge in Asthma,Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma,COMPLETED,,PHASE2,44,ACTUAL,Imperial College London,,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 05:34:06,2024-10-14 05:34:06,OTHER,,,,,,,"Atopix Therapeutics, Ltd.|Imperial College London|Medical Research Council",United Kingdom,Nervous system disorders
NCT02664415,,2016-01-20,2018-08-03,,2021-10-29,2016-01-22,2016-01-27,ESTIMATED,2018-10-16,2018-10-17,ACTUAL,,,,2021-10-29,2021-11-02,ACTUAL,2016-08,,2016-08-31,2021-10,2021-10-31,2017-08-04,ACTUAL,2017-08-04,2017-08-04,ACTUAL,2017-08-04,,INTERVENTIONAL,,,Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection,Safety and Therapeutic Efficacy of the Broadly Neutralizing HIV-1 Specific Monoclonal Antibody VRC01 During Analytic Treatment Interruption in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection,COMPLETED,,PHASE2,23,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 10:16:10,2024-10-14 10:16:10,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Thailand,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02671500,,2016-01-29,2018-12-20,,2018-12-20,2016-01-29,2016-02-02,ESTIMATED,2018-12-20,2019-01-08,ACTUAL,,,,2018-12-20,2019-01-08,ACTUAL,2016-04-19,ACTUAL,2016-04-19,2018-12,2018-12-31,2018-03-27,ACTUAL,2018-03-27,2018-01-05,ACTUAL,2018-01-05,,INTERVENTIONAL,,Safety Analysis Set included participants who were enrolled into the study and received at least 1 dose of study drug.,Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV,"A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV",COMPLETED,,PHASE3,375,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 17:13:28,2024-10-13 17:13:28,INDUSTRY,,,,,,,Gilead Sciences,China|Malaysia|Singapore|Thailand|Vietnam,"Infections and infestations|Injury, poisoning and procedural complications"
NCT02676895,,2016-02-01,2018-03-09,,2018-10-08,2016-02-03,2016-02-08,ESTIMATED,2018-10-08,2019-02-18,ACTUAL,,,,2018-10-08,2019-02-18,ACTUAL,2016-08-08,ACTUAL,2016-08-08,2018-10,2018-10-31,2017-03-10,ACTUAL,2017-03-10,2017-03-10,ACTUAL,2017-03-10,,INTERVENTIONAL,,,A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults,"A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis",COMPLETED,,PHASE2,74,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,TRUE,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 22:55:35,2024-10-14 22:55:35,INDUSTRY,,,,,,,GlaxoSmithKline,Kenya,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02690181,,2016-02-16,2017-10-30,,2024-04-01,2016-02-19,2016-02-24,ESTIMATED,2018-05-21,2018-07-16,ACTUAL,,,,2024-04-01,2024-04-04,ACTUAL,2016-03-29,ACTUAL,2016-03-29,2024-03,2024-03-31,2016-11-02,ACTUAL,2016-11-02,2016-11-02,ACTUAL,2016-11-02,,INTERVENTIONAL,,,Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.,"A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subjects.",COMPLETED,,PHASE2,80,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,FALSE,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20047,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-15 03:12:16,2024-10-15 03:12:16,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02692651,,2016-02-23,2022-02-23,,2022-03-24,2016-02-23,2016-02-26,ESTIMATED,2022-03-24,2022-03-25,ACTUAL,,,,2022-03-24,2022-03-25,ACTUAL,2017-05-01,ACTUAL,2017-05-01,2022-03,2022-03-31,2021-06-23,ACTUAL,2021-06-23,2021-05-23,ACTUAL,2021-05-23,,INTERVENTIONAL,,,A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections,A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections,COMPLETED,,PHASE4,144,ACTUAL,University of Michigan,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 01:39:59,2024-10-13 01:39:59,OTHER,,,,,,,Merck Sharp & Dohme LLC|University of Michigan,United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02706717,,2016-03-08,2018-05-30,,2019-12-18,2016-03-10,2016-03-11,ESTIMATED,2018-05-30,2018-06-27,ACTUAL,,,,2019-12-18,2020-01-06,ACTUAL,2016-04,ACTUAL,2016-04-30,2019-12,2019-12-31,2017-08-28,ACTUAL,2017-08-28,2017-06-05,ACTUAL,2017-06-05,,INTERVENTIONAL,,All enrolled participants.,Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers,"Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study",COMPLETED,,PHASE2,93,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 12:52:45,2024-10-13 12:52:45,NETWORK,,,,,,,"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|Exegi Pharma, LLC|National Institute of Allergy and Infectious Diseases (NIAID)",Puerto Rico|United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders"
NCT02707601,,2016-03-09,2018-09-12,,2018-10-19,2016-03-09,2016-03-14,ESTIMATED,2018-09-12,2018-10-09,ACTUAL,,,,2018-10-19,2018-11-14,ACTUAL,2016-04-01,ACTUAL,2016-04-01,2018-09,2018-09-30,2017-09-29,ACTUAL,2017-09-29,2017-09-14,ACTUAL,2017-09-14,,INTERVENTIONAL,Co-STARs,"Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug (E/C/F/TAF, F/R/TAF, or LDV/SOF).","Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)",COMPLETED,,PHASE3,150,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 01:54:24,2024-10-14 01:54:24,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02707601,,2016-03-09,2018-09-12,,2018-10-19,2016-03-09,2016-03-14,ESTIMATED,2018-09-12,2018-10-09,ACTUAL,,,,2018-10-19,2018-11-14,ACTUAL,2016-04-01,ACTUAL,2016-04-01,2018-09,2018-09-30,2017-09-29,ACTUAL,2017-09-29,2017-09-14,ACTUAL,2017-09-14,,INTERVENTIONAL,Co-STARs,"Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug (E/C/F/TAF, F/R/TAF, or LDV/SOF).","Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)",COMPLETED,,PHASE3,150,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 01:54:24,2024-10-14 01:54:24,INDUSTRY,,,,,,,Gilead Sciences,Puerto Rico|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02714595,,2016-02-26,2020-10-21,2020-03-26,2020-12-18,2016-03-15,2016-03-21,ESTIMATED,2020-11-18,2020-12-17,ACTUAL,2020-03-26,2020-04-01,ACTUAL,2020-12-18,2021-01-12,ACTUAL,2016-09-07,ACTUAL,2016-09-07,2020-12,2020-12-31,2019-04-22,ACTUAL,2019-04-22,2019-04-01,ACTUAL,2019-04-01,,INTERVENTIONAL,CREDIBLE - CR,The Carbapenem-resistant Microbiological Intent-to-treat (CR Micro-ITT) population includes randomized participants who received at least 1 dose of study drug and who had a central laboratory confirmed carbapenem resistant Gram-negative pathogen at Baseline from an appropriate clinical biospecimen.,Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens,"A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens",COMPLETED,,PHASE3,152,ACTUAL,Shionogi Inc.,,2,,,TRUE,,,,TRUE,,,,,,,,,,,,,2024-10-14 15:47:20,2024-10-14 15:47:20,INDUSTRY,,NCT03780140,APPROVED_FOR_MARKETING,,,,Shionogi,"Brazil|Colombia|Croatia|France|Germany|Greece|Guatemala|Israel|Italy|Japan|Korea, Republic of|Spain|Taiwan|Thailand|Turkey|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02714595,,2016-02-26,2020-10-21,2020-03-26,2020-12-18,2016-03-15,2016-03-21,ESTIMATED,2020-11-18,2020-12-17,ACTUAL,2020-03-26,2020-04-01,ACTUAL,2020-12-18,2021-01-12,ACTUAL,2016-09-07,ACTUAL,2016-09-07,2020-12,2020-12-31,2019-04-22,ACTUAL,2019-04-22,2019-04-01,ACTUAL,2019-04-01,,INTERVENTIONAL,CREDIBLE - CR,The Carbapenem-resistant Microbiological Intent-to-treat (CR Micro-ITT) population includes randomized participants who received at least 1 dose of study drug and who had a central laboratory confirmed carbapenem resistant Gram-negative pathogen at Baseline from an appropriate clinical biospecimen.,Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens,"A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens",COMPLETED,,PHASE3,152,ACTUAL,Shionogi Inc.,,2,,,TRUE,,,,TRUE,,,,,,,,,,,,,2024-10-14 15:47:20,2024-10-14 15:47:20,INDUSTRY,,NCT03780140,APPROVED_FOR_MARKETING,,,,Shionogi,"Brazil|Colombia|Croatia|France|Germany|Greece|Guatemala|Israel|Italy|Japan|Korea, Republic of|Spain|Taiwan|Thailand|Turkey|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02715700,,2016-03-17,2018-09-24,,2019-06-12,2016-03-21,2016-03-22,ESTIMATED,2019-02-25,2019-06-03,ACTUAL,,,,2019-06-12,2019-06-25,ACTUAL,2015-09-28,ACTUAL,2015-09-28,2019-06,2019-06-30,2016-08-15,ACTUAL,2016-08-15,2016-06-13,ACTUAL,2016-06-13,,INTERVENTIONAL,,,Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045),A Multiple-Dose Clinical Trial to Study the Effect of MK-1439 (Doravirine) on Methadone Pharmacokinetics,COMPLETED,,PHASE1,14,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 16:12:53,2024-10-14 16:12:53,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Gastrointestinal disorders|General disorders|Investigations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT02716675,,2016-03-17,2021-11-23,,2022-02-08,2016-03-22,2016-03-23,ESTIMATED,2022-01-12,2022-02-08,ACTUAL,,,,2022-02-08,2022-02-23,ACTUAL,2016-04-06,ACTUAL,2016-04-06,2022-02,2022-02-28,2020-12-01,ACTUAL,2020-12-01,2020-12-01,ACTUAL,2020-12-01,,INTERVENTIONAL,,Safety Population,Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men,A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men,COMPLETED,,PHASE2,2699,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 19:51:18,2024-10-13 19:51:18,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Peru|Switzerland|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT02720094,,2016-03-21,2022-09-29,,2024-03-11,2016-03-21,2016-03-25,ESTIMATED,2023-11-21,2023-11-24,ACTUAL,,,,2024-03-11,2024-03-13,ACTUAL,2016-12,,2016-12-31,2024-03,2024-03-31,2024-07-01,ESTIMATED,2024-07-01,2020-05-14,ACTUAL,2020-05-14,,INTERVENTIONAL,,,Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men,A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine For Pre-Exposure Prophylaxis in HIV-Uninfected Men and Transgender Women Who Have Sex With Men,ACTIVE_NOT_RECRUITING,,PHASE2/PHASE3,4570,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 21:10:53,2024-10-13 21:10:53,NIH,,,,,,,Gilead Sciences|National Institute of Allergy and Infectious Diseases (NIAID)|ViiV Healthcare,Argentina|Brazil|Peru|South Africa|Thailand|United States|Vietnam,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT02722837,,2016-03-24,2018-06-20,,2018-10-19,2016-03-24,2016-03-30,ESTIMATED,2018-06-20,2018-07-17,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2016-04-04,ACTUAL,2016-04-04,2018-06,2018-06-30,2017-09-13,ACTUAL,2017-09-13,2017-06-26,ACTUAL,2017-06-26,,INTERVENTIONAL,,Safety Analysis Set: all participants who received at least 1 dose of study drug,Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection,"A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE3,119,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 16:45:10,2024-10-14 16:45:10,INDUSTRY,,,,,,,Gilead Sciences,Russian Federation|Sweden,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Renal and urinary disorders"
NCT02728089,,2016-03-30,2018-08-20,,2019-01-17,2016-03-30,2016-04-05,ESTIMATED,2018-08-20,2018-09-19,ACTUAL,,,,2019-01-17,2019-02-05,ACTUAL,2016-04-14,ACTUAL,2016-04-14,2019-01,2019-01-31,2017-09-05,ACTUAL,2017-09-05,2017-09-05,ACTUAL,2017-09-05,,INTERVENTIONAL,,,Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014),"A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection",COMPLETED,,PHASE3,115,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 02:12:28,2024-10-15 02:12:28,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Cardiac disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
NCT02728089,,2016-03-30,2018-08-20,,2019-01-17,2016-03-30,2016-04-05,ESTIMATED,2018-08-20,2018-09-19,ACTUAL,,,,2019-01-17,2019-02-05,ACTUAL,2016-04-14,ACTUAL,2016-04-14,2019-01,2019-01-31,2017-09-05,ACTUAL,2017-09-05,2017-09-05,ACTUAL,2017-09-05,,INTERVENTIONAL,,,Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014),"A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection",COMPLETED,,PHASE3,115,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 02:12:28,2024-10-15 02:12:28,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Cardiac disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
NCT02728206,,2016-03-31,2019-01-07,,2019-02-05,2016-03-31,2016-04-05,ESTIMATED,2019-02-05,2019-02-06,ACTUAL,,,,2019-02-05,2019-02-06,ACTUAL,2016-06-12,ACTUAL,2016-06-12,2019-02,2019-02-28,2018-01-16,ACTUAL,2018-01-16,2018-01-16,ACTUAL,2018-01-16,,INTERVENTIONAL,,Safety Analysis Set included all participants who took at least 1 dose of study drug.,Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation,"A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting",COMPLETED,,PHASE2,9,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 02:20:45,2024-10-14 02:20:45,INDUSTRY,,,,,,,Gilead Sciences,New Zealand,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02729038,,2016-03-31,2018-06-14,,2020-07-13,2016-03-31,2016-04-06,ESTIMATED,2018-11-11,2018-11-20,ACTUAL,,,,2020-07-13,2020-07-21,ACTUAL,2016-06-29,ACTUAL,2016-06-29,2020-07,2020-07-31,2017-06-20,ACTUAL,2017-06-20,2017-06-20,ACTUAL,2017-06-20,,INTERVENTIONAL,,,Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function,"A Phase I, Open-Label, Single-Dose, Multi-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Subjects With Varying Degrees of Renal Impairment and in Matched Control Subjects With Normal Renal Function",COMPLETED,,PHASE1,32,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,FALSE,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20385,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 15:59:32,2024-10-14 15:59:32,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02734862,,2016-03-16,2020-09-04,,2020-12-04,2016-04-06,2016-04-12,ESTIMATED,2020-12-04,2020-12-08,ACTUAL,,,,2020-12-04,2020-12-08,ACTUAL,2016-07-26,ACTUAL,2016-07-26,2020-12,2020-12-31,2019-07,ACTUAL,2019-07-31,2019-06,ACTUAL,2019-06-30,,INTERVENTIONAL,STRIVE,The Intent-to-Treat (ITT) population analyzed consisted of all subjects randomized to treatment. Subjects were analyzed based on the treatment group to which they were randomized.,CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension,"A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis",COMPLETED,,PHASE2,207,ACTUAL,Cidara Therapeutics Inc.,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-14 17:40:56,2024-10-14 17:40:56,INDUSTRY,,,,,,,Cidara Therapeutics Inc.,Belgium|Bulgaria|Canada|Greece|Hungary|Italy|Romania|Russian Federation|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02735863,,2016-04-08,2022-06-01,,2024-05-16,2016-04-08,2016-04-13,ESTIMATED,2024-05-16,2024-09-19,ACTUAL,,,,2024-05-16,2024-09-19,ACTUAL,2016-05,,2016-05-31,2022-06,2022-06-30,2018-01-11,ACTUAL,2018-01-11,2017-08-30,ACTUAL,2017-08-30,,INTERVENTIONAL,,"Patients who had received at least one dose of the study drug, and who had at least one baseline value.",ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment,"A Multi-center, Randomized, Double-blind, Placebo-controlled Phase IIa Trial to Compare the Safety of ABX464 Given at a Fixed Dose to Placebo in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment (Darunavir/Ritonavir or Darunavir/Cobicistat).",COMPLETED,,PHASE2,30,ACTUAL,Abivax S.A.,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 03:42:21,2024-10-15 03:42:21,INDUSTRY,,,,,,,Abivax S.A.,Belgium|France|Spain,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders"
NCT02737722,,2016-04-05,2019-07-05,,2019-10-31,2016-04-08,2016-04-14,ESTIMATED,2019-10-31,2019-11-19,ACTUAL,,,,2019-10-31,2019-11-19,ACTUAL,2016-04,ACTUAL,2016-04-30,2019-10,2019-10-31,2018-02,ACTUAL,2018-02-28,2017-08,ACTUAL,2017-08-31,,INTERVENTIONAL,,,Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus,"A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus",COMPLETED,,PHASE1/PHASE2,31,ACTUAL,Lakewood-Amedex Inc,"Participants were enrolled into Cohorts 1, 2, and 3; Cohorts 4 and 5 were not enrolled because of challenges with enrolling participants. Additionally, Lakewood Amedex developed a gel formulation to be used for subsequent clinical studies.",2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 19:11:56,2024-10-14 19:11:56,INDUSTRY,,,,,,,Lakewood-Amedex Inc,United States,Cardiac disorders|Infections and infestations
NCT02738138,,2016-04-11,2018-02-27,,2021-07-09,2016-04-11,2016-04-14,ESTIMATED,2018-04-09,2018-05-09,ACTUAL,,,,2021-07-09,2021-07-13,ACTUAL,2016-05-17,ACTUAL,2016-05-17,2021-07,2021-07-31,2017-06-07,ACTUAL,2017-06-07,2017-03-15,ACTUAL,2017-03-15,,INTERVENTIONAL,EXPEDITION-2,,A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2),"A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)",COMPLETED,,PHASE3,153,ACTUAL,AbbVie,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 14:01:33,2024-10-14 14:01:33,INDUSTRY,,,,,,,AbbVie,Australia|Belarus|France|Germany|Poland|Puerto Rico|Russian Federation|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02738138,,2016-04-11,2018-02-27,,2021-07-09,2016-04-11,2016-04-14,ESTIMATED,2018-04-09,2018-05-09,ACTUAL,,,,2021-07-09,2021-07-13,ACTUAL,2016-05-17,ACTUAL,2016-05-17,2021-07,2021-07-31,2017-06-07,ACTUAL,2017-06-07,2017-03-15,ACTUAL,2017-03-15,,INTERVENTIONAL,EXPEDITION-2,,A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2),"A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)",COMPLETED,,PHASE3,153,ACTUAL,AbbVie,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 14:01:33,2024-10-14 14:01:33,INDUSTRY,,,,,,,AbbVie,Australia|Belarus|France|Germany|Poland|Puerto Rico|Russian Federation|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02738333,,2016-04-11,2018-02-12,,2018-10-19,2016-04-11,2016-04-14,ESTIMATED,2018-02-12,2018-03-14,ACTUAL,,,,2018-10-19,2018-11-16,ACTUAL,2016-04-12,ACTUAL,2016-04-12,2018-02,2018-02-28,2017-05-11,ACTUAL,2017-05-11,2017-02-14,ACTUAL,2017-02-14,,INTERVENTIONAL,,Safety Analysis Set: participants who took at least 1 dose of study drug,Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection,"A Phase 3b, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection",COMPLETED,,PHASE3,239,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 06:01:52,2024-10-13 06:01:52,INDUSTRY,,,,,,,Gilead Sciences,Japan,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders"
NCT02739997,,2016-03-30,2018-06-14,,2018-07-11,2016-04-11,2016-04-15,ESTIMATED,2018-07-11,2018-07-12,ACTUAL,,,,2018-07-11,2018-08-09,ACTUAL,2016-04-08,ACTUAL,2016-04-08,2018-07,2018-07-31,2017-07-28,ACTUAL,2017-07-28,2017-07-28,ACTUAL,2017-07-28,,INTERVENTIONAL,,,Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013),"A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Used in Combination With Metronidazole in Japanese Patients With Complicated Intra-abdominal Infection.",COMPLETED,,PHASE3,100,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 08:36:00,2024-10-14 08:36:00,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders"
NCT02739997,,2016-03-30,2018-06-14,,2018-07-11,2016-04-11,2016-04-15,ESTIMATED,2018-07-11,2018-07-12,ACTUAL,,,,2018-07-11,2018-08-09,ACTUAL,2016-04-08,ACTUAL,2016-04-08,2018-07,2018-07-31,2017-07-28,ACTUAL,2017-07-28,2017-07-28,ACTUAL,2017-07-28,,INTERVENTIONAL,,,Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013),"A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Used in Combination With Metronidazole in Japanese Patients With Complicated Intra-abdominal Infection.",COMPLETED,,PHASE3,100,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,,,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf,2024-10-14 08:36:00,2024-10-14 08:36:00,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders"
NCT02741323,,2016-04-13,2023-05-10,,2023-08-17,2016-04-13,2016-04-18,ESTIMATED,2023-08-17,2023-08-21,ACTUAL,,,,2023-08-17,2023-08-21,ACTUAL,2017-01-01,ACTUAL,2017-01-01,2023-08,2023-08-31,2022-05-10,ACTUAL,2022-05-10,2022-05-10,ACTUAL,2022-05-10,,INTERVENTIONAL,,"The analysis population includes all subjects who were randomized, received at least 1 dose of Maraviroc or Placebo, and underwent kidney transplant.",Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients,Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients,COMPLETED,,PHASE2,97,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"For the primary outcome ""measured GFR by iohexol clearance at week 52"", only 30 subjects (vs. 130 planned) could complete the on-site iohexol study due to COVID-19 restrictions and contribute data. There were also consistency/reliability issues with the generated data due to varying laboratory controls. Secondary outcome of ""Mean eGFR at Week 52 Based on CKD-EPI Creatinine Equation"" is a good surrogate for the primary outcome, with better reliability and bigger sample size for group comparison.",2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 17:13:28,2024-10-13 17:13:28,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02744040,,2016-04-08,2021-11-24,,2022-03-02,2016-04-14,2016-04-20,ESTIMATED,2022-03-02,2022-03-29,ACTUAL,,,,2022-03-02,2022-03-29,ACTUAL,2017-08-28,ACTUAL,2017-08-28,2022-03,2022-03-31,2020-11-30,ACTUAL,2020-11-30,2020-11-30,ACTUAL,2020-11-30,,INTERVENTIONAL,MERLIN,,Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use,Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use,COMPLETED,,NA,151,ACTUAL,Fred Hutchinson Cancer Center,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 00:55:42,2024-10-13 00:55:42,OTHER,,,,,,,"Asociación Civil Impacta Salud y Educación, Peru|Fred Hutchinson Cancer Center|National Institute on Drug Abuse (NIDA)|Seattle Children's Hospital|Université de Montréal|University of California, San Francisco|University of Washington",Peru,Gastrointestinal disorders|Infections and infestations|Metabolism and nutrition disorders
NCT02750761,,2016-04-01,2019-12-02,,2019-12-02,2016-04-21,2016-04-25,ESTIMATED,2019-12-02,2019-12-20,ACTUAL,,,,2019-12-02,2019-12-20,ACTUAL,2016-05-02,ACTUAL,2016-05-02,2019-12,2019-12-31,2018-12-21,ACTUAL,2018-12-21,2018-12-16,ACTUAL,2018-12-16,,INTERVENTIONAL,,,"A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)","A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old",COMPLETED,,PHASE1,32,ACTUAL,Merck Sharp & Dohme LLC,,6,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 07:10:08,2024-10-14 07:10:08,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Colombia|Norway|Ukraine|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02752906,,2016-04-22,2020-05-19,2018-01-15,2022-03-24,2016-04-22,2016-04-27,ESTIMATED,2020-05-19,2020-06-05,ACTUAL,2018-01-15,2018-01-18,ACTUAL,2022-03-24,2022-04-05,ACTUAL,2016-04-15,ACTUAL,2016-04-15,2022-03,2022-03-31,2016-12-19,ACTUAL,2016-12-19,2016-12-19,ACTUAL,2016-12-19,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine,Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults,COMPLETED,,PHASE3,810,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 12:34:19,2024-10-14 12:34:19,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT02753413,,2016-04-21,2017-06-13,,2018-05-29,2016-04-25,2016-04-27,ESTIMATED,2017-06-13,2017-07-11,ACTUAL,,,,2018-05-29,2018-06-26,ACTUAL,2016-04-01,,2016-04-01,2018-05,2018-05-31,2016-06-28,ACTUAL,2016-06-28,2016-06-28,ACTUAL,2016-06-28,,INTERVENTIONAL,,,Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women,An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women,COMPLETED,,PHASE2,102,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,,,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 12:25:40,2024-10-13 12:25:40,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02753946,,2016-04-13,2018-11-16,,2019-03-05,2016-04-27,2016-04-28,ESTIMATED,2018-11-16,2018-12-11,ACTUAL,,,,2019-03-05,2019-03-07,ACTUAL,2016-04,ACTUAL,2016-04-30,2019-03,2019-03-31,2017-05-30,ACTUAL,2017-05-30,2017-01-12,ACTUAL,2017-01-12,,INTERVENTIONAL,ZEUS,"All subjects included (note 1 subject randomized discontinued prior to dosing). Note 6 subjects were incorrectly identified as Hispanic or Latino, instead of White in the database; errata recorded to file.",Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections,"Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults",COMPLETED,,PHASE2/PHASE3,465,ACTUAL,Nabriva Therapeutics AG,,2,,,FALSE,,,,TRUE,,,,,,,,ongoing submissions to IND,"IND/NDA submission, CTA submissions",,YES,"Individual IPD data will be shared in listings with FDA, IRB/ECs, Data Monitoring Committee",2024-10-15 02:53:42,2024-10-15 02:53:42,INDUSTRY,,,,,,,"Medpace, Inc.|Nabriva Therapeutics AG",Belarus|Bulgaria|Croatia|Czechia|Czech Republic|Estonia|Georgia|Greece|Hungary|Latvia|Lithuania|Poland|Romania|Russian Federation|Slovakia|Ukraine|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders"
NCT02753946,,2016-04-13,2018-11-16,,2019-03-05,2016-04-27,2016-04-28,ESTIMATED,2018-11-16,2018-12-11,ACTUAL,,,,2019-03-05,2019-03-07,ACTUAL,2016-04,ACTUAL,2016-04-30,2019-03,2019-03-31,2017-05-30,ACTUAL,2017-05-30,2017-01-12,ACTUAL,2017-01-12,,INTERVENTIONAL,ZEUS,"All subjects included (note 1 subject randomized discontinued prior to dosing). Note 6 subjects were incorrectly identified as Hispanic or Latino, instead of White in the database; errata recorded to file.",Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections,"Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults",COMPLETED,,PHASE2/PHASE3,465,ACTUAL,Nabriva Therapeutics AG,,2,,,FALSE,,,,TRUE,,,,,,,,ongoing submissions to IND,"IND/NDA submission, CTA submissions",,YES,"Individual IPD data will be shared in listings with FDA, IRB/ECs, Data Monitoring Committee",2024-10-15 02:53:42,2024-10-15 02:53:42,INDUSTRY,,,,,,,"Medpace, Inc.|Nabriva Therapeutics AG",Belarus|Bulgaria|Croatia|Czechia|Czech Republic|Estonia|Georgia|Greece|Hungary|Latvia|Lithuania|Poland|Romania|Russian Federation|Slovakia|Ukraine|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders"
NCT02756208,,2016-04-17,2019-01-02,,2021-11-15,2016-04-26,2016-04-29,ESTIMATED,2021-10-18,2021-11-16,ACTUAL,,,,2021-11-15,2021-12-16,ACTUAL,2015-11,ACTUAL,2015-11-30,2021-11,2021-11-30,2018-07,ACTUAL,2018-07-31,2018-07,ACTUAL,2018-07-31,,INTERVENTIONAL,FLSC-001,Intention-to-treat Analysis: Subjects who received at least 1 dose of vaccine or placebo.,A Safety and Immunogenicity Trial of IHV01,A Phase I Safety and Immunogenicity Trial of IHV01 in HIV-1 Uninfected Volunteers,COMPLETED,,PHASE1,65,ACTUAL,"University of Maryland, Baltimore",,4,,,FALSE,,,,TRUE,TRUE,,,,,,,,,,YES,,2024-10-14 13:55:50,2024-10-14 13:55:50,OTHER,,,,,,,"Auro Vaccines LLC|Bill and Melinda Gates Foundation|University of Maryland, Baltimore",United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02756351,,2016-04-26,2016-12-08,,2016-12-08,2016-04-27,2016-04-29,ESTIMATED,2016-12-08,2017-02-01,ESTIMATED,,,,2016-12-08,2017-02-01,ESTIMATED,2016-04,,2016-04-30,2016-12,2016-12-31,2016-07,ACTUAL,2016-07-31,2016-06,ACTUAL,2016-06-30,,INTERVENTIONAL,,,A Efficacy and Safety Study of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization,A Double-blinded Randomized Clinical Pilot Trial of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization,COMPLETED,,NA,48,ACTUAL,CytaCoat AB,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-13 19:22:39,2024-10-13 19:22:39,INDUSTRY,,,,,,,CytaCoat AB,Sweden,Skin and subcutaneous tissue disorders|Social circumstances
NCT02778204,,2016-05-13,2020-09-02,,2021-12-30,2016-05-17,2016-05-19,ESTIMATED,2020-10-27,2020-11-23,ACTUAL,,,,2021-12-30,2022-01-04,ACTUAL,2017-06-05,ACTUAL,2017-06-05,2021-12,2021-12-31,2019-11-20,ACTUAL,2019-11-20,2019-09-06,ACTUAL,2019-09-06,,INTERVENTIONAL,,Includes all infants.,Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection,Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection,COMPLETED,,PHASE1,47,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"As with other Antiretrovirals (ARVs) in young infants, maraviroc PK parameters showed high intra- and inter-participant variability.",4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 07:08:06,2024-10-13 07:08:06,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|GlaxoSmithKline|National Institute of Allergy and Infectious Diseases (NIAID)|ViiV Healthcare,Kenya|South Africa|Thailand|Uganda|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02781558,,2016-05-20,2018-10-04,,2018-10-30,2016-05-20,2016-05-24,ESTIMATED,2018-10-04,2018-10-30,ACTUAL,,,,2018-10-30,2018-11-27,ACTUAL,2016-07-29,ACTUAL,2016-07-29,2018-10,2018-10-31,2017-10-27,ACTUAL,2017-10-27,2017-10-06,ACTUAL,2017-10-06,,INTERVENTIONAL,,Safety Analysis Set: participants who took at least 1 dose of any study drug,Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis,"A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis",COMPLETED,,PHASE2,204,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 21:22:01,2024-10-14 21:22:01,INDUSTRY,,,,,,,Gilead Sciences,Spain,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders"
NCT02781571,,2016-05-20,2018-07-25,,2018-10-19,2016-05-20,2016-05-24,ESTIMATED,2018-07-25,2018-08-21,ACTUAL,,,,2018-10-19,2018-11-14,ACTUAL,2016-07-27,ACTUAL,2016-07-27,2018-07,2018-07-31,2017-07-28,ACTUAL,2017-07-28,2017-07-28,ACTUAL,2017-07-28,,INTERVENTIONAL,,Safety Analysis Set: participants who took at least 1 dose of the study drug.,Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant",COMPLETED,,PHASE2,79,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-14 22:49:51,2024-10-14 22:49:51,INDUSTRY,,,,,,,Gilead Sciences,Spain|Switzerland|United Kingdom,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02784704,,2016-05-23,2018-12-21,,2021-12-16,2016-05-26,2016-05-27,ESTIMATED,2019-02-12,2019-02-18,ACTUAL,,,,2021-12-16,2022-01-06,ACTUAL,2016-10-13,ACTUAL,2016-10-13,2021-12,2021-12-31,2017-05-19,ACTUAL,2017-05-19,2017-05-08,ACTUAL,2017-05-08,,INTERVENTIONAL,IGNITE4,Modified Intent-to-Treat Population: all randomized subjects who receive any amount of study drug.,Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections,"A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections",COMPLETED,,PHASE3,500,ACTUAL,La Jolla Pharmaceutical Company,,2,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-13 12:14:37,2024-10-13 12:14:37,INDUSTRY,,,,,,,"Tetraphase Pharmaceuticals, Inc.",Bulgaria|Czechia|Czech Republic|Estonia|Georgia|Hungary|Latvia|Lithuania|Romania|Russian Federation|Ukraine|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02786810,,2016-05-17,2017-10-24,,2018-04-10,2016-05-25,2016-06-01,ESTIMATED,2018-03-05,2018-04-04,ACTUAL,,,,2018-04-10,2018-05-11,ACTUAL,2016-03,,2016-03-31,2016-05,2016-05-31,2016-11,ACTUAL,2016-11-30,2016-11,ACTUAL,2016-11-30,,INTERVENTIONAL,,,Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy,Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy,COMPLETED,,PHASE2,10,ACTUAL,University of Tennessee,,1,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 05:14:37,2024-10-14 05:14:37,OTHER,,,,,,,University of Tennessee,United States,General disorders
NCT02794870,,2016-05-24,2018-06-29,,2018-07-27,2016-06-06,2016-06-09,ESTIMATED,2018-07-27,2018-08-27,ACTUAL,,,,2018-07-27,2018-08-27,ACTUAL,2016-07-15,ACTUAL,2016-07-15,2018-07,2018-07-31,2017-07-07,ACTUAL,2017-07-07,2017-07-07,ACTUAL,2017-07-07,,INTERVENTIONAL,,Baseline analysis population was participants who received inoculation.,"Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age",COMPLETED,,PHASE1,33,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-14 13:13:39,2024-10-14 13:13:39,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02797171,,2016-06-07,2020-10-26,,2024-02-19,2016-06-07,2016-06-13,ESTIMATED,2020-12-14,2021-01-08,ACTUAL,,,,2024-02-19,2024-03-20,ACTUAL,2017-03-01,ACTUAL,2017-03-01,2022-08,2022-08-31,2019-06-05,ACTUAL,2019-06-05,2019-06-05,ACTUAL,2019-06-05,,INTERVENTIONAL,,"In Groups 1-3, participants who have their biopsies collected at visit 2; in Groups 4-5, participants who receive infusion at visit 3","Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults","A Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC-HIVMAB060-00-AB (VRC01) and VRC-HIVMAB080-00-AB (VRC01LS) in the Serum and Mucosa of Healthy, HIV-Uninfected Adult Participants",COMPLETED,,PHASE1,80,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 13:38:09,2024-10-14 13:38:09,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),South Africa|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02797470,,2016-06-08,2023-06-02,,2024-07-29,2016-06-08,2016-06-13,ESTIMATED,2023-07-18,2023-07-20,ACTUAL,,,,2024-07-29,2024-07-31,ACTUAL,2016-06-23,ACTUAL,2016-06-23,2024-07,2024-07-31,2025-06-30,ESTIMATED,2025-06-30,2021-05-13,ACTUAL,2021-05-13,,INTERVENTIONAL,,Participants received Stem Cell Gene Therapy,Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant,"A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells",ACTIVE_NOT_RECRUITING,,PHASE1/PHASE2,11,ACTUAL,AIDS Malignancy Consortium,,1,,,FALSE,,,,TRUE,,,,,,,,,,,UNDECIDED,,2024-10-14 02:20:45,2024-10-14 02:20:45,NETWORK,,,,,,,AIDS Malignancy Consortium|California Institute for Regenerative Medicine (CIRM)|National Cancer Institute (NCI),United States,Investigations|Metabolism and nutrition disorders
NCT02797613,,2016-06-08,2019-03-05,,2020-02-26,2016-06-10,2016-06-13,ESTIMATED,2020-02-26,2020-02-27,ACTUAL,,,,2020-02-26,2020-02-27,ACTUAL,2017-01-01,ACTUAL,2017-01-01,2020-02,2020-02-29,2017-05-01,ACTUAL,2017-05-01,2017-05-01,ACTUAL,2017-05-01,,INTERVENTIONAL,,110 Results randomized. All randomized results were analysed.,Restricted Reporting for Positive Urine Cultures,Restricted Reporting for Positive Urine Cultures Randomized Controlled Trial,COMPLETED,,NA,110,ACTUAL,Memorial University of Newfoundland,"Our design is a proof-of-concept which will require additional trials to verify. It would be impractical to manually screen all inpatient urine specimens using our inclusion criteria, although automated eligibility screening may be possible.",2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 00:26:25,2024-10-13 00:26:25,OTHER,,,,,,,Memorial University of Newfoundland,Canada,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|General disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02814916,,2016-06-08,2024-08-15,,2024-08-15,2016-06-23,2016-06-28,ESTIMATED,2024-08-15,2024-09-19,ACTUAL,,,,2024-08-15,2024-09-19,ACTUAL,2017-03-30,ACTUAL,2017-03-30,2024-08,2024-08-31,2024-01-01,ACTUAL,2024-01-01,2024-01-01,ACTUAL,2024-01-01,,INTERVENTIONAL,,Safety population: all participants in the ITT population who received at least 1 dose of study drug,"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,199,ACTUAL,AbbVie,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/,"Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/",https://vivli.org/ourmember/abbvie/,YES,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2024-10-15 03:42:21,2024-10-15 03:42:21,INDUSTRY,,,,,,,AbbVie,Argentina|Belarus|Brazil|Bulgaria|Chile|Colombia|Georgia|Greece|Guatemala|Latvia|Lithuania|Mexico|Panama|Poland|Romania|Russian Federation|South Africa|Spain|Ukraine|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02814916,,2016-06-08,2024-08-15,,2024-08-15,2016-06-23,2016-06-28,ESTIMATED,2024-08-15,2024-09-19,ACTUAL,,,,2024-08-15,2024-09-19,ACTUAL,2017-03-30,ACTUAL,2017-03-30,2024-08,2024-08-31,2024-01-01,ACTUAL,2024-01-01,2024-01-01,ACTUAL,2024-01-01,,INTERVENTIONAL,,Safety population: all participants in the ITT population who received at least 1 dose of study drug,"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,199,ACTUAL,AbbVie,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/,"Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/",https://vivli.org/ourmember/abbvie/,YES,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2024-10-15 03:42:21,2024-10-15 03:42:21,INDUSTRY,,,,,,,AbbVie,Argentina|Belarus|Brazil|Bulgaria|Chile|Colombia|Georgia|Greece|Guatemala|Latvia|Lithuania|Mexico|Panama|Poland|Romania|Russian Federation|South Africa|Spain|Ukraine|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT02822794,,2016-06-30,2018-05-24,,2018-10-19,2016-06-30,2016-07-04,ESTIMATED,2018-07-02,2018-07-03,ACTUAL,,,,2018-10-19,2018-11-14,ACTUAL,2016-07-25,ACTUAL,2016-07-25,2018-07,2018-07-31,2017-08-25,ACTUAL,2017-08-25,2017-06-02,ACTUAL,2017-06-02,,INTERVENTIONAL,,Safety Analysis Set: participants who received at least 1 dose of study drug,Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen,"A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Subjects With Chronic Genotype 1 or 2 HCV Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen",COMPLETED,,PHASE3,117,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 07:32:15,2024-10-13 07:32:15,INDUSTRY,,,,,,,Gilead Sciences,Japan,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02826798,,2016-06-23,2019-06-13,,2020-04-16,2016-07-05,2016-07-11,ESTIMATED,2020-04-16,2020-04-20,ACTUAL,,,,2020-04-16,2020-04-20,ACTUAL,2016-06-23,ACTUAL,2016-06-23,2020-04,2020-04-30,2017-08-24,ACTUAL,2017-08-24,2016-09-15,ACTUAL,2016-09-15,,INTERVENTIONAL,,,"Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults","A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults",COMPLETED,,PHASE1,128,ACTUAL,VBI Vaccines Inc.,,5,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 16:07:16,2024-10-13 16:07:16,INDUSTRY,,,,,,,"Clinical Trial Data Services, LLC|VBI Vaccines Inc.",Canada,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02831673,,2016-07-08,2019-03-26,,2023-08-01,2016-07-08,2016-07-13,ESTIMATED,2019-03-26,2019-04-18,ACTUAL,,,,2023-08-01,2023-08-24,ACTUAL,2016-07-21,ACTUAL,2016-07-21,2023-07,2023-07-31,2022-08-15,ACTUAL,2022-08-15,2018-03-29,ACTUAL,2018-03-29,,INTERVENTIONAL,,Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population which consisted of all randomized participants who received at least one dose of study treatment.,"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults",COMPLETED,,PHASE3,719,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:53:05,2024-10-13 20:53:05,INDUSTRY,,,,,,,"GlaxoSmithKline|PPD DEVELOPMENT, LP|ViiV Healthcare","Argentina|Australia|Belgium|Canada|France|Germany|Italy|Korea, Republic of|Mexico|Netherlands|Portugal|Romania|Russian Federation|South Africa|Spain|Taiwan|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02831673,,2016-07-08,2019-03-26,,2023-08-01,2016-07-08,2016-07-13,ESTIMATED,2019-03-26,2019-04-18,ACTUAL,,,,2023-08-01,2023-08-24,ACTUAL,2016-07-21,ACTUAL,2016-07-21,2023-07,2023-07-31,2022-08-15,ACTUAL,2022-08-15,2018-03-29,ACTUAL,2018-03-29,,INTERVENTIONAL,,Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population which consisted of all randomized participants who received at least one dose of study treatment.,"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults",COMPLETED,,PHASE3,719,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 20:53:05,2024-10-13 20:53:05,INDUSTRY,,,,,,,"GlaxoSmithKline|PPD DEVELOPMENT, LP|ViiV Healthcare","Argentina|Australia|Belgium|Canada|France|Germany|Italy|Korea, Republic of|Mexico|Netherlands|Portugal|Romania|Russian Federation|South Africa|Spain|Taiwan|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02831764,,2016-07-08,2019-03-28,,2023-12-04,2016-07-08,2016-07-13,ESTIMATED,2019-03-28,2019-04-22,ACTUAL,,,,2023-12-04,2023-12-07,ACTUAL,2016-07-18,ACTUAL,2016-07-18,2023-12,2023-12-31,2022-06-29,ACTUAL,2022-06-29,2018-04-04,ACTUAL,2018-04-04,,INTERVENTIONAL,,Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of study medication.,"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults",COMPLETED,,PHASE3,722,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-15 03:12:16,2024-10-15 03:12:16,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Australia|Belgium|Canada|France|Germany|Italy|Mexico|Peru|Poland|Portugal|Romania|Russian Federation|Spain|Switzerland|Taiwan|United Kingdom|United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02831764,,2016-07-08,2019-03-28,,2023-12-04,2016-07-08,2016-07-13,ESTIMATED,2019-03-28,2019-04-22,ACTUAL,,,,2023-12-04,2023-12-07,ACTUAL,2016-07-18,ACTUAL,2016-07-18,2023-12,2023-12-31,2022-06-29,ACTUAL,2022-06-29,2018-04-04,ACTUAL,2018-04-04,,INTERVENTIONAL,,Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of study medication.,"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults",COMPLETED,,PHASE3,722,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-15 03:12:16,2024-10-15 03:12:16,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,Argentina|Australia|Belgium|Canada|France|Germany|Italy|Mexico|Peru|Poland|Portugal|Romania|Russian Federation|Spain|Switzerland|Taiwan|United Kingdom|United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02833844,,2016-06-13,2020-06-25,,2022-07-15,2016-07-12,2016-07-14,ESTIMATED,2020-07-20,2020-07-21,ACTUAL,,,,2022-07-15,2022-07-22,ACTUAL,2017-05-22,ACTUAL,2017-05-22,2022-07,2022-07-31,2020-01-27,ACTUAL,2020-01-27,2019-07-09,ACTUAL,2019-07-09,,INTERVENTIONAL,,,"Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia","A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects With HIV and With Hyperlipidemia and/or Mixed Dyslipidemia",COMPLETED,,PHASE3,467,ACTUAL,Amgen,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.,"Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.",https://www.amgen.com/datasharing,YES,De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request,2024-10-14 15:41:07,2024-10-14 15:41:07,INDUSTRY,,,,,,,Amgen,Australia|Belgium|Brazil|Canada|France|Greece|Italy|Poland|Portugal|Romania|South Africa|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02836236,,2016-07-14,2018-03-19,,2024-09-09,2016-07-14,2016-07-18,ESTIMATED,2018-03-19,2018-04-18,ACTUAL,,,,2024-09-09,2024-10-02,ACTUAL,2015-06-19,ACTUAL,2015-06-19,2024-09,2024-09-30,2023-09-18,ACTUAL,2023-09-18,2017-04-05,ACTUAL,2017-04-05,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug. Participants were analyzed according to the treatment they actually received during the double-blinded phase.,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China),"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B",COMPLETED,,PHASE3,155,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gileadclinicaltrials.com/transparency-policy/,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy/",2024-10-14 15:59:32,2024-10-14 15:59:32,INDUSTRY,,,,,,,Gilead Sciences,China,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02836249,,2016-07-14,2018-03-19,,2024-08-08,2016-07-14,2016-07-18,ESTIMATED,2018-03-19,2018-04-17,ACTUAL,,,,2024-08-08,2024-09-04,ACTUAL,2015-06-19,ACTUAL,2015-06-19,2024-08,2024-08-31,2023-08-31,ACTUAL,2023-08-31,2017-03-21,ACTUAL,2017-03-21,,INTERVENTIONAL,,Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug. Participants were analyzed according to the treatment they actually received during the double-blinded phase.,Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China),"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B",COMPLETED,,PHASE3,181,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gileadclinicaltrials.com/transparency-policy#Commitment,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment",2024-10-15 01:54:09,2024-10-15 01:54:09,INDUSTRY,,,,,,,Gilead Sciences,China,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02836990,,2016-07-11,2020-02-25,,2020-12-23,2016-07-14,2016-07-19,ESTIMATED,2020-12-23,2020-12-28,ACTUAL,,,,2020-12-23,2020-12-28,ACTUAL,2016-07,,2016-07-31,2020-12,2020-12-31,2019-09,ACTUAL,2019-09-30,2019-09,ACTUAL,2019-09-30,,INTERVENTIONAL,,"Several patients randomized did not receive the randomized treatment based on physician decision, and were excluded from analysis as actual treatment rather than intent to treat was assessed.",Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery,Prevena™ Incision Management System Versus Dermabond in the Prevention of Groin Wound Infections in Patients Undergoing Vascular Surgery,COMPLETED,,NA,105,ACTUAL,State University of New York at Buffalo,,2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 23:50:05,2024-10-13 23:50:05,OTHER,,,,,,,"KCI USA, Inc|State University of New York at Buffalo",United States,Infections and infestations
NCT02839161,,2016-07-18,2024-01-03,,2024-01-03,2016-07-19,2016-07-20,ESTIMATED,2024-01-03,2024-06-10,ACTUAL,,,,2024-01-03,2024-06-10,ACTUAL,2017-01,ACTUAL,2017-01-31,2024-01,2024-01-31,2019-03-28,ACTUAL,2019-03-28,2018-12-13,ACTUAL,2018-12-13,,INTERVENTIONAL,,,Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children,"Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-APR-1 (M74)/Alhydrogel® and Na-GST-1/ Alhydrogel® in Gabonese Children",COMPLETED,,PHASE1,60,ACTUAL,Baylor College of Medicine,,8,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-15 00:30:16,2024-10-15 00:30:16,OTHER,,,,,,,Baylor College of Medicine,Gabon,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02842086,,2016-07-20,2020-01-29,,2024-07-03,2016-07-20,2016-07-22,ESTIMATED,2020-03-03,2020-03-17,ACTUAL,,,,2024-07-03,2024-07-05,ACTUAL,2016-09-02,ACTUAL,2016-09-02,2024-07,2024-07-31,2027-09,ESTIMATED,2027-09-30,2019-01-31,ACTUAL,2019-01-31,,INTERVENTIONAL,DISCOVER,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug. Participants were grouped according to the treatment they actually received.,Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection,"A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection",ACTIVE_NOT_RECRUITING,,PHASE3,5399,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-15 00:35:58,2024-10-15 00:35:58,INDUSTRY,,,,,,,Gilead Sciences,Austria|Canada|Denmark|France|Germany|Ireland|Italy|Netherlands|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT02842853,,2016-07-15,2020-02-24,2018-02-26,2022-03-24,2016-07-20,2016-07-25,ESTIMATED,2020-02-24,2020-03-09,ACTUAL,2018-02-26,2018-02-28,ACTUAL,2022-03-24,2022-04-05,ACTUAL,2016-07-15,ACTUAL,2016-07-15,2022-03,2022-03-31,2017-02-28,ACTUAL,2017-02-28,2017-02-28,ACTUAL,2017-02-28,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years",COMPLETED,,PHASE3,3344,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 09:22:22,2024-10-14 09:22:22,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02842866,,2016-07-15,2020-02-05,2018-02-06,2022-03-24,2016-07-20,2016-07-25,ESTIMATED,2020-02-05,2020-02-18,ACTUAL,2018-02-06,2018-02-09,ACTUAL,2022-03-24,2022-04-05,ACTUAL,2016-07-15,ACTUAL,2016-07-15,2022-03,2022-03-31,2017-02-13,ACTUAL,2017-02-13,2017-02-13,ACTUAL,2017-02-13,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults Age 56 Years and Older,COMPLETED,,PHASE3,907,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 19:59:08,2024-10-14 19:59:08,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02852005,,2016-07-28,2020-12-16,,2022-08-04,2016-07-28,2016-08-02,ESTIMATED,2021-03-30,2021-04-01,ACTUAL,,,,2022-08-04,2022-08-08,ACTUAL,2017-01,ACTUAL,2017-01-31,2022-08,2022-08-31,2019-10-29,ACTUAL,2019-10-29,2018-08-29,ACTUAL,2018-08-29,,INTERVENTIONAL,,,"Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205","A Phase 1 Clinical Trial to Evaluate the Immunogenicity of AIDSVAX B/E Bivalent gp120 Vaccine and MVA/HIV62B in Healthy, HIV-1-Uninfected Adult Participants Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205",COMPLETED,,PHASE1,27,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 21:05:16,2024-10-14 21:05:16,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Peru|United States,"Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders"
NCT02853435,,2016-07-29,2018-09-04,,2020-09-14,2016-07-29,2016-08-03,ESTIMATED,2018-11-02,2018-11-14,ACTUAL,,,,2020-09-14,2020-10-08,ACTUAL,2016-08-04,ACTUAL,2016-08-04,2020-09,2020-09-30,2017-10-17,ACTUAL,2017-10-17,2017-10-17,ACTUAL,2017-10-17,,INTERVENTIONAL,,,"To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.","A Phase I; Multi-Center; Open-Label (Parts 1 and 2); Randomized, Double-Blind, Placebo-Controlled (Part 3); Single-Dose; 3-Part Study to Evaluate the Relative Bioavailability of Three Formulations in Healthy Subjects, Food Effect on Tablet Formulation in Healthy Subjects, and Pharmacokinetics of Gepotidacin (GSK2140944) in Japanese Subjects in Fasted and Fed States",COMPLETED,,PHASE1,48,ACTUAL,GlaxoSmithKline,,7,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-15 01:48:22,2024-10-15 01:48:22,INDUSTRY,,,,,,,GlaxoSmithKline,United States,Gastrointestinal disorders|Nervous system disorders
NCT02858401,,2016-07-26,2020-02-07,,2020-02-07,2016-08-03,2016-08-08,ESTIMATED,2020-02-07,2020-02-21,ACTUAL,,,,2020-02-07,2020-02-21,ACTUAL,2015-01-29,ACTUAL,2015-01-29,2020-02,2020-02-29,2019-02-14,ACTUAL,2019-02-14,2019-02-14,ACTUAL,2019-02-14,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.,"Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults","A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults",COMPLETED,,PHASE1,48,ACTUAL,Gilead Sciences,,10,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 19:11:56,2024-10-14 19:11:56,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT02859558,,2016-08-04,2021-12-02,,2024-05-02,2016-08-04,2016-08-09,ESTIMATED,2021-12-02,2022-01-03,ACTUAL,,,,2024-05-02,2024-05-06,ACTUAL,2017-01,ACTUAL,2017-01-31,2024-05,2024-05-31,2025-04-30,ESTIMATED,2025-04-30,2020-12-02,ACTUAL,2020-12-02,,INTERVENTIONAL,EARLIER,All participants with available baseline measurements.,Early ART to Limit Infection and Establishment of Reservoir,Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses,ACTIVE_NOT_RECRUITING,,PHASE2,195,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 15:37:58,2024-10-13 15:37:58,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Malawi|Peru|South Africa|Thailand|United States|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02861586,,2016-07-28,2021-03-17,,2021-10-15,2016-08-05,2016-08-10,ESTIMATED,2021-05-11,2021-06-08,ACTUAL,,,,2021-10-15,2021-10-29,ACTUAL,2016-08-17,ACTUAL,2016-08-17,2021-10,2021-10-31,2018-04-16,ACTUAL,2018-04-16,2017-09-01,ACTUAL,2017-09-01,,INTERVENTIONAL,MV-CHIK-202,The Safety Population as well as the Modified Intent-to-treat (mITT) population included all randomized subjects who received at least one vaccination and included 263 participants.,Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine,"Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers",COMPLETED,,PHASE2,263,ACTUAL,Themis Bioscience GmbH,,8,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 15:04:55,2024-10-14 15:04:55,INDUSTRY,,,,,,,Themis Bioscience GmbH,Austria|Germany,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02868242,,2016-08-11,2019-07-29,,2020-02-18,2016-08-11,2016-08-16,ESTIMATED,2019-07-29,2019-08-20,ACTUAL,,,,2020-02-18,2020-03-02,ACTUAL,2016-08-28,ACTUAL,2016-08-28,2019-07,2019-07-31,2019-02-03,ACTUAL,2019-02-03,2018-11-12,ACTUAL,2018-11-12,,INTERVENTIONAL,,Safety Analysis Set included participants who took at least 1 dose of study drug.,Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy,"A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoing Cancer Chemotherapy",COMPLETED,,PHASE2,19,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 20:37:13,2024-10-13 20:37:13,INDUSTRY,,,,,,,Gilead Sciences,Egypt,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02873286,,2016-08-09,2020-08-11,,2020-09-01,2016-08-16,2016-08-19,ESTIMATED,2020-09-01,2020-09-22,ACTUAL,,,,2020-09-01,2020-09-22,ACTUAL,2016-09,ACTUAL,2016-09-30,2020-09,2020-09-30,2018-12,ACTUAL,2018-12-31,2018-12,ACTUAL,2018-12-31,,INTERVENTIONAL,,Full Analysis Set,RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults,"A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine",COMPLETED,,PHASE2,420,ACTUAL,Bavarian Nordic,,5,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-13 10:58:26,2024-10-13 10:58:26,INDUSTRY,,,,,,,Bavarian Nordic,United States,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT02877927,,2016-08-15,2018-11-02,2018-02-01,2018-11-28,2016-08-19,2016-08-24,ESTIMATED,2018-11-28,2018-11-30,ACTUAL,2018-02-01,2018-02-05,ACTUAL,2018-11-28,2018-11-30,ACTUAL,2016-08,,2016-08-31,2018-11,2018-11-30,2017-06-06,ACTUAL,2017-06-06,2017-05-26,ACTUAL,2017-05-26,,INTERVENTIONAL,,Safety Population: all randomized participants who received test article,Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI,"A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)",COMPLETED,,PHASE3,735,ACTUAL,Paratek Pharmaceuticals Inc,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:28:19,2024-10-13 19:28:19,INDUSTRY,,,,,,,Paratek Pharmaceuticals Inc,United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02877927,,2016-08-15,2018-11-02,2018-02-01,2018-11-28,2016-08-19,2016-08-24,ESTIMATED,2018-11-28,2018-11-30,ACTUAL,2018-02-01,2018-02-05,ACTUAL,2018-11-28,2018-11-30,ACTUAL,2016-08,,2016-08-31,2018-11,2018-11-30,2017-06-06,ACTUAL,2017-06-06,2017-05-26,ACTUAL,2017-05-26,,INTERVENTIONAL,,Safety Population: all randomized participants who received test article,Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI,"A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)",COMPLETED,,PHASE3,735,ACTUAL,Paratek Pharmaceuticals Inc,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-13 19:28:19,2024-10-13 19:28:19,INDUSTRY,,,,,,,Paratek Pharmaceuticals Inc,United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02878330,,2016-08-22,2019-07-17,,2019-09-24,2016-08-22,2016-08-25,ESTIMATED,2019-09-24,2019-10-14,ACTUAL,,,,2019-09-24,2019-10-14,ACTUAL,2016-11-03,ACTUAL,2016-11-03,2019-09,2019-09-30,2018-12-06,ACTUAL,2018-12-06,2018-07-17,ACTUAL,2018-07-17,,INTERVENTIONAL,MEDI8897 Ph2b,The intent-to-treat (ITT) population included all participants who were randomized in the study and analyzed according to their randomized treatment group.,A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.,"A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants",COMPLETED,,PHASE2,1453,ACTUAL,MedImmune LLC,,2,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 12:37:24,2024-10-13 12:37:24,INDUSTRY,,,,,,,MedImmune LLC,Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Czech Republic|Estonia|Finland|France|Hungary|Italy|Latvia|Lithuania|New Zealand|Poland|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02905825,,2016-09-06,2018-03-25,,2022-12-19,2016-09-14,2016-09-19,ESTIMATED,2018-06-05,2018-07-05,ACTUAL,,,,2022-12-19,2022-12-20,ACTUAL,2017-05-18,ACTUAL,2017-05-18,2018-06,2018-06-30,2017-11-05,ACTUAL,2017-11-05,2017-10-30,ACTUAL,2017-10-30,,INTERVENTIONAL,,,Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics,Clinical Confirmation Study to Confirm Safety and Presence of H. Pylori With 13C-Urea Breath Test Using the BreathID® Hp and BreathID® Hp Lab Systems in the Pediatric Population,COMPLETED,,PHASE3,54,ACTUAL,"Meridian Bioscience, Inc.",,1,,,FALSE,,,,FALSE,TRUE,TRUE,,,,,,,,,NO,,2024-10-14 01:37:23,2024-10-14 01:37:23,INDUSTRY,,,,,,,"Meridian Bioscience, Inc.",Israel|United States,Gastrointestinal disorders
NCT02914184,,2016-09-16,2019-06-26,,2020-07-13,2016-09-22,2016-09-26,ESTIMATED,2019-09-18,2019-10-14,ACTUAL,,,,2020-07-13,2020-07-21,ACTUAL,2016-10-27,ACTUAL,2016-10-27,2020-07,2020-07-31,2018-11-26,ACTUAL,2018-11-26,2018-06-27,ACTUAL,2018-06-27,,INTERVENTIONAL,,,"Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks",COMPLETED,,PHASE3,1612,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20392,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 09:53:28,2024-10-13 09:53:28,INDUSTRY,,,,,,,GlaxoSmithKline,"Costa Rica|Finland|Germany|Japan|Korea, Republic of|Spain|Taiwan|United States","Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02915016,,2016-09-22,2020-08-10,,2022-04-27,2016-09-22,2016-09-26,ESTIMATED,2020-08-26,2020-09-16,ACTUAL,,,,2022-04-27,2022-04-29,ACTUAL,2016-12-07,ACTUAL,2016-12-07,2021-10,2021-10-31,2020-02-12,ACTUAL,2020-02-12,2019-08-07,ACTUAL,2019-08-07,,INTERVENTIONAL,,,"Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults","A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants",COMPLETED,,PHASE1/PHASE2,334,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,8,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 03:37:02,2024-10-13 03:37:02,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),South Africa|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02927873,,2016-10-06,2021-09-28,2020-01-27,2021-09-28,2016-10-06,2016-10-07,ESTIMATED,2021-09-28,2021-10-28,ACTUAL,2020-01-27,2020-02-06,ACTUAL,2021-09-28,2021-10-28,ACTUAL,2017-01-11,ACTUAL,2017-01-11,2021-09,2021-09-30,2020-11-26,ACTUAL,2020-11-26,2019-02-19,ACTUAL,2019-02-19,,INTERVENTIONAL,,,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants","A Phase 1/2, Randomized, Observer-blind, Controlled, Multi-center, Dose-escalation Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine Based on the RSV Viral Proteins F, N and M2-1 Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A), When Administered Intramuscularly According to a 0, 1-month Schedule to RSV-seropositive Infants Aged 12 to 23 Months",COMPLETED,,PHASE1/PHASE2,107,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 00:19:26,2024-10-14 00:19:26,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|Italy|Mexico|Panama|Poland|Spain|Taiwan|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02938013,,2016-10-12,2020-09-08,,2022-02-10,2016-10-17,2016-10-19,ESTIMATED,2020-10-21,2020-11-16,ACTUAL,,,,2022-02-10,2022-02-24,ACTUAL,2017-01,ACTUAL,2017-01-31,2020-10,2020-10-31,2020-09-30,ACTUAL,2020-09-30,2019-09-30,ACTUAL,2019-09-30,,INTERVENTIONAL,deLIVER,,deLIVER: Direct Acting Antiviral Effects on the Liver,deLIVER: Direct Acting Antiviral Effects on the Liver,COMPLETED,,PHASE4,15,ACTUAL,Johns Hopkins University,This study is based on a relatively small sample of the liver,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 10:27:59,2024-10-14 10:27:59,OTHER,,,,,,,Johns Hopkins University,United States,"Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Skin and subcutaneous tissue disorders"
NCT02938520,,2016-09-15,2019-08-05,,2024-02-14,2016-10-17,2016-10-19,ESTIMATED,2019-10-09,2019-10-29,ACTUAL,,,,2024-02-14,2024-02-15,ACTUAL,2016-10-27,ACTUAL,2016-10-27,2024-02,2024-02-29,2026-12-31,ESTIMATED,2026-12-31,2018-08-30,ACTUAL,2018-08-30,,INTERVENTIONAL,,,"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants",ACTIVE_NOT_RECRUITING,,PHASE3,631,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20364,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 11:28:26,2024-10-14 11:28:26,INDUSTRY,,,,,,,GlaxoSmithKline|Janssen Pharmaceuticals|ViiV Healthcare,Canada|France|Germany|Italy|Japan|Netherlands|Russian Federation|South Africa|Spain|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Vascular disorders"
NCT02939989,,2016-10-19,2022-04-07,,2022-04-07,2016-10-19,2016-10-20,ESTIMATED,2022-04-07,2022-05-04,ACTUAL,,,,2022-04-07,2022-05-04,ACTUAL,2016-11-21,ACTUAL,2016-11-21,2022-04,2022-04-30,2021-07-30,ACTUAL,2021-07-30,2021-05-07,ACTUAL,2021-05-07,,INTERVENTIONAL,MAGELLAN-3,The intention-to-treat (ITT) population included all enrolled participants who received at least 1 dose of study drug.,Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study,"An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)",COMPLETED,,PHASE3,33,ACTUAL,AbbVie,,2,,,TRUE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"For details on when studies are available for sharing, please refer to the link below.","Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.",https://vivli.org/ourmember/abbvie/,YES,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications",2024-10-13 19:17:21,2024-10-13 19:17:21,INDUSTRY,,NCT03123965,APPROVED_FOR_MARKETING,,,,AbbVie,"Australia|Brazil|Canada|China|Germany|Korea, Republic of|New Zealand|Russian Federation|Spain|Sweden|Switzerland|United Kingdom|United States","Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02946385,,2016-10-25,2019-02-12,,2019-08-12,2016-10-25,2016-10-27,ESTIMATED,2019-08-12,2019-08-20,ACTUAL,,,,2019-08-12,2019-08-20,ACTUAL,2016-11-15,ACTUAL,2016-11-15,2019-08,2019-08-31,2018-02-13,ACTUAL,2018-02-13,2018-02-13,ACTUAL,2018-02-13,,INTERVENTIONAL,,,Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents,"A Phase 2b Open-Label Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 Years After the Last Meningococcal Vaccination in Study V102_15 (NCT02212457) and the Response to a Booster Dose of GSK MenABCWY or Meningococcal Serogroup B Vaccines, in Healthy Adolescents",COMPLETED,,PHASE2,604,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,YES,Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.,2024-10-14 08:29:25,2024-10-14 08:29:25,INDUSTRY,,,,,,,GlaxoSmithKline,Finland|Poland,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02951052,,2016-09-15,2019-05-23,,2024-02-13,2016-10-27,2016-11-01,ESTIMATED,2019-05-23,2019-06-13,ACTUAL,,,,2024-02-13,2024-02-14,ACTUAL,2016-10-28,ACTUAL,2016-10-28,2024-02,2024-02-29,2026-12-31,ESTIMATED,2026-12-31,2018-05-29,ACTUAL,2018-05-29,,INTERVENTIONAL,,,"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed",ACTIVE_NOT_RECRUITING,,PHASE3,618,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20382,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-13 22:31:13,2024-10-13 22:31:13,INDUSTRY,,,,,,,GlaxoSmithKline|Janssen Pharmaceuticals|ViiV Healthcare,"Argentina|Australia|Canada|France|Germany|Italy|Korea, Republic of|Mexico|Russian Federation|South Africa|Spain|Sweden|United States","Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT02951052,,2016-09-15,2019-05-23,,2024-02-13,2016-10-27,2016-11-01,ESTIMATED,2019-05-23,2019-06-13,ACTUAL,,,,2024-02-13,2024-02-14,ACTUAL,2016-10-28,ACTUAL,2016-10-28,2024-02,2024-02-29,2026-12-31,ESTIMATED,2026-12-31,2018-05-29,ACTUAL,2018-05-29,,INTERVENTIONAL,,,"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed",ACTIVE_NOT_RECRUITING,,PHASE3,618,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below).,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20382,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-13 22:31:13,2024-10-13 22:31:13,INDUSTRY,,,,,,,GlaxoSmithKline|Janssen Pharmaceuticals|ViiV Healthcare,"Argentina|Australia|Canada|France|Germany|Italy|Korea, Republic of|Mexico|Russian Federation|South Africa|Spain|Sweden|United States","Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT02955797,,2016-11-03,2020-05-20,2018-10-25,2022-03-24,2016-11-03,2016-11-04,ESTIMATED,2020-05-20,2020-06-09,ACTUAL,2018-10-25,2018-10-26,ACTUAL,2022-03-24,2022-04-05,ACTUAL,2017-02-24,ACTUAL,2017-02-24,2022-03,2022-03-31,2017-10-26,ACTUAL,2017-10-26,2017-10-26,ACTUAL,2017-10-26,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age.,COMPLETED,,PHASE3,918,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-13 02:41:08,2024-10-13 02:41:08,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Finland|Germany|Hungary|Spain,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT02956837,,2016-11-03,2018-08-29,,2019-06-24,2016-11-03,2016-11-06,ESTIMATED,2018-11-12,2018-11-20,ACTUAL,,,,2019-06-24,2019-07-02,ACTUAL,2016-11-10,ACTUAL,2016-11-10,2019-06,2019-06-30,2018-02-05,ACTUAL,2018-02-05,2017-08-30,ACTUAL,2017-08-30,,INTERVENTIONAL,,,"A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women",An Observer-blind Study to Rank Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A) Administered to Healthy Women,COMPLETED,,PHASE2,406,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,,,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 16:49:33,2024-10-13 16:49:33,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|Estonia|France|Germany,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02961764,,2016-11-07,2020-03-27,,2020-03-27,2016-11-09,2016-11-11,ESTIMATED,2020-03-27,2020-04-10,ACTUAL,,,,2020-03-27,2020-04-10,ACTUAL,2016-11-29,ACTUAL,2016-11-29,2020-03,2020-03-31,2019-03-29,ACTUAL,2019-03-29,2019-03-29,ACTUAL,2019-03-29,,INTERVENTIONAL,,Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion.,Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI),A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections,COMPLETED,,PHASE4,313,ACTUAL,Allergan,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 23:11:12,2024-10-13 23:11:12,INDUSTRY,,,,,,,Allergan,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02968849,,2016-11-01,2022-11-16,,2024-07-10,2016-11-16,2016-11-21,ESTIMATED,2023-01-13,2023-02-08,ACTUAL,,,,2024-07-10,2024-07-22,ACTUAL,2016-10-26,ACTUAL,2016-10-26,2023-12,2023-12-31,2021-11-16,ACTUAL,2021-11-16,2021-11-16,ACTUAL,2021-11-16,,INTERVENTIONAL,HVTN702,Safety Cohort,Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa,"A Pivotal Phase 2b/3 Multisite, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in Preventing HIV-1 Infection in Adults in South Africa",COMPLETED,,PHASE2/PHASE3,5404,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,,,,TRUE,,,,,,NO,,2024-10-14 12:28:13,2024-10-14 12:28:13,NIH,,,,,,,Bill and Melinda Gates Foundation|GlaxoSmithKline|National Institute of Allergy and Infectious Diseases (NIAID)|Sanofi,South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT02969915,,2016-11-18,2022-11-01,,2024-06-06,2016-11-18,2016-11-21,ESTIMATED,2022-11-29,2022-12-22,ACTUAL,,,,2024-06-06,2024-06-20,ACTUAL,2017-10-30,ACTUAL,2017-10-30,2024-06,2024-06-30,2024-05-30,ACTUAL,2024-05-30,2020-03-23,ACTUAL,2020-03-23,,INTERVENTIONAL,,"Data are stratified by key population (PWID and MSM). 600 PWID and 514 MSM were at sites assigned to the incentive intervention (1114 total), and 600 PWID and 600 MSM were at sites assigned to usual care (1200 total).",Strategies to Improve the HIV Care Continuum Among Key Populations in India,Strategies to Improve the HIV Care Continuum Among Key Populations in India,COMPLETED,,NA,2314,ACTUAL,Johns Hopkins University,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,YES,"The investigators will require prospective collaborators to submit concept sheets to the study PIs that include a brief summary of the proposed hypothesis, summary of research methods, specific data or specimens that are being requested, and plans for analysis. Reasonable requests that address relevant scientific questions will be welcomed and supported to the extent possible.",2024-10-14 22:55:35,2024-10-14 22:55:35,OTHER,,,,,,,Elton John AIDS Foundation|Johns Hopkins University|National Institute on Drug Abuse (NIDA)|YR Gaitonde Centre for AIDS Research and Education,India,General disorders
NCT02971007,,2016-11-10,2018-09-07,,2018-10-04,2016-11-18,2016-11-22,ESTIMATED,2018-09-07,2018-10-05,ACTUAL,,,,2018-10-04,2018-11-02,ACTUAL,2016-11,ACTUAL,2016-11-30,2018-10,2018-10-31,2017-05,ACTUAL,2017-05-31,2017-05,ACTUAL,2017-05-31,,INTERVENTIONAL,,,Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC),"A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)",COMPLETED,,PHASE2,137,ACTUAL,"Matinas BioPharma Nanotechnologies, Inc.","This is a proof of concept study not designed or powered to support an indication for the treatment of VVC but to establish safety, tolerability and efficacy in a non-life threatening fungal infection.",3,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 01:54:24,2024-10-14 01:54:24,INDUSTRY,,,,,,,"Matinas BioPharma Nanotechnologies, Inc.",United States,Gastrointestinal disorders|Infections and infestations
NCT02971007,,2016-11-10,2018-09-07,,2018-10-04,2016-11-18,2016-11-22,ESTIMATED,2018-09-07,2018-10-05,ACTUAL,,,,2018-10-04,2018-11-02,ACTUAL,2016-11,ACTUAL,2016-11-30,2018-10,2018-10-31,2017-05,ACTUAL,2017-05-31,2017-05,ACTUAL,2017-05-31,,INTERVENTIONAL,,,Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC),"A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)",COMPLETED,,PHASE2,137,ACTUAL,"Matinas BioPharma Nanotechnologies, Inc.","This is a proof of concept study not designed or powered to support an indication for the treatment of VVC but to establish safety, tolerability and efficacy in a non-life threatening fungal infection.",3,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-14 01:54:24,2024-10-14 01:54:24,INDUSTRY,,,,,,,"Matinas BioPharma Nanotechnologies, Inc.",United States,Gastrointestinal disorders|Infections and infestations
NCT02973503,,2016-10-14,2020-06-30,,2020-09-09,2016-11-22,2016-11-25,ESTIMATED,2020-08-20,2020-09-07,ACTUAL,,,,2020-09-09,2020-10-01,ACTUAL,2017-01-11,ACTUAL,2017-01-11,2020-09,2020-09-30,2019-04,ACTUAL,2019-04-30,2018-11-10,ACTUAL,2018-11-10,,INTERVENTIONAL,STREAGER,5 PATIENTS WERE EXCLUDED DUE TO GENOTYPE NON 1B,"Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis","A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis",COMPLETED,,PHASE3,117,ACTUAL,"University Hospital, Clermont-Ferrand",5 patients were non genotype 1b so they were excluded from the analysis. Patients must have genotype 1b and non severe fibrosis to be treated by 8 weeks elbasvir grazoprevir,1,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 15:23:18,2024-10-14 15:23:18,OTHER,,,,,,,"Merck Sharp & Dohme LLC|University Hospital, Clermont-Ferrand",France,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders
NCT02978157,,2016-11-28,2017-10-20,,2019-03-13,2016-11-29,2016-11-30,ESTIMATED,2019-03-13,2019-03-14,ACTUAL,,,,2019-03-13,2019-03-14,ACTUAL,2015-02,,2015-02-28,2019-03,2019-03-31,2017-09,ACTUAL,2017-09-30,2017-09,ACTUAL,2017-09-30,,INTERVENTIONAL,,Patients received levoflaxacin triple therapy,Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection,A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment,COMPLETED,,NA,102,ACTUAL,Kaohsiung Veterans General Hospital.,The trial was performed in a single country,2,,,FALSE,,,,TRUE,,,,,,,,,,,NO,,2024-10-14 23:29:48,2024-10-14 23:29:48,OTHER,,,,,,,Kaohsiung Medical University Chung-Ho Memorial Hospital|Kaohsiung Veterans General Hospital.,Taiwan,Gastrointestinal disorders
NCT02979431,,2016-11-29,2019-05-22,,2019-09-25,2016-11-30,2016-12-01,ESTIMATED,2019-09-25,2019-10-18,ACTUAL,,,,2019-09-25,2019-10-18,ACTUAL,2017-01-11,ACTUAL,2017-01-11,2019-09,2019-09-30,2018-05-25,ACTUAL,2018-05-25,2018-05-25,ACTUAL,2018-05-25,,INTERVENTIONAL,Respire,"modified Intent-to-Treat Population (mITT): All randomized subjects who received at least 1 study drug administration. In this population, the subjects were classified as randomized (i.e.,using the treatment to which the subject was randomized).",Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection,"A Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study of ALX-0171 in Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection",COMPLETED,,PHASE2,180,ACTUAL,"Ablynx, a Sanofi company",,4,,,FALSE,,,,TRUE,,,,,,,,,,,,,2024-10-13 21:28:59,2024-10-13 21:28:59,INDUSTRY,,,,,,,"Ablynx, a Sanofi company",Belgium|Brazil|Bulgaria|Chile|Colombia|Croatia|Czechia|Estonia|Germany|Hungary|Israel|Latvia|Lithuania|Malaysia|Philippines|Poland|Slovakia|South Africa|Spain|Thailand|United Kingdom,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02986854,,2016-12-06,2018-07-04,,2019-11-14,2016-12-06,2016-12-08,ESTIMATED,2018-08-02,2018-08-03,ACTUAL,,,,2019-11-14,2019-11-25,ACTUAL,2016-12-08,ACTUAL,2016-12-08,2019-11,2019-11-30,2017-12-07,ACTUAL,2017-12-07,2017-07-17,ACTUAL,2017-07-17,,INTERVENTIONAL,,,"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination",COMPLETED,,PHASE3,704,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20103,YES,IPD is available via the Clinical Study Data Request site (click on the link provided below),2024-10-15 01:26:41,2024-10-15 01:26:41,INDUSTRY,,,,,,,GlaxoSmithKline,Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT02987972,,2016-12-06,2019-10-02,,2019-10-02,2016-12-06,2016-12-09,ESTIMATED,2019-10-02,2019-10-23,ACTUAL,,,,2019-10-02,2019-10-23,ACTUAL,2017-03-21,ACTUAL,2017-03-21,2019-09,2019-09-30,2018-10-04,ACTUAL,2018-10-04,2018-10-04,ACTUAL,2018-10-04,,INTERVENTIONAL,,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)","A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Infants",COMPLETED,,PHASE2,1051,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 16:32:17,2024-10-14 16:32:17,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Canada|Denmark|Finland|Israel|Spain|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02990325,,2016-12-07,2022-06-01,,2023-03-30,2016-12-08,2016-12-13,ESTIMATED,2023-03-30,2023-03-31,ACTUAL,,,,2023-03-30,2023-03-31,ACTUAL,2017-03-27,ACTUAL,2017-03-27,2023-03,2023-03-31,2019-10-21,ACTUAL,2019-10-21,2018-12-27,ACTUAL,2018-12-27,,INTERVENTIONAL,,,"A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults","An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults",COMPLETED,,PHASE1/PHASE2,36,ACTUAL,Abivax S.A.,,3,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 03:26:59,2024-10-14 03:26:59,INDUSTRY,,,,,,,Abivax S.A.,Spain,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT02992197,,2016-12-01,2020-06-30,,2020-07-17,2016-12-13,2016-12-14,ESTIMATED,2020-06-30,2020-07-17,ACTUAL,,,,2020-07-17,2020-08-04,ACTUAL,2017-06-12,ACTUAL,2017-06-12,2020-07,2020-07-31,2018-06-07,ACTUAL,2018-06-07,2018-06-07,ACTUAL,2018-06-07,,INTERVENTIONAL,,"The a priori primary analysis was designed to evaluate study outcomes among those who completed the study per-protocol. Due to anticipated levels of attrition, the per-protocol population differs from the total numbers of initial enrollees. Data presented are for the per protocol population.",The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity,"A Double-blind, Randomized Controlled Trial of the Effect of Vaccine Inoculum on Oral Rotavirus Vaccine (Rotarix, GlaxoSmithKline) Take and Immunogenicity in Dhaka, Bangladesh",COMPLETED,,PHASE4,220,ACTUAL,University of Vermont,,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 00:43:25,2024-10-13 00:43:25,OTHER,,,,,,,"Charles H. Hood Foundation|International Centre for Diarrhoeal Disease Research, Bangladesh|Thrasher Research Fund|University of Vermont",Bangladesh,"Gastrointestinal disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders"
NCT02994056,,2016-12-13,2019-09-17,,2020-02-18,2016-12-13,2016-12-15,ESTIMATED,2019-09-17,2019-10-08,ACTUAL,,,,2020-02-18,2020-03-02,ACTUAL,2017-01-23,ACTUAL,2017-01-23,2019-09,2019-09-30,2018-12-12,ACTUAL,2018-12-12,2018-09-25,ACTUAL,2018-09-25,,INTERVENTIONAL,,The Safety Analysis Set included all participants who took at least 1 dose of study drug.,Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis",COMPLETED,,PHASE2,32,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-14 07:44:30,2024-10-14 07:44:30,INDUSTRY,,,,,,,Gilead Sciences,France|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT02996487,,2016-11-17,2024-05-29,,2024-07-17,2016-12-16,2016-12-19,ESTIMATED,2024-07-17,2024-08-13,ACTUAL,,,,2024-07-17,2024-08-13,ACTUAL,2016-12-19,ACTUAL,2016-12-19,2024-07,2024-07-31,2023-06-28,ACTUAL,2023-06-28,2023-06-28,ACTUAL,2023-06-28,,INTERVENTIONAL,StoP CDI,,Screening to Prophylax Against Clostridium Difficile Infection -,Screening to Prophylax Against Clostridium Difficile Infection,COMPLETED,,PHASE4,1294,ACTUAL,William Beaumont Hospitals,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 13:01:13,2024-10-14 13:01:13,OTHER,,,,,,,William Beaumont Hospitals,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT02996682,,2016-12-15,2019-02-01,,2019-02-01,2016-12-15,2016-12-19,ESTIMATED,2019-02-01,2019-02-26,ACTUAL,,,,2019-02-01,2019-02-26,ACTUAL,2016-12-26,ACTUAL,2016-12-26,2019-02,2019-02-28,2018-05-08,ACTUAL,2018-05-08,2018-02-13,ACTUAL,2018-02-13,,INTERVENTIONAL,,Safety Analysis Set included all participants who received at least 1 dose of study drug.,Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis,"A Multicenter, Randomized, Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Decompensated Cirrhosis",COMPLETED,,PHASE3,102,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/about/ethics-and-code-of-conduct/policies,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.",2024-10-14 08:36:00,2024-10-14 08:36:00,INDUSTRY,,,,,,,Gilead Sciences,Japan,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders"
NCT03008122,,2016-12-15,2023-01-27,,2023-03-09,2016-12-29,2017-01-02,ESTIMATED,2023-03-09,2023-04-06,ACTUAL,,,,2023-03-09,2023-04-06,ACTUAL,2017-03-21,ACTUAL,2017-03-21,2018-01,2018-01-31,2021-08-10,ACTUAL,2021-08-10,2021-08-10,ACTUAL,2021-08-10,,INTERVENTIONAL,,,"Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area","Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area",COMPLETED,,PHASE1,91,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-13 10:15:15,2024-10-13 10:15:15,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03009045,,2016-12-21,2023-03-01,,2023-11-21,2016-12-30,2017-01-04,ESTIMATED,2023-11-21,2023-12-13,ACTUAL,,,,2023-11-21,2023-12-13,ACTUAL,2017-02-06,ACTUAL,2017-02-06,2023-11,2023-11-30,2021-08-06,ACTUAL,2021-08-06,2021-03-23,ACTUAL,2021-03-23,,INTERVENTIONAL,,Not different from assignment in participant flow,"Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)","Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections",COMPLETED,,PHASE2,44,ACTUAL,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,YES,"After publication of trial results, data will be shared with investigators upon request to the Principal Investigator and after signing a Data Use Agreement.",2024-10-13 08:47:40,2024-10-13 08:47:40,OTHER,,,,,,,Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center,United States,Skin and subcutaneous tissue disorders
NCT03021668,,2017-01-06,2019-01-02,,2019-08-13,2017-01-12,2017-01-16,ESTIMATED,2019-01-23,2019-02-12,ACTUAL,,,,2019-08-13,2019-08-28,ACTUAL,2017-01,ACTUAL,2017-01-31,2019-08,2019-08-31,2018-06-30,ACTUAL,2018-06-30,2018-05,ACTUAL,2018-05-31,,INTERVENTIONAL,,,Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections,A Randomized Control Trial of Prevena Peel & Place Dressing Versus Standard Closure for Patients Undergoing Pancreaticoduodenectomy Who Have Undergone Neoadjuvant Chemotherapy or Biliary Stent Placement,COMPLETED,,NA,124,ACTUAL,Johns Hopkins University,"The study was conducted at a high volume center for pancreatic surgery with a broad experience using Negative-Pressure Wound Therapy (NPWT), and therefore there is a question about the generalizability of the reductions we observed.",2,,,FALSE,,,,FALSE,,,,,,,,,,,NO,,2024-10-13 09:27:07,2024-10-13 09:27:07,OTHER,,,,,,,Johns Hopkins University,United States,"Gastrointestinal disorders|Hepatobiliary disorders|Respiratory, thoracic and mediastinal disorders"
NCT03022981,,2017-01-13,2020-08-24,,2020-10-05,2017-01-13,2017-01-18,ESTIMATED,2020-10-05,2020-10-08,ACTUAL,,,,2020-10-05,2020-10-08,ACTUAL,2017-01-26,ACTUAL,2017-01-26,2020-10,2020-10-31,2020-02-26,ACTUAL,2020-02-26,2019-11-19,ACTUAL,2019-11-19,,INTERVENTIONAL,,The Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug (SOF/VEL FDC).,Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection,"A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection",COMPLETED,,PHASE2,216,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",2024-10-15 01:09:29,2024-10-15 01:09:29,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Italy|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03032510,,2017-01-17,2019-07-12,,2021-12-16,2017-01-23,2017-01-26,ESTIMATED,2019-09-09,2019-10-02,ACTUAL,,,,2021-12-16,2022-01-06,ACTUAL,2017-01,ACTUAL,2017-01-31,2021-12,2021-12-31,2018-01,ACTUAL,2018-01-31,2017-12,ACTUAL,2017-12-31,,INTERVENTIONAL,IGNITE3,,Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections,"A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections",COMPLETED,,PHASE3,1205,ACTUAL,La Jolla Pharmaceutical Company,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 01:17:29,2024-10-14 01:17:29,INDUSTRY,,,,,,,"Tetraphase Pharmaceuticals, Inc.","Austria|Bulgaria|Estonia|Georgia|Hungary|Latvia|Moldova, Republic of|Romania|Russian Federation|Slovakia|Ukraine|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03035760,,2017-01-26,2019-11-07,,2019-12-04,2017-01-26,2017-01-30,ESTIMATED,2019-12-04,2019-12-17,ACTUAL,,,,2019-12-04,2019-12-17,ACTUAL,2017-05-12,ACTUAL,2017-05-12,2017-07-19,2017-07-19,2019-04-23,ACTUAL,2019-04-23,2018-04-23,ACTUAL,2018-04-23,,INTERVENTIONAL,,All subjects are included in the analysis population,Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers,"A Phase 1 Open Label, Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers",COMPLETED,,PHASE1,36,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-13 22:08:13,2024-10-13 22:08:13,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03036839,,2017-01-27,2019-11-15,,2020-02-18,2017-01-27,2017-01-30,ESTIMATED,2019-11-15,2019-12-09,ACTUAL,,,,2020-02-18,2020-03-02,ACTUAL,2017-06-27,ACTUAL,2017-06-27,2019-11,2019-11-30,2019-02-14,ACTUAL,2019-02-14,2018-11-22,ACTUAL,2018-11-22,,INTERVENTIONAL,ESRD,The Safety Analysis Set included all participants who received at least 1 dose of study drug. Participants were grouped within the Safety Analysis Set according to the treatment they actually received.,Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease,"A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects With Genotype 1, 4, 5 and 6 Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease",COMPLETED,,PHASE2,95,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-14 11:45:21,2024-10-14 11:45:21,INDUSTRY,,,,,,,Gilead Sciences,Belgium|Germany|Italy|Switzerland|Taiwan|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03039621,,2016-12-28,2020-03-18,,2021-08-25,2017-01-30,2017-02-01,ESTIMATED,2020-04-06,2020-04-27,ACTUAL,,,,2021-08-25,2021-08-27,ACTUAL,2016-10-07,ACTUAL,2016-10-07,2019-05,2019-05-31,2019-01-09,ACTUAL,2019-01-09,2019-01-09,ACTUAL,2019-01-09,,INTERVENTIONAL,,,Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children,International Multicenter Double-blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children,COMPLETED,,PHASE4,287,ACTUAL,Materia Medica Holding,,2,,,FALSE,,,,,,,,,,,,,,,,,2024-10-14 15:23:18,2024-10-14 15:23:18,INDUSTRY,,,,,,,Materia Medica Holding,Kazakhstan|Russian Federation,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03039699,,2016-12-28,2020-08-27,,2020-09-23,2017-01-30,2017-02-01,ESTIMATED,2020-09-23,2020-10-19,ACTUAL,,,,2020-09-23,2020-10-19,ACTUAL,2016-06-23,ACTUAL,2016-06-23,2019-11,2019-11-30,2019-06-01,ACTUAL,2019-06-01,2019-06-01,ACTUAL,2019-06-01,,INTERVENTIONAL,,,Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children,"International Multicenter, Double-blind, Randomized, Parallel Group Placebo-Controlled Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children",COMPLETED,,PHASE4,259,ACTUAL,Materia Medica Holding,,2,,,FALSE,,,,FALSE,,,,,,,,,,,,,2024-10-14 03:33:16,2024-10-14 03:33:16,INDUSTRY,,,,,,,Materia Medica Holding,Russian Federation|Uzbekistan,Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Metabolism and nutrition disorders|Psychiatric disorders|Renal and urinary disorders
NCT03045809,,2017-02-02,2019-04-26,,2019-07-31,2017-02-03,2017-02-08,ESTIMATED,2019-07-31,2019-09-11,ACTUAL,,,,2019-07-31,2019-09-11,ACTUAL,2016-07-05,ACTUAL,2016-07-05,2019-07,2019-07-31,2018-08-06,ACTUAL,2018-08-06,2017-03-14,ACTUAL,2017-03-14,,OBSERVATIONAL,WISH,"All 705 women who attended a main visit. Women were aged 18 or older, and at risk of sexually transmitted infections (more than one sex partner and/or having been treated for at least one STI in the past year), with or without urogenital symptoms. HIV-positive and pregnant women were not excluded.",Women's Improvement of Sexual Health (WISH) Demonstration Project,Improving HIV Prevention and Sexual and Reproductive Health Care in High Risk Women in Rwanda Using Lessons Learnt From Previous Rinda Ubuzima Projects,COMPLETED,,,705,ACTUAL,University of Liverpool,The study was implemented in a high prevalence population by experienced staff. Additional studies are required in low prevalence settings and in public primary care clinics. Our recruitment strategies mostly attracted women with symptoms.,,1,,FALSE,,,,FALSE,FALSE,FALSE,,,,SAMPLES_WITH_DNA,The only samples to be retained are two vaginal swabs per participant. DNA will be extracted for qPCR testing of select urogenital organisms.,,,,UNDECIDED,The University of Liverpool and project investigators support open access but university-wide systems are not yet accessible and open access has not yet been negotiated with the Rwandan authorities.,2024-10-13 16:26:35,2024-10-13 16:26:35,OTHER,,,,,,FALSE,"Institute of Tropical Medicine, Belgium|Janneke van de Wijgert|Rinda Ubuzima, Rwanda",Rwanda,Skin and subcutaneous tissue disorders
NCT03045861,,2017-01-12,2019-04-01,,2020-03-02,2017-02-03,2017-02-08,ESTIMATED,2019-05-09,2019-05-29,ACTUAL,,,,2020-03-02,2020-03-11,ACTUAL,2017-03-17,ACTUAL,2017-03-17,2020-03,2020-03-31,2018-04-23,ACTUAL,2018-04-23,2018-04-23,ACTUAL,2018-04-23,,INTERVENTIONAL,,,Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults,"A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults",COMPLETED,,PHASE2,33,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20281,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 20:37:13,2024-10-13 20:37:13,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03045861,,2017-01-12,2019-04-01,,2020-03-02,2017-02-03,2017-02-08,ESTIMATED,2019-05-09,2019-05-29,ACTUAL,,,,2020-03-02,2020-03-11,ACTUAL,2017-03-17,ACTUAL,2017-03-17,2020-03,2020-03-31,2018-04-23,ACTUAL,2018-04-23,2018-04-23,ACTUAL,2018-04-23,,INTERVENTIONAL,,,Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults,"A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults",COMPLETED,,PHASE2,33,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20281,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 20:37:13,2024-10-13 20:37:13,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03048422,,2017-02-07,2021-10-04,,2022-10-28,2017-02-07,2017-02-09,ESTIMATED,2021-10-12,2021-11-10,ACTUAL,,,,2022-10-28,2022-11-21,ACTUAL,2018-01-19,ACTUAL,2018-01-19,2022-10,2022-10-31,2020-10-03,ACTUAL,2020-10-03,2020-10-03,ACTUAL,2020-10-03,,INTERVENTIONAL,VESTED,Enrolled women.,Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants,Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants,COMPLETED,,PHASE3,643,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,6,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH,"* With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
* For what types of analyses? To achieve aims in the proposal approved by the IMPAACT Network.
* By what mechanism will data be made available? Researchers may submit a request for access to data using the IMPAACT ""Data Request"" form at: https://www.impaactnetwork.org/studies/submit-research-proposal. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.",https://www.impaactnetwork.org/studies/submit-research-proposal,YES,"Individual participant data that underlie results in the publication, after deidentification",2024-10-13 20:47:42,2024-10-13 20:47:42,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Brazil|Haiti|India|Malawi|South Africa|Tanzania|Thailand|Uganda|United States|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT03060447,,2017-02-17,2021-02-10,,2021-03-29,2017-02-17,2017-02-23,ACTUAL,2021-03-29,2021-04-21,ACTUAL,,,,2021-03-29,2021-04-21,ACTUAL,2017-05-09,ACTUAL,2017-05-09,2021-03,2021-03-31,2020-02-13,ACTUAL,2020-02-13,2020-02-13,ACTUAL,2020-02-13,,INTERVENTIONAL,,The Safety Analysis Set included all participants who were randomized and received at least 1 dose of study drug.,Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers,"A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers",COMPLETED,,PHASE1,25,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 06:08:12,2024-10-13 06:08:12,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03070600,,2017-02-27,2022-01-10,,2022-07-11,2017-02-27,2017-03-03,ACTUAL,2022-04-14,2022-05-10,ACTUAL,,,,2022-07-11,2022-07-12,ACTUAL,2018-01-15,ACTUAL,2018-01-15,2022-07,2022-07-31,2021-01-15,ACTUAL,2021-01-15,2021-01-15,ACTUAL,2021-01-15,,INTERVENTIONAL,PrIMA,"Enrollment for this study ended on July 31, 2019. At the time that enrollment ended, 4,447 participants had enrolled (consented) into the study out of an anticipated 4,500.",PrEP Implementation for Mothers in Antenatal Care,Delivering PrEP in Pregnancy,COMPLETED,,PHASE4,4447,ACTUAL,University of Washington,"Low HIV incidence limited power of the primary outcome; however, similar HIV incidence in both arms suggest that meaningful differences are unlikely. Changing MoH policies and the COVID-19 pandemic affected study operations. Our observed rates of PrEP adherence and persistence could have been influenced by efforts to optimize study retention, and PrEP adherence relied on self-report, which can overestimate adherence.",2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-14 14:21:02,2024-10-14 14:21:02,OTHER,,,,,,,Kenyatta National Hospital|National Institute of Allergy and Infectious Diseases (NIAID)|University of Washington,Kenya,"Infections and infestations|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders"
NCT03074331,,2017-02-24,2019-02-25,,2019-02-25,2017-03-03,2017-03-08,ACTUAL,2019-02-25,2019-03-19,ACTUAL,,,,2019-02-25,2019-03-19,ACTUAL,2017-03-23,ACTUAL,2017-03-23,2019-02,2019-02-28,2018-02-07,ACTUAL,2018-02-07,2018-02-07,ACTUAL,2018-02-07,,INTERVENTIONAL,,Safety Analysis Set included all participants who took at least 1 dose of study drug.,Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection,"A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection",COMPLETED,,PHASE3,130,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/research/disclosure-and-transparency,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.",2024-10-13 12:58:07,2024-10-13 12:58:07,INDUSTRY,,,,,,,Gilead Sciences,India,Gastrointestinal disorders
NCT03077438,,2017-03-08,2020-05-20,2018-10-08,2022-03-21,2017-03-08,2017-03-13,ACTUAL,2020-06-05,2020-06-09,ACTUAL,2018-10-08,2018-10-10,ACTUAL,2022-03-21,2022-03-28,ACTUAL,2017-02-17,ACTUAL,2017-02-17,2022-03,2022-03-31,2017-10-10,ACTUAL,2017-10-10,2017-10-10,ACTUAL,2017-10-10,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age,COMPLETED,,PHASE3,1000,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 23:24:26,2024-10-14 23:24:26,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03077711,,2017-02-27,2019-12-12,,2020-01-10,2017-03-07,2017-03-13,ACTUAL,2020-01-10,2020-01-14,ACTUAL,,,,2020-01-10,2020-01-14,ACTUAL,2016-06,ACTUAL,2016-06-30,2020-01,2020-01-31,2019-06-21,ACTUAL,2019-06-21,2019-06-21,ACTUAL,2019-06-21,,INTERVENTIONAL,,,Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs,Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs,COMPLETED,,PHASE4,92,ACTUAL,NorthShore University HealthSystem,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,The investigators are currently only recruiting at one institution and only researchers on the original institutional review board will have access to data. Only the principal investigator and research coordinator will have the data to be analyzed.,2024-10-14 01:48:22,2024-10-14 01:48:22,OTHER,,,,,,,NorthShore University HealthSystem,United States,Gastrointestinal disorders|General disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders
NCT03078556,,2017-03-08,2018-08-10,,2018-10-10,2017-03-08,2017-03-13,ACTUAL,2018-10-10,2019-02-21,ACTUAL,,,,2018-10-10,2019-02-21,ACTUAL,2017-03-27,ACTUAL,2017-03-27,2018-08,2018-08-31,2017-08-18,ACTUAL,2017-08-18,2017-08-18,ACTUAL,2017-08-18,,INTERVENTIONAL,,Safety Population: All participants who enrolled in the study and received at least one dose of study drug.,Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine,"An Open-label, Randomized, Single Dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine Versus Dolutegravir and Lamivudine Single Entities and Food Effect Assessment in Healthy Volunteers",COMPLETED,,PHASE1,154,ACTUAL,ViiV Healthcare,,6,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-15 02:24:13,2024-10-15 02:24:13,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,United States,"Injury, poisoning and procedural complications|Nervous system disorders"
NCT03080961,,2017-03-09,2019-02-12,,2020-02-12,2017-03-14,2017-03-15,ACTUAL,2020-02-12,2020-02-13,ACTUAL,,,,2020-02-12,2020-02-13,ACTUAL,2017-03-27,ACTUAL,2017-03-27,2019-10,2019-10-31,2017-11-13,ACTUAL,2017-11-13,2017-11-13,ACTUAL,2017-11-13,,INTERVENTIONAL,SAFE,Adults with recurrent genital herpes due to an HSV-2 infection and that applied VIBLOK at least once.,The VIBLOK SAfety and perFormancE Trial,The VIBLOK SAfety and perFormancE Trial,COMPLETED,,NA,82,ACTUAL,CLJI Worldwide,,1,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 06:46:17,2024-10-13 06:46:17,INDUSTRY,,,,,,,"Applied Clinical Services BV|CLJI Worldwide|EB FlevoResearch BV|PreCare Trial & Recruitment B.V.|UMC Utrecht|University of Rotterdam, The Netherlands|University of Washington",Netherlands,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03090191,,2017-03-20,2022-11-30,,2023-01-17,2017-03-20,2017-03-24,ACTUAL,2023-01-17,2023-02-13,ACTUAL,,,,2023-01-17,2023-02-13,ACTUAL,2017-03-29,ACTUAL,2017-03-29,2023-01,2023-01-31,2021-12-21,ACTUAL,2021-12-21,2021-12-21,ACTUAL,2021-12-21,,INTERVENTIONAL,Clover,Safety analysis population included all participants who received at least 1 dose of the investigational product.,Clostridium Difficile Vaccine Efficacy Trial,"A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER",COMPLETED,,PHASE3,17535,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 23:05:39,2024-10-13 23:05:39,INDUSTRY,,,,,,,Pfizer,"Argentina|Australia|Belgium|Bulgaria|Canada|Chile|Colombia|Czechia|Finland|France|Germany|Hungary|Japan|Korea, Republic of|Peru|Poland|Portugal|Slovakia|Spain|Sweden|Taiwan|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT03095638,,2017-03-23,2018-05-29,,2019-07-11,2017-03-23,2017-03-29,ACTUAL,2018-11-02,2018-12-21,ACTUAL,,,,2019-07-11,2019-07-23,ACTUAL,2017-05-03,ACTUAL,2017-05-03,2019-07,2019-07-31,2017-06-23,ACTUAL,2017-06-23,2017-06-23,ACTUAL,2017-06-23,,INTERVENTIONAL,,,Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir,"A 2-Part, Phase I, Single Dose, Crossover Relative Bioavailability Study of Both TIVICAY 10 mg Conventional Tablets and 5 mg Dispersible Tablets Compared to Conventional TIVICAY Tablets in Fasted Healthy Adult Subjects",COMPLETED,,PHASE1,38,ACTUAL,ViiV Healthcare,,8,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 13:13:39,2024-10-14 13:13:39,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders"
NCT03101371,,2017-03-30,2020-02-03,,2020-03-06,2017-03-30,2017-04-05,ACTUAL,2020-02-03,2020-02-18,ACTUAL,,,,2020-03-06,2020-03-10,ACTUAL,2017-10-10,ACTUAL,2017-10-10,2020-03,2020-03-31,2019-02-15,ACTUAL,2019-02-15,2019-02-15,ACTUAL,2019-02-15,,INTERVENTIONAL,,"99 participants were randomized, however, 9 participants were excluded from analsysis due to early discontinuation for not meeting eligibility criteria (n=3), provider discretion (n=1), and lost to follow-up (n=5).",Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion,Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion,COMPLETED,,PHASE2,99,ACTUAL,"University of Colorado, Denver",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 13:33:57,2024-10-13 13:33:57,OTHER,,,,,,,"University of Colorado, Denver",United States,Blood and lymphatic system disorders|Gastrointestinal disorders|Renal and urinary disorders|Surgical and medical procedures
NCT03101371,,2017-03-30,2020-02-03,,2020-03-06,2017-03-30,2017-04-05,ACTUAL,2020-02-03,2020-02-18,ACTUAL,,,,2020-03-06,2020-03-10,ACTUAL,2017-10-10,ACTUAL,2017-10-10,2020-03,2020-03-31,2019-02-15,ACTUAL,2019-02-15,2019-02-15,ACTUAL,2019-02-15,,INTERVENTIONAL,,"99 participants were randomized, however, 9 participants were excluded from analsysis due to early discontinuation for not meeting eligibility criteria (n=3), provider discretion (n=1), and lost to follow-up (n=5).",Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion,Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion,COMPLETED,,PHASE2,99,ACTUAL,"University of Colorado, Denver",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 13:33:57,2024-10-13 13:33:57,OTHER,,,,,,,"University of Colorado, Denver",United States,Blood and lymphatic system disorders|Gastrointestinal disorders|Renal and urinary disorders|Surgical and medical procedures
NCT03101371,,2017-03-30,2020-02-03,,2020-03-06,2017-03-30,2017-04-05,ACTUAL,2020-02-03,2020-02-18,ACTUAL,,,,2020-03-06,2020-03-10,ACTUAL,2017-10-10,ACTUAL,2017-10-10,2020-03,2020-03-31,2019-02-15,ACTUAL,2019-02-15,2019-02-15,ACTUAL,2019-02-15,,INTERVENTIONAL,,"99 participants were randomized, however, 9 participants were excluded from analsysis due to early discontinuation for not meeting eligibility criteria (n=3), provider discretion (n=1), and lost to follow-up (n=5).",Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion,Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion,COMPLETED,,PHASE2,99,ACTUAL,"University of Colorado, Denver",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 13:33:57,2024-10-13 13:33:57,OTHER,,,,,,,"University of Colorado, Denver",United States,Blood and lymphatic system disorders|Gastrointestinal disorders|Renal and urinary disorders|Surgical and medical procedures
NCT03102034,,2017-03-23,2019-05-23,,2022-01-13,2017-03-29,2017-04-05,ACTUAL,2019-05-23,2019-06-14,ACTUAL,,,,2022-01-13,2022-02-08,ACTUAL,2017-04-06,ACTUAL,2017-04-06,2022-01,2022-01-31,2018-05-25,ACTUAL,2018-05-25,2018-05-25,ACTUAL,2018-05-25,,INTERVENTIONAL,,Baseline analysis population was participants who received inoculation.,"Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/ΔM2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age",COMPLETED,,PHASE1,32,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 13:28:38,2024-10-13 13:28:38,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03106844,,2017-04-04,2020-08-01,,2021-01-25,2017-04-04,2017-04-10,ACTUAL,2020-08-31,2020-09-21,ACTUAL,,,,2021-01-25,2021-02-10,ACTUAL,2017-08-01,ACTUAL,2017-08-01,2020-10,2020-10-31,2020-12-31,ACTUAL,2020-12-31,2020-04-07,ACTUAL,2020-04-07,,INTERVENTIONAL,,,The ICON Study: Outcomes After FMT for Patients With IBD and CDI,The ICON Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation,COMPLETED,,PHASE1/PHASE2,50,ACTUAL,Brigham and Women's Hospital,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 23:53:37,2024-10-14 23:53:37,OTHER,,,,,,,Brigham and Women's Hospital|Icahn School of Medicine at Mount Sinai|Indiana University|The Miriam Hospital,United States,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Nervous system disorders|Renal and urinary disorders
NCT03107377,,2017-03-29,2020-06-09,,2020-07-27,2017-04-04,2017-04-11,ACTUAL,2020-07-27,2020-08-12,ACTUAL,,,,2020-07-27,2020-08-12,ACTUAL,2017-11-03,ACTUAL,2017-11-03,2020-07,2020-07-31,2019-08-22,ACTUAL,2019-08-22,2019-08-22,ACTUAL,2019-08-22,,INTERVENTIONAL,,ITT Population,Phase 2B/3 Double-blinded Placebo-controlled,Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection,COMPLETED,,PHASE2/PHASE3,860,ACTUAL,Evofem Inc.,For the Adverse Event Section: There were no All-Cause Mortalities to Report,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,YES,,2024-10-13 10:20:44,2024-10-13 10:20:44,INDUSTRY,,,,,,,"Clinical Research Management, Inc.|Evofem Inc.",United States,Cardiac disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Reproductive system and breast disorders
NCT03110133,,2017-04-03,2022-04-25,,2022-09-06,2017-04-06,2017-04-12,ACTUAL,2022-06-10,2022-07-06,ACTUAL,,,,2022-09-06,2022-10-05,ACTUAL,2017-05-08,ACTUAL,2017-05-08,2022-09,2022-09-30,2020-06-18,ACTUAL,2020-06-18,2020-02-28,ACTUAL,2020-02-28,,INTERVENTIONAL,PRISM3,Modified Intent to Treat (mITT) population used,"Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff","A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection",COMPLETED,,PHASE2,206,ACTUAL,Finch Research and Development LLC.,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 18:11:05,2024-10-14 18:11:05,INDUSTRY,,,,,,,Finch Research and Development LLC.,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Renal and urinary disorders"
NCT03110380,,2017-04-07,2019-11-01,,2021-12-14,2017-04-07,2017-04-12,ACTUAL,2019-11-01,2019-11-20,ACTUAL,,,,2021-12-14,2022-01-11,ACTUAL,2017-06-12,ACTUAL,2017-06-12,2021-12,2021-12-31,2021-02-10,ACTUAL,2021-02-10,2018-12-04,ACTUAL,2018-12-04,,INTERVENTIONAL,,The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.,Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed,"A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects Who Are Virologically Suppressed",COMPLETED,,PHASE3,567,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",2024-10-14 10:16:10,2024-10-14 10:16:10,INDUSTRY,,,,,,,Gilead Sciences,Austria|Canada|France|Germany|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03110770,,2017-03-28,2020-10-02,,2024-01-08,2017-04-06,2017-04-12,ACTUAL,2020-11-10,2020-12-04,ACTUAL,,,,2024-01-08,2024-01-31,ACTUAL,2017-03-29,ACTUAL,2017-03-29,2024-01,2024-01-31,2019-10-04,ACTUAL,2019-10-04,2019-10-04,ACTUAL,2019-10-04,,INTERVENTIONAL,DNA,Population includes all randomized subjects.,VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents,"VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents",COMPLETED,,PHASE2,2428,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 00:43:25,2024-10-13 00:43:25,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Colombia|Costa Rica|Ecuador|Mexico|Panama|Peru|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03110770,,2017-03-28,2020-10-02,,2024-01-08,2017-04-06,2017-04-12,ACTUAL,2020-11-10,2020-12-04,ACTUAL,,,,2024-01-08,2024-01-31,ACTUAL,2017-03-29,ACTUAL,2017-03-29,2024-01,2024-01-31,2019-10-04,ACTUAL,2019-10-04,2019-10-04,ACTUAL,2019-10-04,,INTERVENTIONAL,DNA,Population includes all randomized subjects.,VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents,"VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents",COMPLETED,,PHASE2,2428,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 00:43:25,2024-10-13 00:43:25,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Colombia|Costa Rica|Ecuador|Mexico|Panama|Peru|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03110770,,2017-03-28,2020-10-02,,2024-01-08,2017-04-06,2017-04-12,ACTUAL,2020-11-10,2020-12-04,ACTUAL,,,,2024-01-08,2024-01-31,ACTUAL,2017-03-29,ACTUAL,2017-03-29,2024-01,2024-01-31,2019-10-04,ACTUAL,2019-10-04,2019-10-04,ACTUAL,2019-10-04,,INTERVENTIONAL,DNA,Population includes all randomized subjects.,VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents,"VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents",COMPLETED,,PHASE2,2428,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 00:43:25,2024-10-13 00:43:25,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Colombia|Costa Rica|Ecuador|Mexico|Panama|Peru|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03110770,,2017-03-28,2020-10-02,,2024-01-08,2017-04-06,2017-04-12,ACTUAL,2020-11-10,2020-12-04,ACTUAL,,,,2024-01-08,2024-01-31,ACTUAL,2017-03-29,ACTUAL,2017-03-29,2024-01,2024-01-31,2019-10-04,ACTUAL,2019-10-04,2019-10-04,ACTUAL,2019-10-04,,INTERVENTIONAL,DNA,Population includes all randomized subjects.,VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents,"VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents",COMPLETED,,PHASE2,2428,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 00:43:25,2024-10-13 00:43:25,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Colombia|Costa Rica|Ecuador|Mexico|Panama|Peru|Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03111108,,2017-04-06,2019-09-16,,2020-05-28,2017-04-06,2017-04-12,ACTUAL,2019-10-22,2019-11-12,ACTUAL,,,,2020-05-28,2020-06-09,ACTUAL,2017-06-20,ACTUAL,2017-06-20,2020-05,2020-05-31,2018-10-15,ACTUAL,2018-10-15,2018-10-15,ACTUAL,2018-10-15,,INTERVENTIONAL,,,Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096),"A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection",COMPLETED,,PHASE4,117,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 20:59:15,2024-10-14 20:59:15,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,France,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT03118232,,2017-02-21,2023-11-09,,2023-12-05,2017-04-14,2017-04-18,ACTUAL,2023-12-05,2023-12-27,ACTUAL,,,,2023-12-05,2023-12-27,ACTUAL,2017-04-03,ACTUAL,2017-04-03,2023-12,2023-12-31,2023-10-10,ACTUAL,2023-10-10,2023-10-10,ACTUAL,2023-10-10,,INTERVENTIONAL,PROTECT,,Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization,Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization,COMPLETED,,PHASE4,13952,ACTUAL,"University of California, Irvine",,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,"The resource sharing plan involves sharing 1) sharing of trial materials and tools, and 2) making bacterial isolates available.",2024-10-13 20:13:23,2024-10-13 20:13:23,OTHER,,,,,,,"Agency for Healthcare Research and Quality (AHRQ)|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center|University of California, Irvine|University of Massachusetts, Amherst",United States,Product Issues
NCT03118843,,2017-04-13,2019-03-08,,2019-03-08,2017-04-17,2017-04-18,ACTUAL,2019-03-08,2019-04-03,ACTUAL,,,,2019-03-08,2019-04-03,ACTUAL,2017-04-25,ACTUAL,2017-04-25,2019-03,2019-03-31,2018-03-19,ACTUAL,2018-03-19,2018-03-19,ACTUAL,2018-03-19,,INTERVENTIONAL,,Safety Analysis Set included all participants who took at least 1 dose of study drug.,Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study,An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects Who Participated in a Prior Gilead-Sponsored HCV Treatment Study,COMPLETED,,PHASE3,31,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/about/ethics-and-code-of-conduct/policies,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.",2024-10-13 22:37:01,2024-10-13 22:37:01,INDUSTRY,,,,,,,Gilead Sciences,Australia|Canada|France|Germany|New Zealand|Puerto Rico|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT03122223,,2017-02-14,2020-10-15,,2023-03-13,2017-04-17,2017-04-20,ACTUAL,2020-12-14,2021-01-08,ACTUAL,,,,2023-03-13,2023-03-14,ACTUAL,2018-01-16,ACTUAL,2018-01-16,2023-03,2023-03-31,2020-07-30,ACTUAL,2020-07-30,2020-07-30,ACTUAL,2020-07-30,,INTERVENTIONAL,HVTN 120,,"Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants","A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants",COMPLETED,,PHASE1/PHASE2,160,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 17:37:34,2024-10-13 17:37:34,NIH,,,,,,,"GlaxoSmithKline|National Institute of Allergy and Infectious Diseases (NIAID)|Sanofi Pasteur, a Sanofi Company",South Africa|Tanzania|United States|Zambia|Zimbabwe,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03124199,,2016-04-07,2017-04-24,,2018-02-26,2017-04-18,2017-04-21,ACTUAL,2017-08-07,2018-02-19,ACTUAL,,,,2018-02-26,2018-03-22,ACTUAL,2014-02,,2014-02-28,2018-02,2018-02-28,2015-06,ACTUAL,2015-06-30,2015-03,ACTUAL,2015-03-31,,INTERVENTIONAL,R+OCA,,Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection,"Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection",COMPLETED,,PHASE3,40,ACTUAL,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,,1,,,FALSE,,,,FALSE,,,,,,,,,,,UNDECIDED,,2024-10-13 09:48:07,2024-10-13 09:48:07,OTHER,,,,,,,Fundación de Investigación Biomédica - Hospital Universitario de La Princesa,Spain,Gastrointestinal disorders|General disorders
NCT03126370,,2017-04-19,2020-10-01,,2021-01-21,2017-04-19,2017-04-24,ACTUAL,2021-01-21,2021-02-11,ACTUAL,,,,2021-01-21,2021-02-11,ACTUAL,2018-01-08,ACTUAL,2018-01-08,2021-01,2021-01-31,2019-10-01,ACTUAL,2019-10-01,2019-07-12,ACTUAL,2019-07-12,,INTERVENTIONAL,,,Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF),Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.,COMPLETED,,PHASE4,10,ACTUAL,"University of Colorado, Denver",,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,NO,"Not Applicable. As per the question above, we do not plan to share IPD",2024-10-13 02:41:08,2024-10-13 02:41:08,OTHER,,,,,,,"University of Colorado, Denver",United States,Renal and urinary disorders
NCT03137173,,2017-04-27,2020-04-16,,2023-05-09,2017-04-29,2017-05-02,ACTUAL,2020-05-15,2020-05-18,ACTUAL,,,,2023-05-09,2023-05-12,ACTUAL,2018-02-19,ACTUAL,2018-02-19,2023-05,2023-05-31,2019-04-22,ACTUAL,2019-04-22,2019-04-22,ACTUAL,2019-04-22,,INTERVENTIONAL,,ITT population,Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections,"A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections",COMPLETED,,PHASE3,679,ACTUAL,Basilea Pharmaceutica,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 02:34:00,2024-10-14 02:34:00,INDUSTRY,,,,,,,Basilea Pharmaceutica,Bulgaria|Hungary|Ukraine|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03138096,,2017-04-19,2020-11-09,,2022-02-23,2017-04-28,2017-05-03,ACTUAL,2021-11-01,2021-12-15,ACTUAL,,,,2022-02-23,2022-03-04,ACTUAL,2017-05-29,ACTUAL,2017-05-29,2017-03,2017-03-31,2018-10-03,ACTUAL,2018-10-03,2018-03-28,ACTUAL,2018-03-28,,INTERVENTIONAL,PbVac,phase 2 was not effected,Safety and Protective Efficacy of Pb(PfCS@UIS4),Safety and Protective Efficacy of Genetically Modified Plasmodium Berghei (Pb(PfCS@UIS4)) Malaria Parasites in Healthy Volunteers,COMPLETED,,PHASE1/PHASE2,24,ACTUAL,Radboud University Medical Center,,5,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,YES,Results will be published,2024-10-13 09:27:07,2024-10-13 09:27:07,OTHER,,,,,,,Erasmus Medical Center|Havenziekenhuis|Radboud University Medical Center|The PATH Malaria Vaccine Initiative (MVI),Netherlands,Blood and lymphatic system disorders|General disorders|Skin and subcutaneous tissue disorders
NCT03149848,,2017-05-09,2018-09-04,,2020-08-27,2017-05-09,2017-05-11,ACTUAL,2018-09-04,2019-02-04,ACTUAL,,,,2020-08-27,2020-09-17,ACTUAL,2017-06-06,ACTUAL,2017-06-06,2020-08,2020-08-31,2017-09-07,ACTUAL,2017-09-07,2017-09-06,ACTUAL,2017-09-06,,INTERVENTIONAL,,,Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects,"Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects",COMPLETED,,PHASE1,15,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20363,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 01:29:17,2024-10-13 01:29:17,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,United Kingdom,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT03149848,,2017-05-09,2018-09-04,,2020-08-27,2017-05-09,2017-05-11,ACTUAL,2018-09-04,2019-02-04,ACTUAL,,,,2020-08-27,2020-09-17,ACTUAL,2017-06-06,ACTUAL,2017-06-06,2020-08,2020-08-31,2017-09-07,ACTUAL,2017-09-07,2017-09-06,ACTUAL,2017-09-06,,INTERVENTIONAL,,,Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects,"Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects",COMPLETED,,PHASE1,15,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20363,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 01:29:17,2024-10-13 01:29:17,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,United Kingdom,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT03150082,,2017-05-10,2018-06-27,,2018-06-27,2017-05-10,2017-05-11,ACTUAL,2018-06-27,2018-12-19,ACTUAL,,,,2018-06-27,2018-12-19,ACTUAL,2017-08-01,ACTUAL,2017-08-01,2018-06,2018-06-30,2017-08-28,ACTUAL,2017-08-28,2017-08-28,ACTUAL,2017-08-28,,INTERVENTIONAL,,,Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects,"An Open-label, Randomised, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of GR37547 Ciprofloxacin 500 mg Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Participants Under Fasting Conditions",COMPLETED,,PHASE1,26,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-14 18:53:55,2024-10-14 18:53:55,INDUSTRY,,,,,,,GlaxoSmithKline|Parexel,South Africa,Gastrointestinal disorders|Infections and infestations|Nervous system disorders
NCT03151967,,2016-01-13,2022-12-16,,2023-02-06,2017-05-10,2017-05-12,ACTUAL,2023-02-06,2023-03-01,ACTUAL,,,,2023-02-06,2023-03-01,ACTUAL,2015-09,ACTUAL,2015-09-30,2023-02,2023-02-28,2017-04-05,ACTUAL,2017-04-05,2017-04-05,ACTUAL,2017-04-05,,INTERVENTIONAL,,,Lactobacillus Probiotic for Prevention of UTI,Lactobacillus Probiotic for Prevention of UTI,COMPLETED,,PHASE2/PHASE3,27,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 06:11:05,2024-10-14 06:11:05,OTHER,,,,,,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Washington,United States,Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders
NCT03155841,,2017-05-10,2023-02-23,,2023-05-03,2017-05-15,2017-05-16,ACTUAL,2023-05-03,2023-05-06,ACTUAL,,,,2023-05-03,2023-05-06,ACTUAL,2018-03-23,ACTUAL,2018-03-23,2023-05,2023-05-31,2022-02-28,ACTUAL,2022-02-28,2022-02-28,ACTUAL,2022-02-28,,INTERVENTIONAL,,,Reducing HIV Vulnerability Through A Multilevel Life Skills Intervention For Adolescent Men,Reducing HIV Vulnerability Through A Multilevel Life Skills Intervention For Adolescent Men,COMPLETED,,NA,600,ACTUAL,University of Pennsylvania,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-12 23:46:56,2024-10-12 23:46:56,OTHER,,,,,,,Emory University|George Washington University|San Diego State University|University of Michigan|University of North Carolina|University of Pennsylvania,United States,Infections and infestations
NCT03158220,,2017-05-16,2019-11-04,,2019-11-04,2017-05-16,2017-05-18,ACTUAL,2019-11-04,2019-11-21,ACTUAL,,,,2019-11-04,2019-11-21,ACTUAL,2017-09-20,ACTUAL,2017-09-20,2019-11,2019-11-30,2018-11-19,ACTUAL,2018-11-19,2018-11-19,ACTUAL,2018-11-19,,INTERVENTIONAL,,,Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004),An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds),COMPLETED,,PHASE3,1212,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 21:39:34,2024-10-13 21:39:34,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Austria|Belgium|Finland|Germany|Italy|Spain,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT03162458,,2017-05-19,2017-05-24,,2018-11-01,2017-05-19,2017-05-22,ACTUAL,2017-10-30,2018-08-03,ACTUAL,,,,2018-11-01,2018-11-28,ACTUAL,2015-01-22,ACTUAL,2015-01-22,2018-11,2018-11-30,2015-04-29,ACTUAL,2015-04-29,2015-04-29,ACTUAL,2015-04-29,,INTERVENTIONAL,,,Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections,Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections,COMPLETED,,PHASE3,142,ACTUAL,Materia Medica Holding,,2,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-14 00:53:47,2024-10-14 00:53:47,INDUSTRY,,,,,,,Materia Medica Holding,Russian Federation,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|Immune system disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03164564,,2017-05-22,2022-03-23,,2024-09-26,2017-05-22,2017-05-23,ACTUAL,2023-03-21,2023-03-28,ACTUAL,,,,2024-09-26,2024-10-01,ACTUAL,2017-11-07,ACTUAL,2017-11-07,2024-09,2024-09-30,2024-11-30,ESTIMATED,2024-11-30,2020-11-05,ACTUAL,2020-11-05,,INTERVENTIONAL,,Overall enrolled participants,Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women,A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women,ACTIVE_NOT_RECRUITING,,PHASE3,3224,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 16:06:18,2024-10-14 16:06:18,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Kenya|Malawi|South Africa|Swaziland|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT03170609,,2017-05-26,2019-06-13,,2019-06-13,2017-05-26,2017-05-31,ACTUAL,2019-06-13,2019-07-02,ACTUAL,,,,2019-06-13,2019-07-02,ACTUAL,2017-06-05,ACTUAL,2017-06-05,2019-06,2019-06-30,2018-06-25,ACTUAL,2018-06-25,2018-06-25,ACTUAL,2018-06-25,,INTERVENTIONAL,,Safety population included all participants who received either GBS6 vaccine or placebo.,"A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age","A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY ADULTS 18 TO 49 YEARS OF AGE",COMPLETED,,PHASE2,365,ACTUAL,Pfizer,,7,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-14 17:03:12,2024-10-14 17:03:12,INDUSTRY,,,,,,,Pfizer,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders"
NCT03176134,,2017-06-01,2024-06-10,,2024-09-10,2017-06-01,2017-06-05,ACTUAL,2024-06-10,2024-07-03,ACTUAL,,,,2024-09-10,2024-09-26,ACTUAL,2019-01-20,ACTUAL,2019-01-20,2024-09,2024-09-30,2023-07-06,ACTUAL,2023-07-06,2023-07-06,ACTUAL,2023-07-06,,INTERVENTIONAL,,All randomized participants.,A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018),"A Phase III Randomized, Active-comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator, in Subjects From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)",COMPLETED,,PHASE3,100,ACTUAL,Merck Sharp & Dohme LLC,,8,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 11:36:27,2024-10-13 11:36:27,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Brazil|Bulgaria|Georgia|Germany|Guatemala|Latvia|Lithuania|Mexico|Poland|Russian Federation|South Africa|Turkey|Ukraine|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03181789,,2017-06-06,2021-07-15,,2024-01-16,2017-06-07,2017-06-09,ACTUAL,2021-09-17,2021-10-14,ACTUAL,,,,2024-01-16,2024-02-07,ACTUAL,2017-10-18,ACTUAL,2017-10-18,2024-01,2024-01-31,2020-04-29,ACTUAL,2020-04-29,2019-10-25,ACTUAL,2019-10-25,,INTERVENTIONAL,HVTN119,,"Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA, in Healthy, HIV-Uninfected Adult Participants",COMPLETED,,PHASE1,56,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,TRUE,TRUE,TRUE,,,,,,,,,,,2024-10-13 17:26:21,2024-10-13 17:26:21,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03182907,,2017-06-08,2023-04-06,,2023-07-25,2017-06-08,2017-06-09,ACTUAL,2023-05-11,2023-06-07,ACTUAL,,,,2023-07-25,2023-07-27,ACTUAL,2018-03-27,ACTUAL,2018-03-27,2023-07,2023-07-31,2022-05-12,ACTUAL,2022-05-12,2022-05-12,ACTUAL,2022-05-12,,INTERVENTIONAL,MODIFY III,,Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001),"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III)",COMPLETED,,PHASE3,148,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 01:42:45,2024-10-15 01:42:45,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Argentina|Brazil|Colombia|Czechia|Germany|Hungary|Malaysia|Mexico|Norway|Poland|Portugal|Romania|South Africa|Spain|Sweden|United Kingdom|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03183128,,2017-06-08,2023-03-07,2021-06-21,2023-04-06,2017-06-08,2017-06-09,ACTUAL,2023-04-06,2023-04-27,ACTUAL,,2023-04-27,ACTUAL,2023-04-06,2023-04-27,ACTUAL,2017-07-10,ACTUAL,2017-07-10,2021-06,2021-06-30,2020-09-29,ACTUAL,2020-09-29,2020-07-03,ACTUAL,2020-07-03,,INTERVENTIONAL,ECOSPORIII,,ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection,"A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults",COMPLETED,,PHASE3,182,ACTUAL,"Seres Therapeutics, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 21:34:22,2024-10-13 21:34:22,INDUSTRY,,,,,,,"Seres Therapeutics, Inc.",Canada|United States,"Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03183141,,2017-06-08,2023-03-07,,2023-04-06,2017-06-08,2017-06-09,ACTUAL,2023-03-07,2023-03-31,ACTUAL,,,,2023-04-06,2023-04-10,ACTUAL,2017-10-23,ACTUAL,2017-10-23,2023-04,2023-04-30,2022-04-29,ACTUAL,2022-04-29,2022-04-29,ACTUAL,2022-04-29,,INTERVENTIONAL,,,ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection,ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI),COMPLETED,,PHASE3,263,ACTUAL,"Seres Therapeutics, Inc.",,1,,,TRUE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 10:09:42,2024-10-14 10:09:42,INDUSTRY,,NCT02437500,APPROVED_FOR_MARKETING,,,,"Seres Therapeutics, Inc.",Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03188523,,2017-06-14,2019-05-03,,2019-05-03,2017-06-14,2017-06-15,ACTUAL,2019-05-03,2019-07-15,ACTUAL,,,,2019-05-03,2019-07-15,ACTUAL,2017-09-08,ACTUAL,2017-09-08,2019-05,2019-05-31,2018-06-04,ACTUAL,2018-06-04,2018-05-21,ACTUAL,2018-05-21,,INTERVENTIONAL,,,"Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)","A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8504 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients",COMPLETED,,PHASE1,12,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 17:47:01,2024-10-14 17:47:01,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany|United Kingdom,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03198507,,2017-06-07,2020-01-21,,2020-02-28,2017-06-21,2017-06-26,ACTUAL,2020-02-28,2020-03-16,ACTUAL,,,,2020-02-28,2020-03-16,ACTUAL,2017-06-18,ACTUAL,2017-06-18,2018-08,2018-08-31,2018-12-13,ACTUAL,2018-12-13,2018-10-24,ACTUAL,2018-10-24,,INTERVENTIONAL,ERADICATE Hp2,"Treatment naïve adult subjects aged 18 to 70 years, complaining of epigastric discomfort that had been screened and found to be positive for H. pylori infection via 13C UBT and follow up upper endoscopy (culture, histology, or CLO test).",ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator,A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection,COMPLETED,,PHASE3,455,ACTUAL,RedHill Biopharma Limited,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 00:43:25,2024-10-13 00:43:25,INDUSTRY,,,,,,,RedHill Biopharma Limited,United States,Gastrointestinal disorders|Metabolism and nutrition disorders|Nervous system disorders
NCT03199911,,2017-06-08,2020-05-19,,2020-07-20,2017-06-24,2017-06-27,ACTUAL,2020-07-20,2020-07-21,ACTUAL,,,,2020-07-20,2020-07-21,ACTUAL,2017-10-02,ACTUAL,2017-10-02,2020-07,2020-07-31,2019-11-14,ACTUAL,2019-11-14,2019-11-14,ACTUAL,2019-11-14,,INTERVENTIONAL,,Data not available for 3 participants who did not proceed with surgery.,Topical Antibiotic Prophylaxis for Eyelids,The Role of Topical Antibiotic Prophylaxis in Eyelid Surgery,COMPLETED,,PHASE4,401,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 23:11:12,2024-10-13 23:11:12,OTHER,,,,,,,"University of California, San Francisco",United States,Skin and subcutaneous tissue disorders
NCT03199911,,2017-06-08,2020-05-19,,2020-07-20,2017-06-24,2017-06-27,ACTUAL,2020-07-20,2020-07-21,ACTUAL,,,,2020-07-20,2020-07-21,ACTUAL,2017-10-02,ACTUAL,2017-10-02,2020-07,2020-07-31,2019-11-14,ACTUAL,2019-11-14,2019-11-14,ACTUAL,2019-11-14,,INTERVENTIONAL,,Data not available for 3 participants who did not proceed with surgery.,Topical Antibiotic Prophylaxis for Eyelids,The Role of Topical Antibiotic Prophylaxis in Eyelid Surgery,COMPLETED,,PHASE4,401,ACTUAL,"University of California, San Francisco",,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 23:11:12,2024-10-13 23:11:12,OTHER,,,,,,,"University of California, San Francisco",United States,Skin and subcutaneous tissue disorders
NCT03205358,,2017-06-28,2020-05-20,2017-09-06,2022-03-24,2017-06-28,2017-07-02,ACTUAL,2020-05-20,2020-06-05,ACTUAL,2017-09-06,2017-09-14,ACTUAL,2022-03-24,2022-04-04,ACTUAL,2015-03-31,ACTUAL,2015-03-31,2022-03,2022-03-31,2015-08-19,ACTUAL,2015-08-19,2015-08-19,ACTUAL,2015-08-19,,INTERVENTIONAL,,The analysis was performed on safety analysis set which included those participants who had received at least 1 dose of the study vaccine and had any safety data available.,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers,A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers,COMPLETED,,PHASE2,188,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 23:13:29,2024-10-14 23:13:29,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Finland,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders"
NCT03207750,,2017-06-16,2019-10-08,,2020-12-07,2017-06-30,2017-07-05,ACTUAL,2019-10-08,2019-10-31,ACTUAL,,,,2020-12-07,2020-12-29,ACTUAL,2017-09-14,ACTUAL,2017-09-14,2020-12,2020-12-31,2019-03-01,ACTUAL,2019-03-01,2018-10-09,ACTUAL,2018-10-09,,INTERVENTIONAL,,,"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","Immunogenicity, Reactogenicity and Safety Study of Pediarix®, Hiberix® and Prevenar 13® Co-administered With Two Different Formulations of GSK Biologicals' HRV Vaccine (444563) in Healthy Infants 6-12 Weeks of Age",COMPLETED,,PHASE3,1280,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20750,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-13 07:42:57,2024-10-13 07:42:57,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03208231,,2017-06-30,2023-04-27,2021-01-31,2023-04-27,2017-06-30,2017-07-05,ACTUAL,2023-04-27,2023-05-24,ACTUAL,2021-01-31,2021-02-04,ACTUAL,2023-04-27,2023-05-24,ACTUAL,2018-08-06,ACTUAL,2018-08-06,2023-04,2023-04-30,2021-02-11,ACTUAL,2021-02-11,2020-06-16,ACTUAL,2020-06-16,,INTERVENTIONAL,,,Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy,"Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 With Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants",COMPLETED,,PHASE1/PHASE2,61,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"Accrual into the study was terminated early due to the outbreak of coronavirus disease 2019 (COVID-19), with 60 evaluable infants out of the targeted 68.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.,"* With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
* For what types of analyses? To achieve aims in the proposal approved by the IMPAACT Network.
* By what mechanism will data be made available? Researchers may submit a request for access to data using the IMPAACT ""Data Request"" form at: https://www.impaactnetwork.org/studies/submit-research-proposal. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.""",https://www.impaactnetwork.org/,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-13 21:56:26,2024-10-13 21:56:26,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Brazil|Haiti|Malawi|South Africa|United States|Zimbabwe,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03212989,,2017-06-29,2023-04-18,,2023-04-18,2017-07-06,2017-07-11,ACTUAL,2023-04-18,2023-05-12,ACTUAL,,,,2023-04-18,2023-05-12,ACTUAL,2017-06-27,ACTUAL,2017-06-27,2022-08,2022-08-31,2022-07-05,ACTUAL,2022-07-05,2022-06-07,ACTUAL,2022-06-07,,INTERVENTIONAL,XTRA,,Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART),IGHID 11627 - A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on Persistent HIV-1 Infection in HIV-Infected Individuals Started on Antiretroviral Therapy (The XTRA Study),COMPLETED,,PHASE1,17,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 18:07:20,2024-10-13 18:07:20,OTHER,,,,,,,"National Heart, Lung, and Blood Institute (NHLBI)|University of North Carolina, Chapel Hill",United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03213405,,2017-06-30,2020-10-09,,2020-11-18,2017-07-07,2017-07-11,ACTUAL,2020-11-18,2020-12-11,ACTUAL,,,,2020-11-18,2020-12-11,ACTUAL,2017-06-27,ACTUAL,2017-06-27,2020-11,2020-11-30,2018-06-01,ACTUAL,2018-06-01,2018-06-01,ACTUAL,2018-06-01,,INTERVENTIONAL,EVA-VRS01,,"A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV","A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age",COMPLETED,,PHASE1,24,ACTUAL,Pontificia Universidad Catolica de Chile,,4,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 21:10:58,2024-10-14 21:10:58,OTHER,,,,,,,Comisión Nacional de Investigación Científica y Tecnológica|Millennium Institute on Immunology and Immunotherapy|Pontificia Universidad Catolica de Chile,Chile,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders
NCT03214679,,2017-06-29,2023-01-26,,2023-01-26,2017-07-07,2017-07-11,ACTUAL,2023-01-26,2023-02-22,ACTUAL,,,,2023-01-26,2023-02-22,ACTUAL,2017-07-20,ACTUAL,2017-07-20,2021-07,2021-07-31,2021-06-30,ACTUAL,2021-06-30,2021-06-30,ACTUAL,2021-06-30,,INTERVENTIONAL,,2 ineligible participants excluded post-randomization (both accessible care arm) are not included,Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID),Accessible Care Intervention for Engaging People Who Inject Illicit Drugs in HCV Care,COMPLETED,,NA,167,ACTUAL,"City University of New York, School of Public Health","he study limitations to generalizability include that the study was conducted at a single site and in an urban environment with a high concentration of harm reduction services and minimal state HCV DAA prescribing restrictions. As observed in this trial, most patients were insured or eligible for insurance, and no participants had their insurance company deny treatment with HCV DAA therapy.",2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,,,2024-10-14 17:47:01,2024-10-14 17:47:01,OTHER,,,,,,,"City University of New York, School of Public Health|National Development and Research Institutes, Inc.|National Institute on Drug Abuse (NIDA)|Weill Medical College of Cornell University",United States,"Cardiac disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT03217136,,2017-07-12,2021-11-22,2021-01-19,2023-05-03,2017-07-12,2017-07-13,ACTUAL,2021-11-22,2021-12-21,ACTUAL,2021-02-26,2021-03-04,ACTUAL,2023-05-03,2023-05-06,ACTUAL,2018-04-03,ACTUAL,2018-04-03,2023-05,2023-05-31,2020-03-16,ACTUAL,2020-03-16,2020-03-16,ACTUAL,2020-03-16,,INTERVENTIONAL,,,MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035),"A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal Infection",COMPLETED,,PHASE2,94,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 07:42:57,2024-10-13 07:42:57,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Brazil|Hungary|Lithuania|Malaysia|Mexico|Romania|Russian Federation|South Africa|Spain|Turkey|Ukraine|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Vascular disorders"
NCT03217565,,2017-07-12,2024-01-17,,2024-01-17,2017-07-12,2017-07-14,ACTUAL,2024-01-17,2024-07-22,ACTUAL,,,,2024-01-17,2024-07-22,ACTUAL,2019-02-06,ACTUAL,2019-02-06,2024-01,2024-01-31,2023-03-29,ACTUAL,2023-03-29,2023-03-18,ACTUAL,2023-03-18,,INTERVENTIONAL,,,A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014),"A Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old",COMPLETED,,PHASE1,47,ACTUAL,Merck Sharp & Dohme LLC,,9,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 03:39:24,2024-10-14 03:39:24,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Bulgaria|Colombia|Norway|United Kingdom|United States,"Blood and lymphatic system disorders|Eye disorders|General disorders|Infections and infestations|Investigations|Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03220724,,2017-07-12,2021-07-14,,2024-05-16,2017-07-13,2017-07-18,ACTUAL,2023-01-30,2023-02-01,ACTUAL,,,,2024-05-16,2024-05-21,ACTUAL,2017-08-22,ACTUAL,2017-08-22,2024-04,2024-04-30,2023-03-21,ACTUAL,2023-03-21,2023-03-21,ACTUAL,2023-03-21,,INTERVENTIONAL,,,"Evaluating the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adults","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of EnvSeq-1 and CH505 M5 gp120 Envs Adjuvanted With GLA-SE in Healthy, HIV-Uninfected Adult Participants",COMPLETED,,PHASE1,117,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,9,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 13:45:03,2024-10-13 13:45:03,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT03227029,,2017-07-20,2020-12-14,,2022-04-20,2017-07-20,2017-07-24,ACTUAL,2020-12-14,2021-01-08,ACTUAL,,,,2022-04-20,2022-04-22,ACTUAL,2017-09-22,ACTUAL,2017-09-22,2022-04,2022-04-30,2020-10-01,ACTUAL,2020-10-01,2019-12-19,ACTUAL,2019-12-19,,INTERVENTIONAL,,Baseline analysis population was participants who received inoculation and were followed on study past Day 0.,"Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age","Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age",COMPLETED,,PHASE1,65,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 05:22:56,2024-10-13 05:22:56,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03230175,,2017-07-19,2021-04-06,2020-03-11,2021-05-20,2017-07-25,2017-07-26,ACTUAL,2021-05-20,2021-06-15,ACTUAL,2021-05-20,2021-06-15,ACTUAL,2021-05-20,2021-06-15,ACTUAL,2017-10-04,ACTUAL,2017-10-04,2021-05,2021-05-31,2019-04-01,ACTUAL,2019-04-01,2019-01-10,ACTUAL,2019-01-10,,INTERVENTIONAL,,,Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01),"A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)",COMPLETED,,PHASE2,32,ACTUAL,"BioTissue Holdings, Inc","The one caveat is the lack of a control group. However, the study was designed to examine the safety and estimate the efficacy of TTAX01 plus standard care in achieving complete would closure of these complex non-healing diabetic foot ulcer with high risk factors.",1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-13 23:27:20,2024-10-13 23:27:20,INDUSTRY,,,,,,,"BioTissue Holdings, Inc",United States,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03230838,,2017-07-24,2021-11-03,,2023-05-03,2017-07-24,2017-07-26,ACTUAL,2021-11-03,2021-12-01,ACTUAL,,,,2023-05-03,2023-05-06,ACTUAL,2018-04-26,ACTUAL,2018-04-26,2023-05,2023-05-31,2020-12-03,ACTUAL,2020-12-03,2020-12-03,ACTUAL,2020-12-03,,INTERVENTIONAL,,,MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034),"A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis",COMPLETED,,PHASE2,134,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 17:28:56,2024-10-14 17:28:56,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Greece|Hungary|Mexico|Poland|Romania|Russian Federation|South Africa|Turkey|Ukraine|United States,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Vascular disorders
NCT03230916,,2017-07-17,2021-07-21,,2024-01-12,2017-07-26,2017-07-27,ACTUAL,2021-10-28,2021-12-13,ACTUAL,,,,2024-01-12,2024-02-06,ACTUAL,2017-11-06,ACTUAL,2017-11-06,2024-01,2024-01-31,2020-08-11,ACTUAL,2020-08-11,2020-07-28,ACTUAL,2020-07-28,,INTERVENTIONAL,,,A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020),"A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections",COMPLETED,,PHASE1,47,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 08:47:40,2024-10-13 08:47:40,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Bulgaria|Colombia|Greece|Norway|Poland|Ukraine|United Kingdom|United States,Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Investigations|Skin and subcutaneous tissue disorders
NCT03231943,,2017-07-24,2019-09-09,,2021-05-28,2017-07-24,2017-07-27,ACTUAL,2019-10-16,2019-10-18,ACTUAL,,,,2021-05-28,2021-06-10,ACTUAL,2017-09-19,ACTUAL,2017-09-19,2021-05,2021-05-31,2018-09-09,ACTUAL,2018-09-09,2018-09-09,ACTUAL,2018-09-09,,INTERVENTIONAL,,,GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers,"A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants",COMPLETED,,PHASE1,78,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20826,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-13 19:04:44,2024-10-13 19:04:44,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,United Kingdom,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03231943,,2017-07-24,2019-09-09,,2021-05-28,2017-07-24,2017-07-27,ACTUAL,2019-10-16,2019-10-18,ACTUAL,,,,2021-05-28,2021-06-10,ACTUAL,2017-09-19,ACTUAL,2017-09-19,2021-05,2021-05-31,2018-09-09,ACTUAL,2018-09-09,2018-09-09,ACTUAL,2018-09-09,,INTERVENTIONAL,,,GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers,"A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants",COMPLETED,,PHASE1,78,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20826,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-13 19:04:44,2024-10-13 19:04:44,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,United Kingdom,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03233438,,2017-07-26,2019-10-30,,2020-01-07,2017-07-26,2017-07-28,ACTUAL,2020-01-07,2020-01-18,ACTUAL,,,,2020-01-07,2020-01-18,ACTUAL,2017-07-24,ACTUAL,2017-07-24,2020-01,2020-01-31,2018-10-30,ACTUAL,2018-10-30,2018-10-30,ACTUAL,2018-10-30,,INTERVENTIONAL,,Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion.,Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI),Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections,COMPLETED,,PHASE4,91,ACTUAL,Allergan,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-15 01:03:51,2024-10-15 01:03:51,INDUSTRY,,,,,,,Allergan,United States,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders
NCT03233438,,2017-07-26,2019-10-30,,2020-01-07,2017-07-26,2017-07-28,ACTUAL,2020-01-07,2020-01-18,ACTUAL,,,,2020-01-07,2020-01-18,ACTUAL,2017-07-24,ACTUAL,2017-07-24,2020-01,2020-01-31,2018-10-30,ACTUAL,2018-10-30,2018-10-30,ACTUAL,2018-10-30,,INTERVENTIONAL,,Full analysis set (FAS) population consists of all enrolled patients that has received at least one dose of antibiotics or one dose of dalbavancin for inclusion.,Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI),Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections,COMPLETED,,PHASE4,91,ACTUAL,Allergan,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-15 01:03:51,2024-10-15 01:03:51,INDUSTRY,,,,,,,Allergan,United States,Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders
NCT03234036,,2017-07-26,2018-11-08,,2020-10-06,2017-07-26,2017-07-31,ACTUAL,2018-11-08,2019-03-07,ACTUAL,,,,2020-10-06,2020-10-28,ACTUAL,2017-08-02,ACTUAL,2017-08-02,2020-10,2020-10-31,2017-11-10,ACTUAL,2017-11-10,2017-11-10,ACTUAL,2017-11-10,,INTERVENTIONAL,,,"A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir",A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232,COMPLETED,,PHASE1,26,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20589,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-14 18:53:55,2024-10-14 18:53:55,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03234036,,2017-07-26,2018-11-08,,2020-10-06,2017-07-26,2017-07-31,ACTUAL,2018-11-08,2019-03-07,ACTUAL,,,,2020-10-06,2020-10-28,ACTUAL,2017-08-02,ACTUAL,2017-08-02,2020-10,2020-10-31,2017-11-10,ACTUAL,2017-11-10,2017-11-10,ACTUAL,2017-11-10,,INTERVENTIONAL,,,"A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir",A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232,COMPLETED,,PHASE1,26,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20589,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-14 18:53:55,2024-10-14 18:53:55,INDUSTRY,,,,,,,GlaxoSmithKline,United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03239483,,2017-08-02,2019-09-19,,2021-10-15,2017-08-02,2017-08-04,ACTUAL,2019-10-18,2019-11-07,ACTUAL,,,,2021-10-15,2021-10-19,ACTUAL,2017-10-26,ACTUAL,2017-10-26,2019-10,2019-10-31,2018-09-20,ACTUAL,2018-09-20,2018-09-20,ACTUAL,2018-09-20,,INTERVENTIONAL,,,Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults,"A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults",COMPLETED,,PHASE1,28,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 19:28:19,2024-10-13 19:28:19,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Thailand|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03239899,,2017-08-03,2024-01-24,,2024-01-24,2017-08-03,2017-08-04,ACTUAL,2024-01-24,2024-02-13,ACTUAL,,,,2024-01-24,2024-02-13,ACTUAL,2018-04-09,ACTUAL,2018-04-09,2023-02-13,2023-02-13,2023-02-13,ACTUAL,2023-02-13,2023-02-13,ACTUAL,2023-02-13,,INTERVENTIONAL,,,PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection,PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection,COMPLETED,,PHASE1,13,ACTUAL,National Institutes of Health Clinical Center (CC),,1,,,FALSE,,,,,TRUE,FALSE,,,,,,"Starting 6 months after publication, or at the time of publication","At request, through existing NIH technology transfer policy methods",,YES,All IPD that underlie results in a publication,2024-10-13 12:47:38,2024-10-13 12:47:38,NIH,,,,,,,National Institute of Neurological Disorders and Stroke (NINDS),United States,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03244644,,2017-08-02,2023-06-09,2021-03-29,2024-07-08,2017-08-08,2017-08-09,ACTUAL,2023-08-10,2023-08-14,ACTUAL,,2023-08-14,ACTUAL,2024-07-08,2024-07-10,ACTUAL,2017-07-31,ACTUAL,2017-07-31,2024-07,2024-07-31,2020-08-03,ACTUAL,2020-08-03,2020-04-02,ACTUAL,2020-04-02,,INTERVENTIONAL,,,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3),"A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection",COMPLETED,,PHASE3,320,ACTUAL,Rebiotix Inc.,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 13:07:17,2024-10-14 13:07:17,INDUSTRY,,,,,,,Rebiotix Inc.,Canada|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03249935,,2017-08-03,2019-09-12,,2019-10-24,2017-08-10,2017-08-15,ACTUAL,2019-10-24,2019-10-28,ACTUAL,,,,2019-10-24,2019-10-28,ACTUAL,2017-08-24,ACTUAL,2017-08-24,2019-09,2019-09-30,2018-09-17,ACTUAL,2018-09-17,2018-09-17,ACTUAL,2018-09-17,,INTERVENTIONAL,,All enrolled participants who tested positive for chlamydia at baseline.,YCFM (Youth Correctional Facilities Males),Treatment Failure and Associated Predictors Following Azithromycin Treatment for Urogenital Chlamydial Infection in Males in Youth Correctional Facilities,COMPLETED,,PHASE2,100,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),"In September 2018, the decision was made to stop enrollment early due to changes in the LA Public Health and YCF standard facility management systems; research staff were not able to overcome the resulting challenges making enrollment infeasible.",1,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-15 00:18:36,2024-10-15 00:18:36,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Gastrointestinal disorders
NCT03261830,,2017-08-23,2023-11-30,,2024-07-16,2017-08-23,2017-08-25,ACTUAL,2024-07-16,2024-08-09,ACTUAL,,,,2024-07-16,2024-08-09,ACTUAL,2017-08-18,ACTUAL,2017-08-18,2024-07,2024-07-31,2023-03-10,ACTUAL,2023-03-10,2023-03-10,ACTUAL,2023-03-10,,INTERVENTIONAL,,,Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS),Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS),COMPLETED,,PHASE4,160,ACTUAL,University of Missouri-Columbia,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-14 21:51:26,2024-10-14 21:51:26,OTHER,,,,,,,Sumit Gupta|University of Missouri-Columbia,United States,Musculoskeletal and connective tissue disorders|Skin and subcutaneous tissue disorders
NCT03262441,,2017-08-23,2020-08-23,,2020-11-10,2017-08-23,2017-08-25,ACTUAL,2020-11-10,2020-12-03,ACTUAL,,,,2020-11-10,2020-12-03,ACTUAL,2018-02-12,ACTUAL,2018-02-12,2020-11,2020-11-30,2019-08-31,ACTUAL,2019-08-31,2019-08-31,ACTUAL,2019-08-31,,INTERVENTIONAL,,,MMF for HIV Reservoir Reduction,Mycophenolate Mofetil Therapy for Reduction of the HIV Reservoir,COMPLETED,,PHASE2,5,ACTUAL,Fred Hutchinson Cancer Center,This was a small and uncontrolled study.,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-15 01:31:57,2024-10-15 01:31:57,OTHER,,,,,,,Fred Hutchinson Cancer Center|University of Washington,United States,Skin and subcutaneous tissue disorders
NCT03272347,,2017-09-01,2022-02-23,,2023-03-03,2017-09-01,2017-09-05,ACTUAL,2022-03-31,2022-04-27,ACTUAL,,,,2023-03-03,2023-03-29,ACTUAL,2017-11-27,ACTUAL,2017-11-27,2023-02,2023-02-28,2022-03-09,ACTUAL,2022-03-09,2021-03-08,ACTUAL,2021-03-08,,INTERVENTIONAL,,,Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011),"A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults",COMPLETED,,PHASE2,123,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 17:34:55,2024-10-14 17:34:55,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Chile|France|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03274466,,2017-09-05,2020-11-11,,2024-09-30,2017-09-05,2017-09-07,ACTUAL,2021-01-20,2021-02-10,ACTUAL,,,,2024-09-30,2024-10-02,ACTUAL,2017-12-05,ACTUAL,2017-12-05,2024-09,2024-09-30,2019-12-19,ACTUAL,2019-12-19,2019-11-27,ACTUAL,2019-11-27,,INTERVENTIONAL,PROMISES,Randomized Subjects (ITT),Closed Incision Negative Pressure Therapy Versus Standard of Care Surgical Dressing in Revision Total Knee Arthroplasty,"Post-market, Randomized, Open-Label, Multicenter, Study to Evaluate the Effectiveness of Closed Incision Negative Pressure Therapy Versus Standard of Care Dressings in Reducing Surgical Site Complications in Subjects With Revision of a Failed Total Knee Arthroplasty (PROMISES)",COMPLETED,,NA,294,ACTUAL,Solventum US LLC,,2,,,FALSE,,,,,FALSE,TRUE,,,FALSE,,,,,,,,2024-10-13 09:59:01,2024-10-13 09:59:01,INDUSTRY,,,,,,,3M|Solventum US LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT03274466,,2017-09-05,2020-11-11,,2024-09-30,2017-09-05,2017-09-07,ACTUAL,2021-01-20,2021-02-10,ACTUAL,,,,2024-09-30,2024-10-02,ACTUAL,2017-12-05,ACTUAL,2017-12-05,2024-09,2024-09-30,2019-12-19,ACTUAL,2019-12-19,2019-11-27,ACTUAL,2019-11-27,,INTERVENTIONAL,PROMISES,Randomized Subjects (ITT),Closed Incision Negative Pressure Therapy Versus Standard of Care Surgical Dressing in Revision Total Knee Arthroplasty,"Post-market, Randomized, Open-Label, Multicenter, Study to Evaluate the Effectiveness of Closed Incision Negative Pressure Therapy Versus Standard of Care Dressings in Reducing Surgical Site Complications in Subjects With Revision of a Failed Total Knee Arthroplasty (PROMISES)",COMPLETED,,NA,294,ACTUAL,Solventum US LLC,,2,,,FALSE,,,,,FALSE,TRUE,,,FALSE,,,,,,,,2024-10-13 09:59:01,2024-10-13 09:59:01,INDUSTRY,,,,,,,3M|Solventum US LLC,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT03278886,,2017-09-05,2020-07-17,,2020-08-07,2017-09-08,2017-09-12,ACTUAL,2020-07-17,2020-08-03,ACTUAL,,,,2020-08-07,2020-08-24,ACTUAL,2018-07-03,ACTUAL,2018-07-03,2020-08,2020-08-31,2018-12-19,ACTUAL,2018-12-19,2018-12-19,ACTUAL,2018-12-19,,INTERVENTIONAL,PETER PAIN,,St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene,Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems,COMPLETED,,PHASE1/PHASE2,11,ACTUAL,Boston Medical Center,,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,http://www.urbanarch.org,YES,All data from the study will be placed into the URBAN ARCH repository.,2024-10-13 10:09:34,2024-10-13 10:09:34,OTHER,,,,,,,Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Russian Federation,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders"
NCT03284710,,2017-09-13,2020-12-14,,2024-09-10,2017-09-13,2017-09-15,ACTUAL,2021-01-31,2021-02-18,ACTUAL,,,,2024-09-10,2024-09-19,ACTUAL,2017-06-19,ACTUAL,2017-06-19,2023-06,2023-06-30,2019-12-12,ACTUAL,2019-12-12,2019-12-12,ACTUAL,2019-12-12,,INTERVENTIONAL,HVTN107,,Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine,"A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants",COMPLETED,,PHASE1/PHASE2,132,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-15 03:36:43,2024-10-15 03:36:43,NIH,,,,,,,"GlaxoSmithKline|HIV Vaccine Trials Network|National Institute of Allergy and Infectious Diseases (NIAID)|Sanofi Pasteur, a Sanofi Company",Mozambique|South Africa|Zimbabwe,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03287089,,2017-09-15,2020-04-22,,2022-08-05,2017-09-15,2017-09-19,ACTUAL,2020-05-28,2020-06-09,ACTUAL,,,,2022-08-05,2022-08-09,ACTUAL,2017-09-29,ACTUAL,2017-09-29,2020-05,2020-05-31,2019-06-01,ACTUAL,2019-06-01,2019-05-30,ACTUAL,2019-05-30,,INTERVENTIONAL,NAUTICA,Analyses were conducted on Intention-to-Treat Principle,Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery,Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial,COMPLETED,,PHASE4,164,ACTUAL,Wake Forest University Health Sciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 03:33:16,2024-10-14 03:33:16,OTHER,,,,,,,Wake Forest University Health Sciences,United States,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders
NCT03289351,,2017-09-18,2023-11-13,,2024-01-10,2017-09-18,2017-09-20,ACTUAL,2024-01-10,2024-01-12,ACTUAL,,,,2024-01-10,2024-01-12,ACTUAL,2017-05-22,ACTUAL,2017-05-22,2023-03,2023-03-31,2023-11-07,ACTUAL,2023-11-07,2021-11-17,ACTUAL,2021-11-17,,INTERVENTIONAL,,,Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis,Randomized Control Trial: Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis,COMPLETED,,PHASE4,162,ACTUAL,Phoenix Children's Hospital,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 17:19:39,2024-10-13 17:19:39,OTHER,,,,,,,Phoenix Children's Hospital,United States,Skin and subcutaneous tissue disorders
NCT03290391,,2017-09-19,2023-02-09,,2023-03-26,2017-09-19,2017-09-21,ACTUAL,2023-03-26,2023-04-18,ACTUAL,,,,2023-03-26,2023-04-18,ACTUAL,2018-09-19,ACTUAL,2018-09-19,2023-03,2023-03-31,2022-04-06,ACTUAL,2022-04-06,2022-04-06,ACTUAL,2022-04-06,,INTERVENTIONAL,LINC-II,,Linking Infectious and Narcology Care-Part II,Linking Infectious and Narcology Care-Part II,COMPLETED,,PHASE4,225,ACTUAL,Boston Medical Center,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 17:34:55,2024-10-14 17:34:55,OTHER,,,,,,,Boston Medical Center|National Institute on Drug Abuse (NIDA),Russian Federation,"Cardiac disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures"
NCT03292432,,2017-09-20,2020-10-28,,2021-02-18,2017-09-20,2017-09-25,ACTUAL,2020-12-14,2021-01-08,ACTUAL,,,,2021-02-18,2021-03-11,ACTUAL,2018-04-12,ACTUAL,2018-04-12,2020-10,2020-10-31,2020-10-12,ACTUAL,2020-10-12,2020-01-06,ACTUAL,2020-01-06,,INTERVENTIONAL,TERA,Includes participants who started study intervention,Triggered Escalating Real-time Adherence (TERA) Intervention,Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression Among Youth Living With HIV Failing Antiretroviral Therapy: The TERA Study,COMPLETED,,NA,89,ACTUAL,"University of North Carolina, Chapel Hill","Accrual was closed before reaching the targeted enrollment of 120 participants. Study visits were paused on March 20, 2020 due to the outbreak of COVID-19, interrupting systematic collection of secondary outcome measures. Statistical comparisons between arms therefore had lower than anticipated power to detect differences. For EDM data, the time the device was opened can only be assumed to correspond with when the participant took their antiretroviral dose.",2,,,FALSE,,,,TRUE,FALSE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 17:54:48,2024-10-13 17:54:48,OTHER,,,,,,,"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA)|National Institute on Minority Health and Health Disparities (NIMHD)|University of North Carolina, Chapel Hill",United States,"Cardiac disorders|Infections and infestations|Injury, poisoning and procedural complications|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT03293485,,2017-09-15,2019-08-23,,2021-01-20,2017-09-25,2017-09-26,ACTUAL,2019-08-23,2019-09-17,ACTUAL,,,,2021-01-20,2021-02-12,ACTUAL,2017-10-04,ACTUAL,2017-10-04,2021-01,2021-01-31,2018-09-14,ACTUAL,2018-09-14,2018-09-14,ACTUAL,2018-09-14,,INTERVENTIONAL,,,Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017),"A Phase III Non-randomized, Non-controlled, Open Label Clinical Trial to Study the Safety and Efficacy of Imipenem/Cilastatin/Relebactam (IMI/REL [MK-7655A]) in Japanese Subjects With Complicated Intra-Abdominal Infection (cIAI) or Complicated Urinary Tract Infection (cUTI)",COMPLETED,,PHASE3,83,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 11:04:01,2024-10-13 11:04:01,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Eye disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Renal and urinary disorders"
NCT03293485,,2017-09-15,2019-08-23,,2021-01-20,2017-09-25,2017-09-26,ACTUAL,2019-08-23,2019-09-17,ACTUAL,,,,2021-01-20,2021-02-12,ACTUAL,2017-10-04,ACTUAL,2017-10-04,2021-01,2021-01-31,2018-09-14,ACTUAL,2018-09-14,2018-09-14,ACTUAL,2018-09-14,,INTERVENTIONAL,,,Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017),"A Phase III Non-randomized, Non-controlled, Open Label Clinical Trial to Study the Safety and Efficacy of Imipenem/Cilastatin/Relebactam (IMI/REL [MK-7655A]) in Japanese Subjects With Complicated Intra-Abdominal Infection (cIAI) or Complicated Urinary Tract Infection (cUTI)",COMPLETED,,PHASE3,83,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 11:04:01,2024-10-13 11:04:01,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Eye disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Renal and urinary disorders"
NCT03297216,,2017-09-15,2021-05-07,,2021-07-21,2017-09-25,2017-09-29,ACTUAL,2021-06-17,2021-07-09,ACTUAL,,,,2021-07-21,2021-07-22,ACTUAL,2018-02-07,ACTUAL,2018-02-07,2020-09,2020-09-30,2020-08-06,ACTUAL,2020-08-06,2020-06-25,ACTUAL,2020-06-25,,INTERVENTIONAL,IPOP,,Improving Pregnancy Outcomes With Progesterone,Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy,COMPLETED,,PHASE3,800,ACTUAL,"University of North Carolina, Chapel Hill",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 00:48:07,2024-10-14 00:48:07,OTHER,,,,,,,"AMAG Pharmaceuticals, Inc.|Bill and Melinda Gates Foundation|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of North Carolina, Chapel Hill",Zambia,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT03299049,,2017-09-26,2020-05-26,,2024-01-02,2017-09-26,2017-10-02,ACTUAL,2020-05-26,2020-06-11,ACTUAL,,,,2024-01-02,2024-01-08,ACTUAL,2017-10-27,ACTUAL,2017-10-27,2024-01,2024-01-31,2026-12-31,ESTIMATED,2026-12-31,2019-06-06,ACTUAL,2019-06-06,,INTERVENTIONAL,ATLAS-2M,,"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed",ACTIVE_NOT_RECRUITING,,PHASE3,1049,ACTUAL,ViiV Healthcare,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 07:59:37,2024-10-13 07:59:37,INDUSTRY,,,,,,,Janssen Research and Development|ViiV Healthcare,"Argentina|Australia|Canada|France|Germany|Italy|Korea, Republic of|Mexico|Russian Federation|South Africa|Spain|Sweden|United States","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03301051,,2017-09-21,2023-05-29,2019-10-31,2023-07-17,2017-09-28,2017-10-04,ACTUAL,2023-07-17,2023-08-14,ACTUAL,,2023-08-14,ACTUAL,2023-07-17,2023-08-14,ACTUAL,2017-08-31,ACTUAL,2017-08-31,2023-07,2023-07-31,2018-05-09,ACTUAL,2018-05-09,2018-05-02,ACTUAL,2018-05-02,,INTERVENTIONAL,,The Safety Analysis Set (SAS) was defined as all participants who received either the Quadrivalent VLP Influenza Vaccine or the placebo.,"Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults","A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of Age",COMPLETED,,PHASE3,10160,ACTUAL,Medicago,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,,Medicago,Canada|Finland|Germany|Philippines|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT03301051,,2017-09-21,2023-05-29,2019-10-31,2023-07-17,2017-09-28,2017-10-04,ACTUAL,2023-07-17,2023-08-14,ACTUAL,,2023-08-14,ACTUAL,2023-07-17,2023-08-14,ACTUAL,2017-08-31,ACTUAL,2017-08-31,2023-07,2023-07-31,2018-05-09,ACTUAL,2018-05-09,2018-05-02,ACTUAL,2018-05-02,,INTERVENTIONAL,,The Safety Analysis Set (SAS) was defined as all participants who received either the Quadrivalent VLP Influenza Vaccine or the placebo.,"Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults","A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of Age",COMPLETED,,PHASE3,10160,ACTUAL,Medicago,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,,Medicago,Canada|Finland|Germany|Philippines|Thailand|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT03303625,,2017-10-03,2023-04-19,2021-04-20,2023-05-30,2017-10-03,2017-10-06,ACTUAL,2023-05-30,2023-06-23,ACTUAL,,2023-06-23,ACTUAL,2023-05-30,2023-06-23,ACTUAL,2017-11-29,ACTUAL,2017-11-29,2023-05,2023-05-31,2020-04-21,ACTUAL,2020-04-21,2020-04-21,ACTUAL,2020-04-21,,INTERVENTIONAL,,,"A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age","A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age, RSV-seropositive Toddlers 12 to 24 Months of Age",COMPLETED,,PHASE1/PHASE2,48,ACTUAL,Janssen Vaccines & Prevention B.V.,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,https://www.janssen.com/clinical-trials/transparency,YES,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2024-10-14 02:45:55,2024-10-14 02:45:55,INDUSTRY,,,,,,,Janssen Vaccines & Prevention B.V.,Finland|United Kingdom|United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03313037,,2017-10-09,2019-12-10,,2019-12-10,2017-10-16,2017-10-18,ACTUAL,2019-12-10,2019-12-26,ACTUAL,,,,2019-12-10,2019-12-26,ACTUAL,2017-10-10,ACTUAL,2017-10-10,2019-12,2019-12-31,2018-12-10,ACTUAL,2018-12-10,2018-12-10,ACTUAL,2018-12-10,,INTERVENTIONAL,,Safety analysis set included all participants who had received 1 dose of 20vPnC or 13vPnC.,Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE",COMPLETED,,PHASE2,444,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 00:37:39,2024-10-13 00:37:39,INDUSTRY,,,,,,,Pfizer,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT03313050,,2017-10-10,2020-05-15,,2020-05-15,2017-10-16,2017-10-18,ACTUAL,2020-05-15,2020-06-04,ACTUAL,,,,2020-05-15,2020-06-04,ACTUAL,2017-10-12,ACTUAL,2017-10-12,2020-05,2020-05-31,2019-05-24,ACTUAL,2019-05-24,2019-05-24,ACTUAL,2019-05-24,,INTERVENTIONAL,,The safety population included all participants who received at least 1 dose of c7vPnC or Tdap or PPSV23 in the study and had post-vaccination follow-up and participants who lacked any safety data were excluded from the analysis.,A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age,"A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE",COMPLETED,,PHASE2,511,ACTUAL,Pfizer,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 21:39:34,2024-10-13 21:39:34,INDUSTRY,,,,,,,Pfizer,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures|Vascular disorders"
NCT03321968,,2017-10-16,2023-05-29,,2023-07-14,2017-10-23,2017-10-26,ACTUAL,2023-07-14,2023-08-04,ACTUAL,,,,2023-07-14,2023-08-04,ACTUAL,2017-09-29,ACTUAL,2017-09-29,2023-07,2023-07-31,2017-12-01,ACTUAL,2017-12-01,2017-12-01,ACTUAL,2017-12-01,,INTERVENTIONAL,,The Safety Analysis Set (SAS) was defined as all participants who received Quadrivalent VLP Influenza Vaccine.,Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults,"A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Healthy Adults 18-49 Years of Age",COMPLETED,,PHASE3,1202,ACTUAL,Medicago,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:04:55,2024-10-14 15:04:55,INDUSTRY,,,,,,,Medicago,Canada,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03321968,,2017-10-16,2023-05-29,,2023-07-14,2017-10-23,2017-10-26,ACTUAL,2023-07-14,2023-08-04,ACTUAL,,,,2023-07-14,2023-08-04,ACTUAL,2017-09-29,ACTUAL,2017-09-29,2023-07,2023-07-31,2017-12-01,ACTUAL,2017-12-01,2017-12-01,ACTUAL,2017-12-01,,INTERVENTIONAL,,The Safety Analysis Set (SAS) was defined as all participants who received Quadrivalent VLP Influenza Vaccine.,Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults,"A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Healthy Adults 18-49 Years of Age",COMPLETED,,PHASE3,1202,ACTUAL,Medicago,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:04:55,2024-10-14 15:04:55,INDUSTRY,,,,,,,Medicago,Canada,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03329092,,2017-10-06,2024-02-21,,2024-04-16,2017-10-27,2017-11-01,ACTUAL,2024-04-16,2024-05-07,ACTUAL,,,,2024-04-16,2024-05-07,ACTUAL,2018-04-05,ACTUAL,2018-04-05,2024-04,2024-04-30,2023-02-23,ACTUAL,2023-02-23,2023-02-23,ACTUAL,2023-02-23,,INTERVENTIONAL,REVISIT,The Intent to Treat (ITT) analysis set included all randomized participants regardless of receipt of study drug. Participants were analyzed according to the treatment to which they were randomized.,"A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.","A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN-LABEL, CENTRAL ASSESSOR-BLINDED, PARALLEL GROUP, COMPARATIVE STUDY TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) ±METRONIDAZOLE (MTZ) VERSUS MEROPENEM±COLISTIN (MER±COL) FOR THE TREATMENT OF SERIOUS INFECTIONS DUE TO GRAM NEGATIVE BACTERIA, INCLUDING METALLO-Β-LACTAMASE (MBL) - PRODUCING MULTIDRUG RESISTANT PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT OPTIONS",COMPLETED,,PHASE3,422,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 08:15:37,2024-10-13 08:15:37,INDUSTRY,,,,,,,Biomedical Advanced Research and Development Authority|Innovative Medicines Initiative (IMI) COMBACTE-CARE (EU)|Pfizer,"Argentina|Bulgaria|Chile|China|Croatia|Czechia|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Malaysia|Mexico|Peru|Philippines|Romania|Russian Federation|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|United States|Vietnam","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT03332095,,2017-11-01,2021-08-05,,2023-01-18,2017-11-01,2017-11-06,ACTUAL,2021-11-03,2021-12-02,ACTUAL,,,,2023-01-18,2023-02-14,ACTUAL,2018-07-02,ACTUAL,2018-07-02,2023-01,2023-01-31,2022-05-25,ACTUAL,2022-05-25,2020-08-19,ACTUAL,2020-08-19,,INTERVENTIONAL,,Participants who received at least one dose of study treatment.,"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents",COMPLETED,,PHASE1/PHASE2,55,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 17:28:56,2024-10-14 17:28:56,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03332459,,2017-10-16,2021-03-18,,2021-03-18,2017-11-01,2017-11-06,ACTUAL,2021-03-18,2021-04-13,ACTUAL,,,,2021-03-18,2021-04-13,ACTUAL,2018-01-05,ACTUAL,2018-01-05,2021-03,2021-03-31,2020-04-13,ACTUAL,2020-04-13,2020-04-13,ACTUAL,2020-04-13,,INTERVENTIONAL,,,A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection,A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection,COMPLETED,,PHASE2,7,ACTUAL,"Janssen Research & Development, LLC","Due to the limited number of participants enrolled in this study (n=7), no meaningful conclusions can be made.",2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-15 02:53:42,2024-10-15 02:53:42,INDUSTRY,,,,,,,"Janssen Research & Development, LLC","Argentina|Australia|Belgium|Brazil|Canada|Chile|Colombia|Czechia|Finland|France|Germany|Ireland|Israel|Italy|Japan|Korea, Republic of|Malaysia|Netherlands|New Zealand|Panama|Portugal|Slovakia|Spain|Sweden|Taiwan|Thailand|Ukraine|United Kingdom|United States","Gastrointestinal disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03336502,,2017-11-06,2019-10-25,,2019-12-02,2017-11-06,2017-11-08,ACTUAL,2019-12-02,2019-12-19,ACTUAL,,,,2019-12-02,2019-12-19,ACTUAL,2017-12-20,ACTUAL,2017-12-20,2019-12,2019-12-31,2018-11-26,ACTUAL,2018-11-26,2018-11-26,ACTUAL,2018-11-26,,INTERVENTIONAL,,"Subgroup 1 - Serial PK group, received at least 10 days of POS, and analyzed for plasma trough determination AND PK parameters Subgroup 2 - Sparse PK group, received at least 10 days of POS, and analyzed for plasma trough determination.

Both groups received the same dose and drug administration, reflect only different blood sampling schedules.",Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120),"Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections",COMPLETED,,PHASE1,70,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 21:44:55,2024-10-13 21:44:55,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03338556,,2017-10-20,2018-04-17,,2018-11-06,2017-11-08,2017-11-09,ACTUAL,2018-05-29,2018-06-27,ACTUAL,,,,2018-11-06,2018-11-09,ACTUAL,2016-04-06,ACTUAL,2016-04-06,2018-11,2018-11-30,2016-09-30,ACTUAL,2016-09-30,2016-09-30,ACTUAL,2016-09-30,,INTERVENTIONAL,,,A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16,"A Phase IIa, Randomised, Double-blind, Placebo-controlled Outpatients Study to Investigate the Duration of Effect and Safety of PrEP-001 Given Prophylactically in Healthy Subjects, Subsequently Challenged With Human Rhinovirus (HRV-16)",COMPLETED,,PHASE2,102,ACTUAL,Prep Biopharm Limited,,4,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-13 22:48:26,2024-10-13 22:48:26,INDUSTRY,,,,,,,Hvivo|Prep Biopharm Limited,United Kingdom,"Injury, poisoning and procedural complications|Investigations|Respiratory, thoracic and mediastinal disorders"
NCT03343626,,2017-11-13,2021-11-24,,2021-11-24,2017-11-13,2017-11-17,ACTUAL,2021-11-24,2022-02-11,ACTUAL,,,,2021-11-24,2022-02-11,ACTUAL,2017-11-13,ACTUAL,2017-11-13,2021-11,2021-11-30,2020-11-24,ACTUAL,2020-11-24,2018-12-28,ACTUAL,2018-12-28,,INTERVENTIONAL,,Safety Analysis Set included all participants who received at least one (1) dose of PIZV or placebo.,"Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years",COMPLETED,,PHASE1,271,ACTUAL,Takeda,,8,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,YES,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2024-10-15 02:48:17,2024-10-15 02:48:17,INDUSTRY,,,,,,,Takeda,Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03349567,,2017-11-17,2021-01-25,,2021-04-02,2017-11-17,2017-11-21,ACTUAL,2021-04-02,2021-04-28,ACTUAL,,,,2021-04-02,2021-04-28,ACTUAL,2018-10-09,ACTUAL,2018-10-09,2021-04,2021-04-30,2019-10-31,ACTUAL,2019-10-31,2019-09-30,ACTUAL,2019-09-30,,INTERVENTIONAL,,These numbers reflect patients seen in the 4 participating EDs during the baseline and intervention periods.,Improving Antimicrobial-Prescribing in Emergency Departments,The Use of Audit-and-Feedback to Improve Antimicrobial-Prescribing in Emergency Departments: a Quasi-experimental Study,COMPLETED,,NA,27,ACTUAL,Iowa City Veterans Affairs Medical Center,"Because the study was not randomized, we cannot exclude temporal confounding or selection bias. By conducting a time-series analysis, we tried to account for confounders that may change over time, and by including a matched-control group, we tried to minimize the possibility of regression to the mean. Second, we cannot exclude the possibility that sites had any other processes in place that could have influenced our outcomes.",2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 09:46:07,2024-10-14 09:46:07,FED,,,,,,,Iowa City Veterans Affairs Medical Center|Merck Sharp & Dohme LLC,United States,Gastrointestinal disorders|General disorders
NCT03351699,,2017-11-20,2019-10-07,,2019-10-07,2017-11-20,2017-11-24,ACTUAL,2019-10-07,2019-10-30,ACTUAL,,,,2019-10-07,2019-10-30,ACTUAL,2018-01-18,ACTUAL,2018-01-18,2019-10,2019-10-31,2018-11-02,ACTUAL,2018-11-02,2018-11-02,ACTUAL,2018-11-02,,INTERVENTIONAL,,Panel F did not enroll because the scientific objectives were met following completion of Panel E.,"Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)","A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-4250 Monotherapy in Anti-Retroviral Therapy (ART)-Naive, HIV-1 Infected Subjects",COMPLETED,,PHASE1,24,ACTUAL,Merck Sharp & Dohme LLC,,5,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 13:45:03,2024-10-13 13:45:03,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03354598,,2017-11-20,2020-11-20,,2020-12-17,2017-11-25,2017-11-28,ACTUAL,2020-11-20,2020-12-17,ACTUAL,,,,2020-12-17,2021-01-12,ACTUAL,2018-08-01,ACTUAL,2018-08-01,2019-12,2019-12-31,2020-01-20,ACTUAL,2020-01-20,2020-01-16,ACTUAL,2020-01-16,,INTERVENTIONAL,,Intent to Treat (ITT) Participants,Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women,A Prospective Phase 3 Randomized Multi-center Double-blind Study of Efficacy Tolerability & Safety of Oral Sulopenem-etzadroxil/Probenecid vs Ciprofloxacin for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women,COMPLETED,,PHASE3,1671,ACTUAL,"Iterum Therapeutics, International Limited",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 14:14:42,2024-10-14 14:14:42,INDUSTRY,,,,,,,"Iterum Therapeutics, International Limited",United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT03357614,,2017-11-20,2020-11-05,,2020-12-03,2017-11-25,2017-11-30,ACTUAL,2020-12-03,2020-12-29,ACTUAL,,,,2020-12-03,2020-12-29,ACTUAL,2018-09-18,ACTUAL,2018-09-18,2019-11,2019-11-30,2019-12-14,ACTUAL,2019-12-14,2019-12-14,ACTUAL,2019-12-14,,INTERVENTIONAL,,,Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults,"Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults",COMPLETED,,PHASE3,1395,ACTUAL,"Iterum Therapeutics, International Limited",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 09:27:07,2024-10-13 09:27:07,INDUSTRY,,,,,,,"Iterum Therapeutics, International Limited",Estonia|Georgia|Hungary|Latvia|United States,"Cardiac disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT03358576,,2017-11-20,2020-10-01,,2020-11-05,2017-11-25,2017-11-30,ACTUAL,2020-11-05,2020-12-01,ACTUAL,,,,2020-11-05,2020-12-01,ACTUAL,2018-09-18,ACTUAL,2018-09-18,2019-11,2019-11-30,2019-10-02,ACTUAL,2019-10-02,2019-10-02,ACTUAL,2019-10-02,,INTERVENTIONAL,,complicated intra-abdominal infections,Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI),"Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability & Safety of Sulopenem & Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults",COMPLETED,,PHASE3,674,ACTUAL,"Iterum Therapeutics, International Limited",,2,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 07:25:54,2024-10-13 07:25:54,INDUSTRY,,,,,,,"Iterum Therapeutics, International Limited",Bulgaria|Estonia|Georgia|Hungary|Latvia|Poland|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03367910,,2017-12-05,2022-02-02,,2022-03-09,2017-12-05,2017-12-11,ACTUAL,2022-02-02,2022-02-28,ACTUAL,,,,2022-03-09,2022-03-18,ACTUAL,2018-02-08,ACTUAL,2018-02-08,2022-03,2022-03-31,2021-12-31,ACTUAL,2021-12-31,2021-12-31,ACTUAL,2021-12-31,,INTERVENTIONAL,,,Fecal Microbiota Transplantation (FMT) for MDRO UTI,Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms,COMPLETED,,PHASE1/PHASE2,1,ACTUAL,Washington University School of Medicine,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 16:07:16,2024-10-13 16:07:16,OTHER,,,,,,,Centers for Disease Control and Prevention|Duke University|Rebiotix Inc.|Rush University|University of Pennsylvania|Washington University School of Medicine,United States,Gastrointestinal disorders
NCT03369249,,2017-11-30,2022-09-27,,2022-12-21,2017-12-05,2017-12-11,ACTUAL,2022-10-28,2022-11-22,ACTUAL,,,,2022-12-21,2023-01-18,ACTUAL,2017-12-09,ACTUAL,2017-12-09,2022-12,2022-12-31,2022-12-01,ACTUAL,2022-12-01,2021-09-30,ACTUAL,2021-09-30,,INTERVENTIONAL,,,Health and Justice: A Continuum of Care for HIV and SU for Justice-Involved Young Adults (PHASE 2),Health and Justice: A Continuum of Care for HIV and SU for Justice-Involved Young Adults (PHASE 2),COMPLETED,,NA,307,ACTUAL,New York State Psychiatric Institute,,2,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-15 02:24:13,2024-10-15 02:24:13,OTHER,,,,,,,Center for Court Innovation|Columbia University|National Institute on Drug Abuse (NIDA)|New York State Psychiatric Institute|The National Center on Addiction and Substance Abuse at Columbia University,United States,Social circumstances
NCT03369951,,2017-12-07,2020-07-16,,2020-11-10,2017-12-07,2017-12-12,ACTUAL,2020-08-13,2020-08-27,ACTUAL,,,,2020-11-10,2020-12-03,ACTUAL,2018-03-28,ACTUAL,2018-03-28,2017-12-04,2017-12-04,2019-07-20,ACTUAL,2019-07-20,2019-07-20,ACTUAL,2019-07-20,,INTERVENTIONAL,,All subjects enrolled and receiving study product are included in the baseline analysis population description.,Minocycline Pharmacokinetics (ACUMIN),A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (ACUMIN),COMPLETED,,PHASE4,58,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-13 11:09:25,2024-10-13 11:09:25,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Cardiac disorders
NCT03379506,,2017-12-13,2020-07-29,,2023-05-03,2017-12-18,2017-12-20,ACTUAL,2020-08-14,2020-08-17,ACTUAL,,,,2023-05-03,2023-05-31,ACTUAL,2018-01-25,ACTUAL,2018-01-25,2023-05,2023-05-31,2020-07-23,ACTUAL,2020-07-23,2019-10-28,ACTUAL,2019-10-28,,INTERVENTIONAL,,,Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079),"A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to Less Than 18 Years With Chronic Hepatitis C Infection",COMPLETED,,PHASE2,57,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 00:48:07,2024-10-14 00:48:07,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Belgium|Czechia|Germany|New Zealand|Norway|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Turkey|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03379675,,2017-12-15,2022-05-13,2020-11-25,2024-09-02,2017-12-15,2017-12-20,ACTUAL,2022-06-22,2022-06-28,ACTUAL,2022-06-22,2022-06-28,ACTUAL,2024-09-02,2024-09-19,ACTUAL,2018-02-06,ACTUAL,2018-02-06,2024-09,2024-09-30,2019-12-26,ACTUAL,2019-12-26,2019-11-27,ACTUAL,2019-11-27,,INTERVENTIONAL,,,"A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus","A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus",COMPLETED,,PHASE2,72,ACTUAL,"Janssen Research & Development, LLC",The Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Scale that replaced Respiratory Infection-Patient Reported Outcomes (RI-PRO) questionnaire was only evaluated in the 5 participants who were enrolled after implementation of protocol amendment 1. This sample size was too small to draw conclusions on comparison between RiiQ and RI-PRO results.,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-15 03:42:21,2024-10-15 03:42:21,INDUSTRY,,,,,,,"Janssen Research & Development, LLC","Argentina|Australia|Belgium|Brazil|Bulgaria|Canada|France|Germany|Japan|Korea, Republic of|Mexico|Poland|Russian Federation|South Africa|Spain|Sweden|Taiwan|Ukraine|United Kingdom|United States","Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03382418,,2017-12-11,2020-12-11,,2021-10-06,2017-12-18,2017-12-22,ACTUAL,2021-07-04,2021-07-27,ACTUAL,,,,2021-10-06,2021-10-08,ACTUAL,2017-12-27,ACTUAL,2017-12-27,2021-10,2021-10-31,2019-09-25,ACTUAL,2019-09-25,2019-09-25,ACTUAL,2019-09-25,,INTERVENTIONAL,,,"Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States","A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US",COMPLETED,,PHASE1,45,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 18:11:05,2024-10-14 18:11:05,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03382834,,2017-12-19,2019-12-02,,2024-06-06,2017-12-19,2017-12-26,ACTUAL,2019-12-02,2019-12-18,ACTUAL,,,,2024-06-06,2024-07-03,ACTUAL,2018-04-26,ACTUAL,2018-04-26,2023-08,2023-08-31,2023-07-27,ACTUAL,2023-07-27,2018-12-04,ACTUAL,2018-12-04,,INTERVENTIONAL,,All enrolled participants,Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors,Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors,COMPLETED,,PHASE2,31,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by the NIH.,"With whom?

Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.

For what types of analyses?

To achieve aims in the proposal approved by the AIDS Clinical Trials Group. By what mechanism will data be made available?

Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://submit.mis.s-3.net/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.""",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-14 14:27:14,2024-10-14 14:27:14,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"General disorders|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT03385304,,2017-12-20,2022-11-15,,2023-03-06,2017-12-20,2017-12-28,ACTUAL,2023-03-06,2023-03-31,ACTUAL,,,,2023-03-06,2023-03-31,ACTUAL,2018-04-08,ACTUAL,2018-04-08,2023-03,2023-03-31,2022-06-27,ACTUAL,2022-06-27,2021-10-19,ACTUAL,2021-10-19,,INTERVENTIONAL,Aqueous-PREP,,Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures,Aqueous-PREP: A Pragmatic Randomized Trial Evaluating Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures,COMPLETED,,PHASE4,1638,ACTUAL,"University of Maryland, Baltimore","The uncontrolled use of adjunctive skin preparations before final antisepsis is a potential limitation of our study design. Although the use of a prewash with adjunctive alcohol was similarly distributed between the treatment groups, post-randomization confounding from this practice might exist. The trial has other limitations, including unmasked treatment allocation and the decision to initiate each recruitment site as soon as possible.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 15:59:32,2024-10-14 15:59:32,OTHER,,,,,,,"McMaster University|United States Department of Defense|University of Maryland, Baltimore",Canada|Spain|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03387137,,2017-12-21,2023-05-18,,2023-07-13,2017-12-21,2017-12-29,ACTUAL,2023-07-13,2023-08-03,ACTUAL,,,,2023-07-13,2023-08-03,ACTUAL,2017-10-13,ACTUAL,2017-10-13,2023-05,2023-05-31,2021-05-31,ACTUAL,2021-05-31,2019-11-22,ACTUAL,2019-11-22,,INTERVENTIONAL,,,"Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children","Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV 6120/∆NS2/1030s, Lot RSV#012A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age",COMPLETED,,PHASE1,45,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 16:51:07,2024-10-14 16:51:07,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03387150,,2017-12-21,2021-12-14,,2023-04-03,2017-12-21,2017-12-29,ACTUAL,2022-02-21,2022-03-21,ACTUAL,,,,2023-04-03,2023-04-05,ACTUAL,2018-02-28,ACTUAL,2018-02-28,2023-04,2023-04-30,2020-12-07,ACTUAL,2020-12-07,2020-12-07,ACTUAL,2020-12-07,,INTERVENTIONAL,,,"Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults","A Multicenter, Randomized, Partially Blinded Phase 1 Clinical Trial to Evaluate the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults",COMPLETED,,PHASE1,124,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,7,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 02:24:36,2024-10-13 02:24:36,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Switzerland|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03388268,,2017-12-05,2021-06-10,,2021-07-22,2017-12-22,2018-01-02,ACTUAL,2021-07-01,2021-07-23,ACTUAL,,,,2021-07-22,2021-07-26,ACTUAL,2017-12-29,ACTUAL,2017-12-29,2021-07,2021-07-31,2021-01-31,ACTUAL,2021-01-31,2021-01-31,ACTUAL,2021-01-31,,INTERVENTIONAL,,,TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment,"Double Blinded, Randomized Controlled Trial of Oral Vancomycin Versus Placebo in Hospitalized Patients With Diarrhea and Stool toXin NEGative But Nucleic Acid Amplification Test Positive for Toxigenic Clostridium Difficile (TOX NEG Trial)",COMPLETED,,PHASE4,15,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,FALSE,TRUE,TRUE,,,FALSE,,,,,,,,2024-10-13 17:02:01,2024-10-13 17:02:01,OTHER,,,,,,,Washington University School of Medicine,United States,Endocrine disorders|Gastrointestinal disorders|General disorders|Vascular disorders
NCT03388645,,2017-12-30,2020-11-12,,2020-11-12,2018-01-02,2018-01-03,ACTUAL,2020-11-12,2020-12-03,ACTUAL,,,,2020-11-12,2020-12-03,ACTUAL,2018-02-20,ACTUAL,2018-02-20,2019-12-06,2019-12-06,2019-12-06,ACTUAL,2019-12-06,2019-11-15,ACTUAL,2019-11-15,,INTERVENTIONAL,,,Challenge Infection of Healthy Adult Volunteers With RSV A2,Challenge Infection of Healthy Adult Volunteers With RSV A2,COMPLETED,,PHASE1,19,ACTUAL,National Institutes of Health Clinical Center (CC),,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-14 15:34:55,2024-10-14 15:34:55,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03405935,,2018-01-12,2019-11-18,,2020-11-06,2018-01-12,2018-01-23,ACTUAL,2019-11-18,2019-12-05,ACTUAL,,,,2020-11-06,2020-12-01,ACTUAL,2018-03-01,ACTUAL,2018-03-01,2020-11,2020-11-30,2020-05-29,ACTUAL,2020-05-29,2018-11-20,ACTUAL,2018-11-20,,INTERVENTIONAL,,The Safety Analysis Set included all participants who were enrolled and received at least 1 dose of study drug.,Study to Evaluate Switching From an E/C/F/TAF Fixed-Dose Combination (FDC) Regimen or a TDF Containing Regimen to B/F/TAF FDC in Human Immunodeficiency Virus-1 (HIV-1) Infected Participants Aged ≥ 65 Years,"A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate Containing Regimen to Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Elderly, Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 65 Years",COMPLETED,,PHASE3,86,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-15 00:30:16,2024-10-15 00:30:16,INDUSTRY,,,,,,,Gilead Sciences,Belgium|France|Italy|Spain|United Kingdom,"Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03408899,,2018-01-18,2022-12-12,,2023-04-13,2018-01-18,2018-01-24,ACTUAL,2023-04-13,2023-04-14,ACTUAL,,,,2023-04-13,2023-04-14,ACTUAL,2018-06-19,ACTUAL,2018-06-19,2023-04,2023-04-30,2019-04-19,ACTUAL,2019-04-19,2019-04-19,ACTUAL,2019-04-19,,INTERVENTIONAL,,,Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults,A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults,COMPLETED,,PHASE1,13,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 19:29:55,2024-10-14 19:29:55,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Ear and labyrinth disorders|Gastrointestinal disorders|Investigations
NCT03409276,,2018-01-09,2021-10-25,,2022-03-28,2018-01-17,2018-01-24,ACTUAL,2022-03-28,2022-04-25,ACTUAL,,,,2022-03-28,2022-04-25,ACTUAL,2018-03-16,ACTUAL,2018-03-16,2022-03,2022-03-31,2020-10-22,ACTUAL,2020-10-22,2020-05-11,ACTUAL,2020-05-11,,INTERVENTIONAL,,,"Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as a Prime-boost Regimen or Co-administered in Repeated Doses, in Healthy, HIV-1-Uninfected Adult Participants",COMPLETED,,PHASE1,60,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,6,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 14:37:52,2024-10-13 14:37:52,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03421743,,2018-01-16,2023-03-24,,2024-01-18,2018-01-29,2018-02-05,ACTUAL,2024-01-18,2024-07-03,ACTUAL,,,,2024-01-18,2024-07-03,ACTUAL,2018-03-01,ACTUAL,2018-03-01,2023-03,2023-03-31,2020-01-13,ACTUAL,2020-01-13,2019-10-15,ACTUAL,2019-10-15,,INTERVENTIONAL,OPTIMA,"No ""analysis sets"" were defined. All participants were included in the analyses/data presentations, equivalent to a Full Analysis Set.",Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection,"An Open-label, Non-controlled, Multicentre, Pilot Clinical Trial of Inhaled Molgramostim in Subjects With Antibiotic-resistant Non-tuberculosis Mycobacterial (NTM) Infection",COMPLETED,,PHASE2,32,ACTUAL,Savara Inc.,"This was an exploratory study without hypothesis testing. Only descriptive statistics were used.

The study included participants with treatment refractory NTM infection, who were severely affected by their background disease (in most cases bronchiectasis). These participants probably had an even lower potential for improvement than was assumed prior to the study.

The study was further limited by the lack of a placebo control.",2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-15 00:35:58,2024-10-15 00:35:58,INDUSTRY,,,,,,,Savara Inc.,Australia|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03422172,,2018-01-30,2021-04-13,,2021-05-12,2018-01-30,2018-02-05,ACTUAL,2021-05-12,2021-05-13,ACTUAL,,,,2021-05-12,2021-05-13,ACTUAL,2018-04-10,ACTUAL,2018-04-10,2021-05,2021-05-31,2020-04-20,ACTUAL,2020-04-20,2020-04-20,ACTUAL,2020-04-20,,INTERVENTIONAL,,,"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men",COMPLETED,,PHASE1,48,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 19:45:33,2024-10-13 19:45:33,INDUSTRY,,,,,,,"PPD DEVELOPMENT, LP|ViiV Healthcare",China,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03425396,,2017-12-28,2020-05-15,,2020-06-05,2018-02-06,2018-02-07,ACTUAL,2020-05-15,2020-06-04,ACTUAL,,,,2020-06-05,2020-06-09,ACTUAL,2018-01-04,ACTUAL,2018-01-04,2020-06,2020-06-30,2019-06-05,ACTUAL,2019-06-05,2019-05-15,ACTUAL,2019-05-15,,INTERVENTIONAL,,The Intent-to-Treat (ITT) Population consisted of all randomized participants regardless of whether or not the participant received study drug.,Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis,"A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of Oral Omadacycline and Oral Nitrofurantoin in the Treatment of Female Adults With Cystitis",COMPLETED,,PHASE2,225,ACTUAL,Paratek Pharmaceuticals Inc,"An additional treatment group (omadacycline 450/450 once every 12 hours) was added with Protocol Amendment 2. However, the majority of enrollment was completed by this time, and therefore, fewer participants were enrolled in this group.",5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 15:34:55,2024-10-14 15:34:55,INDUSTRY,,,,,,,Paratek Pharmaceuticals Inc,United States,Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders
NCT03441984,,2018-02-15,2019-04-23,,2019-11-20,2018-02-15,2018-02-22,ACTUAL,2019-11-20,2019-12-09,ACTUAL,,,,2019-11-20,2019-12-09,ACTUAL,2018-02-26,ACTUAL,2018-02-26,2019-11,2019-11-30,2018-04-28,ACTUAL,2018-04-28,2018-04-28,ACTUAL,2018-04-28,,INTERVENTIONAL,,,To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers,"A 2-Part, Phase I, Single-Dose, 3-Period Crossover Relative Bioavailability Study of a Pediatric TRIUMEQ Dispersible Tablet and Pediatric Dolutegravir and Lamivudine (DTG/3TC) Fixed Dose Combination Dispersible Tablet Formulations as Compared With Adult Tablets in Healthy Volunteers",COMPLETED,,PHASE1,36,ACTUAL,ViiV Healthcare,,12,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available, within 6 months of publishing the results of the primary endpoints of the study.","Access is provided, after a research proposal is submitted and has submitted approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided, for an initial period of 12 months but an extension can be granted, when justified for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 11:51:49,2024-10-13 11:51:49,INDUSTRY,,,,,,,"GlaxoSmithKline|Pharmaceutical Product Development (PPD), Inc|ViiV Healthcare",United States,Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders
NCT03445195,,2018-02-20,2019-05-14,,2020-01-20,2018-02-20,2018-02-26,ACTUAL,2019-05-14,2019-06-05,ACTUAL,,,,2020-01-20,2020-01-22,ACTUAL,2018-01-17,ACTUAL,2018-01-17,2019-06,2019-06-30,2018-05-17,ACTUAL,2018-05-17,2018-05-17,ACTUAL,2018-05-17,,INTERVENTIONAL,,,Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections,"A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis",COMPLETED,,PHASE2,80,ACTUAL,Entasis Therapeutics,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 07:50:54,2024-10-14 07:50:54,INDUSTRY,,,,,,,Entasis Therapeutics,Bulgaria,Nervous system disorders|Vascular disorders
NCT03446053,,2018-02-04,2021-06-16,,2021-10-26,2018-02-19,2018-02-26,ACTUAL,2021-09-12,2021-10-08,ACTUAL,,,,2021-10-26,2021-11-03,ACTUAL,2018-02-07,ACTUAL,2018-02-07,2021-09,2021-09-30,2019-02-07,ACTUAL,2019-02-07,2019-02-07,ACTUAL,2019-02-07,,INTERVENTIONAL,,,"A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers","A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Dose-Escalating Phase 1b Study to Evaluate the Safety, PK, PD and Immunogenicity of N-Rephasin® SAL200 After Continuous IV Infusion in Healthy Volunteers",COMPLETED,,PHASE1,33,ACTUAL,"Intron Biotechnology, Inc.",,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,There is not a plan to make IPD available.,2024-10-15 00:12:34,2024-10-15 00:12:34,INDUSTRY,,,,,,,"Intron Biotechnology, Inc.","Korea, Republic of","Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03446573,,2018-01-05,2020-04-16,,2023-07-17,2018-02-19,2018-02-27,ACTUAL,2020-05-18,2020-06-02,ACTUAL,,,,2023-07-17,2023-07-19,ACTUAL,2018-01-18,ACTUAL,2018-01-18,2023-07,2023-07-31,2022-05-03,ACTUAL,2022-05-03,2019-05-20,ACTUAL,2019-05-20,,INTERVENTIONAL,,Baseline Characteristics data are reported for participants in the ITT-E Population,Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO),"A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed",COMPLETED,,PHASE3,743,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-14 20:35:44,2024-10-14 20:35:44,INDUSTRY,,,,,,,GlaxoSmithKline|ViiV Healthcare,"Australia|Belgium|Canada|Denmark|Finland|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Puerto Rico|Spain|Sweden|United Kingdom|United States","Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03454048,,2018-02-27,2019-11-06,,2020-06-15,2018-02-27,2018-03-05,ACTUAL,2020-03-17,2020-03-31,ACTUAL,,,,2020-06-15,2020-07-07,ACTUAL,2018-05-07,ACTUAL,2018-05-07,2020-03,2020-03-31,2018-11-20,ACTUAL,2018-11-20,2018-11-01,ACTUAL,2018-11-01,,INTERVENTIONAL,CHMI-trans2,,Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2,Controlled Human Malaria Infection Study to Assess Gametocytemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite or Blood Stage Challenge to Establish a Model for the Evaluation of Transmission-blocking Interventions,COMPLETED,,NA,24,ACTUAL,Radboud University Medical Center,,4,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,,,2024-10-13 23:33:16,2024-10-13 23:33:16,OTHER,,,,,,,QIMR Berghofer Medical Research Institute|Radboud University Medical Center|The PATH Malaria Vaccine Initiative (MVI),Netherlands,Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations
NCT03455491,,2018-02-28,2019-02-18,,2019-10-14,2018-02-28,2018-03-06,ACTUAL,2019-10-14,2019-11-04,ACTUAL,,,,2019-10-14,2019-11-04,ACTUAL,2018-02-12,ACTUAL,2018-02-12,2019-10,2019-10-31,2018-06-28,ACTUAL,2018-06-28,2018-06-28,ACTUAL,2018-06-28,,INTERVENTIONAL,,,Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections,"Multicenter Double-blinded Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy, Safety and Choice of an Optimum Dose of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Adults",COMPLETED,,PHASE2,120,ACTUAL,PHARMENTERPRISES LLC,,3,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 20:30:57,2024-10-13 20:30:57,INDUSTRY,,,,,,,PHARMENTERPRISES LLC,Russian Federation,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03468478,,2018-03-09,2022-11-04,,2023-04-20,2018-03-15,2018-03-16,ACTUAL,2023-04-20,2023-04-24,ACTUAL,,,,2023-04-20,2023-04-24,ACTUAL,2017-06-18,ACTUAL,2017-06-18,2023-04,2023-04-30,2021-08-23,ACTUAL,2021-08-23,2021-03-18,ACTUAL,2021-03-18,,INTERVENTIONAL,SEM,,Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation,"Comparison of the Efficacy and Safety of Sirolimus, Everolimus or Mycophenolate in Renal Transplant Recipients Receiving Induction With Anti-thymocyte Globulin, Tacrolimus and Prednisone",COMPLETED,,PHASE4,1209,ACTUAL,Hospital do Rim e Hipertensão,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 16:56:00,2024-10-13 16:56:00,OTHER,,,,,,,Hospital do Rim e Hipertensão,Brazil,"Gastrointestinal disorders|General disorders|Infections and infestations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03468933,,2018-03-05,2020-12-05,,2021-01-16,2018-03-12,2018-03-19,ACTUAL,2021-01-16,2021-02-04,ACTUAL,,,,2021-01-16,2021-02-04,ACTUAL,2017-11-01,ACTUAL,2017-11-01,2021-01,2021-01-31,2019-12-30,ACTUAL,2019-12-30,2019-12-30,ACTUAL,2019-12-30,,INTERVENTIONAL,,,Fibrinolysis Compared to Thoracoscopy for Pleural Infection,Intrapleural Tissue Plasminogen Activator and Deoxyribonuclease Therapy Versus Early Medical Thoracoscopy for Treatment of Pleural Infection: A Randomized Clinical Trial,COMPLETED,,PHASE4,32,ACTUAL,Tulane University,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 09:53:28,2024-10-13 09:53:28,OTHER,,,,,,,Tulane University,United States,"Respiratory, thoracic and mediastinal disorders"
NCT03476135,,2018-03-19,2020-05-19,2019-09-05,2022-03-24,2018-03-19,2018-03-23,ACTUAL,2020-05-19,2020-06-05,ACTUAL,2019-09-05,2019-09-12,ACTUAL,2022-03-24,2022-04-06,ACTUAL,2018-02-27,ACTUAL,2018-02-27,2022-03,2022-03-31,2018-09-10,ACTUAL,2018-09-10,2018-09-10,ACTUAL,2018-09-10,,INTERVENTIONAL,,Analysis was performed on all enrolled participants.,Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children,Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as Toddlers,COMPLETED,,PHASE3,91,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-15 02:59:07,2024-10-15 02:59:07,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Finland,General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT03480763,,2018-03-22,2020-12-10,,2021-10-25,2018-03-22,2018-03-29,ACTUAL,2020-12-10,2021-01-06,ACTUAL,,,,2021-10-25,2021-11-02,ACTUAL,2018-06-22,ACTUAL,2018-06-22,2021-10,2021-10-31,2019-12-23,ACTUAL,2019-12-23,2019-12-23,ACTUAL,2019-12-23,,INTERVENTIONAL,PNEU-PATH,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)",COMPLETED,,PHASE3,652,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 09:27:55,2024-10-14 09:27:55,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Korea, Republic of|Spain|Taiwan|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT03480802,,2018-03-22,2020-11-02,,2022-04-13,2018-03-22,2018-03-29,ACTUAL,2020-11-02,2020-11-25,ACTUAL,,,,2022-04-13,2022-05-05,ACTUAL,2018-07-06,ACTUAL,2018-07-06,2022-04,2022-04-30,2020-01-17,ACTUAL,2020-01-17,2019-09-16,ACTUAL,2019-09-16,,INTERVENTIONAL,PNEU-WAY,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)",COMPLETED,,PHASE3,302,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 21:50:37,2024-10-13 21:50:37,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,France|Peru|South Africa|Thailand|United States,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03483116,,2018-03-23,2023-06-05,,2023-07-06,2018-03-23,2018-03-30,ACTUAL,2023-07-06,2023-07-10,ACTUAL,,,,2023-07-06,2023-07-10,ACTUAL,2018-06-15,ACTUAL,2018-06-15,2023-07,2023-07-31,2020-01-27,ACTUAL,2020-01-27,2020-01-27,ACTUAL,2020-01-27,,INTERVENTIONAL,,,A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine,"A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.",COMPLETED,,PHASE2,711,ACTUAL,Murdoch Childrens Research Institute,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,For 24 months from publication of the primary outcome.,"1. Data access agreement
2. Approval by local Ethics committee",,YES,"Deidentified group data may be available for sharing on application to the Sponsor. This application must include the relevant proposal detailing the intended use of the data, the Ethics approval for this proposal and requires a signed data sharing agreement. Additional study documents including the study protocol, statistical analysis plan and informed consent are available on application to the Sponsor.",2024-10-14 01:11:36,2024-10-14 01:11:36,OTHER,,,,,,,Murdoch Childrens Research Institute,Malawi,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03483961,,2018-03-16,2021-09-14,,2023-06-29,2018-03-23,2018-03-30,ACTUAL,2021-10-12,2021-11-09,ACTUAL,,,,2023-06-29,2023-07-03,ACTUAL,2018-04-18,ACTUAL,2018-04-18,2023-06,2023-06-30,2020-09-21,ACTUAL,2020-09-21,2020-09-14,ACTUAL,2020-09-14,,INTERVENTIONAL,,Randomized participants.,"Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults","A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)",COMPLETED,,PHASE2,445,ACTUAL,Bavarian Nordic,,10,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:47:20,2024-10-14 15:47:20,INDUSTRY,,,,,,,Bavarian Nordic|Emergent BioSolutions,United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT03486834,,2018-03-28,2021-10-01,,2024-01-19,2018-03-28,2018-04-03,ACTUAL,2021-10-13,2021-11-10,ACTUAL,,,,2024-01-19,2024-01-23,ACTUAL,2018-04-30,ACTUAL,2018-04-30,2024-01,2024-01-31,2021-06-30,ACTUAL,2021-06-30,2020-10-30,ACTUAL,2020-10-30,,INTERVENTIONAL,,,V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002),"Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age",COMPLETED,,PHASE2,2200,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 00:09:32,2024-10-13 00:09:32,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Canada|Finland|Israel|Russian Federation|Spain|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03487549,,2018-03-21,2021-06-07,,2021-08-05,2018-03-27,2018-04-04,ACTUAL,2021-08-05,2021-09-01,ACTUAL,,,,2021-08-05,2021-09-01,ACTUAL,2018-03-27,ACTUAL,2018-03-27,2021-08,2021-08-31,2019-07-15,ACTUAL,2019-07-15,2019-05-16,ACTUAL,2019-05-16,,INTERVENTIONAL,COVE-1,Study participants enrolled into Cohort 1 were not included in Cohort 2. New subjects were enrolled into Cohort 2.,Cantharidin and Occlusion in Verruca Epithelium,"A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)",COMPLETED,,PHASE2,56,ACTUAL,Verrica Pharmaceuticals Inc.,,1,,,FALSE,,,,FALSE,TRUE,TRUE,TRUE,,FALSE,,,,,,NO,,2024-10-14 03:26:59,2024-10-14 03:26:59,INDUSTRY,,,,,,,"ALMAC Clinical Services|BioClinica, Inc.|Instat Consulting, Inc.|Paidion Research, Inc.|Verrica Pharmaceuticals Inc.",United States,General disorders|Infections and infestations
NCT03487549,,2018-03-21,2021-06-07,,2021-08-05,2018-03-27,2018-04-04,ACTUAL,2021-08-05,2021-09-01,ACTUAL,,,,2021-08-05,2021-09-01,ACTUAL,2018-03-27,ACTUAL,2018-03-27,2021-08,2021-08-31,2019-07-15,ACTUAL,2019-07-15,2019-05-16,ACTUAL,2019-05-16,,INTERVENTIONAL,COVE-1,Study participants enrolled into Cohort 1 were not included in Cohort 2. New subjects were enrolled into Cohort 2.,Cantharidin and Occlusion in Verruca Epithelium,"A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)",COMPLETED,,PHASE2,56,ACTUAL,Verrica Pharmaceuticals Inc.,,1,,,FALSE,,,,FALSE,TRUE,TRUE,TRUE,,FALSE,,,,,,NO,,2024-10-14 03:26:59,2024-10-14 03:26:59,INDUSTRY,,,,,,,"ALMAC Clinical Services|BioClinica, Inc.|Instat Consulting, Inc.|Paidion Research, Inc.|Verrica Pharmaceuticals Inc.",United States,General disorders|Infections and infestations
NCT03487549,,2018-03-21,2021-06-07,,2021-08-05,2018-03-27,2018-04-04,ACTUAL,2021-08-05,2021-09-01,ACTUAL,,,,2021-08-05,2021-09-01,ACTUAL,2018-03-27,ACTUAL,2018-03-27,2021-08,2021-08-31,2019-07-15,ACTUAL,2019-07-15,2019-05-16,ACTUAL,2019-05-16,,INTERVENTIONAL,COVE-1,Study participants enrolled into Cohort 1 were not included in Cohort 2. New subjects were enrolled into Cohort 2.,Cantharidin and Occlusion in Verruca Epithelium,"A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)",COMPLETED,,PHASE2,56,ACTUAL,Verrica Pharmaceuticals Inc.,,1,,,FALSE,,,,FALSE,TRUE,TRUE,TRUE,,FALSE,,,,,,NO,,2024-10-14 03:26:59,2024-10-14 03:26:59,INDUSTRY,,,,,,,"ALMAC Clinical Services|BioClinica, Inc.|Instat Consulting, Inc.|Paidion Research, Inc.|Verrica Pharmaceuticals Inc.",United States,General disorders|Infections and infestations
NCT03488355,,2018-03-26,2020-10-20,,2022-04-22,2018-04-04,2018-04-05,ACTUAL,2022-04-22,2023-01-25,ACTUAL,,,,2022-04-22,2023-01-25,ACTUAL,2018-11-05,ACTUAL,2018-11-05,2022-04,2022-04-30,2019-07-31,ACTUAL,2019-07-31,2019-07-31,ACTUAL,2019-07-31,,INTERVENTIONAL,,,Modified Reporting From Indwelling Catheters,"Modified Reporting of Positive Urine Cultures Collected From Indwelling Catheters, a Randomized Controlled Trial",COMPLETED,,NA,100,ACTUAL,Memorial University of Newfoundland,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 02:59:02,2024-10-13 02:59:02,OTHER,,,,,,,Memorial University of Newfoundland,Canada,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03497676,,2018-04-06,2024-02-12,,2024-09-03,2018-04-06,2018-04-13,ACTUAL,2024-04-22,2024-05-14,ACTUAL,,,,2024-09-03,2024-09-19,ACTUAL,2019-04-03,ACTUAL,2019-04-03,2024-07,2024-07-31,2025-06-17,ESTIMATED,2025-06-17,2023-02-18,ACTUAL,2023-02-18,,INTERVENTIONAL,MOCHA,"Participants who have taken at least 1 dose of any study product on the respective cohort. For participants enrolled in both Cohort 1 and Cohort 2, the baseline value summarized is from the corresponding cohort. Baseline characteristics for parents/caregivers are not reported.",More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents,"Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents",ACTIVE_NOT_RECRUITING,,PHASE1/PHASE2,168,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.,"* With whom?

  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
* For what types of analyses?

  * To achieve aims in the proposal approved by the IMPAACT Network.
* By what mechanism will data be made available?

  * Researchers may submit a request for access to data using the IMPAACT ""Data Request"" form at: https://www.impaactnetwork.org/resources/study-proposals.htm. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-15 03:54:19,2024-10-15 03:54:19,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|ViiV Healthcare,Botswana|Puerto Rico|South Africa|Thailand|Uganda|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT03497806,,2018-04-06,2022-06-29,,2022-08-10,2018-04-12,2018-04-13,ACTUAL,2022-08-10,2022-08-30,ACTUAL,,,,2022-08-10,2022-08-30,ACTUAL,2018-05-01,ACTUAL,2018-05-01,2022-08,2022-08-31,2021-04-01,ACTUAL,2021-04-01,2020-12-31,ACTUAL,2020-12-31,,INTERVENTIONAL,PRISM-EXT,Modified Intent to Treat (mITT) population,Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection,PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection,COMPLETED,,PHASE2,132,ACTUAL,Finch Research and Development LLC.,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 19:51:18,2024-10-13 19:51:18,INDUSTRY,,,,,,,"Finch Research and Development LLC.|Medpace, Inc.",Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03497806,,2018-04-06,2022-06-29,,2022-08-10,2018-04-12,2018-04-13,ACTUAL,2022-08-10,2022-08-30,ACTUAL,,,,2022-08-10,2022-08-30,ACTUAL,2018-05-01,ACTUAL,2018-05-01,2022-08,2022-08-31,2021-04-01,ACTUAL,2021-04-01,2020-12-31,ACTUAL,2020-12-31,,INTERVENTIONAL,PRISM-EXT,Modified Intent to Treat (mITT) population,Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection,PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection,COMPLETED,,PHASE2,132,ACTUAL,Finch Research and Development LLC.,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 19:51:18,2024-10-13 19:51:18,INDUSTRY,,,,,,,"Finch Research and Development LLC.|Medpace, Inc.",Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03502993,,2018-03-27,2022-02-03,,2023-10-12,2018-04-18,2018-04-19,ACTUAL,2023-10-12,2023-10-13,ACTUAL,,,,2023-10-12,2023-10-13,ACTUAL,2016-06-02,ACTUAL,2016-06-02,2023-10,2023-10-31,2021-12-31,ACTUAL,2021-12-31,2021-01-25,ACTUAL,2021-01-25,,OBSERVATIONAL,PERFORM,,Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM),Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM),COMPLETED,,,7247,ACTUAL,Imperial College London,,,2,,FALSE,,,,FALSE,FALSE,FALSE,,,,SAMPLES_WITH_DNA,"blood, urine, nasopharyngeal aspirate/throat swab, stool",,,,NO,,2024-10-13 20:58:47,2024-10-13 20:58:47,OTHER,,,,,,FALSE,"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|BioMérieux|Erasmus Medical Center|Imperial College London|London School of Hygiene and Tropical Medicine|Ludwig-Maximilians - University of Munich|Medical Research Council Unit, The Gambia|Micropathology Ltd, University of Warwick|National and Kapodistrian University of Athens|Riga Stradiņs University|Servizo Galego de Saúde|Stichting Katholieke Universiteit|University Hospital, Paris|University of Bern|University of Graz|University of Liverpool|University of Ljubljana|University of Newcastle Upon-Tyne|University of Oxford|University of Santiago de Compostela",United Kingdom,Blood and lymphatic system disorders
NCT03503513,,2018-04-06,2024-03-14,,2024-05-29,2018-04-11,2018-04-19,ACTUAL,2024-05-29,2024-06-25,ACTUAL,,,,2024-05-29,2024-06-25,ACTUAL,2018-08-24,ACTUAL,2018-08-24,2024-05,2024-05-31,2023-09-30,ACTUAL,2023-09-30,2023-09-08,ACTUAL,2023-09-08,,INTERVENTIONAL,,Baseline data is provided for all participants who started treatment,Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury,The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial,COMPLETED,,PHASE2/PHASE3,23,ACTUAL,University of Michigan,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 19:11:06,2024-10-13 19:11:06,OTHER,,,,,,,Department of Health and Human Services|University of Michigan,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03512210,,2018-04-19,2021-05-21,,2022-01-27,2018-04-19,2018-04-30,ACTUAL,2021-06-28,2021-07-16,ACTUAL,,,,2022-01-27,2022-02-04,ACTUAL,2018-10-22,ACTUAL,2018-10-22,2022-01,2022-01-31,2021-02-28,ACTUAL,2021-02-28,2020-07-30,ACTUAL,2020-07-30,,INTERVENTIONAL,MINMON,Participants who enrolled into study and received first dose of study medication.,"Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection",A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study,COMPLETED,,PHASE4,400,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-14 14:58:21,2024-10-14 14:58:21,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Puerto Rico|South Africa|Thailand|Uganda|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Social circumstances|Vascular disorders"
NCT03512288,,2018-04-11,2021-02-08,,2021-02-27,2018-04-27,2018-04-30,ACTUAL,2021-02-27,2021-03-02,ACTUAL,,,,2021-02-27,2021-03-02,ACTUAL,2018-04-16,ACTUAL,2018-04-16,2021-02,2021-02-28,2020-02-11,ACTUAL,2020-02-11,2020-02-11,ACTUAL,2020-02-11,,INTERVENTIONAL,,All randomized participants.,Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants,"A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS",COMPLETED,,PHASE2,460,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 15:01:30,2024-10-13 15:01:30,INDUSTRY,,,,,,,Pfizer,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03523962,,2018-04-30,2024-03-22,,2024-09-23,2018-05-10,2018-05-14,ACTUAL,2024-09-23,2024-10-04,ACTUAL,,,,2024-09-23,2024-10-04,ACTUAL,2018-08-21,ACTUAL,2018-08-21,2024-09,2024-09-30,2024-02-02,ACTUAL,2024-02-02,2023-03-15,ACTUAL,2023-03-15,,INTERVENTIONAL,PREPARE,,Pre-operative Alcohol Skin Solutions in Fractured Extremities,PREPARE: A Pragmatic Randomized Trial Evaluating Pre-operative Alcohol Skin Solutions in FRactured Extremites,COMPLETED,,PHASE4,8485,ACTUAL,"University of Maryland, Baltimore","1. The patients and their surgeons were aware of the trial-group assignments.
2. The trial was limited to patients undergoing surgery for a fracture, so the generalizability of these findings to other surgical populations is unknown.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 11:57:49,2024-10-13 11:57:49,OTHER,,,,,,,"McMaster University|Patient-Centered Outcomes Research Institute|University of Maryland, Baltimore",Canada|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03524118,,2018-05-11,2023-08-29,,2023-11-10,2018-05-11,2018-05-14,ACTUAL,2023-11-10,2023-11-29,ACTUAL,,,,2023-11-10,2023-11-29,ACTUAL,2018-09-20,ACTUAL,2018-09-20,2023-11,2023-11-30,2022-09-14,ACTUAL,2022-09-14,2022-09-14,ACTUAL,2022-09-14,,INTERVENTIONAL,,,"Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)","A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants",COMPLETED,,PHASE1/PHASE2,183,ACTUAL,Merck Sharp & Dohme LLC,,8,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 00:21:11,2024-10-13 00:21:11,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Chile|Colombia|Korea, Republic of|South Africa|Spain|United States","Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03527745,,2018-05-03,2020-08-11,,2023-05-11,2018-05-16,2018-05-17,ACTUAL,2020-12-10,2021-01-06,ACTUAL,,,,2023-05-11,2023-06-12,ACTUAL,2018-10-23,ACTUAL,2018-10-23,2023-05,2023-05-31,2019-04-17,ACTUAL,2019-04-17,2019-04-17,ACTUAL,2019-04-17,,INTERVENTIONAL,,The Placebo against hookworm in PSAC arm was removed from the trial after discussion with with principal investigators.,Albendazole Dose Finding and Pharmacokinetics in Children and Adults,Efficacy and Safety of Ascending Dosages of Albendazole Against T. Trichiura and Hookworm in Preschool- and School-aged Children and Adults: a Randomized Controlled Trial,COMPLETED,,PHASE2,700,ACTUAL,Swiss Tropical & Public Health Institute,,5,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,UNDECIDED,,2024-10-14 08:04:12,2024-10-14 08:04:12,OTHER,,,,,,,Centre Suisse de Recherches Scientifiques en Cote d'Ivoire|Jennifer Keiser,Côte D'Ivoire,Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT03529773,,2018-04-17,2020-11-18,,2022-03-01,2018-05-07,2018-05-18,ACTUAL,2021-02-11,2021-03-04,ACTUAL,,,,2022-03-01,2022-03-03,ACTUAL,2018-04-18,ACTUAL,2018-04-18,2022-03,2022-03-31,2020-12-28,ACTUAL,2020-12-28,2019-11-20,ACTUAL,2019-11-20,,INTERVENTIONAL,,Safety analysis set included all participants in the sentinel and expanded cohorts who received at least 1 dose of the investigational products.,A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults,"A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY ADULTS",COMPLETED,,PHASE2,1235,ACTUAL,Pfizer,,20,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Starting 24 months after study completion.,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 20:58:47,2024-10-13 20:58:47,INDUSTRY,,,,,,,Pfizer,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT03544138,,2018-05-09,2022-09-22,,2022-11-18,2018-05-21,2018-06-01,ACTUAL,2022-11-18,2022-12-14,ACTUAL,,,,2022-11-18,2022-12-14,ACTUAL,2018-07-24,ACTUAL,2018-07-24,2022-11,2022-11-30,2022-09-12,ACTUAL,2022-09-12,2022-09-06,ACTUAL,2022-09-06,,INTERVENTIONAL,,,In-Office Study of the Hummingbird® in Children 6 Months-21 Years Old,Pivotal Study of the Preceptis Medical Inc. Hummingbird™ Tympanostomy Tube System (H-TTS) in the Otolaryngology Clinic,COMPLETED,,NA,258,ACTUAL,"Preceptis Medical, Inc.",,1,,,FALSE,,,,FALSE,FALSE,TRUE,,,FALSE,,,,,,NO,There is no plan to make IPD available to other researchers.,2024-10-14 08:17:12,2024-10-14 08:17:12,INDUSTRY,,,,,,,"Preceptis Medical, Inc.",United States,Surgical and medical procedures
NCT03546621,,2018-05-23,2019-11-13,,2021-04-13,2018-05-23,2018-06-06,ACTUAL,2019-12-09,2019-12-30,ACTUAL,,,,2021-04-13,2021-05-10,ACTUAL,2016-02-16,ACTUAL,2016-02-16,2021-04,2021-04-30,2018-01-31,ACTUAL,2018-01-31,2018-01-31,ACTUAL,2018-01-31,,INTERVENTIONAL,,,"A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D","A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D",COMPLETED,,PHASE2,120,ACTUAL,Hepatera Ltd.,,4,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-15 02:48:17,2024-10-15 02:48:17,INDUSTRY,,,,,,,Data Matrix Solutions|Hepatera Ltd.,Germany|Russian Federation,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT03546842,,2018-05-23,2020-01-15,,2020-02-14,2018-05-23,2018-06-06,ACTUAL,2020-01-15,2020-02-05,ACTUAL,,,,2020-02-14,2020-02-25,ACTUAL,2018-06-29,ACTUAL,2018-06-29,2020-02,2020-02-29,2019-01-29,ACTUAL,2019-01-29,2019-01-29,ACTUAL,2019-01-29,,INTERVENTIONAL,,,"Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)",A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam,COMPLETED,,PHASE3,201,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 08:29:25,2024-10-14 08:29:25,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Vietnam,General disorders|Infections and infestations
NCT03547167,,2018-05-24,2020-12-14,,2020-12-21,2018-05-24,2018-06-06,ACTUAL,2020-12-21,2021-01-15,ACTUAL,,,,2020-12-21,2021-01-15,ACTUAL,2018-07-16,ACTUAL,2018-07-16,2020-12,2020-12-31,2020-01-20,ACTUAL,2020-01-20,2020-01-20,ACTUAL,2020-01-20,,INTERVENTIONAL,,All randomized participants who received at least 1 dose of study vaccination.,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY)",COMPLETED,,PHASE3,1515,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 13:45:03,2024-10-13 13:45:03,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Canada|Chile|New Zealand|Poland|Russian Federation|United States,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Social circumstances|Vascular disorders"
NCT03547908,,2018-05-24,2023-02-17,,2024-03-15,2018-05-24,2018-06-06,ACTUAL,2023-02-17,2023-03-15,ACTUAL,,,,2024-03-15,2024-03-19,ACTUAL,2018-05-30,ACTUAL,2018-05-30,2024-03,2024-03-31,2024-03-07,ACTUAL,2024-03-07,2022-02-25,ACTUAL,2022-02-25,,INTERVENTIONAL,Alliance,,"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults","A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults",COMPLETED,,PHASE3,244,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gileadclinicaltrials.com/transparency-policy#Commitment,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment",2024-10-14 22:26:35,2024-10-14 22:26:35,INDUSTRY,,,,,,,Gilead Sciences,"China|Dominican Republic|France|Greece|Hong Kong|Japan|Korea, Republic of|Malaysia|Puerto Rico|Singapore|Spain|Taiwan|Thailand|Turkey|United States","Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03552536,,2018-05-29,2020-02-14,,2020-02-14,2018-05-29,2018-06-12,ACTUAL,2020-02-14,2020-03-04,ACTUAL,,,,2020-02-14,2020-03-04,ACTUAL,2018-10-07,ACTUAL,2018-10-07,2020-02,2020-02-29,2019-03-11,ACTUAL,2019-03-11,2019-03-11,ACTUAL,2019-03-11,,INTERVENTIONAL,,"Only participants from Panel A were recruited. Due to an earlier than anticipated achievement of the study objectives, a decision was made not to conduct Panels B and C.",MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002),"A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti- Retroviral Activity of MK-8583 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients",COMPLETED,,PHASE1,5,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 00:30:16,2024-10-15 00:30:16,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany,"Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Vascular disorders"
NCT03554603,,2018-06-01,2022-09-05,,2023-07-26,2018-06-07,2018-06-13,ACTUAL,2023-07-26,2024-03-01,ACTUAL,,,,2023-07-26,2024-03-01,ACTUAL,2018-11-05,ACTUAL,2018-11-05,2023-07,2023-07-31,2019-07-31,ACTUAL,2019-07-31,2019-07-31,ACTUAL,2019-07-31,,INTERVENTIONAL,,,Modified Reporting of Positive Urine Cultures Collected From Long Term Care,"Modified Reporting of Positive Urine Cultures Collected From Long Term Care, a Randomized Controlled Trial",COMPLETED,,NA,100,ACTUAL,Memorial University of Newfoundland,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 11:28:26,2024-10-14 11:28:26,OTHER,,,,,,,Memorial University of Newfoundland,Canada,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Infections and infestations|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03555396,,2018-06-01,2024-06-05,,2024-09-30,2018-06-12,2018-06-13,ACTUAL,2024-07-01,2024-07-03,ACTUAL,,,,2024-09-30,2024-10-10,ESTIMATED,2020-10-26,ACTUAL,2020-10-26,2024-09,2024-09-30,2024-06-30,ACTUAL,2024-06-30,2023-03-09,ACTUAL,2023-03-09,,INTERVENTIONAL,,Each arm contained HIV-positive people who inject drugs and their treatment support partners. Treatment support partners may or may not be HIV-positive and may or may not inject drugs.,Couples ART Adherence Intervention for PWID in Kazakhstan,A Couple-based Antiretroviral Therapy Adherence Intervention for People Who Inject Drugs in Kazakhstan,COMPLETED,,NA,132,ACTUAL,Columbia University,"Data were collected during the Coronavirus-19 (COVID-19) pandemic. Many participants experienced problems using electronic monitoring devices, and research staff were not allowed to make home visits to trouble-shoot. During COVID-19, many opioid substitution therapy (OST) clinics in Kazakhstan also closed, making it difficult for participants to access (OST).",2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,Data will become available to other researchers starting 12 months after publication of the final results.,Data can be accessed by emailing the PI of the study and obtaining appropriate Institutional Review Board (IRB) approvals.,,YES,Unidentified data can be shared with other researchers in accordance with IRB regulations upon completion and analysis of the study.,2024-10-13 08:20:46,2024-10-13 08:20:46,OTHER,,,,,,,Columbia University|National Institute on Drug Abuse (NIDA),Kazakhstan,Infections and infestations|Social circumstances
NCT03560258,,2018-06-06,2022-02-08,,2022-03-28,2018-06-06,2018-06-18,ACTUAL,2022-03-28,2022-04-26,ACTUAL,,,,2022-03-28,2022-04-26,ACTUAL,2019-03-26,ACTUAL,2019-03-26,2022-03,2022-03-31,2021-02-10,ACTUAL,2021-02-10,2021-02-10,ACTUAL,2021-02-10,,INTERVENTIONAL,,Participants who received at least one study treatment dose.,HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study,HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy,COMPLETED,,PHASE1/PHASE2,45,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"* With whom?

  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
* For what types of analyses?

  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
* By what mechanism will data be made available?

  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.""",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-13 10:04:36,2024-10-13 10:04:36,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT03562117,,2018-05-15,2019-11-26,,2021-03-17,2018-06-07,2018-06-19,ACTUAL,2019-11-26,2019-12-17,ACTUAL,,,,2021-03-17,2021-04-12,ACTUAL,2018-06-14,ACTUAL,2018-06-14,2021-03,2021-03-31,2018-12-26,ACTUAL,2018-12-26,2018-12-26,ACTUAL,2018-12-26,,INTERVENTIONAL,,,Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function,"A Phase I, Open-Label, Single-Dose, Two-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Participants With Varying Degrees of Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function",COMPLETED,,PHASE1,25,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20791,YES,IPD for this study is available via the Clinical Study Data Request site.,2024-10-13 14:44:18,2024-10-13 14:44:18,INDUSTRY,,,,,,,Biomedical Advanced Research and Development Authority|GlaxoSmithKline,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders"
NCT03565900,,2018-06-12,2022-08-09,,2023-07-20,2018-06-12,2018-06-21,ACTUAL,2022-09-23,2022-10-20,ACTUAL,,,,2023-07-20,2023-07-28,ACTUAL,2018-09-12,ACTUAL,2018-09-12,2023-07,2023-07-31,2021-11-04,ACTUAL,2021-11-04,2021-11-04,ACTUAL,2021-11-04,,INTERVENTIONAL,,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","A Phase 3, Randomized, Double-blind, Active Comparator-controlled, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Recipients of Allogeneic Hematopoietic Stem Cell Transplant (PNEU-STEM)",COMPLETED,,PHASE3,277,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 13:49:54,2024-10-14 13:49:54,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Belgium|Brazil|Canada|Colombia|France|Germany|Mexico|Sweden|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03568942,,2018-06-11,2019-12-13,,2020-06-12,2018-06-14,2018-06-26,ACTUAL,2019-12-13,2020-01-07,ACTUAL,,,,2020-06-12,2020-06-29,ACTUAL,2018-07-23,ACTUAL,2018-07-23,2020-06,2020-06-30,2019-01-07,ACTUAL,2019-01-07,2019-01-07,ACTUAL,2019-01-07,,INTERVENTIONAL,,,Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis),"A Phase IIa Single-Center, Open-Label Study Evaluating the Pharmacokinetics of Repeat Oral Doses of Gepotidacin (GSK2140944) in Adult Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)",COMPLETED,,PHASE2,22,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (click on the link provided below),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com/Posting.aspx?ID=20368,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 06:52:22,2024-10-13 06:52:22,INDUSTRY,,,,,,,Biomedical Advanced Research and Development Authority|GlaxoSmithKline,United States,Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders
NCT03570918,,2018-06-18,2022-02-07,,2022-08-31,2018-06-18,2018-06-27,ACTUAL,2022-08-31,2022-09-02,ACTUAL,,,,2022-08-31,2022-09-02,ACTUAL,2018-09-25,ACTUAL,2018-09-25,2022-08,2022-08-31,2021-09-28,ACTUAL,2021-09-28,2021-09-28,ACTUAL,2021-09-28,,INTERVENTIONAL,,"The 3 participants treated with multiple doses of MGD014 were also treated with single doses of MGD014 at 10, 100 and 300 mg, respectively.",MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy,"A Phase 1 Study to Evaluate the Safety, Immunologic and Virologic Responses of MGD014 Therapy in HIV-Infected Individuals on Suppressive Antiretroviral Therapy",COMPLETED,,PHASE1,21,ACTUAL,MacroGenics,,9,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 23:47:47,2024-10-14 23:47:47,INDUSTRY,,,,,,,MacroGenics|National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03571607,,2018-06-20,2019-11-20,,2020-02-05,2018-06-20,2018-06-27,ACTUAL,2019-11-20,2019-12-10,ACTUAL,,,,2020-02-05,2020-02-18,ACTUAL,2018-07-12,ACTUAL,2018-07-12,2020-02,2020-02-29,2018-11-16,ACTUAL,2018-11-16,2018-11-16,ACTUAL,2018-11-16,,INTERVENTIONAL,,Safety analysis set included all participants who received 1 dose of study vaccine.,A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.,"A PHASE 3, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SINGLE DOSE OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN JAPANESE SUBJECTS AGED 6 TO 64 YEARS WHO ARE CONSIDERED TO BE AT INCREASED RISK OF PNEUMOCOCCAL DISEASE AND WHO ARE NAIVE TO PNEUMOCOCCAL VACCINES",COMPLETED,,PHASE3,206,ACTUAL,Pfizer,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-14 18:11:05,2024-10-14 18:11:05,INDUSTRY,,,,,,,Pfizer,Japan,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03572049,,2018-02-01,2022-06-02,,2023-06-21,2018-06-18,2018-06-28,ACTUAL,2022-09-08,2022-10-06,ACTUAL,,,,2023-06-21,2023-07-07,ACTUAL,2018-09-17,ACTUAL,2018-09-17,2022-09,2022-09-30,2022-04-29,ACTUAL,2022-04-29,2021-05-31,ACTUAL,2021-05-31,,INTERVENTIONAL,MSG15,,Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole,"SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial",COMPLETED,,PHASE2/PHASE3,88,ACTUAL,University of Alabama at Birmingham,,2,,,,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 05:21:07,2024-10-14 05:21:07,OTHER,,,,,,,"University of Alabama at Birmingham|University of California, Davis|Washington University School of Medicine",Panama|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03574389,,2018-05-22,2022-08-23,,2023-11-06,2018-06-19,2018-07-02,ACTUAL,2023-11-06,2024-04-26,ACTUAL,,,,2023-11-06,2024-04-26,ACTUAL,2018-06-23,ACTUAL,2018-06-23,2023-11,2023-11-30,2023-10-13,ACTUAL,2023-10-13,2021-08-23,ACTUAL,2021-08-23,,INTERVENTIONAL,,,A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children,"A PHASE 3 OPEN-LABEL TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN INFANTS AND YOUNG CHILDREN IN CHINA WHO ARE NAIVE TO PNEUMOCOCCAL VACCINATION",COMPLETED,,PHASE3,936,ACTUAL,Pfizer,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 07:48:16,2024-10-13 07:48:16,INDUSTRY,,,,,,,Pfizer,China,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03575962,,2018-06-12,2019-07-24,,2019-07-24,2018-06-29,2018-07-03,ACTUAL,2019-07-24,2019-09-06,ACTUAL,,,,2019-07-24,2019-09-06,ACTUAL,2018-06-18,ACTUAL,2018-06-18,2019-07,2019-07-31,2018-08-06,ACTUAL,2018-08-06,2018-08-06,ACTUAL,2018-08-06,,INTERVENTIONAL,,,A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254,"A Single Centre, 2-period, Randomized, Open-label Phase 1 Study to Assess the Relative Bioavailability of a Mesylate Salt Capsule of GSK3640254 Compared to a Hydrochloride Salt Capsule in Healthy Participants",COMPLETED,,PHASE1,14,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,"IPD will be made available, within 6 months of publishing the results of the primary endpoints of the study.","Access is provided, after a research proposal is submitted and has submitted approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided, for an initial period of 12 months but an extension can be granted, when justified for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 11:41:43,2024-10-13 11:41:43,INDUSTRY,,,,,,,ViiV Healthcare,United Kingdom,"Gastrointestinal disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03576183,,2018-05-15,2020-06-29,,2021-03-29,2018-06-21,2018-07-03,ACTUAL,2021-03-29,2021-04-23,ACTUAL,,,,2021-03-29,2021-04-23,ACTUAL,2018-06-04,ACTUAL,2018-06-04,2021-03,2021-03-31,2018-11-30,ACTUAL,2018-11-30,2018-06-26,ACTUAL,2018-06-26,,INTERVENTIONAL,,Challenge Population = all subjects who received two doses of the vaccine and the challenge dose,Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701,Randomized Double-Blinded Pilot Study Confirming A Human Challenge Model Using LSN03-016011/A Expressing LT And CS17 And Investigating The Safety Of VLA1701 (An Investigational Oral Cholera And ETEC (Enterotoxigenic E Coli) (Vaccine),COMPLETED,,PHASE2,34,ACTUAL,Valneva Austria GmbH,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 12:15:54,2024-10-14 12:15:54,INDUSTRY,,,,,,,Johns Hopkins University|Naval Medical Research Center|Valneva Austria GmbH,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03583164,,2018-05-17,2024-06-13,,2024-07-09,2018-07-10,2018-07-11,ACTUAL,2024-07-09,2024-07-10,ACTUAL,,,,2024-07-09,2024-07-10,ACTUAL,2018-06-06,ACTUAL,2018-06-06,2024-07,2024-07-31,2023-02-10,ACTUAL,2023-02-10,2023-02-10,ACTUAL,2023-02-10,,INTERVENTIONAL,FORMULA-OLS,,Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options,"Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options",COMPLETED,,PHASE2,203,ACTUAL,F2G Biotech GmbH,,1,,,,,,,TRUE,TRUE,FALSE,,,,,,From 3 months after publication of the primary manuscript (no end date),Requests should be directed to F2G for review.,,YES,"Individual participant data that underlie the results can be available to researchers after the primary publication of results for this study, after deidentification (text, tables, figures, appendices)",2024-10-13 02:46:59,2024-10-13 02:46:59,INDUSTRY,,,,,,,F2G Biotech GmbH|Iqvia Pty Ltd,"Australia|Belgium|Brazil|Egypt|France|Germany|Israel|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Thailand|Turkey|United Kingdom|United States|Vietnam","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT03593538,,2018-06-25,2021-02-09,,2021-03-02,2018-07-09,2018-07-20,ACTUAL,2021-03-02,2021-03-26,ACTUAL,,,,2021-03-02,2021-03-26,ACTUAL,2016-04-01,ACTUAL,2016-04-01,2021-03,2021-03-31,2020-03-13,ACTUAL,2020-03-13,2020-03-13,ACTUAL,2020-03-13,,INTERVENTIONAL,MEP,Individuals who started study medication,Effects of Metformin During Nicotine Withdrawal,Effects of Metformin on Mood and Cognition During Nicotine Withdrawal,COMPLETED,,PHASE2,80,ACTUAL,University of Pennsylvania,,3,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 13:20:12,2024-10-14 13:20:12,OTHER,,,,,,,Pennsylvania Department of Health|University of Pennsylvania,United States,"Gastrointestinal disorders|General disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03593629,,2018-06-02,2022-07-06,,2024-05-12,2018-07-09,2018-07-20,ACTUAL,2022-08-30,2022-09-27,ACTUAL,,,,2024-05-12,2024-06-04,ACTUAL,2018-05-28,ACTUAL,2018-05-28,2024-05,2024-05-31,2021-05-25,ACTUAL,2021-05-25,2020-12-10,ACTUAL,2020-12-10,,INTERVENTIONAL,,,Kenya HIV Self-Testing in PrEP Delivery,HIV Self-Testing to Improve the Efficiency of PrEP Delivery,COMPLETED,,NA,790,ACTUAL,University of Washington,,3,,,FALSE,,,,TRUE,FALSE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 19:41:41,2024-10-14 19:41:41,OTHER,,,,,,,National Institute of Mental Health (NIMH)|University of Washington,Kenya,Reproductive system and breast disorders
NCT03593655,,2018-07-10,2022-12-09,,2023-06-20,2018-07-10,2018-07-20,ACTUAL,2023-01-09,2023-02-03,ACTUAL,,,,2023-06-20,2023-06-22,ACTUAL,2019-01-14,ACTUAL,2019-01-14,2023-01,2023-01-31,2021-09-09,ACTUAL,2021-09-09,2021-09-09,ACTUAL,2021-09-09,,INTERVENTIONAL,,,Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population,A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population,COMPLETED,,PHASE2,247,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 08:47:40,2024-10-13 08:47:40,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Kenya|South Africa|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT03595553,,2018-06-11,2022-11-16,,2023-03-01,2018-07-11,2018-07-23,ACTUAL,2023-03-01,2023-03-03,ACTUAL,,,,2023-03-01,2023-03-03,ACTUAL,2019-01-28,ACTUAL,2019-01-28,2023-03,2023-03-31,2021-11-17,ACTUAL,2021-11-17,2021-11-17,ACTUAL,2021-11-17,,INTERVENTIONAL,Ri-CoDIFy 1,,Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection,"A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of Clostridium Difficile Infection (CDI)",COMPLETED,,PHASE3,759,ACTUAL,Summit Therapeutics,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 20:58:47,2024-10-13 20:58:47,INDUSTRY,,,,,,,Summit Therapeutics,"Argentina|Australia|Belarus|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Germany|Greece|Hungary|Korea, Republic of|Mexico|New Zealand|Peru|Poland|Portugal|Romania|Russian Federation|Spain|United States","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT03606213,,2018-07-02,2022-10-20,2022-03-21,2023-05-26,2018-07-27,2018-07-30,ACTUAL,2023-05-26,2023-05-31,ACTUAL,,2023-05-31,ACTUAL,2023-05-26,2023-05-31,ACTUAL,2018-08-01,ACTUAL,2018-08-01,2023-05,2023-05-31,2021-05-17,ACTUAL,2021-05-17,2021-05-17,ACTUAL,2021-05-17,,INTERVENTIONAL,,,Therapeutic Vaccination in Treated HIV Disease,"Safety, Immunogenicty and Anti-Reservoir Activity of an Electroporation-Administered HIV DNA Vaccine Encoding GAG, POL and ENV Proteins With IL-12 Plasmid in HIV-Infected Adults on Antriretroviral Therapy.",COMPLETED,,PHASE1/PHASE2,56,ACTUAL,"University of California, San Francisco",,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 20:53:21,2024-10-14 20:53:21,OTHER,,,,,,,"Inovio Pharmaceuticals|National Institute of Allergy and Infectious Diseases (NIAID)|Steven Deeks|University of California, Los Angeles",United States,General disorders|Infections and infestations
NCT03608774,,2018-06-28,2020-09-25,,2020-12-10,2018-07-30,2018-08-01,ACTUAL,2020-12-10,2021-01-07,ACTUAL,,,,2020-12-10,2021-01-07,ACTUAL,2018-07-13,ACTUAL,2018-07-13,2019-01-25,2019-01-25,2020-02-21,ACTUAL,2020-02-21,2020-02-21,ACTUAL,2020-02-21,,INTERVENTIONAL,,"All randomized subjects, receiving or not receiving the study product, are included in the baseline analysis population.",Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM,"A Phase 4, Randomized, Double-Blinded, Placebo-Controlled Trial of Azithromycin Versus Doxycycline for the Treatment of Rectal Chlamydia in Men Who Have Sex With Men",COMPLETED,,PHASE4,177,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,,FALSE,FALSE,,,FALSE,,,,,,,,2024-10-13 06:20:43,2024-10-13 06:20:43,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Infections and infestations
NCT03613649,,2018-07-26,2019-12-24,,2020-03-26,2018-08-01,2018-08-03,ACTUAL,2020-03-26,2020-03-27,ACTUAL,,,,2020-03-26,2020-03-27,ACTUAL,2018-09-25,ACTUAL,2018-09-25,2019-05-07,2019-05-07,2019-01-02,ACTUAL,2019-01-02,2019-01-02,ACTUAL,2019-01-02,,INTERVENTIONAL,,,Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects,"A Phase 1, Randomized, Double-blinded, Four-period Crossover, Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects",COMPLETED,,PHASE1,72,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 15:53:27,2024-10-14 15:53:27,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Gastrointestinal disorders|Investigations|Nervous system disorders
NCT03615482,,2018-07-31,2020-06-09,,2024-05-20,2018-07-31,2018-08-03,ACTUAL,2020-06-09,2020-06-29,ACTUAL,,,,2024-05-20,2024-05-22,ACTUAL,2018-09-14,ACTUAL,2018-09-14,2024-05,2024-05-31,2019-06-24,ACTUAL,2019-06-24,2019-06-24,ACTUAL,2019-06-24,,INTERVENTIONAL,,The analysis population consisted of all randomized participants who received at least 1 dose of study vaccination.,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (PNEU-FLU)",COMPLETED,,PHASE3,1200,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 11:19:49,2024-10-13 11:19:49,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03618056,,2018-08-01,2021-10-13,,2022-01-31,2018-08-01,2018-08-07,ACTUAL,2021-11-30,2021-12-29,ACTUAL,,,,2022-01-31,2022-02-07,ACTUAL,2018-12-19,ACTUAL,2018-12-19,2022-01,2022-01-31,2020-07-17,ACTUAL,2020-07-17,2020-07-17,ACTUAL,2020-07-17,,INTERVENTIONAL,,,Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus,A Phase 1b Open Label Clinical Trial to Evaluate HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus,COMPLETED,,PHASE1,1,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 21:22:54,2024-10-13 21:22:54,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Infections and infestations
NCT03620162,,2018-08-03,2021-07-28,,2023-01-12,2018-08-03,2018-08-08,ACTUAL,2021-07-28,2021-08-23,ACTUAL,,,,2023-01-12,2023-01-17,ACTUAL,2018-10-18,ACTUAL,2018-10-18,2023-01,2023-01-31,2020-12-14,ACTUAL,2020-12-14,2020-12-14,ACTUAL,2020-12-14,,INTERVENTIONAL,,,A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION),"A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ With Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)",COMPLETED,,PHASE3,900,ACTUAL,Merck Sharp & Dohme LLC,,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 19:23:54,2024-10-14 19:23:54,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Puerto Rico|Thailand|Turkey|United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03621657,,2018-07-25,2021-02-19,,2021-02-19,2018-08-03,2018-08-08,ACTUAL,2021-02-19,2021-03-15,ACTUAL,,,,2021-02-19,2021-03-15,ACTUAL,2019-03-21,ACTUAL,2019-03-21,2021-02,2021-02-28,2020-02-27,ACTUAL,2020-02-27,2020-02-27,ACTUAL,2020-02-27,,INTERVENTIONAL,GRAFT,Study was completed with only 1 participant enrolled.,The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation,"A Phase II Randomized, Double-blind Placebo-controlled Trial to Determine if Fecal Microbiota Transplantation is Efficacious for Hospitalized Patients With C. Difficile Infection History During Antibiotic Treatment",COMPLETED,,PHASE2,1,ACTUAL,"University of Wisconsin, Madison",,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-15 02:42:24,2024-10-15 02:42:24,OTHER,,,,,,,"Agency for Healthcare Research and Quality (AHRQ)|University of Wisconsin, Madison",United States,"Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
NCT03624946,,2018-08-07,2020-06-25,,2024-03-14,2018-08-09,2018-08-10,ACTUAL,2020-06-25,2020-07-13,ACTUAL,,,,2024-03-14,2024-03-18,ACTUAL,2018-06-27,ACTUAL,2018-06-27,2024-03,2024-03-31,2019-03-06,ACTUAL,2019-03-06,2019-03-06,ACTUAL,2019-03-06,,INTERVENTIONAL,,,Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG),Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers,COMPLETED,,PHASE1,30,ACTUAL,Emergent BioSolutions,"Due to the limited number of plasma donors used to generate the plasma pool for manufacture of the ZIKV-IG clinical lot, donor plasma with high isoagglutinin titers (e.g., anti-A antibodies) were not excluded from plasma pools used for the manufacture of ZIKV-IG. Therefore, in this study ZIKV-IG was for use by individuals with blood type O only.",2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 21:50:37,2024-10-13 21:50:37,INDUSTRY,,,,,,,Emergent BioSolutions,Canada,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03629080,,2018-05-29,2023-06-23,,2023-10-24,2018-08-10,2018-08-14,ACTUAL,2023-10-24,2023-10-26,ACTUAL,,,,2023-10-24,2023-10-26,ACTUAL,2018-12-12,ACTUAL,2018-12-12,2023-10,2023-10-31,2022-06-22,ACTUAL,2022-06-22,2022-06-22,ACTUAL,2022-06-22,,INTERVENTIONAL,,,A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients,"A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation From Living CMV-Seropositive Donors (D+).",COMPLETED,,PHASE2,83,ACTUAL,Hookipa Biotech GmbH,,6,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 12:46:59,2024-10-14 12:46:59,INDUSTRY,,,,,,,Hookipa Biotech GmbH,Austria|Belgium|Denmark|France|Germany|Netherlands|Norway|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03630705,,2018-08-03,2023-09-06,2023-02-15,2023-09-26,2018-08-09,2018-08-15,ACTUAL,2023-09-26,2023-10-19,ACTUAL,,2023-03-20,ACTUAL,2023-09-26,2023-10-19,ACTUAL,2018-10-17,ACTUAL,2018-10-17,2023-09,2023-09-30,2022-02-18,ACTUAL,2022-02-18,2022-02-18,ACTUAL,2022-02-18,,INTERVENTIONAL,MET33,Analysis was performed on all randomized participants.,Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico,Safety and Immunogenicity of a 3-Dose Schedule of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers,COMPLETED,,PHASE3,525,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 17:47:01,2024-10-14 17:47:01,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Mexico|Russian Federation,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT03631732,,2018-08-13,2020-08-12,,2021-08-09,2018-08-13,2018-08-15,ACTUAL,2020-08-12,2020-08-27,ACTUAL,,,,2021-08-09,2021-09-05,ACTUAL,2018-08-28,ACTUAL,2018-08-28,2021-08,2021-08-31,2020-08-19,ACTUAL,2020-08-19,2019-08-12,ACTUAL,2019-08-12,,INTERVENTIONAL,BRAAVE 2020,The Safety Analysis Set included all participants who were randomized into the study and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1).,"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants",COMPLETED,,PHASE3,496,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.",2024-10-13 20:42:35,2024-10-13 20:42:35,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03632720,,2018-08-03,2023-10-10,,2023-10-10,2018-08-13,2018-08-15,ACTUAL,2023-10-10,2023-11-07,ACTUAL,,,,2023-10-10,2023-11-07,ACTUAL,2018-10-10,ACTUAL,2018-10-10,2023-10,2023-10-31,2022-12-05,ACTUAL,2022-12-05,2022-12-05,ACTUAL,2022-12-05,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom,Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care,COMPLETED,,PHASE3,788,ACTUAL,Sanofi,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 20:41:55,2024-10-14 20:41:55,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",United Kingdom,"Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03635086,,2018-07-24,2021-08-17,,2021-10-21,2018-08-14,2018-08-17,ACTUAL,2021-09-22,2021-10-20,ACTUAL,,,,2021-10-21,2021-10-22,ACTUAL,2018-08-22,ACTUAL,2018-08-22,2021-10,2021-10-31,2019-11-16,ACTUAL,2019-11-16,2019-01-25,ACTUAL,2019-01-25,,INTERVENTIONAL,,,"Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)","Observer Blinded, Randomised Study to Investigate Safety, Tolerability and Long-term Immunogenicity of Different Dose Regimens and Formulations of MV-CHIK in Healthy Volunteers",COMPLETED,,PHASE2,60,ACTUAL,Themis Bioscience GmbH,,5,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 16:13:59,2024-10-13 16:13:59,INDUSTRY,,,,,,,Themis Bioscience GmbH,United Kingdom,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03636906,,2018-08-16,2022-05-13,,2022-07-05,2018-08-16,2018-08-17,ACTUAL,2022-07-05,2022-07-27,ACTUAL,,,,2022-07-05,2022-07-27,ACTUAL,2019-04-08,ACTUAL,2019-04-08,2022-07,2022-07-31,2021-07-22,ACTUAL,2021-07-22,2020-01-16,ACTUAL,2020-01-16,,INTERVENTIONAL,,"Analysis of this study results were reported for the RSV1D pooled, RSV2D pooled, and comparator_placebo pooled groups as data collection was based on different standard of care provided at participating counties rather than randomization to each of the groups. According to the pre-specified analysis plan, data collected for participant flow, baseline characteristics and adverse events reporting were not analyzed for the individual groups.",Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV,"A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Infants",COMPLETED,,PHASE1/PHASE2,201,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 22:02:15,2024-10-13 22:02:15,INDUSTRY,,,,,,,GlaxoSmithKline,Argentina|Australia|Belgium|Brazil|Canada|Colombia|Finland|Hong Kong|Italy|Mexico|Panama|Poland|Russian Federation|Spain|Thailand|Turkey|United Kingdom|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03639311,,2018-08-10,2020-11-20,,2024-05-13,2018-08-20,2018-08-21,ACTUAL,2021-01-13,2021-01-15,ACTUAL,,,,2024-05-13,2024-06-11,ACTUAL,2018-09-24,ACTUAL,2018-09-24,2024-05,2024-05-31,2023-01-30,ACTUAL,2023-01-30,2019-12-11,ACTUAL,2019-12-11,,INTERVENTIONAL,,,"Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study","A Phase IIb, Multicenter, Open-label, Rollover Study Evaluating the Efficacy, Safety and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months in HIV-1 Infected Adults Who Are Virologically Suppressed and Participated in Study LAI116482",COMPLETED,,PHASE2,97,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"IPD will be made available, within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided, after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided, for an initial period of 12 months but an extension can be granted, when justified for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 08:23:13,2024-10-14 08:23:13,INDUSTRY,,,,,,,"Janssen, LP|ViiV Healthcare",Canada|United States,"Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03643952,,2018-08-21,2021-03-03,,2022-04-19,2018-08-21,2018-08-23,ACTUAL,2021-03-03,2021-03-30,ACTUAL,,,,2022-04-19,2022-05-13,ACTUAL,2018-12-06,ACTUAL,2018-12-06,2022-04,2022-04-30,2020-04-07,ACTUAL,2020-04-07,2020-04-07,ACTUAL,2020-04-07,,INTERVENTIONAL,,,"Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)","A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years With Complicated Skin and Soft Tissue Infections or Bacteremia Caused by Gram-positive Cocci",COMPLETED,,PHASE2,18,ACTUAL,Merck Sharp & Dohme LLC,"The study was concluded due to the difficulty of enrolling pediatric patients into the study during the COVID-19 pandemic. This study concluded enrollment with 18 participants, versus the 20 that were originally planned.",1,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 08:42:20,2024-10-13 08:42:20,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03652610,,2018-08-28,2021-01-20,2020-01-17,2021-01-20,2018-08-28,2018-08-29,ACTUAL,2021-01-20,2021-02-09,ACTUAL,2020-02-18,2020-02-25,ACTUAL,2021-01-20,2021-02-09,ACTUAL,2018-09-07,ACTUAL,2018-09-07,2021-01,2021-01-31,2019-06-11,ACTUAL,2019-06-11,2019-01-17,ACTUAL,2019-01-17,,INTERVENTIONAL,,,A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age,"Immunogenicity, Reactogenicity and Safety of Two Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) in Healthy Adults 18 to 40 Years of Age",COMPLETED,,PHASE2,996,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 14:08:24,2024-10-13 14:08:24,INDUSTRY,,,,,,,GlaxoSmithKline,Australia|Belgium|Canada|Estonia|Germany|Italy,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03660839,,2018-08-20,2020-11-05,,2022-03-10,2018-09-04,2018-09-07,ACTUAL,2020-11-05,2020-12-02,ACTUAL,,,,2022-03-10,2022-03-21,ACTUAL,2018-09-11,ACTUAL,2018-09-11,2022-03,2022-03-31,2019-11-06,ACTUAL,2019-11-06,2019-11-06,ACTUAL,2019-11-06,,INTERVENTIONAL,,Analysis was performed on all randomized participants.,Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria,"A Randomized, Open Label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 Dose Levels of Artefenomel (OZ439) Given in Combination With Ferroquine (FQ) and FQ Alone, in African Patients With Uncomplicated Plasmodium Falciparum Malaria",COMPLETED,,PHASE2,140,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 08:23:13,2024-10-14 08:23:13,INDUSTRY,,,,,,,Medicines for Malaria Venture|Sanofi,Benin|Burkina Faso|Gabon|Kenya|Uganda,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT03667690,,2018-08-30,2022-10-07,,2022-12-13,2018-09-11,2018-09-12,ACTUAL,2022-12-13,2023-01-06,ACTUAL,,,,2022-12-13,2023-01-06,ACTUAL,2018-10-07,ACTUAL,2018-10-07,2022-12,2022-12-31,2021-10-07,ACTUAL,2021-10-07,2021-10-07,ACTUAL,2021-10-07,,INTERVENTIONAL,ReSTORE,The Intent-to-Treat (ITT) population analyzed consisted of all subjects randomized to treatment. Subjects were analyzed based on the treatment group to which they were randomized.,Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis,"A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis",COMPLETED,,PHASE3,199,ACTUAL,Cidara Therapeutics Inc.,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-15 01:21:06,2024-10-15 01:21:06,INDUSTRY,,,,,,,Cidara Therapeutics Inc.,"Argentina|Australia|Belgium|Bulgaria|China|Colombia|France|Germany|Greece|Israel|Italy|Korea, Republic of|Singapore|Spain|Taiwan|Thailand|Turkey|United States","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03673462,,2018-09-13,2023-09-14,,2023-12-11,2018-09-14,2018-09-17,ACTUAL,2023-10-03,2023-10-05,ACTUAL,,,,2023-12-11,2023-12-14,ACTUAL,2018-09-17,ACTUAL,2018-09-17,2023-12,2023-12-31,2023-03-16,ACTUAL,2023-03-16,2023-03-16,ACTUAL,2023-03-16,,INTERVENTIONAL,MET41,Analysis was performed on all randomized participants.,Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers,A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers,COMPLETED,,PHASE3,2797,ACTUAL,Sanofi,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-13 09:53:28,2024-10-13 09:53:28,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03674177,,2018-09-14,2020-03-17,,2021-08-12,2018-09-14,2018-09-17,ACTUAL,2020-04-02,2020-04-15,ACTUAL,,,,2021-08-12,2021-08-13,ACTUAL,2018-10-30,ACTUAL,2018-10-30,2021-08,2021-08-31,2019-09-02,ACTUAL,2019-09-02,2019-04-16,ACTUAL,2019-04-16,,INTERVENTIONAL,,,"A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Unadjuvanted RSV Maternal Vaccine Compared to Placebo When Administered to Healthy Non-pregnant Women.",COMPLETED,,PHASE1,502,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,,TRUE,FALSE,,,,,,IPD is available via the Clinical Study Data Request site (copy the URL below to your browser),"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.clinicalstudydatarequest.com/Posting.aspx?ID=20864,YES,IPD for this study is available via the Clinical Study Data Request site,2024-10-13 08:10:23,2024-10-13 08:10:23,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|Finland|Germany|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03682107,,2018-09-20,2021-09-09,,2022-10-27,2018-09-20,2018-09-24,ACTUAL,2021-09-16,2021-10-14,ACTUAL,,,,2022-10-27,2022-11-22,ACTUAL,2019-02-19,ACTUAL,2019-02-19,2021-04-06,2021-04-06,2020-09-23,ACTUAL,2020-09-23,2020-09-23,ACTUAL,2020-09-23,,INTERVENTIONAL,,,Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device,"A Phase I, Randomized, Placebo Controlled, Double-Blind, Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection System in Normal Healthy Adults",COMPLETED,,PHASE1,48,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 13:38:09,2024-10-14 13:38:09,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03682848,,2018-09-21,2022-05-31,,2024-08-12,2018-09-21,2018-09-25,ACTUAL,2022-07-13,2022-08-08,ACTUAL,,,,2024-08-12,2024-08-29,ACTUAL,2019-04-09,ACTUAL,2019-04-09,2024-08,2024-08-31,2024-09-30,ESTIMATED,2024-09-30,2021-12-01,ACTUAL,2021-12-01,,INTERVENTIONAL,,,Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents,"An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥12 to <18 Years of Age Who Weigh at Least 25 kg",ACTIVE_NOT_RECRUITING,,PHASE3,32,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf,YES,"GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.",2024-10-14 14:45:38,2024-10-14 14:45:38,INDUSTRY,,,,,,,ViiV Healthcare,Kenya|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03691610,,2018-09-28,2024-05-14,,2024-06-21,2018-09-28,2018-10-02,ACTUAL,2024-06-21,2024-06-25,ACTUAL,,,,2024-06-21,2024-06-25,ACTUAL,2018-10-04,ACTUAL,2018-10-04,2024-06,2024-06-30,2023-10-20,ACTUAL,2023-10-20,2023-10-20,ACTUAL,2023-10-20,,INTERVENTIONAL,,All randomized participants who received at least 1 dose of the study vaccine.,Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers,Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers,COMPLETED,,PHASE3,950,ACTUAL,Sanofi,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-13 23:50:05,2024-10-13 23:50:05,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT03691623,,2018-09-28,2022-02-24,,2022-04-06,2018-09-28,2018-10-02,ACTUAL,2022-04-06,2022-05-03,ACTUAL,,,,2022-04-06,2022-05-03,ACTUAL,2018-10-15,ACTUAL,2018-10-15,2019-08,2019-08-31,2019-10-18,ACTUAL,2019-10-18,2019-09-30,ACTUAL,2019-09-30,,INTERVENTIONAL,,"In Part 1, one participant in the Safety Analysis Set did not receive study treatment and is not included in this baseline analysis population.",A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model,"A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model.",COMPLETED,,PHASE2,179,ACTUAL,"Enanta Pharmaceuticals, Inc",,6,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 23:16:28,2024-10-13 23:16:28,INDUSTRY,,,,,,,"Enanta Pharmaceuticals, Inc|hVIVO Services Limited",United Kingdom,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03692871,,2018-09-28,2022-03-09,,2023-07-20,2018-09-28,2018-10-02,ACTUAL,2022-04-15,2022-05-10,ACTUAL,,,,2023-07-20,2023-07-28,ACTUAL,2018-12-14,ACTUAL,2018-12-14,2023-07,2023-07-31,2021-03-26,ACTUAL,2021-03-26,2021-03-26,ACTUAL,2021-03-26,,INTERVENTIONAL,,,A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK),"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU-LINK)",COMPLETED,,PHASE3,2409,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Canada|Finland|Germany|Israel|Malaysia|Peru|Taiwan|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03695393,,2018-10-01,2021-08-04,,2021-09-02,2018-10-02,2018-10-04,ACTUAL,2021-09-02,2021-09-05,ACTUAL,,,,2021-09-02,2021-09-05,ACTUAL,2019-10-10,ACTUAL,2019-10-10,2021-09,2021-09-30,2021-03-10,ACTUAL,2021-03-10,2020-10-16,ACTUAL,2020-10-16,,INTERVENTIONAL,SCRIPT,,"Stigma, Risk Behaviors and Health Care Among HIV-infected Russian People Who Inject Drugs","Stigma, Risk Behaviors and Health Care Among HIV-infected Russian People Who Inject Drugs",COMPLETED,,NA,100,ACTUAL,Boston Medical Center,,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 00:42:30,2024-10-14 00:42:30,OTHER,,,,,,,Boston Medical Center|National Institute on Drug Abuse (NIDA),Russian Federation,"Immune system disorders|Infections and infestations|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT03701061,,2018-10-06,2020-02-05,,2020-02-28,2018-10-06,2018-10-09,ACTUAL,2020-02-28,2020-03-11,ACTUAL,,,,2020-02-28,2020-03-11,ACTUAL,2018-10-11,ACTUAL,2018-10-11,2020-02,2020-02-29,2020-01-31,ACTUAL,2020-01-31,2019-02-28,ACTUAL,2019-02-28,,INTERVENTIONAL,HIPCVAX-010S,,Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response,Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response,COMPLETED,,PHASE4,12,ACTUAL,Emory University,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 02:27:29,2024-10-14 02:27:29,OTHER,,,,,,,Emory University|National Institute of Allergy and Infectious Diseases (NIAID),United States,General disorders
NCT03702049,,2018-10-08,2024-01-02,,2024-03-21,2018-10-08,2018-10-10,ACTUAL,2024-03-21,2024-04-18,ACTUAL,,,,2024-03-21,2024-04-18,ACTUAL,2019-01-24,ACTUAL,2019-01-24,2024-03,2024-03-31,2020-09-04,ACTUAL,2020-09-04,2020-05-29,ACTUAL,2020-05-29,,INTERVENTIONAL,3HP-LTBI,,Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV,Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV,COMPLETED,,NA,50,ACTUAL,"University of California, Irvine",,1,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,UNDECIDED,,2024-10-14 10:39:45,2024-10-14 10:39:45,OTHER,,,,,,,"National Institute on Minority Health and Health Disparities (NIMHD)|University of California, Irvine|University of California, Los Angeles",United States,Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders
NCT03707912,,2018-10-12,2020-06-26,,2020-08-18,2018-10-12,2018-10-16,ACTUAL,2020-08-18,2020-09-02,ACTUAL,,,,2020-08-18,2020-09-02,ACTUAL,2018-10-09,ACTUAL,2018-10-09,2020-08,2020-08-31,2019-03-15,ACTUAL,2019-03-15,2019-03-15,ACTUAL,2019-03-15,,INTERVENTIONAL,,,Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections,Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections,COMPLETED,,PHASE4,204,ACTUAL,Materia Medica Holding,,2,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-14 08:52:59,2024-10-14 08:52:59,INDUSTRY,,,,,,,Materia Medica Holding,Russian Federation,"General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03707977,,2018-10-12,2022-12-02,,2024-09-30,2018-10-12,2018-10-16,ACTUAL,2023-01-18,2023-02-14,ACTUAL,,,,2024-09-30,2024-10-10,ESTIMATED,2019-06-17,ACTUAL,2019-06-17,2023-01,2023-01-31,2021-12-03,ACTUAL,2021-12-03,2021-12-03,ACTUAL,2021-12-03,,INTERVENTIONAL,,2 participants who entered the PK Step (a lead-in to the main study) in Group B did not proceed to Step 1 due to ineligibility for Step 1. Baseline characteristics of these 2 participants are reported separately. Baseline characteristics (at the time of study entry) for all 28 other participants (including those who entered the study in the PK Step and proceeded to Step 1) are shown in the Steps 1-3 group results.,Dual bNAb Treatment in Children,A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children),COMPLETED,,PHASE1/PHASE2,30,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 08:26:34,2024-10-13 08:26:34,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Botswana,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03721328,,2018-10-17,2021-09-28,,2021-12-27,2018-10-24,2018-10-26,ACTUAL,2021-11-09,2021-12-09,ACTUAL,,,,2021-12-27,2022-01-11,ACTUAL,2018-10-26,ACTUAL,2018-10-26,2021-12,2021-12-31,2020-08-25,ACTUAL,2020-08-25,2020-08-25,ACTUAL,2020-08-25,,INTERVENTIONAL,,,Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation,A Phase 2 Multicenter Feasibility Trial to Evaluate Safety and Efficacy in Patients Treated for Hip or Knee Prosthetic Joint Infection (PJI) With Alternating Irrigation of Vancomycin Hydrochloride (HCl) and Tobramycin Sulfate in Two-Stage Exchange Arthroplasty,COMPLETED,,PHASE2,15,ACTUAL,"Osteal Therapeutics, Inc.",,1,,,FALSE,,,,FALSE,TRUE,TRUE,TRUE,,,,,,,,NO,,2024-10-13 22:53:54,2024-10-13 22:53:54,INDUSTRY,,,,,,,"Osteal Therapeutics, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT03721549,,2018-10-24,2020-01-09,,2020-01-09,2018-10-24,2018-10-26,ACTUAL,2020-01-09,2020-01-22,ACTUAL,,,,2020-01-09,2020-01-22,ACTUAL,2018-10-03,ACTUAL,2018-10-03,2020-01,2020-01-31,2018-11-28,ACTUAL,2018-11-28,2018-11-28,ACTUAL,2018-11-28,,INTERVENTIONAL,,,Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model,Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model,COMPLETED,,PHASE1,16,ACTUAL,WCCT Global,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 03:05:32,2024-10-14 03:05:32,INDUSTRY,,,,,,,Vaxart|WCCT Global,United States,"Gastrointestinal disorders|Injury, poisoning and procedural complications"
NCT03725293,,2018-10-25,2021-12-02,,2022-01-06,2018-10-29,2018-10-31,ACTUAL,2022-01-06,2022-01-14,ACTUAL,,,,2022-01-06,2022-01-14,ACTUAL,2019-01-14,ACTUAL,2019-01-14,2022-01,2022-01-31,2020-11-26,ACTUAL,2020-11-26,2020-11-26,ACTUAL,2020-11-26,,INTERVENTIONAL,,,Midlines and Thrombophlebitis,Randomized Comparative Evaluation of Midline Catheters for Thrombophlebitis,COMPLETED,,NA,212,ACTUAL,William Beaumont Hospitals,,2,,,FALSE,,,,FALSE,FALSE,TRUE,,,TRUE,,,,,,NO,,2024-10-14 01:37:23,2024-10-14 01:37:23,OTHER,,,,,,,Teleflex|William Beaumont Hospitals,United States,Blood and lymphatic system disorders
NCT03728426,,2018-10-31,2023-01-06,,2023-02-09,2018-10-31,2018-11-02,ACTUAL,2023-02-09,2023-03-08,ACTUAL,,,,2023-02-09,2023-03-08,ACTUAL,2019-01-11,ACTUAL,2019-01-11,2023-02,2023-02-28,2022-03-28,ACTUAL,2022-03-28,2022-03-28,ACTUAL,2022-03-28,,INTERVENTIONAL,,,Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection,A Phase 2 Study of Letermovir Treatment for Patients Experiencing Refractory or Resistant Cytomegalovirus Infection or Disease With Concurrent Organ Dysfunction,COMPLETED,,PHASE2,10,ACTUAL,Dana-Farber Cancer Institute,This study did not reach the target number of participants needed to achieve target power and statistically reliable results. The study was closed early due to difficulty in recruiting during the COVID-19 pandemic.,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:23:18,2024-10-14 15:23:18,OTHER,,,,,,,"Amy C. Sherman, MD|Merck Sharp & Dohme LLC",United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03728608,,2018-10-24,2024-02-15,,2024-04-10,2018-10-30,2018-11-02,ACTUAL,2024-02-15,2024-03-13,ACTUAL,,,,2024-04-10,2024-04-11,ACTUAL,2017-05-10,ACTUAL,2017-05-10,2024-04,2024-04-30,2023-05-31,ACTUAL,2023-05-31,2023-02-02,ACTUAL,2023-02-02,,INTERVENTIONAL,,,Optimal Feeding Tube Dwell Time in VLBW Infants to Reduce Feeding Tube Contamination,Optimal Feeding Tube Dwell Time in VLBW Infants to Reduce Feeding Tube Contamination,COMPLETED,,NA,151,ACTUAL,University of Florida,,2,,,FALSE,,,,TRUE,FALSE,TRUE,,,,,,,,,,,2024-10-13 09:37:59,2024-10-13 09:37:59,OTHER,,,,,,,National Center for Advancing Translational Sciences (NCATS)|National Institute of Nursing Research (NINR)|University of Florida,United States,Gastrointestinal disorders
NCT03731182,,2018-11-02,2021-05-21,,2021-05-21,2018-11-02,2018-11-06,ACTUAL,2021-05-21,2021-06-16,ACTUAL,,,,2021-05-21,2021-06-16,ACTUAL,2019-01-23,ACTUAL,2019-01-23,2021-05,2021-05-31,2020-06-08,ACTUAL,2020-06-08,2020-06-08,ACTUAL,2020-06-08,,INTERVENTIONAL,,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)","A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (PNEU-SICKLE)",COMPLETED,,PHASE3,104,ACTUAL,Merck Sharp & Dohme LLC,,2,,,,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 07:04:43,2024-10-14 07:04:43,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Brazil|Colombia|Dominican Republic|Greece|Italy|Panama|United States,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03735849,,2018-11-07,2021-12-14,,2022-03-04,2018-11-07,2018-11-08,ACTUAL,2022-03-04,2022-03-07,ACTUAL,,,,2022-03-04,2022-03-07,ACTUAL,2019-01-18,ACTUAL,2019-01-18,2022-03,2022-03-31,2020-12-21,ACTUAL,2020-12-21,2020-12-21,ACTUAL,2020-12-21,,INTERVENTIONAL,VRC07-523LS,Participants who have their biopsies collected,"Evaluating the Safety and Pharmacokinetics of VRC07-523LS in the Sera and Mucosae of Healthy, HIV-Uninfected Adult Participants","A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of VRC-HIVMAB075-00-AB (VRC07-523LS) in the Sera and Mucosae of Healthy, HIV-1-Uninfected Adult Participants",COMPLETED,,PHASE1,28,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 13:56:51,2024-10-13 13:56:51,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03739112,,2018-11-08,2023-05-29,,2023-05-29,2018-11-08,2018-11-13,ACTUAL,2023-05-29,2023-06-23,ACTUAL,,,,2023-05-29,2023-06-23,ACTUAL,2018-09-18,ACTUAL,2018-09-18,2023-05,2023-05-31,2019-07-16,ACTUAL,2019-07-16,2019-05-17,ACTUAL,2019-05-17,,INTERVENTIONAL,,"The Safety Analysis Set (SAS) was defined as all participants who received either the Quadrivalent VLP Influenza Vaccine or the active comparator. Participants that were non-compliant to protocol/Good Clinical Practice (GCP), as per investigator, were excluded from analysis.",Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly,"A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older",COMPLETED,,PHASE3,12794,ACTUAL,Medicago,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 06:20:43,2024-10-13 06:20:43,INDUSTRY,,,,,,,Medicago,Canada|Finland|Germany|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT03739112,,2018-11-08,2023-05-29,,2023-05-29,2018-11-08,2018-11-13,ACTUAL,2023-05-29,2023-06-23,ACTUAL,,,,2023-05-29,2023-06-23,ACTUAL,2018-09-18,ACTUAL,2018-09-18,2023-05,2023-05-31,2019-07-16,ACTUAL,2019-07-16,2019-05-17,ACTUAL,2019-05-17,,INTERVENTIONAL,,"The Safety Analysis Set (SAS) was defined as all participants who received either the Quadrivalent VLP Influenza Vaccine or the active comparator. Participants that were non-compliant to protocol/Good Clinical Practice (GCP), as per investigator, were excluded from analysis.",Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly,"A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older",COMPLETED,,PHASE3,12794,ACTUAL,Medicago,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 06:20:43,2024-10-13 06:20:43,INDUSTRY,,,,,,,Medicago,Canada|Finland|Germany|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT03739866,,2018-11-02,2020-11-12,,2021-03-16,2018-11-09,2018-11-14,ACTUAL,2020-11-12,2020-12-09,ACTUAL,,,,2021-03-16,2021-04-09,ACTUAL,2018-11-26,ACTUAL,2018-11-26,2021-03,2021-03-31,2020-06-15,ACTUAL,2020-06-15,2019-11-14,ACTUAL,2019-11-14,,INTERVENTIONAL,,Safety Analysis Set included all participants who were randomized/enrolled and received at least 1 dose of study drug.,"Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults","A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects",COMPLETED,,PHASE1,53,ACTUAL,Gilead Sciences,,8,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 13:50:53,2024-10-13 13:50:53,INDUSTRY,,,,,,,Gilead Sciences,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03747497,,2018-11-12,2021-04-06,,2022-10-16,2018-11-16,2018-11-20,ACTUAL,2021-04-06,2021-04-30,ACTUAL,,,,2022-10-16,2022-11-08,ACTUAL,2018-11-15,ACTUAL,2018-11-15,2022-10,2022-10-31,2019-03-26,ACTUAL,2019-03-26,2019-03-26,ACTUAL,2019-03-26,,INTERVENTIONAL,,,Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection,"A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection",COMPLETED,,PHASE2,196,ACTUAL,MicuRx,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 03:33:16,2024-10-14 03:33:16,INDUSTRY,,,,,,,MicuRx,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders"
NCT03748992,,2018-11-19,2021-03-25,,2021-05-17,2018-11-19,2018-11-21,ACTUAL,2021-05-17,2021-05-18,ACTUAL,,,,2021-05-17,2021-05-18,ACTUAL,2019-01-28,ACTUAL,2019-01-28,2021-05,2021-05-31,2020-03-26,ACTUAL,2020-03-26,2020-03-26,ACTUAL,2020-03-26,,INTERVENTIONAL,,,A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection,A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection,COMPLETED,,PHASE2,10,ACTUAL,Medical University of South Carolina,,1,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 17:48:39,2024-10-13 17:48:39,OTHER,,,,,,,Cystic Fibrosis Foundation|Medical University of South Carolina|Oregon Health and Science University,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03760458,,2018-11-29,2022-12-09,,2023-05-30,2018-11-29,2018-11-30,ACTUAL,2023-01-18,2023-02-13,ACTUAL,,,,2023-05-30,2023-06-27,ACTUAL,2020-09-09,ACTUAL,2020-09-09,2023-05,2023-05-31,2022-05-31,ACTUAL,2022-05-31,2021-12-14,ACTUAL,2021-12-14,,INTERVENTIONAL,,All enrolled participants,"The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age","Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age",COMPLETED,,PHASE1/PHASE2,57,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.,"* With whom?

  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
* For what types of analyses?

  * To achieve aims in the proposal approved by the IMPAACT Network.
* By what mechanism will data be made available?

  * Researchers may submit a request for access to data using the IMPAACT ""Data Request"" form at: https://www.impaactnetwork.org/studies/submit-research-proposal. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-14 16:32:17,2024-10-14 16:32:17,NIH,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Mental Health (NIMH)|ViiV Healthcare,Botswana|South Africa|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03784079,,2018-12-19,2021-01-27,,2021-01-27,2018-12-19,2018-12-21,ACTUAL,2021-01-27,2021-02-16,ACTUAL,,,,2021-01-27,2021-02-16,ACTUAL,2019-01-31,ACTUAL,2019-01-31,2021-01,2021-01-31,2020-02-06,ACTUAL,2020-02-06,2020-02-06,ACTUAL,2020-02-06,,INTERVENTIONAL,,,A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults,"A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatment-Naïve Adults",COMPLETED,,PHASE2,34,ACTUAL,ViiV Healthcare,,7,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 20:07:31,2024-10-13 20:07:31,INDUSTRY,,,,,,,ViiV Healthcare,France|Germany|Italy|South Africa|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03788434,,2018-12-19,2022-08-29,,2023-06-29,2018-12-21,2018-12-27,ACTUAL,2023-06-29,2023-07-03,ACTUAL,,,,2023-06-29,2023-07-03,ACTUAL,2019-02-08,ACTUAL,2019-02-08,2023-06,2023-06-30,2021-09-15,ACTUAL,2021-09-15,2021-06-02,ACTUAL,2021-06-02,,INTERVENTIONAL,CONSORTIUM,,Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection,CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection,COMPLETED,,PHASE2,79,ACTUAL,"Vedanta Biosciences, Inc.",,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:34:55,2024-10-14 15:34:55,INDUSTRY,,,,,,,"Vedanta Biosciences, Inc.",Canada|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03788434,,2018-12-19,2022-08-29,,2023-06-29,2018-12-21,2018-12-27,ACTUAL,2023-06-29,2023-07-03,ACTUAL,,,,2023-06-29,2023-07-03,ACTUAL,2019-02-08,ACTUAL,2019-02-08,2023-06,2023-06-30,2021-09-15,ACTUAL,2021-09-15,2021-06-02,ACTUAL,2021-06-02,,INTERVENTIONAL,CONSORTIUM,,Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection,CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection,COMPLETED,,PHASE2,79,ACTUAL,"Vedanta Biosciences, Inc.",,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:34:55,2024-10-14 15:34:55,INDUSTRY,,,,,,,"Vedanta Biosciences, Inc.",Canada|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03788434,,2018-12-19,2022-08-29,,2023-06-29,2018-12-21,2018-12-27,ACTUAL,2023-06-29,2023-07-03,ACTUAL,,,,2023-06-29,2023-07-03,ACTUAL,2019-02-08,ACTUAL,2019-02-08,2023-06,2023-06-30,2021-09-15,ACTUAL,2021-09-15,2021-06-02,ACTUAL,2021-06-02,,INTERVENTIONAL,CONSORTIUM,,Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection,CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection,COMPLETED,,PHASE2,79,ACTUAL,"Vedanta Biosciences, Inc.",,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:34:55,2024-10-14 15:34:55,INDUSTRY,,,,,,,"Vedanta Biosciences, Inc.",Canada|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03788434,,2018-12-19,2022-08-29,,2023-06-29,2018-12-21,2018-12-27,ACTUAL,2023-06-29,2023-07-03,ACTUAL,,,,2023-06-29,2023-07-03,ACTUAL,2019-02-08,ACTUAL,2019-02-08,2023-06,2023-06-30,2021-09-15,ACTUAL,2021-09-15,2021-06-02,ACTUAL,2021-06-02,,INTERVENTIONAL,CONSORTIUM,,Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection,CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection,COMPLETED,,PHASE2,79,ACTUAL,"Vedanta Biosciences, Inc.",,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:34:55,2024-10-14 15:34:55,INDUSTRY,,,,,,,"Vedanta Biosciences, Inc.",Canada|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03788967,,2018-12-22,2022-05-13,2021-05-07,2022-06-27,2018-12-26,2018-12-28,ACTUAL,2022-06-27,2022-07-25,ACTUAL,2022-06-27,2022-07-25,ACTUAL,2022-06-27,2022-07-25,ACTUAL,2019-06-03,ACTUAL,2019-06-03,2022-06,2022-06-30,2020-05-27,ACTUAL,2020-05-27,2020-05-20,ACTUAL,2020-05-20,,INTERVENTIONAL,ADAPT-PO,Safety population included all randomized participants who received any amount of study drug.,"Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",COMPLETED,,PHASE3,1372,ACTUAL,Spero Therapeutics,,2,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 01:42:37,2024-10-14 01:42:37,INDUSTRY,,,,,,,Spero Therapeutics,"Bulgaria|Czechia|Estonia|Georgia|Hungary|Latvia|Moldova, Republic of|Poland|Romania|Russian Federation|Serbia|Slovakia|South Africa|Ukraine|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03797014,,2019-01-04,2023-06-05,,2023-10-31,2019-01-07,2019-01-08,ACTUAL,2023-07-17,2023-07-18,ACTUAL,,,,2023-10-31,2023-11-03,ACTUAL,2019-04-30,ACTUAL,2019-04-30,2023-10,2023-10-31,2023-05-05,ACTUAL,2023-05-05,2022-11-22,ACTUAL,2022-11-22,,INTERVENTIONAL,BEST-HBV,,B/F/TAF Switch Study for HIV-HBV Coinfection,"Efficacy, Safety, and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-HBV Coinfection",COMPLETED,,PHASE4,28,ACTUAL,"University of Maryland, Baltimore",This study did not achieve its enrollment target of 60 and was adversely affected by COVID-19 pandemic travel and research restrictions particularly during April 2020 to August 2020.,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,Individual participant data is available upon reasonable request from the investigator.,2024-10-13 03:37:02,2024-10-13 03:37:02,OTHER,,,,,,,"Gilead Sciences|University of Maryland, Baltimore",United States,Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders|Vascular disorders
NCT03803605,,2019-01-10,2021-11-04,,2021-11-04,2019-01-10,2019-01-14,ACTUAL,2021-11-04,2021-12-02,ACTUAL,,,,2021-11-04,2021-12-02,ACTUAL,2019-02-12,ACTUAL,2019-02-12,2021-07,2021-07-31,2021-01-28,ACTUAL,2021-01-28,2021-01-28,ACTUAL,2021-01-28,,INTERVENTIONAL,,,Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons,"IGHID 11802 - Combination Therapy With the Novel Clearance Modality (VRC07-523LS) and the Latency Reversal Agent (Vorinostat) to Reduce the Frequency of Latent, Resting CD4+ T Cell Infection (The VOR-07 Study)",COMPLETED,,PHASE1,15,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 12:58:07,2024-10-13 12:58:07,OTHER,,,,,,,"National Institute of Allergy and Infectious Diseases (NIAID)|University of North Carolina, Chapel Hill",United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT03807245,,2019-01-09,2020-11-30,,2021-01-30,2019-01-15,2019-01-16,ACTUAL,2020-11-30,2020-12-24,ACTUAL,,,,2021-01-30,2021-02-02,ACTUAL,2019-01-09,ACTUAL,2019-01-09,2020-11,2020-11-30,2020-05-07,ACTUAL,2020-05-07,2019-10-14,ACTUAL,2019-10-14,,INTERVENTIONAL,MVX0002,,Group B Streptococcus Vaccine in Healthy Females,"A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Group B Streptococcus Vaccine (GBS-NN/NN2 With Alhydrogel®) in Healthy Female Subjects Aged 18 to 40",COMPLETED,,PHASE1,60,ACTUAL,Minervax ApS,,4,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-14 01:42:37,2024-10-14 01:42:37,OTHER,,,,,,,Minervax ApS|Simbec Research,United Kingdom,"Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT03807843,,2019-01-15,2022-04-20,,2022-09-06,2019-01-15,2019-01-17,ACTUAL,2022-04-20,2022-05-16,ACTUAL,,,,2022-09-06,2022-09-08,ACTUAL,2019-07-16,ACTUAL,2019-07-16,2022-09,2022-09-30,2021-05-13,ACTUAL,2021-05-13,2021-05-13,ACTUAL,2021-05-13,,INTERVENTIONAL,,,Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006),Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Adults,COMPLETED,,PHASE2,41,ACTUAL,Themis Bioscience GmbH,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 19:53:14,2024-10-14 19:53:14,INDUSTRY,,,,,,,Themis Bioscience GmbH|Walter Reed Army Institute of Research (WRAIR),Puerto Rico,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03814590,,2019-01-11,2022-02-22,2020-12-11,2022-08-04,2019-01-18,2019-01-24,ACTUAL,2022-02-22,2022-03-23,ACTUAL,2020-12-15,2020-12-21,ACTUAL,2022-08-04,2022-08-05,ACTUAL,2019-01-21,ACTUAL,2019-01-21,2022-07,2022-07-31,2020-11-30,ACTUAL,2020-11-30,2019-12-12,ACTUAL,2019-12-12,,INTERVENTIONAL,,,"A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults","Phase I/II, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Subjects Aged 18-40 or 60-80 Years",COMPLETED,,PHASE1/PHASE2,1053,ACTUAL,GlaxoSmithKline,,14,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 00:53:47,2024-10-14 00:53:47,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03814720,,2019-01-23,2022-04-04,,2022-04-04,2019-01-23,2019-01-24,ACTUAL,2022-04-04,2022-04-29,ACTUAL,,,,2022-04-04,2022-04-29,ACTUAL,2019-04-01,ACTUAL,2019-04-01,2022-04,2022-04-30,2021-04-06,ACTUAL,2021-04-06,2021-04-06,ACTUAL,2021-04-06,,INTERVENTIONAL,,Population includes all enrolled participants.,"Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults","VRC 321: A Phase I Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability, and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine, VRCFLUNPF099-00-VP, in Healthy Adults",COMPLETED,,PHASE1,52,ACTUAL,National Institutes of Health Clinical Center (CC),"All 52 participants received at least one study product administration. Groups 1 and 2A completed the product administration schedule per protocol. While most participants in Groups 2B-2D completed the second product administration per protocol, one participant was not able to receive the second dose due to moving out of the area and 11 participants were not able to receive their second dose because of visit interruptions due to the COVID-19 pandemic.",5,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 16:06:18,2024-10-14 16:06:18,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03816696,,2019-01-22,2020-03-04,,2020-03-04,2019-01-22,2019-01-25,ACTUAL,2020-03-04,2020-03-19,ACTUAL,,,,2020-03-04,2020-03-19,ACTUAL,2019-01-23,ACTUAL,2019-01-23,2020-02,2020-02-29,2019-04-10,ACTUAL,2019-04-10,2019-03-30,ACTUAL,2019-03-30,,INTERVENTIONAL,,,Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG),An Open-Label Two-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Dolutegravir in Healthy Subjects,COMPLETED,,PHASE1,16,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-15 03:36:43,2024-10-15 03:36:43,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Ear and labyrinth disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders"
NCT03819114,,2019-01-25,2021-11-02,,2021-12-22,2019-01-25,2019-01-28,ACTUAL,2021-11-02,2021-11-30,ACTUAL,,,,2021-12-22,2021-12-27,ACTUAL,2019-05-06,ACTUAL,2019-05-06,2021-12,2021-12-31,2020-11-30,ACTUAL,2020-11-30,2020-11-02,ACTUAL,2020-11-02,,INTERVENTIONAL,,Participants who took assigned dose of LNG and prescribed doses of background drugs (ART or TB treatment) and who had LNG PK concentrations available over the sampling time frame.,Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy,"An Open-Label, Phase II Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy",COMPLETED,,PHASE2,122,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH,"* With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
* For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
* By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-13 00:03:31,2024-10-13 00:03:31,NETWORK,,,,,,,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Botswana|Brazil|Kenya|Malawi|South Africa|Thailand|United States,Gastrointestinal disorders|Nervous system disorders|Reproductive system and breast disorders
NCT03820323,,2019-01-23,2022-10-11,2021-12-17,2024-04-08,2019-01-25,2019-01-29,ACTUAL,2022-12-05,2022-12-27,ACTUAL,2021-12-27,2021-12-28,ACTUAL,2024-04-08,2024-04-10,ACTUAL,2019-03-07,ACTUAL,2019-03-07,2024-04,2024-04-30,2020-12-31,ACTUAL,2020-12-31,2020-12-31,ACTUAL,2020-12-31,,INTERVENTIONAL,Opt4Kids,,Optimizing Viral Load Suppression in Kenyan Children on Antiretroviral Therapy,Optimizing Viral Load Suppression in Kenyan Children on Antiretroviral Therapy,COMPLETED,,NA,704,ACTUAL,University of Alabama at Birmingham,"First, it is possible we had sample biased towards higher levels of viral suppression (VS). Second, though our package of POC VL testing, DRM testing, and clinical decision support was only offered to intervention group, the same providers cared for participants in intervention and control groups. Third, VS was assessed on different schedules for intervention and control, the intervention group participants had a greater number of opportunities to act on their test results and detect viremia.",2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,After primary outcomes results are published.,Contact PIs of the study and obtain institutional ethic review approvals.,,YES,De-identified individual participant data for all outcome measures will be made available after study completion,2024-10-13 10:15:15,2024-10-13 10:15:15,OTHER,,,,,,,"Kenya Medical Research Institute|National Institute of Mental Health (NIMH)|University of Alabama at Birmingham|University of Colorado, Denver|University of Washington",Kenya,Gastrointestinal disorders
NCT03830333,,2019-02-04,2021-09-24,,2023-01-13,2019-02-04,2019-02-05,ACTUAL,2021-09-24,2021-10-22,ACTUAL,,,,2023-01-13,2023-01-17,ACTUAL,2019-03-20,ACTUAL,2019-03-20,2023-01,2023-01-31,2020-10-14,ACTUAL,2020-10-14,2020-10-14,ACTUAL,2020-10-14,,INTERVENTIONAL,7625ACNPhase3,"The intent to treat (ITT) population consisted of all randomized participants. Participants in the ITT population were analyzed based on the treatment they were randomized to, irrespective of what they actually received.",Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015),"A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infection",COMPLETED,,PHASE3,268,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 13:44:10,2024-10-14 13:44:10,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,China,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03834038,,2019-02-06,2022-09-15,,2024-05-30,2019-02-06,2019-02-07,ACTUAL,2024-05-30,2024-09-23,ACTUAL,,,,2024-05-30,2024-09-23,ACTUAL,2015-10-01,ACTUAL,2015-10-01,2024-05,2024-05-31,2020-03-17,ACTUAL,2020-03-17,2018-03-01,ACTUAL,2018-03-01,,INTERVENTIONAL,,,Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridioides Difficile Infection,"Prospective, Open-label Trial to Evaluate Efficacy of Lyophilized Fecal Microbiota Transplantation for Treatment of Recurrent C. Difficile Infection",COMPLETED,,NA,158,ACTUAL,Vancouver Island Health Authority,One of the significant limitations of the study was the open-labelled nature of the study and the introduction of inherent bias but attempts were made to reduce the outcome bias by tracking the consistency and the number of bowel movements during the 13-week follow-up period; the stool was tested for CD toxin/gene when the participants experienced symptoms consistent with recurrent CDI.,1,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 18:01:21,2024-10-13 18:01:21,OTHER,,,,,,,Vancouver Island Health Authority,Canada,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT03836729,,2019-02-07,2020-03-17,,2020-04-07,2019-02-07,2019-02-11,ACTUAL,2020-03-17,2020-04-02,ACTUAL,,,,2020-04-07,2020-04-21,ACTUAL,2019-02-11,ACTUAL,2019-02-11,2020-04,2020-04-30,2019-04-30,ACTUAL,2019-04-30,2019-03-30,ACTUAL,2019-03-30,,INTERVENTIONAL,,,Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine,An Open-Label One-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Subjects,COMPLETED,,PHASE1,16,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 06:29:23,2024-10-14 06:29:23,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|Immune system disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03840135,,2018-11-26,2020-06-05,,2020-07-14,2019-02-12,2019-02-15,ACTUAL,2020-06-05,2020-06-25,ACTUAL,,,,2020-07-14,2020-07-29,ACTUAL,2018-11-07,ACTUAL,2018-11-07,2020-07,2020-07-31,2019-12-10,ACTUAL,2019-12-10,2019-02-26,ACTUAL,2019-02-26,,INTERVENTIONAL,,"172 patients were randomized, 8 people dropped out during the trial (due to protocol violations and withdrawal of informed consent). 164 patients completed the study, data from 155 children were accepted for the final analysis (9 patients were excluded from the analysis due to protocol violations).","Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI","A Multicenter Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged From 1 to 12 Years With ARI (Acute Respiratory Infection)",COMPLETED,,PHASE3,172,ACTUAL,NPO Petrovax,,2,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 06:29:23,2024-10-14 06:29:23,INDUSTRY,,,,,,,NPO Petrovax,Russian Federation,"Ear and labyrinth disorders|Gastrointestinal disorders|Investigations|Respiratory, thoracic and mediastinal disorders"
NCT03840148,,2019-02-06,2024-03-23,2022-12-08,2024-05-01,2019-02-12,2019-02-15,ACTUAL,2024-05-01,2024-05-29,ACTUAL,,2024-05-29,ACTUAL,2024-05-01,2024-05-29,ACTUAL,2019-08-07,ACTUAL,2019-08-07,2024-03,2024-03-31,2021-12-14,ACTUAL,2021-12-14,2021-12-14,ACTUAL,2021-12-14,,INTERVENTIONAL,CERTAIN-1,Intent-to-treat (ITT) population: all randomized patients,Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections,"A Phase 3, Randomized, Double-blind, Active Controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis",COMPLETED,,PHASE3,661,ACTUAL,"Venatorx Pharmaceuticals, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 16:39:05,2024-10-14 16:39:05,INDUSTRY,,,,,,,"Venatorx Pharmaceuticals, Inc.",Argentina|Brazil|Bulgaria|China|Croatia|Czechia|Hungary|Latvia|Mexico|Peru|Romania|Russian Federation|Serbia|Turkey|Ukraine|United States,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03840174,,2019-02-12,2021-10-15,,2023-05-04,2019-02-12,2019-02-15,ACTUAL,2021-10-15,2021-11-15,ACTUAL,,,,2023-05-04,2023-05-06,ACTUAL,2019-03-08,ACTUAL,2019-03-08,2023-05,2023-05-31,2019-11-07,ACTUAL,2019-11-07,2019-11-07,ACTUAL,2019-11-07,,INTERVENTIONAL,,,Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003),"A Phase I Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of V160 (Human Cytomegalovirus Vaccine) in Healthy Japanese Men",COMPLETED,,PHASE1,18,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 03:17:56,2024-10-13 03:17:56,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Gastrointestinal disorders|General disorders|Immune system disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT03840811,,2019-02-07,2020-11-12,,2021-02-26,2019-02-12,2019-02-15,ACTUAL,2021-02-26,2021-03-23,ACTUAL,,,,2021-02-26,2021-03-23,ACTUAL,2017-04-23,ACTUAL,2017-04-23,2020-09-16,2020-09-16,2019-11-25,ACTUAL,2019-11-25,2019-11-25,ACTUAL,2019-11-25,,INTERVENTIONAL,,The baseline analysis population includes all enrolled participants.,Experimental Human Infection With Neisseria Gonorrhoeae,Experimental Human Infection With Isogenic Mutants of Neisseria Gonorrhoeae,COMPLETED,,PHASE1,27,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 06:53:38,2024-10-14 06:53:38,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Investigations|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders
NCT03844386,,2019-02-14,2022-07-12,,2022-07-12,2019-02-14,2019-02-18,ACTUAL,2022-07-12,2022-08-09,ACTUAL,,,,2022-07-12,2022-08-09,ACTUAL,2019-04-22,ACTUAL,2019-04-22,2022-07,2022-07-31,2022-04-04,ACTUAL,2022-04-04,2021-11-11,ACTUAL,2021-11-11,,INTERVENTIONAL,M&M,,Study to Assess Safety and Ability to Induce Immune Responses of HIV-1 Vaccines M3 and M4 Given Alone or in Combination in HIV-infected Adults,A Phase I Pilot Study to Evaluate the Safety and Immunogenicity of the HIV-1 Vaccines MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4) Given Alone or In Combination in HIV-1-Infected Adults Suppressed on Antiretroviral Therapy - The M&M Study,COMPLETED,,PHASE1,26,ACTUAL,"University of North Carolina, Chapel Hill",,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 12:46:59,2024-10-14 12:46:59,OTHER,,,,,,,"National Institute of Allergy and Infectious Diseases (NIAID)|University of North Carolina, Chapel Hill",United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT03848065,,2019-02-19,2022-12-09,,2024-05-28,2019-02-19,2019-02-20,ACTUAL,2022-12-09,2023-10-11,ACTUAL,,,,2024-05-28,2024-06-11,ACTUAL,2019-04-02,ACTUAL,2019-04-02,2024-05,2024-05-31,2020-06-24,ACTUAL,2020-06-24,2020-06-24,ACTUAL,2020-06-24,,INTERVENTIONAL,,,"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","A Phase I, Double-Blind, Randomized, Multicenter Trial of the Safety,Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants",COMPLETED,,PHASE1,133,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 02:46:59,2024-10-13 02:46:59,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03848325,,2019-02-13,2023-07-31,,2023-11-27,2019-02-18,2019-02-20,ACTUAL,2023-09-19,2023-10-12,ACTUAL,,,,2023-11-27,2023-11-29,ACTUAL,2020-11-09,ACTUAL,2020-11-09,2023-11,2023-11-30,2022-07-31,ACTUAL,2022-07-31,2022-07-31,ACTUAL,2022-07-31,,INTERVENTIONAL,SASH,,Poor Sleep and Inflammation in HIV-Infected Adults,Impact of Poor Sleep on Inflammation and the Adenosine Signaling Pathway in HIV Infection,COMPLETED,,NA,20,ACTUAL,University of Pittsburgh,,1,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-12 23:41:00,2024-10-12 23:41:00,OTHER,,,,,,,"National Heart, Lung, and Blood Institute (NHLBI)|University of Pittsburgh",United States,Skin and subcutaneous tissue disorders
NCT03851588,,2019-02-15,2022-11-07,,2024-06-25,2019-02-21,2019-02-22,ACTUAL,2022-11-07,2023-09-18,ACTUAL,,,,2024-06-25,2024-07-18,ACTUAL,2019-12-19,ACTUAL,2019-12-19,2024-06,2024-06-30,2022-06-28,ACTUAL,2022-06-28,2022-01-20,ACTUAL,2022-01-20,,INTERVENTIONAL,RADIANT-TB,,Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis,Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis: a Phase 2 Non-comparative Randomised Controlled Trial,COMPLETED,,PHASE2,108,ACTUAL,University of Cape Town,,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,FALSE,,,From the time the final results are published,"Data will be shared with other organizations or individuals for further research upon a reasonable request to the University of Cape Town PI, provided that certain conditions are met (including but not limited to the ethical standards upheld by HREC that approved the initial study.",,YES,"Data will be shared with other organizations or individuals for further research upon a reasonable request to the University of Cape Town PI, provided that certain conditions are met (including but not limited to the ethical standards upheld by HREC that approved the initial study.",2024-10-14 11:16:14,2024-10-14 11:16:14,OTHER,,,,,,,"Medecins Sans Frontieres, Netherlands|University of Cape Town|Wellcome Trust",South Africa,"Gastrointestinal disorders|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03856996,,2019-02-14,2022-03-17,,2024-07-11,2019-02-26,2019-02-27,ACTUAL,2022-06-15,2022-07-11,ACTUAL,,,,2024-07-11,2024-07-12,ACTUAL,2019-05-23,ACTUAL,2019-05-23,2024-04,2024-04-30,2021-09-07,ACTUAL,2021-09-07,2021-03-16,ACTUAL,2021-03-16,,INTERVENTIONAL,,,"A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells","A Phase 1 Double-blind, Randomized, Controlled Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells",COMPLETED,,PHASE1,30,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 10:47:40,2024-10-13 10:47:40,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03859739,,2019-02-28,2021-05-05,,2021-05-05,2019-02-28,2019-03-01,ACTUAL,2021-05-05,2021-05-28,ACTUAL,,,,2021-05-05,2021-05-28,ACTUAL,2019-04-26,ACTUAL,2019-04-26,2021-05,2021-05-31,2020-05-29,ACTUAL,2020-05-29,2020-05-29,ACTUAL,2020-05-29,,INTERVENTIONAL,,,"Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)","A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants",COMPLETED,,PHASE1,21,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 00:24:31,2024-10-15 00:24:31,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany|Romania,"Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03862495,,2019-02-22,2024-07-10,,2024-08-29,2019-03-01,2019-03-05,ACTUAL,2024-08-29,2024-09-05,ACTUAL,,,,2024-08-29,2024-09-05,ACTUAL,2020-05-21,ACTUAL,2020-05-21,2023-02,2023-02-28,2024-03-03,ACTUAL,2024-03-03,2024-03-03,ACTUAL,2024-03-03,,INTERVENTIONAL,RCT,,Genital CT Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Pilot RCT,Genital Chlamydia Trachomatis Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Randomized Control Trial Pilot Study,COMPLETED,,NA,200,ACTUAL,"University of North Carolina, Chapel Hill",,2,,,FALSE,,,,FALSE,FALSE,TRUE,,,TRUE,,,From December 2020 to May 2023,"Investigator who proposes to use the data should have approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use agreement with UNC.",,YES,"Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2024-10-14 01:31:21,2024-10-14 01:31:21,OTHER,,,,,,,"Southern Medical University, China|University of North Carolina, Chapel Hill",China,"Pregnancy, puerperium and perinatal conditions"
NCT03873987,,2019-03-11,2021-03-18,,2021-03-18,2019-03-12,2019-03-14,ACTUAL,2021-03-18,2021-04-13,ACTUAL,,,,2021-03-18,2021-04-13,ACTUAL,2019-07-16,ACTUAL,2019-07-16,2021-03,2021-03-31,2019-09-04,ACTUAL,2019-09-04,2019-08-27,ACTUAL,2019-08-27,,INTERVENTIONAL,,,Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients,"A Randomized, Open-label, PK and Safety Study to Evaluate the Relative Exposure and Safety of a New Formulation vs the Approved Formulation of a Single 1200 mg IV Dose of ORBACTIV® (Oritavancin) in Subjects Being Treated for ABSSSI",COMPLETED,,PHASE1,102,ACTUAL,"Melinta Therapeutics, Inc.",,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 06:20:43,2024-10-13 06:20:43,INDUSTRY,,,,,,,"Melinta Therapeutics, Inc.",United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders"
NCT03879603,,2019-03-08,2021-02-23,,2021-03-23,2019-03-14,2019-03-19,ACTUAL,2021-02-23,2021-03-19,ACTUAL,,,,2021-03-23,2021-03-24,ACTUAL,2019-04-02,ACTUAL,2019-04-02,2021-03,2021-03-31,2020-02-26,ACTUAL,2020-02-26,2020-02-26,ACTUAL,2020-02-26,,INTERVENTIONAL,,Population includes all enrolled subjects.,VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults,"A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Virus-Like Particle (VLP) Encephalitis Vaccine, VRC-WEVVLP073-00-VP, in Healthy Adults",COMPLETED,,PHASE1,30,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,6,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 10:42:25,2024-10-13 10:42:25,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03883906,,2019-03-19,2021-10-12,,2022-11-20,2019-03-19,2019-03-21,ACTUAL,2022-11-20,2022-12-13,ACTUAL,,,,2022-11-20,2022-12-13,ACTUAL,2019-03-16,ACTUAL,2019-03-16,2022-11,2022-11-30,2021-10-01,ACTUAL,2021-10-01,2020-10-31,ACTUAL,2020-10-31,,INTERVENTIONAL,,,Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant,Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant,COMPLETED,,PHASE2,30,ACTUAL,"Children's Hospital Medical Center, Cincinnati",,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 08:17:12,2024-10-14 08:17:12,OTHER,,,,,,,"Children's Hospital Medical Center, Cincinnati|Hoxworth Blood Center",United States,Gastrointestinal disorders|Skin and subcutaneous tissue disorders
NCT03885934,,2019-03-20,2021-08-26,,2023-01-12,2019-03-20,2019-03-22,ACTUAL,2021-08-26,2021-09-23,ACTUAL,,,,2023-01-12,2023-01-13,ACTUAL,2019-06-25,ACTUAL,2019-06-25,2023-01,2023-01-31,2020-12-09,ACTUAL,2020-12-09,2020-12-09,ACTUAL,2020-12-09,,INTERVENTIONAL,PNEU-PLAN,,Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024),"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Catch-up Vaccination Regimens of V114 in Healthy Infants, Children, and Adolescents (PNEU-PLAN)",COMPLETED,,PHASE3,606,ACTUAL,Merck Sharp & Dohme LLC,,6,,,FALSE,,,,,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 10:09:42,2024-10-14 10:09:42,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Finland|Malaysia|Poland|Russian Federation|Thailand,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders"
NCT03893448,,2019-03-26,2022-01-11,,2023-07-20,2019-03-26,2019-03-28,ACTUAL,2022-02-25,2022-03-25,ACTUAL,,,,2023-07-20,2023-07-28,ACTUAL,2019-06-19,ACTUAL,2019-06-19,2023-07,2023-07-31,2021-05-24,ACTUAL,2021-05-24,2021-05-24,ACTUAL,2021-05-24,,INTERVENTIONAL,PNEU-PED,,"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants (PNEU-PED)",COMPLETED,,PHASE3,1720,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 07:48:16,2024-10-13 07:48:16,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Puerto Rico|Thailand|Turkey|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03902418,,2019-01-10,2023-12-22,,2024-03-20,2019-04-01,2019-04-04,ACTUAL,2024-02-20,2024-03-19,ACTUAL,,,,2024-03-20,2024-04-09,ACTUAL,2019-08-01,ACTUAL,2019-08-01,2024-03,2024-03-31,2024-06-01,ESTIMATED,2024-06-01,2023-02-09,ACTUAL,2023-02-09,,OBSERVATIONAL,PrEP-PP,Pregnant women in PrEP-PP study,Evaluation of Pre-Exposure Prophylaxis (PrEP) in Pregnant and Breastfeeding Women,"Evaluation of Pre-Exposure Prophylaxis (PrEP) Initiation, Retention, and Adherence in Pregnant and Breastfeeding Women",ACTIVE_NOT_RECRUITING,,,1195,ACTUAL,"University of California, Los Angeles","We originally indicated reporting ""Participants Missing Pre-natal Visit"" as a Secondary Outcome, however are unable to report as the data is unavailable.",,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,SAMPLES_WITHOUT_DNA,Serum,,,,,,2024-10-13 12:14:37,2024-10-13 12:14:37,OTHER,,,,,,FALSE,"University of California, Los Angeles|University of Cape Town",South Africa,"Infections and infestations|Pregnancy, puerperium and perinatal conditions"
NCT03910673,,2019-03-28,2021-12-02,,2023-10-05,2019-04-09,2019-04-10,ACTUAL,2022-01-13,2022-01-19,ACTUAL,,,,2023-10-05,2023-10-23,ACTUAL,2019-06-27,ACTUAL,2019-06-27,2020-03-13,2020-03-13,2020-12-17,ACTUAL,2020-12-17,2020-12-17,ACTUAL,2020-12-17,,INTERVENTIONAL,,The safety population includes all participants who received any amount of ZTI-01 (started the first infusion).,Intravenous Fosfomycin Pharmacokinetics Study,A Phase 1 Safety and Intrapulmonary Pharmacokinetics Study of ZTI-01 (Intravenous Fosfomycin Disodium) in Healthy Adult Subjects,COMPLETED,,PHASE1,39,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,5,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 13:55:50,2024-10-14 13:55:50,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03915470,,2019-04-01,2022-03-24,,2023-10-09,2019-04-15,2019-04-16,ACTUAL,2022-05-06,2022-06-01,ACTUAL,,,,2023-10-09,2023-10-16,ACTUAL,2019-08-29,ACTUAL,2019-08-29,2022-05,2022-05-31,2021-03-29,ACTUAL,2021-03-29,2021-01-04,ACTUAL,2021-01-04,,INTERVENTIONAL,,Safety Population: all patients who received at least 1 dose of study drug,Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection,A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections,COMPLETED,,PHASE2,124,ACTUAL,Destiny Pharma Plc,Study recruitment was affected by the impact of the COVID-19 pandemic as hospitals and staff were reassigned to provide care needed to treat patients with COVID-19.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-15 01:54:09,2024-10-15 01:54:09,INDUSTRY,,,,,,,Destiny Pharma Plc,Georgia|Serbia|United States,"Blood and lymphatic system disorders|Cardiac disorders|Infections and infestations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03915470,,2019-04-01,2022-03-24,,2023-10-09,2019-04-15,2019-04-16,ACTUAL,2022-05-06,2022-06-01,ACTUAL,,,,2023-10-09,2023-10-16,ACTUAL,2019-08-29,ACTUAL,2019-08-29,2022-05,2022-05-31,2021-03-29,ACTUAL,2021-03-29,2021-01-04,ACTUAL,2021-01-04,,INTERVENTIONAL,,Safety Population: all patients who received at least 1 dose of study drug,Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection,A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections,COMPLETED,,PHASE2,124,ACTUAL,Destiny Pharma Plc,Study recruitment was affected by the impact of the COVID-19 pandemic as hospitals and staff were reassigned to provide care needed to treat patients with COVID-19.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-15 01:54:09,2024-10-15 01:54:09,INDUSTRY,,,,,,,Destiny Pharma Plc,Georgia|Serbia|United States,"Blood and lymphatic system disorders|Cardiac disorders|Infections and infestations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT03921424,,2019-04-17,2021-11-10,,2023-05-11,2019-04-17,2019-04-19,ACTUAL,2021-11-10,2021-12-09,ACTUAL,,,,2023-05-11,2023-06-07,ACTUAL,2019-11-05,ACTUAL,2019-11-05,2023-05,2023-05-31,2021-05-03,ACTUAL,2021-05-03,2021-05-03,ACTUAL,2021-05-03,,INTERVENTIONAL,PNEU-WAY PED,,Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED),"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Children Infected With Human Immunodeficiency Virus (HIV) (PNEU-WAY PED)",COMPLETED,,PHASE3,407,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 20:19:01,2024-10-13 20:19:01,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,South Africa|Thailand|Ukraine,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders"
NCT03921723,,2019-04-17,2020-07-09,,2020-07-09,2019-04-17,2019-04-19,ACTUAL,2020-07-09,2020-07-31,ACTUAL,,,,2020-07-09,2020-07-31,ACTUAL,2019-05-07,ACTUAL,2019-05-07,2020-07,2020-07-31,2019-07-25,ACTUAL,2019-07-25,2019-07-25,ACTUAL,2019-07-25,,INTERVENTIONAL,,,Dolutegravir Pediatric Liquid Formulation Study,"Non-randomized, Sequential, Fixed-sequence Evaluation of Prototype Dolutegravir Liquid Formulations Versus 5mg Dolutegravir Dispersible Tablets Following Single-dose Fasted-state Administrations to Normal Healthy Adult Participants",COMPLETED,,PHASE1,22,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 17:26:21,2024-10-13 17:26:21,INDUSTRY,,,,,,,ViiV Healthcare,United Kingdom,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03923426,,2019-04-18,2023-03-03,,2024-01-08,2019-04-18,2019-04-22,ACTUAL,2023-12-14,2023-12-18,ACTUAL,,,,2024-01-08,2024-06-21,ACTUAL,2018-11-27,ACTUAL,2018-11-27,2024-01,2024-01-31,2022-03-28,ACTUAL,2022-03-28,2022-03-28,ACTUAL,2022-03-28,,OBSERVATIONAL,EZTEAM,The full analysis set (FAS) included all those enrolled participants who met the study eligibility criteria. Baseline characteristics were analyzed and reported for FAS72+ which included FAS participants with at least 72 hours of exposure to ceftazidime-avibactam and FAS72- which included FAS participants with less than (\<) 72 hours of exposure to ceftazidime-avibactam.,Real-World Observational Study Of Zavicefta to Characterize Use Patterns,"REAL-WORLD OBSERVATIONAL STUDY OF ZAVICEFTA (REGISTERED) (CEFTAZIDIME-AVIBACTAM) TO CHARACTERIZE USE PATTERNS, EFFECTIVENESS AND SAFETY - EZTEAM STUDY",COMPLETED,,,572,ACTUAL,Pfizer,,,,,FALSE,,,,,,,,,,,,,,,NO,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 20:30:57,2024-10-13 20:30:57,INDUSTRY,,,,,,FALSE,Pfizer,Argentina|Austria|Brazil|Colombia|France|Germany|Greece|Italy|Russian Federation|Spain|United Kingdom,Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT03926208,,2019-04-22,2020-11-24,,2021-01-25,2019-04-23,2019-04-24,ACTUAL,2021-01-25,2021-02-12,ACTUAL,,,,2021-01-25,2021-02-12,ACTUAL,2019-05-24,ACTUAL,2019-05-24,2021-01,2021-01-31,2020-01-01,ACTUAL,2020-01-01,2019-12-10,ACTUAL,2019-12-10,,INTERVENTIONAL,,,Dilute Betadine Soak and Scrub for Foot and Ankle Surgery,Randomized Trial of Dilute Betadine Soak and Scrub for Foot and Ankle Surgery,COMPLETED,,NA,242,ACTUAL,Rush University Medical Center,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,IPD will not be made available to other researchers.,2024-10-15 03:36:43,2024-10-15 03:36:43,OTHER,,,,,,,Rush University Medical Center,United States,Musculoskeletal and connective tissue disorders
NCT03928821,,2019-04-23,2022-03-14,,2022-06-15,2019-04-23,2019-04-26,ACTUAL,2022-06-15,2022-07-11,ACTUAL,,,,2022-06-15,2022-07-11,ACTUAL,2019-07-17,ACTUAL,2019-07-17,2022-06,2022-06-30,2021-03-25,ACTUAL,2021-03-25,2021-03-25,ACTUAL,2021-03-25,,INTERVENTIONAL,,,"Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants","A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants",COMPLETED,,PHASE1,27,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 14:44:18,2024-10-13 14:44:18,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03930615,,2019-04-26,2022-10-05,,2024-07-29,2019-04-26,2019-04-29,ACTUAL,2022-10-05,2022-11-01,ACTUAL,,,,2024-07-29,2024-08-22,ACTUAL,2019-06-21,ACTUAL,2019-06-21,2024-07,2024-07-31,2022-03-16,ACTUAL,2022-03-16,2021-10-27,ACTUAL,2021-10-27,,INTERVENTIONAL,,Treated participants,Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040),"A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)",COMPLETED,,PHASE3,220,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 05:21:07,2024-10-14 05:21:07,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,France|Germany|Italy|Japan|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03931941,,2019-04-26,2024-07-12,,2024-07-12,2019-04-26,2019-04-30,ACTUAL,2024-07-12,2024-08-07,ACTUAL,,,,2024-07-12,2024-08-07,ACTUAL,2019-07-30,ACTUAL,2019-07-30,2023-04,2023-04-30,2023-07-21,ACTUAL,2023-07-21,2023-07-21,ACTUAL,2023-07-21,,INTERVENTIONAL,CD3-OLS,Safety Population,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS),A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile Infection,COMPLETED,,PHASE3,793,ACTUAL,Rebiotix Inc.,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-12 23:46:56,2024-10-12 23:46:56,INDUSTRY,,,,,,,Rebiotix Inc.,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT03931941,,2019-04-26,2024-07-12,,2024-07-12,2019-04-26,2019-04-30,ACTUAL,2024-07-12,2024-08-07,ACTUAL,,,,2024-07-12,2024-08-07,ACTUAL,2019-07-30,ACTUAL,2019-07-30,2023-04,2023-04-30,2023-07-21,ACTUAL,2023-07-21,2023-07-21,ACTUAL,2023-07-21,,INTERVENTIONAL,CD3-OLS,Safety Population,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS),A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile Infection,COMPLETED,,PHASE3,793,ACTUAL,Rebiotix Inc.,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-12 23:46:56,2024-10-12 23:46:56,INDUSTRY,,,,,,,Rebiotix Inc.,Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT03934541,,2019-04-29,2022-02-08,,2022-06-15,2019-04-29,2019-05-02,ACTUAL,2022-04-20,2022-05-12,ACTUAL,,,,2022-06-15,2022-07-06,ACTUAL,2019-08-26,ACTUAL,2019-08-26,2022-06,2022-06-30,2021-05-26,ACTUAL,2021-05-26,2021-02-05,ACTUAL,2021-02-05,,INTERVENTIONAL,,,"Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants","A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants",COMPLETED,,PHASE1,24,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 01:37:23,2024-10-14 01:37:23,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03935217,,2019-04-30,2021-10-27,,2023-10-02,2019-04-30,2019-05-02,ACTUAL,2023-10-02,2023-10-04,ACTUAL,,,,2023-10-02,2023-10-04,ACTUAL,2019-04-23,ACTUAL,2019-04-23,2023-09,2023-09-30,2020-03-25,ACTUAL,2020-03-25,2020-03-02,ACTUAL,2020-03-02,,INTERVENTIONAL,,Safety Population,A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis,"Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis",COMPLETED,,PHASE3,147,ACTUAL,Lupin Research Inc,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"After publication of the primary study results, the research team will prepare final research data files that may be shared with other investigators, upon request.","Requests for research data must be submitted to author CAM in writing, via a standard data request form, with a justification for how the data will be used. Author CAM and Lupin Pharmaceuticals will review all requests for research data obtained from this study. The mechanism by which the data will be made available to investigators will follow all NIH guidelines for data sharing as they evolve. At a minimum this would consist of a data use agreement that provides for commitments to use the data for research purposes only, secure the data with appropriate computer technology, obtain IRB approval, and destroy (or return) the data after analyses are complete.",,YES,All IPD that underlie results in a publication,2024-10-13 10:58:26,2024-10-13 10:58:26,INDUSTRY,,,,,,,Lupin Research Inc,United States,Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Reproductive system and breast disorders
NCT03940586,,2019-05-06,2023-11-29,,2024-07-30,2019-05-06,2019-05-07,ACTUAL,2024-01-05,2024-01-30,ACTUAL,,,,2024-07-30,2024-08-22,ACTUAL,2019-08-08,ACTUAL,2019-08-08,2024-07,2024-07-31,2023-08-25,ACTUAL,2023-08-25,2023-01-04,ACTUAL,2023-01-04,,INTERVENTIONAL,,Treated Participants,Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030),"A Phase 2b Open-label, Single-arm Study to Evaluate Pharmacokinetics, Efficacy, Safety and Tolerability of Letermovir in Pediatric Participants From Birth to Less Than 18 Years of Age at Risk of Developing CMV Infection and/or Disease Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)",COMPLETED,,PHASE2,65,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 05:57:38,2024-10-14 05:57:38,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Colombia|France|Germany|Israel|Japan|Mexico|Poland|Spain|Turkey|United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03945981,,2019-05-08,2021-03-26,,2021-09-20,2019-05-08,2019-05-10,ACTUAL,2021-04-27,2021-04-28,ACTUAL,,,,2021-09-20,2021-10-21,ACTUAL,2019-07-02,ACTUAL,2019-07-02,2021-09,2021-09-30,2020-10-20,ACTUAL,2020-10-20,2020-04-29,ACTUAL,2020-04-29,,INTERVENTIONAL,,,Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults,"A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen",COMPLETED,,PHASE3,131,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 07:13:49,2024-10-13 07:13:49,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03950622,,2019-05-13,2021-02-10,,2021-03-26,2019-05-13,2019-05-15,ACTUAL,2021-02-22,2021-03-18,ACTUAL,,,,2021-03-26,2021-04-26,ACTUAL,2019-06-13,ACTUAL,2019-06-13,2021-03,2021-03-31,2020-03-30,ACTUAL,2020-03-30,2020-03-30,ACTUAL,2020-03-30,,INTERVENTIONAL,PNEU-AGE,,Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE),"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-AGE)",COMPLETED,,PHASE3,1205,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 13:15:50,2024-10-13 13:15:50,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Canada|Japan|Spain|Taiwan|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT03950856,,2019-05-13,2021-03-16,,2021-03-16,2019-05-13,2019-05-15,ACTUAL,2021-03-16,2021-04-12,ACTUAL,,,,2021-03-16,2021-04-12,ACTUAL,2019-06-12,ACTUAL,2019-06-12,2021-03,2021-03-31,2020-04-03,ACTUAL,2020-04-03,2020-04-03,ACTUAL,2020-04-03,,INTERVENTIONAL,PNEU-TRUE,,Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020),"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older (PNEU-TRUE)",COMPLETED,,PHASE3,2340,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 21:45:37,2024-10-14 21:45:37,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Chile|Denmark|Finland|United Kingdom|United States,"Cardiac disorders|Eye disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT03954743,,2019-05-15,2021-05-24,,2022-02-25,2019-05-15,2019-05-17,ACTUAL,2021-05-24,2021-06-18,ACTUAL,,,,2022-02-25,2022-03-10,ACTUAL,2019-07-19,ACTUAL,2019-07-19,2022-02,2022-02-28,2020-11-30,ACTUAL,2020-11-30,2020-11-30,ACTUAL,2020-11-30,,INTERVENTIONAL,,,"Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks","A Phase III, Observer-blind, Randomized, Multi-country Study to Assess the Reactogenicity and Safety of the Porcine Circovirus (PCV) Free Liquid Formulation of GSK's Oral Live Attenuated Human Rotavirus (HRV) Vaccine as Compared to the Lyophilized Formulation of the GSK's HRV Vaccine, When Administered as a 2-dose Vaccination in Infants Starting at Age 6-12 Weeks",COMPLETED,,PHASE3,1351,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 09:37:59,2024-10-13 09:37:59,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|Hong Kong|Taiwan|Turkey|United States,"Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03959488,,2019-05-21,2023-08-16,2022-02-23,2023-09-20,2019-05-21,2019-05-22,ACTUAL,2023-09-20,2023-09-21,ACTUAL,,2023-09-21,ACTUAL,2023-09-20,2023-09-21,ACTUAL,2019-07-30,ACTUAL,2019-07-30,2023-09,2023-09-30,2023-01-20,ACTUAL,2023-01-20,2021-05-03,ACTUAL,2021-05-03,,INTERVENTIONAL,,,A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children,"A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)",COMPLETED,,PHASE2/PHASE3,925,ACTUAL,AstraZeneca,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,YES,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2024-10-14 17:34:55,2024-10-14 17:34:55,INDUSTRY,,,,,,,AstraZeneca,"Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|Colombia|Czechia|Estonia|Finland|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Mexico|New Zealand|Panama|Poland|Russian Federation|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT03960645,,2019-05-21,2023-02-14,,2024-06-04,2019-05-21,2019-05-23,ACTUAL,2023-12-13,2024-05-28,ACTUAL,,,,2024-06-04,2024-06-14,ACTUAL,2019-06-28,ACTUAL,2019-06-28,2023-12,2023-12-31,2022-08-18,ACTUAL,2022-08-18,2022-07-21,ACTUAL,2022-07-21,,INTERVENTIONAL,,B/F/TAF: Safety analysis set included all adult participants who took at least 1 dose of study drug (B/F/TAF). Neonates: Safety analysis set included neonates who were born to women participating in the study and had been enrolled into the study as well.,"Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters","A Phase 1b, Open-label Study to Evaluate the PK, Safety and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters",COMPLETED,,PHASE1,62,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gileadclinicaltrials.com/transparency-policy#Commitment,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment",2024-10-13 13:56:51,2024-10-13 13:56:51,INDUSTRY,,,,,,,Gilead Sciences,Dominican Republic|Puerto Rico|Thailand|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Respiratory, thoracic and mediastinal disorders"
NCT03964493,,2019-04-30,2022-01-13,,2023-11-08,2019-05-24,2019-05-28,ACTUAL,2023-11-08,2023-12-01,ACTUAL,,,,2023-11-08,2023-12-01,ACTUAL,2019-04-20,ACTUAL,2019-04-20,2023-11,2023-11-30,2020-09-28,ACTUAL,2020-09-28,2020-09-28,ACTUAL,2020-09-28,,INTERVENTIONAL,P2_ABSSSI,,TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection,"Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in Adults",COMPLETED,,PHASE2,120,ACTUAL,TenNor Therapeutics Inc.,,2,,,,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 02:20:45,2024-10-14 02:20:45,INDUSTRY,,,,,,,TenNor Therapeutics Limited,United States,Gastrointestinal disorders|Infections and infestations|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT03964493,,2019-04-30,2022-01-13,,2023-11-08,2019-05-24,2019-05-28,ACTUAL,2023-11-08,2023-12-01,ACTUAL,,,,2023-11-08,2023-12-01,ACTUAL,2019-04-20,ACTUAL,2019-04-20,2023-11,2023-11-30,2020-09-28,ACTUAL,2020-09-28,2020-09-28,ACTUAL,2020-09-28,,INTERVENTIONAL,P2_ABSSSI,,TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection,"Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in Adults",COMPLETED,,PHASE2,120,ACTUAL,TenNor Therapeutics Inc.,,2,,,,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-14 02:20:45,2024-10-14 02:20:45,INDUSTRY,,,,,,,TenNor Therapeutics Limited,United States,Gastrointestinal disorders|Infections and infestations|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT03978091,,2019-05-23,2021-11-23,,2022-05-12,2019-06-05,2019-06-06,ACTUAL,2021-11-23,2021-12-23,ACTUAL,,,,2022-05-12,2022-06-07,ACTUAL,2019-07-09,ACTUAL,2019-07-09,2020-02-07,2020-02-07,2020-11-23,ACTUAL,2020-11-23,2020-11-23,ACTUAL,2020-11-23,,INTERVENTIONAL,,Baseline analysis population includes the number of participants in the safety population.,A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam,"A Phase 1, Open-Label Study in Healthy Adults to Evaluate the Safety and Pharmacokinetics of AVYCAZ(R) in Combination With Aztreonam (COMBINE)",COMPLETED,,PHASE1/PHASE2,48,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,6,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 11:16:14,2024-10-14 11:16:14,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT03979313,,2019-05-30,2023-08-21,2022-02-03,2024-02-05,2019-06-06,2019-06-07,ACTUAL,2024-02-05,2024-02-28,ACTUAL,,2024-02-28,ACTUAL,2024-02-05,2024-02-28,ACTUAL,2019-07-23,ACTUAL,2019-07-23,2024-02,2024-02-29,2023-03-21,ACTUAL,2023-03-21,2021-03-11,ACTUAL,2021-03-11,,INTERVENTIONAL,MELODY,These are the Overall Number of All Subjects Population,A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY),"A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)",COMPLETED,,PHASE3,3012,ACTUAL,AstraZeneca,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,YES,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2024-10-14 19:35:45,2024-10-14 19:35:45,INDUSTRY,,,,,,,AstraZeneca,"Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|Colombia|Czechia|Estonia|Finland|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Mexico|New Zealand|Panama|Poland|Russian Federation|South Africa|Spain|Sweden|Turkey|Ukraine|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT03981822,,2019-06-06,2021-06-18,,2021-08-27,2019-06-06,2019-06-11,ACTUAL,2021-08-27,2021-09-22,ACTUAL,,,,2021-08-27,2021-09-22,ACTUAL,2019-06-25,ACTUAL,2019-06-25,2021-08,2021-08-31,2020-07-08,ACTUAL,2020-07-08,2020-05-21,ACTUAL,2020-05-21,,INTERVENTIONAL,CARE-1,ITT population,A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts,"A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts",COMPLETED,,PHASE2,105,ACTUAL,Verrica Pharmaceuticals Inc.,"Due to logistical and/or scheduling difficulties related to the SARS-CoV-2 (coronavirus-19; COVID-19) pandemic during the course of the study, six subjects discontinued due to COVID-19 related reasons.",8,,,FALSE,,,,FALSE,TRUE,TRUE,TRUE,,,,,,,,NO,,2024-10-13 12:58:07,2024-10-13 12:58:07,INDUSTRY,,,,,,,"BioClinica, Inc.|Instat Consulting, Inc.|Paidion Research, Inc.|Verrica Pharmaceuticals Inc.",United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Surgical and medical procedures"
NCT03984825,,2019-06-10,2020-07-20,,2020-08-18,2019-06-10,2019-06-13,ACTUAL,2020-08-18,2020-08-27,ACTUAL,,,,2020-08-18,2020-08-27,ACTUAL,2019-06-13,ACTUAL,2019-06-13,2020-08,2020-08-31,2019-08-16,ACTUAL,2019-08-16,2019-08-16,ACTUAL,2019-08-16,,INTERVENTIONAL,,,Effect of GSK3640254 on the Pharmacokinetics of a Combination Oral Contraceptive,The Effect of Coadministration of GSK3640254 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects,COMPLETED,,PHASE1,23,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 22:09:19,2024-10-14 22:09:19,INDUSTRY,,,,,,,ViiV Healthcare,United States,Gastrointestinal disorders|Investigations|Nervous system disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders
NCT03984838,,2019-06-10,2020-06-25,,2020-06-25,2019-06-10,2019-06-13,ACTUAL,2020-06-25,2020-07-14,ACTUAL,,,,2020-06-25,2020-07-14,ACTUAL,2019-06-17,ACTUAL,2019-06-17,2020-06,2020-06-30,2019-08-13,ACTUAL,2019-08-13,2019-08-13,ACTUAL,2019-08-13,,INTERVENTIONAL,,,"Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent","A Phase I, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Dolutegravir + Rilpivirine (JULUCA™) 50 mg/25 mg Tablets in Healthy Participants of Japanese Descent",COMPLETED,,PHASE1,16,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 01:11:36,2024-10-14 01:11:36,INDUSTRY,,,,,,,"Janssen, LP|ViiV Healthcare",United States,Gastrointestinal disorders|General disorders|Nervous system disorders
NCT03990766,,2019-06-17,2022-01-19,,2022-03-07,2019-06-17,2019-06-19,ACTUAL,2022-03-07,2022-03-31,ACTUAL,,,,2022-03-07,2022-03-31,ACTUAL,2019-05-15,ACTUAL,2019-05-15,2022-03,2022-03-31,2021-01-15,ACTUAL,2021-01-15,2021-01-15,ACTUAL,2021-01-15,,INTERVENTIONAL,SCENT,,Smell Changes & Efficacy of Nasal Theophylline,SCENT Trial: Nasal Theophylline Irrigation for Treatment of Post-Viral Olfactory Dysfunction,COMPLETED,,PHASE2,27,ACTUAL,Washington University School of Medicine,"The diagnosis of PVOD is by patient history and is thus subject to recall bias. In addition, PVOD treatment response may differ according to the causative virus, which is rarely known. The sample size was limited since all non-life saving clinical research and recruitment were halted at our institution at the time due to COVID-19. Lastly, the optimal dosing of theophylline irrigations is yet to be determined.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-13 23:44:43,2024-10-13 23:44:43,OTHER,,,,,,,Washington University School of Medicine,United States,Blood and lymphatic system disorders
NCT03991013,,2019-05-31,2024-02-26,,2024-09-04,2019-06-16,2019-06-19,ACTUAL,2024-02-26,2024-08-09,ACTUAL,,,,2024-09-04,2024-10-01,ACTUAL,2019-08-08,ACTUAL,2019-08-08,2024-09,2024-09-30,2022-10-27,ACTUAL,2022-10-27,2022-04-26,ACTUAL,2022-04-26,,INTERVENTIONAL,ARTIST,,Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial,AntiRetroviral Therapy In Second-line: Investigating Tenofovir-lamivudine-dolutegravir (ARTIST): a Randomised Controlled Trial,COMPLETED,,PHASE2,192,ACTUAL,University of Cape Town,,2,,,FALSE,,,,,FALSE,FALSE,,,FALSE,,,From the time the final results are published,"Data will be shared with other organisations or individuals for further research upon a reasonable request to the University of Cape Town PI, provided that certain conditions are met (including but not limited to the ethical standards upheld by HREC that approved the initial study).",,YES,"Data will be shared with other organisations or individuals for further research upon a reasonable request to the University of Cape Town PI, provided that certain conditions are met (including but not limited to the ethical standards upheld by Human Research Ethics Committee (HREC) that approved the initial study).",2024-10-14 16:06:18,2024-10-14 16:06:18,OTHER,,,,,,,"Médecins Sans Frontières, Belgium|University of Cape Town|Wellcome Trust",South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT03995680,,2019-05-30,2020-06-15,,2020-07-17,2019-06-21,2019-06-24,ACTUAL,2020-07-17,2020-07-20,ACTUAL,,,,2020-07-17,2020-07-20,ACTUAL,2019-07-12,ACTUAL,2019-07-12,2020-07,2020-07-31,2019-10-09,ACTUAL,2019-10-09,2019-10-09,ACTUAL,2019-10-09,,INTERVENTIONAL,CHEW_MEB_PEMBA,,Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm,"Efficacy and Safety of a New Chewable Tablet of Mebendazole Versus the Swallowable, Standard Tablet of Mebendazole Against Hookworm Infections in Children: a Randomized Controlled Trial",COMPLETED,,PHASE2,397,ACTUAL,Swiss Tropical & Public Health Institute,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-15 00:06:20,2024-10-15 00:06:20,OTHER,,,,,,,Public Health Laboratory Ivo de Carneri|Swiss Tropical & Public Health Institute,Tanzania,General disorders
NCT03998176,,2019-06-21,2022-11-04,,2023-09-26,2019-06-21,2019-06-26,ACTUAL,2022-11-29,2022-12-20,ACTUAL,,,,2023-09-26,2023-10-04,ACTUAL,2019-10-09,ACTUAL,2019-10-09,2023-09,2023-09-30,2022-04-01,ACTUAL,2022-04-01,2021-10-01,ACTUAL,2021-10-01,,INTERVENTIONAL,BASE,All 43 participants received 1 dose of B/F/TAF and are included in the intent-to-treat analysis.,Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE,"A Phase 4, Single-Arm Study of the Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients With Active Illicit Substance Use",COMPLETED,,PHASE4,43,ACTUAL,University of Nebraska,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 19:40:01,2024-10-13 19:40:01,OTHER,,,,,,,Gilead Sciences|University of Nebraska,United States,Investigations|Psychiatric disorders
NCT04001803,,2019-06-10,2021-09-29,,2023-03-16,2019-06-26,2019-06-28,ACTUAL,2021-12-10,2022-01-10,ACTUAL,,,,2023-03-16,2023-04-14,ACTUAL,2019-07-08,ACTUAL,2019-07-08,2023-03,2023-03-31,2022-03-18,ACTUAL,2022-03-18,2020-10-05,ACTUAL,2020-10-05,,INTERVENTIONAL,,"Baseline characteristics were reported for Safety Population(comprised of all participants enrolled,who received atleast 1 dose of CAB LA+RPV LA).Study staff participants only provided input through completion of surveys,semi-structured interviews,facilitation calls and didn't have to complete the informed consent process and did not receive oral lead-in medication or CAB+RPV LA injections. Demographics for study staff participants were not collected because it was not required per study design",Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US),A Qualitative Hybrid III Implementation Study to Identify and Evaluate Strategies for Successful Implementation of the Cabotegravir + Rilpivirine Long-acting Injectable Regimen in the US,COMPLETED,,PHASE3,115,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-14 17:52:48,2024-10-14 17:52:48,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04003103,,2019-06-27,2023-02-21,,2023-04-10,2019-06-27,2019-07-01,ACTUAL,2023-02-21,2023-03-21,ACTUAL,,,,2023-04-10,2023-04-12,ACTUAL,2019-09-19,ACTUAL,2019-09-19,2023-04,2023-04-30,2022-11-24,ACTUAL,2022-11-24,2022-03-18,ACTUAL,2022-03-18,,INTERVENTIONAL,,,Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016),"A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low- Risk for HIV-1 Infection",COMPLETED,,PHASE2,242,ACTUAL,Merck Sharp & Dohme LLC,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 05:21:07,2024-10-14 05:21:07,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Israel|South Africa|United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders"
NCT04016714,,2019-07-10,2022-09-30,,2023-05-02,2019-07-10,2019-07-11,ACTUAL,2022-11-11,2022-12-01,ACTUAL,,,,2023-05-02,2023-05-06,ACTUAL,2019-08-28,ACTUAL,2019-08-28,2023-05,2023-05-31,2021-10-29,ACTUAL,2021-10-29,2021-10-29,ACTUAL,2021-10-29,,INTERVENTIONAL,PNEU-PED-EU-2,,"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2)",COMPLETED,,PHASE3,1191,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 21:27:39,2024-10-14 21:27:39,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Denmark|Finland|Italy|Norway|Sweden,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04020341,,2019-07-11,2023-05-29,,2023-05-29,2019-07-11,2019-07-16,ACTUAL,2023-05-29,2023-06-22,ACTUAL,,,,2023-05-29,2023-06-22,ACTUAL,2019-10-17,ACTUAL,2019-10-17,2023-05,2023-05-31,2022-11-30,ACTUAL,2022-11-30,2022-11-30,ACTUAL,2022-11-30,,INTERVENTIONAL,,Participants randomly assigned to the study treatment were included in the ITT population.,A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI),"A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)",COMPLETED,,PHASE3,1531,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 08:58:34,2024-10-13 08:58:34,INDUSTRY,,,,,,,GlaxoSmithKline,Bulgaria|Czechia|Germany|Greece|Hungary|India|Mexico|Romania|Slovakia|Spain|United Kingdom|United States,Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Nervous system disorders
NCT04021290,,2019-07-11,2022-04-18,,2023-10-12,2019-07-11,2019-07-16,ACTUAL,2022-06-06,2022-07-01,ACTUAL,,,,2023-10-12,2023-10-19,ACTUAL,2019-11-11,ACTUAL,2019-11-11,2023-10,2023-10-31,2022-09-09,ACTUAL,2022-09-09,2021-04-23,ACTUAL,2021-04-23,,INTERVENTIONAL,,,Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA),"A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed",COMPLETED,,PHASE3,493,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 22:15:13,2024-10-14 22:15:13,INDUSTRY,,,,,,,"GlaxoSmithKline|PPD DEVELOPMENT, LP|ViiV Healthcare",Argentina|Belgium|Brazil|Canada|China|Denmark|France|Germany|Italy|Mexico|Russian Federation|South Africa|Spain|Sweden|Taiwan|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT04021628,,2019-07-01,2022-09-16,,2023-12-20,2019-07-15,2019-07-16,ACTUAL,2023-12-20,2024-06-07,ACTUAL,,,,2023-12-20,2024-06-07,ACTUAL,2019-04-01,ACTUAL,2019-04-01,2023-12,2023-12-31,2021-12-01,ACTUAL,2021-12-01,2021-10-01,ACTUAL,2021-10-01,,OBSERVATIONAL,cCHIPS,,Cytomegalovirus Shedding Characteristics in Pregnant Women,"An Observational, Longitudinal, Natural History, Feasibility Cohort Study to Evaluate the Characteristics of Cytomegalovirus (CMV) Shedding in CMV Seropositive Women Throughout Pregnancy",COMPLETED,,,160,ACTUAL,"St George's, University of London",,,,,FALSE,,,,,FALSE,FALSE,,,,SAMPLES_WITH_DNA,"Samples with DNA of CMV virus, not human DNA",,,,NO,,2024-10-14 02:39:47,2024-10-14 02:39:47,OTHER,,,,,,FALSE,"St George's University Hospitals NHS Foundation Trust|St George's, University of London",United Kingdom,Gastrointestinal disorders|Infections and infestations|Reproductive system and breast disorders
NCT04026009,,2019-07-16,2024-05-09,,2024-05-09,2019-07-18,2019-07-19,ACTUAL,2024-05-09,2024-09-23,ACTUAL,,,,2024-05-09,2024-09-23,ACTUAL,2019-08-05,ACTUAL,2019-08-05,2024-05,2024-05-31,2022-05-10,ACTUAL,2022-05-10,2022-05-10,ACTUAL,2022-05-10,,INTERVENTIONAL,,,Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years,"A Phase I, Single-center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK's Clostridium Difficile Investigational Vaccine Based on the F2 Antigen With or Without AS01B Adjuvant, When Administered Intramuscularly According to a 0, 1-month Schedule to Healthy Adults Aged Between 18-45 Years and Between 50-70 Years, Followed by an Additional Dose Administered in a Partial Blind Manner Within an Interval of Approximately 15 Months After Dose 2, in a Subcohort of Subjects Aged 50-70 Years",COMPLETED,,PHASE1,140,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 23:41:58,2024-10-14 23:41:58,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04031846,,2019-07-22,2022-03-09,,2023-07-20,2019-07-22,2019-07-24,ACTUAL,2022-06-23,2023-05-03,ACTUAL,,,,2023-07-20,2023-07-28,ACTUAL,2019-09-04,ACTUAL,2019-09-04,2023-07,2023-07-31,2021-08-05,ACTUAL,2021-08-05,2021-08-05,ACTUAL,2021-08-05,,INTERVENTIONAL,PNEU-PED-EU-1,,"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (PNEU-PED-EU-1)",COMPLETED,,PHASE3,1184,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 14:33:21,2024-10-14 14:33:21,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Belgium|Czechia|Estonia|Germany|Greece|Poland|Russian Federation|Spain,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04032093,,2019-07-22,2022-09-20,,2022-09-20,2019-07-22,2019-07-25,ACTUAL,2022-09-20,2022-10-18,ACTUAL,,,,2022-09-20,2022-10-18,ACTUAL,2019-08-07,ACTUAL,2019-08-07,2022-09,2022-09-30,2021-09-30,ACTUAL,2021-09-30,2021-09-30,ACTUAL,2021-09-30,,INTERVENTIONAL,,Maternal safety population included all randomized maternal participants who received investigational product and were analyzed according to the investigational product they received. Infant safety population included all infant participants who were born to vaccinated maternal participants and were analyzed according to the investigational product their mothers received.,"A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN","A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS",COMPLETED,,PHASE2,1153,ACTUAL,Pfizer,,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-12 23:57:38,2024-10-12 23:57:38,INDUSTRY,,,,,,,Pfizer,Argentina|Australia|Chile|New Zealand|South Africa|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04033068,,2019-07-08,2021-10-28,,2021-10-28,2019-07-24,2019-07-25,ACTUAL,2021-10-28,2021-12-06,ACTUAL,,,,2021-10-28,2021-12-06,ACTUAL,2019-08-02,ACTUAL,2019-08-02,2021-10,2021-10-31,2020-06-10,ACTUAL,2020-06-10,2020-01-30,ACTUAL,2020-01-30,,INTERVENTIONAL,MV-ZIKA-RSP,,Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001),"Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP",COMPLETED,,PHASE1,48,ACTUAL,Themis Bioscience GmbH,,4,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 01:09:29,2024-10-15 01:09:29,INDUSTRY,,,,,,,Themis Bioscience GmbH,Austria,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04035187,,2019-07-24,2023-09-11,,2023-09-11,2019-07-24,2019-07-29,ACTUAL,2023-09-11,2023-10-05,ACTUAL,,,,2023-09-11,2023-10-05,ACTUAL,2020-02-10,ACTUAL,2020-02-10,2023-09,2023-09-30,2022-05-21,ACTUAL,2022-05-21,2022-05-21,ACTUAL,2022-05-21,,INTERVENTIONAL,,,Itraconazole Oral Absorption,Prediction of Itraconazole Oral Absorption From In Vitro Dissolution,COMPLETED,,PHASE4,17,ACTUAL,"University of Maryland, Baltimore",,4,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 09:27:55,2024-10-14 09:27:55,OTHER,,,,,,,"University of Maryland, Baltimore",United States,Gastrointestinal disorders|General disorders|Nervous system disorders
NCT04039412,,2019-07-04,2019-09-22,,2019-11-23,2019-07-29,2019-07-31,ACTUAL,2019-11-23,2019-11-26,ACTUAL,,,,2019-11-23,2019-11-26,ACTUAL,2018-06-01,ACTUAL,2018-06-01,2019-11,2019-11-30,2019-06-30,ACTUAL,2019-06-30,2018-12-22,ACTUAL,2018-12-22,,INTERVENTIONAL,,,Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt,"Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial",COMPLETED,,PHASE4,330,ACTUAL,Zagazig University,,3,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,After study publication,,,YES,,2024-10-13 05:56:17,2024-10-13 05:56:17,OTHER_GOV,,,,,,,Ayman Magd Eldin Mohammad Sadek,Egypt,Gastrointestinal disorders|General disorders
NCT04041453,,2019-07-22,2020-05-08,,2020-07-27,2019-07-31,2019-08-01,ACTUAL,2020-07-27,2020-07-29,ACTUAL,,,,2020-07-27,2020-07-29,ACTUAL,2019-10-09,ACTUAL,2019-10-09,2020-07,2020-07-31,2020-03-07,ACTUAL,2020-03-07,2020-03-07,ACTUAL,2020-03-07,,INTERVENTIONAL,HI4T,,Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients,"Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients",COMPLETED,,PHASE2,176,ACTUAL,Universidad Nacional de Salta,,4,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,"After study data analysis completion, with submission for publication to a peer review journal..",Database will be made available through a publication.,,YES,All IPD that underlie results in a publication.,2024-10-13 17:32:20,2024-10-13 17:32:20,OTHER,,,,,,,Alejandro Krolewiecki|Brock University|Universidad Nacional Autonoma de Honduras|Universidad Nacional del Centro de la Provincia de Buenos Aires,Argentina|Honduras,Eye disorders|Gastrointestinal disorders|General disorders|Skin and subcutaneous tissue disorders
NCT04042740,,2019-07-31,2024-05-15,,2024-07-02,2019-07-31,2019-08-02,ACTUAL,2024-07-02,2024-07-11,ACTUAL,,,,2024-07-02,2024-07-11,ACTUAL,2019-11-20,ACTUAL,2019-11-20,2024-07,2024-07-31,2023-08-22,ACTUAL,2023-08-22,2023-05-18,ACTUAL,2023-05-18,,INTERVENTIONAL,PURGE-C,All eligible participants who initiated study treatment,Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection,Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C),COMPLETED,,PHASE2,45,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,Beginning 3 months following publication and throughout period of funding of the ACTG Network by NIH.,"* With whom?

  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
* For what types of analyses?

  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
* By what mechanism will data be made available?

  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-13 19:28:19,2024-10-13 19:28:19,NETWORK,,,,,,,AbbVie|Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Puerto Rico|United States,"Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT04042740,,2019-07-31,2024-05-15,,2024-07-02,2019-07-31,2019-08-02,ACTUAL,2024-07-02,2024-07-11,ACTUAL,,,,2024-07-02,2024-07-11,ACTUAL,2019-11-20,ACTUAL,2019-11-20,2024-07,2024-07-31,2023-08-22,ACTUAL,2023-08-22,2023-05-18,ACTUAL,2023-05-18,,INTERVENTIONAL,PURGE-C,All eligible participants who initiated study treatment,Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection,Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C),COMPLETED,,PHASE2,45,ACTUAL,Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,Beginning 3 months following publication and throughout period of funding of the ACTG Network by NIH.,"* With whom?

  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
* For what types of analyses?

  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
* By what mechanism will data be made available?

  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-13 19:28:19,2024-10-13 19:28:19,NETWORK,,,,,,,AbbVie|Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID),Brazil|Puerto Rico|United States,"Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT04047420,,2019-08-05,2023-09-14,,2023-12-04,2019-08-05,2019-08-06,ACTUAL,2023-12-04,2023-12-22,ACTUAL,,,,2023-12-04,2023-12-22,ACTUAL,2019-12-11,ACTUAL,2019-12-11,2023-12,2023-12-31,2021-04-07,ACTUAL,2021-04-07,2021-03-03,ACTUAL,2021-03-03,,INTERVENTIONAL,,,Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally,A Phase 1 Open Label Safety and Pharmacokinetic Study of Rectal Administration of a Tenofovir Alafenamide/Elvitegravir Insert at Two Dose Levels,COMPLETED,,PHASE1,23,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-15 00:35:58,2024-10-15 00:35:58,NIH,,,,,,,CONRAD|National Institute of Allergy and Infectious Diseases (NIAID),United States,Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders
NCT04048356,,2019-08-02,2023-06-20,,2023-06-20,2019-08-05,2019-08-07,ACTUAL,2023-06-20,2023-07-10,ACTUAL,,,,2023-06-20,2023-07-10,ACTUAL,2019-07-15,ACTUAL,2019-07-15,2023-06,2023-06-30,2021-03-14,ACTUAL,2021-03-14,2021-02-28,ACTUAL,2021-02-28,,INTERVENTIONAL,CLNUP,,Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures,Chlorhexidine Gluconate Versus Povidone Iodine for Vaginal Surgical Preparation for Urogynecological Procedures,COMPLETED,,PHASE3,137,ACTUAL,University of New Mexico,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 00:09:32,2024-10-13 00:09:32,OTHER,,,,,,,University of New Mexico,United States,"Infections and infestations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04048356,,2019-08-02,2023-06-20,,2023-06-20,2019-08-05,2019-08-07,ACTUAL,2023-06-20,2023-07-10,ACTUAL,,,,2023-06-20,2023-07-10,ACTUAL,2019-07-15,ACTUAL,2019-07-15,2023-06,2023-06-30,2021-03-14,ACTUAL,2021-03-14,2021-02-28,ACTUAL,2021-02-28,,INTERVENTIONAL,CLNUP,,Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures,Chlorhexidine Gluconate Versus Povidone Iodine for Vaginal Surgical Preparation for Urogynecological Procedures,COMPLETED,,PHASE3,137,ACTUAL,University of New Mexico,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 00:09:32,2024-10-13 00:09:32,OTHER,,,,,,,University of New Mexico,United States,"Infections and infestations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04048356,,2019-08-02,2023-06-20,,2023-06-20,2019-08-05,2019-08-07,ACTUAL,2023-06-20,2023-07-10,ACTUAL,,,,2023-06-20,2023-07-10,ACTUAL,2019-07-15,ACTUAL,2019-07-15,2023-06,2023-06-30,2021-03-14,ACTUAL,2021-03-14,2021-02-28,ACTUAL,2021-02-28,,INTERVENTIONAL,CLNUP,,Chlorhexidine vs. Iodine for Vaginal Preparation in Urogynecologic Procedures,Chlorhexidine Gluconate Versus Povidone Iodine for Vaginal Surgical Preparation for Urogynecological Procedures,COMPLETED,,PHASE3,137,ACTUAL,University of New Mexico,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 00:09:32,2024-10-13 00:09:32,OTHER,,,,,,,University of New Mexico,United States,"Infections and infestations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04050540,,2019-08-06,2023-12-16,,2024-07-03,2019-08-06,2019-08-08,ACTUAL,2024-07-03,2024-07-10,ACTUAL,,,,2024-07-03,2024-07-10,ACTUAL,2020-02-05,ACTUAL,2020-02-05,2024-07,2024-07-31,2022-10-30,ACTUAL,2022-10-30,2022-10-30,ACTUAL,2022-10-30,,INTERVENTIONAL,dPEP-KE,,Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP,PrEP and dPEP: Doxycycline Post-exposure Prophylaxis for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV Pre-exposure Prophylaxis,COMPLETED,,PHASE4,449,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 02:52:02,2024-10-14 02:52:02,OTHER,,,,,,,"Kenya Medical Research Institute|Kenya National AIDS & STI Control Programme|National Institute of Allergy and Infectious Diseases (NIAID)|University of California, San Francisco|University of Washington",Kenya,"Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT04050540,,2019-08-06,2023-12-16,,2024-07-03,2019-08-06,2019-08-08,ACTUAL,2024-07-03,2024-07-10,ACTUAL,,,,2024-07-03,2024-07-10,ACTUAL,2020-02-05,ACTUAL,2020-02-05,2024-07,2024-07-31,2022-10-30,ACTUAL,2022-10-30,2022-10-30,ACTUAL,2022-10-30,,INTERVENTIONAL,dPEP-KE,,Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP,PrEP and dPEP: Doxycycline Post-exposure Prophylaxis for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV Pre-exposure Prophylaxis,COMPLETED,,PHASE4,449,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 02:52:02,2024-10-14 02:52:02,OTHER,,,,,,,"Kenya Medical Research Institute|Kenya National AIDS & STI Control Programme|National Institute of Allergy and Infectious Diseases (NIAID)|University of California, San Francisco|University of Washington",Kenya,"Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT04050540,,2019-08-06,2023-12-16,,2024-07-03,2019-08-06,2019-08-08,ACTUAL,2024-07-03,2024-07-10,ACTUAL,,,,2024-07-03,2024-07-10,ACTUAL,2020-02-05,ACTUAL,2020-02-05,2024-07,2024-07-31,2022-10-30,ACTUAL,2022-10-30,2022-10-30,ACTUAL,2022-10-30,,INTERVENTIONAL,dPEP-KE,,Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP,PrEP and dPEP: Doxycycline Post-exposure Prophylaxis for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV Pre-exposure Prophylaxis,COMPLETED,,PHASE4,449,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 02:52:02,2024-10-14 02:52:02,OTHER,,,,,,,"Kenya Medical Research Institute|Kenya National AIDS & STI Control Programme|National Institute of Allergy and Infectious Diseases (NIAID)|University of California, San Francisco|University of Washington",Kenya,"Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT04050540,,2019-08-06,2023-12-16,,2024-07-03,2019-08-06,2019-08-08,ACTUAL,2024-07-03,2024-07-10,ACTUAL,,,,2024-07-03,2024-07-10,ACTUAL,2020-02-05,ACTUAL,2020-02-05,2024-07,2024-07-31,2022-10-30,ACTUAL,2022-10-30,2022-10-30,ACTUAL,2022-10-30,,INTERVENTIONAL,dPEP-KE,,Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP,PrEP and dPEP: Doxycycline Post-exposure Prophylaxis for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV Pre-exposure Prophylaxis,COMPLETED,,PHASE4,449,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 02:52:02,2024-10-14 02:52:02,OTHER,,,,,,,"Kenya Medical Research Institute|Kenya National AIDS & STI Control Programme|National Institute of Allergy and Infectious Diseases (NIAID)|University of California, San Francisco|University of Washington",Kenya,"Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT04052139,,2019-08-08,2022-09-09,,2022-10-14,2019-08-08,2019-08-09,ACTUAL,2022-10-14,2022-11-10,ACTUAL,,,,2022-10-14,2022-11-10,ACTUAL,2021-01-25,ACTUAL,2021-01-25,2022-10,2022-10-31,2021-12-15,ACTUAL,2021-12-15,2021-11-16,ACTUAL,2021-11-16,,INTERVENTIONAL,UH3,,St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin,Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems,COMPLETED,,PHASE2,45,ACTUAL,Boston Medical Center,,3,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,YES,All data from the study will be placed into the URBAN ARCH repository.,2024-10-13 22:25:16,2024-10-13 22:25:16,OTHER,,,,,,,Boston Medical Center|National Institute on Alcohol Abuse and Alcoholism (NIAAA),Russian Federation,Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders
NCT04071158,,2019-08-26,2020-12-07,,2021-01-26,2019-08-26,2019-08-28,ACTUAL,2021-01-26,2021-02-15,ACTUAL,,,,2021-01-26,2021-02-15,ACTUAL,2019-10-01,ACTUAL,2019-10-01,2021-01,2021-01-31,2019-12-11,ACTUAL,2019-12-11,2019-12-11,ACTUAL,2019-12-11,,INTERVENTIONAL,,Safety analysis set included all randomized participants who received investigational product. Participants were analyzed according to the investigational product they actually received.,A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS,"A PHASE 2b, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE",COMPLETED,,PHASE2,713,ACTUAL,Pfizer,,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-15 02:18:46,2024-10-15 02:18:46,INDUSTRY,,,,,,,Pfizer,United States,"Blood and lymphatic system disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04079452,,2019-09-03,2022-02-27,,2022-04-27,2019-09-03,2019-09-06,ACTUAL,2022-04-27,2022-04-28,ACTUAL,,,,2022-04-27,2022-04-28,ACTUAL,2020-02-18,ACTUAL,2020-02-18,2022-04,2022-04-30,2020-08-31,ACTUAL,2020-08-31,2020-08-31,ACTUAL,2020-08-31,,INTERVENTIONAL,,,Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals,Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals,COMPLETED,,PHASE3,15,ACTUAL,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 10:58:04,2024-10-14 10:58:04,OTHER,,,,,,,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Hospital Universitari de Bellvitge|Institut d'Investigació Biomèdica de Bellvitge",Spain,Gastrointestinal disorders|Musculoskeletal and connective tissue disorders
NCT04079790,,2019-09-03,2020-08-18,,2020-08-18,2019-09-03,2019-09-06,ACTUAL,2020-08-18,2020-09-04,ACTUAL,,,,2020-08-18,2020-09-04,ACTUAL,2019-09-04,ACTUAL,2019-09-04,2020-08,2020-08-31,2019-11-25,ACTUAL,2019-11-25,2019-11-25,ACTUAL,2019-11-25,,INTERVENTIONAL,,,Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects,"A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants",COMPLETED,,PHASE1,34,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 19:29:55,2024-10-14 19:29:55,INDUSTRY,,,,,,,GlaxoSmithKline,United States,Cardiac disorders|Gastrointestinal disorders|General disorders|Investigations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT04090658,,2019-09-12,2021-12-07,,2021-12-07,2019-09-12,2019-09-16,ACTUAL,2021-12-07,2022-02-25,ACTUAL,,,,2021-12-07,2022-02-25,ACTUAL,2019-09-25,ACTUAL,2019-09-25,2021-12,2021-12-31,2020-12-11,ACTUAL,2020-12-11,2020-01-10,ACTUAL,2020-01-10,,INTERVENTIONAL,,,A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults,"Phase I, Observer-blind, Safety, Reactogenicity and Immunogenicity Study of GSK's Respiratory Syncytial Virus (RSV) Vaccine GSK3844766A in Japanese Subjects Aged 60-80 Years",COMPLETED,,PHASE1,40,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 10:22:11,2024-10-14 10:22:11,INDUSTRY,,,,,,,GlaxoSmithKline,Japan,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04091672,,2019-09-13,2023-07-24,,2024-07-09,2019-09-13,2019-09-17,ACTUAL,2023-09-18,2023-09-21,ACTUAL,,,,2024-07-09,2024-07-30,ACTUAL,2020-03-02,ACTUAL,2020-03-02,2024-07,2024-07-31,2023-02-02,ACTUAL,2023-02-02,2022-03-07,ACTUAL,2022-03-07,,INTERVENTIONAL,,Experimental: All Participants (within patient control),RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction,A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of the RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction,COMPLETED,,NA,65,ACTUAL,Avita Medical,,1,,,FALSE,,,,FALSE,FALSE,TRUE,,,,,,,,,,,2024-10-13 11:41:43,2024-10-13 11:41:43,INDUSTRY,,,,,,,Avita Medical,United States,"General disorders|Infections and infestations|Injury, poisoning and procedural complications|Product Issues|Skin and subcutaneous tissue disorders"
NCT04094870,,2019-09-16,2021-09-01,,2021-10-12,2019-09-16,2019-09-19,ACTUAL,2021-10-12,2021-11-10,ACTUAL,,,,2021-10-12,2021-11-10,ACTUAL,2019-10-30,ACTUAL,2019-10-30,2020-12,2020-12-31,2020-10-30,ACTUAL,2020-10-30,2020-10-30,ACTUAL,2020-10-30,,INTERVENTIONAL,,,A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women,Z 31801 - A Pilot Trial of Perinatal Depression Treatment in HIV Infected Women,COMPLETED,,PHASE4,80,ACTUAL,"University of North Carolina, Chapel Hill",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,9 to 36 months following publication,"Investigator who proposes to use the data has IRB, IEC, or REB approval, as applicable, and an executed data use/sharing agreement with UNC.",,YES,"Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2024-10-14 08:04:12,2024-10-14 08:04:12,OTHER,,,,,,,"National Institute of Mental Health (NIMH)|University of North Carolina, Chapel Hill",Zambia,Gastrointestinal disorders|Nervous system disorders|Psychiatric disorders
NCT04094883,,2019-09-16,2021-06-24,,2021-06-24,2019-09-16,2019-09-19,ACTUAL,2021-06-24,2021-07-15,ACTUAL,,,,2021-06-24,2021-07-15,ACTUAL,2019-10-09,ACTUAL,2019-10-09,2021-06,2021-06-30,2020-09-01,ACTUAL,2020-09-01,2020-09-01,ACTUAL,2020-09-01,,INTERVENTIONAL,4CMenB,,Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine,Institute for Global Health and Infectious Diseases (IGHID) 11911 - Cross-reactive N. Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine,COMPLETED,,PHASE4,11,ACTUAL,"University of North Carolina, Chapel Hill",,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,12-24 months after publication,"Other investigators/researchers who propose to use the individual participant data (IPD) from this study will need to have approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and execute a data use/sharing agreement with UNC.",,YES,"De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2024-10-13 03:37:02,2024-10-13 03:37:02,OTHER,,,,,,,"North Carolina Translational and Clinical Sciences Institute|University of North Carolina, Chapel Hill",United States,Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Surgical and medical procedures
NCT04097925,,2019-09-18,2022-02-27,,2022-06-15,2019-09-19,2019-09-20,ACTUAL,2022-05-24,2022-05-25,ACTUAL,,,,2022-06-15,2022-07-06,ACTUAL,2020-02-18,ACTUAL,2020-02-18,2022-06,2022-06-30,2020-08-24,ACTUAL,2020-08-24,2020-08-24,ACTUAL,2020-08-24,,INTERVENTIONAL,,,Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals,Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals,COMPLETED,,PHASE2,30,ACTUAL,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia",,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 03:12:53,2024-10-14 03:12:53,OTHER,,,,,,,"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Hospital Universitari de Bellvitge|Institut d'Investigació Biomèdica de Bellvitge",Spain,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04112303,,2019-09-30,2022-03-23,,2022-03-23,2019-09-30,2019-10-02,ACTUAL,2022-03-23,2022-04-20,ACTUAL,,,,2022-03-23,2022-04-20,ACTUAL,2019-10-16,ACTUAL,2019-10-16,2022-03,2022-03-31,2021-06-25,ACTUAL,2021-06-25,2021-03-26,ACTUAL,2021-03-26,,INTERVENTIONAL,,Safety Analysis Set included all participants who took at least 1 dose of the study drug.,Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis,"A Phase 3 Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection and Compensated Cirrhosis",COMPLETED,,PHASE3,37,ACTUAL,Gilead Sciences,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",http://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",2024-10-15 02:42:24,2024-10-15 02:42:24,INDUSTRY,,,,,,,Gilead Sciences,Japan,"Gastrointestinal disorders|Injury, poisoning and procedural complications|Nervous system disorders"
NCT04126213,,2019-10-11,2021-11-12,2021-04-16,2021-11-12,2019-10-11,2019-10-15,ACTUAL,2021-11-12,2021-12-13,ACTUAL,2021-04-16,2021-04-19,ACTUAL,2021-11-12,2021-12-13,ACTUAL,2019-11-05,ACTUAL,2019-11-05,2021-11,2021-11-30,2021-05-14,ACTUAL,2021-05-14,2020-07-23,ACTUAL,2020-07-23,,INTERVENTIONAL,,,"Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants","A Phase II, Randomised, Observer-blind, Placebo Controlled Multi-country Study to Assess the Safety, Reactogenicity and Immunogenicity of a Single Intramuscular Dose of GSK Biologicals' Investigational RSV Maternal Unadjuvanted Vaccine (GSK3888550A), in Healthy Pregnant Women Aged 18 to 40 Years and Infants Born to Vaccinated Mothers",COMPLETED,,PHASE2,534,ACTUAL,GlaxoSmithKline,,6,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",https://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 12:03:14,2024-10-14 12:03:14,INDUSTRY,,,,,,,GlaxoSmithKline,Australia|Canada|Finland|France|New Zealand|Panama|South Africa|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04129398,,2019-10-15,2023-09-25,,2024-07-29,2019-10-15,2019-10-16,ACTUAL,2023-09-25,2024-04-01,ACTUAL,,,,2024-07-29,2024-08-21,ACTUAL,2019-12-27,ACTUAL,2019-12-27,2024-07,2024-07-31,2022-10-06,ACTUAL,2022-10-06,2022-10-06,ACTUAL,2022-10-06,,INTERVENTIONAL,,,MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042),"A Phase 3, Open-Label, Single-Arm Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of MK-8228 (Letermovir) for the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients",COMPLETED,,PHASE3,22,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 21:33:25,2024-10-14 21:33:25,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Blood and lymphatic system disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Psychiatric disorders|Renal and urinary disorders|Vascular disorders"
NCT04134767,,2019-10-11,2023-10-26,,2023-12-01,2019-10-18,2019-10-22,ACTUAL,2023-12-01,2023-12-21,ACTUAL,,,,2023-12-01,2023-12-21,ACTUAL,2019-11-15,ACTUAL,2019-11-15,2023-12,2023-12-31,2022-10-27,ACTUAL,2022-10-27,2022-10-27,ACTUAL,2022-10-27,,INTERVENTIONAL,,One participant from the Health Linkage Arm did not have demographic data available,Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE),Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) - UH3 PHASE,COMPLETED,,NA,234,ACTUAL,University of Kentucky,"Because of the impact of the COVID-19 pandemic, we were unable to accrue the target number of participants in either the intervention counties or the comparison counties. As a result, analyses of intervention effectiveness are underpowered. Further, data related to the follow-up HCV testing outcome should be interpreted with caution; measuring RNA-based follow-up testing for HCV is too nuanced to capture via a survey item, as it can be easily misinterpreted by participants.",2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,YES,"Data from the University of Kentucky are required to be submitted to the University of Washington as part of the NIH-funded Rural Opioid Initiative (ROI) data harmonization project. The University of Washington Data Harmonization Coordinating Center (DCC) will be harmonizing data across 8 ROI studies in order to create new, harmonized datasets to be used for analyses across the consortium. The University of Washington and other ROI grantees will perform data analyses on these data for peer-reviewed publication. The harmonized datasets will be provided to other ROI grantees as required for analysis and will be considered under the umbrella of mandated DCC activities. No third parties outside of the ROI will be given access to this harmonized data. Harmonized datasets will be built to specific project concept proposals, and all project proposals must be reviewed and approved by the ROI consortium's Publications Working Group before distribution of the customized dataset.",2024-10-14 15:11:22,2024-10-14 15:11:22,OTHER,,,,,C2H Counties,,Appalachian Regional Commission|April M Young|Centers for Disease Control and Prevention|Emory University|National Institute on Drug Abuse (NIDA)|Substance Abuse and Mental Health Services Administration (SAMHSA),United States,General disorders|Infections and infestations|Social circumstances
NCT04134767,,2019-10-11,2023-10-26,,2023-12-01,2019-10-18,2019-10-22,ACTUAL,2023-12-01,2023-12-21,ACTUAL,,,,2023-12-01,2023-12-21,ACTUAL,2019-11-15,ACTUAL,2019-11-15,2023-12,2023-12-31,2022-10-27,ACTUAL,2022-10-27,2022-10-27,ACTUAL,2022-10-27,,INTERVENTIONAL,,One participant from the Health Linkage Arm did not have demographic data available,Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE),Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) - UH3 PHASE,COMPLETED,,NA,234,ACTUAL,University of Kentucky,"Because of the impact of the COVID-19 pandemic, we were unable to accrue the target number of participants in either the intervention counties or the comparison counties. As a result, analyses of intervention effectiveness are underpowered. Further, data related to the follow-up HCV testing outcome should be interpreted with caution; measuring RNA-based follow-up testing for HCV is too nuanced to capture via a survey item, as it can be easily misinterpreted by participants.",2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,YES,"Data from the University of Kentucky are required to be submitted to the University of Washington as part of the NIH-funded Rural Opioid Initiative (ROI) data harmonization project. The University of Washington Data Harmonization Coordinating Center (DCC) will be harmonizing data across 8 ROI studies in order to create new, harmonized datasets to be used for analyses across the consortium. The University of Washington and other ROI grantees will perform data analyses on these data for peer-reviewed publication. The harmonized datasets will be provided to other ROI grantees as required for analysis and will be considered under the umbrella of mandated DCC activities. No third parties outside of the ROI will be given access to this harmonized data. Harmonized datasets will be built to specific project concept proposals, and all project proposals must be reviewed and approved by the ROI consortium's Publications Working Group before distribution of the customized dataset.",2024-10-14 15:11:22,2024-10-14 15:11:22,OTHER,,,,,C2H Counties,,Appalachian Regional Commission|April M Young|Centers for Disease Control and Prevention|Emory University|National Institute on Drug Abuse (NIDA)|Substance Abuse and Mental Health Services Administration (SAMHSA),United States,General disorders|Infections and infestations|Social circumstances
NCT04134767,,2019-10-11,2023-10-26,,2023-12-01,2019-10-18,2019-10-22,ACTUAL,2023-12-01,2023-12-21,ACTUAL,,,,2023-12-01,2023-12-21,ACTUAL,2019-11-15,ACTUAL,2019-11-15,2023-12,2023-12-31,2022-10-27,ACTUAL,2022-10-27,2022-10-27,ACTUAL,2022-10-27,,INTERVENTIONAL,,One participant from the Health Linkage Arm did not have demographic data available,Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE),Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) - UH3 PHASE,COMPLETED,,NA,234,ACTUAL,University of Kentucky,"Because of the impact of the COVID-19 pandemic, we were unable to accrue the target number of participants in either the intervention counties or the comparison counties. As a result, analyses of intervention effectiveness are underpowered. Further, data related to the follow-up HCV testing outcome should be interpreted with caution; measuring RNA-based follow-up testing for HCV is too nuanced to capture via a survey item, as it can be easily misinterpreted by participants.",2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,YES,"Data from the University of Kentucky are required to be submitted to the University of Washington as part of the NIH-funded Rural Opioid Initiative (ROI) data harmonization project. The University of Washington Data Harmonization Coordinating Center (DCC) will be harmonizing data across 8 ROI studies in order to create new, harmonized datasets to be used for analyses across the consortium. The University of Washington and other ROI grantees will perform data analyses on these data for peer-reviewed publication. The harmonized datasets will be provided to other ROI grantees as required for analysis and will be considered under the umbrella of mandated DCC activities. No third parties outside of the ROI will be given access to this harmonized data. Harmonized datasets will be built to specific project concept proposals, and all project proposals must be reviewed and approved by the ROI consortium's Publications Working Group before distribution of the customized dataset.",2024-10-14 15:11:22,2024-10-14 15:11:22,OTHER,,,,,C2H Counties,,Appalachian Regional Commission|April M Young|Centers for Disease Control and Prevention|Emory University|National Institute on Drug Abuse (NIDA)|Substance Abuse and Mental Health Services Administration (SAMHSA),United States,General disorders|Infections and infestations|Social circumstances
NCT04138056,,2019-10-22,2022-11-18,2021-01-28,2024-07-29,2019-10-22,2019-10-24,ACTUAL,2022-11-18,2022-12-19,ACTUAL,2021-02-08,2021-02-09,ACTUAL,2024-07-29,2024-08-21,ACTUAL,2019-11-05,ACTUAL,2019-11-05,2024-07,2024-07-31,2021-11-22,ACTUAL,2021-11-22,2020-02-25,ACTUAL,2020-02-25,,INTERVENTIONAL,,,"A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women","A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine",COMPLETED,,PHASE2,509,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf,YES,"GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf",2024-10-14 21:39:23,2024-10-14 21:39:23,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04140266,,2019-10-24,2023-04-10,,2023-07-14,2019-10-24,2019-10-25,ACTUAL,2023-07-14,2023-08-04,ACTUAL,,,,2023-07-14,2023-08-04,ACTUAL,2020-09-24,ACTUAL,2020-09-24,2023-07,2023-07-31,2021-11-04,ACTUAL,2021-11-04,2021-11-04,ACTUAL,2021-11-04,,INTERVENTIONAL,,,Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs,"Phase 3B, Randomized, Open-Label, Safety, and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs",COMPLETED,,PHASE3,394,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,within 8 weeks of request approval and to be available as long as needed.,MTN-043 study management team approval,,YES,Individual participant data will be made available to researchers upon request. The IPD to be shared will be negotiated with the researchers,2024-10-13 16:37:52,2024-10-13 16:37:52,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Malawi|South Africa|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04141930,,2019-10-23,2021-04-02,,2021-07-13,2019-10-24,2019-10-28,ACTUAL,2021-07-13,2021-08-05,ACTUAL,,,,2021-07-13,2021-08-05,ACTUAL,2019-11-01,ACTUAL,2019-11-01,2021-07,2021-07-31,2020-04-01,ACTUAL,2020-04-01,2020-04-01,ACTUAL,2020-04-01,,INTERVENTIONAL,pCHIMES,Based on individuals that contributed data during the test-and-treat phase of the protocol.,Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle,Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle (pCHIMES),COMPLETED,,PHASE4,481,ACTUAL,University of Washington,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,"We do not currently expect to share specimens with outside investigators, but if compelling opportunities arise that will advance the overall objectives of this research, the Executive Committee of the study will consider such requests. They alone have the authority to make such decisions.

All biospecimens (nasal swabs) will be coded and identifiable through the study's main database. Any specimens shared with external investigators (if deemed appropriate by the Executive Committee) will have identifiers removed prior to sharing.",2024-10-14 13:07:17,2024-10-14 13:07:17,OTHER,,,,,,,"Genentech, Inc.|University of Washington",United States,"Gastrointestinal disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders"
NCT04142242,,2019-10-24,2021-03-26,,2023-11-27,2019-10-25,2019-10-29,ACTUAL,2021-03-26,2021-04-26,ACTUAL,,,,2023-11-27,2023-12-19,ACTUAL,2019-10-04,ACTUAL,2019-10-04,2023-11,2023-11-30,2022-05-25,ACTUAL,2022-05-25,2020-04-01,ACTUAL,2020-04-01,,INTERVENTIONAL,,Analysis was performed on all enrolled participants.,Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49,Safety and Immunogenicity of a Single Dose of MenACYW Conjugate Vaccine at Least 3 Years Following Initial Vaccination With Either Menomune® Vaccine or MenACYW Conjugate Vaccine in Older Adults,COMPLETED,,PHASE3,471,ACTUAL,Sanofi,,6,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-14 11:28:26,2024-10-14 11:28:26,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Puerto Rico|United States,"General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT04143594,,2019-10-28,2022-09-29,,2024-09-09,2019-10-28,2019-10-29,ACTUAL,2022-11-22,2022-12-19,ACTUAL,,,,2024-09-09,2024-10-02,ACTUAL,2019-11-22,ACTUAL,2019-11-22,2024-09,2024-09-30,2023-09-19,ACTUAL,2023-09-19,2021-10-05,ACTUAL,2021-10-05,,INTERVENTIONAL,CALIBRATE,Safety Analysis Set included all participants who were randomized and received at least 1 dose of study drug.,Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV,"A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV",COMPLETED,,PHASE2,183,ACTUAL,Gilead Sciences,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gileadclinicaltrials.com/transparency-policy#Commitment,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment",2024-10-14 16:06:18,2024-10-14 16:06:18,INDUSTRY,,,,,,,Gilead Sciences,Dominican Republic|Puerto Rico|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT04146116,,2019-10-29,2022-11-15,,2023-06-09,2019-10-29,2019-10-31,ACTUAL,2023-06-09,2023-06-28,ACTUAL,,,,2023-06-09,2023-06-28,ACTUAL,2020-02-19,ACTUAL,2020-02-19,2023-06,2023-06-30,2021-06-08,ACTUAL,2021-06-08,2021-06-08,ACTUAL,2021-06-08,,INTERVENTIONAL,,Patients who received orthopedic trauma surgery who consented to the intervention.,Nasal Decolonization for Orthopedic Trauma Patients,Feasibility of Pre-operative Povidone Iodine Decolonization Among Orthopedic Trauma Surgery Patients To Reduce Staphylococcus Aureus Surgical Site Infections,COMPLETED,,PHASE4,65,ACTUAL,University of Iowa,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 12:28:13,2024-10-14 12:28:13,OTHER,,,,,,,"Professional Disposables International, Inc.|University of Iowa",United States,"Product Issues|Respiratory, thoracic and mediastinal disorders"
NCT04148287,,2019-10-30,2022-12-13,,2024-05-16,2019-10-30,2019-11-01,ACTUAL,2022-12-13,2023-01-09,ACTUAL,,,,2024-05-16,2024-06-03,ACTUAL,2019-12-13,ACTUAL,2019-12-13,2024-05,2024-05-31,2020-12-31,ACTUAL,2020-12-31,2020-11-30,ACTUAL,2020-11-30,,INTERVENTIONAL,APEX,Analysis was performed on all enrolled participants.,An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris,An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Patients With Candidemia and/or Invasive Candidiasis Caused by Candida Auris,COMPLETED,,PHASE2,9,ACTUAL,Basilea Pharmaceutica,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 10:16:10,2024-10-14 10:16:10,INDUSTRY,,,,,,,Basilea Pharmaceutica,Panama|South Africa,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04150068,,2019-10-28,2021-09-28,,2024-06-26,2019-10-31,2019-11-04,ACTUAL,2021-09-28,2021-10-20,ACTUAL,,,,2024-06-26,2024-07-23,ACTUAL,2019-11-21,ACTUAL,2019-11-21,2024-06,2024-06-30,2027-01,ESTIMATED,2027-01-31,2020-10-05,ACTUAL,2020-10-05,,INTERVENTIONAL,CAPELLA,Safety Analysis Set included participants who were enrolled and received at least 1 dose of study drug.,Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance,A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance,ACTIVE_NOT_RECRUITING,,PHASE2/PHASE3,72,ACTUAL,Gilead Sciences,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 16:45:10,2024-10-14 16:45:10,INDUSTRY,,,,,,,Gilead Sciences,Canada|Dominican Republic|France|Germany|Italy|Japan|South Africa|Spain|Taiwan|Thailand|United States,"Blood and lymphatic system disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT04167670,,2019-11-15,2022-03-09,,2022-03-09,2019-11-15,2019-11-19,ACTUAL,2022-03-09,2022-04-05,ACTUAL,,,,2022-03-09,2022-04-05,ACTUAL,2019-12-10,ACTUAL,2019-12-10,2022-03,2022-03-31,2021-03-18,ACTUAL,2021-03-18,2021-03-10,ACTUAL,2021-03-10,,INTERVENTIONAL,,Randomized Set - All participants randomly assigned to receive study drug regardless of whether or not they received a dose of study drug during the study.,Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection,A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg Daily in Patients With Helicobacter Pylori Infection,COMPLETED,,PHASE3,1046,ACTUAL,"Phathom Pharmaceuticals, Inc.",,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 20:04:52,2024-10-14 20:04:52,INDUSTRY,,,,,,,"Phathom Pharmaceuticals, Inc.",Bulgaria|Czechia|Hungary|Poland|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Vascular disorders"
NCT04187144,,2019-12-03,2023-05-29,,2023-07-15,2019-12-03,2019-12-05,ACTUAL,2023-07-15,2023-07-18,ACTUAL,,,,2023-07-15,2023-07-18,ACTUAL,2020-04-23,ACTUAL,2020-04-23,2023-07,2023-07-31,2022-12-01,ACTUAL,2022-12-01,2022-12-01,ACTUAL,2022-12-01,,INTERVENTIONAL,,Participants randomly assigned to the study treatment were included in the ITT population.,Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI),"A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)",COMPLETED,,PHASE3,1606,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 23:36:02,2024-10-14 23:36:02,INDUSTRY,,,,,,,GlaxoSmithKline,"Australia|Bulgaria|India|Korea, Republic of|Poland|United States","Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Pregnancy, puerperium and perinatal conditions"
NCT04191148,,2019-12-04,2021-09-27,,2022-03-15,2019-12-06,2019-12-09,ACTUAL,2022-03-15,2022-03-16,ACTUAL,,,,2022-03-15,2022-03-16,ACTUAL,2019-12-30,ACTUAL,2019-12-30,2021-11,2021-11-30,2020-11-19,ACTUAL,2020-11-19,2020-11-19,ACTUAL,2020-11-19,,INTERVENTIONAL,,,"Safety, Tolerability, and PK of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli","A Multi-Center Randomized, Double-Blind Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LBP-EC01 in Patients With Lower Urinary Tract Colonization Caused by E. Coli",COMPLETED,,PHASE1,36,ACTUAL,Locus Biosciences,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 15:49:25,2024-10-13 15:49:25,INDUSTRY,,,,,,,Locus Biosciences,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04191967,,2019-12-06,2022-11-17,,2023-01-05,2019-12-06,2019-12-10,ACTUAL,2023-01-05,2023-01-25,ACTUAL,,,,2023-01-05,2023-01-25,ACTUAL,2019-09-25,ACTUAL,2019-09-25,2022-12,2022-12-31,2021-11-30,ACTUAL,2021-11-30,2021-11-30,ACTUAL,2021-11-30,,INTERVENTIONAL,,"Candidates for ablation must had had a fully visualized, squamocolumnar junction; cervical lesions, if present, that covered \< 75% of the cervix; and no endocervical component of the lesion or suspicion for cancer.",Thermocoagulation for Treatment of Precancerous Cervical Lesions,"Cervical Cancer Screening Among HIV-infected Women in Western Kenya: Evaluation of the Safety, Acceptability, and Efficacy of an Alternative Ablation Method for Treatment of Precancerous Lesions",COMPLETED,,NA,379,ACTUAL,"University of California, San Francisco",,1,,,FALSE,,,,TRUE,FALSE,TRUE,,,TRUE,,,,,,NO,,2024-10-14 00:13:26,2024-10-14 00:13:26,OTHER,,,,,,,"Fogarty International Center of the National Institute of Health|National Institutes of Health (NIH)|University of California, San Francisco",Kenya,"Injury, poisoning and procedural complications|Reproductive system and breast disorders"
NCT04198571,,2019-11-05,2022-07-22,,2024-03-25,2019-12-12,2019-12-13,ACTUAL,2024-03-25,2024-03-26,ACTUAL,,,,2024-03-25,2024-03-26,ACTUAL,2020-05-17,ACTUAL,2020-05-17,2023-09,2023-09-30,2021-08-30,ACTUAL,2021-08-30,2021-07-23,ACTUAL,2021-07-23,,OBSERVATIONAL,,Full analysis set included all participants with the respective type of infection who were eligible for the study and whose data was entered into the study database.,"Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries","MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalised for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated With Zinforo (REGISTERED) (Ceftaroline Fosamil) in a Usual Care Setting",COMPLETED,,,317,ACTUAL,Pfizer,,,1,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,NONE_RETAINED,Not Applicable for this study,,,,NO,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 16:37:52,2024-10-13 16:37:52,INDUSTRY,,,,,,FALSE,Pfizer,Brazil|Colombia|France|Greece|Italy|Russian Federation|Spain,Blood and lymphatic system disorders|General disorders
NCT04211909,,2019-12-23,2021-09-29,,2021-09-29,2019-12-23,2019-12-26,ACTUAL,2021-09-29,2021-10-27,ACTUAL,,,,2021-09-29,2021-10-27,ACTUAL,2020-01-03,ACTUAL,2020-01-03,2021-09,2021-09-30,2020-11-12,ACTUAL,2020-11-12,2020-11-12,ACTUAL,2020-11-12,,INTERVENTIONAL,,The Safety Analysis Set included all participants who took at least 1 dose of the study drug.,Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection,"A Phase 3b Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection",COMPLETED,,PHASE3,87,ACTUAL,Gilead Sciences,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,18 months after study completion,"A secured external environment with username, password, and RSA code.",https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy,YES,"Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy",2024-10-13 00:43:25,2024-10-13 00:43:25,INDUSTRY,,,,,,,Gilead Sciences,"Korea, Republic of","Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT04216589,,2019-12-30,2024-03-15,,2024-09-06,2019-12-30,2020-01-02,ACTUAL,2024-04-22,2024-05-17,ACTUAL,,,,2024-09-06,2024-10-01,ACTUAL,2021-02-19,ACTUAL,2021-02-19,2024-09,2024-09-30,2023-09-15,ACTUAL,2023-09-15,2023-03-16,ACTUAL,2023-03-16,,INTERVENTIONAL,,All participants who were enrolled to the study.,"Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)","A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)",COMPLETED,,PHASE2,51,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"* With whom?

  * Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
* For what types of analyses?

  * To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
* By what mechanism will data be made available?

  * Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://submit.mis.s-3.net/ Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-14 16:06:18,2024-10-14 16:06:18,NIH,,,,,,,"National Institute of Allergy and Infectious Diseases (NIAID)|The University of Texas Health Science Center, Houston",Brazil|United States,"Gastrointestinal disorders|General disorders|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders"
NCT04218110,,2019-12-30,2021-06-17,,2021-10-04,2020-01-03,2020-01-06,ACTUAL,2021-10-04,2021-10-22,ACTUAL,,,,2021-10-04,2021-10-22,ACTUAL,2020-02-11,ACTUAL,2020-02-11,2021-10,2021-10-31,2020-03-31,ACTUAL,2020-03-31,2020-03-10,ACTUAL,2020-03-10,,INTERVENTIONAL,,Baseline Participant data is based on the Intent to Treat (ITT) data set.,Preoperative Skin Preparation Study to Evaluate the Antimicrobial Capabilities of Four Test Substances,Preoperative Skin Preparation Study Following ASTM E1173 Methods to Evaluate the Antimicrobial Capabilities of Four Test Substances,COMPLETED,,PHASE3,329,ACTUAL,"Professional Disposables International, Inc.",,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 13:03:43,2024-10-13 13:03:43,INDUSTRY,,,,,,,"Professional Disposables International, Inc.",Romania,"Pregnancy, puerperium and perinatal conditions"
NCT04223778,,2020-01-08,2022-08-22,,2024-09-12,2020-01-08,2020-01-10,ACTUAL,2022-08-22,2022-09-19,ACTUAL,,,,2024-09-12,2024-09-27,ACTUAL,2020-02-18,ACTUAL,2020-02-18,2024-09,2024-09-30,2024-08-26,ACTUAL,2024-08-26,2021-09-08,ACTUAL,2021-09-08,,INTERVENTIONAL,,,Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017),"A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy",COMPLETED,,PHASE3,672,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 11:16:14,2024-10-14 11:16:14,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Canada|Chile|Colombia|France|Italy|Japan|New Zealand|Poland|Russian Federation|South Africa|Spain|Switzerland|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04223791,,2020-01-08,2022-07-26,,2024-07-26,2020-01-08,2020-01-10,ACTUAL,2022-07-26,2022-08-22,ACTUAL,,,,2024-07-26,2024-08-20,ACTUAL,2020-02-18,ACTUAL,2020-02-18,2024-07,2024-07-31,2025-02-25,ESTIMATED,2025-02-25,2021-08-26,ACTUAL,2021-08-26,,INTERVENTIONAL,,,Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018),"A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)",ACTIVE_NOT_RECRUITING,,PHASE3,643,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 09:40:26,2024-10-14 09:40:26,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Australia|Austria|Canada|Finland|France|Germany|Italy|Japan|Puerto Rico|Spain|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT04233216,,2020-01-15,2023-11-07,,2023-11-15,2020-01-15,2020-01-18,ACTUAL,2023-11-15,2023-12-08,ACTUAL,,,,2023-11-15,2023-12-08,ACTUAL,2020-03-18,ACTUAL,2020-03-18,2023-11,2023-11-30,2023-11-01,ACTUAL,2023-11-01,2022-11-21,ACTUAL,2022-11-21,,INTERVENTIONAL,,,Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019),"A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL",COMPLETED,,PHASE3,35,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 00:21:11,2024-10-13 00:21:11,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Australia|Canada|Chile|Colombia|France|Germany|Italy|Japan|Korea, Republic of|Peru|Portugal|Puerto Rico|Russian Federation|South Africa|Spain|Ukraine|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04233879,,2020-01-15,2023-10-30,,2023-10-30,2020-01-15,2020-01-18,ACTUAL,2023-10-30,2023-11-21,ACTUAL,,,,2023-10-30,2023-11-21,ACTUAL,2020-02-28,ACTUAL,2020-02-28,2023-10,2023-10-31,2025-03-03,ESTIMATED,2025-03-03,2022-11-17,ACTUAL,2022-11-17,,INTERVENTIONAL,,All randomized participants.,"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatment-Naïve Participants",ACTIVE_NOT_RECRUITING,,PHASE3,599,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 11:16:14,2024-10-14 11:16:14,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Argentina|Canada|Chile|Colombia|France|Germany|Israel|Italy|Japan|South Africa|Spain|Taiwan|United States,"Cardiac disorders|Gastrointestinal disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Vascular disorders"
NCT04244084,,2019-12-13,2021-05-24,,2022-04-28,2020-01-27,2020-01-28,ACTUAL,2021-09-08,2021-10-06,ACTUAL,,,,2022-04-28,2022-05-17,ACTUAL,2019-10-08,ACTUAL,2019-10-08,2021-10,2021-10-31,2020-04-09,ACTUAL,2020-04-09,2020-04-09,ACTUAL,2020-04-09,,INTERVENTIONAL,,,Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection,Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of MMH-407 in the Treatment of Acute Respiratory Viral Infection,COMPLETED,,PHASE3,240,ACTUAL,Materia Medica Holding,,2,,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-14 15:11:22,2024-10-14 15:11:22,INDUSTRY,,,,,,,Materia Medica Holding,Russian Federation,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT04246996,,2020-01-27,2022-09-21,,2022-10-17,2020-01-28,2020-01-29,ACTUAL,2022-10-17,2022-11-08,ACTUAL,,,,2022-10-17,2022-11-08,ACTUAL,2020-01-29,ACTUAL,2020-01-29,2022-10,2022-10-31,2021-12-05,ACTUAL,2021-12-05,2021-12-05,ACTUAL,2021-12-05,,INTERVENTIONAL,GIVEIT,,Gentamicin Intravesical Efficacy for Infection of Urinary Tract,Gentamicin Intravesical Efficacy for Infection of Urinary Tract,COMPLETED,,PHASE2,370,ACTUAL,Kaiser Permanente,,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 03:45:16,2024-10-14 03:45:16,OTHER,,,,,,,"Kaiser Permanente|University of California, San Diego",United States,"Endocrine disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT04258995,,2020-02-04,2021-08-18,,2021-10-11,2020-02-04,2020-02-06,ACTUAL,2021-10-11,2021-10-13,ACTUAL,,,,2021-10-11,2021-10-13,ACTUAL,2020-02-11,ACTUAL,2020-02-11,2021-10,2021-10-31,2020-09-15,ACTUAL,2020-09-15,2020-09-15,ACTUAL,2020-09-15,,INTERVENTIONAL,,Safety population included all participants who received 1 booster dose and had at least 1 safety assessment after receiving the booster dose.,"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS","A PHASE 2, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS",COMPLETED,,PHASE2,151,ACTUAL,Pfizer,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-15 00:35:58,2024-10-15 00:35:58,INDUSTRY,,,,,,,Pfizer,United States,"Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders"
NCT04263142,,2020-02-06,2021-02-09,,2021-02-09,2020-02-06,2020-02-10,ACTUAL,2021-02-09,2021-03-03,ACTUAL,,,,2021-02-09,2021-03-03,ACTUAL,2020-01-27,ACTUAL,2020-01-27,2021-02,2021-02-28,2020-03-24,ACTUAL,2020-03-24,2020-03-24,ACTUAL,2020-03-24,,INTERVENTIONAL,,,A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants,"A Two-Part, Randomized, Open-Label, Single Dose, Crossover Clinical Trial to Assess the Relative Bioavailability of a Tablet Compared to a Capsule of GSK3640254 and to Assess the Effect of Food on the GSK3640254 Tablet in Healthy Participants",COMPLETED,,PHASE1,39,ACTUAL,ViiV Healthcare,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.,"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 00:19:26,2024-10-14 00:19:26,INDUSTRY,,,,,,,ViiV Healthcare,United States,Eye disorders|Gastrointestinal disorders
NCT04294472,,2020-02-26,2023-02-09,,2023-06-05,2020-03-02,2020-03-04,ACTUAL,2023-05-01,2023-05-24,ACTUAL,,,,2023-06-05,2023-06-07,ACTUAL,2020-08-05,ACTUAL,2020-08-05,2023-02,2023-02-28,2022-02-10,ACTUAL,2022-02-10,2022-02-10,ACTUAL,2022-02-10,,INTERVENTIONAL,,"The Participant Flow module included 30 participants randomized; two subjects randomized but not treated were identified, leaving 28 randomized and treated subjects in subsequent modified intent-to-treat analyses. Overall Number of Baseline Participants was based on 28 randomized and treated participants.","A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients","A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients (Neutra4)",COMPLETED,,PHASE2,30,ACTUAL,"Vera Therapeutics, Inc.",,4,,,,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-13 05:11:43,2024-10-13 05:11:43,INDUSTRY,,,,,,,"Vera Therapeutics, Inc.",Canada|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04295772,,2020-03-03,2022-12-07,,2024-01-09,2020-03-03,2020-03-04,ACTUAL,2023-02-23,2023-02-24,ACTUAL,,,,2024-01-09,2024-01-31,ACTUAL,2020-11-26,ACTUAL,2020-11-26,2024-01,2024-01-31,2023-01-25,ACTUAL,2023-01-25,2021-12-21,ACTUAL,2021-12-21,,INTERVENTIONAL,,,Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028),"A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine/Islatravir in Pediatric Participants With HIV-1 Infection Who Are Virologically Suppressed or Treatment-Naïve, Are Less Than 18 Years of Age, and Weigh Greater Than or Equal to 35 kg",COMPLETED,,PHASE2,42,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 02:52:51,2024-10-13 02:52:51,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Italy|Russian Federation|South Africa|Thailand|United States,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04301934,,2020-03-06,2024-03-01,,2024-03-01,2020-03-06,2020-03-10,ACTUAL,2024-03-01,2024-03-26,ACTUAL,,,,2024-03-01,2024-03-26,ACTUAL,2020-06-01,ACTUAL,2020-06-01,2024-03,2024-03-31,2023-04-30,ACTUAL,2023-04-30,2023-04-30,ACTUAL,2023-04-30,,INTERVENTIONAL,,,Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection,Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection,COMPLETED,,NA,12,ACTUAL,Mayo Clinic,,2,,,FALSE,,,,FALSE,FALSE,TRUE,,,,,,,,,NO,,2024-10-14 23:24:26,2024-10-14 23:24:26,OTHER,,,,,,,Mayo Clinic,United States,Gastrointestinal disorders|Renal and urinary disorders|Reproductive system and breast disorders|Vascular disorders
NCT04303156,,2020-03-09,2021-09-29,,2021-09-29,2020-03-09,2020-03-10,ACTUAL,2021-09-29,2021-10-28,ACTUAL,,,,2021-09-29,2021-10-28,ACTUAL,2020-06-18,ACTUAL,2020-06-18,2021-09,2021-09-30,2020-10-19,ACTUAL,2020-10-19,2020-10-19,ACTUAL,2020-10-19,,INTERVENTIONAL,,,Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026),"An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Subjects With Severe Renal Impairment",COMPLETED,,PHASE1,12,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 12:52:45,2024-10-13 12:52:45,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Germany|United States,Musculoskeletal and connective tissue disorders
NCT04308668,,2020-03-11,2021-04-26,,2021-05-11,2020-03-11,2020-03-16,ACTUAL,2021-05-11,2021-05-13,ACTUAL,,,,2021-05-11,2021-05-13,ACTUAL,2020-03-17,ACTUAL,2020-03-17,2021-05,2021-05-31,2020-05-20,ACTUAL,2020-05-20,2020-05-20,ACTUAL,2020-05-20,,INTERVENTIONAL,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,COMPLETED,,PHASE3,1312,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,YES,De-identified dataset will be available within 1 month of publication.,2024-10-14 04:04:40,2024-10-14 04:04:40,OTHER,,,,,,,McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Alberta|University of Manitoba|University of Minnesota,Canada|United States,Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT04308668,,2020-03-11,2021-04-26,,2021-05-11,2020-03-11,2020-03-16,ACTUAL,2021-05-11,2021-05-13,ACTUAL,,,,2021-05-11,2021-05-13,ACTUAL,2020-03-17,ACTUAL,2020-03-17,2021-05,2021-05-31,2020-05-20,ACTUAL,2020-05-20,2020-05-20,ACTUAL,2020-05-20,,INTERVENTIONAL,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,COMPLETED,,PHASE3,1312,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,YES,De-identified dataset will be available within 1 month of publication.,2024-10-14 04:04:40,2024-10-14 04:04:40,OTHER,,,,,,,McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Alberta|University of Manitoba|University of Minnesota,Canada|United States,Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT04308668,,2020-03-11,2021-04-26,,2021-05-11,2020-03-11,2020-03-16,ACTUAL,2021-05-11,2021-05-13,ACTUAL,,,,2021-05-11,2021-05-13,ACTUAL,2020-03-17,ACTUAL,2020-03-17,2021-05,2021-05-31,2020-05-20,ACTUAL,2020-05-20,2020-05-20,ACTUAL,2020-05-20,,INTERVENTIONAL,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,COMPLETED,,PHASE3,1312,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,at time of publication,To be publicly provided. Please register at the website to receive the dataset.,https://covidpep.umn.edu/data,YES,De-identified dataset will be available within 1 month of publication.,2024-10-14 04:04:40,2024-10-14 04:04:40,OTHER,,,,,,,McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Alberta|University of Manitoba|University of Minnesota,Canada|United States,Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT04310085,,2020-03-09,2021-08-09,,2021-09-03,2020-03-12,2020-03-17,ACTUAL,2021-09-03,2021-09-05,ACTUAL,,,,2021-09-03,2021-09-05,ACTUAL,2020-02-19,ACTUAL,2020-02-19,2021-09,2021-09-30,2020-12-17,ACTUAL,2020-12-17,2020-12-17,ACTUAL,2020-12-17,,INTERVENTIONAL,,,Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites,"A Single Centre, Open Label, Pilot Phase Ib Study to Investigate Blood Stage Malaria Infection After Direct Venous Inoculation of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites (PfSPZ-DVI) in Malaria naïve Healthy Adult Volunteers",COMPLETED,,PHASE1,16,ACTUAL,Medicines for Malaria Venture,"This exploratory study focused on the methodology of malaria inoculation in healthy participants. No formal sample size calculation was performed.

No formal statistical analysis was performed for the primary endpoint ""Changes from baseline in haematology, clinical chemistry and urinalysis parameters, vital signs and electrocardiogram (ECG) parameters"". A qualitative interpretation is available if requested.",1,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-13 20:07:31,2024-10-13 20:07:31,OTHER,,,,,,,"FGK Representative Service B.V., The Netherlands|Institute of Tropical Medicine, Belgium|Iqvia Pty Ltd|Medicines for Malaria Venture|PrimeVigilance Ltd., UK|Sanaria Inc.|SGS Life Sciences, a division of SGS Belgium NV|Swiss BioQuant A.G., Switzerland",Belgium,Blood and lymphatic system disorders|General disorders|Investigations
NCT04311177,,2020-03-13,2022-03-16,,2022-05-02,2020-03-13,2020-03-17,ACTUAL,2022-05-02,2022-05-04,ACTUAL,,,,2022-05-02,2022-05-04,ACTUAL,2020-04-09,ACTUAL,2020-04-09,2022-05,2022-05-31,2021-02-01,ACTUAL,2021-02-01,2021-02-01,ACTUAL,2021-02-01,,INTERVENTIONAL,,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,COMPLETED,,PHASE2,117,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-14 00:25:50,2024-10-14 00:25:50,OTHER,,,,,,,University of Minnesota,United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT04311177,,2020-03-13,2022-03-16,,2022-05-02,2020-03-13,2020-03-17,ACTUAL,2022-05-02,2022-05-04,ACTUAL,,,,2022-05-02,2022-05-04,ACTUAL,2020-04-09,ACTUAL,2020-04-09,2022-05,2022-05-31,2021-02-01,ACTUAL,2021-02-01,2021-02-01,ACTUAL,2021-02-01,,INTERVENTIONAL,,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,COMPLETED,,PHASE2,117,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-14 00:25:50,2024-10-14 00:25:50,OTHER,,,,,,,University of Minnesota,United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances"
NCT04311697,,2020-03-14,2023-02-02,,2023-07-21,2020-03-14,2020-03-17,ACTUAL,2023-07-21,2023-07-24,ACTUAL,,,,2023-07-21,2023-07-24,ACTUAL,2020-05-15,ACTUAL,2020-05-15,2021-09,2021-09-30,2021-02-22,ACTUAL,2021-02-22,2021-02-22,ACTUAL,2021-02-22,,INTERVENTIONAL,COVID-AIV,Please note that 5 patients in Aviptadil group were randomized but did not receive Investigational Product. and 2 patients in placebo group were randomized but did not receive treatment - numbers reflect those receiving investigational product,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure,COMPLETED,,PHASE2/PHASE3,203,ACTUAL,APR Applied Pharma Research s.a.,,2,,,TRUE,,,,TRUE,TRUE,FALSE,,,,,,Currently available,Public access,,YES,NeuroRx will share study protocol and statistical analysis plan upon request by qualified researchers,2024-10-13 19:56:46,2024-10-13 19:56:46,OTHER,,NCT04453839,NO_LONGER_AVAILABLE,,,,APR Applied Pharma Research s.a.,Israel|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04312009,,2020-03-13,2022-03-15,,2022-06-27,2020-03-13,2020-03-17,ACTUAL,2022-06-27,2022-06-29,ACTUAL,,,,2022-06-27,2022-06-29,ACTUAL,2020-04-13,ACTUAL,2020-04-13,2022-06,2022-06-30,2021-02-01,ACTUAL,2021-02-01,2021-02-01,ACTUAL,2021-02-01,,INTERVENTIONAL,,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,COMPLETED,,PHASE2,205,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 21:16:59,2024-10-13 21:16:59,OTHER,,,,,,,Bill and Melinda Gates Foundation|University of Minnesota,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04312009,,2020-03-13,2022-03-15,,2022-06-27,2020-03-13,2020-03-17,ACTUAL,2022-06-27,2022-06-29,ACTUAL,,,,2022-06-27,2022-06-29,ACTUAL,2020-04-13,ACTUAL,2020-04-13,2022-06,2022-06-30,2021-02-01,ACTUAL,2021-02-01,2021-02-01,ACTUAL,2021-02-01,,INTERVENTIONAL,,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,COMPLETED,,PHASE2,205,ACTUAL,University of Minnesota,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 21:16:59,2024-10-13 21:16:59,OTHER,,,,,,,Bill and Melinda Gates Foundation|University of Minnesota,United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04323592,,2020-03-19,2020-05-21,,2020-06-23,2020-03-24,2020-03-26,ACTUAL,2020-05-28,2020-06-04,ACTUAL,,,,2020-06-23,2020-06-24,ACTUAL,2020-03-23,ACTUAL,2020-03-23,2020-06,2020-06-30,2020-05-10,ACTUAL,2020-05-10,2020-05-10,ACTUAL,2020-05-10,4 Weeks,OBSERVATIONAL,MP-C19,,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,COMPLETED,,,173,ACTUAL,University of Trieste,,,2,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,NONE_RETAINED,"Previous specific informed consent, blood samples of some patients treated with methylprednisolone were collected, in order to have the possibility to do",,,,NO,Anonymised data will be available only to data manager who can visualise clinical chart anytime when is needed,2024-10-14 19:47:33,2024-10-14 19:47:33,OTHER,,,,,,TRUE,University of Trieste,Italy,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04325906,,2020-03-26,2022-02-02,,2022-02-28,2020-03-27,2020-03-30,ACTUAL,2022-02-24,2022-02-28,ACTUAL,,,,2022-02-28,2022-03-02,ACTUAL,2020-04-02,ACTUAL,2020-04-02,2022-02,2022-02-28,2021-02-21,ACTUAL,2021-02-21,2021-01-26,ACTUAL,2021-01-26,,INTERVENTIONAL,,,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,COMPLETED,,NA,224,ACTUAL,Rush University Medical Center,,2,,,FALSE,,,,FALSE,FALSE,TRUE,,,,,,,,,NO,,2024-10-14 00:59:41,2024-10-14 00:59:41,OTHER,,,,,,,Rush University Medical Center,United States,Surgical and medical procedures
NCT04327388,,2020-03-26,2021-04-28,,2022-03-15,2020-03-26,2020-03-31,ACTUAL,2021-05-11,2021-05-13,ACTUAL,,,,2022-03-15,2022-03-17,ACTUAL,2020-03-28,ACTUAL,2020-03-28,2022-03,2022-03-31,2020-09-02,ACTUAL,2020-09-02,2020-07-31,ACTUAL,2020-07-31,,INTERVENTIONAL,,Analysis was performed on randomized population.,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",COMPLETED,,PHASE3,420,ACTUAL,Sanofi,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-13 20:58:47,2024-10-13 20:58:47,INDUSTRY,,,,,,,Regeneron Pharmaceuticals|Sanofi,Argentina|Brazil|Canada|Chile|France|Germany|Israel|Italy|Japan|Russian Federation|Spain,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04328467,,2020-03-27,2021-06-25,,2021-06-30,2020-03-30,2020-03-31,ACTUAL,2021-06-25,2021-06-30,ACTUAL,,,,2021-06-30,2021-07-02,ACTUAL,2020-04-06,ACTUAL,2020-04-06,2021-06,2021-06-30,2020-07-13,ACTUAL,2020-07-13,2020-07-13,ACTUAL,2020-07-13,,INTERVENTIONAL,,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,COMPLETED,,PHASE3,1483,ACTUAL,University of Minnesota,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-13 14:31:53,2024-10-13 14:31:53,OTHER,,,,,,,University of Minnesota,United States,"Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Injury, poisoning and procedural complications|Renal and urinary disorders|Surgical and medical procedures"
NCT04328961,,2020-03-23,2021-10-08,,2021-12-14,2020-03-29,2020-04-01,ACTUAL,2021-12-14,2021-12-16,ACTUAL,,,,2021-12-14,2021-12-16,ACTUAL,2020-03-31,ACTUAL,2020-03-31,2021-12,2021-12-31,2020-10-08,ACTUAL,2020-10-08,2020-09-24,ACTUAL,2020-09-24,,INTERVENTIONAL,,The above participants contributed to the Modified Intention-to-Treat Cohort.,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",COMPLETED,,PHASE2/PHASE3,943,ACTUAL,University of Washington,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,YES,De-identified data from the study will be made available in accordance with the funder's open access policy.,2024-10-14 12:34:19,2024-10-14 12:34:19,OTHER,,,,,,,Bill and Melinda Gates Foundation|University of Washington,United States,Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Skin and subcutaneous tissue disorders
NCT04329104,,2020-03-30,2024-04-03,,2024-04-03,2020-03-31,2020-04-01,ACTUAL,2024-04-03,2024-05-02,ACTUAL,,,,2024-04-03,2024-05-02,ACTUAL,2021-02-15,ACTUAL,2021-02-15,2024-04,2024-04-30,2023-07-05,ACTUAL,2023-07-05,2022-01-26,ACTUAL,2022-01-26,,INTERVENTIONAL,,,Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali,"Safety and Efficacy of VRC-MALMAB0100-00-AB (CIS43LS), a Human Monoclonal Antibody Against Plasmodium Falciparum, in a Dose-Escalation Trial and a Randomized, Double-Blind Trial of Adults in Mali",COMPLETED,,PHASE2,348,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,6,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 08:15:37,2024-10-13 08:15:37,NIH,,,,,,,"Harvard School of Public Health (HSPH)|Malaria Research and Training Center, Bamako, Mali|National Institute of Allergy and Infectious Diseases (NIAID)|University of Washington",Mali,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04330989,,2020-03-30,2022-12-13,,2023-01-09,2020-03-30,2020-04-02,ACTUAL,2022-12-13,2023-01-09,ACTUAL,,,,2023-01-09,2023-01-11,ACTUAL,2020-03-01,ACTUAL,2020-03-01,2022-01,2022-01-31,2022-02-10,ACTUAL,2022-02-10,2022-02-10,ACTUAL,2022-02-10,,INTERVENTIONAL,,,An Integrated Strategy to Support Antiretroviral Therapy and Pre-exposure Prophylaxis Adherence for HIV Prevention in Pregnant and Breastfeeding Women,UNCPMZ 41901 - An Integrated Strategy to Support Antiretroviral Therapy and Pre-exposure Prophylaxis Adherence for HIV Prevention in Pregnant and Breastfeeding Women: a Pilot Study,COMPLETED,,NA,300,ACTUAL,"University of North Carolina, Chapel Hill",,4,,,FALSE,,,,FALSE,FALSE,FALSE,,,TRUE,,,,,,,,2024-10-14 02:14:10,2024-10-14 02:14:10,OTHER,,,,,,,"National Institute of Allergy and Infectious Diseases (NIAID)|University of North Carolina, Chapel Hill",Malawi|Zambia,"Infections and infestations|Pregnancy, puerperium and perinatal conditions"
NCT04332991,,2020-03-31,2021-02-09,,2021-03-12,2020-03-31,2020-04-03,ACTUAL,2021-03-12,2021-03-17,ACTUAL,,,,2021-03-12,2021-03-17,ACTUAL,2020-04-02,ACTUAL,2020-04-02,2021-03,2021-03-31,2020-07-23,ACTUAL,2020-07-23,2020-06-19,ACTUAL,2020-06-19,,INTERVENTIONAL,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,COMPLETED,,PHASE3,479,ACTUAL,Massachusetts General Hospital,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 15:13:45,2024-10-13 15:13:45,OTHER,,,,,,,"Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)",United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04332991,,2020-03-31,2021-02-09,,2021-03-12,2020-03-31,2020-04-03,ACTUAL,2021-03-12,2021-03-17,ACTUAL,,,,2021-03-12,2021-03-17,ACTUAL,2020-04-02,ACTUAL,2020-04-02,2021-03,2021-03-31,2020-07-23,ACTUAL,2020-07-23,2020-06-19,ACTUAL,2020-06-19,,INTERVENTIONAL,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,COMPLETED,,PHASE3,479,ACTUAL,Massachusetts General Hospital,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 15:13:45,2024-10-13 15:13:45,OTHER,,,,,,,"Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)",United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04340557,,2020-04-06,2021-05-20,,2021-05-24,2020-04-08,2020-04-09,ACTUAL,2021-05-24,2021-05-26,ACTUAL,,,,2021-05-24,2021-05-26,ACTUAL,2020-03-27,ACTUAL,2020-03-27,2021-05,2021-05-31,2020-06-13,ACTUAL,2020-06-13,2020-06-13,ACTUAL,2020-06-13,,INTERVENTIONAL,,,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,COMPLETED,,PHASE4,31,ACTUAL,Sharp HealthCare,"The generalizability is limited by small size of the study population, unblinded design, and all the subjects being screened from three hospitals in close proximity in one geographic area in Southern California.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 19:34:17,2024-10-13 19:34:17,OTHER,,,,,,,Sharp HealthCare,United States,General disorders|Vascular disorders
NCT04342169,,2020-04-07,2022-11-21,,2023-01-19,2020-04-09,2020-04-10,ACTUAL,2023-01-19,2023-02-15,ACTUAL,,,,2023-01-19,2023-02-15,ACTUAL,2020-04-04,ACTUAL,2020-04-04,2023-01,2023-01-31,2021-11-15,ACTUAL,2021-11-15,2021-10-30,ACTUAL,2021-10-30,,INTERVENTIONAL,,"Randomized participants. \*one person who was erroneously administered study treatment before consenting/randomization due to a participant mix up, so although this individual will be omitted from the study's ITT-based analysis they will be included in the safety analysis.",University of Utah COVID-19 Hydrochloroquine Trial,Hydroxychloroquine for Outpatients With Confirmed COVID-19,COMPLETED,,PHASE2,368,ACTUAL,University of Utah,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,,2024-10-14 19:11:56,2024-10-14 19:11:56,OTHER,,,,,,,University of Utah,United States,"Gastrointestinal disorders|Infections and infestations|Investigations|Respiratory, thoracic and mediastinal disorders|Surgical and medical procedures"
NCT04348370,,2020-03-30,2024-08-13,,2024-09-11,2020-04-14,2020-04-16,ACTUAL,2024-09-11,2024-10-08,ACTUAL,,,,2024-09-11,2024-10-08,ACTUAL,2020-04-20,ACTUAL,2020-04-20,2024-09,2024-09-30,2023-04-21,ACTUAL,2023-04-21,2023-04-21,ACTUAL,2023-04-21,,INTERVENTIONAL,BADAS,,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,COMPLETED,,PHASE4,659,ACTUAL,Texas A&M University,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,,NO,There is not a plan to make IPD available.,2024-10-13 11:51:49,2024-10-13 11:51:49,OTHER,,,,,,,Baylor College of Medicine|Cedars-Sinai Medical Center|Harvard University|M.D. Anderson Cancer Center|Texas A&M University,United States,"General disorders|Injury, poisoning and procedural complications"
NCT04349098,,2020-04-14,2021-10-05,,2023-01-19,2020-04-14,2020-04-16,ACTUAL,2021-10-27,2021-11-01,ACTUAL,,,,2023-01-19,2023-01-20,ACTUAL,2020-04-17,ACTUAL,2020-04-17,2023-01,2023-01-31,2020-10-05,ACTUAL,2020-10-05,2020-10-05,ACTUAL,2020-10-05,,INTERVENTIONAL,Coronavirus,PV 1-6 population included participants randomized into the study under protocol versions 1-6.,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,COMPLETED,,PHASE2,190,ACTUAL,Karyopharm Therapeutics Inc,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-14 21:16:32,2024-10-14 21:16:32,INDUSTRY,,,,,,,Karyopharm Therapeutics Inc,Austria|France|Israel|Spain|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04355728,,2020-04-13,2021-10-15,,2021-12-01,2020-04-17,2020-04-21,ACTUAL,2021-12-01,2021-12-06,ACTUAL,,,,2021-12-01,2021-12-06,ACTUAL,2020-04-25,ACTUAL,2020-04-25,2021-12,2021-12-31,2020-10-31,ACTUAL,2020-10-31,2020-10-31,ACTUAL,2020-10-31,,INTERVENTIONAL,,,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),COMPLETED,,PHASE1/PHASE2,24,ACTUAL,University of Miami,"The inferences we make from the efficacy results observed in this phase 1/2a trial in 24 subjects, including the outcome of survival, are still subject to limitations of sample size and potential bias because of factors we were not yet aware of.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 01:17:48,2024-10-13 01:17:48,OTHER,,,,,,,Camillo Ricordi,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04359810,,2020-04-21,2021-11-03,,2024-08-22,2020-04-21,2020-04-24,ACTUAL,2024-08-22,2024-09-19,ACTUAL,,,,2024-08-22,2024-09-19,ACTUAL,2020-04-21,ACTUAL,2020-04-21,2024-08,2024-08-31,2020-12-30,ACTUAL,2020-12-30,2020-12-30,ACTUAL,2020-12-30,,INTERVENTIONAL,,,Plasma Therapy of COVID-19 in Severely Ill Patients,"A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19",COMPLETED,,PHASE2,223,ACTUAL,Columbia University,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,YES,The data-sharing plans for this study will be made available at a later date.,2024-10-15 04:00:26,2024-10-15 04:00:26,OTHER,,,,,,,"Amazon.com, Inc.|Max O'Donnell|New York Blood Center",Brazil|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04364737,,2020-04-22,2022-03-28,,2023-01-24,2020-04-24,2020-04-28,ACTUAL,2022-03-30,2022-04-01,ACTUAL,,,,2023-01-24,2023-01-26,ACTUAL,2020-04-17,ACTUAL,2020-04-17,2023-01,2023-01-31,2022-12-12,ACTUAL,2022-12-12,2021-03-29,ACTUAL,2021-03-29,,INTERVENTIONAL,,,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients,COMPLETED,,PHASE2,941,ACTUAL,NYU Langone Health,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Mila.Ortigoza@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",,YES,"IPD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared.",2024-10-14 11:09:57,2024-10-14 11:09:57,OTHER,,,,,,,"Albert Einstein College of Medicine|National Center for Advancing Translational Sciences (NCATS)|NYU Langone Health|The University of Texas Health Science Center at Tyler|The University of Texas Health Science Center, Houston|University of Miami|Yale University",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04371380,,2020-04-28,2022-12-08,,2023-11-03,2020-04-28,2020-05-01,ACTUAL,2023-11-03,2024-04-22,ACTUAL,,,,2023-11-03,2024-04-22,ACTUAL,2020-09-16,ACTUAL,2020-09-16,2023-11,2023-11-30,2021-12-26,ACTUAL,2021-12-26,2021-12-26,ACTUAL,2021-12-26,,INTERVENTIONAL,,All enrolled population included participants who signed the informed consent form and received at least 1 dose of study drug.,Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants,"A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Tolerability of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in the Vastus Lateralis Muscle of Healthy Adult Participants",COMPLETED,,PHASE1,15,ACTUAL,ViiV Healthcare,,1,,,TRUE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 06:40:51,2024-10-13 06:40:51,INDUSTRY,,NCT03462810,AVAILABLE,,,,GlaxoSmithKline|Janssen Pharmaceuticals|ViiV Healthcare,United States,"Eye disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Surgical and medical procedures"
NCT04374565,,2020-04-27,2021-04-14,,2022-03-30,2020-05-01,2020-05-05,ACTUAL,2022-03-30,2022-04-01,ACTUAL,,,,2022-03-30,2022-04-01,ACTUAL,2020-05-05,ACTUAL,2020-05-05,2022-03,2022-03-31,2021-03-05,ACTUAL,2021-03-05,2021-03-05,ACTUAL,2021-03-05,,INTERVENTIONAL,,,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial,COMPLETED,,PHASE2,29,ACTUAL,University of Virginia,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-13 11:09:25,2024-10-13 11:09:25,OTHER,,,,,,,University of Virginia,United States,"Blood and lymphatic system disorders|Cardiac disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04377672,,2020-05-04,2022-11-01,,2024-03-26,2020-05-04,2020-05-06,ACTUAL,2024-03-26,2024-03-27,ACTUAL,,,,2024-03-26,2024-03-27,ACTUAL,2020-05-28,ACTUAL,2020-05-28,2024-03,2024-03-31,2021-12-13,ACTUAL,2021-12-13,2021-09-01,ACTUAL,2021-09-01,,INTERVENTIONAL,,,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2,COMPLETED,,PHASE1,14,ACTUAL,Johns Hopkins University,"The sample size of this cohort is small. Some participants in this study were immunocompromised, which could have altered their endogenous antibody responses. Single donor plasma was utilized rather than hyperimmune globulin due to practical issues of producing the product in the settings of a rapid response to a pandemic. Pharmacokinetic analysis for three participants was limited by the fact they received intravenous immunoglobulins as part of their routine care.",1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 01:11:36,2024-10-14 01:11:36,OTHER,,,,,,,Johns Hopkins University,United States,Immune system disorders
NCT04380701,,2020-05-06,2022-05-30,,2024-01-31,2020-05-07,2020-05-08,ACTUAL,2024-01-31,2024-07-12,ACTUAL,,,,2024-01-31,2024-07-12,ACTUAL,2020-04-23,ACTUAL,2020-04-23,2024-01,2024-01-31,2022-04-13,ACTUAL,2022-04-13,2021-06-30,ACTUAL,2021-06-30,,INTERVENTIONAL,,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",COMPLETED,,PHASE1/PHASE2,512,ACTUAL,BioNTech SE,,9,,,FALSE,,,,FALSE,FALSE,FALSE,,,FALSE,,,,,,NO,,2024-10-14 06:11:05,2024-10-14 06:11:05,INDUSTRY,,,,,,,BioNTech SE,Germany,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT04380701,,2020-05-06,2022-05-30,,2024-01-31,2020-05-07,2020-05-08,ACTUAL,2024-01-31,2024-07-12,ACTUAL,,,,2024-01-31,2024-07-12,ACTUAL,2020-04-23,ACTUAL,2020-04-23,2024-01,2024-01-31,2022-04-13,ACTUAL,2022-04-13,2021-06-30,ACTUAL,2021-06-30,,INTERVENTIONAL,,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",COMPLETED,,PHASE1/PHASE2,512,ACTUAL,BioNTech SE,,9,,,FALSE,,,,FALSE,FALSE,FALSE,,,FALSE,,,,,,NO,,2024-10-14 06:11:05,2024-10-14 06:11:05,INDUSTRY,,,,,,,BioNTech SE,Germany,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT04380701,,2020-05-06,2022-05-30,,2024-01-31,2020-05-07,2020-05-08,ACTUAL,2024-01-31,2024-07-12,ACTUAL,,,,2024-01-31,2024-07-12,ACTUAL,2020-04-23,ACTUAL,2020-04-23,2024-01,2024-01-31,2022-04-13,ACTUAL,2022-04-13,2021-06-30,ACTUAL,2021-06-30,,INTERVENTIONAL,,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",COMPLETED,,PHASE1/PHASE2,512,ACTUAL,BioNTech SE,,9,,,FALSE,,,,FALSE,FALSE,FALSE,,,FALSE,,,,,,NO,,2024-10-14 06:11:05,2024-10-14 06:11:05,INDUSTRY,,,,,,,BioNTech SE,Germany,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT04380701,,2020-05-06,2022-05-30,,2024-01-31,2020-05-07,2020-05-08,ACTUAL,2024-01-31,2024-07-12,ACTUAL,,,,2024-01-31,2024-07-12,ACTUAL,2020-04-23,ACTUAL,2020-04-23,2024-01,2024-01-31,2022-04-13,ACTUAL,2022-04-13,2021-06-30,ACTUAL,2021-06-30,,INTERVENTIONAL,,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy and Immunocompromised Adults",COMPLETED,,PHASE1/PHASE2,512,ACTUAL,BioNTech SE,,9,,,FALSE,,,,FALSE,FALSE,FALSE,,,FALSE,,,,,,NO,,2024-10-14 06:11:05,2024-10-14 06:11:05,INDUSTRY,,,,,,,BioNTech SE,Germany,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Surgical and medical procedures|Vascular disorders"
NCT04380857,,2020-05-05,2023-06-09,,2023-09-18,2020-05-07,2020-05-08,ACTUAL,2023-08-24,2023-09-21,ACTUAL,,,,2023-09-18,2023-10-06,ACTUAL,2020-06-18,ACTUAL,2020-06-18,2023-09,2023-09-30,2021-06-21,ACTUAL,2021-06-21,2021-06-21,ACTUAL,2021-06-21,,INTERVENTIONAL,,,Assessing Dextenza Insert After SMILE Procedure,"Assessing the Efficacy of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Comparison to Topical Prednisolone Acetate Following Bilateral Small Incision Lenticule Extraction (SMILE)",COMPLETED,,PHASE4,20,ACTUAL,Cleveland Eye Clinic,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 07:13:49,2024-10-13 07:13:49,OTHER,,,,,,,"William Wiley, MD",United States,Eye disorders
NCT04384107,,2020-05-11,2022-09-06,,2023-07-20,2020-05-11,2020-05-12,ACTUAL,2022-10-26,2022-11-15,ACTUAL,,,,2023-07-20,2023-07-28,ACTUAL,2020-07-01,ACTUAL,2020-07-01,2023-07,2023-07-31,2021-12-01,ACTUAL,2021-12-01,2021-12-01,ACTUAL,2021-12-01,,INTERVENTIONAL,,,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)","A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants",COMPLETED,,PHASE3,694,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-15 00:47:13,2024-10-15 00:47:13,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,"Congenital, familial and genetic disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04390022,,2020-05-07,2020-12-09,,2020-12-10,2020-05-14,2020-05-15,ACTUAL,2020-12-10,2020-12-17,ACTUAL,,,,2020-12-10,2020-12-17,ACTUAL,2020-07-31,ACTUAL,2020-07-31,2020-12,2020-12-31,2020-10-09,ACTUAL,2020-10-09,2020-09-17,ACTUAL,2020-09-17,,INTERVENTIONAL,SAINT,,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,COMPLETED,,PHASE2,24,ACTUAL,"Clinica Universidad de Navarra, Universidad de Navarra",,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-13 18:31:10,2024-10-13 18:31:10,OTHER,,,,,,,"Barcelona Institute for Global Health|Clinica Universidad de Navarra, Universidad de Navarra",Spain,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT04390022,,2020-05-07,2020-12-09,,2020-12-10,2020-05-14,2020-05-15,ACTUAL,2020-12-10,2020-12-17,ACTUAL,,,,2020-12-10,2020-12-17,ACTUAL,2020-07-31,ACTUAL,2020-07-31,2020-12,2020-12-31,2020-10-09,ACTUAL,2020-10-09,2020-09-17,ACTUAL,2020-09-17,,INTERVENTIONAL,SAINT,,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,COMPLETED,,PHASE2,24,ACTUAL,"Clinica Universidad de Navarra, Universidad de Navarra",,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-13 18:31:10,2024-10-13 18:31:10,OTHER,,,,,,,"Barcelona Institute for Global Health|Clinica Universidad de Navarra, Universidad de Navarra",Spain,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Skin and subcutaneous tissue disorders
NCT04391179,,2020-05-15,2022-03-04,,2022-03-18,2020-05-15,2020-05-18,ACTUAL,2022-03-18,2022-03-24,ACTUAL,,,,2022-03-18,2022-03-24,ACTUAL,2020-05-31,ACTUAL,2020-05-31,2022-03,2022-03-31,2021-02-22,ACTUAL,2021-02-22,2021-02-22,ACTUAL,2021-02-22,,INTERVENTIONAL,DICER,,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,COMPLETED,,PHASE2,99,ACTUAL,University of Michigan,,2,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 17:47:01,2024-10-14 17:47:01,OTHER,,,,,,,University of Michigan,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04391179,,2020-05-15,2022-03-04,,2022-03-18,2020-05-15,2020-05-18,ACTUAL,2022-03-18,2022-03-24,ACTUAL,,,,2022-03-18,2022-03-24,ACTUAL,2020-05-31,ACTUAL,2020-05-31,2022-03,2022-03-31,2021-02-22,ACTUAL,2021-02-22,2021-02-22,ACTUAL,2021-02-22,,INTERVENTIONAL,DICER,,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,COMPLETED,,PHASE2,99,ACTUAL,University of Michigan,,2,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 17:47:01,2024-10-14 17:47:01,OTHER,,,,,,,University of Michigan,United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04399551,,2020-05-18,2023-03-06,,2024-04-04,2020-05-18,2020-05-22,ACTUAL,2023-04-24,2023-05-19,ACTUAL,,,,2024-04-04,2024-04-05,ACTUAL,2020-09-28,ACTUAL,2020-09-28,2024-04,2024-04-30,2023-03-13,ACTUAL,2023-03-13,2022-03-07,ACTUAL,2022-03-07,,INTERVENTIONAL,,,A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries,"A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings",COMPLETED,,PHASE3,437,ACTUAL,ViiV Healthcare,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 10:04:36,2024-10-13 10:04:36,INDUSTRY,,,,,,,Janssen Pharmaceuticals|ViiV Healthcare,Belgium|France|Germany|Netherlands|Spain,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04402060,,2020-05-22,2022-01-04,,2022-03-21,2020-05-22,2020-05-26,ACTUAL,2022-03-21,2022-03-23,ACTUAL,,,,2022-03-21,2022-03-23,ACTUAL,2020-05-28,ACTUAL,2020-05-28,2022-03,2022-03-31,2021-02-13,ACTUAL,2021-02-13,2021-02-13,ACTUAL,2021-02-13,,INTERVENTIONAL,,The safety set included all subjects who received at least 1 dose of study drug. Subjects were analyzed according to the actual treatment they received.,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,"A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19",COMPLETED,,PHASE1/PHASE2,72,ACTUAL,"Apellis Pharmaceuticals, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 02:52:51,2024-10-13 02:52:51,INDUSTRY,,,,,,,"Apellis Pharmaceuticals, Inc.",Brazil|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04404855,,2020-05-13,2022-09-01,,2024-03-11,2020-05-21,2020-05-28,ACTUAL,2023-08-17,2024-03-12,ACTUAL,,,,2024-03-11,2024-03-12,ACTUAL,2019-12-18,ACTUAL,2019-12-18,2024-03,2024-03-31,2022-08-31,ACTUAL,2022-08-31,2022-01-31,ACTUAL,2022-01-31,,INTERVENTIONAL,ACCESS,50 subjects from the intervention group were included in the analysis population and 86 in the control group. Other subjects were screen failures or non-compliant with study procedures.,Antibiotic Selection Using Next Generation Sequencing vs Urine Culture,Randomized Clinical Trial Using Next Generation Microbial Sequencing to Direct Antibiotic Selection Before Kidney Stone Lithotripsy Using an Interprofessional Model,COMPLETED,,NA,240,ACTUAL,The University of Texas Health Science Center at San Antonio,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,At the time of publication in a peer review journal,,,YES,"Deidentified data be shared, in addition to the individual participant data set and data dictionaries for the IPD itself.",2024-10-13 06:14:24,2024-10-13 06:14:24,OTHER,,,,,,,MicroGen DX|The University of Texas Health Science Center at San Antonio,United States,Metabolism and nutrition disorders
NCT04405570,,2020-05-26,2022-01-18,,2022-02-14,2020-05-26,2020-05-28,ACTUAL,2022-02-14,2022-02-16,ACTUAL,,,,2022-02-14,2022-02-16,ACTUAL,2020-06-19,ACTUAL,2020-06-19,2022-02,2022-02-28,2021-02-21,ACTUAL,2021-02-21,2021-02-21,ACTUAL,2021-02-21,,INTERVENTIONAL,,,"Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2RNA Detection in Persons With COVID-19",COMPLETED,,PHASE2,204,ACTUAL,"Ridgeback Biotherapeutics, LP",,4,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,NO,There is not a plan to make IPD available.,2024-10-14 08:52:59,2024-10-14 08:52:59,INDUSTRY,,,,,,,"Merck Sharp & Dohme LLC|Ridgeback Biotherapeutics, LP",United States,"Investigations|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders"
NCT04405999,,2020-05-18,2022-03-21,,2022-04-11,2020-05-26,2020-05-28,ACTUAL,2022-04-11,2022-04-13,ACTUAL,,,,2022-04-11,2022-04-13,ACTUAL,2020-05-14,ACTUAL,2020-05-14,2022-03,2022-03-31,2020-08-31,ACTUAL,2020-08-31,2020-08-09,ACTUAL,2020-08-09,,INTERVENTIONAL,,,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial,COMPLETED,,PHASE4,50,ACTUAL,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 23:07:13,2024-10-14 23:07:13,OTHER,,,,,,,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",Russian Federation,"Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04414618,,2020-05-26,2022-02-03,,2022-03-17,2020-05-29,2020-06-04,ACTUAL,2022-03-17,2022-03-21,ACTUAL,,,,2022-03-17,2022-03-21,ACTUAL,2020-07-02,ACTUAL,2020-07-02,2022-03,2022-03-31,2020-12-23,ACTUAL,2020-12-23,2020-11-26,ACTUAL,2020-11-26,,INTERVENTIONAL,COVID-19,,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia",COMPLETED,,PHASE2,42,ACTUAL,RedHill Biopharma Limited,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 13:07:17,2024-10-14 13:07:17,INDUSTRY,,,,,,,RedHill Biopharma Limited,Israel|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04425902,,2020-06-05,2022-03-03,,2023-12-22,2020-06-05,2020-06-11,ACTUAL,2022-03-03,2022-05-23,ACTUAL,,,,2023-12-22,2024-01-05,ACTUAL,2020-12-16,ACTUAL,2020-12-16,2023-12,2023-12-31,2021-03-10,ACTUAL,2021-03-10,2021-03-10,ACTUAL,2021-03-10,,INTERVENTIONAL,,Safety Population consisted of all participants who received at least 1 dose of study medication.,"Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults","Effects of GSK3640254 on the Single-Dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects",COMPLETED,,PHASE1,20,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-13 09:37:59,2024-10-13 09:37:59,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Gastrointestinal disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04451707,,2020-06-24,2021-02-19,,2023-10-26,2020-06-25,2020-06-30,ACTUAL,2021-02-19,2021-03-15,ACTUAL,,,,2023-10-26,2023-10-31,ACTUAL,2020-03-12,ACTUAL,2020-03-12,2023-10,2023-10-31,2020-06-17,ACTUAL,2020-06-17,2020-06-17,ACTUAL,2020-06-17,,OBSERVATIONAL,INFECTIVE,,Epidemiology Non-cholera Vibrio Infections,Multicentre Retrospective Study on the Clinical and Epidemiological Characteristics and Therapeutic Management of Non-cholera Vibrio Infections,COMPLETED,,,67,ACTUAL,Groupe Hospitalier de la Rochelle Ré Aunis,,,1,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,From publication and up to 15 years after publication,Contact the corresponding author of the publication,,YES,"Data will be made available with publication. Keyword are infection, non-cholera Vibrio, epidemiology The only available version will be the locked database. The database will be made available by the study director upon request up to 15 years after publication.

Medical Subject Headings (MESH) terms will be used to describe clinical data. Methodology for will be provided in the publication. International standard unit will be used.",2024-10-13 21:22:54,2024-10-13 21:22:54,OTHER,,,,,,FALSE,Groupe Hospitalier de la Rochelle Ré Aunis,France,Infections and infestations
NCT04467840,,2020-07-09,2023-01-28,,2023-09-25,2020-07-09,2020-07-13,ACTUAL,2023-09-25,2023-10-19,ACTUAL,,,,2023-09-25,2023-10-19,ACTUAL,2020-08-21,ACTUAL,2020-08-21,2023-09,2023-09-30,2021-07-18,ACTUAL,2021-07-18,2021-07-18,ACTUAL,2021-07-18,,INTERVENTIONAL,,,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia",COMPLETED,,PHASE2/PHASE3,475,ACTUAL,RedHill Biopharma Limited,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 10:52:51,2024-10-13 10:52:51,INDUSTRY,,,,,,,RedHill Biopharma Limited,Brazil|Colombia|Israel|Italy|Mexico|Peru|Poland|Russian Federation|United Kingdom|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04468204,,2020-07-08,2022-09-23,,2022-11-22,2020-07-10,2020-07-13,ACTUAL,2022-11-22,2022-12-20,ACTUAL,,,,2022-11-22,2022-12-20,ACTUAL,2020-10-01,ACTUAL,2020-10-01,2022-11,2022-11-30,2021-07-01,ACTUAL,2021-07-01,2021-06-30,ACTUAL,2021-06-30,,INTERVENTIONAL,,,Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI),Use of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory (URI),COMPLETED,,NA,95,ACTUAL,Medical University of South Carolina,,2,,,FALSE,,,,,FALSE,TRUE,,,FALSE,,,,,,NO,Not Applicable. The investigators plan to publish this study.,2024-10-13 05:22:56,2024-10-13 05:22:56,OTHER,,,,,,,Medical University of South Carolina,United States,Ear and labyrinth disorders
NCT04469218,,2020-07-08,2022-04-27,,2023-12-19,2020-07-10,2020-07-13,ACTUAL,2023-12-19,2024-01-16,ACTUAL,,,,2023-12-19,2024-01-16,ACTUAL,2020-07-14,ACTUAL,2020-07-14,2023-12,2023-12-31,2020-12-31,ACTUAL,2020-12-31,2020-12-31,ACTUAL,2020-12-31,,INTERVENTIONAL,DIPPER,,A Clinical Trial Using a New Medical Device to Evaluate Its Impact on IV Care and Clinical Complications,Dislodgement Infiltration Phlebitis Prevention Eliminating Restarts (DIPPER),COMPLETED,,NA,148,ACTUAL,Lineus Medical,,2,,,FALSE,,,,FALSE,FALSE,TRUE,,,TRUE,,,,,,NO,,2024-10-13 12:09:05,2024-10-13 12:09:05,INDUSTRY,,,,,,,Hartford HealthCare|Hartford Hospital|Lineus Medical|Technomics Research,United States,"Blood and lymphatic system disorders|Cardiac disorders|General disorders|Injury, poisoning and procedural complications|Product Issues|Psychiatric disorders|Renal and urinary disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT04472377,,2020-07-09,2023-07-21,,2024-09-19,2020-07-13,2020-07-15,ACTUAL,2024-03-07,2024-08-12,ACTUAL,,,,2024-09-19,2024-10-03,ACTUAL,2020-05-29,ACTUAL,2020-05-29,2024-09,2024-09-30,2022-04-18,ACTUAL,2022-04-18,2021-12-21,ACTUAL,2021-12-21,,INTERVENTIONAL,,,HPV Typing Between Self- and Physician-sampled,"Evaluate the Agreement of High-risk Human Papillomavirus Type Between Self-collected Vaginal Discharge Sample Using ""HygeiaTouch Self Sampling Kit for Woman"" and Physician Collected Sample From the Cervix",COMPLETED,,NA,1210,ACTUAL,Hygeia Touch Inc.,,1,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,3 months after accepting for report publication,to the public,,YES,For clinical trial participation.,2024-10-13 10:04:36,2024-10-13 10:04:36,INDUSTRY,,,,,,,Hygeia Touch Inc.,Taiwan,Product Issues
NCT04484935,,2020-06-30,2023-08-29,,2023-10-25,2020-07-20,2020-07-24,ACTUAL,2023-10-25,2023-11-15,ACTUAL,,,,2023-10-25,2023-11-15,ACTUAL,2020-08-19,ACTUAL,2020-08-19,2023-10,2023-10-31,2023-02-17,ACTUAL,2023-02-17,2023-02-17,ACTUAL,2023-02-17,,INTERVENTIONAL,MUSIC,The As-treated population consisted of all participants who were enrolled and received any dose of nirsevimab.,"Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children","A Phase 2, Open-label, Uncontrolled, Single-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Children ≤ 24 Months of Age",COMPLETED,,PHASE2,100,ACTUAL,AstraZeneca,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"AstraZeneca will meet or exceed data availability as per the commitments made to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,YES,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AstraZeneca (AZ) disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AstraZeneca (AZ) are accepting requests for Individual Participant Data (IPD), but this does not mean all requests will be shared.",2024-10-13 12:52:45,2024-10-13 12:52:45,INDUSTRY,,,,,,,AstraZeneca|Iqvia Pty Ltd,Belgium|Japan|Poland|South Africa|Spain|Ukraine|United Kingdom|United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04488770,,2020-07-23,2022-05-10,,2022-05-10,2020-07-23,2020-07-28,ACTUAL,2022-05-10,2023-02-17,ACTUAL,,,,2022-05-10,2023-02-17,ACTUAL,2020-08-24,ACTUAL,2020-08-24,2022-05,2022-05-31,2021-05-14,ACTUAL,2021-05-14,2021-05-14,ACTUAL,2021-05-14,,INTERVENTIONAL,,,"Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.","A Double-Blind Randomized, Placebo-Controlled, Single and Repeated Oral Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Effect) of GSK3882347 in Healthy Participants",COMPLETED,,PHASE1,61,ACTUAL,GlaxoSmithKline,,12,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 17:54:48,2024-10-13 17:54:48,INDUSTRY,,,,,,,Department of Health and Human Services|GlaxoSmithKline|Wellcome Trust,United Kingdom,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders"
NCT04491877,,2020-07-27,2024-04-12,,2024-05-20,2020-07-27,2020-07-29,ACTUAL,2024-05-20,2024-06-13,ACTUAL,,,,2024-05-20,2024-06-13,ACTUAL,2020-09-17,ACTUAL,2020-09-17,2024-05,2024-05-31,2023-04-13,ACTUAL,2023-04-13,2023-04-13,ACTUAL,2023-04-13,,INTERVENTIONAL,VAD00001,Randomized participants included all participants allocated to a vaccine group.,Study of an Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers,"Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers",COMPLETED,,PHASE1/PHASE2,259,ACTUAL,Sanofi,,9,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,YES,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org",2024-10-13 17:07:27,2024-10-13 17:07:27,INDUSTRY,,,,,,,"Sanofi Pasteur, a Sanofi Company",Chile|Honduras|United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04493684,,2020-07-20,2022-08-29,,2023-08-20,2020-07-29,2020-07-30,ACTUAL,2023-08-20,2023-08-23,ACTUAL,,,,2023-08-20,2023-08-23,ACTUAL,2020-07-31,ACTUAL,2020-07-31,2023-08,2023-08-31,2021-08-30,ACTUAL,2021-08-30,2021-08-30,ACTUAL,2021-08-30,,INTERVENTIONAL,,,GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers,"A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3739937 in Healthy Participants",COMPLETED,,PHASE1,91,ACTUAL,ViiV Healthcare,,15,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-15 00:18:36,2024-10-15 00:18:36,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04493931,,2020-07-28,2021-12-09,,2021-12-09,2020-07-28,2020-07-30,ACTUAL,2021-12-09,2022-03-04,ACTUAL,,,,2021-12-09,2022-03-04,ACTUAL,2020-08-14,ACTUAL,2020-08-14,2021-12,2021-12-31,2020-12-21,ACTUAL,2020-12-21,2020-12-21,ACTUAL,2020-12-21,,INTERVENTIONAL,,,Drug-drug Interaction Study of Gepotidacin,"A Pharmacokinetic, Multi-cohort Study in Healthy Adult Subjects to Assess Gepotidacin as Victim and as Perpetrator of Drug-Drug Interactions Via CYP450, Renal and Intestinal Transporters, and to Assess Gepotidacin Pharmacokinetics in Japanese Healthy Adults",COMPLETED,,PHASE1,64,ACTUAL,GlaxoSmithKline,,7,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 09:21:12,2024-10-13 09:21:12,INDUSTRY,,,,,,,GlaxoSmithKline,United States,Gastrointestinal disorders|Investigations|Nervous system disorders
NCT04502693,,2020-08-04,2023-12-21,2023-09-04,2024-02-09,2020-08-04,2020-08-06,ACTUAL,2024-02-09,2024-03-05,ACTUAL,,2024-03-05,ACTUAL,2024-02-09,2024-03-05,ACTUAL,2020-08-14,ACTUAL,2020-08-14,2024-02,2024-02-29,2022-09-13,ACTUAL,2022-09-13,2022-09-13,ACTUAL,2022-09-13,,INTERVENTIONAL,,"As pre-specified in the protocol, data reported in the Baseline characteristics are presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.",Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults,"A Phase III, Randomized, Controlled, Observer-blind Study to Demonstrate Effectiveness, Immunogenicity and Safety of GSK's Meningococcal Group B and Combined ABCWY Vaccines When Administered to Healthy Adolescents and Young Adults",COMPLETED,,PHASE3,3657,ACTUAL,GlaxoSmithKline,,7,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 03:41:50,2024-10-13 03:41:50,INDUSTRY,,,,,,,GlaxoSmithKline,Australia|Canada|Czechia|Estonia|Finland|Turkey|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT04507321,,2020-08-06,2021-11-19,,2021-11-19,2020-08-06,2020-08-11,ACTUAL,2021-11-19,2022-01-31,ACTUAL,,,,2021-11-19,2022-01-31,ACTUAL,2020-09-24,ACTUAL,2020-09-24,2021-11,2021-11-30,2020-11-23,ACTUAL,2020-11-23,2020-11-23,ACTUAL,2020-11-23,,INTERVENTIONAL,,,Pharmacokinetics and Metabolism of 14 Carbon [14C]-GSK3640254,"A Two-period Study in Healthy Male Participants to Determine the Pharmacokinetics, Balance/Excretion, and Metabolism of [14C]-GSK3640254 Following a Single Intravenous Radiolabeled Microtracer Dose (Concomitant With a Non-radiolabeled Oral Dose) and a Single Oral Radiolabeled Dose",COMPLETED,,PHASE1,5,ACTUAL,ViiV Healthcare,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 19:41:41,2024-10-14 19:41:41,INDUSTRY,,,,,,,ViiV Healthcare,United Kingdom,Gastrointestinal disorders|General disorders
NCT04510194,,2020-08-07,2023-04-18,,2024-05-13,2020-08-10,2020-08-12,ACTUAL,2023-06-21,2023-07-13,ACTUAL,,,,2024-05-13,2024-05-16,ACTUAL,2021-01-01,ACTUAL,2021-01-01,2024-05,2024-05-31,2022-02-14,ACTUAL,2022-02-14,2022-02-14,ACTUAL,2022-02-14,,INTERVENTIONAL,,,COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19),COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19),COMPLETED,,PHASE3,1323,ACTUAL,University of Minnesota,,6,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-14 00:42:30,2024-10-14 00:42:30,OTHER,,,,,,,"Hennepin County Medical Center, Minneapolis|Northwestern University|Olive View-UCLA Education & Research Institute|UnitedHealth Group|University of Colorado, Denver|University of Minnesota",United States,General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT04513899,,2020-08-05,2023-06-30,,2024-02-27,2020-08-13,2020-08-14,ACTUAL,2024-02-27,2024-03-01,ACTUAL,,,,2024-02-27,2024-03-01,ACTUAL,2020-10-05,ACTUAL,2020-10-05,2024-02,2024-02-29,2022-07-20,ACTUAL,2022-07-20,2022-07-20,ACTUAL,2022-07-20,,INTERVENTIONAL,,All enrolled participants randomized to a study arm,Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults,Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults,COMPLETED,,NA,10,ACTUAL,"University of California, Irvine","A major limitation is the small sample size due in part to low enrollment of PEH testing presumptive positive in the study as well as low numbers of PEH testing HCV positive. Finally, another limitation is the lack of generalizability of the study to other settings, such as urban settings outside of Skid Row and rural area.",2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,UNDECIDED,,2024-10-14 17:09:10,2024-10-14 17:09:10,OTHER,,,,,,,"National Institute on Minority Health and Health Disparities (NIMHD)|University of California, Irvine|University of California, Los Angeles",United States,Gastrointestinal disorders|General disorders|Nervous system disorders
NCT04515641,,2020-08-14,2022-07-25,,2022-07-25,2020-08-14,2020-08-17,ACTUAL,2022-07-25,2023-07-03,ACTUAL,,,,2022-07-25,2023-07-03,ACTUAL,2020-11-05,ACTUAL,2020-11-05,2022-07,2022-07-31,2021-09-13,ACTUAL,2021-09-13,2021-09-13,ACTUAL,2021-09-13,,INTERVENTIONAL,,,Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030),"An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Participants With Moderate Hepatic Impairment",COMPLETED,,PHASE1,12,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 16:57:09,2024-10-14 16:57:09,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Nervous system disorders
NCT04525079,,2020-07-30,2021-10-28,,2021-11-11,2020-08-20,2020-08-25,ACTUAL,2021-11-11,2021-11-16,ACTUAL,,,,2021-11-11,2021-11-16,ACTUAL,2020-07-18,ACTUAL,2020-07-18,2021-09,2021-09-30,2020-11-05,ACTUAL,2020-11-05,2020-08-07,ACTUAL,2020-08-07,,INTERVENTIONAL,,,"To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects","A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects",COMPLETED,,PHASE1,32,ACTUAL,Celltrion,,4,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-14 16:32:17,2024-10-14 16:32:17,INDUSTRY,,,,,,,Celltrion,"Korea, Republic of","General disorders|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Skin and subcutaneous tissue disorders"
NCT04527471,,2020-08-06,2022-08-26,,2022-08-26,2020-08-24,2020-08-26,ACTUAL,2022-08-26,2022-09-22,ACTUAL,,,,2022-08-26,2022-09-22,ACTUAL,2020-09-04,ACTUAL,2020-09-04,2020-08,2020-08-31,2021-05-01,ACTUAL,2021-05-01,2021-02-15,ACTUAL,2021-02-15,,INTERVENTIONAL,,,Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19",COMPLETED,,PHASE2,45,ACTUAL,Verona Pharma plc,This was an un-powered pilot study of ensifentrine pMDI in patients hospitalized for moderate COVID-19 infection.,2,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,NO,Verona Pharma will not be sharing individual deidentified participant data or other relevant study documents.,2024-10-14 07:04:43,2024-10-14 07:04:43,INDUSTRY,,,,,,,Verona Pharma Inc,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Investigations|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04532372,,2020-08-25,2024-05-23,,2024-07-01,2020-08-27,2020-08-31,ACTUAL,2024-07-01,2024-07-03,ACTUAL,,,,2024-07-01,2024-07-03,ACTUAL,2021-01-07,ACTUAL,2021-01-07,2024-07,2024-07-31,2021-10-27,ACTUAL,2021-10-27,2021-08-26,ACTUAL,2021-08-26,,INTERVENTIONAL,,"Due to the low accrual rate, the study was terminated after two subjects enrolled in Phase I.",Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,A Phase 1/2 Trial of Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,COMPLETED,,PHASE1/PHASE2,2,ACTUAL,City of Hope Medical Center,,3,,,,,,,,TRUE,FALSE,,,,,,,,,,,2024-10-13 18:53:36,2024-10-13 18:53:36,OTHER,,,,,,,City of Hope Medical Center|National Cancer Institute (NCI),United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04538040,,2020-08-26,2023-12-20,,2024-03-04,2020-09-02,2020-09-03,ACTUAL,2024-03-04,2024-03-05,ACTUAL,,,,2024-03-04,2024-03-05,ACTUAL,2019-12-19,ACTUAL,2019-12-19,2024-03,2024-03-31,2021-11-11,ACTUAL,2021-11-11,2021-11-11,ACTUAL,2021-11-11,,INTERVENTIONAL,,,Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine,"An Open Label Study Evaluating the Safety and Efficacy of Switching From Rilpivirine/Emtricitabine/Tenofovir Alafenamide in Combination With Dolutegravir, to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Combination With Doravirine, in Male HIV+ Subjects > 45 Years With Multi-drug Resistant Virus and Virologic Suppression (Documented With at Least One Viral Load Result < 50 Copies Per mL) During the Last 6 Months on Current Therapy",COMPLETED,,PHASE4,20,ACTUAL,Quest Clinical Research,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 07:21:26,2024-10-14 07:21:26,OTHER,,,,,,,Gilead Sciences|Quest Clinical Research,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT04542070,,2020-09-01,2023-07-12,,2024-06-03,2020-09-01,2020-09-09,ACTUAL,2023-08-23,2023-09-13,ACTUAL,,,,2024-06-03,2024-06-04,ACTUAL,2020-11-09,ACTUAL,2020-11-09,2024-06,2024-06-30,2023-04-17,ACTUAL,2023-04-17,2022-07-13,ACTUAL,2022-07-13,,INTERVENTIONAL,SOLAR,,A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed,"A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed",COMPLETED,,PHASE3,687,ACTUAL,ViiV Healthcare,,4,,,TRUE,,,,FALSE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,YES,Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/,2024-10-13 06:46:17,2024-10-13 06:46:17,INDUSTRY,,NCT03462810,AVAILABLE,,,,"Janssen, LP|ViiV Healthcare",Australia|Austria|Belgium|Canada|France|Germany|Ireland|Italy|Japan|Netherlands|Spain|Switzerland|United Kingdom|United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures"
NCT04542226,,2020-09-08,2020-11-12,,2020-12-07,2020-09-08,2020-09-09,ACTUAL,2020-11-24,2020-12-03,ACTUAL,,,,2020-12-07,2020-12-09,ACTUAL,2020-03-31,ACTUAL,2020-03-31,2020-12,2020-12-31,2020-10-30,ACTUAL,2020-10-30,2020-07-15,ACTUAL,2020-07-15,,OBSERVATIONAL,,,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Open Observational Study of Efficacy and Safety of Polyoxidonium in Complex Therapy of Hospitalized Patients With COVID-19,COMPLETED,,,81,ACTUAL,NPO Petrovax,"There was no control or comparison group, polyoxidonium was used in the treatment of all patients, it is not possible to compare the results of treatment of patients with and without Polyoxidonium. The study used various treatment regimens for COVID-19 (antiviral agents, antimalarial agents, anticoagulants), depending on the base of the study, so it is impossible to fully determine whether these agents influenced the effectiveness of Polyoxidonium.",,1,,FALSE,,,,,FALSE,FALSE,,,,,,,,,,,2024-10-13 10:15:15,2024-10-13 10:15:15,INDUSTRY,,,,,,FALSE,NPO Petrovax,Belarus|Russian Federation,General disorders|Infections and infestations|Investigations
NCT04546724,,2020-09-04,2022-05-18,,2023-06-07,2020-09-04,2020-09-14,ACTUAL,2022-06-28,2022-07-25,ACTUAL,,,,2023-06-07,2023-06-28,ACTUAL,2020-09-17,ACTUAL,2020-09-17,2023-06,2023-06-30,2021-10-15,ACTUAL,2021-10-15,2021-05-19,ACTUAL,2021-05-19,,INTERVENTIONAL,,,Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults,"A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Pivotal Study To Evaluate Safety And Immunogenicity Of A Live-Attenuated Chikungunya Virus Vaccine Candidate In Adults Aged 18 Years And Above",COMPLETED,,PHASE3,4128,ACTUAL,Valneva Austria GmbH,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 13:07:17,2024-10-14 13:07:17,INDUSTRY,,,,,,,Valneva Austria GmbH,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04551911,,2020-09-15,2024-03-29,,2024-05-24,2020-09-15,2020-09-16,ACTUAL,2024-05-24,2024-05-28,ACTUAL,,,,2024-05-24,2024-05-28,ACTUAL,2020-11-02,ACTUAL,2020-11-02,2024-05,2024-05-31,2021-10-08,ACTUAL,2021-10-08,2021-10-08,ACTUAL,2021-10-08,,INTERVENTIONAL,,"Analysis is for the per protocol population, subjects who had a baseline aggregate five symptom score of \>5 and did not have a major protocol deviation prior to resolution.",Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,"A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)",COMPLETED,,PHASE2,171,ACTUAL,"OPKO Health, Inc.","A caveat in the analysis is the variability of 25D at baseline. The study is also limited by timing differences between the onset of symptoms and diagnosis of COVID-19, and between COVID-19 diagnosis and the initiation of treatment among participants.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 11:51:08,2024-10-14 11:51:08,INDUSTRY,,,,,,,"OPKO Health, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04557826,,2020-08-31,2024-09-05,,2024-09-05,2020-09-15,2020-09-22,ACTUAL,2024-09-05,2024-10-03,ACTUAL,,,,2024-09-05,2024-10-03,ACTUAL,2020-08-31,ACTUAL,2020-08-31,2024-09,2024-09-30,2020-12-07,ACTUAL,2020-12-07,2020-09-23,ACTUAL,2020-09-23,,INTERVENTIONAL,,,Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens,"A Phase I Open-label, First-in-Man Acute Safety, Tolerability and Device Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Tract Pathogens",COMPLETED,,NA,25,ACTUAL,KNOWBio Inc.,"This is a phase I, open-label, safety study and is not designed to test any statistical hypotheses. Rather, this is a descriptive study intended to obtain preliminary estimates in healthy adults of the safety, including reactogenicity, of the EmitBio™ RD19 Device.",1,,,FALSE,,,,FALSE,FALSE,TRUE,TRUE,,FALSE,,,,,,NO,,2024-10-13 10:04:36,2024-10-13 10:04:36,INDUSTRY,,,,,,,EmitBio Inc.,United States,Gastrointestinal disorders|General disorders|Nervous system disorders|Vascular disorders
NCT04563845,,2020-09-18,2022-10-10,,2023-12-04,2020-09-18,2020-09-25,ACTUAL,2023-12-04,2023-12-06,ACTUAL,,,,2023-12-04,2023-12-06,ACTUAL,2020-11-09,ACTUAL,2020-11-09,2023-11,2023-11-30,2021-10-30,ACTUAL,2021-10-30,2021-10-30,ACTUAL,2021-10-30,,INTERVENTIONAL,,Baseline characteristics were reported for Safety Population.,Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin,A Study to Evaluate the Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin in Healthy Adult Participants,COMPLETED,,PHASE1,50,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 03:58:09,2024-10-14 03:58:09,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04568603,,2020-09-23,2022-06-01,,2023-03-28,2020-09-23,2020-09-29,ACTUAL,2023-03-28,2023-12-11,ACTUAL,,,,2023-03-28,2023-12-11,ACTUAL,2020-10-16,ACTUAL,2020-10-16,2023-03,2023-03-31,2021-07-09,ACTUAL,2021-07-09,2021-07-09,ACTUAL,2021-07-09,,INTERVENTIONAL,,,Islatravir and Methadone Pharmacokinetics (MK-8591-029),A Clinical Trial to Study the Effect of a Single Dose of Islatravir (MK-8591) on the Pharmacokinetics of Methadone,COMPLETED,,PHASE1,14,ACTUAL,Merck Sharp & Dohme LLC,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 22:20:56,2024-10-14 22:20:56,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,United States,Gastrointestinal disorders|General disorders|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders
NCT04575038,,2020-10-01,2022-04-12,,2022-04-14,2020-10-01,2020-10-05,ACTUAL,2022-04-14,2022-04-19,ACTUAL,,,,2022-04-14,2022-04-19,ACTUAL,2020-11-19,ACTUAL,2020-11-19,2022-04,2022-04-30,2021-04-28,ACTUAL,2021-04-28,2021-04-28,ACTUAL,2021-04-28,,INTERVENTIONAL,CRISIS2,The Intent-to-Treat (ITT) Population was used for efficacy analyses. The ITT Set consisted of all randomized subjects. ITT subjects were analyzed according to their randomized treatment.,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,"The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2",COMPLETED,,PHASE2,115,ACTUAL,"Clear Creek Bio, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 06:35:12,2024-10-14 06:35:12,INDUSTRY,,,,,,,"Clear Creek Bio, Inc.",United States,Gastrointestinal disorders|Infections and infestations|Skin and subcutaneous tissue disorders
NCT04588480,,2020-10-14,2022-11-23,,2023-01-13,2020-10-14,2020-10-19,ACTUAL,2023-01-13,2023-02-01,ACTUAL,,,,2023-01-13,2023-02-01,ACTUAL,2020-10-21,ACTUAL,2020-10-21,2023-01,2023-01-31,2021-11-25,ACTUAL,2021-11-25,2021-11-25,ACTUAL,2021-11-25,,INTERVENTIONAL,,Safety population included all randomized participants who received at least 1 dose of the study intervention.,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS",COMPLETED,,PHASE4,160,ACTUAL,BioNTech SE,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 12:20:10,2024-10-13 12:20:10,INDUSTRY,,,,,,,BioNTech SE|Pfizer,Japan,"Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT04593641,,2020-10-05,2021-12-23,,2022-04-06,2020-10-18,2020-10-20,ACTUAL,2022-04-06,2022-04-08,ACTUAL,,,,2022-04-06,2022-04-08,ACTUAL,2020-09-04,ACTUAL,2020-09-04,2022-04,2022-04-30,2021-04-05,ACTUAL,2021-04-05,2020-10-26,ACTUAL,2020-10-26,,INTERVENTIONAL,,,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection",COMPLETED,,PHASE1,18,ACTUAL,Celltrion,,3,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,,,2024-10-13 15:19:47,2024-10-13 15:19:47,INDUSTRY,,,,,,,Celltrion,"Korea, Republic of","Cardiac disorders|Eye disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04596319,,2020-10-15,2023-12-04,,2024-01-04,2020-10-20,2020-10-22,ACTUAL,2024-01-04,2024-01-31,ACTUAL,,,,2024-01-04,2024-01-31,ACTUAL,2020-12-22,ACTUAL,2020-12-22,2024-01,2024-01-31,2022-12-14,ACTUAL,2022-12-14,2022-12-14,ACTUAL,2022-12-14,,INTERVENTIONAL,SWARM-Pa,,Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis,"A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection",COMPLETED,,PHASE1/PHASE2,29,ACTUAL,"Armata Pharmaceuticals, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 19:41:41,2024-10-14 19:41:41,INDUSTRY,,,,,,,"Armata Pharmaceuticals, Inc.|Cystic Fibrosis Foundation",United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT04596319,,2020-10-15,2023-12-04,,2024-01-04,2020-10-20,2020-10-22,ACTUAL,2024-01-04,2024-01-31,ACTUAL,,,,2024-01-04,2024-01-31,ACTUAL,2020-12-22,ACTUAL,2020-12-22,2024-01,2024-01-31,2022-12-14,ACTUAL,2022-12-14,2022-12-14,ACTUAL,2022-12-14,,INTERVENTIONAL,SWARM-Pa,,Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis,"A Phase 1b/2a, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AP-PA02 Multi-Phage Therapeutic Candidate for Inhalation in Subjects With Cystic Fibrosis and Chronic Pulmonary Pseudomonas Aeruginosa (Pa) Infection",COMPLETED,,PHASE1/PHASE2,29,ACTUAL,"Armata Pharmaceuticals, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 19:41:41,2024-10-14 19:41:41,INDUSTRY,,,,,,,"Armata Pharmaceuticals, Inc.|Cystic Fibrosis Foundation",United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT04600752,,2020-10-19,2023-11-10,,2024-05-24,2020-10-19,2020-10-23,ACTUAL,2023-11-10,2024-04-25,ACTUAL,,,,2024-05-24,2024-06-10,ACTUAL,2022-05-07,ACTUAL,2022-05-07,2024-05,2024-05-31,2022-11-12,ACTUAL,2022-11-12,2022-11-12,ACTUAL,2022-11-12,,INTERVENTIONAL,,,Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India,"A Multicenter, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 in Children With Acute Otitis Media (AOM) in India",COMPLETED,,PHASE4,310,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 13:03:43,2024-10-13 13:03:43,INDUSTRY,,,,,,,GlaxoSmithKline|Iqvia Pty Ltd,India,"Gastrointestinal disorders|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders"
NCT04600752,,2020-10-19,2023-11-10,,2024-05-24,2020-10-19,2020-10-23,ACTUAL,2023-11-10,2024-04-25,ACTUAL,,,,2024-05-24,2024-06-10,ACTUAL,2022-05-07,ACTUAL,2022-05-07,2024-05,2024-05-31,2022-11-12,ACTUAL,2022-11-12,2022-11-12,ACTUAL,2022-11-12,,INTERVENTIONAL,,,Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India,"A Multicenter, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 in Children With Acute Otitis Media (AOM) in India",COMPLETED,,PHASE4,310,ACTUAL,GlaxoSmithKline,,1,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 13:03:43,2024-10-13 13:03:43,INDUSTRY,,,,,,,GlaxoSmithKline|Iqvia Pty Ltd,India,"Gastrointestinal disorders|Metabolism and nutrition disorders|Respiratory, thoracic and mediastinal disorders"
NCT04602000,,2020-10-18,2022-05-10,,2022-06-27,2020-10-23,2020-10-26,ACTUAL,2022-06-27,2022-07-20,ACTUAL,,,,2022-06-27,2022-07-20,ACTUAL,2020-10-05,ACTUAL,2020-10-05,2022-06,2022-06-30,2021-10-20,ACTUAL,2021-10-20,2021-05-21,ACTUAL,2021-05-21,,INTERVENTIONAL,,,A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection,"A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With SARS-CoV-2 Infection",COMPLETED,,PHASE2/PHASE3,1642,ACTUAL,Celltrion,,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 20:04:52,2024-10-14 20:04:52,INDUSTRY,,,,,,,Celltrion,"Korea, Republic of","Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04605484,,2020-10-15,2024-04-23,,2024-04-23,2020-10-22,2020-10-28,ACTUAL,2024-04-23,2024-05-16,ACTUAL,,,,2024-04-23,2024-05-16,ACTUAL,2021-03-22,ACTUAL,2021-03-22,2024-04,2024-04-30,2022-10-20,ACTUAL,2022-10-20,2022-10-20,ACTUAL,2022-10-20,,INTERVENTIONAL,,Intent-to-Treat (ITT) Population: Included all randomized participants.,Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia,"Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 2-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred Posoleuccel (ALVR105) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia",COMPLETED,,PHASE2,61,ACTUAL,AlloVir,,3,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 05:06:15,2024-10-13 05:06:15,INDUSTRY,,,,,,,AlloVir,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04622306,,2020-11-02,2023-02-28,2022-11-16,2023-09-28,2020-11-06,2020-11-09,ACTUAL,2023-06-06,2023-06-28,ACTUAL,,2023-06-28,ACTUAL,2023-09-28,2023-10-06,ACTUAL,2020-10-12,ACTUAL,2020-10-12,2023-09,2023-09-30,2021-12-30,ACTUAL,2021-12-30,2021-12-06,ACTUAL,2021-12-06,,INTERVENTIONAL,,The baseline analysis population is the number of couples who were consented to join the study,Evaluation of Polyurethane Male Condoms,"A Randomized, Masked, 3-way Cross-over, Multi-center, Clinical Investigation to Evaluate Two Polyurethane Condoms in Healthy Monogamous Couples Compared With a Standard Latex Condom",COMPLETED,,NA,300,ACTUAL,"Sagami Rubber Industries Co., Ltd.","All condom use events were self reported. There is a potential for misreporting the number of events.

Since the trial was masked it was not feasible to preselect men with smaller penises to use the smaller Condom B. Instead, a post hoc analysis of the association between penis size and clinical failure rates was conducted followed by a further non-inferiority analysis after excluding men with penis lengths exceeding the specified nominal length of Condom B (170 mm).",3,,,FALSE,,,,,FALSE,TRUE,TRUE,,FALSE,,,,,,NO,,2024-10-13 02:59:02,2024-10-13 02:59:02,INDUSTRY,,,,,,,"Essential Access Health|Sagami Rubber Industries Co., Ltd.",United States,Skin and subcutaneous tissue disorders
NCT04630002,,2020-11-11,2022-09-27,,2024-08-13,2020-11-11,2020-11-16,ACTUAL,2022-09-27,2023-08-21,ACTUAL,,,,2024-08-13,2024-08-29,ACTUAL,2020-10-28,ACTUAL,2020-10-28,2024-08,2024-08-31,2021-10-02,ACTUAL,2021-10-02,2021-10-02,ACTUAL,2021-10-02,,INTERVENTIONAL,,Baseline characteristics were reported for Safety Population.,Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR),"Open-Label, Single-Sequence Study to Evaluate the Effects of Darunavir/Ritonavir and/or Etravirine on the Pharmacokinetics of GSK3640254 and the Effects of GSK3640254 on the Pharmacokinetics of Darunavir/Ritonavir and/or Etravirine in Heathy Adults",COMPLETED,,PHASE1,54,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf,YES,"ViiV will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf",2024-10-14 14:58:21,2024-10-14 14:58:21,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04631666,,2020-11-05,2022-12-06,,2023-10-11,2020-11-14,2020-11-17,ACTUAL,2023-10-11,2024-04-08,ACTUAL,,,,2023-10-11,2024-04-08,ACTUAL,2020-12-08,ACTUAL,2020-12-08,2023-10,2023-10-31,2021-08-11,ACTUAL,2021-08-11,2021-08-11,ACTUAL,2021-08-11,,INTERVENTIONAL,,,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion,A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,COMPLETED,,PHASE1/PHASE2,57,ACTUAL,University of Cologne,,6,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 07:59:37,2024-10-13 07:59:37,OTHER,,,,,,,Boehringer Ingelheim|University of Cologne|ZKS Köln,Germany,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04644484,,2020-11-16,2023-02-24,,2023-03-29,2020-11-19,2020-11-25,ACTUAL,2023-03-29,2023-04-21,ACTUAL,,,,2023-03-29,2023-04-21,ACTUAL,2020-09-23,ACTUAL,2020-09-23,2023-03,2023-03-31,2022-12-16,ACTUAL,2022-12-16,2022-06-24,ACTUAL,2022-06-24,,INTERVENTIONAL,,,A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety,A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure Risks,COMPLETED,,PHASE3,1000,ACTUAL,"Synermore Biologics (Suzhou) Co., Ltd.",,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 01:42:37,2024-10-14 01:42:37,INDUSTRY,,,,,,,"Simoon Record Pharma Information Consulting Co., Ltd.|Synermore Biologics (Suzhou) Co., Ltd.",China,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04644484,,2020-11-16,2023-02-24,,2023-03-29,2020-11-19,2020-11-25,ACTUAL,2023-03-29,2023-04-21,ACTUAL,,,,2023-03-29,2023-04-21,ACTUAL,2020-09-23,ACTUAL,2020-09-23,2023-03,2023-03-31,2022-12-16,ACTUAL,2022-12-16,2022-06-24,ACTUAL,2022-06-24,,INTERVENTIONAL,,,A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety,A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure Risks,COMPLETED,,PHASE3,1000,ACTUAL,"Synermore Biologics (Suzhou) Co., Ltd.",,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 01:42:37,2024-10-14 01:42:37,INDUSTRY,,,,,,,"Simoon Record Pharma Information Consulting Co., Ltd.|Synermore Biologics (Suzhou) Co., Ltd.",China,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04644484,,2020-11-16,2023-02-24,,2023-03-29,2020-11-19,2020-11-25,ACTUAL,2023-03-29,2023-04-21,ACTUAL,,,,2023-03-29,2023-04-21,ACTUAL,2020-09-23,ACTUAL,2020-09-23,2023-03,2023-03-31,2022-12-16,ACTUAL,2022-12-16,2022-06-24,ACTUAL,2022-06-24,,INTERVENTIONAL,,,A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety,A Phase III Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Category III Rabies Exposure Risks,COMPLETED,,PHASE3,1000,ACTUAL,"Synermore Biologics (Suzhou) Co., Ltd.",,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 01:42:37,2024-10-14 01:42:37,INDUSTRY,,,,,,,"Simoon Record Pharma Information Consulting Co., Ltd.|Synermore Biologics (Suzhou) Co., Ltd.",China,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04657198,,2020-12-01,2022-06-02,,2022-06-02,2020-12-01,2020-12-08,ACTUAL,2022-06-02,2022-06-29,ACTUAL,,,,2022-06-02,2022-06-29,ACTUAL,2020-12-09,ACTUAL,2020-12-09,2022-06,2022-06-30,2021-10-25,ACTUAL,2021-10-25,2021-06-03,ACTUAL,2021-06-03,,INTERVENTIONAL,,,Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study,"A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study",COMPLETED,,PHASE2,126,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 15:23:18,2024-10-14 15:23:18,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04661813,,2020-10-29,2024-04-15,,2024-06-04,2020-12-09,2020-12-10,ACTUAL,2024-06-04,2024-06-26,ACTUAL,,,,2024-06-04,2024-06-26,ACTUAL,2021-03-01,ACTUAL,2021-03-01,2024-06,2024-06-30,2023-01-15,ACTUAL,2023-01-15,2023-01-15,ACTUAL,2023-01-15,,INTERVENTIONAL,AAIM-High,,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,COMPLETED,,NA,81,ACTUAL,Case Western Reserve University,,1,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,After publication of the primary manuscript,Data will be made available upon request or on a data share site after publication of the primary manuscript.,,YES,"In collaboration with the National Institutes of Health funding body, we will develop a process to facilitate providing other investigators with access to appropriately de-identified study data. We will make the following available upon request after the primary manuscript is published: de-identified data set, trial description information, data collection forms, and data structure.",2024-10-14 05:39:26,2024-10-14 05:39:26,OTHER,,,,,,,"Case Western Reserve University|Duke University|Metro Health, Michigan|National Heart, Lung, and Blood Institute (NHLBI)|University Hospitals Cleveland Medical Center|University of Washington",United States,Cardiac disorders|General disorders
NCT04665050,,2020-12-08,2022-08-04,,2023-09-27,2020-12-08,2020-12-11,ACTUAL,2022-08-04,2023-07-07,ACTUAL,,,,2023-09-27,2023-10-04,ACTUAL,2021-02-04,ACTUAL,2021-02-04,2023-09,2023-09-30,2021-04-06,ACTUAL,2021-04-06,2021-04-06,ACTUAL,2021-04-06,,INTERVENTIONAL,,,"Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)","A Phase 1, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults.",COMPLETED,,PHASE1,102,ACTUAL,Merck Sharp & Dohme LLC,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-13 06:20:43,2024-10-13 06:20:43,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Japan,General disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT04668352,,2020-12-08,2021-05-31,,2021-05-31,2020-12-08,2020-12-16,ACTUAL,2021-05-31,2021-06-23,ACTUAL,,,,2021-05-31,2021-06-23,ACTUAL,2019-04-15,ACTUAL,2019-04-15,2021-05,2021-05-31,2019-12-02,ACTUAL,2019-12-02,2019-12-02,ACTUAL,2019-12-02,,INTERVENTIONAL,,,A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly,A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly,COMPLETED,,PHASE3,1024,ACTUAL,Restorbio Inc.,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 21:05:07,2024-10-13 21:05:07,INDUSTRY,,,,,,,Restorbio Inc.,New Zealand,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04671017,,2020-12-15,2022-03-07,,2022-04-19,2020-12-15,2020-12-17,ACTUAL,2022-03-22,2022-03-24,ACTUAL,,,,2022-04-19,2022-04-22,ACTUAL,2020-12-16,ACTUAL,2020-12-16,2022-04,2022-04-30,2022-04-06,ACTUAL,2022-04-06,2021-02-26,ACTUAL,2021-02-26,,INTERVENTIONAL,,,"Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects","A Phase I/II Randomized, Two Parts, Dose-Finding Study To Evaluate The Safety, Tolerability and Immunogenicity Of An Inactivated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate (VLA2001), Against Covid-19 In Healthy Subjects",COMPLETED,,PHASE1/PHASE2,153,ACTUAL,Valneva Austria GmbH,,4,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,UNDECIDED,,2024-10-12 23:46:56,2024-10-12 23:46:56,INDUSTRY,,,,,,,"National Institute for Health Research, United Kingdom|Valneva Austria GmbH",United Kingdom,"Blood and lymphatic system disorders|Injury, poisoning and procedural complications|Investigations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders"
NCT04672083,,2020-12-08,2022-10-31,,2023-01-24,2020-12-14,2020-12-17,ACTUAL,2023-01-24,2023-02-21,ACTUAL,,,,2023-01-24,2023-02-21,ACTUAL,2020-11-16,ACTUAL,2020-11-16,2023-01,2023-01-31,2021-04-29,ACTUAL,2021-04-29,2021-04-26,ACTUAL,2021-04-26,,INTERVENTIONAL,,,A Clinical Study of the HIV Drug CPT31 in Healthy Volunteers,"A Phase Ia Clinical Study of HIV Entry Inhibitor CPT31: Single Ascending Dose Study of Safety, Tolerability, Immunogenicity, and Pharmacokinetics in Healthy Adults",COMPLETED,,PHASE1,32,ACTUAL,"Navigen, Inc.",,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 22:14:22,2024-10-13 22:14:22,INDUSTRY,,,,,,,"Covance|National Institute of Allergy and Infectious Diseases (NIAID)|Navigen, Inc.",United States,General disorders|Infections and infestations|Skin and subcutaneous tissue disorders
NCT04677543,,2020-12-16,2024-05-08,,2024-06-26,2020-12-16,2020-12-21,ACTUAL,2024-06-26,2024-06-28,ACTUAL,,,,2024-06-26,2024-06-28,ACTUAL,2020-12-22,ACTUAL,2020-12-22,2024-06,2024-06-30,2023-05-09,ACTUAL,2023-05-09,2023-05-09,ACTUAL,2023-05-09,,INTERVENTIONAL,ARISE,Intent-to-treat (ITT) Analysis Set comprises all participants who were randomized.,Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex,"A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)",COMPLETED,,PHASE3,99,ACTUAL,Insmed Incorporated,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 22:38:08,2024-10-14 22:38:08,INDUSTRY,,,,,,,Insmed Incorporated,"Argentina|Australia|Austria|Canada|Chile|Denmark|Germany|Greece|Hungary|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|Spain|Taiwan|Turkey|United States","Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04679675,,2020-12-09,2023-07-19,,2023-09-06,2020-12-16,2020-12-22,ACTUAL,2023-08-22,2023-08-24,ACTUAL,,,,2023-09-06,2023-09-18,ACTUAL,2020-11-20,ACTUAL,2020-11-20,2023-09,2023-09-30,2023-07-29,ACTUAL,2023-07-29,2022-07-29,ACTUAL,2022-07-29,,INTERVENTIONAL,STEP,,Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial,Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer: the STEP Trial,COMPLETED,,NA,32771,ACTUAL,Kaiser Permanente,,4,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,YES,Resources developed during the study will be made available in accordance with the NIH Data Sharing Policy to researchers in both the private and public sector free or for a nominal charge and with minimal restriction. Deidentified data will be made available to qualified investigators within 6 months of acceptance of the manuscript describing major outcomes. Requestors will be required to obtain IRB approval and sign a data use agreement before data will be released. The data use agreement must include the following commitments: a commitment to using the data for research purposes only and not to identify any individual participants or to disclose Kaiser Permanente proprietary information; a commitment to securing the data using appropriate computer technology; a commitment to destroying or returning the data after analyses are completed; and a commitment to meet any additional requirements that might be stipulated by Kaiser Permanente's Human Subjects Review Committee.,2024-10-13 13:39:19,2024-10-13 13:39:19,OTHER,,,,,,,Kaiser Permanente|National Cancer Institute (NCI)|University of Texas Southwestern Medical Center|University of Washington,United States,Reproductive system and breast disorders
NCT04682197,,2020-12-16,2024-08-07,,2024-08-29,2020-12-22,2020-12-23,ACTUAL,2024-08-07,2024-08-29,ACTUAL,,,,2024-08-29,2024-09-19,ACTUAL,2021-12-14,ACTUAL,2021-12-14,2024-07,2024-07-31,2023-10-10,ACTUAL,2023-10-10,2023-08-23,ACTUAL,2023-08-23,,INTERVENTIONAL,,,Cereset Research In Healthcare Workers During COVID-19,Cereset Research To Reduce Stress In Healthcare Workers In The Time Of COVID-19,COMPLETED,,NA,144,ACTUAL,Wake Forest University Health Sciences,,2,,,FALSE,,,,FALSE,FALSE,TRUE,TRUE,,TRUE,,,,,,NO,,2024-10-15 03:36:43,2024-10-15 03:36:43,OTHER,,,,,,,"The Susanne Marcus Collins Foundation, Inc|Wake Forest University Health Sciences",United States,Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Reproductive system and breast disorders|Surgical and medical procedures
NCT04693637,,2020-12-09,2023-12-19,,2024-05-07,2020-12-31,2021-01-05,ACTUAL,2024-04-11,2024-05-07,ACTUAL,,,,2024-05-07,2024-05-09,ACTUAL,2021-01-15,ACTUAL,2021-01-15,2024-05,2024-05-31,2023-01-19,ACTUAL,2023-01-19,2023-01-19,ACTUAL,2023-01-19,,INTERVENTIONAL,Prevent,Analysis Population will include all patients who received posoleucel.,"Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant",COMPLETED,,PHASE2/PHASE3,26,ACTUAL,AlloVir,,1,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,AlloVir,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04693637,,2020-12-09,2023-12-19,,2024-05-07,2020-12-31,2021-01-05,ACTUAL,2024-04-11,2024-05-07,ACTUAL,,,,2024-05-07,2024-05-09,ACTUAL,2021-01-15,ACTUAL,2021-01-15,2024-05,2024-05-31,2023-01-19,ACTUAL,2023-01-19,2023-01-19,ACTUAL,2023-01-19,,INTERVENTIONAL,Prevent,Analysis Population will include all patients who received posoleucel.,"Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant",COMPLETED,,PHASE2/PHASE3,26,ACTUAL,AlloVir,,1,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,AlloVir,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04693637,,2020-12-09,2023-12-19,,2024-05-07,2020-12-31,2021-01-05,ACTUAL,2024-04-11,2024-05-07,ACTUAL,,,,2024-05-07,2024-05-09,ACTUAL,2021-01-15,ACTUAL,2021-01-15,2024-05,2024-05-31,2023-01-19,ACTUAL,2023-01-19,2023-01-19,ACTUAL,2023-01-19,,INTERVENTIONAL,Prevent,Analysis Population will include all patients who received posoleucel.,"Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant",COMPLETED,,PHASE2/PHASE3,26,ACTUAL,AlloVir,,1,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,AlloVir,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04693637,,2020-12-09,2023-12-19,,2024-05-07,2020-12-31,2021-01-05,ACTUAL,2024-04-11,2024-05-07,ACTUAL,,,,2024-05-07,2024-05-09,ACTUAL,2021-01-15,ACTUAL,2021-01-15,2024-05,2024-05-31,2023-01-19,ACTUAL,2023-01-19,2023-01-19,ACTUAL,2023-01-19,,INTERVENTIONAL,Prevent,Analysis Population will include all patients who received posoleucel.,"Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant",COMPLETED,,PHASE2/PHASE3,26,ACTUAL,AlloVir,,1,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,AlloVir,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04693637,,2020-12-09,2023-12-19,,2024-05-07,2020-12-31,2021-01-05,ACTUAL,2024-04-11,2024-05-07,ACTUAL,,,,2024-05-07,2024-05-09,ACTUAL,2021-01-15,ACTUAL,2021-01-15,2024-05,2024-05-31,2023-01-19,ACTUAL,2023-01-19,2023-01-19,ACTUAL,2023-01-19,,INTERVENTIONAL,Prevent,Analysis Population will include all patients who received posoleucel.,"Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant",COMPLETED,,PHASE2/PHASE3,26,ACTUAL,AlloVir,,1,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,AlloVir,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04693637,,2020-12-09,2023-12-19,,2024-05-07,2020-12-31,2021-01-05,ACTUAL,2024-04-11,2024-05-07,ACTUAL,,,,2024-05-07,2024-05-09,ACTUAL,2021-01-15,ACTUAL,2021-01-15,2024-05,2024-05-31,2023-01-19,ACTUAL,2023-01-19,2023-01-19,ACTUAL,2023-01-19,,INTERVENTIONAL,Prevent,Analysis Population will include all patients who received posoleucel.,"Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant","Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant",COMPLETED,,PHASE2/PHASE3,26,ACTUAL,AlloVir,,1,,,,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 14:20:06,2024-10-13 14:20:06,INDUSTRY,,,,,,,AlloVir,United States,"Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04696861,,2020-12-22,2024-07-30,,2024-09-26,2021-01-04,2021-01-06,ACTUAL,2024-09-26,2024-10-01,ACTUAL,,,,2024-09-26,2024-10-01,ACTUAL,2023-05-17,ACTUAL,2023-05-17,2024-09,2024-09-30,2025-03-31,ESTIMATED,2025-03-31,2023-12-08,ACTUAL,2023-12-08,,INTERVENTIONAL,,,Telehealth to Reduce Suicidality and Improve HIV Care Engagement in Tanzania,Telehealth to Reduce Suicidality and Improve HIV Care Engagement in Tanzania,ACTIVE_NOT_RECRUITING,,NA,60,ACTUAL,Duke University,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-14 15:59:32,2024-10-14 15:59:32,OTHER,,,,,,,"Duke University|Kilimanjaro Christian Medical Centre, Tanzania|National Institute of Mental Health (NIMH)",Tanzania,Immune system disorders
NCT04707664,,2021-01-11,2022-12-20,,2023-02-02,2021-01-11,2021-01-13,ACTUAL,2023-02-02,2023-02-06,ACTUAL,,,,2023-02-02,2023-02-06,ACTUAL,2021-04-27,ACTUAL,2021-04-27,2022-12,2022-12-31,2022-01-31,ACTUAL,2022-01-31,2021-12-28,ACTUAL,2021-12-28,,INTERVENTIONAL,SCOPE,,Sargramostim Use in COVID-19 to Recover Patient Health,A Randomized Phase 2b Trial Evaluating Clinical Outcomes of Inhaled Sargramostim in High-risk Patients With Mild-moderate COVID-19,COMPLETED,,PHASE2,600,ACTUAL,"Partner Therapeutics, Inc.",,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 16:56:00,2024-10-13 16:56:00,INDUSTRY,,,,,,,"Partner Therapeutics, Inc.|United States Department of Defense",Argentina|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04712110,,2021-01-14,2023-03-27,,2023-05-12,2021-01-14,2021-01-15,ACTUAL,2023-05-12,2023-06-06,ACTUAL,,,,2023-05-12,2023-06-06,ACTUAL,2021-02-12,ACTUAL,2021-02-12,2023-05,2023-05-31,2022-03-28,ACTUAL,2022-03-28,2022-03-28,ACTUAL,2022-03-28,,INTERVENTIONAL,,The safety analysis set included all participants who received at least 1 dose of the treatment.,A Study of TAK-019 in Healthy Japanese Adults (COVID-19),"A Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TAK-019 by Intramuscular Injection in Healthy Japanese Male and Female Adults Aged 20 Years and Older (COVID-19)",COMPLETED,,PHASE1/PHASE2,200,ACTUAL,Takeda,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,,"IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.",https://vivli.org/ourmember/takeda/,YES,"Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.",2024-10-13 20:24:49,2024-10-13 20:24:49,INDUSTRY,,,,,,,Takeda,Japan,Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT04713553,,2021-01-15,2022-07-18,,2022-11-30,2021-01-15,2021-01-19,ACTUAL,2022-11-30,2022-12-22,ACTUAL,,,,2022-11-30,2022-12-22,ACTUAL,2021-02-15,ACTUAL,2021-02-15,2022-11,2022-11-30,2021-07-22,ACTUAL,2021-07-22,2021-07-22,ACTUAL,2021-07-22,,INTERVENTIONAL,,Safety Population comprising of all randomized participants who received at least 1 dose of the study intervention were included.,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE",COMPLETED,,PHASE3,1574,ACTUAL,BioNTech SE,,7,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 12:28:13,2024-10-14 12:28:13,INDUSTRY,,,,,,,BioNTech SE|Pfizer,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Skin and subcutaneous tissue disorders"
NCT04718974,,2021-01-06,2022-08-02,,2023-07-11,2021-01-19,2021-01-22,ACTUAL,2023-07-11,2024-02-21,ACTUAL,,,,2023-07-11,2024-02-21,ACTUAL,2020-08-12,ACTUAL,2020-08-12,2023-07,2023-07-31,2022-06-30,ACTUAL,2022-06-30,2022-05-30,ACTUAL,2022-05-30,,INTERVENTIONAL,C4L-Youth,Young people 15-24 years initiating or on ART since 2019.,Call for Life Youth ART Adherence Study,"Acceptability, Effect and Cost of Mobile-health on ART Adherence Among Youths: A Mixed Methods Sequential Study in Kiryandongo",COMPLETED,,NA,206,ACTUAL,Makerere University,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 20:42:35,2024-10-13 20:42:35,OTHER,,,,,,,"Infectious Diseases Institute, Uganda|Makerere University",Uganda,Infections and infestations|Musculoskeletal and connective tissue disorders
NCT04726969,,2021-01-18,2022-09-01,,2024-01-22,2021-01-25,2021-01-27,ACTUAL,2023-01-16,2023-02-02,ACTUAL,,,,2024-01-22,2024-01-24,ACTUAL,2021-06-15,ACTUAL,2021-06-15,2024-01,2024-01-31,2021-09-09,ACTUAL,2021-09-09,2021-09-09,ACTUAL,2021-09-09,,INTERVENTIONAL,,,Efficacy and Safety of MOX/ALB Co-administration,"Efficacy and Safety of Combination Moxidectin and Albendazole, Ivermectin and Albendazole and Albendazole Alone in Adolescents and Adults Infected With Trichuris Trichiura: a Randomized Controlled Trial",COMPLETED,,PHASE3,255,ACTUAL,Swiss Tropical & Public Health Institute,,3,,,FALSE,,,,,TRUE,FALSE,,,TRUE,,,,,,UNDECIDED,,2024-10-13 00:37:39,2024-10-13 00:37:39,OTHER,,,,,,,Centre Suisse de Recherches Scientifiques en Cote d'Ivoire|Jennifer Keiser,Côte D'Ivoire,Gastrointestinal disorders|General disorders|Immune system disorders|Skin and subcutaneous tissue disorders
NCT04732871,,2021-01-27,2023-10-25,2023-06-07,2023-12-20,2021-01-27,2021-02-01,ACTUAL,2023-12-20,2023-12-21,ACTUAL,,2023-12-21,ACTUAL,2023-12-20,2023-12-21,ACTUAL,2021-02-15,ACTUAL,2021-02-15,2023-12,2023-12-31,2026-05-25,ESTIMATED,2026-05-25,2022-06-06,ACTUAL,2022-06-06,,INTERVENTIONAL,,,"Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above",ACTIVE_NOT_RECRUITING,,PHASE3,1720,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 16:43:39,2024-10-13 16:43:39,INDUSTRY,,,,,,,GlaxoSmithKline,Finland|Germany|Japan|Taiwan|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04756804,,2021-02-11,2024-01-24,,2024-02-20,2021-02-11,2021-02-16,ACTUAL,2024-02-20,2024-03-20,ACTUAL,,,,2024-02-20,2024-03-20,ACTUAL,2021-06-21,ACTUAL,2021-06-21,2024-02,2024-02-29,2022-09-29,ACTUAL,2022-09-29,2022-09-29,ACTUAL,2022-09-29,,INTERVENTIONAL,,,Perioperative Patient Skin Antiseptic Preparation Evaluation,"A Randomized, Controlled Clinical Trial Evaluating A Novel Perioperative Patient Skin Antiseptic Preparation",COMPLETED,,PHASE3,51,ACTUAL,"Zurex Pharma, Inc.","This was a pilot study of surgical patients, the majority of which had significant comorbidities with several AEs reported in more than one patient across the study.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-15 02:12:28,2024-10-15 02:12:28,INDUSTRY,,,,,,,"Zurex Pharma, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|General disorders|Hepatobiliary disorders|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04761822,,2021-02-17,2023-04-13,,2023-11-30,2021-02-17,2021-02-21,ACTUAL,2023-05-22,2023-06-15,ACTUAL,,,,2023-11-30,2023-12-04,ACTUAL,2021-04-07,ACTUAL,2021-04-07,2023-11,2023-11-30,2022-04-27,ACTUAL,2022-04-27,2022-04-20,ACTUAL,2022-04-20,,INTERVENTIONAL,SARS,All participants who initiated study treatment.,COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations,Systemic Allergic Reactions to SARS-CoV-2 Vaccination,COMPLETED,,PHASE2,746,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"After completion of the trial, within 24 months status post database lock.","Registration is available for the Immunology Database and Analysis Portal (ImmPort) at: https://www.immport.org/registration. Submit a rationale for the purpose of requesting study data access.

ImmPort is a long-term archive of clinical and mechanistic data, a National Institute of Allergy and Infectious Diseases Division of Allergy, Immunology and Transplantation (NIAID DAIT)-funded data repository. This archive is in support of the NIH mission to share data with the public. Data shared through ImmPort is provided by NIH-funded programs, other research organizations and individual scientists, ensuring these discoveries will be the foundation of future research.",https://www.immport.org/home,YES,Participant level data access and additional relevant materials will be made available upon completion of the trial.,2024-10-13 02:46:59,2024-10-13 02:46:59,NIH,,,,,,,"Immune Tolerance Network (ITN)|National Institute of Allergy and Infectious Diseases (NIAID)|Rho Federal Systems Division, Inc.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04766086,,2021-02-18,2024-04-25,,2024-04-25,2021-02-18,2021-02-23,ACTUAL,2024-04-25,2024-05-24,ACTUAL,,,,2024-04-25,2024-05-24,ACTUAL,2022-08-12,ACTUAL,2022-08-12,2024-04,2024-04-30,2023-04-27,ACTUAL,2023-04-27,2023-04-27,ACTUAL,2023-04-27,,INTERVENTIONAL,,Safety set included all participants who received at least 1 dose of the study interventions and had at least 1 valid post dose safety assessment.,"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women","A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE",COMPLETED,,PHASE2,306,ACTUAL,Pfizer,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 09:43:00,2024-10-13 09:43:00,INDUSTRY,,,,,,,Pfizer,United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04771611,,2021-02-24,2023-07-13,,2023-07-13,2021-02-24,2021-02-25,ACTUAL,2023-07-13,2023-08-01,ACTUAL,,,,2023-07-13,2023-08-01,ACTUAL,2021-07-14,ACTUAL,2021-07-14,2023-07,2023-07-31,2022-09-27,ACTUAL,2022-09-27,2022-09-27,ACTUAL,2022-09-27,,INTERVENTIONAL,COVFIS-HOME,,COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications,COVFIS-HOME: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Decrease Complications in At-Risk Outpatients,COMPLETED,,PHASE2,55,ACTUAL,Mayo Clinic,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 19:17:21,2024-10-13 19:17:21,OTHER,,,,,,,"James L. Kirkland, MD, PhD",United States,"Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04785612,,2021-02-12,2022-04-05,,2024-02-26,2021-03-04,2021-03-08,ACTUAL,2024-02-26,2024-08-07,ACTUAL,,,,2024-02-26,2024-08-07,ACTUAL,2020-11-10,ACTUAL,2020-11-10,2024-02,2024-02-29,2021-08-16,ACTUAL,2021-08-16,2021-04-08,ACTUAL,2021-04-08,,INTERVENTIONAL,,,Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults,"A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of A Respiratory Syncytial Virus Vaccine (RSVpreF) in A Virus Challenge Model in Healthy Adults",COMPLETED,,PHASE2,70,ACTUAL,Hvivo,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-13 22:25:16,2024-10-13 22:25:16,INDUSTRY,,,,,,,Hvivo|Pfizer,United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04786444,,2021-02-22,2022-07-21,,2023-09-27,2021-03-05,2021-03-08,ACTUAL,2023-09-27,2023-09-28,ACTUAL,,,,2023-09-27,2023-09-28,ACTUAL,2021-02-22,ACTUAL,2021-02-22,2023-09,2023-09-30,2022-01-26,ACTUAL,2022-01-26,2021-07-22,ACTUAL,2021-07-22,,INTERVENTIONAL,,,Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults,"A Randomized, Double-Blinded Phase 3 Study to Demonstrate Lot-to-Lot Consistency of Three Lots of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Adults Aged 18 to 45 Years",COMPLETED,,PHASE3,409,ACTUAL,Valneva Austria GmbH,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-13 08:26:34,2024-10-13 08:26:34,INDUSTRY,,,,,,,Valneva Austria GmbH,United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Pregnancy, puerperium and perinatal conditions|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04789499,,2021-03-08,2022-12-22,,2023-04-27,2021-03-08,2021-03-09,ACTUAL,2023-04-27,2023-05-24,ACTUAL,,,,2023-04-27,2023-05-24,ACTUAL,2021-03-15,ACTUAL,2021-03-15,2023-04,2023-04-30,2021-12-30,ACTUAL,2021-12-30,2021-12-30,ACTUAL,2021-12-30,,INTERVENTIONAL,SCENT2,,Smell in Covid-19 and Efficacy of Nasal Theophylline,Smell in Covid-19 and Efficacy of Nasal Theophylline,COMPLETED,,PHASE2,51,ACTUAL,Washington University School of Medicine,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,,,2024-10-13 02:52:51,2024-10-13 02:52:51,OTHER,,,,,,,Washington University School of Medicine,United States,Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Nervous system disorders
NCT04790201,,2021-02-18,2024-05-30,,2024-07-17,2021-03-04,2021-03-10,ACTUAL,2024-07-17,2024-08-13,ACTUAL,,,,2024-07-17,2024-08-13,ACTUAL,2022-02-28,ACTUAL,2022-02-28,2024-05,2024-05-31,2023-07-31,ACTUAL,2023-07-31,2023-07-31,ACTUAL,2023-07-31,,INTERVENTIONAL,VITAL,Two of the randomized participants (1-Friendship Bench Delivered by Professional Counselor and 1-Enhanced Usual Care) were found to be ineligible for the study shortly after enrollment and were excluded from all analyses.,Friendship Bench Adaptation to Improve Mental Health & HIV Care Engagement Outcomes Among PLWH and PWID in Vietnam,Adaptation of the Friendship Bench Counseling Intervention to Improve Mental Health and HIV Care Engagement Outcomes Among People Living With HIV Who Inject Drugs in Vietnam,COMPLETED,,NA,77,ACTUAL,"University of North Carolina, Chapel Hill",,3,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,9 to 36 months following publication,"The investigator who proposes to use the data has approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC.",,YES,"Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina at Chapel Hill (UNC).",2024-10-14 19:47:33,2024-10-14 19:47:33,OTHER,,,,,,,"Hanoi Medical University|National Institute on Drug Abuse (NIDA)|The Friendship Bench Trust|University of North Carolina, Chapel Hill",Vietnam,Hepatobiliary disorders|Psychiatric disorders
NCT04790201,,2021-02-18,2024-05-30,,2024-07-17,2021-03-04,2021-03-10,ACTUAL,2024-07-17,2024-08-13,ACTUAL,,,,2024-07-17,2024-08-13,ACTUAL,2022-02-28,ACTUAL,2022-02-28,2024-05,2024-05-31,2023-07-31,ACTUAL,2023-07-31,2023-07-31,ACTUAL,2023-07-31,,INTERVENTIONAL,VITAL,Two of the randomized participants (1-Friendship Bench Delivered by Professional Counselor and 1-Enhanced Usual Care) were found to be ineligible for the study shortly after enrollment and were excluded from all analyses.,Friendship Bench Adaptation to Improve Mental Health & HIV Care Engagement Outcomes Among PLWH and PWID in Vietnam,Adaptation of the Friendship Bench Counseling Intervention to Improve Mental Health and HIV Care Engagement Outcomes Among People Living With HIV Who Inject Drugs in Vietnam,COMPLETED,,NA,77,ACTUAL,"University of North Carolina, Chapel Hill",,3,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,9 to 36 months following publication,"The investigator who proposes to use the data has approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC.",,YES,"Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina at Chapel Hill (UNC).",2024-10-14 19:47:33,2024-10-14 19:47:33,OTHER,,,,,,,"Hanoi Medical University|National Institute on Drug Abuse (NIDA)|The Friendship Bench Trust|University of North Carolina, Chapel Hill",Vietnam,Hepatobiliary disorders|Psychiatric disorders
NCT04796935,,2021-03-10,2024-01-02,2022-11-22,2024-06-07,2021-03-10,2021-03-15,ACTUAL,2024-06-04,2024-06-06,ACTUAL,,2024-06-06,ACTUAL,2024-06-07,2024-06-11,ACTUAL,2021-04-04,ACTUAL,2021-04-04,2024-06,2024-06-30,2021-11-24,ACTUAL,2021-11-24,2021-11-24,ACTUAL,2021-11-24,,INTERVENTIONAL,,This population includes all randomized subjects and is referred to as the Intent-to-Treat (ITT) population.,A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control,"An Open-Label, Parallel, Randomized Study to Evaluate the Performance of Needle Placements for Diagnostic and Therapeutic Neuraxial Procedures, Using a Handheld Tactile Imaging-based Method Versus Palpation",COMPLETED,,NA,95,ACTUAL,"IntuiTap Medical, Inc","The enrollment period (April 2021-November 2021) was closed due to COVID concerns prior to reaching 96 evaluable subjects. Due to limitations in the emergency medicine setting at one site, emergency medicine providers at that site performed procedures for approximately half of the subjects enrolled in that site's neurology setting. Due to scheduling limitations, only MDs (including residents) performed procedures, and not all providers had the opportunity to use the device more than once.",2,,,FALSE,,,,FALSE,FALSE,TRUE,TRUE,,TRUE,,,,,,NO,,2024-10-13 11:25:16,2024-10-13 11:25:16,INDUSTRY,,,,,,,"ICON plc|IntuiTap Medical, Inc",United States,Blood and lymphatic system disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT04808908,,2021-03-18,2024-02-02,,2024-03-05,2021-03-18,2021-03-22,ACTUAL,2024-03-05,2024-04-02,ACTUAL,,,,2024-03-05,2024-04-02,ACTUAL,2021-04-01,ACTUAL,2021-04-01,2024-03,2024-03-31,2023-01-01,ACTUAL,2023-01-01,2022-07-18,ACTUAL,2022-07-18,,INTERVENTIONAL,,,Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease,Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease,COMPLETED,,PHASE1,10,ACTUAL,University of Minnesota,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 10:09:42,2024-10-14 10:09:42,OTHER,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID)|University of Minnesota,United States,Blood and lymphatic system disorders|General disorders
NCT04816669,,2021-03-24,2022-11-30,,2022-11-30,2021-03-24,2021-03-25,ACTUAL,2022-11-30,2022-12-23,ACTUAL,,,,2022-11-30,2022-12-23,ACTUAL,2021-04-01,ACTUAL,2021-04-01,2022-11,2022-11-30,2021-12-02,ACTUAL,2021-12-02,2021-12-01,ACTUAL,2021-12-01,,INTERVENTIONAL,,Safety population set included all randomized participants who received at least 1 dose of the study intervention.,"A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults","A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE",COMPLETED,,PHASE3,629,ACTUAL,BioNTech SE,,5,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 00:21:11,2024-10-13 00:21:11,INDUSTRY,,,,,,,BioNTech SE|Pfizer,United States,"Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04818216,,2021-03-24,2023-09-20,2022-10-21,2023-12-06,2021-03-24,2021-03-26,ACTUAL,2023-12-06,2023-12-26,ACTUAL,,2023-12-26,ACTUAL,2023-12-06,2023-12-26,ACTUAL,2021-06-11,ACTUAL,2021-06-11,2023-12,2023-12-31,2022-01-03,ACTUAL,2022-01-03,2021-12-09,ACTUAL,2021-12-09,,INTERVENTIONAL,NIRVANA,,Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection,NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection,COMPLETED,,PHASE2,28,ACTUAL,The University of Texas Health Science Center at San Antonio,,2,,,,,,,TRUE,TRUE,FALSE,,,,,,At the time when summary data are published or otherwise made available,,,YES,"All collected IPD, all IPD that underlie results in a publication",2024-10-14 23:19:03,2024-10-14 23:19:03,OTHER,,,,,,,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|The University of Texas Health Science Center at San Antonio,United States,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT04822467,,2021-03-26,2023-03-23,,2023-05-05,2021-03-26,2021-03-30,ACTUAL,2023-05-05,2023-06-02,ACTUAL,,,,2023-05-05,2023-06-02,ACTUAL,2021-12-10,ACTUAL,2021-12-10,2023-05,2023-05-31,2022-12-07,ACTUAL,2022-12-07,2022-12-07,ACTUAL,2022-12-07,,INTERVENTIONAL,,,SQ53 Disinfectant Wipes for Prevention of CRBSI,SQ53 Disinfectant Wipes for Prevention of Catheter Related Blood Stream Infection in Patients Receiving Home Parenteral Nutrition: A Single Blind Randomized Placebo-controlled Clinical Trial,COMPLETED,,NA,59,ACTUAL,The Cleveland Clinic,,2,,,FALSE,,,,FALSE,FALSE,TRUE,TRUE,,FALSE,,,,,,NO,,2024-10-14 04:04:40,2024-10-14 04:04:40,OTHER,,,,,,,"JVS Products, Ltd.|The Cleveland Clinic",United States,Skin and subcutaneous tissue disorders
NCT04824131,,2021-01-06,2024-02-28,,2024-07-26,2021-03-26,2021-04-01,ACTUAL,2024-07-26,2024-07-30,ACTUAL,,,,2024-07-26,2024-07-30,ACTUAL,2020-11-04,ACTUAL,2020-11-04,2024-07,2024-07-31,2023-01-10,ACTUAL,2023-01-10,2023-01-10,ACTUAL,2023-01-10,,INTERVENTIONAL,,Includes all enrolled participants,"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females","Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084",COMPLETED,,PHASE2,55,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-13 06:08:12,2024-10-13 06:08:12,NIH,,,,,,,Bill and Melinda Gates Foundation|National Institute of Allergy and Infectious Diseases (NIAID)|ViiV Healthcare,South Africa|Uganda|Zimbabwe,"Blood and lymphatic system disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Skin and subcutaneous tissue disorders"
NCT04827134,,2021-03-23,2022-07-21,,2022-07-21,2021-03-31,2021-04-01,ACTUAL,2022-07-21,2023-06-05,ACTUAL,,,,2022-07-21,2023-06-05,ACTUAL,2021-05-07,ACTUAL,2021-05-07,2022-06,2022-06-30,2021-07-23,ACTUAL,2021-07-23,2021-07-23,ACTUAL,2021-07-23,,INTERVENTIONAL,,,A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants,"A Randomized, 2-Cohort, 2-Period, Single Dose, Crossover Clinical Study to Assess the Effect of Food on the Pediatric Dispersible Tablet Formulations of TRIUMEQ (Dolutegravir/Abacavir/Lamivudine) and DOVATO (Dolutegravir/Lamivudine) in Healthy Adult Participants",COMPLETED,,PHASE1,33,ACTUAL,ViiV Healthcare,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 10:26:13,2024-10-13 10:26:13,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Gastrointestinal disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT04833127,,2021-03-21,2023-04-17,,2024-05-26,2021-04-03,2021-04-06,ACTUAL,2024-05-26,2024-09-23,ACTUAL,,,,2024-05-26,2024-09-23,ACTUAL,2021-03-17,ACTUAL,2021-03-17,2024-05,2024-05-31,2022-12-31,ACTUAL,2022-12-31,2022-06-24,ACTUAL,2022-06-24,,INTERVENTIONAL,Masibambane,,A Gender-Enhanced Pre-Exposure Prophylaxis (PrEP) Information-Motivational Workshop for Young South African Women,Developing a Gender-Enhanced Pre-Exposure Prophylaxis (PrEP) Information-Motivational Workshop for Young South African Women,COMPLETED,,PHASE1,100,ACTUAL,New York State Psychiatric Institute,"Pilot trial with sample size of 100 participants, designed to assess feasibility and acceptability rather than efficacy.",2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 17:48:39,2024-10-13 17:48:39,OTHER,,,,,,,"Brown University|Medical Research Council, South Africa|New York State Psychiatric Institute",South Africa,General disorders
NCT04839146,,2021-03-11,2023-06-07,,2023-06-14,2021-04-08,2021-04-09,ACTUAL,2023-06-14,2024-02-12,ACTUAL,,,,2023-06-14,2024-02-12,ACTUAL,2021-03-11,ACTUAL,2021-03-11,2022-03,2022-03-31,2022-02-25,ACTUAL,2022-02-25,2021-12-30,ACTUAL,2021-12-30,,INTERVENTIONAL,COUGH-1,,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),First-in-human Trial of the Coronavirus Virus-like Particle Subunit Vaccine ABNCoV2 in SARS-CoV-2-naïve Adult Volunteers in Good Health,COMPLETED,,PHASE1,45,ACTUAL,Radboud University Medical Center,,7,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-13 02:46:59,2024-10-13 02:46:59,OTHER,,,,,,,European Union|Radboud University Medical Center,Netherlands,"General disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Skin and subcutaneous tissue disorders"
NCT04841577,,2021-04-08,2022-09-20,,2024-08-14,2021-04-08,2021-04-12,ACTUAL,2022-09-20,2022-10-18,ACTUAL,,,,2024-08-14,2024-09-03,ACTUAL,2021-04-27,ACTUAL,2021-04-27,2024-08,2024-08-31,2022-02-08,ACTUAL,2022-02-08,2021-09-22,ACTUAL,2021-09-22,,INTERVENTIONAL,,,A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above,"A Phase 3, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU-QIV Vaccine in Adults Aged 60 Years and Above",COMPLETED,,PHASE3,976,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf,YES,"GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf",2024-10-14 13:55:50,2024-10-14 13:55:50,INDUSTRY,,,,,,,GlaxoSmithKline,New Zealand|Panama|South Africa,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04842747,,2021-04-09,2023-02-23,,2023-03-24,2021-04-09,2021-04-13,ACTUAL,2023-03-24,2023-04-18,ACTUAL,,,,2023-03-24,2023-04-18,ACTUAL,2021-05-18,ACTUAL,2021-05-18,2023-03,2023-03-31,2022-07-06,ACTUAL,2022-07-06,2022-07-06,ACTUAL,2022-07-06,,INTERVENTIONAL,VERU-111,,VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study,"Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).",COMPLETED,,PHASE3,204,ACTUAL,Veru Inc.,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-15 03:05:50,2024-10-15 03:05:50,INDUSTRY,,,,,,,Veru Inc.,Argentina|Brazil|Bulgaria|Colombia|Mexico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT04848688,,2021-04-08,2023-04-24,,2024-01-24,2021-04-13,2021-04-19,ACTUAL,2023-04-24,2024-01-24,ACTUAL,,,,2024-01-24,2024-01-25,ACTUAL,2022-02-05,ACTUAL,2022-02-05,2024-01,2024-01-31,2022-07-17,ACTUAL,2022-07-17,2022-07-17,ACTUAL,2022-07-17,,INTERVENTIONAL,StrongMoxi_KH,,Efficacy and Safety of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis,Efficacy and Safety of Moxidectin in Comparison to Ivermectin Against Strongyloides Stercoralis Infection in Adults: a Randomized Controlled Non-inferiority Trial,COMPLETED,,PHASE3,332,ACTUAL,Swiss Tropical & Public Health Institute,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,UNDECIDED,,2024-10-14 10:09:42,2024-10-14 10:09:42,OTHER,,,,,,,"Jennifer Keiser|National Centre for Parasitology, Entomology and Malaria Control, Cambodia",Cambodia,Gastrointestinal disorders|General disorders|Skin and subcutaneous tissue disorders
NCT04857892,,2021-04-20,2022-09-05,,2023-08-18,2021-04-20,2021-04-23,ACTUAL,2023-08-18,2024-03-12,ACTUAL,,,,2023-08-18,2024-03-12,ACTUAL,2021-04-21,ACTUAL,2021-04-21,2023-08,2023-08-31,2021-09-10,ACTUAL,2021-09-10,2021-09-10,ACTUAL,2021-09-10,,INTERVENTIONAL,,,A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants,"A Two-Part, Randomized, Open-Label, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Fixed-Dose Combinations of GSK3640254 and Dolutegravir and to Assess the Effect of Food on the Select Fixed Dose Combination of GSK3640254 and Dolutegravir in Healthy Participants",COMPLETED,,PHASE1,41,ACTUAL,ViiV Healthcare,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 01:31:21,2024-10-14 01:31:21,INDUSTRY,,,,,,,ViiV Healthcare,United States,General disorders|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders
NCT04870138,,2021-04-29,2021-07-08,,2021-11-02,2021-04-29,2021-05-03,ACTUAL,2021-11-02,2021-12-02,ACTUAL,,,,2021-11-02,2021-12-02,ACTUAL,2013-03-10,ACTUAL,2013-03-10,2020-09,2020-09-30,2015-04-28,ACTUAL,2015-04-28,2015-04-28,ACTUAL,2015-04-28,,INTERVENTIONAL,,The baseline analysis population includes all enrolled participants.,Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial),Experimental Human Infection With Isogenic Mutants of Neisseria Gonorrhoeae (LptA Trial),COMPLETED,,PHASE1,16,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,3,,,FALSE,,,,,TRUE,FALSE,,,FALSE,,,,,,,,2024-10-14 12:22:18,2024-10-14 12:22:18,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),United States,"Gastrointestinal disorders|General disorders|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders"
NCT04871113,,2021-04-28,2023-10-27,,2023-10-27,2021-04-28,2021-05-04,ACTUAL,2023-10-27,2023-11-18,ACTUAL,,,,2023-10-27,2023-11-18,ACTUAL,2021-06-22,ACTUAL,2021-06-22,2023-10,2023-10-31,2023-09-21,ACTUAL,2023-09-21,2022-10-27,ACTUAL,2022-10-27,,INTERVENTIONAL,,,"A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults","A Phase 2a Multicentre, Randomized, Open-Label, Two-Part Adaptive Design Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A, an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody in Antiretroviral-naïve HIV-1-Infected Adults",COMPLETED,,PHASE2,63,ACTUAL,ViiV Healthcare,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 19:59:08,2024-10-14 19:59:08,INDUSTRY,,,,,,,ViiV Healthcare,Argentina|Brazil|Canada|Mexico|Peru|United States,"Blood and lymphatic system disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04875676,,2021-04-19,2023-02-21,,2024-05-18,2021-04-30,2021-05-06,ACTUAL,2024-05-18,2024-05-22,ACTUAL,,,,2024-05-18,2024-05-22,ACTUAL,2021-04-30,ACTUAL,2021-04-30,2024-05,2024-05-31,2022-02-16,ACTUAL,2022-02-16,2021-10-30,ACTUAL,2021-10-30,,INTERVENTIONAL,VXA-NVV-105,,Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines,"A Phase 1b, Open-label, Boost-optimization Study of an Adenoviral- Vector Based Oral Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 Administered Orally to Healthy Adult Volunteers",COMPLETED,,PHASE1/PHASE2,30,ACTUAL,Vaxart,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 18:31:10,2024-10-13 18:31:10,INDUSTRY,,,,,,,Vaxart,United States,Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders
NCT04883060,,2021-05-06,2023-02-17,,2024-01-04,2021-05-06,2021-05-12,ACTUAL,2024-01-04,2024-01-30,ACTUAL,,,,2024-01-04,2024-01-30,ACTUAL,2019-01-01,ACTUAL,2019-01-01,2024-01,2024-01-31,2019-07-01,ACTUAL,2019-07-01,2019-07-01,ACTUAL,2019-07-01,,INTERVENTIONAL,MMD,,Pilot Testing for Midline Measuring Device,Pilot Testing for Midline Measuring Device,COMPLETED,,NA,40,ACTUAL,University of Iowa,,1,,,FALSE,,,,FALSE,FALSE,TRUE,,,FALSE,,,,,,NO,,2024-10-13 16:37:52,2024-10-13 16:37:52,OTHER,,,,,,,University of Iowa,United States,Surgical and medical procedures
NCT04886596,,2021-04-29,2023-04-10,,2024-09-20,2021-05-10,2021-05-14,ACTUAL,2023-07-14,2023-08-04,ACTUAL,,,,2024-09-20,2024-10-08,ACTUAL,2021-05-25,ACTUAL,2021-05-25,2024-09,2024-09-30,2024-05-31,ACTUAL,2024-05-31,2022-04-11,ACTUAL,2022-04-11,,INTERVENTIONAL,,,Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above,"A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above",COMPLETED,,PHASE3,26668,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 11:51:49,2024-10-13 11:51:49,INDUSTRY,,,,,,,GlaxoSmithKline,"Australia|Belgium|Canada|Estonia|Finland|Germany|Italy|Japan|Korea, Republic of|Mexico|New Zealand|Poland|Russian Federation|South Africa|Spain|United Kingdom|United States","Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04887948,,2021-05-10,2022-10-07,,2022-11-17,2021-05-10,2021-05-14,ACTUAL,2022-11-17,2022-12-14,ACTUAL,,,,2022-11-17,2022-12-14,ACTUAL,2021-05-20,ACTUAL,2021-05-20,2022-11,2022-11-30,2021-12-08,ACTUAL,2021-12-08,2021-12-08,ACTUAL,2021-12-08,,INTERVENTIONAL,,Safety population included all participants who received at least 1 dose of the study intervention and had safety follow-up after vaccination.,Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2,"A PHASE 3, RANDOMIZED, DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162b2 IN ADULTS 65 YEARS OF AGE AND OLDER",COMPLETED,,PHASE3,570,ACTUAL,Pfizer,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 09:59:01,2024-10-13 09:59:01,INDUSTRY,,,,,,,Pfizer,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders"
NCT04895982,,2021-05-05,2024-07-03,,2024-10-01,2021-05-17,2021-05-21,ACTUAL,2024-10-01,2024-10-09,ACTUAL,,,,2024-10-01,2024-10-09,ACTUAL,2021-10-15,ACTUAL,2021-10-15,2024-10,2024-10-31,2023-07-23,ACTUAL,2023-07-23,2023-07-23,ACTUAL,2023-07-23,,INTERVENTIONAL,,"Safety population included all participants who received at least 1 dose of study intervention. To avoid risk of identification of participant, any baseline measure data is not disclosed for reporting arm including (\>=18 Years with Non-Small Cell Lung Cancer, \>= 18 Years with Haemodialysis) and baseline measure data other than age is not disclosed for reporting arm (\>=12 to \<18 Years with Solid Organ Transplant) and reported the participant under category- Not Disclosed","Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years","A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE",COMPLETED,,PHASE2,124,ACTUAL,BioNTech SE,,1,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 13:01:13,2024-10-14 13:01:13,INDUSTRY,,,,,,,BioNTech SE|Pfizer,Brazil|Germany|Mexico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Surgical and medical procedures|Vascular disorders"
NCT04897737,,2021-05-18,2022-03-04,,2023-03-07,2021-05-18,2021-05-21,ACTUAL,2023-03-07,2023-12-08,ACTUAL,,,,2023-03-07,2023-12-08,ACTUAL,2020-11-05,ACTUAL,2020-11-05,2023-03,2023-03-31,2021-05-18,ACTUAL,2021-05-18,2021-04-30,ACTUAL,2021-04-30,,INTERVENTIONAL,PPS,,Postpartum Pre-exposure Prophylaxis (PrEP) Study to Evaluate an Adherence Promotion Package for Postpartum Women on PrEP,Study of the Feasibility and Acceptability of an Adherence Promotion Package for Postpartum Women on Pre-exposure Prophylaxis (PrEP),COMPLETED,,NA,106,ACTUAL,"University of California, Los Angeles",,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,1 year,To contact PI for access to study data,,YES,Researchers can contact PI to decide on sharing IPD for further analyses.,2024-10-13 12:25:40,2024-10-13 12:25:40,OTHER,,,,,,,"University of California, Los Angeles|University of Cape Town",South Africa,Psychiatric disorders
NCT04927312,,2021-06-04,2023-09-11,,2024-03-08,2021-06-14,2021-06-15,ACTUAL,2023-09-11,2024-03-08,ACTUAL,,,,2024-03-08,2024-03-13,ACTUAL,2021-10-01,ACTUAL,2021-10-01,2024-03,2024-03-31,2022-09-15,ACTUAL,2022-09-15,2022-09-15,ACTUAL,2022-09-15,,INTERVENTIONAL,,Safety analysis set included all participants who received any amount of IV study intervention.,Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection,"A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF CEFTAZIDIME-AVIBACTAM (PF-06947386) PLUS METRONIDAZOLE IN JAPANESE ADULT PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTION REQUIRING HOSPITALIZATION",COMPLETED,,PHASE3,60,ACTUAL,Pfizer,,1,,,FALSE,,,,,TRUE,FALSE,,,TRUE,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 22:31:13,2024-10-13 22:31:13,INDUSTRY,,,,,,,Pfizer,Japan,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04949490,,2021-06-25,2023-09-15,,2024-05-02,2021-06-25,2021-07-02,ACTUAL,2024-05-02,2024-09-19,ACTUAL,,,,2024-05-02,2024-09-19,ACTUAL,2021-07-26,ACTUAL,2021-07-26,2024-05,2024-05-31,2022-09-16,ACTUAL,2022-09-16,2022-04-14,ACTUAL,2022-04-14,,INTERVENTIONAL,,,A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects,"A Phase II, Open-label, Rollover Trial to Evaluate the Safety and Immunogenicity of One or Two Boosting Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 Trial Subjects, or Two Boosting Doses of Comirnaty in BNT162-04 Trial Subjects",COMPLETED,,PHASE2,137,ACTUAL,BioNTech SE,,4,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-12 23:41:00,2024-10-12 23:41:00,INDUSTRY,,,,,,,BioNTech SE,Germany,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Vascular disorders"
NCT04952402,,2021-06-28,2023-02-22,,2023-05-22,2021-07-02,2021-07-07,ACTUAL,2023-05-17,2023-05-19,ACTUAL,,,,2023-05-22,2023-05-24,ACTUAL,2021-07-09,ACTUAL,2021-07-09,2023-05,2023-05-31,2023-01-10,ACTUAL,2023-01-10,2022-02-28,ACTUAL,2022-02-28,,INTERVENTIONAL,,"All A5404 trial participants. For baseline characteristics, ACTIV-2/A5401 participants regardless of the exposure (select active therapy or Camostat or placebo) are considered as one cohort, and COVID-naïve participants are considered as the second cohort.",SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine,COMPLETED,,PHASE4,43,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),The study closed early to accrual due to difficulty enrolling participants. Therefore the sample size is very small and precision is limited.,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"* With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
* For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
* By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",,YES,"Individual participant data that underlie results in the publication, after deidentification.",2024-10-13 05:11:43,2024-10-13 05:11:43,NIH,,,,,,,National Institute of Allergy and Infectious Diseases (NIAID),Puerto Rico|United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT04973488,,2021-07-20,2022-11-29,,2024-08-01,2021-07-20,2021-07-22,ACTUAL,2024-08-01,2024-08-26,ACTUAL,,,,2024-08-01,2024-08-26,ACTUAL,2020-07-25,ACTUAL,2020-07-25,2024-08,2024-08-31,2021-01-10,ACTUAL,2021-01-10,2021-01-10,ACTUAL,2021-01-10,,INTERVENTIONAL,,,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients,COMPLETED,,NA,38,ACTUAL,"University of Medicine and Pharmacy ""Victor Babes"" Timisoara",Limitations of the study include the small number of patients enrolled and the non-randomized nature of the study. Also antibody titer was not determined in patients prior to the treatment.,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,Data will become available at 6 months after registering the study. It will be available for 36 months,"Data will be shared with interested researchers, contact: novacescu_alex@yahoo.com",,YES,"We plan on sharing treatment protocol, demographic data of the study cohort, primary outcomes, secondary outcomes, miscellaneous data, treatment scheme, statystical data",2024-10-13 07:32:15,2024-10-13 07:32:15,OTHER,,,,,,,"Novacescu Alexandru|University of Medicine and Pharmacy ""Victor Babes"" Timisoara",Romania,Cardiac disorders
NCT04978818,,2021-07-16,2024-05-28,,2024-06-20,2021-07-16,2021-07-27,ACTUAL,2024-06-20,2024-06-24,ACTUAL,,,,2024-06-20,2024-06-24,ACTUAL,2022-01-27,ACTUAL,2022-01-27,2024-06,2024-06-30,2023-10-26,ACTUAL,2023-10-26,2023-10-26,ACTUAL,2023-10-26,,INTERVENTIONAL,,,Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study),Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children,COMPLETED,,PHASE4,333,ACTUAL,Johns Hopkins Bloomberg School of Public Health,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-15 01:09:29,2024-10-15 01:09:29,OTHER,,,,,,,Johns Hopkins Bloomberg School of Public Health|Merck Sharp & Dohme LLC,United States,"Gastrointestinal disorders|Infections and infestations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT05005247,,2021-08-05,2024-01-23,,2024-07-15,2021-08-05,2021-08-13,ACTUAL,2024-07-15,2024-10-10,ESTIMATED,,,,2024-07-15,2024-10-10,ESTIMATED,2021-08-17,ACTUAL,2021-08-17,2024-07,2024-07-31,2022-08-05,ACTUAL,2022-08-05,2022-08-05,ACTUAL,2022-08-05,,INTERVENTIONAL,,,Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine,"A follow-on Study to Assess the Safety and Immunogenicity of a Booster Dose of GBS-NN/NN2 Vaccine 1 to 5 Years After GBS-NN/NN2 Recipients in Study MVX0002 Have Completed the Primary Vaccination Course, in Comparison With a Single Dose of GBS-NN/NN2 Administered in Placebo Participants From Study MVX0002 or Vaccine naïve Participants",COMPLETED,,PHASE1,27,ACTUAL,Minervax ApS,,1,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-13 00:26:25,2024-10-13 00:26:25,OTHER,,,,,,,Minervax ApS,United Kingdom,"Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT05022212,,2021-05-07,2024-05-06,,2024-07-18,2021-08-19,2021-08-26,ACTUAL,2024-07-18,2024-08-13,ACTUAL,,,,2024-07-18,2024-08-13,ACTUAL,2021-05-10,ACTUAL,2021-05-10,2024-07,2024-07-31,2023-03-31,ACTUAL,2023-03-31,2023-03-31,ACTUAL,2023-03-31,,INTERVENTIONAL,,,Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition,"Phase 2 Placebo-controlled Randomized Trial of LACTIN-V (Lactobacillus Crispatus CTV-05) Among Women at High Risk of HIV Acquisition in Durban, South Africa",COMPLETED,,PHASE2,45,ACTUAL,"University of California, San Francisco","In consideration of a set of circumstances that complicated the study progress (a 1-year delay of study start because of COVID-19 in 2020, a further 4-month delay because of destruction of the clinic site during social unrest in July 2021, and expiration of study product in March 2023), the study team together with the DSMB and the sponsor NICHD decided to stop enrollment at the end of 2022 at n=45, instead of the initial goal of n=60.",2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-14 13:20:12,2024-10-14 13:20:12,OTHER,,,,,,,"Aurum Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Harvard University|Health Systems Trust|Osel, Inc.|University of California, San Francisco|University of KwaZulu",South Africa,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT05036668,,2021-08-31,2023-11-14,,2024-06-27,2021-08-31,2021-09-05,ACTUAL,2024-06-27,2024-10-02,ACTUAL,,,,2024-06-27,2024-10-02,ACTUAL,2022-04-07,ACTUAL,2022-04-07,2024-06,2024-06-30,2022-12-27,ACTUAL,2022-12-27,2022-11-07,ACTUAL,2022-11-07,,INTERVENTIONAL,,,Study of Efficacy and Safety of ABO809 in Healthy Participants,An Open Label Cryptosporidium Controlled Human Infection Model (CHIM) to Assess the Efficacy and Safety of ABO809 in Healthy Participants,COMPLETED,,PHASE1,30,ACTUAL,Novartis,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 15:59:32,2024-10-14 15:59:32,INDUSTRY,,,,,,,Novartis Pharmaceuticals,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05041439,,2021-09-02,2023-08-27,,2023-11-25,2021-09-02,2021-09-13,ACTUAL,2023-11-25,2023-12-15,ACTUAL,,,,2023-11-25,2023-12-15,ACTUAL,2021-07-06,ACTUAL,2021-07-06,2023-11,2023-11-30,2022-11-06,ACTUAL,2022-11-06,2022-08-31,ACTUAL,2022-08-31,,INTERVENTIONAL,,,Adherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico,Adherence to Care for Children Born to Mothers With Laboratory Evidence of Confirmed or Possible Congenital Zika Virus Infection During Pregnancy.,COMPLETED,,NA,50,ACTUAL,Massachusetts General Hospital,,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,,,,,,,,,2024-10-13 15:13:45,2024-10-13 15:13:45,OTHER,,,,,,,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Massachusetts General Hospital|University of Puerto Rico,Puerto Rico,Musculoskeletal and connective tissue disorders
NCT05045144,,2021-09-06,2023-06-02,,2023-09-12,2021-09-06,2021-09-16,ACTUAL,2023-09-12,2023-10-05,ACTUAL,,,,2023-09-12,2023-10-05,ACTUAL,2021-10-26,ACTUAL,2021-10-26,2023-09,2023-09-30,2022-06-06,ACTUAL,2022-06-06,2022-06-06,ACTUAL,2022-06-06,,INTERVENTIONAL,,,A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.,"A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.",COMPLETED,,PHASE3,1586,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 06:08:12,2024-10-13 06:08:12,INDUSTRY,,,,,,,GlaxoSmithKline,"Canada|Finland|Korea, Republic of|Spain|United States","Blood and lymphatic system disorders|Congenital, familial and genetic disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Social circumstances|Vascular disorders"
NCT05054114,,2021-09-21,2022-08-29,,2024-03-04,2021-09-21,2021-09-23,ACTUAL,2024-03-04,2024-08-09,ACTUAL,,,,2024-03-04,2024-08-09,ACTUAL,2020-12-21,ACTUAL,2020-12-21,2021-09,2021-09-30,2021-09-02,ACTUAL,2021-09-02,2021-05-25,ACTUAL,2021-05-25,,INTERVENTIONAL,,,"Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19","Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19",COMPLETED,,NA,630,ACTUAL,SPP Pharmaclon Ltd.,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,,2024-10-13 20:37:13,2024-10-13 20:37:13,INDUSTRY,,,,,,,SPP Pharmaclon Ltd.,Russian Federation,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Vascular disorders"
NCT05059301,,2021-09-17,2023-01-21,,2023-01-21,2021-09-17,2021-09-28,ACTUAL,2023-01-21,2023-02-15,ACTUAL,,,,2023-01-21,2023-02-15,ACTUAL,2021-10-01,ACTUAL,2021-10-01,2023-01,2023-01-31,2022-06-30,ACTUAL,2022-06-30,2022-01-24,ACTUAL,2022-01-24,,INTERVENTIONAL,,,A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above,"A Phase 3, Randomized, Double-blind, Multi-country Study to Evaluate Consistency, Safety, and Reactogenicity of 3 Lots of RSVPreF3 OA Investigational Vaccine Administrated as a Single Dose in Adults Aged 60 Years and Above",COMPLETED,,PHASE3,770,ACTUAL,GlaxoSmithKline,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 23:19:03,2024-10-14 23:19:03,INDUSTRY,,,,,,,GlaxoSmithKline,Canada|Sweden|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05070546,,2021-09-27,2023-08-11,,2023-10-03,2021-09-27,2021-10-07,ACTUAL,2023-10-03,2023-10-04,ACTUAL,,,,2023-10-03,2023-10-04,ACTUAL,2021-09-29,ACTUAL,2021-09-29,2023-09,2023-09-30,2022-08-12,ACTUAL,2022-08-12,2022-08-12,ACTUAL,2022-08-12,,INTERVENTIONAL,,"Full analysis set (FAS) included all participants who received study vaccine, regardless of the occurrence of protocol deviations and vaccine type (study vaccine or placebo).","A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection","A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59 Years, Including Those at High-risk for Severe RSV",COMPLETED,,PHASE3,1124,ACTUAL,Janssen Vaccines & Prevention B.V.,,6,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,https://www.janssen.com/clinical-trials/transparency,YES,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2024-10-13 01:45:43,2024-10-13 01:45:43,INDUSTRY,,,,,,,Janssen Vaccines & Prevention B.V.,Belgium|Germany|Spain|Sweden|United States,"Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05070754,,2021-09-27,2023-12-01,,2024-03-30,2021-09-27,2021-10-07,ACTUAL,2024-03-30,2024-04-05,ACTUAL,,,,2024-03-30,2024-04-05,ACTUAL,2021-12-02,ACTUAL,2021-12-02,2024-03,2024-03-31,2022-12-31,ACTUAL,2022-12-31,2022-12-31,ACTUAL,2022-12-31,,INTERVENTIONAL,,,Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca,Using a Cold Atmospheric Plasma Device to Treat Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients,COMPLETED,,PHASE4,17,ACTUAL,Medical University of South Carolina,"Limitations:

* Study was adequately powered with the number of lesions, but a small number of patients enrolled
* Low enrollment of patients with skin of color
* Patients limited to only three treatments with the NTAP device
* Assessment of sustained treatment response was limited to 4 weeks after treatment \& may not represent long-term response
* Post-treatment sequelae were measured at the end of the study period. We are unable to determine whether they persisted or self-resolved.",3,,,FALSE,,,,FALSE,TRUE,TRUE,,,FALSE,,,,,,NO,,2024-10-14 10:22:11,2024-10-14 10:22:11,OTHER,,,,,Lesions,,Medical University of South Carolina|The Skin Center Dermatology Group,United States,Skin and subcutaneous tissue disorders
NCT05093530,,2021-09-29,2023-03-17,,2024-01-10,2021-10-13,2021-10-26,ACTUAL,2024-01-10,2024-01-11,ACTUAL,,,,2024-01-10,2024-01-11,ACTUAL,2021-10-12,ACTUAL,2021-10-12,2024-01,2024-01-31,2022-04-05,ACTUAL,2022-04-05,2022-04-05,ACTUAL,2022-04-05,,INTERVENTIONAL,,,Safety and Tolerability of Single and Multiple Doses of Neumifil,"A Two-part, Randomized, Double-blind, Placebo Controlled, Ascending Dose Study to Assess the Safety and Tolerability of Single and Multiple Doses of Neumifil (a Novel Drug Candidate With Potential for Treatment of COVID-19)",COMPLETED,,PHASE1,60,ACTUAL,Pneumagen Ltd.,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,,,2024-10-14 16:19:13,2024-10-14 16:19:13,INDUSTRY,,,,,,,Pneumagen Ltd.,United Kingdom,"Gastrointestinal disorders|General disorders|Infections and infestations|Nervous system disorders|Product Issues|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT05118386,,2021-10-06,2023-12-01,,2023-12-01,2021-11-11,2021-11-12,ACTUAL,2023-12-01,2024-05-20,ACTUAL,,,,2023-12-01,2024-05-20,ACTUAL,2021-11-16,ACTUAL,2021-11-16,2023-12,2023-12-31,2022-12-07,ACTUAL,2022-12-07,2022-08-23,ACTUAL,2022-08-23,,INTERVENTIONAL,,Safety Population: included all participants who received the study treatment.,"Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults","A Phase 1 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of RSM01, a Monoclonal Antibody Targeting Respiratory Syncytial Virus, in Healthy Adults",COMPLETED,,PHASE1,56,ACTUAL,Bill & Melinda Gates Medical Research Institute,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,YES,"Anonymized or deidentified, as appropriate, participant level data may be shared with external researchers in accordance with the trial participants' written and executed informed consent document and any local or applicable regulations on data sharing. Qualified researchers may submit a request for anonymized or de-identified participant level data along with a research proposal to Gates MRI for review. A data sharing agreement must be in place before any clinical trial data are shared. There are additional circumstances that may prevent the sharing of data with external researchers, including but not limited to contractual obligations to existing partners and any restrictions imposed by regulatory bodies.",2024-10-13 23:55:37,2024-10-13 23:55:37,OTHER,,,,,,,Bill & Melinda Gates Medical Research Institute|PPD Phase I Clinic - Orlando,United States,"Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders"
NCT05119348,,2021-11-12,2022-09-22,,2024-08-05,2021-11-12,2021-11-15,ACTUAL,2024-08-05,2024-08-09,ACTUAL,,,,2024-08-05,2024-08-09,ACTUAL,2020-09-14,ACTUAL,2020-09-14,2024-08,2024-08-31,2021-10-21,ACTUAL,2021-10-21,2021-08-04,ACTUAL,2021-08-04,,INTERVENTIONAL,TRACE,,Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments,Transmission of COVID19 in Crowded Environments,COMPLETED,,NA,245,ACTUAL,Desmond Tutu HIV Foundation,,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,,,,NO,There are no plans to share individual participant data with other researchers.,2024-10-14 12:40:41,2024-10-14 12:40:41,OTHER,,,,,,,Amsterdam Institute for Global Health and Development|Desmond Tutu HIV Foundation|European and Developing Countries Clinical Trials Partnership (EDCTP)|University of Cape Town,South Africa,"Respiratory, thoracic and mediastinal disorders"
NCT05142306,,2021-11-30,2023-02-15,,2024-05-27,2021-11-30,2021-12-02,ACTUAL,2023-12-12,2024-05-20,ACTUAL,,,,2024-05-27,2024-06-20,ACTUAL,2021-12-07,ACTUAL,2021-12-07,2024-05,2024-05-31,2022-05-31,ACTUAL,2022-05-31,2022-03-28,ACTUAL,2022-03-28,,INTERVENTIONAL,,Data is from the safety population which includes all subjects who received any amount of study treatment.,"A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults","A Phase 1, Open-Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) Administered Through Intramuscular, Subcutaneous or Intravenous Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults",COMPLETED,,PHASE1,23,ACTUAL,Emergent BioSolutions,,3,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,,,2024-10-14 22:09:19,2024-10-14 22:09:19,INDUSTRY,,,,,,,Emergent BioSolutions|United States Department of Defense,United States,"Eye disorders|Gastrointestinal disorders|Infections and infestations|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05158140,,2021-12-03,2024-01-18,,2024-09-11,2021-12-03,2021-12-15,ACTUAL,2024-01-18,2024-02-13,ACTUAL,,,,2024-09-11,2024-09-27,ACTUAL,2022-01-12,ACTUAL,2022-01-12,2024-09,2024-09-30,2023-02-21,ACTUAL,2023-02-21,2023-02-21,ACTUAL,2023-02-21,,INTERVENTIONAL,,,"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine With a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older.",COMPLETED,,PHASE3,850,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 11:03:59,2024-10-14 11:03:59,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,Puerto Rico|United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT05169905,,2021-12-10,2023-02-24,,2023-04-06,2021-12-10,2021-12-27,ACTUAL,2023-04-06,2023-04-07,ACTUAL,,,,2023-04-06,2023-04-07,ACTUAL,2022-02-02,ACTUAL,2022-02-02,2023-04,2023-04-30,2022-08-03,ACTUAL,2022-08-03,2022-08-03,ACTUAL,2022-08-03,,INTERVENTIONAL,,,A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age,"A Phase III, Randomized, Open-label, Active Vaccine-controlled Crossover Study to Evaluate the Reactogenicity, Safety and Immune Response of Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Girls From 9 to 17 Years of Age, and in Non-pregnant Adult Women From 18 to 49 Years of Age",COMPLETED,,PHASE3,9,ACTUAL,GlaxoSmithKline,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,FALSE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-14 19:59:08,2024-10-14 19:59:08,INDUSTRY,,,,,,,GlaxoSmithKline,Spain|United States,Gastrointestinal disorders|General disorders|Nervous system disorders|Reproductive system and breast disorders
NCT05172050,,2021-12-23,2022-06-06,,2023-12-21,2021-12-23,2021-12-29,ACTUAL,2023-03-17,2023-12-14,ACTUAL,,,,2023-12-21,2023-12-26,ACTUAL,2021-01-22,ACTUAL,2021-01-22,2022-06,2022-06-30,2021-06-12,ACTUAL,2021-06-12,2021-06-12,ACTUAL,2021-06-12,,INTERVENTIONAL,,"The Full Analysis Set (FAS) population included all randomized patients who received at least one dose of the study medication. The FAS population was used for demographics, and primary and secondary efficacy analyses","Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.","Multicenter, Adaptive, Randomized, Placebo-controlled, Double Blind, Parallel-group Phase 2/3 Trial, to Study Efficacy and Safety of Two Doses of Raloxifene in Adult Paucisymptomatic COVID-19 Patients.",COMPLETED,,PHASE2/PHASE3,61,ACTUAL,Dompé Farmaceutici S.p.A,,3,,,FALSE,,,,,FALSE,FALSE,,,FALSE,,,,,,NO,,2024-10-13 17:13:28,2024-10-13 17:13:28,INDUSTRY,,,,,,,Dompé Farmaceutici S.p.A,France|Italy|Spain,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05210101,,2022-01-25,2024-02-28,,2024-08-13,2022-01-26,2022-01-27,ACTUAL,2024-08-13,2024-08-15,ACTUAL,,,,2024-08-13,2024-08-15,ACTUAL,2022-02-07,ACTUAL,2022-02-07,2024-08,2024-08-31,2023-02-28,ACTUAL,2023-02-28,2023-02-28,ACTUAL,2023-02-28,,INTERVENTIONAL,,,A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals,A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 Infection in Immunocompromised Individuals With Impaired SARS-CoV-2 Humoral Immunity,COMPLETED,,PHASE2,93,ACTUAL,Brigham and Women's Hospital,,1,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 16:32:17,2024-10-14 16:32:17,OTHER,,,,,,,"Dana-Farber Cancer Institute|GlaxoSmithKline|Massachusetts General Hospital|Sophia Koo, M.D.",United States,"Blood and lymphatic system disorders|Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT05219877,,2022-01-20,2022-04-18,,2023-02-01,2022-01-21,2022-02-02,ACTUAL,2023-02-01,2023-11-13,ACTUAL,,,,2023-02-01,2023-11-13,ACTUAL,2022-02-04,ACTUAL,2022-02-04,2023-02,2023-02-28,2022-04-13,ACTUAL,2022-04-13,2022-04-03,ACTUAL,2022-04-03,,INTERVENTIONAL,,,Effectiveness of Preurodynamic With Posturodynamic Levofloxacin on the Incidence of UTI,Comparison of the Effectiveness of Preurodynamic Single Dose of Levofloxacin With Posturodynamic Levofloxacin for Three Days on the Incidence of Urinary Tract Infections,COMPLETED,,PHASE1/PHASE2,134,ACTUAL,Indonesia University,The limitation of the study is that many of the patients with UTIs refuse to undergo urine culture tests due to several reasons.,2,,,FALSE,,,,TRUE,FALSE,FALSE,,,FALSE,,,Immediately following publication. No end date,Anyone who wishes to access the data,,YES,These are the study protocol used in this study,2024-10-13 08:10:23,2024-10-13 08:10:23,OTHER,,,,,,,Indonesia University,Indonesia,Gastrointestinal disorders|Renal and urinary disorders
NCT05291520,,2022-02-16,2024-04-09,,2024-04-09,2022-03-11,2022-03-22,ACTUAL,2024-04-09,2024-09-19,ACTUAL,,,,2024-04-09,2024-09-19,ACTUAL,2022-02-23,ACTUAL,2022-02-23,2024-04,2024-04-30,2023-04-10,ACTUAL,2023-04-10,2023-04-10,ACTUAL,2023-04-10,,INTERVENTIONAL,SPAN,,"A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants","A Phase 1, Open-Label, Single-Dose Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, GSK3810109, Administered Either Subcutaneously or Intravenously With Recombinant Human Hyaluronidase PH20 (rHuPH20) to Healthy Adults",COMPLETED,,PHASE1,24,ACTUAL,ViiV Healthcare,,3,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-15 03:36:43,2024-10-15 03:36:43,INDUSTRY,,,,,,,ViiV Healthcare,United States,"Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders"
NCT05304611,,2022-02-28,2024-06-12,,2024-06-12,2022-03-30,2022-03-31,ACTUAL,2024-06-12,2024-07-10,ACTUAL,,,,2024-06-12,2024-07-10,ACTUAL,2022-03-18,ACTUAL,2022-03-18,2024-06,2024-06-30,2024-04-20,ACTUAL,2024-04-20,2023-01-31,ACTUAL,2023-01-31,,INTERVENTIONAL,L9LS,,Anti-malaria MAb in Malian Children,"Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium Falciparum, in a Dose-Escalation Trial in Adults and Children and a Randomized, Double-Blind Trial of Children in Mali",COMPLETED,,PHASE2,365,ACTUAL,National Institute of Allergy and Infectious Diseases (NIAID),,9,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,Data will be shared at the time of publication or shortly thereafter.,Data from this study may be requested from other researchers indefinitely after the completion of the primary endpoint by contacting Laboratory of Immunogenetics at NIH,,YES,"Human data generated in this study for future research will be shared as follows:

* De-identified or identified data with approved outside collaborators under appropriate agreements.
* De-identified results or data in publication and/or public presentations.",2024-10-14 12:09:42,2024-10-14 12:09:42,NIH,,,,,,,"Harvard School of Public Health (HSPH)|Indiana University School of Medicine|Malaria Research and Training Center, Bamako, Mali|National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health (NIH)|University of the Sciences, Techniques and Technologies of Bamako|University of Washington",Mali,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Nervous system disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05310084,,2022-03-25,2023-10-04,,2024-05-14,2022-03-25,2022-04-04,ACTUAL,2023-11-22,2023-11-24,ACTUAL,,,,2024-05-14,2024-06-12,ACTUAL,2022-04-20,ACTUAL,2022-04-20,2024-05,2024-05-31,2022-10-05,ACTUAL,2022-10-05,2022-10-05,ACTUAL,2022-10-05,,INTERVENTIONAL,,Safety population included all participants who received any of the study intervention.,Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age,"A PHASE 3, RANDOMIZED, OBSERVER-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF BNT162b2 WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE (SIIV) IN ADULTS 18 THROUGH 64 YEARS OF AGE",COMPLETED,,PHASE3,1134,ACTUAL,BioNTech SE,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,TRUE,,,,,,NO,,2024-10-13 11:41:43,2024-10-13 11:41:43,INDUSTRY,,,,,,,BioNTech SE|Pfizer,Australia|New Zealand,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders"
NCT05342532,,2022-04-19,2023-01-06,,2023-01-06,2022-04-19,2022-04-22,ACTUAL,2023-01-06,2023-02-01,ACTUAL,,,,2023-01-06,2023-02-01,ACTUAL,2019-06-12,ACTUAL,2019-06-12,2023-01-05,2023-01-05,2022-01-01,ACTUAL,2022-01-01,2022-01-01,ACTUAL,2022-01-01,,INTERVENTIONAL,,,High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population,High-Dose Dual Therapy vs Standard Triple Therapy for Treatment-Naïve H. Pylori: A Prospective Randomized Control Trial in a Diverse Urban New York City Population,COMPLETED,,PHASE4,112,ACTUAL,Icahn School of Medicine at Mount Sinai,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,Immediately following publication. No end date.,Anyone who wishes to access the data. Any purpose. Data are available indefinitely at (Link to be included in the URL field below).,,YES,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).",2024-10-13 02:02:46,2024-10-13 02:02:46,OTHER,,,,,,,Icahn School of Medicine at Mount Sinai,United States,Gastrointestinal disorders
NCT05425732,,2022-06-15,2024-05-10,,2024-09-10,2022-06-15,2022-06-21,ACTUAL,2024-05-10,2024-06-10,ACTUAL,,,,2024-09-10,2024-10-01,ACTUAL,2022-07-13,ACTUAL,2022-07-13,2024-09,2024-09-30,2023-05-18,ACTUAL,2023-05-18,2023-05-18,ACTUAL,2023-05-18,,INTERVENTIONAL,,All vaccinated participants. Includes two participants from Cohort 1 who had unplanned vaccinations with both V116 and PCV20,"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)","A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults",COMPLETED,,PHASE3,2663,ACTUAL,Merck Sharp & Dohme LLC,,4,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,http://engagezone.msd.com/ds_documentation.php,YES,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2024-10-14 15:59:32,2024-10-14 15:59:32,INDUSTRY,,,,,,,Merck Sharp & Dohme LLC,"Australia|Belgium|Chile|Germany|Korea, Republic of|New Zealand|Puerto Rico|Sweden|Taiwan|Turkey|United States","Cardiac disorders|Ear and labyrinth disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Product Issues|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders"
NCT05513625,,2022-08-22,2022-09-16,,2024-02-19,2022-08-22,2022-08-24,ACTUAL,2023-09-11,2023-09-15,ACTUAL,,,,2024-02-19,2024-02-22,ACTUAL,2020-07-13,ACTUAL,2020-07-13,2022-09,2022-09-30,2020-10-13,ACTUAL,2020-10-13,2020-10-13,ACTUAL,2020-10-13,,INTERVENTIONAL,,Safety Set,Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir,"A Single-center, Open-label, 2-period Fixed-sequence Phase I Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Pritelivir",COMPLETED,,PHASE1,16,ACTUAL,AiCuris Anti-infective Cures AG,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,,,2024-10-13 19:40:01,2024-10-13 19:40:01,INDUSTRY,,,,,,,AiCuris Anti-infective Cures AG,United States,"Gastrointestinal disorders|Infections and infestations|Injury, poisoning and procedural complications|Musculoskeletal and connective tissue disorders|Nervous system disorders"
NCT05526911,,2022-08-31,2023-12-22,,2024-07-08,2022-08-31,2022-09-02,ACTUAL,2024-07-08,2024-10-08,ACTUAL,,,,2024-07-08,2024-10-08,ACTUAL,2022-06-30,ACTUAL,2022-06-30,2024-07,2024-07-31,2022-09-26,ACTUAL,2022-09-26,2022-09-26,ACTUAL,2022-09-26,,INTERVENTIONAL,,,"A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults","A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects",COMPLETED,,PHASE1,28,ACTUAL,Global Alliance for TB Drug Development,,1,,,FALSE,,,,,TRUE,FALSE,,,,,,,,,UNDECIDED,,2024-10-13 11:57:49,2024-10-13 11:57:49,OTHER,,,,,,,Global Alliance for TB Drug Development,United States,"Cardiac disorders|Gastrointestinal disorders|General disorders|Infections and infestations|Investigations|Musculoskeletal and connective tissue disorders|Nervous system disorders|Respiratory, thoracic and mediastinal disorders|Vascular disorders"
NCT05559476,,2022-09-26,2024-03-07,,2024-09-09,2022-09-26,2022-09-29,ACTUAL,2024-03-07,2024-04-04,ACTUAL,,,,2024-09-09,2024-09-24,ACTUAL,2022-10-20,ACTUAL,2022-10-20,2024-09,2024-09-30,2023-08-15,ACTUAL,2023-08-15,2023-03-07,ACTUAL,2023-03-07,,INTERVENTIONAL,,,A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above,"A Phase 3, Open-label, Randomized, Controlled, Multicountry Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU HD Vaccine in Adults Aged 65 Years and Above",COMPLETED,,PHASE3,1029,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,TRUE,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf,YES,"GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf",2024-10-13 18:01:21,2024-10-13 18:01:21,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|United States,"Blood and lymphatic system disorders|Cardiac disorders|Ear and labyrinth disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Immune system disorders|Infections and infestations|Injury, poisoning and procedural complications|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05568797,,2022-10-03,2024-02-16,,2024-09-09,2022-10-03,2022-10-06,ACTUAL,2024-02-16,2024-03-15,ACTUAL,,,,2024-09-09,2024-09-24,ACTUAL,2022-10-14,ACTUAL,2022-10-14,2024-09,2024-09-30,2023-07-17,ACTUAL,2023-07-17,2023-02-17,ACTUAL,2023-02-17,,INTERVENTIONAL,,,A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above,"A Phase III, Open-label, Randomized, Controlled, Multi-country Study to Evaluate the Immune Response, Safety and Reactogenicity of an RSVPreF3 OA Investigational Vaccine When Co-administered With FLU aQIV (Inactivated Influenza Vaccine - Adjuvanted) in Adults Aged 65 Years and Above",COMPLETED,,PHASE3,1045,ACTUAL,GlaxoSmithKline,,2,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.","Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.",https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf,YES,"GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf",2024-10-14 18:04:38,2024-10-14 18:04:38,INDUSTRY,,,,,,,GlaxoSmithKline,Belgium|Finland|France|Spain|United Kingdom,"Blood and lymphatic system disorders|Cardiac disorders|Endocrine disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05576662,,2022-10-10,2024-08-14,,2024-09-19,2022-10-10,2022-10-12,ACTUAL,2024-09-19,2024-09-25,ACTUAL,,,,2024-09-19,2024-09-25,ACTUAL,2022-11-08,ACTUAL,2022-11-08,2024-09,2024-09-30,2023-09-12,ACTUAL,2023-09-12,2023-08-14,ACTUAL,2023-08-14,,INTERVENTIONAL,STOP-PASC,,Paxlovid for Treatment of Long Covid,Selective Trial Of Paxlovid for PASC (STOP-PASC): Randomized Double-Blind Placebo-Controlled Pilot Trial of Paxlovid for the Treatment of PASC,COMPLETED,,PHASE2,168,ACTUAL,Stanford University,,2,,,FALSE,,,,TRUE,TRUE,FALSE,,,,,,,,,NO,"Currently, there is no plan for data sharing.",2024-10-13 11:25:16,2024-10-13 11:25:16,OTHER,,,,,,,Pfizer|Stanford University,United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05590403,,2022-10-18,2024-03-13,,2024-04-25,2022-10-18,2022-10-21,ACTUAL,2024-04-25,2024-05-21,ACTUAL,,,,2024-04-25,2024-05-21,ACTUAL,2022-10-28,ACTUAL,2022-10-28,2024-04,2024-04-30,2024-04-03,ACTUAL,2024-04-03,2023-03-13,ACTUAL,2023-03-13,,INTERVENTIONAL,,,"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above","A Phase 3, Observer-blind, Randomized, Placebo-controlled Study to Evaluate the Non-inferiority of the Immune Response and Safety of the RSVPreF3 OA Investigational Vaccine in Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults ≥60 Years of Age",COMPLETED,,PHASE3,1544,ACTUAL,GlaxoSmithKline,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,FALSE,,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",,YES,IPD for this study will be made available via the Clinical Study Data Request site.,2024-10-13 23:05:39,2024-10-13 23:05:39,INDUSTRY,,,,,,,GlaxoSmithKline,Argentina|Canada|Germany|Japan|Netherlands|Poland|Spain|United States,"Blood and lymphatic system disorders|Cardiac disorders|Eye disorders|Gastrointestinal disorders|General disorders|Hepatobiliary disorders|Infections and infestations|Injury, poisoning and procedural complications|Investigations|Metabolism and nutrition disorders|Musculoskeletal and connective tissue disorders|Neoplasms benign, malignant and unspecified (incl cysts and polyps)|Nervous system disorders|Psychiatric disorders|Renal and urinary disorders|Reproductive system and breast disorders|Respiratory, thoracic and mediastinal disorders|Skin and subcutaneous tissue disorders|Vascular disorders"
NCT05799495,,2023-04-04,2024-09-12,,2024-09-12,2023-04-04,2023-04-05,ACTUAL,2024-09-12,2024-10-09,ACTUAL,,,,2024-09-12,2024-10-09,ACTUAL,2023-05-23,ACTUAL,2023-05-23,2024-09,2024-09-30,2023-10-11,ACTUAL,2023-10-11,2023-09-13,ACTUAL,2023-09-13,,INTERVENTIONAL,,The full analysis set (FAS) included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention Participants were analyzed according to the intervention they were actually randomized.,A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized,"A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF-07817883 IN NON-HOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19",COMPLETED,,PHASE2,240,ACTUAL,Pfizer,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2024-10-13 08:20:46,2024-10-13 08:20:46,INDUSTRY,,,,,,,Pfizer,United States,Cardiac disorders|Investigations
NCT06017479,,2023-08-24,2024-04-23,,2024-10-02,2023-08-24,2023-08-30,ACTUAL,2024-10-02,2024-10-09,ACTUAL,,,,2024-10-02,2024-10-09,ACTUAL,2022-12-30,ACTUAL,2022-12-30,2024-10,2024-10-31,2024-03-25,ACTUAL,2024-03-25,2024-03-25,ACTUAL,2024-03-25,,INTERVENTIONAL,,"Besides the required samples are 126 samples to complete the study. There are 59 samples that didn't meet the inclusion criteria of the study, which are because of there are 8 samples who refuse to participate, 14 samples that are under 18 years old, 7 samples that have history of antibiotics consumption in 1 month prior to the study, 19 samples that are UTI proved through urinalysis, 11 samples that use of urinary catheter prior to the study.",Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic for UTI Prevention,Effectiveness of Single Dose Fosfomycin and Single Dose Levofloxacin as Pre-urodynamic Antibiotic Prophylaxis for Urinary Tract Infection Prevention in Post-Urodynamic Examination,COMPLETED,,PHASE1/PHASE2,126,ACTUAL,Indonesia University,The limitation of the study is that many of the patients with UTIs refuse to undergo urine culture tests due to several reasons.,2,,,FALSE,,,,FALSE,FALSE,FALSE,,,,,,Immediately following publication. No end date,Anyone who wishes to access the data,,YES,These are the study protocol used in this study,2024-10-14 12:46:59,2024-10-14 12:46:59,OTHER,,,,,,,Indonesia University,Indonesia,Gastrointestinal disorders
NCT06076681,,2023-09-25,2023-11-02,,2023-11-02,2023-10-07,2023-10-11,ACTUAL,2023-11-02,2023-11-22,ACTUAL,,,,2023-11-02,2023-11-22,ACTUAL,2021-09-27,ACTUAL,2021-09-27,2023-11,2023-11-30,2022-01-06,ACTUAL,2022-01-06,2022-01-06,ACTUAL,2022-01-06,,INTERVENTIONAL,,,"A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules","A Phase Ⅰb/Ⅱa, Single-center, Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Helicobacter Pylori Eradication Efficacy in Asymptomatic Subjects With Helicobacter Pylori Infection After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules",COMPLETED,,PHASE1/PHASE2,40,ACTUAL,TenNor Therapeutics Inc.,,4,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-14 07:44:30,2024-10-14 07:44:30,INDUSTRY,,,,,,,TenNor Therapeutics (Suzhou) Limited,China,Gastrointestinal disorders|Investigations|Metabolism and nutrition disorders
NCT06076694,,2023-09-26,2023-11-23,,2023-11-23,2023-10-07,2023-10-11,ACTUAL,2023-11-23,2023-12-12,ACTUAL,,,,2023-11-23,2023-12-12,ACTUAL,2022-06-26,ACTUAL,2022-06-26,2023-10,2023-10-31,2022-09-20,ACTUAL,2022-09-20,2022-09-20,ACTUAL,2022-09-20,,INTERVENTIONAL,,,"Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants","Single-center, Randomized, Open-label Phase Ic/IIb Clinical Study to Evaluate the Efficacy and Safety of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Combined With Multiple Doses of Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Compared With Multiple Doses of Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Combined With Multiple Doses in Helicobacter Pylori Infection-positive Population",COMPLETED,,PHASE2,80,ACTUAL,TenNor Therapeutics Inc.,,5,,,FALSE,,,,FALSE,TRUE,FALSE,,,,,,,,,NO,,2024-10-13 06:35:41,2024-10-13 06:35:41,INDUSTRY,,,,,,,TenNor Therapeutics (Suzhou) Limited,China,Investigations|Metabolism and nutrition disorders
